<SEC-DOCUMENT>0001493152-23-003681.txt : 20230206
<SEC-HEADER>0001493152-23-003681.hdr.sgml : 20230206
<ACCEPTANCE-DATETIME>20230206142830
ACCESSION NUMBER:		0001493152-23-003681
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		16
FILED AS OF DATE:		20230206
DATE AS OF CHANGE:		20230206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neuraxis, INC
		CENTRAL INDEX KEY:			0001933567
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		IRS NUMBER:				455079684
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-269179
		FILM NUMBER:		23589891

	BUSINESS ADDRESS:	
		STREET 1:		11550 N. MERIDIAN STREET
		STREET 2:		SUITE 325
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
		BUSINESS PHONE:		(812) 689-0791

	MAIL ADDRESS:	
		STREET 1:		11550 N. MERIDIAN STREET
		STREET 2:		SUITE 325
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>forms-1a.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">As filed with the U.S. Securities and Exchange Commission
on February 6, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333-269179</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>AMENDMENT NO.2 </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-size: 14pt">TO</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
S-1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT UNDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>NEURAXIS,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Exact
name of registrant as specified in its charter)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3845</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>45-5079684</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(State
    or other jurisdiction of</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>incorporation
    or organization)</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Primary
    Standard Industrial</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Classification
    Code Number)</I></FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(I.R.S.
    Employer</I></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Identification
    Number)</I></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11550
N. Meridian Street, Suite 325</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carmel,
IN 46032</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telephone:
(812) 689-0791</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address,
including zip code and telephone number, including area code, of registrant&rsquo;s principal executive offices)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Brian
Carrico</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Chief
Executive Officer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neuraxis,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11550
N. Meridian Street, Suite 325</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carmel,
IN 46032</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Telephone:
(812) 689-0791</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name,
address, including zip code and telephone number, including area code, of agent for service)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Copies
of all communications, including communications sent to agent for service, should be sent to:</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Joseph
    M. Lucosky, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lahdan
S. Rahmati, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lucosky
    Brookman LLP</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>101
    Wood Avenue South, 5th Floor</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Woodbridge,
    NJ 08830</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(732)
    395-4496</B></FONT></P></TD>
    <TD STYLE="text-align: center; width: 2%"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>
                          <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; width: 49%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ross
    D. Carmel, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Barry
    P. Biggar, Esq.</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Carmel,
    Milazzo &amp; Feil LLP</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>55
    West 39th Street, 18th Floor</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
    York, NY 10018</B></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(212)
    658-0458</B></FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
date of commencement of proposed sale to the public:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
soon as practicable after the effective date of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 check the following box. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.
&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller
reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer &#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company &#9746;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company &#9746;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the
registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933 or until this registration statement shall become effective on such date
as the Commission, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
information in this preliminary prospectus is not complete and may be changed. These securities included in this Registration Statement,
of which this prospectus, are subject to an effective Registration Statement. This preliminary prospectus is not an offer to sell these
securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">SUBJECT
TO COMPLETION, DATED FEBRUARY 6, 2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">PRELIMINARY
PROSPECTUS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1a_001.jpg" ALT="" STYLE="height: 72.75pt; width: 194.25pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>NEURAXIS,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>1,875,000</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Shares
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are offering 1,875,000 shares of common stock, par value $0.001 per share, of Neuraxis, Inc. at an estimated initial public
offering price between $7.00 and $9.00 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for our common stock. We have applied to have our common stock listed on the Nasdaq
Capital Market (&ldquo;Nasdaq&rdquo;) under the symbol &ldquo;NRXS&rdquo;. We will not proceed with this offering in the event the common
stock is not approved for listing on Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; under applicable Securities and Exchange Commission rules and will be subject to reduced
public company reporting requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in our securities involves a high degree of risk. See &ldquo;<I>Risk Factors</I>&rdquo; beginning on page 12 of this prospectus. You
should carefully consider these risk factors, as well as the information contained in this prospectus, before purchasing any of the securities
offered by this prospectus.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%">Public offering price</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">&nbsp;&nbsp;&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Underwriting discounts and commissions (1)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Proceeds to us, before expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
We have agreed to pay Alexander Capital L.P., as the representative of the underwriters named in this prospectus (the &ldquo;Underwriter&rdquo;),
an underwriting discount of seven percent (7%) of the amount raised in the offering. In addition, we have also
agreed to pay to the underwriters a non-accountable expense allowance in the amount of 1% of the gross offering amount (including shares
purchased upon exercise of the over-allotment option). We have also agreed to issue to the Underwriter, on the closing date
of this offering, warrants in an amount equal to six percent (6%) of the aggregate number of shares of common stock sold by us in this
offering and exercisable at a price per share equal to one hundred and twenty percent (120%) of the public offering price (the &ldquo;Underwriter&rsquo;s
Warrants&rdquo;). For a description of compensation to be received by the Underwriter, see &ldquo;<I>Underwriting</I>&rdquo; for more
information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the Underwriter an option, exercisable for up to 45 days from the date of this prospectus, to purchase a maximum of 281,250
shares of common stock (equal to fifteen percent (15%) of the aggregate number of shares of common stock sold in this offering) on
the same terms as the other shares of common stock being purchased by the Underwriter from us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering is being conducted on a firm commitment basis. The Underwriter is obligated to take and purchase all of the shares of common
stock offered under this prospectus if any such shares are taken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriter expects to deliver the securities to purchasers in the offering on or about &nbsp;, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole
Book Running Manager</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ALEXANDER
CAPITAL L.P.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prospectus
dated &nbsp;, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>TABLE
OF CONTENTS</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#A1_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY
    NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#A1_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#A1_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SUMMARY OF THE OFFERING</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#A1_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#eds_008">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#M_001">DIVIDEND POLICY</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#M_002">CAPITALIZATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#M_003">DILUTION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#M_004">MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#M_005">BUSINESS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_001">MANAGEMENT</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_002">EXECUTIVE
    OFFICER AND DIRECTOR COMPENSATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_003">PRINCIPAL STOCKHOLDERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_004">CERTAIN
    RELATIONSHIPS AND RELATED PERSONS TRANSACTIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_005">DESCRIPTION OF OUR SECURITIES</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">97</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_006">SHARES ELIGIBLE FOR FUTURE SALE</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_007">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">102</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_008">UNDERWRITING</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">105</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_009">LEGAL MATTERS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_010">EXPERTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#ka_011">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#eds_001">INDEX
    TO FINANCIAL STATEMENTS</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>You
should rely only on the information contained in this prospectus. We have not authorized anyone to provide any information or to make
any representations other than those contained in this prospectus we have prepared. We take no responsibility for and can provide no
assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities
offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus
is current only as of its date. You should also read this prospectus together with the additional information described under &ldquo;Additional
Information.&rdquo;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="A1_001"></A>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains &ldquo;forward-looking statements&rdquo;. Forward-looking statements discuss matters that are not historical facts.
Because they discuss future events or conditions, forward-looking statements may include words such as &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo;
&ldquo;estimate,&rdquo; &ldquo;intend,&rdquo; &ldquo;could,&rdquo; &ldquo;should,&rdquo; &ldquo;would,&rdquo; &ldquo;may,&rdquo; &ldquo;seek,&rdquo;
&ldquo;plan,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
&ldquo;forecast,&rdquo; &ldquo;potential,&rdquo; and &ldquo;continue&rdquo; or the negatives thereof or similar expressions. Forward-looking
statements speak only as of the date they are made, are based on various underlying assumptions and current expectations about the future
and are not guarantees of future performance. Such statements involve known and unknown risks, uncertainties and other factors that may
cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or
plans expressed or implied by such forward-looking statements. You are cautioned to not place undue reliance on these forward-looking
statements, which speak only as of their dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict all the risks and uncertainties that may impact our business, financial condition, or results of operations. Accordingly,
the forward-looking statements in this prospectus should not be regarded as representations that the results or conditions described
in such statements will occur or that our objectives and plans will be achieved. These forward-looking statements are found at various
places throughout this prospectus and include information concerning possible or projected future results of our operations, including
statements about potential acquisition or merger targets, strategies or plans; business strategies; prospects; future cash flows; financing
plans; plans and objectives of management; any other statements regarding future cash needs, future operations, business plans and future
financial results; and any other statements that are not historical facts. <FONT STYLE="background-color: white">We qualify all of
the forward-looking statements in this prospectus by this cautionary note.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
forward-looking statements represent our intentions, plans, expectations, assumptions and beliefs about future events and are subject
to a variety of factors and risks, including, but not limited to, those set forth under &ldquo;<I>Risk Factors</I>&rdquo; starting page
12 of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
of those risk factors are outside of our control and could cause actual results to differ materially from the results expressed
or implied by those forward-looking statements. Considering these risks, uncertainties and assumptions, the events described in the forward-looking
statements might not occur or might occur to a different extent or at a different time than we have described. All subsequent written
and oral forward-looking statements concerning other matters addressed in this prospectus and attributable to us or any person acting
on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of
new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MARKET
AND INDUSTRY DATA</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains statistical data, estimates and forecasts that are based on independent industry publications or other publicly available
information, as well as other information based on our internal sources. While we believe the industry and market data included in this
prospectus are reliable and are based on reasonable assumptions, these data involve many assumptions and limitations, and you are cautioned
not to give undue weight to these estimates. The industry in which we operate is subject to a high degree of uncertainty and risk due
to a variety of factors, including those described in the sections titled &ldquo;Cautionary Note Regarding Forward-Looking Statements&rdquo;
and &ldquo;Risk Factors&rdquo; included in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRADEMARKS
AND TRADE NAMES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business.
This prospectus may also contain trademarks, service marks and trade names of third parties, which are the property of their respective
owners. Our use or display of third parties&rsquo; trademarks, service marks, trade names or products in this prospectus is not intended
to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks
and trade names referred to in this prospectus may appear without the <SUP>&reg;</SUP>, TM or SM symbols, but such references are not
intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the
applicable licensor to these trademarks, service marks and trade names.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>GLOSSARY
OF CERTAIN TERMS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a neuromodulation therapy device company, describing our business involves several technical terms and acronyms. We are providing the
following glossary to assist readers with certain technical terms and acronyms and to also define certain frequently used terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&ldquo;AAP&rdquo; means the American Academy of Pediatrics, the largest
professional association of pediatricians in the U.S. </P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;ACA&rdquo;
means the Affordable Care Act, a comprehensive reform law which increases health insurance coverage for the uninsured and implements
reforms to the health insurance market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CBT&rdquo;
means cognitive behavioral therapy, a form of psychological treatment that has been demonstrated to be effective for a range of problems
including depression, anxiety disorders, alcohol and drug use problems, marital problems, eating disorders, and severe mental illness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CCPA&rdquo;
means the California Consumer Privacy Act, a state statute intended to enhance privacy rights and consumer protection for residents of
California.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CE&rdquo;
means that the manufacturer or importer of a commercial product affirms the product&rsquo;s conformity with European health, safety and
environmental safety standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CE
Certificate&rdquo; means the CE mark that is placed on the backside of certain products sold in the European Economic Area and the European
Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;cGCPs&rdquo;
means current Good Clinical Practices, which is an international ethical and scientific quality standard for designing, conducting, recording
and reporting trials that involve the participation of human subjects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CMS&rdquo;
means Centers for Medicare and Medicaid Services, a federal agency within the United States Department of Health and Human Services
that administers the Medicare program and works in partnership with state governments to administer Medicaid, the Children&rsquo;s Health
Insurance Program, and health insurance portability standards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CPRA&rdquo;
means the California Privacy Rights Act of 2020, is a California ballot proposition that expands California&rsquo;s consumer privacy
law and builds upon the California Consumer Privacy Act of 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CPT
codes&rdquo; means the Common Procedural Terminology codes, a medical code set that is used to report medical, surgical, and diagnostic
procedures and services to entities such as physicians, health insurance companies and accreditation organizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;DHS&rdquo;
means designated health services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;EEA&rdquo;
means the European Economic Area.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;EU&rdquo;
means the European Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;FATCA&rdquo;
means the Foreign Account Tax Compliance Act, which requires all non-U.S. foreign financial institutions to search their records for
customers with indicia of a connection to the U.S., including indications in records of birth or prior residency in the U.S., or the
like, and to report the assets and identities of such persons to the U.S. Department of the Treasury.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;FDA&rdquo;
means the U.S. Food and Drug Administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;FDCA&rdquo;
means the Federal Food, Drug, and Cosmetic Act, a set of laws giving authority to the U.S. Food and Drug Administration to oversee the
safety of food, drugs, medical devices, and cosmetics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;FSCA&rdquo;
means Field Safety Corrective Action, which is an action taken by a manufacturer to reduce a risk of death or serious deterioration
in the state of health associated with the use of a medical device that is already placed on the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;FTC&rdquo;
means Federal Trade Commission, an independent agency of the United States government whose principal mission is the enforcement of civil
U.S. antitrust law and the promotion of consumer protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;FAPD&rdquo;
means functional abdominal pain disorder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;GDPR&rdquo;
means General Data Protection Regulation, a regulation in EU law on data protection and privacy in the EU and the EEA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;HDE&rdquo;
means Humanitarian Device Exemption, a regulatory pathway for products intended for diseases or conditions that affect small, rare populations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;HIPAA&rdquo;
means Health Insurance Portability and Accountability Act, which is a US law designed to provide privacy standards to protect patients&rsquo;
medical records and other health information provided to health plans, doctors, hospitals and other health care providers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;IBS&rdquo;
means irritable bowel syndrome, a group of symptoms that occur together, including repeated pain in abdomen and changes in bowel movements,
which may be diarrhea, constipation, or both.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;IRB&rdquo;
means Institutional Review Board, which is any group that has been formally designated to review and monitor biomedical research involving
human subjects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;JOBS
Act&rdquo; means the Jumpstart Our Business Startups Act of 2012, as amended, which is a law intended to encourage funding of small businesses
in the U.S. by easing many of the country&rsquo;s securities regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Masimo&rdquo;
means Masimo Corporation, a global medical technology company that develops, manufactures, and markets a variety of noninvasive patient
monitoring technologies, hospital automation solutions, home monitoring devices, ventilation solutions, and consumer products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;MACs&rdquo;
means Medicare Administrative Contractors, which is a private health care insurer that has been awarded a geographic jurisdiction to
process Medicare Part A and Part B medical claims or Durable Medical Equipment claims for Medicare Fee-For-Service beneficiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;MDR&rdquo;
means the medical device reporting, one of the post-market surveillance tools the FDA uses to monitor device performance, detect potential
device-related safety issues, and contribute to benefit-risk assessments of these products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;MHLW&rdquo;
means Ministry of Health, Labour and Welfare of Japan, a cabinet level ministry of the Japanese government that provides services on
health, labor and welfare.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;NASPGHAN&rdquo;
means the American Academy of Pediatrics and the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;PENFS&rdquo;
means Percutaneous Electrical Nerve Field Stimulation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;PMA&rdquo;
means the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;QSR&rdquo;
means quality system regulations maintained by the FDA that must be followed by all medical device manufacturers who wish to sell devices
in the U.S. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;RCT&rdquo; means Randomized Controlled Trial, which is a study
in which people are allocated at random (by chance alone) to receive one of several clinical interventions, including a standard of comparison
or control in for the form of a placebo (e.g., a sugar pill) or no intervention at all.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;SSRI&rdquo;
is a type of antidepressant drug that inhibits the reabsorption of serotonin by neurons, so increasing the availability of serotonin
as a neurotransmitter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;TCA&rdquo;
means the EU-UK Trade and Cooperation Agreement, a free trade agreement signed on December 30, 2020, between the EU, the European Atomic
Energy Community, and the United Kingdom that provides for free trade in goods and limited mutual market access in services, as well
as for cooperation mechanisms in a range of policy areas, transitional provisions about EU access to UK fisheries, and UK participation
in some EU programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;TKBMN&rdquo;
means TKBMN, LLC, an Indiana company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;UKCA&rdquo;
means UK conformity assessment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;UKCA
Marking&rdquo; means a certification mark that indicates conformity with the applicable requirements for products sold within Great Britain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;USPTO&rdquo;
means United States Patent and Trademark Office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="A1_002"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>This
prospectus summary contains an overview of the information from this prospectus but may not contain all of the information that is important
to you. This prospectus includes specific terms of the offering of our securities, information about our business, and financial data.
We encourage you to read this prospectus, including the &ldquo;Risk Factors&rdquo; section beginning on page 12 and the financial statements
and the notes thereto, in its entirety before making an investing decision. As used in this prospectus, the terms &ldquo;we,&rdquo; &ldquo;us,&rdquo;,
&ldquo;the Company&rdquo;, &ldquo;our,&rdquo; and &ldquo;Neuraxis&rdquo; refer to Neuraxis, Inc., a corporation organized under the laws
of Delaware, including our subsidiaries, unless the context indicates a different meaning.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children.
We are dedicated to advancing science with our proprietary PENFS technology, which we developed. We believe that superior science and
evidence-based research are necessary for adoption by the medical and scientific community. With one FDA indication&mdash;functional
abdominal pain associated with IBS in adolescents 11-18 years old&mdash;on the market, additional clinical trials of PENFS
in multiple pediatric conditions are underway focused on unmet healthcare needs in children, see &ldquo;<I>&mdash;Our Pipeline</I>&rdquo;
for more information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Since
our inception, we have incurred significant operating losses. Our net loss was $3.0 million and $3.7 million for the years ended December
31, 2021, and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $29.2 million. Our auditors have expressed
substantial doubt about our ability to continue as a going concern paragraph in their audit opinion. We expect to incur significant expenses
and operating losses for the foreseeable future as we continue to pursue widespread insurance coverage of our IB-Stim device and seek
FDA clearance of our device for other indications. There are a number of milestones and conditions that we must satisfy before we will
be able to generate sufficient revenue to fund our operations, including FDA clearance of our IB-Stim device to treat future indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Mission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to provide solutions that create value and provide better and safer patient outcomes. We believe in improving lives and
minimizing suffering; particularly in the pediatric population, where research and therapeutics are usually lacking. The FDA has
already cleared our IB-Stim therapy for functional abdominal pain, associated with IBS, in children. Through innovation and
research, we are reimagining the future of patient care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Our</B><B> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pipeline</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim device is to be used for the indication</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
of functional abdominal pain associated with IBS and functional nausea in children. The same underlying technology will be
used for the remaining pipeline indications, but we may use a name other than &ldquo;IB-Stim&rdquo; for marketing and commercialization
purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
one FDA indication&mdash;functional abdominal pain associated with IBS in adolescents 11-18 years old&mdash;on the market, additional
clinical trials of PENFS in multiple pediatric conditions are underway focused on unmet healthcare needs in children. These indications
consist of chronic nausea,</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> post-concussion syndrome,
chemotherapy-induced nausea and vomiting, cyclic vomiting syndrome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chart below shows our status in the FDA process for IB-Stim and each of the following pediatric indications:</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Chronic nausea -- RCT completed, and data being analyzed, see ClinicalTrials.gov Identifier: NCT03675321.</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Post-concussion syndrome -- RCT currently enrolling patients, see ClinicalTrials.gov Identifier: NCT04978571.</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Chemotherapy-induced nausea and vomiting -- RCT currently enrolling patients, see ClinicalTrials.gov Identifier: NCT05143554.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
Cyclic vomiting syndrome -- Pilot study completed, see ClinicalTrials.gov Identifier: NCT03434652; multicenter RCT is anticipated
to begin enrolling patients in the first half of 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
step in the FDA process differs in duration and cannot be predicted with accuracy. Timing</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
of FDA review and approval, if ever received, cannot be assured and the process and any approval is within the sole control and discretion
of the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="forms-1a_002.jpg" ALT="" STYLE="height: 351px; width: 624px">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Product</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. IB-Stim
already has market clearance from the FDA for functional abdominal pain associated with IBS in children. FDA has classified the
non-implanted nerve stimulator for functional abdominal pain relief as Class II devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim is intended to be used for 120 hours per week for three consecutive weeks, and not to exceed four (4) consecutive weeks, through
application to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the
reduction of pain when combined with other therapies for IBS DEN180057. In published studies, patients treated with IB-Stim demonstrated
significant improvement in pain, disability and global symptoms with no serious adverse events, and minimal to no side effects, including
localized skin irritation. See <I>Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents:
a randomized, double-blind, sham-controlled trial</I>, Kovacic K, et.al., Lancet Gastroenterol Hepatol. 2017;2:727-737; <I>Efficacy of
Auricular Neurostimulation in Adolescents With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial</I>, Krasaelap A et.al.,
Clin Gastroenterol Hepatol. 2020;18:1987-1994; <I>Effect of percutaneous electrical nerve field stimulation on mechanosensitivity, sleep,
and psychological comorbidities in adolescents with functional abdominal pain disorders</I>, Santucci et.al., Neurogastroenterol Motil.
2022;34:e14358.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the IB-Stim to produce systemic effects by modulating the central nervous system has been demonstrated in a pre-clinical animal
model of IBS (see &ldquo;<I>Business</I>&mdash;<I>Technology&mdash;Pre-Clinical Data</I>&rdquo;). In patients with IBS, the largest effect
on all pain measures, including composite pain scores, worst pain, disability and global symptoms, was seen after completing three consecutive
weeks of treatment (see &ldquo;<I>Business</I>&mdash;<I>Technology&mdash;Clinical Data</I>&rdquo;). A fourth consecutive week of treatment
was included in clinical testing; no safety concerns were identified with this extra consecutive week of treatment. In the trial of 115
subjects, 10 patients reported side-effects and only three discontinued the study because of side-effects. Of such 10 patients, six experienced
ear discomfort (three in the PENFS group, three in the sham group), three experienced adhesive allergy ( one in the PENFS group,
2 in the sham group), and one experienced syncope due to needle phobia (in the sham group). There were no serious adverse events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
providers are trained to place the IB-Stim through IB-Stim Training and Certification. Once the provider is trained, the device can be
placed in the outpatient clinic and can be removed by the provider in the clinic or the patient at home. IB-Stim stays on for a total
of five-days to allow delivery of gentle electrical pulses to nerves below the skin that access the central nervous system. A study in
adolescents showed greater improvement in functional abdominal pain and global symptom improvement with every week of treatment (up to
four weeks). At the end of the four-week study, 95% of adolescents stated they would recommend the treatment to family or friends. Safety
of percutaneous electrical nerve field stimulation has also been reported in a separate study of over 1200 adult patients with no serious
adverse events and minimal to no side-effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
wearing our IB-Stim device, patients can still attend school and extracurricular activities, exercise or play non-contact sports, shower,
wear ear buds or headphones, and travel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
IB-Stim device costs $1,195 per device, and each patient will use three to four devices. Potential patients with other indications are
expected to use six or more devices per patient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pediatrics
Industry Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pediatric
providers, as a whole, had expressed concern about the lack of attention given to children with functional abdominal pain disorders (including
IBS) and the limited treatment options available for a population that suffers from significant disabilities. With 20% of the
United States population under age 18, our Company focus is on opportunities in pediatrics industry. The pediatrics industry
has multi-billion-dollar market opportunities. The following points clearly outline the unmet need in children:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional
    abdominal pain in children is one of the most common conditions seen by pediatricians and pediatric gastroenterologists.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Children
    with functional abdominal pain report lower quality of life compared with their healthy peers and equal to those with inflammatory
    bowel disease.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall,
    35-45% of children with functional abdominal pain disorders continue to have symptoms into adulthood, which impacts quality of life
    and healthcare spending.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    study published in 2021 demonstrates insufficient evidence for the use of medications in pediatric functional abdominal pain disorders.
    This lack of evidence for drugs has been supported in by the American Academy of Pediatrics and NASPGHAN.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-Stim
    is the only therapy that has shown to improve pain, global symptoms, and functional disability in children with FAP and IBS.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-Stim
    is the only currently used therapy that is better than placebo in a randomized controlled trial and received FDA clearance for pediatric
    IBS.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total addressable market (&ldquo;TAM&rdquo;) for our target pediatric indications is $9 billion. The TAM is calculated by the total number
of patients we target to treat multiplied by the revenue potential from each patient. This aggregate target TAM is broken down
into five (5) pipeline indications. The first pipeline indication is functional abdominal pain associated with irritable bowel syndrome
which has a TAM of $1.48 billion, followed by functional nausea in children which has a TAM of $2.26 billion, cyclic vomiting
syndrome which has a TAM of $2.8 billion, followed by post-concussion syndrome which has a TAM of $1.9 billion, and finally chemo-therapy
induced nausea and vomiting in children which has a TAM of $0.72 billion.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
years, physicians and qualified healthcare professionals have resorted to the use off-label medications without proper evidence of efficacy
or safety. This is despite a technical report from the American Academy of Pediatrics and NASPGHAN which found very little evidence to
endorse the use of any drugs in the treatment of FAPDs in children. Medications including tricyclic antidepressants, SSRIs and gabapentinoids
continue to be used off-label despite lack of evidence to support efficacy or safety. Not only have the most commonly used medications
(amitriptyline and SSRIs) failed to beat placebos in clinical trials, but new studies also suggest significant risks with the potential
for serious side effects with these drugs. For example, significant risk of TCA side effects in children include increased risk of
suicidal ideation, mood changes, EKG disturbance, and long-term risk of dementia. Other side effects of pharmaceuticals given are depression
and weight gain. The absence of conclusive data to support treatments based on scientific evidence, and the fact no drug therapies
have been approved by the FDA for the treatment of FAPDs or IBS in children, presents a unique market opportunity for Neuraxis. Below
are the current standard treatments in children with functional abdominal pain and IBS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1a_004.jpg" ALT="" STYLE="height: 169.5pt; width: 6in"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Solutions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered the pediatric market with clinical evidence, coverage and payment, and key opinion leaders and society endorsement, including
a signed letter from the American Academy of Pediatrics and NASPGHAN supporting our request for insurers to pay for our IB-Stim device.
Our IB-Stim is a non-drug alternative to reduce functional abdominal pain in patients with IBS. In June 2019, the FDA cleared IB-Stim,
a non-surgical, neuromodulation device for children and adolescents who suffer from IBS, through a de novo process (DEN180057). The FDA
created a new classification of PENFS for the IB-Stim device. This is based on pre-clinical and clinical studies demonstrating the mechanism
of action and efficacy. Based on this new class of devices, the IB-Stim falls under 21 CFR Part 876, Subpart F &ndash; Therapeutic Devices,
876.5340, Product Code QHH. As a PENFS device, it is non-implantable and provides field stimulation to cranial nerves V, VII, IX and
X in the ear to access the CNS. It stimulates remotely from the source of pain to modulate central pain regions, such as the limbic system,
and relieve functional abdominal pain associated with IBS. Studies have demonstrated long-term benefits in functional disability, psychological
co-morbidities, and pain. For more information, see &ldquo;Business&mdash;Our Solutions.&rdquo; We have only submitted one FDA
De Novo request and have not submitted any additional 510(k) premarket notifications for our pipeline indications to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with treatment so far has been outstanding with the four weeks of therapy required to sustain long-term benefits. Compliance has been
an issue with non-pharmacological treatment for children, particularly with some of the psychological approaches such as cognitive behavioral
therapy or guided imagery, which sometimes requires 8-12 weeks of treatment. In fact, 95% of adolescents who used IB-Stim said that they
would recommend this treatment to family and friends. Many children&rsquo;s hospitals across the country are already treating children
with IB-Stim successfully, since it provides a better alternative for therapy in children with IBS and disability and allows them to
treat them safely and effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have concentrated our marketing focus on 260 children&rsquo;s hospitals. To date, we have sold our IB-Stim product to approximately
50 children&rsquo;s hospitals within our target market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competitive landscape for therapies includes off-label drugs and drugs with FDA approved only for adults with IBS. There is no FDA
indicated treatments for patients 11-18 years of age with functional abdominal pain associated with IBS and Rx often contain FDA black
box labels. Current treatments treat locally and peripheral whereas IB-Stim treats at the level of the brain gut axis. It also includes
devices that could theoretically be used, but do not have supporting data or FDA clearance for functional bowel disorders or IBS. Our
method patents also limit other devices from targeting IBS through stimulation of cranial nerve branches in the ear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approved
drugs for adults with IBS:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rifaximin:
    an intraluminal antibiotic approved for IBS-diarrhea</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitiza:
    a drug that stimulates fluid secretion from the intestine, approved for IBS-diarrhea</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linzess:
    a drug that stimulates fluid secretion from the intestine, approved for IBS-constipation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plecanatide:
    a drug that stimulates fluid secretion from the intestine, approved IBS-constipation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eluxadoline:
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a schedule IV-controlled substance that is a
    mixed opioid receptor agonist/antagonist in the intestine approved for IBS-diarrhea</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Devices:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gammaCore:
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transcutaneous, cervical vagal nerve stimulator
    cleared for cluster and migraine headaches. Recent studies using this device for adults with gastroparesis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transcranial
    Magnetic Stimulation: Multiple devices cleared to treat major depressive disorder and obsessive-compulsive disorder. To date,
    no known gastrointestinal indications.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roo
    System and Sparrow therapy system: Transcutaneous auricular stimulation devices-cleared for neonatal and adult opioid withdrawal.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
neurostimulation market is predominantly comprised of surgically implanted, invasive technologies that are not directly competitive with
our technology. Several neurostimulation companies are large, publicly-traded companies that have a history in the market, have significantly
easier access to capital and other resources and have an established product pipeline. The combined clinical research and product development
done by the industry, including by us and all of our competitors, is uncovering the beneficial effects of neurostimulation which now
establishes neuromodulation as a valid and scientifically supported approach to the treatment of neurological conditions, and accordingly,
we expect for competition in the non-implanted space to grow in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
many companies have joined the neuromodulation space, there are no companies targeting the CNS or the brain-gut axis through auricular
nerves for functional bowel disorders or IBS. Currently, the Neuraxis method patents protect access to the brain, particularly the limbic
systems through branches of cranial nerves in the ear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Competitive Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the following competitive strengths will enable us to compete effectively:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    to market</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    portfolio of device and method patents</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    market opportunities</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    pediatric pipeline </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Academic
    Society Support</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
    capital expenditures in nurse, trainers, and representatives for first line therapy</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    clinical data carried out in leading academic institutions in the U.S. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Growth Strategies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    price of our product is $1,195 per device and $4,780 per patient </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross margin</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct
    sales force</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Target
    customers are children&rsquo;s hospitals and pediatric clinics</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. was established in 2011 and incorporated in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions,
Inc. The name was changed to Neuraxis, Inc. in March of 2022. Additionally, the Company filed a Certificate of Conversion to become a
Delaware corporation on June 23, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 7, 2021, the Company&rsquo;s board of directors authorized a 4-for-1 stock split and increased the number of authorized
common stock shares from 2,700,000 to 10,800,000. On September 9, 2021, the board authorized another increase of authorized
shares of common stock from 10,800,000 to 13,400,000 in anticipation of this offering. All share and per share amounts for our
common stock in this prospectus, including the financial statements, have been retroactively restated to give effect to the
split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the conversion to a Delaware corporation, the total number of shares of all classes of stock which we have authority to
issue was set at 101,120, 000 shares, consisting of (1) 100,000,000 shares of common stock, par value $0.001 per
share and (ii) 1,120,000 shares of preferred stock, par value $0.001 per share 1,000,000
of which was designated as &ldquo;Series A Preferred Stock&rdquo; and 120,000 of which was designated as &ldquo;Series
Seed Preferred Stock&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2023, we filed a certificate of amendment to our certificate of incorporation with the Secretary of State of the State of
Delaware and effectuated a reverse stock split of our common stock at a ratio of 1-for-2. All share information in this prospectus,
including historical share information in our financial statements, has been adjusted for this reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From June through November of 2022, we entered into
Securities Purchase Agreements (the &ldquo;SPAs&rdquo;) with Leonite Fund I, <FONT STYLE="background-color: white">LP, Emmis Capital
II</FONT>, LLC, Bigger Capital Fund, LP, District 2 Capital Fund, LP, and Exchange Listing, LLC, which provide for advances of up to
$3.0 million in proceeds to us, subject to our satisfaction of certain conditions. Pursuant to the SPAs, from June 2022 through November
of 2022, we issued Senior Secured Convertible Promissory Notes (&ldquo;Notes&rdquo;) with an aggregate principal amount of $3,333,333,
which amount included an original issue discount (&ldquo;OID&rdquo;) of $333,333, and legal fees for $130,000, resulting in advance proceeds
to us of $3.0 million. In connection with the issuance of the Notes, we also issued five-year warrants exercisable for an aggregate of
353,111 shares of common stock with an exercise price of the lower of (a) $11.80 and (b) a 12% discount to the price per share in any
subsequent offering by the Company, and we entered into a Pledge and Security Agreement with Leonite Fund I, LP, dated June 3, 2022.
Pursuant to the Pledge and Security Agreement, the Company granted a security interest in all of its assets in favor of Leonite Fund
I, LP, in its capacity as collateral agent for the purchasers parties under the SPAs. For more information regarding the warrants issued
under the SPAs, see &ldquo;<I>Description of Our Securities&mdash;Warrants</I>.&rdquo; We plan to use a portion of the proceeds of
this offering to repay the entire amount owed pursuant to these Notes. See &ldquo;<I>Use of Proceeds</I>&rdquo; for additional information. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Notes were issued with OID of 10% of the
principal amount and bear interest at the greater of (a) the prime rate of interest, as published by the Wall Street Journal, plus
8.5% per annum, or (b) 12%. The Notes will mature in twelve (12) months from their respective issue dates. Any amount of principal,
interest, other amounts due hereunder or penalties on this Note, which is not paid by maturity date, shall bear interest at the
lesser of the rate of twenty four percent (24%) per annum or the maximum legal amount permitted by law, from the due date thereof
until the same is paid in full, including following the entry of a judgment in favor of the Noteholder. The Notes are convertible at
the option of the holder into shares of common stock at the lower of (a) $9.44 per share, or (b) a discount of 30% to the
price per share in any subsequent offering, subject to adjustment in the event of common stock distribution, stock splits,
fundamental transactions, dilutive issuances or similar events affecting our common stock and the conversion price. Interest accrues
on the aggregate principal amount (which includes OID) and is payable monthly, at the Company&rsquo;s election, in cash or
in-kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the advance of the consideration under the SPAs, the Company is required to issue to the noteholders a number of shares of common stock,
calculated based on the value of 10% of the principal amount of the Notes issued in such advance, at a value per share equal to the conversion
price of the Notes at the date of such advance (the &ldquo;Commitment Shares&rdquo;). Accordingly, in connection with the initial
advance and issuance of Notes, assuming a conversion price of $9.44 per share, we will be issuing 35,317 Commitment Shares
to the Noteholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">See &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&mdash;Recent
Developments</I>&rdquo; for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
December 2022 through January 2023, the Company issued unsecured convertible promissory notes to three existing investors, Todd Maxwell,
Rogan O&rsquo;Donnell and Michael &amp; Michele Robuck, with an aggregate principal amount of $222,222, which amount included an OID
of $22,222, resulting in advance proceeds to us of $200,000. The notes carry an OID of 10% of the principal amount and have an interest
rate of 12% per annum. The notes will mature at the earlier of (i) twelve (12) months from the issue date or (ii) the date upon which
the Company completes a registered public offering of shares of the Company, which encompasses the closing of this offering. The notes
are convertible into shares of common stock at the higher of (i) $9.44 per share, or (ii) the price per share of common stock
issued pursuant to the next registered public offering of shares of the Company made prior to the conversion of any portion of the note.
Interest accrues on the aggregate principal amount (which includes OID) and is payable on the maturity date, at the Company&rsquo;s election,
in cash or in-kind. The holders of the notes are entitled to piggyback registration rights on any registration statement filed by the
Company, other than the registration statement of which this prospectus forms a part and any registration filed on Form S-4 or Form S-8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to two advisory agreements with Exchange Listing, LLC, a consultant engaged in connection with listing our common stock for
trading on Nasdaq. Pursuant to the first advisory agreement with Exchange Listing, dated March 3, 2022, we have agreed to pay Exchange
Listing a monthly consulting fee of $5,000 and a final payment of $50,000 upon a successful Nasdaq listing, and, also upon such listing,
to issue Exchange Listing 76,426 shares of our common stock (representing 1.5% of our outstanding shares after giving effect to
this offering, as presented in the pro forma as adjusted column under &ldquo;Capitalization&rdquo;) and to issue Exchange Listing
five-year warrants to purchase 153,515 shares of our common stock (representing 2.0% of our outstanding shares after giving effect
to this offering on a fully-diluted basis, as presented in the pro forma as adjusted column under &ldquo;Capitalization&rdquo;)
with an exercise price of $8.00 per share (representing the midpoint of the price range set forth on the cover page of this
prospectus ). Pursuant to the second advisory agreement with Exchange Listing, dated June 20, 2022, and amended December 20, 2022,
we have agreed to pay Exchange Listing fees in the aggregate of up to $136,166 for advice in connection with communication and other
related matters leading up to, and in connection with, this offering and to issue Exchange Listing 12,500 shares of common stock
upon a successful Nasdaq listing. We have agreed to piggyback registration rights with respect to all shares issued to Exchange Listing
under both advisory agreements, including shares issuable upon exercise of the warrants.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being a Smaller Reporting Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &ldquo;smaller reporting company&rdquo; as defined in Rule 10(f)(1) of Regulation S-K. Smaller reporting companies may take
advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial
statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our
shares held by non-affiliates equals or exceeds $250 million as of the prior June 30th, or (2) our annual revenues equaled or exceeded $100 million during such completed fiscal year and the market value of our shares held by non-affiliates equals or exceeds
$700 million as of the prior June 30th. Such reduced disclosure and corporate governance obligations may make it more challenging
for investors to analyze our results of operations and financial prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information, see &ldquo;<I>Risk Factors -&thinsp;Because the Company is a &lsquo;smaller reporting company,&rsquo; we may
take advantage of certain scaled disclosures available to us, resulting in holders of our securities receiving less Company information
than they would receive from a public company that is not a smaller reporting company&rdquo; and &ldquo;As a &lsquo;smaller reporting
company&rsquo;, we may at some time in the future choose to exempt our company from certain corporate governance requirements
that could have an adverse effect on our public stockholders.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the &ldquo;JOBS
Act&rdquo;). We will remain an emerging growth company until the earlier of (1) December 31, 2024, (2) the last day of the fiscal year
in which we have total annual gross revenue of at least $1.235 billion, (3) the last day of the fiscal year in which we are deemed
to be a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;), which would occur on the date on which we have issued more than $1.0 billion in non-convertible debt securities during the
prior three-year period. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of
certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company, we
may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">present
    only two years of audited financial statements, plus unaudited condensed financial statements for any interim period, and related
    management&rsquo;s discussion and analysis of financial condition and results of operations in this prospectus;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">avail
    ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our
    internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002 (the &ldquo;Sarbanes-Oxley
    Act&rdquo;);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reduced disclosure about our executive compensation arrangements; </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    require stockholder non-binding advisory votes on executive compensation or golden parachute arrangements;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">defer
    complying with certain changes in accounting standards; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    comply with requirements of PCAOB regarding communications of critical audit matters (CAMS) in the auditor&rsquo;s report on the
    financial statements.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an emerging growth company, and under the JOBS Act, an emerging growth company can delay the adoption of certain accounting standards
until those standards would otherwise apply to private companies. We have elected not to take advantage of the extended transition period
for complying with new or revised accounting standards provided to emerging growth companies under the JOBS Act. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incorporated in Indiana on April 17, 2012, under the name Innovative Health Solutions, Inc. On March 11, 2022, we amended our Articles
of Incorporation to change our name to Neuraxis, Inc. On June 23, 2022, we changed our state of incorporation from Indiana
to Delaware.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at 11550 N. Meridian Street, Suite 325, Carmel, IN 46032, and our telephone number is (812) 689-0791.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="A1_003"></A>SUMMARY
OF THE OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuer:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities Offered:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,875,000
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, at an estimated
    public offering price between $7.00 and 9.00 per share.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-allotment option:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have granted the Underwriter a 45-day option to purchase up to a total of 281,250 shares of common stock (equal to fifteen
    percent (15%) of the aggregate number of shares of common stock sold in this offering) at the public offering price per share
    in this offering, less the underwriting discounts payable by us, solely to cover over-allotments, if any. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter&rsquo;s warrants:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have agreed to issue to Alexander Capital L.P., as the Underwriter, the Underwriter&rsquo;s Warrants to purchase a number of shares
    of common stock equal in the aggregate to six percent (6%) of the total number of shares issued in this offering. The Underwriter&rsquo;s
    Warrants will be exercisable at a per share exercise price equal to one hundred and twenty percent (120%) of the public offering
    price per share of common stock sold in this offering. The registration statement also registers the shares of common stock issuable
    upon exercise of the Underwriter&rsquo;s Warrants. The Underwriter&rsquo;s Warrants have been deemed compensation by the Financial
    Industry Regulatory Authority (&ldquo;FINRA&rdquo;) and are therefore also subject to a 180-day lock-up pursuant to FINRA Rule
    5110. Except as permitted by Rule 5110, the Underwriter (or permitted assignees under the Rule) will not sell, transfer, assign,
    pledge, or hypothecate the Underwriter&rsquo;s Warrants or the securities underlying the Underwriter&rsquo;s Warrants, nor will any
    of them engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition
    of the option or the underlying securities for a period of 180 days from the commencement of sales under this prospectus. See &ldquo;<I>Underwriting</I>&rdquo;
    for more information.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock issued and outstanding immediately before this offering (1):</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,963,321
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    stock issued and outstanding after the offering (2):</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,082,549
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
                                            estimate that the net proceeds to us from this offering will be approximately $13.3
                                            million, or approximately $14.1 million if the Underwriter exercises its over-allotment
                                            option in full, assuming an offering price of $8.00 per share (the midpoint of
                                            the price range set forth on the cover page of this prospectus), after deducting underwriting
                                            discounts and commissions and estimated offering expenses payable by us.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    intend to use the net proceeds of this offering primarily for sales and marketing activities, research and development, repayment
    of our convertible notes, certain payments to our executive officers pursuant to their respective
employment agreements, and general corporate purposes. See &ldquo;<I>Use of Proceeds</I>&rdquo; for additional information.</FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Proposed Nasdaq Capital Market Trading Symbol and
    Listing:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have applied to list our common stock on the Nasdaq Capital Market under the symbol &ldquo;NRXS&rdquo;. We believe that upon the
    effective date of the registration statement of which this prospectus forms a part, we will meet the standards for listing
    on Nasdaq. The closing of this offering is contingent upon the successful listing of our common stock on the Nasdaq Capital Market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk Factors:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See &ldquo;<I>Risk Factors</I>&rdquo;
    beginning on page 12 and the other information contained in this prospectus for a discussion of factors you should carefully consider
    before investing in our securities.</FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-up:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
    our directors, executive officers, and certain stockholders who own five percent (5%) or more of our outstanding common stock
    have agreed with the Underwriter not to offer for sale, issue, sell, contract to sell, sell any option or contract to purchase, purchase
    any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly
    or indirectly, any shares of capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares
    of capital stock of the Company, in the case of the Company for a period of 180 days after the date of this prospectus, and in the
    case of our directors and executive officers and our five percent (5%) and greater stockholders for a period of 180 days after the
    date of this prospectus, without the prior written consent of the Underwriter. See &ldquo;<I>Underwriting</I>&rdquo; for additional
    information.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(1)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>
</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0">The amount outstanding immediately
                                            before this offering includes 11,774 shares issued for convertible notes after September
                                            30, 2022.</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    total number of shares of common stock that will be outstanding after this offering is based on 1,951,547 shares of common
    stock outstanding as of September 30, 2022. Unless otherwise indicated, the shares outstanding after this offering excludes the following:
    </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">289,779
                                            shares of our common stock issuable upon exercise of warrants to purchase shares of Series
                                            A Preferred Stock converting to warrants to purchase shares of common stock.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
                                            (see &ldquo;<I>Description of Our Securities&mdash;Warrants</I>&rdquo; for more information);</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">405,962 shares of our common stock issuable upon exercise
    of warrants to purchase common stock (see &ldquo;<I>Description of Our Securities&mdash;Warrants</I>&rdquo; for more information);</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">112,500 shares of our common stock issuable upon
    exercise of the Underwriter&rsquo;s Warrants to purchase common stock;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">23,540 shares of our common stock issuable upon conversion
    of our unsecured convertible promissory notes, assuming a conversion price of $9.44 per share (see &ldquo;<I>Prospectus Summary&mdash;Recent Developments</I>&rdquo;
    for more information);</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">88,926 shares of common stock and an additional
    153,515 issuable upon exercise of warrants issuable to Exchange Listing, LLC upon the listing of our common stock on Nasdaq
    (see &ldquo;<I>Prospectus Summary&mdash;Recent Developments</I>&rdquo; for more information); and</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,319,394
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock  issuable upon exercise
of options to purchase common stock.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, this prospectus reflects and assumes no exercise by the Underwriter of its over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUMMARY
OF RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business is subject to a number of risks and uncertainties of which you should be aware before making an investment decision. You should
consider all of the information set forth in this prospectus and, in particular, the specific factors set forth under &ldquo;<I>Risk
Factors</I>&rdquo; in deciding whether to invest in our securities. These risks include, without limitation, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Business and Our Product</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    business and prospects depend entirely on our current product, IB-Stim. Even though we have received FDA clearance for our product,
    it will remain subject to ongoing regulatory review. If we are unable to maintain regulatory clearance and commercialize our product
    or are significantly delayed or limited in our commercialization efforts, our business and prospects will be materially
    harmed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    date, we have not generated any operating profits, and due to our long-term research and development efforts, we have a history of
    incurring substantial operating losses.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
    the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and
    in its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no
    assurance that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern
    is dependent upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise additional
    funds by way of a public or private offering. Neither future cash generated from operating activities, nor management&rsquo;s contingency
    plans to mitigate the risk and extend cash resources through the evaluation period, are considered probable, and therefore substantial
    doubt is deemed to exist about the Company&rsquo;s ability to continue as a going concern.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    clinical studies could be delayed or otherwise adversely affected by many factors, including difficulties in enrolling patients.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    we are unable to develop an adequate sales and marketing organization or contract with third parties to assist us, we may not be
    able to successfully commercialize our products for current and future indications.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be successful in achieving market acceptance of our products by healthcare professionals, patients and/or third-party payers
    in the timeframes we anticipate, or at all, which could have a material adverse effect on our business, prospects, financial condition
    and results of operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
    to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of our products
    and reduce our revenues.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be successful in maintaining reimbursement codes necessary to facilitate accurate and timely billing for our products or
    physician services attendant to our products.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may depend on single-source suppliers for some of our components. The loss of these suppliers could prevent or delay shipments of
    our products, delay our clinical studies or otherwise adversely affect our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quality
    control problems with respect to devices and components supplied by third-party suppliers could have a material adverse effect on
    our reputation, our clinical studies or the commercialization of our products and, as a result, a material adverse effect on our
    business, prospects, financial condition and results of operations.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continued
    testing of our products may not yield successful results and could reveal currently unknown aspects or safety hazards associated
    with our products.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    size and expected growth of our available market has not been established with precision and may be smaller than we estimate.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    physicians and patients do not accept our current and future products or if the market for indications for which any product candidate
    is approved is smaller than expected, we may be unable to generate significant revenue, if any.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
    of the specialized nature of our business, the termination of relationships with our key employees, consultants and advisors may
    prevent us from successfully operating our business, including developing our products, conducting clinical studies, commercializing
    our products and obtaining any necessary financing.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    or third-party complaints or negative reviews or publicity about our company or our products could harm our reputation and brand.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Developing
    medical technology entails significant technical, regulatory and business risks.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may not be able to compete with treatments now being marketed and developed, or which may be developed and marketed in the future
    by other companies.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Legal and Regulatory Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
    liability suits, whether or not meritorious, could be brought against us due to alleged defective devices or for the misuse of our
    products, which could result in expensive and time-consuming litigation, payment of substantial damages and/or expenses and an increase
    in our insurance rates.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices.
    Our actual or perceived failure to comply with such obligations could harm our business, and changes in such regulations or laws
    could require us to modify our products or marketing or advertising efforts.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are increasingly dependent on information technology systems and are subject to privacy and security laws. Our products and our systems
    and infrastructure face certain risks, including from cyber security breaches and data leakage.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may choose to, or may be required to, suspend, repeat or terminate our clinical studies if they are not conducted in accordance with
    regulatory requirements, the results are negative or inconclusive or the studies are not well designed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legislative
    and regulatory changes in the U.S. and in other countries regarding healthcare insurance and government-sponsored reimbursement programs
    (such as Medicare in the United States) may adversely affect our business and financial results.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    are subject to extensive post-marketing regulation by the FDA and comparable authorities in other jurisdictions, which could impact
    the sales and marketing of our products and could cause us to incur significant costs to maintain compliance. In addition, we may
    become subject to additional regulation in other jurisdictions if we market and sell our products outside of the U.S.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition to FDA requirements, we will spend considerable time and money complying with other federal, state, local and foreign rules,
    regulations and guidance and, if we are unable to fully comply with such rules, regulations and guidance, we could face substantial
    penalties.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    products may in the future be subject to recalls that could harm our reputation, business and financial results.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device
    reporting regulations, which can result in voluntary corrective actions or agency enforcement actions.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    may be subject to fines, penalties or injunctions if we are determined to be promoting the use of our products for unapproved or
    off-label uses.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    pediatrics and medical device industries are characterized by patent and other intellectual property litigation and disputes, and
    any litigation, dispute or claim against us may cause us to incur substantial costs, could place a significant strain on our financial
    resources, divert the attention of management from our business, harm our reputation and require us to remove certain devices from
    the market.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding-right: 0.1in; padding-left: 0.1in; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our devices.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intellectual
    property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our
    products.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    depend extensively on our patents and proprietary technology and the patents, and we must protect those assets in order to preserve
    our business.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    to legal and factual uncertainties regarding the scope and protection afforded by patents and other proprietary rights, we may not
    have meaningful protection from competition.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    the third parties on which we rely for the conduct of our clinical trials and results do not perform our clinical trial activities
    in accordance with good clinical practices and related regulatory requirements, we may be unable to obtain regulatory approval for
    or commercialize our product candidates.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Common Stock and This Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There has been
    no public market for our common stock prior to this offering, and an active market in which investors can resell their shares of
    our common stock may not develop.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of our
    common stock may fluctuate, and you could lose all or part of your investment.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to satisfy
    listing requirements of Nasdaq or maintain a listing of our common stock on Nasdaq.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have considerable discretion
    as to the use of the net proceeds from this offering and we may use these proceeds in ways with which you may not agree.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You will experience immediate
    and substantial dilution as a result of this offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We do not expect to declare
    or pay dividends in the foreseeable future.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If securities industry
    analysts do not publish research reports on us, or publish unfavorable reports on us, then the market price and market trading volume
    of our common stock could be negatively affected.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future issuances of our
    common stock or securities convertible into, or exercisable or exchangeable for, our common stock, or the expiration of lock-up agreements
    that restrict the issuance of new common stock or the trading of outstanding common stock, could cause the market price of our common
    stock to decline and would result in the dilution of your holdings.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our shares of common
    stock become subject to the penny stock rules, it would become more difficult to trade our shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will be subject to ongoing
    public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging growth companies
    and our stockholders could receive less information than they might expect to receive from more mature public companies.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because the Company is
    a &ldquo;smaller reporting company,&rdquo; we may take advantage of certain scaled disclosures available to us, resulting in holders
    of our securities receiving less Company information than they would receive from a public company that is not a smaller reporting
    company.</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="A1_004"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our securities involves a high degree of risk. You should carefully consider and evaluate all of the information contained in this
prospectus before you decide to purchase our common stock. The risks and uncertainties described in this prospectus are not the only
ones we may face. Additional risks and uncertainties that we do not presently know about or that we currently believe are not material
may also adversely affect our business, business prospects, results of operations or financial condition. Any of the risks and uncertainties
set forth herein, could materially and adversely affect our business, results of operations and financial condition. This could cause
the market price of our common stock to decline, perhaps significantly, and you may lose part or all of your investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Business and Our Product</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business and prospects depend entirely on our current product, IB-Stim. Even though we have received FDA clearance for our product, it
will remain subject to ongoing regulatory review. If we are unable to maintain regulatory clearance and commercialize our product or
are significantly delayed or limited in our commercialization efforts, our business and prospects will be materially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Almost
all of our revenues have been derived from sales and royalties from sales of IB-Stim, and we expect to develop, market, and sell
other neuromodulation therapy devices for the treatment of chronic and debilitating conditions in children. The commercial success of
our products and our ability to generate and maintain revenues from the sale of our products will depend on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to develop and obtain additional regulatory clearances and further commercialize our products for additional indications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to expand into new markets and future indications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    acceptance of our products by patients and the healthcare community, including physicians and third-party payers (both private and
    governmental), as therapeutically effective and safe;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accomplishment of various scientific, engineering, clinical, regulatory and other goals, which we sometimes refer to as milestones,
    on our anticipated timeline;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    relative cost, safety and efficacy of alternative therapies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to obtain and maintain sufficient coverage or reimbursement by private and governmental third-party payers and to comply
    with applicable health care laws and regulations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability of our third-party manufacturers to manufacture our products in sufficient quantities with acceptable quality;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to provide marketing, distribution and customer support for our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    potential presence of competitive products in our active indications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">results
    of future clinical studies relating to our products or other competitor products for similar indications;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance
    with applicable laws and regulatory requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    maintenance of our existing regulatory clearance; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    consequences of any reportable adverse events involving our products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the promotion of our products is limited to approved indications, which vary by geography. The labelling for our device in
the U.S. is limited in certain respects, which may limit the number of patients to whom it is prescribed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate future revenues will also depend on achieving regulatory approval of, and eventual commercialization of, our products
for additional indications and in additional geographies, which is not guaranteed. Our near-term prospects are substantially dependent
on our ability to obtain regulatory approvals on the timetable we have anticipated, and thereafter to further successfully commercialize
our products for additional indications. Regulatory changes or actions in areas in which we operate or propose to operate may further
affect our ability to obtain regulatory clearances on our anticipated timetable. If we are not able to receive such approvals, meet other
anticipated milestones, or further commercialize our products, or are significantly delayed or limited in doing so, our business and
prospects will be materially harmed and we may need to reduce expenses by delaying, reducing or curtailing the development of our products
and we may need to raise additional capital to fund our operations, which we may not be able to obtain on favorable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>To
date, we have not generated any operating profits, and due to our long-term research and development efforts, we have a history of incurring
substantial operating losses.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were founded in 2011 and have a history of incurring substantial operating losses. We anticipate continuing to incur significant
costs associated with developing and commercializing our products for approved indications including signal development, device hardware
and software development, product sales, marketing, manufacturing, and distribution expenses. We expect our research, development, and
clinical study expenses to increase in connection with our ongoing activities and as additional indications enter clinical development
and as we advance our product development. Our expenses could increase beyond expectations if, for example, we are required by the FDA,
or other regulatory agencies or similar governing bodies, to change manufacturing processes for our products or to perform clinical,
nonclinical or other types of studies in addition to those that we currently anticipate. Our revenues are dependent, in part, upon the
size of the markets in the jurisdictions in which we receive regulatory approval, the accepted price for our products and the ability
to obtain reimbursement at the accepted applicable price. If the number of addressable patients is not as significant as we or our strategic
partners and licensees estimate, the indications approved by regulatory authorities are narrower than we expect or the eligible population
for treatment is narrowed by competition, regulatory approvals, physician choice or treatment guidelines, we may not generate significant
revenues. If we are not able to generate significant revenues, we may never be sustainably profitable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
clinical studies could be delayed or otherwise adversely affected by many factors, including difficulties in enrolling patients.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing can be costly and take many years, and the outcome is uncertain and susceptible to varying interpretations. Moreover, success
in pre-clinical and early clinical studies does not ensure that large-scale studies will be successful or predict final results. Acceptable
results in early studies may not be replicable in later studies. A number of companies in therapeutics industries have suffered significant
setbacks in advanced clinical studies, even after promising results in earlier studies. Negative or inconclusive results or adverse events
or incidents during a clinical study could cause the clinical study to be redone or terminated. In addition, failure to appropriately
construct clinical studies could result in high rates of adverse events or incidents, which could cause a clinical study to be suspended,
redone or terminated. Our failure or the failure of third-party participants in our studies to comply with their obligations to follow
protocols and/or legal requirements may also result in our inability to use the affected data in our submissions to regulatory authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical studies depends, among other things, on our ability to enroll a sufficient number of patients who remain
in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical studies for a variety of reasons,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    severity of the disease under investigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    limited size and nature of the patient population;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    patient eligibility criteria defined in our protocol and other clinical study protocols;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    nature of the study protocol, including the attractiveness of, or the discomforts and risks associated with, the treatments received
    by enrolled subjects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties
    and delays in clinical studies that may occur as a result of the COVID-19 pandemic;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to obtain IRB approval at clinical study locations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&rsquo;
    and patients&rsquo; perceptions as to the potential advantages, disadvantages and side effects of our products in relation to other
    available therapies, including any new drugs or treatments that may be approved for the indications we are pursuing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
    of other clinical studies that exclude use of our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility or perception that enrolling in a product&rsquo;s clinical study may limit the patient&rsquo;s ability to enroll in future
    clinical studies for other therapies due to protocol restrictions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    possibility or perception that our software is not secure enough to maintain patient privacy;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    referral practices of physicians;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    ability to monitor patients adequately during and after treatment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    availability of appropriate clinical study investigators, support staff, drugs and other therapeutic supplies and proximity of patients
    to clinical sites;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians&rsquo;
    or our ability to obtain and maintain patient consents; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    risk that when we collaborate with a third-party for research of a product in a particular institution, we can expect to relinquish
    some or all of the control over the future success of that study to the third-party.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we have difficulty enrolling and retaining a sufficient number or diversity of patients to conduct our clinical studies as planned, or
encounter other difficulties, we may need to delay, terminate or modify ongoing or planned clinical studies, any of which would have
an adverse effect on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to develop an adequate sales and marketing organization or contract with third parties to assist us, we may not be able
to successfully commercialize our products for current and future indications.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
achieve commercial success for our products, we must compliantly develop and grow our sales and marketing organization and, as necessary,
enter into sales and distribution relationships with third parties to market and sell our products. Developing and managing a sales and
marketing organization is a difficult, expensive and time consuming process. We may not be able to successfully develop adequate sales
and marketing capabilities to achieve our growth objectives. We compete with other medical device, pharmaceutical and life sciences companies
to recruit, hire, train and retain the sales and marketing personnel that we anticipate we will need, and the nature of our products
may make it more difficult to compete for sales and marketing personnel. In addition, because our current products require, and we anticipate
our future products will require, physician training and education, our sales and marketing organization may need to grow substantially
as we expand our approved indications and markets. As a consequence, our expenses associated with building up and maintaining our sales
force and marketing capabilities may be disproportionate to the revenues we may be able to generate on sales of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to establish adequate sales and marketing capabilities or successful sales and distribution relationships, we may fail
to realize the full revenue potential of our products for current and future indications, and we may not be able to achieve the necessary
growth in a cost-effective manner or realize a positive return on our investment. In our future sales and distribution agreements with
other companies, we generally may not have control over the resources or degree of effort that any of these third parties may devote
to our products, and if they fail to devote sufficient time and resources to the marketing of our products, or if their performance is
substandard, our revenues may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
success of our business may be dependent on the actions of our collaborative partners.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy includes, in part, the consummation of collaborative arrangements with companies who will support the development and
commercialization of our products and technology. We may also enter into clinical collaborations with third parties to test our products
and technology together with other products and technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we collaborate with a third party for commercialization of a product in a particular territory, we can expect to relinquish some or all
of the control over the future success of that product to the third party in that territory. In addition, our collaborative partners
may have the right to terminate applicable agreements, including payment obligations, prior to or upon the expiration of the agreed-upon
terms. We may not be successful in establishing or maintaining collaborative arrangements on acceptable terms or at all, collaborative
partners may terminate funding before completion of projects, our products may not achieve the criteria for milestone payments, our collaborative
arrangements may not result in successful product commercialization, our products may not receive acceptable pricing and we may not derive
any revenue from such arrangements. Additionally, our collaborators may not perform their obligations as expected or in compliance with
study protocols or applicable laws. Acts or omissions by collaborators may disqualify study data for use in regulatory submissions and/or
create liability for us in the jurisdictions in which we operate. Any disagreements with collaborators, including disagreements over
proprietary rights, contract interpretation or the preferred course of commercialization, might cause delays or termination of the commercialization
of products, might lead to additional responsibilities for us with respect to commercializing products, or might result in litigation
or arbitration, any of which would be time-consuming and expensive. To the extent that we are not able to develop and maintain collaborative
arrangements, we would need to devote substantial capital to undertake commercialization activities on our own in order to further expand
our reach, and we may be forced to limit the territories in which we commercialize our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in achieving market acceptance of our products by healthcare professionals, patients and/or third-party payers
in the timeframes we anticipate, or at all, which could have a material adverse effect on our business, prospects, financial condition
and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not achieve market acceptance of our products for current or future indications within the timeframes we have anticipated, or at
all, for a number of different reasons, including the following factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    may be difficult to gain broad acceptance of our products because they are new technologies and involve a novel or derivative mechanism
    of action and, as such, physicians may be reluctant to prescribe our products without prior experience or additional data or training;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians
    may be reluctant to prescribe our products due to their perception that the supporting clinical study designs have limitations, as
    they are, for example, unblinded;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians
    at large academic universities and medical centers may prefer to enroll patients into clinical studies instead of prescribing our
    products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
    may be difficult to gain broad acceptance at community hospitals where the number of patients seeking treatment may be more limited
    than at larger medical centers, and such community hospitals may not be willing to invest in the resources necessary for their physicians
    to become trained to use our products, which could lead to reluctance to prescribe our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    may be reluctant to use our products for various reasons, including a perception that the treatment is untested or difficult to use
    or a perception that our software is not secure;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    products may have side effects and our products cannot be worn in all circumstances; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each
    patient will use more than one device and therefore, as the duration of the treatment course increases, the overall price will increase
    correspondingly and, when used in combination with other treatments, the overall cost of treatment will be greater than using a single
    type of treatment.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, our products may not achieve market acceptance for current or future indications because of the following additional factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    patient acceptance could be difficult because not all patients are willing to comply with requirements of treatment with our products,
    and other patients may forego our products for financial, privacy, cosmetic, visibility or mobility reasons;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving
    patient compliance may be difficult because the recommended use of our products is 120 hours per week for three (3) consecutive
    weeks, and not to exceed four (4) weeks, which to some extent restricts physical mobility because our products cannot be worn
    in all circumstances, and the patient or a caregiver must ensure that it remains continuously operable and this may also impact the
    pool of patients to whom physicians may be willing to prescribe our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">there
    may be certain perceived limitations to our study designs or data obtained from our clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy
    may also be limited in instances where patients take a break from the device when experiencing skin rashes, or while bathing or swimming
    (because our products should not be immersed in water); and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients
    may decline therapy or prescribers may be unwilling to prescribe our products due to certain adverse events attributable to the device
    reported in clinical studies by patients treated with our products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we are successful in achieving market acceptance of our products for IBS or other indications, we may be unsuccessful
in achieving market acceptance of our products for other indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be other factors that are presently unknown to us that also may negatively impact our ability to achieve market acceptance of our
products. If we do not achieve market acceptance of our products in the timeframes we anticipate, or are unable to achieve market acceptance
at all, our business, prospects, financial condition and results of operations could be materially adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Failure
to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of our products
and reduce our revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the majority of our revenues will come from third-party payers, primarily children&rsquo;s hospitals, either directly to
us in markets where we provide our products or plan to provide our device candidates to patients or indirectly via payments made to hospitals
or other entities providing our products or which may in the future provide our device candidates to patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., private payers cover the largest segment of the population, with the remainder either uninsured or covered by governmental
payers. The majority of the third-party payers outside the U.S. are government agencies, government sponsored entities or other payers
operating under significant regulatory requirements from national or regional governments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payers may decline to cover and reimburse certain procedures, supplies or services. Additionally, some third-party payers may decline
to cover and reimburse our products for a particular patient even if the payer has a favorable coverage policy addressing our products
or previously approved reimbursement for our products. Additionally, private and government payers may consider the cost of a treatment
in approving coverage or in setting reimbursement for the treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
and government payers are increasingly challenging the prices charged for medical products and services. Additionally, the containment
of healthcare costs has become a priority of governments. Adoption of additional price controls and cost-containment measures, and adoption
of more restrictive policies in jurisdictions with existing controls and measures, could further limit our revenues and operating results.
If third-party payers do not consider our products or the combination of our products with additional treatments to be cost-justified
under a required cost-testing model, they may not cover our products for their populations or, if they do, the level of reimbursement
may not be sufficient to allow us to sell our products on a profitable basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimbursement
for the treatment of patients with medical devices is governed by complex mechanisms. These mechanisms vary widely among countries, can
be informal, somewhat unpredictable, and evolve constantly, reflecting the efforts of these countries to reduce public spending on healthcare.
As a result, obtaining and maintaining reimbursement for the treatment of patients with medical devices has become more challenging.
We cannot guarantee that the use of our products will receive reimbursement approvals and cannot guarantee that our existing reimbursement
approvals will be maintained in any country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to secure or maintain adequate coverage or reimbursement for our products by third-party payers in the U.S. or in the other jurisdictions
in which we market our products could have a material adverse effect on our business, revenues and results of operations and cause our
stock price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be successful in maintaining reimbursement codes necessary to facilitate accurate and timely billing for our products or physician
services attendant to our products</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payers, healthcare systems, government agencies or other groups often issue reimbursement codes to facilitate billing for products and
physician services used in the delivery of healthcare. Our technology specific CAT III CPT Code (0720T) was published on
December 30, 2021 and effective on July 1, 2022. We may not be able to maintain the CPT code for physician services related to our products.
Our future revenues and results may be affected by the absence of CPT codes, as physicians may be less likely to prescribe the therapy
when there is no certainty that adequate reimbursement will be available for the time, effort, skill, practice expense and malpractice
costs required to provide the therapy to patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the U.S., we have not secured codes to describe our products or to document physician services related to the delivery of therapy using
our products. The failure to obtain and maintain these codes could affect the future growth of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may depend on single-source suppliers for some of our components. The loss of these suppliers could prevent or delay shipments of our
products, delay our clinical studies or otherwise adversely affect our business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
certain jurisdictions, we may source some of the components of our products from only a single vendor. If any one of these single-source
suppliers were to fail to continue to provide components to us on a timely basis, or at all, our business and reputation could be harmed.
We will seek and maintain second-source suppliers, but we can provide no assurance that we will secure or maintain such suppliers. We
have developed or are in the process of developing and obtaining regulatory approval for second sources for components in all jurisdictions.
Various steps must be taken before securing these suppliers, including qualifying these suppliers in accordance with regulatory requirements,
but we may never receive such approvals. The risks associated with the failure of our suppliers to comply with strictly enforced regulatory
requirements as described below are exacerbated by our dependence on single-source suppliers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience any deficiency in the quality of, delay in or loss of availability of any components supplied to us by third-party suppliers,
or if we switch suppliers or components, we may face additional regulatory delays and the manufacture and delivery of our products would
be interrupted for an extended period of time, which could materially adversely affect our business, prospects, financial condition and
results of operations. If we are required to obtain prior regulatory approval from the FDA or regulatory authorities or similar governing
bodies in other jurisdictions or to conduct a new conformity assessment procedure for our products, regulatory approval for our products
may not be received on a timely basis, or at all, which would have a material adverse effect on our business, prospects, financial condition
and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Quality
control problems with respect to devices and components supplied by third-party suppliers could have a material adverse effect on our
reputation, our clinical studies or the commercialization of our products and, as a result, a material adverse effect on our business,
prospects, financial condition and results of operations</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products, which are manufactured by third parties, are highly technical and are required to meet exacting specifications. Any quality
control problems that we experience with respect to the devices and components supplied by third-party suppliers could have a material
adverse effect on our reputation, our attempts to complete our clinical studies, our operating expenses or the commercialization of our
products. The failure of our suppliers to comply with strictly enforced regulatory requirements could expose us to regulatory action,
including warning letters, product recalls, suspension or termination of distribution, product seizures or civil penalties. If we experience
any delay in the receipt or deficiency in the quality of products supplied to us by third-party suppliers, or if we have to switch to
replacement suppliers, we may face additional regulatory delays and the manufacture and delivery of our products would be interrupted
for an extended period of time, which would materially adversely affect our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently do not own a manufacturing facility and rely on a sole manufacturer for the production of our product</I></B>. <B><I>Any
significant disruption to the sole manufacturer&rsquo;s operations or facilities could have a material adverse effect on our business,
financial condition and results of operations</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on a sole manufacturer for the production of our products. We do not have control over the operations of the facilities of the third-party
manufacturer that we use. A significant disruption to our manufacturer could have a material adverse effect on our business, financial
condition and results of operations. Our reliance on our manufacturer poses a number of risks, including lack of control over the manufacturing
process and ultimately over the quality and timing of delivery of our product. A change in our relationship with our manufacturer could
result in a material adverse effect on our business, financial condition and results of operations. A decision to change manufacturers
would result in longer times for design and production as we secure any necessary licenses or clearances, develop quality control measures,
and implement manufacturing processes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Continued
testing of our products may not yield successful results and could reveal currently unknown aspects or safety hazards associated with
our products</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development programs are designed to test the safety and efficacy of our products through extensive pre-clinical and clinical
testing. Even if our ongoing and future pre-clinical and clinical studies are completed as planned, we cannot be certain that their results
will support our claims or that the FDA and other regulatory authorities will agree with our conclusions. Success in pre-clinical studies
and early clinical studies does not ensure that later clinical studies will be successful, and we cannot be sure that the later studies
will replicate the results of prior studies and pre-clinical studies. The clinical study process may fail to demonstrate that our device
candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a device candidate and may delay development
of others. It is also possible that patients enrolled in clinical studies will experience adverse side effects that have not been previously
observed. In addition, our pre-clinical and clinical studies for our device candidates involve a relatively small patient population
and, as a result, these studies may not be indicative of future results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent further commercialization
of our products, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-clinical
    and clinical testing for our products may not produce the desired effect, may be inconclusive or may not be predictive of safety
    or efficacy results obtained in future clinical studies, following long-term use or in much larger populations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    adverse events or other side effects that are not currently known may occur during our clinical studies that may preclude additional
    regulatory approval or result in additional limitations to commercial use if approved; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    data collected from our clinical studies may not reach statistical significance or otherwise not be sufficient to support FDA or
    other regulatory approval.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
unacceptable side effects arise in the development of our products for future indications, we could suspend or terminate our clinical
studies or the FDA or other regulatory authorities could order us to cease clinical studies or deny approval of our device candidates
for any or all targeted indications, narrow the approved indications for use or otherwise require restrictive product labeling or marketing
or require further clinical studies, which may be time-consuming and expensive and may not produce results supporting FDA or other regulatory
approval of our products in a specific indication. Treatment-related side effects could also affect patient recruitment or the ability
of enrolled patients to complete the study or result in potential product liability claims. In addition, these side effects may not be
appropriately recognized or managed by the treating medical staff. We expect to have a need to train medical personnel using our devices
for clinical studies and upon any commercialization of our products for future indications. Inadequate training in recognizing or managing
the potential side effects of our products could result in patient injury or death. Any of these occurrences may harm our business, prospects
and financial condition significantly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or termination of our clinical studies will delay the filing of submissions for regulatory approvals of our products and ultimately
our ability to commercialize our products and generate revenues. Furthermore, we may abandon our products for indications that we previously
believed to be promising. Any of these events could have a material adverse effect on our business, prospects, financial condition and
results of operations and cause our stock price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
we expand, we may experience difficulties managing our growth</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
anticipated growth will place a significant strain on our management and on our operational and financial resources and systems. We could
face challenges inherent in efficiently managing a more complex business with an increased number of employees over large geographic
distances, including the need to implement appropriate systems, policies, benefits and compliance programs. Failure to manage our growth
effectively could materially adversely affect our business. Additionally, our anticipated growth will increase the demands placed on
our third-party suppliers, resulting in an increased need to carefully monitor the available supply of components and services and to
scale up our quality assurance programs. There is no guarantee that our suppliers will be able to support our anticipated growth. Any
failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization
goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
size and expected growth of our available market has not been established with precision and may be smaller than we estimate.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
data on the available market for our current products and future products is based on a number of internal and third-party research reports,
estimates and assumptions. While we believe that such research, our assumptions and the data underlying our estimates are reasonable,
these assumptions and estimates may not be correct. In addition, the statements in this prospectus relating to, among other things, the
expected growth in the market for our IB-Stim are based on a number of internal and third-party data, estimates and assumptions, and
may prove to be inaccurate. If the actual number of consumers who would benefit from our products, the price at which we can sell future
products or the available market for our products is smaller than we estimate, it could have a material adverse effect on our business,
financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
physicians and patients do not accept our current and future products or if the market for indications for which any product candidate
is approved is smaller than expected, we may be unable to generate significant revenue, if any.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
when any of our product candidates obtain regulatory approval, they may not gain market acceptance among physicians, patients, and third-party
payers. Physicians may decide not to recommend our treatments for a variety of reasons including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing
    of market introduction of competitive products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration
    of clinical safety and efficacy compared to other products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effectiveness;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited
    or no coverage by third-party payers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">convenience
    and ease of administration;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevalence
    and severity of adverse side effects;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    in the label of the device;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other
    potential advantages of alternative treatment methods; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffective
    marketing and distribution support of its products.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates is approved but fails to achieve market acceptance or such market is smaller than anticipated, we may not
be able to generate significant revenue and our business would suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Because
of the specialized nature of our business, the termination of relationships with our key employees, consultants and advisors may prevent
us from successfully operating our business, including developing our products, conducting clinical studies, commercializing our products
and obtaining any necessary financing</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on the members of our executive team, the loss of whose services may adversely impact the achievement of our objectives.
While we have entered into employment agreements with each of our key executives, any of them could leave our employment at any time.
We do not have &ldquo;key person&rdquo; insurance on any of our employees. The loss of the services of one or more of our current employees
might impede the achievement of our business objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competition for qualified personnel in the medical device fields is intense, and we rely heavily on our ability to attract and retain
qualified scientific, technical and managerial personnel. Our future success depends upon our ability to attract, retain and motivate
highly skilled employees. In order to commercialize our products successfully, we will be required to expand our workforce, particularly
in the areas of research and development and clinical studies, sales and marketing and supply chain management. These activities will
require the addition of new personnel and the development of additional expertise by existing management personnel. We face intense competition
for qualified individuals from numerous pharmaceutical, biopharmaceutical and biotechnology companies, as well as academic and other
research institutions. We may not be able to attract and retain these individuals on acceptable terms or at all. Failure to do so could
materially harm our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Customer
or third-party complaints or negative reviews or publicity about our company or our products could harm our reputation and brand.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are heavily dependent on customers who use our IB-Stim device to provide good reviews and word-of-mouth recommendations to contribute
to our growth. Customers who are dissatisfied with their experiences with our products or services may post negative reviews. We may
also be the subject of blog, forum or other media postings that include inaccurate statements and/or create negative publicity. In addition,
any negative news regarding similar products may adversely impact our business. Any negative reviews or publicity, whether real or perceived,
disseminated by word-of-mouth, by the general media, by electronic or social networking means or by other methods, could harm our reputation
and brand and could severely diminish consumer confidence in our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Adverse
global economic conditions could have a negative effect on our business, results of operations and financial condition and liquidity.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
general slowdown in the global economy, including a recession, or in a particular region or industry, an increase in trade tensions with
U.S. trading partners, inflation or a tightening of the credit markets could negatively impact our business, financial condition and
liquidity. Adverse global economic conditions have from time to time caused or exacerbated significant slowdowns in the industries and
markets in which we operate, which have adversely affected our business and results of operations. Macroeconomic weakness and uncertainty
also make it more difficult for us to accurately forecast revenue, gross profit and expenses, and may make it more difficult to
raise or refinance debt. Sustained uncertainty about, or worsening of, current global economic conditions and further escalation of trade
tensions between the U.S. and its trading partners, could result in a global economic slowdown and long-term changes to global trade.
Such events may also (i) cause our customers and consumers to reduce, delay or forgo spending, (ii) result in customers sourcing products
from other suppliers not subject to such restrictions or tariffs, (iii) lead to the insolvency or consolidation of key suppliers and
customers, and (iv) intensify pricing pressures. Any or all of these factors could negatively affect demand for our products and our
business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
economic conditions in certain regions may also be affected by natural disasters and public health emergencies, such as extreme weather
events, and could have a significant adverse effect on our business, including interruption of our commercial and clinical operations,
supply chain disruption, endangerment of our personnel, fewer patient visits, increased patient drop-out rates, delays in recruitment
of new patients, and other delays or losses of materials and results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
COVID-19 pandemic could materially adversely impact our business</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the COVID-19 pandemic continues around the globe, we have experienced and will likely continue to experience disruptions that could severely
impact our business and clinical studies, which could include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    and/or difficulties in onboarding active patients and enrolling patients in our clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    and/or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site
    staff;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">declines
    in prescriptions written due to a perception that our products are difficult to administer remotely or if patients are unwilling
    to travel to treatment sites or receive in-home treatment assistance from us or other caregivers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reductions
    in third-party reimbursements, which could materially affect our revenue, as most of our patients rely on third-party payers to cover
    the cost of our products and a material number of our patients could lose access to their private health insurance plan if they or
    someone in their family lose their job;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion
    of healthcare resources away from conducting clinical studies, including the diversion of hospitals serving as our clinical study
    sites and hospital staff supporting the conduct of our clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    of key clinical study activities, such as clinical study site monitoring, due to limitations on travel imposed or recommended by
    federal or state governments, employers and others;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">staff
    disruptions and turnover internally and at treatment sites and third-party providers who provide support, either directly as a result
    of illness or indirectly as a result of vaccine mandates and other changes in terms of employment;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in receiving approval from local regulatory authorities or IRBs to initiate our planned clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in clinical sites receiving the supplies and materials needed to conduct our clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption
    in shipping that may affect the transport of active patient and clinical study materials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in local regulations as part of a response to the COVID-19 outbreak that may require us to change the ways in which our clinical
    studies are conducted, which may result in unexpected costs, or to discontinue the clinical studies altogether;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
    in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations
    in employee resources or forced furlough of government employees;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
    of our supply chain as our suppliers and common carriers are unable to meet our requirements to provide us the materials we need
    for clinical study and active patient care needs;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">indirect
    consequences of the COVID-19 pandemic on the economy in general, such as an increase in bankruptcies of our key suppliers, or the
    inability of our third-party payers to meet their obligations reimburse us in a timely fashion or at all;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">postponements
    and cancellations of key conferences and meetings and travel restrictions could interfere with our ability to interact with key thought
    leaders in the field, leading to a disruption in the rate of adoption of our technology;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">access
    restrictions at offices, hospitals, and treatment centers, and stakeholder illness could interfere with the ability of our sales
    force to engage in face-to-face visits with providers, leading to a disruption in the rate of adoption of our technology;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases
    in expenditures for technology and other tools necessary to provide patient care in an environment where both patient and care-giver
    travel is restricted and access to in-person interaction is limited;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    of the FDA to accept data from clinical studies in affected geographies outside the United States; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    delays in seeking or receiving treatment, either due to fear of infection or lack of access to treatment and study sites, leading
    to fewer diagnoses of the indications our products are approved to treat or more advanced procession of the disease, which may contraindicate
    the use of our products or disqualify the patient from participating in a given study.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global status of the COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic may impact our business and clinical
studies will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate
geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing guidelines, business closures
or business disruptions and the effectiveness of actions taken to contain and treat the disease. The response to the pandemic may result
in permanent changes to the environment in which we operate as described above in ways we are unable to predict. The COVID-19 pandemic
may also have the effect of heightening many of the other risks described herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Developing
medical technology entails significant technical, regulatory and business risks</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may fail to adapt our technology to user requirements or emerging treatment standards. Neuromodulation therapies are not currently considered
standard of care for IBS and may not ever be considered standard of care. Treatment standards may not evolve to incorporate our product.
New industry standards for the development, manufacture and marketing of medical devices may evolve and we may not be able to conform
to the changes, meet new standards in a timely fashion or maintain a competitive position in the market. In particular, regulatory standards
for electrical treatments of medical conditions are evolving. If we face material delays in introducing our products and new technology,
we may fail to attract new customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
Company has an evolving business strategy and investors must be willing to accept a substantial degree of uncertainty.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s strategic focus is on the development of developing neuromodulation therapies to address chronic and debilitating conditions
in children. The Company may engage in ongoing discussions with potential licensees, other strategic partners and institutional or private
financing sources, the result of which could add to or alter its current strategic focus, cash needs or ownership structure. Investors
must be willing to accept a substantial degree of uncertainty and must be willing to rely upon the Company&rsquo;s board of directors
and management to complete an appropriate business strategy to commercially exploit targeted business opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to compete with treatments now being marketed and developed, or which may be developed and marketed in the future by
other companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products will compete with existing and new therapies and treatments for chronic and debilitating conditions in children. We are aware
of a number of companies currently seeking to develop alternative therapies or treatment for such diseases and conditions at least in
part. Numerous pharmaceutical, biotechnology, drug delivery and medical device companies, hospitals, research organizations, individual
scientists, and nonprofit organizations are engaged in the development of alternatives to our technology. Some of these companies have
greater research and development capabilities, experience, manufacturing, marketing, financial, and managerial resources than we do.
Collaborations or mergers between large pharmaceutical or biotechnology companies with competing treatment technologies could enhance
our competitors&rsquo; financial, marketing, and other resources. Developments by other medical device companies could make our products
or technologies uncompetitive or obsolete. Accordingly, our competitors may succeed in developing competing technologies, obtaining FDA
clearances and/or approval for products or gaining market acceptance more rapidly than we can.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Due
in part to our limited financial resources, we may fail to select or capitalize on the most scientifically, clinically or commercially
promising or profitable indications or therapeutic areas for our product candidates, and/or we may be unable to pursue the clinical trials
that we would like to pursue.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited technical, managerial, and financial resources to determine the indications on which we should focus the development efforts
related to our product candidates. Due to our limited available financial resources, we may have curtailed clinical development programs
and activities that might otherwise have led to more rapid progress of our product candidates through the regulatory and development
processes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may make incorrect determinations with regard to the indications and clinical trials on which to focus the available resources that we
do have. Furthermore, we cannot assure you that we will be able to retain adequate staffing levels to run our operations and/or to accomplish
all of the objectives that we otherwise would seek to accomplish. Our decisions to allocate our research, management, and financial resources
toward particular indications or therapeutic areas for our product candidates may not lead to the development of viable commercial products
and may divert resources from better opportunities. Similarly, our decisions to delay or terminate product development programs may also
cause us to miss valuable opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have material weaknesses in our internal control over financing reporting. If we fail to establish and maintain proper and effective
internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements
on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control over financial
reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements in accordance with generally accepted accounting principles. Prior to this offering, due to accounting resource
constraints, we have had limited review controls. These constraints have resulted in (1) a lack of segregation of duties, since we have
a limited administrative staff, and (2) lack of internal controls structure review. As a result of these constraints, we have a material
weakness in our internal control over financing reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is composed of a small number of individuals resulting in a situation where limitations on segregation of duties exist.  All responsibility for accounting entries and the
creation of financial statements is held by a single person, though the Company  engages multiple accounting consultants for accounting, tax and audit support. To remedy this situation, we would need to hire
additional staff or financial consultant support. Currently, we are unable to hire additional staff to facilitate greater segregation
of duties but will reassess our capabilities after completion of the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, we intend to begin the process of documenting, reviewing and improving our internal controls and procedures
for compliance with Section 404 of the Sarbanes-Oxley Act, which will require annual management
assessment of the effectiveness of our internal control over financial reporting. To comply with the requirements of being a public company,
the Company has undertaken various actions, and will take additional actions, such as remediating the material weaknesses described above,
implementing additional internal controls and procedures and hiring internal audit staff or financial consultants. Testing and maintaining
internal controls can divert our management&rsquo;s attention from other matters that are important to the operation of our business.
Additionally, when evaluating internal controls over financial reporting, the Company may identify additional material weaknesses that
it may not be able to remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements of Section
404 of the Sarbanes-Oxley Act. If the Company identifies any additional material weaknesses in its internal control over financial reporting
or is unable to remediate the material weakness described above or comply with the requirements of Section 404 of the Sarbanes-Oxley
Act in a timely manner or if the Company&rsquo;s independent registered public accounting firm is unable to express an unqualified opinion
as to the effectiveness of our internal control over financial reporting once it is no longer an emerging growth company, or if the Company
is unable to conclude in our quarterly and annual reports that our disclosure controls and procedures are effective, investors may lose
confidence in the accuracy and completeness of the Company&rsquo;s financial reports and the market price of our Common Stock could be
negatively affected, and the Company could become subject to investigations by the stock exchange on which our securities are listed,
the SEC or other regulatory authorities, which could require additional financial and management resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Company fails to remediate any material weakness, including the material weaknesses described above, our financial statements
could be inaccurate and the Company could face restricted access to capital markets. Our small size and internal control deficiencies
may adversely affect our financial condition, results of operation and access to capital. <FONT STYLE="background-color: white">Moreover,
our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well
designed and operated, can provide only reasonable, not absolute, assurance that the control system&rsquo;s objectives will be met. Because
of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to
error or fraud will not occur or that all control issues and instances of fraud will be detected.</FONT> If we cannot provide reliable
financial reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment
existed, and our business and reputation with investors may be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I></I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>We restated our previously issued financial statements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We determined that a restatement of our December
31, 2021 audited financial statements was required after discussions among management and our independent registered public account firm,
Rosenberg Rich Baker Berman, P.A., for certain disclosures that have been expanded or have added clarifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
should consult with a tax expert before investing in our Company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should consult with your own tax advisor about the tax consequences of investing in the Company through the purchase of its securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Legal and Regulatory Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Product
liability suits, whether or not meritorious, could be brought against us due to alleged defective devices or for the misuse of our products,
which could result in expensive and time-consuming litigation, payment of substantial damages and/or expenses and an increase in our
insurance rates</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our current or future devices are defectively designed or manufactured, contain defective components or are misused, or if someone claims
any of the foregoing, whether or not meritorious, we may become subject to substantial and costly litigation. For example, we may be
sued if our products cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing,
marketing or sale. This may occur if our products are misused or damaged, have a sudden failure or malfunction (including with respect
to safety features) or are otherwise impaired due to wear and tear. Even absent a product liability suit, malfunctions of our products
or misuse by physicians or patients would need to be remedied swiftly in order to maintain continuous use and ensure efficacy of our
products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent
in the device, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection
acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required
to limit commercialization of our products. Even successful defense may require significant financial and management resources. Regardless
of the merits or eventual outcome, liability claims may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased
    demand for our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury
    to our reputation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
    of clinical study participants and inability to continue clinical studies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation
    of investigations by regulators;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs
    to prepare for and defend the related litigation;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    diversion of management&rsquo;s time and our resources;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial
    monetary awards to study participants or patients;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    recalls, withdrawals or labeling, marketing or promotional restrictions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
    of revenues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exhaustion
    of any available insurance and our capital resources;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability to commercialize any device candidate; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a
    decline in our share price.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
liability claims could divert management&rsquo;s attention from our core business, be expensive to defend and result in sizable damage
awards against us. We may not have sufficient insurance coverage for all claims. Any product liability claims brought against us, with
or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, could harm our
reputation in the industry and could reduce revenues. Product liability claims in excess of our insurance coverage would be paid out
of cash reserves, if any, which could have a material adverse effect on our business, prospects, financial condition and results of operations
and cause our stock price to decline. Even if our agreements with our third-party manufacturers and suppliers entitle us to indemnification
against losses, such indemnification may not be available or adequate should any claim arise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
future litigation and regulatory actions could have a material adverse impact on the Company</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be subject to litigation and other legal and regulatory proceedings relating to our business or investigations or
other actions by governmental agencies. No assurances can be given that the results of these or new matters will be favorable to us.
An adverse resolution of lawsuits, arbitrations, investigations or other proceedings or actions could have a material adverse effect
on our financial condition and results of operations, including as a result of non-monetary remedies. Defending ourselves in these matters
may be time-consuming, expensive and disruptive to normal business operations and may result in significant expense and a diversion of
management&rsquo;s time and attention from the operation of our business, which could impede our ability to achieve our business objectives.
Additionally, any amount that we may be required to pay to satisfy a judgment, settlement, fine or penalty may not be covered by insurance.
Subject to the Delaware General Corporation Law, our certificate of incorporation permit us to indemnify any director against any liability,
to purchase and maintain insurance against any liability for any director and to provide any director with funds (whether by loan or
otherwise) to meet expenditures incurred or to be incurred by such director in defending any criminal, regulatory or civil proceedings
or in connection with an application for relief (or to enable any such director to avoid incurring such expenditure). In addition, under
our Articles of Incorporation and bylaws (the &ldquo;Bylaws&rdquo;) we are obligated to indemnify each of our directors and officers
against certain liabilities and expenses arising from their being a director or officer to the maximum extent permitted by Delaware law.
In the event we are required to make such payments to our directors and officers, there can be no assurance that any of these payments
will not be material.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our
actual or perceived failure to comply with such obligations could harm our business, and changes in such regulations or laws could require
us to modify our products or marketing or advertising efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the marketing or advertisement of our products, we could be the target of claims relating to false, misleading, deceptive
or otherwise noncompliant advertising or marketing practices, including under the auspices of the FTC and state consumer protection statutes.
If we rely on third parties to provide any marketing and advertising of our products, we could be liable for, or face reputational harm
as a result of, their marketing practices if, for example, they fail to comply with applicable statutory and regulatory requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have breached any consumer protection, advertising, unfair competition or other laws or regulations, we may be subject
to enforcement actions that require us to change our marketing and business practices in a manner that may negatively impact us. This
could also result in litigation, fines, penalties and adverse publicity that could cause reputational harm and loss of customer trust,
which could have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are increasingly dependent on information technology systems and are subject to privacy and security laws. Our products and our systems
and infrastructure face certain risks, including from cyber security breaches and data leakage</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
increasingly rely upon technology systems and infrastructure. Our technology systems, including our products, are potentially vulnerable
to breakdown or other interruption by fire, power loss, system malfunction, unauthorized access and other events. Likewise, data privacy
breaches by employees and others with both permitted and unauthorized access to our products and our systems may pose a risk that protected
patient information (&ldquo;PI&rdquo;) may be exposed to unauthorized persons or to the public, or may be permanently lost. The increasing
use and evolution of technology, including cloud-based computing, creates additional opportunities for the unintentional dissemination
of information, intentional destruction of confidential information stored in our systems or in non-encrypted portable media or storage
devices. We could also experience a business interruption, information theft of confidential information, or reputational damage from
industrial espionage attacks, malware or other cyber incidents, which may compromise our system infrastructure or lead to data leakage,
either internally or at our third-party service providers or other business partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
size and complexity of our computer systems, and scope of our geographic reach, make us potentially vulnerable to information technology
system breakdowns, internal and external malicious intrusion, cyberattacks and computer viruses. Because the techniques used to obtain
unauthorized access, or to sabotage systems, change frequently and generally are not recognized until launched against a target, we may
be unable to anticipate these techniques or to implement adequate preventative measures. If we do not allocate and effectively manage
the resources necessary to build and sustain the proper technology infrastructure or properly manage third-party contractors who perform
data management services on our behalf, then a security breach could subject us to, among other things, transaction errors, business
process inefficiencies, the loss of customers, damage to our reputation, business disruptions or the loss of or damage to intellectual
property. Such security breaches could expose us to a risk of loss of information, litigation, penalties, remediation costs and potentially
significant liability to customers, employees, business partners and regulatory authorities, including, for example, under the Health
Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;) in the United States and Regulation 2016/679 on the protection
of natural persons with regard to the processing of personal data and on the free movement of such data under GDPR in the EU. If our
data management systems (including third party data management systems) do not effectively collect, secure, store, process and report
relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies, or human
error, our ability to effectively plan, forecast and execute our business plan and comply with applicable laws and regulations will be
impaired. Any such impairment could materially and adversely affect our financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we have invested heavily in the protection of data and information technology and in related training, there can be no assurance that
our efforts will prevent significant breakdowns, breaches in our systems or other cyber incidents or ensure compliance with all applicable
security and privacy laws, regulations, and standards, including with respect to third-party service providers that utilize sensitive
personal information, including PI, on our behalf.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
security breach, whether of our products, systems or third-party hosting services we utilize, could disrupt treatments being provided
by our products, disrupt access to our customers&rsquo; stored information, such as patient treatment data and health information, and
could lead to the loss of, damage to or public disclosure of such data and information, including patient health information. Such an
event could have serious negative consequences, including possible patient injury, regulatory action, fines, penalties and damages, reduced
demand for our products, an unwillingness of customers to use our products, harm to our reputation and brand and time-consuming and expensive
litigation, any of which could have a material adverse effect on our financial results. We currently carry cyber and privacy liability
insurance with an aggregate limit of $1,000,000, but the amount of insurance coverage that we purchased and may purchase in the future
may be inadequate. In the future, our insurance coverage may be expensive or not be available on acceptable terms or in sufficient amounts,
if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may choose to, or may be required to, suspend, repeat or terminate our clinical studies if they are not conducted in accordance with
regulatory requirements, the results are negative or inconclusive or the studies are not well designed</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
studies must be conducted in accordance with the FDA&rsquo;s cGCPs and the equivalent laws and regulations applicable in other jurisdictions
in which the clinical studies are conducted. The clinical studies are subject to oversight by the FDA, regulatory agencies in other jurisdictions,
ethics committees and institutional review boards at the medical institutions where the clinical studies are conducted. In addition,
clinical studies must be conducted with device candidates produced under the FDA&rsquo;s QSR and in accordance with the applicable regulatory
requirements in the other jurisdictions in which the clinical studies are conducted. The conduct of clinical studies may require large
numbers of test patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or regulatory agencies in other jurisdictions might delay or terminate our clinical studies of a device candidate for various reasons,
including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    device candidate may have unforeseen adverse side effects or may not appear to be more effective than current therapies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
    may not agree with the FDA, a regulatory authority in another jurisdiction or an ethics committee regarding the protocol for the
    conduct of a clinical study;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">new
    therapies may become the standard of care while we are conducting our clinical studies, which may require us to revise or amend our
    clinical study protocols or terminate a clinical study; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fatalities
    may occur during a clinical study due to medical problems that may or may not be related to clinical study treatments.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the process of obtaining and maintaining regulatory approvals in the U.S. and other jurisdictions is lengthy, expensive and uncertain.
It can vary substantially, based on the type, complexity and novelty of the product involved. Accordingly, any of our device candidates
could take a significantly longer time than we expect to, or may never, gain regulatory approval, which could have a material adverse
effect on our business, prospects, financial condition and results of operations and cause our stock price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Legislative
and regulatory changes in the U.S. and in other countries regarding healthcare insurance and government-sponsored reimbursement programs
(such as Medicare in the United States) may adversely affect our business and financial results</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely to a material degree on highly regulated private and government-run health insurance programs for our revenue in most of the countries
in which we operate. The laws and regulations regarding health care programs, both public and private, are driven by public policy considerations
that may be unrelated to the direct provision of patient care, such as lowering costs or requiring or limiting access to healthcare options.
These laws and regulations are very complicated and there are many requirements we must satisfy in order for our products to become and
remain eligible for reimbursement under these programs. In many cases we may have limited negotiating power when negotiating reimbursement
rates for our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, lawmakers and regulators could also pass additional healthcare laws and implement other regulatory changes at both the national
and local levels. These laws and regulations could potentially affect coverage and reimbursement for our products. However, we cannot
predict the ultimate content, timing or effect of any future healthcare initiatives or the impact any future legislation or regulation
will have on us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to countries outside the U.S., the national competent authorities in the EU member states, the UK, Switzerland, Israel, Japan,
and other jurisdictions are also increasingly active in their goal of reducing public spending on healthcare. We cannot, therefore, guarantee
that the treatment of patients with our products would be reimbursed in any particular country or, if successfully included on reimbursement
lists, whether we will remain on such lists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are subject to extensive post-marketing regulation by the FDA and comparable authorities in other jurisdictions, which could impact the
sales and marketing of our products and could cause us to incur significant costs to maintain compliance. In addition, we may become
subject to additional regulation in other jurisdictions if we market and sell our products outside of the U.S</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
market and sell our products subject to extensive regulation by the FDA and numerous other federal, state and governmental authorities
in other jurisdictions. These regulations are broad and relate to, among other things, the conduct of pre-clinical and clinical studies,
product design, development, manufacturing, labeling, testing, product storage and shipping, premarket clearance and approval, conformity
assessment procedures, premarket clearance and approval of modifications introduced in marketed products, post-market surveillance and
monitoring, reporting of adverse events and incidents, pricing and reimbursement, interactions with healthcare professionals, interactions
with patients, information security, advertising and promotion and product sales and distribution. Although IB-Stim already has market
clearance from FDA for functional abdominal pain associated with IBS in children, we will require additional FDA clearances to market
our products for treating other indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, before our products can be marketed in the EU, our products must obtain a CE Certificate from a notified body. New intended
uses of CE marked medical devices falling outside the scope of the current CE Certificate require a completely new conformity assessment
before the device can be CE marked and marketed in the EU for the new intended use. The process required to gather necessary information
and draw up documentation in order to obtain CE Certification of a medical device in the EU can be expensive and lengthy and its outcome
can be uncertain. We may make modifications to our products in the future that we believe do not or will not require notifications to
our notified body or new conformity assessments to permit the maintenance of our current CE Certificate. If the competent authorities
of the EU member states or our notified body disagree and require the conduct of a new conformity assessment, the modification of the
existing CE Certificate or the issuance of a new CE Certificate, we may be required to recall or suspend the marketing of the modified
versions of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Japan, new medical devices or new therapeutic uses of medical devices falling outside the scope of the existing approval by the MHLW
require a new assessment and approval for each such new device or use. Accordingly, we may be required to obtain a new approval from
MHLW before we launch a modified version of our products or the use of our products for additional indications. Approval time frames
from the MHLW vary from simple notifications to review periods of one or more years, depending on the complexity and risk level of the
device. In addition, importation into Japan of medical devices is subject to &ldquo;Quality Management System (QMS) Ordinance,&rdquo;
which includes the equivalent of &ldquo;Good Import&rdquo; regulations in the U.S. As with any highly regulated market, significant changes
in the regulatory environment could adversely affect our ability to commercialize our products in Japan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S. and other jurisdictions, we also are subject to numerous post-marketing regulatory requirements, which include regulations under
the QSR related to the manufacturing of our products, labeling regulations and medical device reporting regulations, which require us
to report to the FDA or comparable regulatory authorities in other jurisdictions and our notified body if our products cause or contributes
to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury. In addition,
these regulatory requirements may in the future change in a way that adversely affects us. If we fail to comply with present or future
regulatory requirements that are applicable to us, we may be subject to enforcement action by the FDA or comparable regulatory authorities
in other jurisdictions and notified bodies, which may include any of the following sanctions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled
    letters, warning letters, fines, injunctions, consent decrees and civil penalties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated
    expenditures to address or defend such actions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient
    notification, or orders for repair, replacement or refunds;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary
    or mandatory recall, withdrawal or seizure of our current or future devices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">administrative
    detention by the FDA or other regulatory authority in another jurisdiction of medical devices believed to be adulterated or misbranded;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions, suspension or shutdown of production;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    or delay of our requests for approval for new intended uses for or modifications to our products or for approval of new devices;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    or delay in obtaining CE Certificates for new intended uses for or modifications to our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension,
    variation or withdrawal of the CE Certificates granted by our notified body in the EU;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibition
    or restriction of products being placed on the market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating
    restrictions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of approvals that have already been granted;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to grant export approval for our products or any device candidates; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
    prosecution.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of these events could have a material adverse effect on our business, prospects, financial condition and results of
operations and cause our stock price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Over
time, we expect to make modifications to our products that are designed to improve efficacy, reduce side effects, enhance the user experience
or for other purposes. Modifications to our products may require approvals, modified or new CE Certificates and analogous regulatory
approvals in other jurisdictions or even require us to cease promoting or to recall the modified versions of our products until such
clearances, approvals or modified or new CE Certificates are obtained, and the FDA, comparable regulatory authorities in other jurisdictions
or our notified body may not agree with our conclusions regarding whether new approvals are required</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any substantial change introduced to a medical device or to the quality system certified by our notified body requires a new
conformity assessment of the device and can lead to changes to the CE Certificates or the preparation of a new CE Certificate of Conformity.
Substantial changes may include, among others, the introduction of a new intended use of the device, a change in its design or a change
in the Company&rsquo;s suppliers. Responsibility for determination that a modification constitutes a substantial change lies with the
manufacturer of the medical device. We must inform the notified body that conducted the conformity assessment of the products we market
or sell in the EU of any planned substantial changes to our quality system or changes to our products that could, among other things,
affect compliance with the MDR or the devices&rsquo; intended use. The notified body will then assess the changes and verify whether
they affect the product&rsquo;s conformity with the Essential Requirements laid down in Annex I to the MDD or the conditions for the
use of the device. If the assessment is favorable, the notified body will issue a new CE Certificate or an addendum to the existing CE
Certificate attesting compliance with the Essential Requirements laid down in Annex I to the MDD. There is a risk that the competent
authorities of the EU member states or our notified body may disagree with our assessment of the changes introduced to our products.
The competent authorities of the EU member states or our notified body also may come to a different conclusion than the FDA on any given
product modification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, medical devices that have obtained a CE Certification under the MDD may in principle continue to be marketed under such CE
Certificate until the CE Certificate expires and at the latest until May 27, 2024, provided that the manufacturer complies with the MDR&rsquo;s
additional requirements related to post-marketing surveillance, market surveillance, vigilance, and registration of economic operators
and of devices. However, if such medical devices undergo a significant change in their design or intended use, we would need to obtain
a new CE Certificate under the MDR for these devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA disagrees with us and requires us to submit a new application for then-existing modifications and/or the competent authorities
of the EU member states or our notified body disagree with our assessment of the change introduced in a product, its design or its intended
use, we may be required to cease promoting or to recall the modified product until we obtain approval and/or until a new conformity assessment
has been conducted in relation to the product, as applicable. In addition, we could be subject to significant regulatory fines or other
penalties. Furthermore, our products could be subject to recall if the FDA, comparable regulatory authorities in other jurisdictions,
or our notified body determine, for any reason, that our products are not safe or effective or that appropriate regulatory submissions
were not made. Any recall or requirement that we seek additional approvals or clearances could result in significant delays, fines, increased
costs associated with modification of a product, loss of revenues and potential operating restrictions imposed by the FDA, comparable
foreign regulatory authorities in other jurisdictions, or our notified body. Delays in receipt or failure to receive approvals/certification,
or the failure to comply with any other existing or future regulatory requirements, could reduce our sales, profitability and future
growth prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>In
addition to FDA requirements, we will spend considerable time and money complying with other federal, state, local and foreign rules,
regulations and guidance and, if we are unable to fully comply with such rules, regulations and guidance, we could face substantial penalties</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to extensive regulation by the U.S. federal government and the states and other countries in which we conduct our business.
U.S. federal government healthcare laws apply when we submit a claim on behalf of a U.S. federal healthcare program beneficiary, or when
a customer submits a claim for an item or service that is reimbursed under a U.S. federal government-funded healthcare program, such
as Medicare or Medicaid. The laws that affect our ability to operate our business in addition to the Federal Food, Drug, and Cosmetic
Act and FDA regulations include, but are not limited to, the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    U.S. federal Anti-Kickback Statute, an intent-based federal criminal statute which prohibits knowingly and willfully offering, providing,
    soliciting or receiving remuneration of any kind to induce or reward, or in return for, referrals or the purchase, lease, order or
    recommendation or arranging of any items or services reimbursable by a federal healthcare program;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Federal Civil False Claims Act, which imposes civil penalties, including through civil whistleblower or &ldquo;qui tam&rdquo; actions,
    for knowingly submitting or causing the submission of false or fraudulent claims of payment to the federal government, knowingly
    making, using or causing to be made or used a false statement or record material to payment of a false claim or avoiding, decreasing
    or concealing an obligation to pay money to the federal government;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Federal Criminal False Claims Act, which is similar to the Federal Civil False Claims Act and imposes criminal liability on those
    that make or present a false, fictitious or fraudulent claim to the federal government;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicare
    laws and regulations that prescribe requirements for coverage and reimbursement, and laws prohibiting false claims or unduly influencing
    selection of products for reimbursement under Medicare and Medicaid;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">healthcare
    fraud statutes that prohibit false statements and improper claims to any third-party payer;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Federal Physician Self-Referral Law, commonly known as the Stark law, which, absent an applicable exception, prohibits physicians
    from referring Medicare and Medicaid patients to an entity for the provision of certain designated health services (&ldquo;DHS&rdquo;),
    if the physician (or a member of the physician&rsquo;s immediate family) has an impermissible financial relationship with that entity
    and prohibits the DHS entity from billing for such improperly referred services;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Federal Beneficiary Anti-Inducement Statute, which prohibits the offering of any remuneration to a beneficiary of Medicare or Medicaid
    that is likely to influence that beneficiary&rsquo;s choice of provider or supplier. This can include, but is not limited to, inappropriate
    provision of patient services including financial assistance. Recent government investigations have focused on this particular prohibition.
    There are established exceptions from liability, but we cannot guarantee that all of our practices will fall squarely within those
    exceptions;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 94%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the U.S. Foreign
    Corrupt Practices Act, which can be used to prosecute companies in the U.S. for arrangements with physicians or other parties outside
    the U.S. if the physician or party is a government official of another country and the arrangement violates the law of that country;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Federal Trade Commission
    Act, the Lanham Act and similar federal and state laws regulating truthfulness in advertising and consumer protection; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Federal Physician Payments
    Sunshine Act, the French Sunshine Act and similar state and foreign laws, which require periodic reporting of payments and other
    transfers of value made to U.S. and French-licensed physicians, teaching hospitals, and in the U.S., physician assistants, nurse
    practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
laws exist in the EU, individual EU member states and other countries. These laws are complemented by EU or national professional codes
of practices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
provides data privacy and security provisions for safeguarding medical information. Additionally, states in the U.S. are enacting local
privacy laws (e.g., California). In the EU, the GDPR harmonizes data privacy laws and rules on the processing of personal data, including
patient and employee data, across the EU. The GDPR has a number of strict data protection and security requirements for companies processing
data of EU residents, including when such data is transferred outside of the EU. Additionally, we need to comply with analogous privacy
laws in other jurisdictions in which we operate, such as the Israeli Privacy Protection Law, the Asia Pacific Economic Cooperation Privacy
Framework, and Japan&rsquo;s Act on the Protection of Personal Information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws and codes of practices applicable to us are subject to evolving interpretations. Moreover, certain U.S. federal and state laws regarding
healthcare fraud and abuse and certain laws in other jurisdictions regarding interactions with healthcare professionals and patients
are broad and we may be required to restrict certain of our practices to be in compliance with these laws. Healthcare fraud and abuse
laws also are complex and even minor, inadvertent irregularities, or even the perception of impropriety, can potentially give rise to
claims that a statute has been violated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
violation of these laws could have a material adverse effect on our business, prospects, financial condition and results of operations
and cause our stock price to decline. Similarly, if there is a change in law, regulation or administrative or judicial interpretations,
we may have to change our business practices or our existing business practices could be challenged as unlawful, which likewise could
have a material adverse effect on our business, prospects, financial condition and results of operations and cause our stock price to
decline. Fines and penalties for violations of these laws and regulations could include severe criminal and civil penalties, including,
for example, significant monetary damages, exclusion from participation in the federal healthcare programs and permanent disbarment of
key employees. Any penalties, damages, fines, curtailment or restructuring of our operations would adversely affect our ability to operate
our business, our prospects and our financial results. In addition, any action against us for violation of these laws, even if we successfully
defend against it, could cause us to incur significant legal expenses, divert our management&rsquo;s attention from the operation of
our business and damage our reputation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, although we believe that we have the required licenses, permits and accreditation to dispense our products in the future, a
regulator could find that we need to obtain additional licenses or permits. We also may be subject to mandatory reaccreditation and other
requirements in order to maintain our billing privileges. Failure to satisfy those requirements could cause us to lose our privileges
to bill governmental and private payers. If we are required to obtain permits or licenses that we do not already possess, we also may
become subject to substantial additional regulation or incur significant expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure compliance with Medicare, Medicaid and other regulations, federal and state governmental agencies and their agents, including
MACs, may conduct audits of our operations to support our claims submitted for reimbursement of items furnished to beneficiaries and
health care providers. Depending on the nature of the conduct found in such audits and whether the underlying conduct could be considered
systemic, the resolution of these audits could adversely impact our revenue, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we, our collaborative partners, our contract manufacturers or our component suppliers fail to comply with the FDA&rsquo;s QSR or equivalent
regulations established in other countries, the manufacturing and distribution of our products could be interrupted, and our product
sales and results of operations could suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
our collaborative partners, our contract manufacturers and our component suppliers are required to comply with the FDA&rsquo;s QSR and
the equivalent quality system requirements imposed by the laws and regulations in other jurisdictions, which are a complex regulatory
framework that covers the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging,
sterilization, storage and shipping of our products. We cannot assure you that our facilities or our contract manufacturers&rsquo; or
component suppliers&rsquo; facilities would pass any future quality system inspection. If our or any of our contract manufacturers&rsquo;
or component suppliers&rsquo; facilities fails a quality system inspection, the manufacturing or distribution of our products could be
interrupted and our operations disrupted. Failure to take adequate and timely corrective action in response to an adverse quality system
inspection could force a suspension or shutdown of our packaging and labeling operations or the manufacturing operations of our contract
manufacturers, and lead to suspension, variation or withdrawal of our regulatory approvals or a recall of our products. If any of these
events occurs, we may not be able to provide our customers with our products on a timely basis, our reputation could be harmed and we
could lose customers, any or all of which could have a material adverse effect on our business, prospects, financial condition and results
of operations and cause our stock price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
products may in the future be subject to recalls that could harm our reputation, business and financial results</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and similar governmental authorities in other jurisdictions have the authority to require the recall of commercialized products in
the event of material deficiencies or defects in design or manufacture. In the case of the FDA, the authority to require a recall must
be based on an FDA finding that there is a reasonable probability that the device would cause serious injury or death. In addition, governmental
bodies in other jurisdictions have the authority to require the recall of our products in the event of material deficiencies or defects
in design or manufacture. Distributors and manufacturers may, under their own initiative, recall a product if any material deficiency
in a device is found. A government-mandated or voluntary recall by us or one of our manufacturers could occur as a result of component
failures, manufacturing errors, design or labeling defects or other deficiencies and issues. The FDA requires that certain classifications
of recalls be reported to the FDA within ten working days after the recall is initiated. Requirements for the reporting of product recalls
to the competent authorities are imposed in other jurisdictions in which our products are or would be marketed in the future. Companies
are required to maintain certain records of recalls, even if they are not reportable to the FDA or to the competent authorities of other
countries. In the future, we may initiate voluntary recalls involving our products that we determine do not require notification of the
FDA or to other equivalent non-U.S. authorities. If the FDA or the equivalent non-U.S. authorities disagree with our determinations,
they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively
affect our sales. In addition, the FDA and the equivalent non-U.S. authorities could take enforcement action if we fail to report the
recalls when they were conducted. Recalls of our products would divert managerial and financial resources and could have a material adverse
effect on our business, prospects, financial condition and results of operations and cause our stock price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device
reporting regulations, which can result in voluntary corrective actions or agency enforcement actions</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDA Medical Device Reporting regulations and the equivalent regulations applicable in other jurisdictions in which our products are
or may be marketed in the future, medical device manufacturers are required to report to the FDA and to the equivalent non-U.S. authorities
information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would
likely cause or contribute to death or serious injury if the malfunction of the device or one of our similar devices were to recur. If
we fail to report these events to the FDA or to the equivalent authorities in other jurisdictions within the required time frames, or
at all, the FDA or the equivalent authorities in other jurisdictions could take enforcement action against us. Any such adverse event
involving our products also could result in future voluntary corrective actions, such as recalls or customer notifications, or agency
action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves
in a lawsuit, will require the dedication of our time and capital, distract management from operating our business, and may harm our
reputation and financial results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to fines, penalties or injunctions if we are determined to be promoting the use of our products for unapproved or off-label
uses</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices may be marketed only for the indications for which they are approved. Our promotional materials and training materials must comply
with FDA regulations and other applicable laws and regulations governing the promotion of our products in the U.S. and other jurisdictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA or the competent authorities in other jurisdictions determine that our promotional materials or training constitutes promotion
of an unapproved use, they could request that we modify our training or promotional materials or subject us to regulatory or enforcement
actions, including the issuance of an untitled or warning letter, an injunction, seizure, civil fines and criminal penalties. It is also
possible that authorities in other federal, state or national enforcement in other jurisdictions might take action if they consider our
promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties
under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged
and the commercialization of our products could be impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are affected by and subject to environmental laws and regulations that could be costly to comply with or that may result in costly liabilities</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to environmental laws and regulations, including those that impose various environmental controls on the manufacturing, transportation,
storage, use and disposal of hazardous chemicals and other materials used in, and hazardous waste produced by, the manufacturing of our
products. We incur and expect to continue to incur costs to comply with these environmental laws and regulations. Additional or modified
environmental laws and regulations, including those relating to the manufacture, transportation, storage, use and disposal of materials
used to manufacture our products or restricting disposal or transportation of batteries, may be imposed that may result in higher costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we cannot predict the effect that additional or modified environmental laws and regulations may have on us, our third-party
suppliers of equipment and our products or our customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
pediatrics and medical device industries are characterized by patent and other intellectual property litigation and disputes, and any
litigation, dispute or claim against us may cause us to incur substantial costs, could place a significant strain on our financial resources,
divert the attention of management from our business, harm our reputation and require us to remove certain devices from the market</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
a product infringes a patent or violates other intellectual property rights involves complex legal and factual issues, the determination
of which is often uncertain. Any intellectual property dispute, even a meritless or unsuccessful one, would be time consuming and expensive
to defend and could result in the diversion of our management&rsquo;s attention from our business and result in adverse publicity, the
disruption of research and development and marketing efforts, injury to our reputation and loss of revenues. Any of these events could
negatively affect our business, prospects, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert that our products, the methods employed in the use of our products or other activities infringe on their patents.
Such claims may be made by competitors seeking to obtain a competitive advantage or by other parties, many of whom have significantly
larger intellectual property portfolios than we have. Additionally, in recent years, individuals and groups have begun purchasing intellectual
property assets for the purpose of making claims of infringement and attempting to extract settlements from companies like ours. With
respect to our current products, the risk of infringement claims is exacerbated by the fact that there are numerous issued and pending
patents relating to the treatment of cancer. Because patent applications can take many years to issue, and in many cases remain unpublished
for many months after filing, there may be applications now pending of which we are unaware that may later result in issued patents that
our products may infringe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
could also be existing patents that one or more components of our products or other device candidates may inadvertently infringe. As
the number of competitors in the market or other device candidates grows, the possibility of inadvertent patent infringement by us or
a patent infringement claim against us increases. To the extent we gain greater market visibility, our risk of being subject to such
claims is also likely to increase. If a third party&rsquo;s patent was upheld as valid and enforceable and we were found to be infringing,
we could be prevented from making, using, selling, offering to sell or importing our products or other device candidates, unless we were
able to obtain a license under that patent or to redesign our systems to avoid infringement. A license may not be available at all or
on terms acceptable to us, and we may not be able to redesign our products to avoid any infringement. Modification of our products or
development of device candidates to avoid infringement could require us to conduct additional clinical studies and to revise our filings
with the FDA and other regulatory bodies, which would be time-consuming and expensive. If we are not successful in obtaining a license
or redesigning our devices, we may be unable to make, use, sell, offer to sell or import our devices and our business could suffer. We
may also be required to pay substantial damages and undertake remedial activities, which could cause our business to suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to claims alleging that we infringe or violate other intellectual property rights, such as copyrights or trademarks,
may have to defend against allegations that we misappropriated trade secrets, and may face claims based on competing claims of ownership
of our intellectual property. The confidentiality and assignment of inventions agreements that our employees, consultants and other third
parties sign may not in all cases be enforceable or sufficient to protect our intellectual property rights. In addition, we may face
claims from third parties based on competing claims to ownership of our intellectual property.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may employ individuals who were previously employed at other medical device companies, and as such we may be subject to claims that such
employees have inadvertently or otherwise used or disclosed the alleged trade secrets or other proprietary information of their former
employers. Any such litigation, dispute or claim could be costly to defend and could subject us to substantial damages, injunctions or
other remedies, which could have a material adverse effect on our business, prospects, financial condition and results of operations
and cause our stock price to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Changes
in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our devices</I></B><I>.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other medical device companies, our success is heavily dependent on our intellectual property rights, and particularly
on our patent rights. Obtaining and enforcing patents in the medical device industry involves both technological and legal complexity,
and is therefore costly, time consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently implementing
wide-ranging patent reform legislation. Certain U.S. Supreme Court rulings have narrowed the scope of patent protection available in
certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard
to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents
once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents
could change in unpredictable ways that could further negatively impact the value of our patents, narrow the scope of available patent
protection or weaken the rights of patent owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
regulatory action remains uncertain.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in a highly regulated and evolving environment with rigorous regulatory enforcement. Any legal or regulatory action could be
time-consuming and costly. If we or the manufacturers or distributors that supply our products fail to comply with all applicable laws,
standards, and regulations, action by the FDA or other regulatory agencies could result in significant restrictions, including restrictions
on the marketing or use of the products we sell or the withdrawal of the products we sell from the market. Any such restrictions or withdrawals
could materially affect our reputation, business and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
product candidates will remain subject to ongoing regulatory review even after they receive marketing clearances, and if we fail to comply
with continuing regulations, we could lose these clearances and the sale of any of our approved commercial products could be suspended.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
as we received regulatory clearance to market the IB-Stim, the manufacturing, labeling, packaging, adverse event reporting, storage,
advertising, promotion, and record keeping related to IB-Stim will remain subject to extensive regulatory requirements. If we fail to
comply with the regulatory requirements of the FDA and other applicable domestic and foreign regulatory authorities or discover any previously
unknown problems with any approved product, manufacturer, or manufacturing process, we could be subject to administrative or judicially
imposed sanctions, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
    on the products, manufacturers, or manufacturing processes;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
    letters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
    or criminal penalties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
    seizures or detentions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">pressure
    to initiate voluntary product recalls;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
    or withdrawal of regulatory clearances and/or approvals; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
    to approve pending applications for marketing clearances and/or approval of new products or supplements to approved applications.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Intellectual
property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
therapeutic medical device and pharmaceutical industries are characterized by extensive intellectual property litigation and, from time
to time, we may become the subject of claims of infringement or misappropriation. Regardless of outcome, such claims are expensive to
defend and divert management and operating personnel from other business issues. A successful claim or claims of patent or other intellectual
property infringement against us could result in payment of significant monetary damages and/or royalty payments or negatively impact
our ability to sell current or future products in the affected category.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 40; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend extensively on our patents and proprietary technology and the patents, and we must protect those assets in order to preserve our
business.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we expect to seek patent protection for any devices, <I>in silico</I> products (if any), systems, and processes we discover and/or for
any specific use we discover for new or previously known compounds, devices, biologics, products, systems, or processes, any or all of
these may not be subject to effective patent protection. In addition, our issued patents may be declared invalid or our competitors may
find ways to avoid the claims in the patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend, in part, on our ability to obtain patents, protect our trade secrets and proprietary knowledge and operate without
infringing on the proprietary rights of others. We are the sole assignee of numerous granted United States patents, pending United States
patent applications and international patents. The patent position of pharmaceutical and biotechnology firms like us are generally highly
uncertain and involves complex legal and factual questions, resulting in both an apparent inconsistency regarding the breadth of claims
allowed in United States patents and general uncertainty as to their legal interpretation and enforceability. Accordingly, patent applications
assigned to us may not result in patents being issued, any issued patents assigned to us may not provide us with competitive protection
or may be challenged by others, and the current or future granted patents of others may have an adverse effect on our ability to do business
and achieve profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
others may independently develop similar products, may duplicate our products, or may design around our patent rights. In addition, as
a result of the assertion of rights by a third-party or otherwise, we may be required to obtain licenses to patents or other proprietary
rights of others in or outside of the United States. Any licenses required under any such patents or proprietary rights may not be made
available on terms acceptable to us, if at all. If we do not obtain such licenses, we could encounter delays in product market introductions
during our attempts to design around such patents or could find that the development, manufacture or sale of products requiring such
licenses is foreclosed. In addition, we could incur substantial costs in defending suits brought against us or in connection with patents
to which we hold licenses or in bringing suit to protect our own patents against infringement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Due
to legal and factual uncertainties regarding the scope and protection afforded by patents and other proprietary rights, we may not have
meaningful protection from competition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
long-term success will substantially depend upon our ability to protect our proprietary technologies from infringement, misappropriation,
discovery and duplication, and avoid infringing the proprietary rights of others. Our patent rights and the patent rights of biotechnology
and pharmaceutical companies in general, are highly uncertain and include complex legal and factual issues. Because of this, our pending
patent applications may not be granted. These uncertainties also mean that any patents that we own or will obtain in the future could
be subject to challenge, and even if not challenged, may not provide us with meaningful protection from competition. Due to our financial
uncertainties, we may not possess the financial resources necessary to enforce our patents. Patents already issued to us or our pending
applications may become subject to dispute, and any dispute could be resolved against us. Because a substantial number of patents have
been issued in the field of neuromodulation therapy and because patent positions can be highly uncertain and frequently involve complex
legal and factual questions, the breadth of claims obtained in any application or the enforceability of our patents cannot be predicted.
Consequently, we do not know whether any of our pending or future patent applications will result in the issuance of patents or, to the
extent patents have been issued or will be issued, whether these patents will be subject to further proceedings limiting their scope,
will provide significant proprietary protection or competitive advantage, or will be circumvented or invalidated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
because of these legal and factual uncertainties, and because pending patent applications are held in secrecy for varying periods in
the United States and other countries, even after reasonable investigation, we may not know with certainty whether any products that
we (or a licensee) may develop will infringe upon any patent or other intellectual property right of a third party. We believe that the
patents that we own or have applied for do not infringe any third-party patents; however, we cannot know for certain whether we could
successfully defend our position, if challenged. We may incur substantial costs if we are required to defend our intellectual property
in patent suits brought by third parties. These legal actions could seek damages and seek to enjoin testing, manufacturing and marketing
of the accused product or process. In addition to potential liability for significant damages, we could be required to obtain a license
to continue to manufacture or market the accused product or process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
the third parties on which we rely for the conduct of our clinical trials and results do not perform our clinical trial activities in
accordance with good clinical practices and related regulatory requirements, we may be unable to obtain regulatory approval for or commercialize
our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may use independent clinical investigators and other third-party service providers to conduct and/or oversee the clinical trials of our
product candidates for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA requires us and our clinical investigators to comply with regulations and standards, commonly referred to as good clinical practices,
for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate,
and that the trial participants are adequately protected. Our reliance on third parties that we do not control does not relieve us of
these responsibilities and requirements. Third parties may not complete activities on schedule or may not conduct our clinical trials
in accordance with regulatory requirements or the respective trial plans and protocols. The failure of these third parties to carry out
their obligations could delay or prevent the development, approval, and commercialization of our product candidates or result in enforcement
action against us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Common Stock and this Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
has been no public market for our common stock prior to this offering, and an active market in which investors can resell their shares
of our common stock may not develop.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has been no public market for our common stock. We have applied to list our common stock on Nasdaq under the
symbol &ldquo;NRXS.&rdquo; The closing of this offering is contingent upon the successful listing of our common stock on the Nasdaq Capital
Market. There is no guarantee that Nasdaq, or any other exchange or quotation system, will permit our common stock to be listed and traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if our common stock is approved for listing on Nasdaq, a liquid public market for our common stock may not develop. The initial public
offering price for our common stock has been determined by negotiation between us and the Underwriter based upon several factors, including
prevailing market conditions, our historical performance, estimates of our business potential and earnings prospects, and the market
valuations of similar companies. The price at which the common stock is traded after this offering may decline below the initial public
offering price, meaning that you may experience a decrease in the value of your common stock regardless of our operating performance
or prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Volatility
in the</I></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I> market price of our common
stock may prevent investors from being able to sell their common stock at or above the initial public offering price.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
this offering, the market price for our common stock is likely to be volatile, in part because our shares have not been traded publicly.
In addition, the market price of our common stock may fluctuate significantly in response to several factors, most of which we cannot
control, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actual
    or anticipated variations in our periodic operating results;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">actual or anticipated changes in our growth rate relative
    to our competitors;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases
    in market interest rates that lead investors of our common stock to demand a higher investment return;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in earnings estimates;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
    in market valuations of similar companies;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    or announcements by our competitors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    market reaction to any increased indebtedness we may incur in the future;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">sales of our common stock by our officers, directors,
    or significant stockholders;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">additions
    or departures of key personnel;</FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our progress toward
    developing our products;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the commencement, enrollment
    and results of our future clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse results from,
    delays in or termination of our clinical trials;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse regulatory decisions,
    including failure to receive regulatory approval;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">publication of research
    reports about us or our industry or positive or negative recommendations or withdrawal of research coverage by securities analysts,
    if any;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">perceptions about the
    market acceptance of our products and the recognition of our brand;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">threatened or actual
    litigation and governmental investigations;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions
    by stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">speculation
    in the media, online forums, or investment community; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    intentions and ability to list our common stock on Nasdaq and our subsequent ability to maintain such listing.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
public offering price of our common stock has been determined by negotiations between us and the underwriter based upon many factors
and may not be indicative of prices that will prevail following the closing of this offering. In addition, the stock market in general,
and the stock of early-stage companies like ours in particular, has experienced extreme price and volume fluctuations that have often
been unrelated or disproportionate to the operating performance of these companies. Such rapid and substantial price volatility, including
any stock run-up, may be unrelated to our actual or expected operating performance, financial condition or prospects, making it difficult
for investors to assess the rapidly changing value of our stock. Volatility in the market price of our common stock may prevent investors
from being able to sell their common stock at or above the initial public offering price. As a result, you may suffer a loss on your
investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> <B><I>Certain recent initial public offerings
of companies with relatively small public floats comparable to our anticipated&nbsp;public&nbsp;float&nbsp;have experienced extreme volatility
that was seemingly unrelated to the underlying performance of the respective company. Our common stock may potentially experience rapid
and substantial price volatility, which may make it difficult for prospective investors to assess the value of our common stock.</I></B>&nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> In addition to the risks addressed above under
&ldquo;<I>Volatility in the market price of our common stock may prevent investors from being able to sell their common stock at or above
the initial public offering price</I>,&rdquo; our common stock may be subject to rapid and substantial price volatility. We may experience
extreme stock price volatility unrelated to our actual or expected operating performance, financial condition or prospects, making it
difficult for prospective investors to assess the rapidly changing value of our ordinary shares. Recently, there have been instances
of extreme stock price run-ups followed by rapid price declines and strong stock price volatility with a number of recent initial public
offerings, especially among companies with relatively smaller public floats. As a relatively small-capitalization company with relatively
small&nbsp;public&nbsp;float, we may experience greater stock price volatility, extreme price run-ups, lower trading volume and less
liquidity than large-capitalization companies. In particular, our common stock may be subject to rapid and substantial price volatility,
low volumes of trades and large spreads in bid and ask prices. Such volatility, including any stock-run up, may be unrelated to our actual
or expected operating performance, financial condition or prospects, making it difficult for prospective investors to assess the rapidly
changing value of our common stock. Because of the&nbsp;low&nbsp;public&nbsp;float&nbsp;and the absence of any significant trading volume,
the reported prices may not reflect the price at which you would be able to sell shares if you want to sell any shares you own or buy
shares if you wish to buy share. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> In addition, if the trading volumes of our
shares of common stock are low, persons buying or selling in relatively small quantities may easily influence prices of our shares of
common stock. This low volume of trades could also cause the price of our common stock to fluctuate greatly, with large percentage changes
in price occurring in any trading day session. Holders of our common stock may also not be able to readily liquidate their investment
or may be forced to sell at depressed prices due to low volume trading. Broad market fluctuations and general economic and political
conditions may also adversely affect the market price of our common stock. As a result of this volatility, investors may experience losses
on their investment in our common stock. A decline in the market price of our common stock also could adversely affect our ability to
issue additional shares of common stock or other securities and our ability to obtain additional financing in the future. No assurance
can be given that an active market in our common stock will develop or be sustained. If an active market does not develop, holders of
our common stock may be unable to readily sell the shares they hold or may not be able to sell their shares at all. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to satisfy listing requirements of Nasdaq or maintain a listing of our common stock on Nasdaq.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our common stock is listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq&rsquo;s
listing requirements, or if we fail to meet any of Nasdaq&rsquo;s listing standards, our common stock may be delisted. In addition, our
board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of
such listing. A delisting of our common stock from Nasdaq may materially impair our stockholders&rsquo; ability to buy and sell our common
stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting
of our common stock could significantly impair our ability to raise capital and the value of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have considerable discretion as to the use of the net proceeds from this offering and we may use these proceeds in ways with which you
may not agree.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to use the proceeds from this offering for working capital, sales and marketing activities, research and development, and repayment
of our convertible notes. However, we have considerable discretion in the application of the proceeds. Because of the number and variability
of factors that will determine our use of our net proceeds from this offering, their ultimate use may vary substantially from their currently
intended use. You will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately.
You must rely on the judgment of our management regarding the application of the net proceeds of this offering. The net proceeds may
be used for corporate or other purposes with which you do not agree or that do not improve our profitability or increase our share price.
The net proceeds from this offering may also be placed in investments that do not produce income or that lose value. Please see &ldquo;<I>Use
of Proceeds</I>&rdquo; below for more information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>You
will experience immediate and substantial dilution as a result of this offering.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, our net tangible book value was approximately $(6.4) million, or approximately $(3.28) per share.
Since the effective price per share of our common stock being offered in this offering is substantially higher than the net tangible
book value per share of our common stock, you will suffer substantial dilution with respect to the net tangible book value of the common
stock you purchase in this offering. Based on the assumed public offering price of $8 per share of common stock being sold in
this offering, which is the midpoint of the estimated offering range set forth on the cover page of this prospectus, and our net tangible
book value per share as of September 30, 2022, if you purchase shares of common stock in this offering, you will suffer immediate and
substantial dilution of $5.95 per share (or $5.64 per share if the Underwriter exercises the over-allotment option in full)
with respect to the net tangible book value of the common stock. See the section titled &ldquo;<I>Dilution</I>&rdquo; for a more detailed
discussion of the dilution you will incur if you purchase securities in this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not expect to declare or pay dividends in the foreseeable future.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to declare or pay dividends in the foreseeable future, as we anticipate that we will invest future earnings in the development
and growth of our business. Therefore, holders of our common stock will not receive any return on their investment unless they sell their
securities, and holders may be unable to sell their securities on favorable terms or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
securities industry analysts do not publish research reports on us, or publish unfavorable reports on us, then the market price and market
trading volume of our common stock could be negatively affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
trading market for our common stock may be influenced in part by any research reports that securities industry analysts publish about
us. We do not currently have and may never obtain research coverage by securities industry analysts. If no securities industry analysts
commence coverage of us, the market price and market trading volume of our common stock could be negatively affected. In the event we
are covered by analysts, and one or more of such analysts downgrade our securities, or otherwise reports on us unfavorably, or discontinues
coverage of us, the market price and market trading volume of our common stock could be negatively affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
issuances of our common stock or securities convertible into, or exercisable or exchangeable for, our common stock, or the expiration
of lock-up agreements that restrict the issuance of new common stock or the trading of outstanding common stock, could cause the market
price of our common stock to decline and would result in the dilution of your holdings.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
issuances of our common stock or securities convertible into, or exercisable or exchangeable for, our common stock, or the expiration
of lock-up agreements that restrict the issuance of new common stock or the trading of outstanding common stock, could cause the market
price of our common stock to decline. We cannot predict the effect, if any, of future issuances of our securities, or the future expirations
of lock-up agreements, on the price of our common stock. In all events, future issuances of our common stock would result in the dilution
of your holdings. In addition, the perception that new issuances of our securities could occur, or the perception that locked-up parties
will sell their securities when the lock-ups expire, could adversely affect the market price of our common stock. In connection with
this offering, we will enter into a lock-up agreement that prevents us, subject to certain exceptions, from offering additional shares
of capital stock for up to six months after the closing of this offering, as further described in the section titled &ldquo;<I>Underwriting</I>.&rdquo;
In addition to any adverse effects that may arise upon the expiration of these lock-up agreements, the lock-up provisions in these agreements
may be waived, at any time and without notice. If the restrictions under the lock-up agreements are waived, our common stock may become
available for resale, subject to applicable law, including without notice, which could reduce the market price for our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
issuances of debt securities, which would rank senior to our common stock upon our bankruptcy or liquidation, and future issuances of
preferred stock, which could rank senior to our common stock for the purposes of dividends and liquidating distributions, may adversely
affect the level of return you may be able to achieve from an investment in our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may attempt to increase our capital resources by offering debt securities. Upon bankruptcy or liquidation, holders of
our debt securities, and lenders with respect to other borrowings we may make, would receive distributions of our available assets prior
to any distributions being made to holders of our common stock. Moreover, if we issue preferred stock, the holders of such preferred
stock could be entitled to preferences over holders of common stock in respect of the payment of dividends and the payment of liquidating
distributions. Because our decision to issue debt or preferred stock in any future offering, or borrow money from lenders, will depend
in part on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any
such future offerings or borrowings. Holders of our common stock must bear the risk that any future offerings we conduct or borrowings
we make may adversely affect the level of return, if any, they may be able to achieve from an investment in our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally
equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized
for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions
in such securities is provided by the exchange or system. If we do not retain a listing on Nasdaq or another national securities exchange
and if the price of our common stock is less than $5.00, our common stock could be deemed a penny stock. The penny stock rules require
a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure
document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny
stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable
investment for the purchaser and receive (i) the purchaser&rsquo;s written acknowledgment of the receipt of a risk disclosure statement;
(ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement.
These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and
therefore stockholders may have difficulty selling their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will be subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not emerging
growth companies, and our stockholders could receive less information than they might expect to receive from more mature public
companies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the completion of this offering, we will be required to publicly report on an ongoing basis as an &ldquo;emerging growth company&rdquo;
(as defined in the JOBS Act) under the reporting rules set forth under the Exchange Act. For so long as we remain an emerging growth
company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other Exchange Act reporting
companies that are not emerging growth companies, including but not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    permitted to comply with reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements;
    and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being
    exempt from the requirement to hold a non-binding advisory vote on executive compensation and stockholder approval of any golden
    parachute payments not previously approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to take advantage of these reporting exemptions until we are no longer an emerging growth company. We would remain an emerging
growth company for up to five years, although if the market value of our common stock that is held by non-affiliates exceeds $700 million
as of any June 30 before that time, we would cease to be an emerging growth company as of the following December 31.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we will be subject to ongoing public reporting requirements that are less rigorous than Exchange Act rules for companies that are not
emerging growth companies, our stockholders could receive less information than they might expect to receive from more mature public
companies. We cannot predict if investors will find our common stock less attractive if we elect to rely on these exemptions, or if taking
advantage of these exemptions would result in less active trading or more volatility in the price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Because
the Company is a &ldquo;smaller reporting company,&rdquo; we may take advantage of certain scaled disclosures available to us, resulting
in holders of our securities receiving less Company information than they would receive from a public company that is not a smaller reporting
company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &ldquo;smaller reporting company&rdquo; as defined in the Exchange Act. As a smaller reporting company, we may take advantage of
certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures
for so long as (i) our common stock held by non-affiliates is less than $250 million measured on the last business day of our
second fiscal quarter, or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and our common
stock held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter. To the
extent we take advantage of any reduced disclosure obligations, it may make it harder for investors to analyze the Company&rsquo;s results
of operations and financial prospectus in comparison with other public companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a smaller reporting company, we are permitted to comply with scaled-back disclosure obligations in our SEC filings compared to other
issuers, including with respect to disclosure obligations regarding executive compensation in our periodic reports and proxy statements.
We have elected to adopt the accommodations available to smaller reporting companies. Until we cease to be a smaller reporting company,
the scaled-back disclosure in our SEC filings will result in less information about our company being available than for other public
companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
investors consider our common stock less attractive as a result of our election to use the scaled-back disclosure permitted for
smaller reporting companies, there may be a less active trading market for our common stock and our share price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>As
a &ldquo;smaller reporting company,&rdquo; we may at some time in the future choose to exempt our Company from certain corporate governance
requirements that could have an adverse effect on our public shareholders.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Nasdaq rules, a &ldquo;smaller reporting company,&rdquo; as defined in Rule 12b-2 under the Exchange Act, is not subject to certain corporate
governance requirements otherwise applicable to companies listed on Nasdaq. For example, a smaller reporting company is exempt from the
requirement of having a compensation committee composed solely of directors meeting certain enhanced independence standards, as long
as the compensation committee has at least two members who do meet such standards. Although we have determined not to avail ourselves
of this or other exemptions from Nasdaq requirements that are or may be afforded to smaller reporting companies while we will seek to
maintain our shares on Nasdaq, in the future we may elect to rely on any or all of these exemptions. By electing to utilize any such
exemptions, our Company may be subject to greater risks of poor corporate governance, poorer management decision-making processes, and
reduced results of operations from problems in our corporate organization. Consequently, if we were to avail ourselves of these exemptions,
our stock price might suffer, and there is no assurance that we would be able to continue to meet all continuing listing requirements
of Nasdaq from which we would not be exempt, including minimum stock price requirements.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="eds_008"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
upon an assumed public offering price of $8.00 per share, the midpoint of the price range set forth on the cover page of this
prospectus, we estimate that we will receive net proceeds from this offering, after deducting the underwriting discounts and the
estimated offering expenses payable by us, of approximately $13.3 million assuming the Underwriter does not exercise its over-allotment
option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
plan to use the net proceeds we receive from this offering for the following purposes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 11pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Use of Net Proceeds</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Sales and Marketing</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 20%; text-align: right">5,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and Development<SUP>(1)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Repayment of Convertible Notes<SUP>(2)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3,555,555</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Officer Contract Payments <SUP>(3)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,190,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General Corporate Purposes<SUP>(4)</SUP></FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">555,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Includes all funding of our
    IB-Stim device through the 510(k) De Novo FDA review for functional abdominal pain and IBS in children, as well as anticipated funding
    needed to achieve the regulatory milestones for our technology in respect of other indications identified in the chart captioned
    &ldquo;FDA Pipeline Indications&rdquo; under &ldquo;<I>Prospectus Summary&mdash;Our Pipeline</I>.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">Includes OID accreted through
    December 31, 2022. $3,333,333 of the Notes were issued with an OID of 10% of the principal amount and bear interest at the
    greater of (a) the prime rate of interest, as published by the Wall Street Journal, plus 8.5% per annum, or (b) 12%. $222,222
    of the Notes were issued with an OID of 10% of the principal amount and bear interest at 12%. The Notes mature twelve (12) months
    from their respective issue dates. For additional information, see &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial
    Condition and Results of Operations&ndash;Recent Developments</I>&rdquo;.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(3)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Represents payments to our executive officers pursuant
    to their respective employment agreements. For more information, see &ldquo;<I>Executive Officer and Director Compensation &mdash;Employment
    Agreements</I>.&rdquo;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">(4)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="text-align: justify; margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Includes
                                            $50,000 payable to Exchange Listing upon <FONT STYLE="font-family: Times New Roman, Times, Serif">the
                                            listing of our common stock on Nasdaq</FONT> and approximately $50,000 to repay the balance
                                            of two loans payable to a member of our board of directors. See &ldquo;<I>Prospectus Summary&mdash;Recent
                                            Developments</I>&rdquo; and &ldquo;<I>Certain Relationships and Related Persons Transactions,</I>&rdquo;
                                            respectively, for more information.</FONT></P>


</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our existing cash and cash equivalents, together with proceeds from this offering, will be sufficient to fund our operating
expenses and capital expenditure requirements through at least the next 12 months. The foregoing represents our current intentions
based upon our present plans and business conditions to use and allocate the net proceeds of this offering. However, the nature, amounts
and timing of our actual expenditures may vary significantly depending on numerous factors. As a result, our management has and will
retain broad discretion over the allocation of the net proceeds from this offering. We may find it necessary or advisable to use the
net proceeds from this offering for other purposes, and we will have broad discretion in the application of net proceeds from this offering.
To the extent that the net proceeds we receive from this offering are not immediately used for the above purposes, we intend to invest
our net proceeds in short-term, interest-bearing bank deposits or debt instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 46; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="M_001"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has not declared or paid any cash dividend on its common stock, and it currently intends to retain future earnings, if any, to
finance the expansion of its business, and the Company does not expect to pay any cash dividends in the foreseeable future. The decision
whether to pay cash dividends on its common stock will be made by its board of directors, in their discretion, and will depend on the
Company&rsquo;s financial condition, results of operations, capital requirements and other factors that its board of directors considers
significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="M_002"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
forth below is our capitalization as of September 30, 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    an actual basis;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    a pro forma basis to reflect conversion of the Series A and Series Seed Preferred Stock in connection with this offering; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
    a pro forma as adjusted basis to reflect the issuance and sale of the shares by us in this offering at the assumed public offering
    price of $8.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated
    underwriting discounts and the estimated offering expenses payable by us and the elimination of the derivative liability of $1,586,124
    and warrant liability of $2,514,726 valued at September 30, 2022 due to the embedded conversion feature of the convertible notes.
    The pro forma and pro forma as adjusted columns below do not reflect the issuance of the following promissory notes issued after
    September 30, 2022 (a) Senior Secured Convertible Promissory Notes in the principal amount of $1,111,111 and (b) unsecured convertible
    promissory notes in the principal amount of $222,222. The pro forma as adjusted column below, however, does reflect our plan to use
    a portion of the proceeds of this offering to repay the entire amount owed pursuant to these Senior Secured Convertible Promissory
    Notes and the unsecured convertible promissory notes &ndash; a total of $3,555,555. See &ldquo;Use of Proceeds&rdquo; for additional
    information.</FONT> </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The
as adjusted information below is illustrative only, and our capitalization following the completion of this offering will be adjusted
based on the actual public offering price and other terms of this offering determined at pricing. You should consider this table in conjunction
with &ldquo;Use of Proceeds&rdquo; above as well as our &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and
Results of Operations of the Company,&rdquo; and our audited and unaudited financial statements and the notes to those financial statements
included elsewhere in this prospectus.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="10" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of September 30, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Actual</FONT></P><P STYLE="margin: 0">(Unaudited)</P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
Forma</FONT></P>
                                                                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pro
    Forma As Adjusted</FONT><P STYLE="margin: 0">(Unaudited)</P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Cash and cash equivalents </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 7,820 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 7,820 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 9,771,789 </P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 52%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
                                            liabilities</FONT></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893,339</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893,339</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 12%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,795,618</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&rsquo; equity:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, par value $0.001 per share, 100,000,000 shares authorized, 1,951,547 shares issued and outstanding as of September
    30, 2022;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,952</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,196</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,071</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    Series A Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, 506,637 shares issued and outstanding as of September
    30, 2022;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">507</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    Series Seed Preferred Stock, par value $0.001 per share, 120,000 shares authorized, 115,477 shares issued and outstanding as of September
    30, 2022;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&mdash;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid in capital</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,353,817</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">28,353,195</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,976,320</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    (deficit)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">(33,917,800</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(33,917,800<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(32,042,301</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT> </TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&rsquo; (deficit) equity</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,561,409</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,561,409<TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8,939,090</FONT> </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Capitalization</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,331,930</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,331,930</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 11,734,708 </TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&ldquo;Actual&rdquo; column in the table above is based on 1,951,547 shares of common stock outstanding as of September 30, 2022, the
&ldquo;Pro Forma&rdquo; and Pro Forma As Adjusted&rdquo; columns include an additional 3,119,228 shares of common stock issuable
upon conversion of the Series A Preferred Stock and the Series Seed Preferred Stock in connection with the closing of this offering,
and in all cases excludes, as of such date:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">289,779
                                            shares of our common stock issuable upon exercise of warrants to purchase shares of Series
                                            A Preferred Stock converting to warrants to purchase shares of common stock. (See
                                            &ldquo;<I>Description of Our Securities&mdash;Warrants</I>&rdquo; for more information);</P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">405,962 shares of our common stock issuable upon exercise
    of warrants to purchase common stock (see &ldquo;<I>Description of Our Securities&mdash;Warrants</I>&rdquo; for more information);</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,500
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock issuable upon exercise
    of the Underwriter&rsquo;s Warrants to purchase common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">353,111
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock issuable upon conversion
    of the Notes, assuming a conversion price of $9.44 per share (see &ldquo;<I>Prospectus Summary&mdash;Recent Developments</I>&rdquo;
    for more information);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">23,540 shares of our common stock issuable upon conversion
    of our unsecured convertible promissory notes, assuming a conversion price of $9.44 per share (see &ldquo;<I>Prospectus Summary&mdash;Recent Developments</I>&rdquo;
    for more information);</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">88,926 shares of common stock and an additional
    153,515 issuable upon exercise of warrants issuable to Exchange Listing, LLC upon the listing of our common stock on Nasdaq
    (see &ldquo;<I>Prospectus Summary&mdash;Recent Developments</I>&rdquo; for more information);</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,319,394
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock issuable upon exercise of options to purchase common stock; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">11,774 Commitment Shares related to Notes issued after
    September 30,2022 (see &ldquo;<I>Prospectus Summary-Recent Developments</I>&rdquo; for more information.)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="M_003"></A>DILUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
you invest in our common stock, your ownership interest will be diluted to the extent of the difference between the offering price
per share of its common stock and the as-adjusted net tangible book value per share of its common stock immediately after the offering.
Historical net tangible book value per share represents the amount of the Company&rsquo;s total tangible assets less total liabilities,
divided by the number of shares of its common stock outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
historical net tangible book value (deficit) of our common stock as of September 30, 2022, was approximately $(6.4) million or
$(3.28) per share based upon shares of common stock outstanding on such date. Historical net tangible book value (deficit) per
share represents the amount of its total tangible assets reduced by the amount of its total liabilities, divided by the total number
of shares of common stock outstanding. The effect of the conversion of the series A and series seed to the historical net tangible
book value (deficit) is $2.00 per share based upon shares of common stock outstanding as of September 30, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
giving effect to the Company&rsquo;s sale of all of the 1,875,000 shares of common stock offered in this offering at a public
offering price of $8.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, after
deducting estimated underwriting discounts and commissions and the Company&rsquo;s estimated offering expenses, the Company&rsquo;s pro
forma as adjusted net tangible book value as of September 30, 2022 would have been $11.0 million or $2.17 per share. This
represents an immediate increase in net tangible book value of $4.17 per share to the Company&rsquo;s existing stockholders, and
an immediate dilution in net tangible book value of $5.83 per share to new investors. The following table illustrates this per
share dilution:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 84%">Assumed public offering price per share</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">8.00</P></TD><TD STYLE="width: 1%; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Historical net tangible value (deficit) per share as of September 30, 2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(3.28</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Increase per share attributable to the conversion of preferred stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1.28</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Pro forma deficiency in net tangible book value per share as of September 30, 2022, before giving effect to this offering</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(2.00</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Increase attributable to new investors in this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.17</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt">As adjusted, net tangible book value per share after the offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.17</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Dilution per share to new investors in this offering</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.83</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
information discussed above is illustrative only, and the dilution information following this offering will be adjusted based on the
actual public offering price and other terms of this offering determined at pricing. A $1.00 increase (decrease) in the assumed
public offering price of $8.00 per share would increase (decrease) the pro forma as adjusted net tangible book value by $0.34,
$(0.34) per share and increase the dilution to new investors by $0.66 per share and decrease the dilution to new
investors by $0.66 per share, assuming the number of shares offered by the Company, as set forth on the cover page of this
prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated expenses
payable by the Company. The Company may also increase or decrease the number of shares it is offering. An increase of 100,000 shares
offered by it would increase the pro forma as adjusted net tangible book value by $0.10 per share and decrease the dilution
to new investors by $0.10 per share, assuming the assumed public offering price of $8.00 per share remains the same
and after deducting the estimated underwriting discounts and commissions and estimated expenses payable by the Company. Similarly, a
decrease of 100,000 shares offered by the Company would decrease the pro forma as adjusted net tangible book value by $0.10
per share and increase the dilution to new investors by $0.10 per share, assuming the assumed public offering price of $8.00
per share remains the same and after deducting the estimated underwriting discounts and commissions and estimated expenses payable
by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Underwriter&rsquo;s over-allotment option to purchase additional shares from the Company is exercised in full, and based on the assumed
public offering price of $8.00 per share, the midpoint of the price range set forth on the cover page of this prospectus,
the pro forma as adjusted net tangible book value per share after this offering would be $2.45 per share, the increase in as adjusted
net tangible book value per share to existing stockholders would be $.28 per share and the dilution to new investors purchasing
shares in this offering would be $5.55 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
number of shares of common stock outstanding is based on 1,951,547 shares of common stock issued and outstanding as of September
30, 2022, and excludes the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">289,779
    shares of our common stock issuable upon exercise of warrants to purchase shares of Series A Preferred Stock converting to warrants
    to purchase shares of common stock. (See &ldquo;<I>Description of Our Securities&mdash;Warrants</I>&rdquo; for more information);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">405,962 shares of our common stock issuable upon exercise
    of warrants to purchase common stock (see &ldquo;Description of Our Securities&mdash;Warrants&rdquo; for more information);</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">112,500 <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of our common stock issuable upon exercise of the Underwriter&rsquo;s Warrants to purchase common stock;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">353,111
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of our common stock issuable upon conversion
    of the Notes, assuming a conversion price of $9.44 per share (see &ldquo;<I>Prospectus Summary&mdash;Recent Developments</I>&rdquo;
    for more information);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0">23,540
                                            shares of our common stock issuable upon conversion of our unsecured convertible promissory
                                            notes, assuming a conversion price of $9.44 per share (see &ldquo;<I>Prospectus Summary&mdash;Recent
                                            Developments</I>&rdquo; for more information);</P>
</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">88,926 shares of common stock and an additional 153,515
    issuable upon exercise of warrants issuable to Exchange Listing, LLC upon the listing of our common stock on Nasdaq (see &ldquo;<I>Prospectus
    Summary&mdash;Recent Developments</I>&rdquo; for more information);</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">1,319,394 shares of our common stock issuable upon exercise of options to purchase common stock; and</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">11,774 Commitment Shares related to Notes issued after
    September 30,2022 (see &ldquo;<I>Prospectus Summary-Recent Developments</I>&rdquo; for more information.)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
as otherwise indicated herein, all information in this prospectus assumes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the outstanding options or warrants, or conversion of the convertible notes, described above; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">no
    exercise of the Underwriter&rsquo;s option to purchase up to an additional 281,250 shares of common stock to cover over-allotments,
    if any, or any warrants issued to the Underwriter as compensation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="M_004"></A>MANAGEMENT&rsquo;S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><I>You
should read the following discussion and analysis of our financial condition and results of operations together with our financial statements
and the related notes appearing at the end of this prospectus. Some of the information contained in this discussion and analysis or set
forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related financing,
includes forward-looking statements that involve risks, uncertainties, and assumptions. You should read the &ldquo;Certain Note Regarding
Forward-Looking Statements&rdquo; and &ldquo;Risk Factors&rdquo; sections of this prospectus for a discussion of important factors that
could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained
in the following discussion and analysis.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children.
Our mission is to provide solutions that create value and provide better and safer patient outcomes. Our IB-Stim device is a PENFS system
intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. Our device already has market
clearance from FDA for functional abdominal pain associated with IBS in children. Other indications in our pipeline are comprised of
functional nausea in children, post-concussion syndrome in children, and cyclic vomiting syndrome in children. For more information, see &ldquo;<I>Business&mdash;Our Pipeline</I>&rdquo; and <I>&ldquo;&mdash;Products</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have incurred significant operating losses. Our net loss was $4.8 million and $2.2 million for the nine-months
ended September 30, 2022 and 2021, respectively, and $3.0 million and $3.7 million for the years ended December 31, 2021, and 2020,
respectively. As of September 30, 2022, we had an accumulated deficit of $33.9 million. Our auditors have expressed
substantial doubt about our ability to continue as a going concern paragraph in their audit opinion. We expect to incur significant expenses
and operating losses for the foreseeable future as we continue to pursue widespread insurance coverage of our IB-Stim device and seek
FDA clearance of our device for other indications. There are a number of milestones and conditions that we must satisfy before we will
be able to generate sufficient revenue to fund our operations, including FDA clearance of our IB-Stim device to treat future indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Factors
Affecting our Business and Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenue</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenue is derived from the sale of our IB-Stim device to healthcare companies, primarily hospitals and clinics. Sales generally are
not seasonal and only mildly correlated with economic cycles. Our IB-Stim device costs $1,195 per device, and each child being treated
for functional abdominal pain associated with IBS will use three to four devices. Potential patients with future indications are expected
to use six or more devices per patient</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
sales typically are made on a purchase order basis rather than through long-term purchase commitments. We enter into sales agreements
with customers for IB-Stim devices based on purchase orders and standard terms, which vary slightly based on the customer&rsquo;s form,
and conditions of sale. Standard payment terms generally are that payment is due within 30 to 90 days. Our largest sales were to four
hospitals representing approximately 51% and 60% of total sales for the nine months ended September 30, 2022 and 2021,
respectively, and 58% and 67% of total sales for the years ended December 31, 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
did not have a material impact on our operations for any applicable period, and we do not expect inflation to have a material impact
on our operations for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have four categories of expenses: cost of goods sold, selling expenses, research and development (&ldquo;R&amp;D&rdquo;), and
general and administrative (&ldquo;G&amp;A&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">Costs
of goods sold consists of costs paid for the IB-Stim device to our contract manufacturer along with periodic inventory adjustments and
expired inventory write-offs. We ramped up production in 2018 and 2019 to meet expected demand and avoid any inventory shortages. This
resulted in some excess inventory that did expire. We had no costs for expired inventory for the nine months ended September 30, 2022,
and such costs were $48,000 for the nine months ended September 30, 2021, representing 12% of our costs of goods sold in the 2021 period.
The costs of expired inventory were $48k and $14k for the years ended December 31, 2021 and 2020, respectively, representing 10.4%
and 3.0% of our costs of goods sold, respectively. Expired inventory expense is related to our FDA clearance for our device in the treatment
of functional abdominal pain associated with IBS in children. Specifically, a certain component of our IB-Stim device is cleared for
a two-year period after the date the device is manufactured, and if the device is not sold in such period, we must take the device
out of inventory and write it off. We had no expired inventory for the nine months ended September 30, 2022, and expired inventory
was 2.2% of sales for the nine months ended September, 30, 2021. Accordingly, expired inventory has not been
material to our results, averaging less than 1.0% of revenue over the past three years. We have a fixed-price contract with the manufacturer
of our IB-Stim device to produce the device. We expect production costs to remain relatively constant and only nominal inventory expirations
in the foreseeable future.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
core selling expenses primarily consist of commissions and shipping costs. These expense items are generally correlated with sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
expense is attributable to our clinical trials and related efforts to have our IB-Stim device cleared by the FDA for other indications.
We expect to spend approximately $0.3 million for research and development in 2022, and we anticipate that these costs will increase
in 2023 as clinical trials for post-concussion syndrome in children, and cyclic vomiting syndrome in children are completed, although we cannot assure that these trials will be completed on time, will be successful,
or that trial results will lead to FDA clearance for any particular indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G&amp;A
expense consists of payroll and professional fees and is our most significant expense category. Payroll and professional fees account
for approximately 90% of our G&amp;A expenses. The balance of the expenses are normal operating expenses for facility expenses, utilities,
travel, etc. We expect G&amp;A expenses to increase as we transition to operating as a public company, but we expect G&amp;A expense
to stabilize within two years of completion of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><I>Gross Profit and Gross
Margin</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">Our management uses gross
profit and gross margin to evaluate the efficiency of operations and as a key component to determining the effectiveness and allocation
of resources. We calculate gross profit as revenue less cost of goods sold, and gross margin as gross profit divided by revenue. Our
gross margin has been and will continue to be affected by a variety of factors, primarily the average selling price of our IB-Stim device,
production volume, order flows, change in mix of customers, third-party manufacturing costs related to components of our IB-Stim device,
and cost-reduction strategies. We expect our gross profit to increase for the foreseeable future as our revenue grows, both through broader
insurer acceptance of our IB-Stim device in the near term and approval of our technology for the treatment of other indications over
the longer term. Our gross margin may fluctuate from quarter to quarter due to changes in average selling prices, particularly as we
introduce enhancements to our IB-Stim device and new products to address other indications, and as we adopt new manufacturing processes
and technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of Nine Months Ended September 30, 2022, and Nine Months Ended September 30, 2021</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="5" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nine
    Months Ended September 30,</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
    sales</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,071,653</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,254,520</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
    of goods sold</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right"><P STYLE="margin: 0">221,846</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right">398,318<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gross
    profit</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,849,807</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,856,202</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
    expenses</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">344,892</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">380,743</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and development</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">144,239</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,120</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right">3,746,688</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right">3,447,069</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
    loss</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid">(2,386,012</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,128,730</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
    income (expense):</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    charges</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,473,892</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">---</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Interest expense</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">(161,291</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">(24,776</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value of warrant liability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(660,189</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(22,007</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of derivative liability</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(68,032</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">---</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accretion
    of debt discount and issuance cost</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28,973</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">---</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right">11,956</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right">---</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other income (expense)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right">(2,380,421</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: right">(46,783</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Net
    loss</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,766,433</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>$</B></FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: black 2.25pt double"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,175,513</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 51; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
Sales</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
sales decreased approximately $0.2 million, or 8%, from $2.3 million for the nine months ended September 30, 2021, to $2.1 million for
the nine months ended September 30, 2022. The decrease was primarily due to ordering patterns of our major customers. We believe net
sales will increase as we ramp up our marketing efforts and as our IB-Stim device is cleared by the FDA for other indications, such as
functional nausea, post-concussion syndrome and cyclic vomiting syndrome in children. For more information, see &ldquo;<I>Business&mdash;Our
Pipeline</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Costs
of Goods Sold</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
of goods sold decreased approximately 44% in the nine months ended September 3, 2022, as compared to the nine months ended
September 30, 2021, mainly because there was no expired inventory and lower sales. We expect costs of goods sold to remain relatively
constant as we grow, primarily due to our current pricing with our contract manufacturer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Gross
Profit</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit decreased approximately $6 thousand, from $1.856 million for the nine months ended September 30, 2021, to $1.850 million for the
nine months ended September 30, 2022, representing 89% of revenue in the 2022 period and 82% of revenue in the 2021 period. The
increase was primarily due to no expired inventory in 2022. We believe gross profit will continue to grow as sales increase, which,
in turn, is tied to broader insurance coverage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Gross Margin</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Gross margin increased approximately 7.0%, from
82.3% for the year ended September 30, 2022, to 89.3% for the year ended September 30, 2021. The increase was primarily due to no expired
inventory and cost efficiencies in 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Selling
Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
expenses were down slightly in the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021. This
was primarily due to lower sales in 2022. Commission costs decreased and shipping costs remained constant the nine months ended September
30, 2022. The commission costs were directly attributable to the decrease in net sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
expense decreased 8% in the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021, and this decrease
was due to slightly more studies and clinical trials expense in the 2021 period. R&amp;D costs remained at 7% of net sales in the 2022
and 2021 periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G&amp;A
expense increased approximately 9% in the nine months ended September 30, 2022, as compared to the nine months ended September 30, 2021.
This was due primarily to professional fees. We expect G&amp;A expense to decrease in 2023 primarily because
of reduced costs after the offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Loss</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating loss increased $0.26 million, or 12%, for the nine months ended September 30, 2022, as compared to the nine months ended
September 30, 2021, primarily due to increased professional fees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Income (Expense)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expense increased 2.3 million for the nine months ended September 30, 2022 and was primarily attributable to financing charges in connection
with convertible debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
Loss</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net loss increased approximately $2.6 million, or 119%, in the nine months ended September 30, 2022, as compared to the nine months
ended September 30, 2021. The change was primarily attributable to expenses directly related to securing convertible debt in
2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 52; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of Year Ended December 31, 2021, and Year Ended December 31, 2020</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-weight: bold; text-align: left">Net sales</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,721,286</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">1,930,228</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Costs of goods sold</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">467,656</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">481,089</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Gross profit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,253,630</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,449,139</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Selling expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">455,879</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">521,034</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Research and development</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">203,414</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">166,798</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,564,371</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,882,045</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,970,034</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,120,738</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Other income (expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Interest expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(36,928</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(75,711</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Interest income</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">License revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Gain on loan forgiveness</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">220,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Change in fair value of derivative financial instruments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(29,342</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,911</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,923</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,272</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">275</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total other income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(57,998</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">394,589</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,028,032</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(3,726,149</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
Sales</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net sales increased approximately $0.8 million, or
41%, from $1.9 million for the year ended December 31, 2020, to $2.7 million for the year ended December 31, 2021. The increase was primarily
due to certain insurance carriers covering the cost of our device for the treatment of functional abdominal pain associated with IBS in
children.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Costs
of Goods Sold</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
of goods sold decreased slightly, approximately 3%, in the year ended December 31, 2021, as compared to the year ended December
31, 2020, mainly because of a transition from our previous contract manufacturer to our current manufacturer. There were inefficiencies
in the inventory process in 2020 that were remedied in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Gross
Profit</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit increased approximately $0.8 million, from $1.5 million for the year ended December 31, 2020, to $2.3 million for the year ended
December 31, 2021, representing 82.8% of revenue in 2021 and 75.1% of revenue in 2020. The increase was primarily due to
the decrease in cost of goods sold combined with higher sales in 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><I>Gross Margin</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Gross margin increased approximately 7.7%,
from 75.1% for the year ended December 31, 2020, to 82.8% for the year ended December 31, 2021. The increase was primarily due to an increase in sales and cost efficiencies from increased sales
in 2021.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Selling
Expenses</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
expenses were down slightly in the year ended December 31, 2021, as compared to the year ended December 31, 2020. This was primarily
due to a decrease in promotional inventory distributed. Commission and shipping costs both increased in the year ended December 31,
2021, and these increases were directly attributable to the increase in net sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Research
and Development</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">R&amp;D
expense increased 22% in the year ended December 31, 2021, as compared to the year ended December 31, 2020, and this increase was due
to our support and expansion of clinical trials to get our IB-Stim device cleared for other indications. R&amp;D costs represented
7.5% of net sales and 8.6% of net sales in 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
and Administrative</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">G&amp;A
expense decreased approximately 6.5% in the year ended December 31, 2021, as compared to the year ended December 31, 2020. This
was due primarily to reduced payroll cost. We expect G&amp;A expense to increase in 2022 primarily because of costs incurred in connection
with this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Loss</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating loss decreased $1.2 million, or 27.9%, for the year ended December 31, 2021, as compared to the year ended December
31, 2020, primarily due to increased net sales and reduced payroll expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Income (Expense)</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
expense for the year ended December 31, 2021, was primarily attributable to interest expense. We recorded other income of $0.4 million
for the year ended December 31, 2020, due to a one-time license fee payment of $250,000 from Masimo and forgiveness of a $220,000 loan
we received under the Paycheck Protection Program established as part of the Coronavirus Aid, Relief and Economic Security Act
in 2020 (&ldquo;PPP Loan&rdquo;), partially offset by higher interest expense in 2020. For more information regarding the Masimo license,
see &ldquo;<I>Business&mdash;License Agreements&mdash;Masimo License and Collaboration Agreement</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Net
Loss</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net loss decreased approximately $0.7 million, or 18.7%, in the year ended December 31, 2021, as compared to the year ended
December 31, 2020. The change was primarily attributable to increased net sales, reduced payroll expense, partially offset by
other income from the Masimo license fee and the PPP Loan forgiveness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had cash on hand of approximately $8,000 at September 30, 2022, as compared to cash-on-hand of approximately $0.3 million at September
30, 2021. Working capital for September 30, 2022 was $(6.4) million, as compared to working capital of $(0.1) million at September 30,
2021. The decrease in working capital was due to liabilities assumed in connection with issuance of the Notes. See &ldquo;&mdash;<I>Recent
Developments.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had cash on hand of approximately $0.3 million at December 31, 2021, as compared to cash-on-hand of approximately $1.9 million at
December 31, 2020. Working capital at December 30, 2021 was $(0.9) million, as compared to working capital of $1.5 million at
December 31, 2020. The decrease in working capital was due to cash used by operating activities of $2.2 million, partially offset by
capital raised in 2021 of $0.7 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
anticipate our sales over the next 12 months to be approximately $5.0 million, assuming our expectations with respect to acceptance by
insurance providers are generally correct, and we anticipate our liquidity needs over this period to be approximately $7.0 million. We
expect proceeds from this offering to fund our capital needs for the following 12 months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we will have to meet all the financial disclosure and reporting requirements associated with being a publicly reporting company. Our
management will have to spend additional time on policies and procedures to make sure it is compliant with various regulatory requirements,
especially that of Section 404 of the Sarbanes-Oxley Act. This additional corporate governance time required of management could limit
the amount of time our management has to implement our business plan and may delay our anticipated growth plans. We anticipate over the
next 12 months the cost of being a reporting public company will be approximately $0.5 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows from operating, investing, and financing activities for the nine months ended September 30,
2022 and 2021:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nine
    Months Ended September 30,</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2022</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2021</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used in operating activities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,171,383</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right">(2,038,707</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used by investing activities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(11,390</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">---</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,869,735</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">417,050</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Activities</I> &ndash; Cash used in operating activities primarily consisted of general and administrative expense resulting in a
net loss for the year. The net loss was partially offset by favorable changes in accounts payable and accrued expenses in the 2022
period, and the net loss was negatively impacted with changes in accounts receivable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
Activities</I> &ndash; Net cash provided by investing activities primarily consisted of equipment additions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financing
Activities &ndash;</I> Net cash provided by financing activities in the nine months ended September 30, 2022, primarily consisted of
proceeds from new convertible debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities in the nine months ended September 30, 2021, primarily consisted of proceeds from the sale of preferred
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows from operating, investing, and financing activities for the years ended December 31, 2021
and 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(2,234,326</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">(4,139,329</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net cash used by investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,390</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(27,719</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net cash provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">661,099</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,054,023</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Operating
Activities</I> &ndash; Cash used in operating activities primarily consisted of general and administrative expense that more than offset
sales, resulting in a net loss for the year. The net loss was partially offset by favorable changes in accounts receivable and accounts
payable in 2021, and net loss was negatively impacted with changes in accounts receivable and accounts receivable in 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 55; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
Activities</I> &ndash; Net cash used in investing activities primarily consisted of equipment additions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Financing
Activities</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities in 2021 primarily consisted of proceeds from the sale of preferred stock. We also borrowed $250,000
from a third party in December 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash provided by financing activities in 2020 primarily consisted of proceeds from the sale of preferred stock to Masimo. For more
information, see &ldquo;<I>Business&mdash;License Agreements&mdash;Masimo License and Collaboration Agreement</I>.&rdquo; We also borrowed
$220,000 under a PPP Loan. Our PPP Loan was approved for total forgiveness in December 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Founders&rsquo;
</I></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock Issuance</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the founding of the Company, Christopher Robin Brown and Gary Peterson, each a member of our board of directors, each
received 936,000 of shares of our common stock, and each executed and delivered a promissory note, dated January 1, 2016, for
$548,448 and $548,320, respectively, which amounts include accrued and unpaid interest through September 30, 2022. The promissory notes
are unsecured and payable on demand by the Company. As of December 31, 2019, the Company recorded a collection allowance against the
promissory notes and accrued interest receivable and, therefore, the promissory notes and related accrued interest are no longer itemized
as an asset on our balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2023, we filed a certificate of amendment to our certificate of incorporation with the Secretary of State of the State of
Delaware and effectuated a reverse stock split of our common stock at a ratio of 1-for-2. All share information in this prospectus,
including historical share information in our financial statements, has been adjusted for this reverse stock split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
June through November of 2022, we entered into Securities Purchase Agreements (the &ldquo;SPAs&rdquo;) with Leonite Fund I, LP, <FONT STYLE="background-color: white">Emmis
Capital II</FONT>, LLC, Bigger Capital Fund, LP, District 2 Capital Fund, LP, and Exchange Listing, LLC, which provide for advances of
up to $3.0 million in proceeds to us, subject to our satisfaction of certain conditions. Pursuant to the SPAs, from June through November
of 2022, we issued Senior Secured Convertible Promissory Notes (&ldquo;Notes&rdquo;) with an aggregate principal amount of $3,333,333,
which amount included an original issue discount (&ldquo;OID&rdquo;) of $333,333, and legal fees for $130,000, resulting in advance proceeds
to us of $3.0 million. In connection with the issuance of the Notes, we also issued five-year warrants exercisable for an aggregate of
353,111 shares of common stock with an exercise price of the lower of (a) $11.80 and (b) a 12% discount to the price per share in any
subsequent offering by the Company, and we entered into a Pledge and Security Agreement with Leonite Fund I, LP, dated June 3, 2022.
Pursuant to the Pledge and Security Agreement, the Company granted a security interest in all of its assets in favor of Leonite Fund
I, LP, in its capacity as collateral agent for the purchaser&rsquo;s parties under the SPAs. For more information regarding the warrants
issued under the SPAs, see &ldquo;<I>Description of Our Securities&mdash;Warrants</I>.&rdquo; We plan to use a portion of the proceeds
of this offering to repay the entire amount owed pursuant to these Notes. See &ldquo;<I>Use of Proceeds</I>&rdquo; for additional information. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Notes were issued with OID of 10% of the
principal amount and bear interest at the greater of (a) the prime rate of interest, as published by the Wall Street Journal, plus 8.5%
per annum, or (b) 12%. The Notes will mature in twelve (12) months from their respective issue dates. Any amount of principal, interest,
other amounts due hereunder or penalties on this Note, which is not paid by maturity date, shall bear interest at the lesser of the rate
of twenty four percent (24%) per annum or the maximum legal amount permitted by law, from the due date thereof until the same is paid
in full, including following the entry of a judgment in favor of Noteholder. The Notes are convertible into shares of common stock at
the lower of (a) $9.44 per share, or (b) a discount of 30% to the price per share in any subsequent offering, subject to adjustment
in the event of common stock distribution, stock splits, fundamental transactions, dilutive issuances or similar events affecting our
common stock and the conversion price. Interest accrues on the aggregate principal amount (which includes OID) and is payable monthly,
at the Company&rsquo;s election, in cash or in-kind.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the advance of the consideration under the SPAs, the Company is required to issue to the noteholders a number of shares of common stock,
calculated based on the value of 10% of the principal amount of the Notes issued in such advance, at a value per share equal to the conversion
price of the Notes at the date of such advance (the &ldquo;Commitment Shares&rdquo;). Accordingly, in connection with the initial
advance and issuance of Notes, assuming a conversion price of $9.44 per share, we will be issuing 35,317 Commitment Shares
to the Noteholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 56; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes have certain restrictions on the Company&rsquo;s issuance of securities, including, among other restrictions, (i) the Company
shall not without the Noteholder&rsquo;s written consent (a) pay, declare or set apart for such payment, any dividend or other
distribution (whether in cash, property or other securities) on the common stock of the Company other than dividends on common stock
solely in the form of additional common stock, or (b) directly or indirectly or through any subsidiary make any other payment or distribution
in respect of common stock or equivalents, (ii) unless approved by the Noteholders in writing, the Company shall not enter into
an agreement or amend an existing agreement to effect any sale of securities involving, or convert any securities previously issued under,
a variable rate transaction, which means a transaction in which the Company (A) issues or sells any convertible securities either (x)
at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of, or quotations
for, the common stock, or (y) with a conversion, exercise or exchange price that is subject to being reset at some future date
after the initial issuance of such convertible securities or upon the occurrence of specified or contingent events directly or indirectly
related to the business of the Company, or the market for the common stock, or (B) enters into any agreement whereby the Company may
sell securities at a future determined price (other than standard and customary &ldquo;preemptive&rdquo; or &ldquo;participation&rdquo;
rights), (iii) the Noteholders have the right, but not the obligation, to participate in the purchase of the securities being
offered up to an amount equal to thirty percent (30%) of the principal amount of the Notes (the &ldquo; Participation Right&rdquo;) when
the Company or its subsidiary proposes to offer and sell its securities, whether in the form of debt, equity financing, or any other
financing transaction (each a &ldquo;Future Offering&rdquo;); provided that, the Participation Right shall not exceed the lesser of (i)
one-third of the aggregate amount of the Future Offering, and (ii) an amount equal to the principal amount (allocated to the Noteholder&rsquo;s
pro-rata to their portion of the principal amount), and (iv) if the Company has a bona fide offer of capital or financing from
any third party that the Company intends to act upon, other than an underwritten initial public offering of the Company&rsquo;s common
shares, then the Company must first offer such opportunity to the Noteholders to provide such capital or financing to the Company on
the same terms. The Note holders waived their Participation Right to participate in the December 2022 and January 2023 convertible note issuances described
below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay to the Noteholders any outstanding principal amount of the Notes, all accrued and unpaid interest, and fees
and penalties, if any, from any future financing proceeds (which includes proceeds to us from this offering) and other future receipts,
at the Noteholder&rsquo;s discretion, except for the right of the Company to make bona fide payments to vendors with common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
December 2022 through January 2023, the Company issued unsecured convertible promissory notes to three existing investors, Todd Maxwell,
Rogan O&rsquo;Donnell and Michael &amp; Michele Robuck, with an aggregate principal amount of $222,222, which amount included an OID
of $22,222, resulting in advance proceeds to us of $200,000. The notes carry an OID of 10% of the principal amount and have an interest
rate of 12% per annum. The notes will mature at the earlier of (i) twelve (12) months from the issue date or (ii) the date upon which
the Company completes a registered public offering of shares of the Company, which encompasses the closing of this offering. The notes
are convertible into shares of common stock at the higher of (i) $9.44 per share, or (ii) the price per share of common stock
issued pursuant to the next registered public offering of shares of the Company made prior to the conversion of any portion of the note.
Interest accrues on the aggregate principal amount (which includes OID) and is payable on the maturity date, at the Company&rsquo;s election,
in cash or in-kind. The holders of the notes are entitled to piggyback registration rights on any registration statement filed by the
Company, other than the registration statement of which this prospectus forms a part and any registration filed on Form S-4 or Form S-8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to two advisory agreements with Exchange Listing, LLC, a consultant engaged in connection with listing our common stock for
trading on Nasdaq. Pursuant to the first advisory agreement with Exchange Listing, dated March 3, 2022, we have agreed to pay Exchange
Listing a monthly consulting fee of $5,000 and a final payment of $50,000 upon a successful Nasdaq listing, and, also upon such listing,
to issue Exchange Listing 76,426 shares of our common stock (representing 1.5% of our outstanding shares after giving effect to
this offering, as presented in the pro forma as adjusted column under &ldquo;Capitalization&rdquo;) and to issue Exchange Listing
five-year warrants to purchase 153,515 shares of our common stock (representing 2.0% of our outstanding shares after giving effect
to this offering on a fully-diluted basis, as presented in the pro forma as adjusted column under &ldquo;Capitalization&rdquo;)
with an exercise price of $8.00 per share (representing the estimated public offering price per share, the midpoint
of the price range set forth on the cover page of this prospectus). Pursuant to the second advisory agreement with Exchange Listing,
dated June 20, 2022, and amended December 20, 2022, we have agreed to pay Exchange Listing fees in the aggregate of up to $136,166 for
advice in connection with communication and other related matters leading up to, and in connection with, this offering and to issue Exchange
Listing 12,500 shares of common stock upon a successful Nasdaq listing. We have agreed to piggyback registration rights with respect
to all shares issued to Exchange Listing under both advisory agreements, including shares issuable upon exercise of the warrants.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Quantitative
and Qualitative Disclosures About Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not utilized any derivative financial instruments such as futures contracts, options and swaps, forward foreign exchange contracts
or interest rate swaps and futures. We believe that adequate controls are in place to monitor any hedging activities. We do not intend
to hedge any existing or future borrowings and, consequently, we do not expect to be affected by changes in market interest rates. We
do not currently have any sales or own assets and operate facilities in countries outside the United States and, consequently, we are
not affected by foreign currency fluctuations or exchange rate changes. Overall, we believe that our exposure to interest rate risk and
foreign currency exchange rate changes is not material to our financial condition or results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
prepare our financial statements in conformity with accounting principles generally accepted in the United States (&ldquo;U.S. GAAP&rdquo;),
which requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent
assets and liabilities on the date of the financial statements and the reported amounts of revenues and expenses during the financial
reporting period. We continually evaluate these estimates and assumptions based on the most recently available information, our own historical
experience and on various other assumptions that we believe to be reasonable under the circumstances. Since the use of estimates is an
integral component of the financial reporting process, actual results could differ from those estimates. Some of our accounting policies
require higher degrees of judgment than others in their application. We consider the policies discussed below to be critical to an understanding
of our financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 57; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC defines critical accounting policies as those that are, in management&rsquo;s view, most important to the portrayal of our financial
condition and results of operations and those that require significant judgments and estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accounting principles we utilized in preparing our financial statements conform in all material respects to U.S GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Inventories</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost or net realizable value. Our inventory is comprised of finished medical devices on hand.
Certain components within the devices have an expiration date and are removed from current inventory and expensed at the date of expiration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Leases</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
account for our leases under Accounting Standards Update No. 2016-02, <I>Leases</I>. We do not record an operating lease right of use
(&ldquo;ROU&rdquo;) asset and corresponding lease liability for leases with an expected term of 12 months or less and recognize lease
expense for these leases as incurred over the lease term. Operating lease ROU assets and operating lease liabilities for leases with
an expected term of more than 12 months are recognized based on the present value of lease payments over the lease term. For lease present
value calculations, absent a rate implicit in the lease, we determine a comparable incremental borrowing rate. The present value is then
recognized as lease expense on a straight-line basis over the lease term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Derivative
Financial Instruments</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
evaluate our financial instruments and other contracts to determine if those contracts or embedded components of those contracts qualify
as derivatives to be separately accounted for in accordance with Accounting Standards Codification 815, <I>Derivatives and Hedging </I>(&ldquo;ASC
815&rdquo;). The result of this accounting treatment is that the fair value of the derivative is re-measured at each balance sheet date
and recorded as a liability or asset and the change in fair value is recorded in the  statements of operations and comprehensive loss.
As of December 31, 2020, our derivative financial instruments were comprised of warrants issued in connection with capital raising transactions.
Upon settlement of a derivative financial instrument, the instrument is re-measured at the settlement date and the fair value of the
underlying instrument is reclassified to equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
classification of derivative financial instruments, including whether such instruments should be recorded as liabilities/assets or as
equity, is reassessed at the end of each reporting period. Derivative financial instruments that become subject to reclassification are
reclassified at the fair value of the instrument on the reclassification date. Derivative financial instruments will be classified in
the balance sheet as current if the right to exercise or settle the derivative financial instrument lies with the holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenue
Recognition</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Revenue is recognized in one major product segment
&ndash; commercial products. The timing of revenue recognition for this product segment occurs as goods are transferred at a point in
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
estimate credit losses on accounts receivable by estimating expected credit losses over the contractual term of the receivable using
a discounted cash flow method. When developing this estimate of expected credit losses, we consider all available information (past,
current, and future) relevant to assessing the collectability of cash flows. The Company has concluded that realization losses on balances
outstanding at year-end will be immaterial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are several recently issued accounting pronouncements that have been reviewed and adopted. The pronouncements regarding leases had a
material impact on our financial statements.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
There are no other recently issued accounting pronouncements that we have not yet adopted that we believe are applicable or
would have a material impact on our financial statements. For more information regarding recent accounting pronouncements, refer to
Note 1 to our audited financial statements contained elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an emerging growth company, and under the JOBS Act, an emerging growth company can delay the adoption of certain accounting standards
until those standards would otherwise apply to private companies. We have elected not to take advantage of the extended transition period
for complying with new or revised accounting standards provided to emerging growth companies under the JOBS Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 58; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="M_005"></A>BUSINESS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children.
We are dedicated to advancing science with our proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology,
which was developed internally by the Company. We believe that superior science and evidence-based research, are necessary
for adoption by the medical and scientific community. With one FDA indication (functional abdominal pain associated with IBS in adolescents
11-18 years old) on the market, additional clinical trials of PENFS in multiple pediatric conditions are underway focused
on unmet healthcare needs in children, see &ldquo;&mdash;<I>Our Pipeline</I>&rdquo; for more information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first product, IB-Stim, is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated
with IBS. IB-Stim is a US FDA Class II medical device that has received one regulatory clearance: DEN180057, under the regulation name
of &ldquo;non-implanted nerve stimulator for functional abdominal pain relief.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Mission</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to provide solutions that create value and provide better and safer patient outcomes. We believe in improving lives and minimizing
suffering; particularly in the pediatric population, where research and therapeutics are usually lacking. The Company already has market
clearance for its IB-Stim &reg; that targets functional abdominal pain associated with IBS, in children, with a total addressable
market of up to 6 million children. Through innovation and research, we are reimagining the future of patient care.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Corporate History</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc.  was established in 2011 and incorporated
in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions, Inc. The name was changed to Neuraxis, Inc.
in March of 2022. Additionally, the Company filed a Certificate of Conversion to become a Delaware corporation on June 23, 2022. The
authorized shares were increased, and a par value established. On September 7, 2021, the Company&rsquo;s board of directors authorized
a 4-for-1 stock split. They also increased the number of authorized common stock shares from 2,700,000 to 10,800,000. Furthermore, on
September 9, 2021, the board authorized and increase of authorized shares of common stock from 10,800,000 to 13,400,000 in anticipation
of a capital offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As part of the conversion to a Delaware corporation,
the total number of shares of all classes of stock which the Corporation shall have authority to issue is 101,120,000 share, consisting
of (1) 100,000,000 shares of Common Stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;) and (ii) 1,120,000 shares of Preferred
Stock, par value $0.001 per share (&ldquo;Preferred Stock&rdquo;), 1,000,000 of which is designated as &ldquo;Series A Preferred Stock&rdquo;
and 120,000 of which is designated as &ldquo;Series Seed Preferred Stock&rdquo;.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Furthermore, on January
10, 2023, the Company&rsquo;s board of directors authorized a 1-for-2 reverse stock split. All per share information has been adjusted
for this reverse stock split. The reverse split became effective on January 12, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed three FDA cleared products, the IB-Stim (DEN180057, 2019), the NSS-2 Bridge (DEN170018, 2017), and the original 510(K)
clearance (K140530, 2014), all of which were developed internally by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    IB-Stim is a PENFS device that is indicated in patients 11-18 years of age with functional abdominal pain associated with irritable
    bowel syndrome. The IB-Stim currently is the only product marketed and sold by the Company.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    NSS-2 Bridge is a percutaneous nerve field stimulator, or PNFS, device indicated for use in the reduction of the symptoms of opioid
    withdrawal. The NSS-2 Bridge device was licensed to Masimo in April 2020, and we received a one-time licensing fee of $250,000 from
    Masimo. Masimo markets and sells this product as its <I>Masimo Bridge</I>, and we will not receive any further licensing payments
    or other revenue from this product.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    original 510(K) device was the electroacupuncture device (&ldquo;EAD&rdquo;), now called <I>NeuroStim</I>. The EAD is no longer being
    manufactured, sold or distributed but reserved only for research purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 59; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pediatrics
Industry Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pediatric
providers, as a whole, had expressed concern about the lack of attention given to children with functional abdominal pain disorders (including
IBS) and the limited treatment options available for a population that suffers from significant disabilities. With 20% of the
United States population under age 18, our Company focus is on opportunities in pediatrics industry. The pediatrics industry
has multi-billion-dollar market opportunities. The following points clearly outline the unmet need in children:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional
    abdominal pain in children is one of the most common conditions seen by pediatricians and pediatric gastroenterologists.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Children
    with functional abdominal pain report lower quality of life compared with their healthy peers and equal to those with inflammatory
    bowel disease.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall,
    35-45% of children with functional abdominal pain disorders continue to have symptoms into adulthood, which impacts quality of life
    and healthcare spending.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    study published in 2021 demonstrates insufficient evidence for the use of medications in pediatric functional abdominal pain disorders.
    This lack of evidence for drugs has been supported in by the American Academy of Pediatrics and NASPGHAN.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-Stim
    is the only therapy that has shown to improve pain, global symptoms, and functional disability in children with FAP and IBS.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-Stim
    is the only currently used therapy that is better than placebo in a randomized controlled trial and received FDA clearance for pediatric
    IBS.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Opportunity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
years, physicians and qualified healthcare professionals have resorted to the use off-label medications without proper evidence of efficacy
or safety. This is despite a technical report from the American Academy of Pediatrics and NASPGHAN which found very little evidence to
endorse the use of any drugs in the treatment of FAPDs in children. Medications including tricyclic antidepressants, SSRIs and gabapentinoids
continue to be used off-label despite lack of evidence to support efficacy or safety. Not only have the most commonly used medications
(amitriptyline and SSRIs) failed to beat placebo in clinical trials, but new studies also suggest significant risks with the potential
for serious side effects with these drugs. The absence of conclusive data to support treatments based on scientific evidence, and the
fact no drug therapies have been approved by the FDA for the treatment of FAPDs or IBS in children, presents a unique market opportunity
to for Neuraxis. Below are the current standard treatments in children with functional abdominal pain and IBS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1a_005.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 60; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Solutions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered into the pediatric market with clinical evidence, coverage and payment, and key opinion leaders and society endorsement, including
a signed letter from the American Academy of Pediatrics and NASPGHAN supporting our request for insurers to pay for our IB-Stim device.
Our IB-Stim&reg; is a non-drug alternative to reduce functional abdominal pain in patients with IBS. In June 2019, the FDA cleared
IB-Stim, a non-surgical, neuromodulation device for children and adolescents who suffer from IBS, through a de novo process (DEN180057).
The FDA created a new classification of PENFS for the IB-Stim device. This is based on pre-clinical and clinical studies demonstrating
the mechanism of action and efficacy. Based on this new class of devices, the IB-Stim falls under 21 CFR Part 876, Subpart F &ndash;
Therapeutic Devices, 876.5340, Product Code QHH. As a PENFS device, it is non-implantable and provides field stimulation to cranial nerves
V, VII, IX and X in the ear to access the CNS. It stimulates remotely from the source of pain to modulate central pain regions, such
as the limbic system, and relieve functional abdominal pain associated with IBS. Studies have demonstrated long-term benefits in functional
disability, psychological co-morbidities and pain. For example, the table below is from a recently published study of IB-Stim in a
population of patients with chronic functional abdominal pain. The follow-up was done at 6-12 months post-treatment and shows improvements
in validated questionnaires compared to baseline (API), functional disability index (FDI), pain catastrophizing scale (PCS), Screen for
Childhood Anxiety Related Disorders (SCARED) and the Promis Anxiety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Santucci
NR, King C, El-Chammas KI, Wongteerasut A, Damrongmanee A, Graham K, Fei L, Sahay R, Jones C, Cunningham NR, Coghill RC. <I>Effect of
percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological comorbidities in adolescents with functional
abdominal pain disorders.</I> Neurogastroenterol Motil. 2022;34:e14358.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1a_021.jpg" ALT="" STYLE="height: 307px; width: 625px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only submitted one FDA De Novo request and have not submitted any additional 510(k) premarket notifications for our pipeline indications
to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with treatment so far has been outstanding with the four weeks of therapy required to sustain long-term benefits. Compliance has been
an issue with non-pharmacological treatment for children, particularly with some of the psychological approaches such as cognitive behavioral
therapy or guided imagery, which sometimes requires 8-12 weeks of treatment. In fact, 95% of adolescents who used IB-Stim said that they
would recommend this treatment to family and friends. Many children&rsquo;s hospitals across the country are already treating children
with IB-Stim successfully since it provides a better alternative for therapy in children with IBS and disability and allows them to treat
them safely and effectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have concentrated our marketing focus on the 260 children&rsquo;s hospitals. To date, we have sold our IB-Stim product
to approximately 50 children&rsquo;s hospitals within our target market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-1a_014.jpg" ALT="" STYLE="height: 261px; width: 625px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competitive landscape for therapies includes off-label drugs and drugs with FDA approved only for adults with IBS while there is no
FDA indicated treatments for patients 11-18 years of age with functional abdominal pain associated with IBS and Rx often contain FDA
black box labels. It also includes devices that could theoretically be used, but do not have supporting data or FDA clearance for
functional bowel disorders or IBS. Our method patents also limit other devices from targeting IBS through stimulation of cranial nerve
branches in the ear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="forms-1a_025.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Approved
drugs for Adults with IBS</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rifaximin:
    an intraluminal antibiotic approved for IBS-diarrhea</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitiza:
    a drug that stimulates fluid secretion from the intestine, approved for IBS-diarrhea</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linzess<B>:
    </B>a drug that stimulates fluid secretion from the intestine, approved for IBS-constipation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plecanatide:
    a drug that stimulates fluid secretion from the intestine, approved IBS-constipation</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eluxadoline:
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a schedule IV-controlled substance that is a
    mixed opioid receptor agonist/antagonist in the intestine approved for IBS-diarrhea</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Devices</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gammaCore:
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a transcutaneous, cervical vagal nerve stimulator
    cleared for cluster and migraine headaches. Recent studies using this device for adults with gastroparesis.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transcranial
    Magnetic Stimulation: Multiple devices cleared to treat major depressive disorder and obsessive-compulsive disorder. To date,
    no known gastrointestinal indications.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roo
    System and Sparrow therapy system: Transcutaneous auricular stimulation devices-cleared for neonatal and adult opioid withdrawal.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
neurostimulation market is predominantly comprised of surgically implanted, invasive technologies that are not directly competitive
with our technology. Several neurostimulation companies are large, publicly traded companies that have a history in the market, have
significantly easier access to capital and other resources and have an established product pipeline. The combined clinical research
and product development done by the industry, including by us and all of our competitors, is uncovering the beneficial effects of
neurostimulation which now establishes neuromodulation as a valid and scientifically supported approach to the treatment of
neurological conditions, and accordingly, we expect for competition in the non-implanted space to grow in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 61; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
many companies have joined the neuromodulation space, there are no companies targeting the CNS or the brain-gut axis through auricular
nerves for functional bowel disorders or IBS. Currently, the Neuraxis method patents protect access to the brain, particularly the limbic
systems through branches of cranial nerves in the ear.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Competitive Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the following competitive strengths will enable us to compete effectively:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First
    to market</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    portfolio of device and method patents</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    Market Opportunities</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    pediatric pipeline </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Academic
    Society Support</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower
    capital expenditures in nurse, trainers, and representatives for first line therapy</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    clinical data carried out in leading academic institutions in the U.S. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Growth Strategies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
    price of our product is $1,195 per device and $4,780 per patient </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">gross margin</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct
    sales force</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Target
    customers are children&rsquo;s hospitals and pediatric clinics</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim device is to be used for the indication</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
of functional abdominal pain associated with IBS and functional nausea in children. The same underlying technology will be
used for the remaining pipeline indications, but we may use a name other than &ldquo;IB-Stim&rdquo; for marketing and commercialization
purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
one FDA indication&mdash;functional abdominal pain associated with IBS in adolescents 11-18 years old&mdash;on the market, additional
clinical trials of PENFS in multiple pediatric conditions are underway focused on unmet healthcare needs in children. These indications
consist of chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, cyclic vomiting syndrome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chart below shows our status in the FDA process for IB-Stim and each of the following pediatric indications:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Chronic nausea&mdash;RCT completed, and data being analyzed. ClinicalTrials.gov Identifier: NCT03675321, <I>Defining Adolescent
Nausea Through Brain-Gut Physiology and Non-Invasive Neurostimulation Response.</I> A randomized, double blind, placebo-controlled trial
to evaluate the efficacy of IB-Stim in children with functional nausea. The primary endpoint was to measure improvements in nausea using
the Nausea Severity Scale after IB-Stim therapy compared to a placebo device. The study will enrolled 110 participants and was conducted
at Children&rsquo;s Wisconsin/Medical College of Wisconsin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Post-concussion syndrome&mdash;RCT currently enrolling patients. ClinicalTrials.gov Identifier: NCT04978571, <I>A Prospective Study on
the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome (PCS). </I>A
randomized, double blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with post-concussion symptoms. The
primary endpoint will be to measure improvements in validated measures, including the Immediate Post-Concussion Assessment, Post-Concussion
Symptom Scale, and Balance Error Scoring Symptom compared to placebo. The study will enroll 100 participants and is being conducted
at Children&rsquo;s Hospital of Orange County.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Chemotherapy-induced nausea and vomiting&mdash;RCT currently enrolling patients. ClinicalTrials.gov Identifier: NCT05143554, <I>Efficacy
of Auricular Neurostimulation for Children Adolescents and Young Adults with Chemotherapy Induced Nausea and Vomiting.</I> Subject will
be randomized to five days of active vs placebo device during administered chemotherapy known to cause moderate to severe nausea/vomiting.
With the next scheduled identical chemotherapy cycle, each subject will cross over to the other device (active vs placebo). The primary
endpoint will be to measure improvements in validated measures of nausea and vomiting including the Baxter Retching Faces Scale, Rhodes
Index of Nausea, Vomiting and Retching, and also assessment of rescue medication. The study will enroll 50 participants and is being
conducted at Children&rsquo;s Wisconsin/Medical College of Wisconsin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
Cyclic vomiting syndrome&mdash;Pilot study completed, see ClinicalTrials.gov Identifier: NCT03434652. <I>Auricular Neurostimulation
for Children with Cyclic Vomiting Syndrome: A randomized, placebo-controlled trial.</I> RCT anticipated to begin enrolling patients
in the first half of 2033. This will be a multi-center, randomized, double blind, placebo-controlled trial to evaluate efficacy of
IB-Stim in pediatric patients with cyclic vomiting syndrome. The primary endpoint will be to measure decreases in the frequency and severity
of cyclic vomiting episodes compared to a placebo device. The study will include a minimum of 120 patients and the 3 sites are yet to
be finalized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
step in the FDA process differs in duration and cannot be predicted with accuracy. Timing</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
of FDA review and approval, if ever received, cannot be assured and the process and any approval is within the sole control and discretion
of the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<IMG SRC="forms-1a_002.jpg" ALT="" STYLE="height: 351px; width: 624px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 62; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Products</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim is a percutaneous PENFS system intended to be used in patients 11-18 years of age with functional
abdominal pain associated with IBS. IB-Stim already has market clearance from FDA for functional abdominal pain associated with IBS in
children. FDA has classified the non-implanted nerve stimulator for functional abdominal pain relief as Class II devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim is intended to be used for 120 hours per week for three (3) consecutive weeks, and not to exceed four (4) weeks, through application
to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction
of pain when combined with other therapies for IBS DEN180057. In published studies, patients treated with IB-Stim demonstrated significant
improvement in pain, disability and global symptoms with no serious adverse events, and minimal to no side effects, including localized
skin irritation. See <I>Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents: a randomized,
double-blind, sham-controlled trial</I>, Kovacic K, et.al., Lancet Gastroenterol Hepatol. 2017;2:727-737; <I>Efficacy of Auricular Neurostimulation
in Adolescents With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial</I>, Krasaelap A et.al., Clin Gastroenterol Hepatol.
2020;18:1987-1994; <I>Effect of percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological comorbidities
in adolescents with functional abdominal pain disorders</I>, Santucci et.al., Neurogastroenterol Motil. 2022;34:e14358.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the IB-Stim to produce systemic effects by modulating the central nervous system has been demonstrated in a pre-clinical animal
model of IBS (see &ldquo;<I>Pre-Clinical Data</I>&rdquo; in the section titled &ldquo;<I>Technology</I>&rdquo;). In patients with
IBS, the largest effect on all pain measures, including composite pain scores, worst pain, disability and global symptoms,
was seen after completing three consecutive weeks of treatment (see &ldquo;<I>Clinical Data</I>&rdquo; in the section titled &ldquo;<I>Technology</I>&rdquo;).
A fourth consecutive week of treatment was included in clinical testing; no safety concerns were identified with this extra consecutive
week of treatment. In the trial of 115 subjects, 10 patients reported side-effects and only three discontinued the study because of
side-effects. Of such 10 patients, six experienced ear discomfort (three in the PENFS group, three in the sham group), three experienced
adhesive allergy (one in the PENFS group, 2 in the sham group), and one experienced syncope due to needle phobia (in the sham group).
There were no serious adverse events.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
providers are trained to place the IB-Stim through IB-Stim Training and Certification. Once the provider is trained, the device can be
placed in the outpatient clinic and can be removed by the provider in the clinic or the patient at home. IB-Stim stays on for a total
of five-days to allow delivery of gentle electrical pulses to nerves below the skin that access the central nervous system. A study in
adolescents showed greater improvement in functional abdominal pain and global symptom improvement with every week of treatment (up to
four weeks). At the end of the four-week study, 95% of adolescents stated they would recommend the treatment to family or friends. Safety
of percutaneous electrical nerve field stimulation has also been reported in a separate study of over 1200 adult patients with no serious
adverse events and minimal to no side-effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
wearing our IB-Stim device and following an easy-to-learn and efficient procedure, patients can still attend school and extracurricular
activities, exercise or play non-contact sports, shower, wear ear buds or headphones, and travel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
IB-Stim device costs $1,195 per device, and each patient will use four (4) devices. Potential patients with other indications are expected
to use six (6) or more devices per patient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 63; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Technology</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
maladaptive central nervous system can process pain and emotions differently. This often occurs in children following a traumatic event,
viral infections, inflammation or trauma. Changes in brain pathways are known to be involved in the pathophysiology of functional bowel
disorders and IBS. The IB-Stim works by sending gentle electrical impulses into cranial nerve bundles located in the ear. This stimulation
targets brain areas that process pain and helps reduce functional abdominal pain associated with IBS. An animal model of IBS demonstrated
that the firing of neurons in the amygdala could be reduced by more than 50% in just 15 minutes of stimulation with the IB-Stim
technology. A recent human study in adults with pain related to fibromyalgia suggested that the IB-Stim technology exerts its effect
by modulating emotional and executive control centers related to pain processing, see <I>Feasibility of Auricular Field Stimulation
in Fibromyalgia: Evaluation by Functional Magnetic Resonance Imaging, Randomized Trial</I>, Woodbury et.al.<I>,</I> Pain Med. 2021;22:715-726.
The field of art pertains to an electrical stimulation device, including a stimulator containing a generator to deliver electrical
pulses with defined parameters, and a power supply for supplying the electrical energy through four separate needles, and at least one
of which is a needle array.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-1a_008.jpg" ALT="" STYLE="height: 476px; width: 550px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Pre-Clinical
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an animal model of IBS, extracellular, electrophysiologic recordings were performed from neurons in the rat amygdala before and 15 minutes
after PENFS treatment. There was a 65% decrease in the spontaneous firing of these neurons after 15 minutes of PENFS.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
This dampening of neurons in the CNS likely accounts for the modulation of pain responses in a model of post-inflammatory visceral and
somatic hyperalgesia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1a_015.jpg" ALT="" STYLE="height: 258px; width: 150px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 64; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
goal is to have over 700 published patients specific to our first FDA indication which is functional abdominal pain associated with irritable
bowel syndrome in patients 11-18 years of age by July 1, 2023. A published patient is defined as a patient who went through a study and
the study was analyzed and now the study has been published in a peer-reviewed journal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
randomized, controlled study in children 11-18 year of age used primary endpoint of improvements in abdominal pain. The Pain Frequency-Severity-Duration
(&ldquo;PFSD&rdquo;) questionnaires was completed at baseline by all subjects and after each week of treatment (weeks 1&ndash;3), as
well as at extended follow-up occurring in the 8&ndash;12 weeks following the end of treatment. The PFSD scale incorporates multiple
aspects of the pain experience and was administered weekly during treatment and at extended follow-up appointments. The PFSD scale validated
for chronic pain in children (aged 8&ndash;18 years). The PFSD was also used to rate weekly worst abdominal pain on a numerical rating
scale (0 for no pain, 10 for worst pain). Patients were followed up for a median of 9.2 weeks from the last week of treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the active PENFS group, median worst pain at follow-up remained lower (baseline: 8.0 vs. follow-up: 6.0), whereas there was no difference
at follow-up in the control group (baseline: 7.5 vs. follow-up: 7.0). The between-group differences in worst pain ratings after 3 weeks
of treatment showed that the PENFS group improved to a greater extent, with the control group reporting significantly higher worst pain
(median 7.0) than the PENFS group (median 5.0).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
long-term follow-up, median PFSD composite scores were 12.6 (IQR 3.6&ndash;22.5) in the PENFS group and 16.8 (4.8&ndash;33.6) in the
control group. A comparison of changes in PFSD composite scores (baseline to follow-up) showed that patients in the PENFS group reported
significantly greater improvement in pain (median &ndash;8.4) than those in the control group (median 0.0). This study was published
in the Lancet Gastroenterology Hepatology, (Kovacic K, et.al.. Lancet Gastroenterol Hepatol. 2017;2:727-737).</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><IMG SRC="forms-1a_010.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
secondary endpoint in the same study used the</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> functional
disability index (FDI) to assess functional disability in those treated with PENFS and compared to sham treatment. Those treated with
PENFS changed from moderate disability to minimal at the 2&ndash;3-month follow-up while the sham device group had
no change.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-1a_016.jpg" ALT=""></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>


<!-- Field: Page; Sequence: 65; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A separate published paper looked at 51
pediatric patients with IBS and used the symptoms response scale (SRS) to assess global symptoms improvement following PENFS
treatment compared to sham. Global symptom improvement was assessed with a validated pediatric questionnaire, Symptom Response Scale
(SRS). Symptoms were recorded as better, worse, or no change based on a 15-point scale across individual domains for both
improvement and deterioration of overall symptoms. Findings from several studies that used the SRS have shown that using 7-point
scale response options in disease-specific measures, a change score of 0.5 represents the minimal clinically important difference
(Juniper et.al. J Clin Epidemiol 1994; 47: 81&ndash;87 and Guyatt GH et.al..1987; 42: 773&ndash;78). As previously noted, a minimum
change in score of <FONT STYLE="font-family: DengXian">&ge;</FONT>2 was chosen for this study as a more stringent criterion for
global improvement before and after PENFS treatment and to compare between groups. Patients and providers were blinded in terms of
those who received active PENFS or sham. At the end 3 weeks of therapy using the change of <FONT STYLE="font-family: DengXian">&ge;</FONT>2,
81% of the PENFS group compared with 26% of the sham group (*p<FONT STYLE="font-family: DengXian">&le; </FONT>0.001, #p=0.002)
reported overall symptom improvement. When applying an even more stringent criteria with a change <FONT STYLE="font-family: DengXian">&ge;</FONT>3
on the SRS, 67% of the PENFS group compared with 22% of the sham group reported symptoms improvement (p=0.002) (Krasaelap A et.al.
Efficacy of Auricular Neurostimulation in Adolescents With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. Clin
Gastroenterol Hepatol. 2020;18:1987-1994).</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1a_017.jpg" ALT="" STYLE="height: 215px; width: 200px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
more recent open-label study of 20 patients treated with PENFS in a &ldquo;real-world&rdquo; clinical setting at Cincinnati Children&rsquo;s
Hospital demonstrated that after PENFS, abdominal pain (p &lt; 0.0001), nausea (p=0.001), pain catastrophizing (p = 0.001), functional
disability (p&lt;0.0001), and anxiety (p = 0.03) exhibited significant improvements, and were sustained 6-12 months after treatment (Santucci
et.al.. Effect of percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological comorbidities in adolescents
with functional abdominal pain disorders. Neurogastroenterol Motil. 2022;34:e14358). Validated questionnaires</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
included the abdominal pain index (API), nausea severity scale (NSS), functional disability index (FDI), as well as psychological measures
of catastrophizing (PCS-C) and anxiety (SCARED). The table below summarizes the results pre, during and post PENFS results at long-term
follow-up (Santucci et.al.. Effect of percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological
comorbidities in adolescents with functional abdominal pain disorders. Neurogastroenterol Motil. 2022;34:e14358).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; color: Red"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1a_012.jpg" ALT="" STYLE="height: 295px; width: 625px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
clinically meaningful endpoint is the number needed to treat (NNT) used in treatment for abdominal pain-related functional gastrointestinal
disorders in adolescents. NNT means the number of patients that need to be treated for one patient to get the targeted improvement (</FONT><FONT STYLE="font-family: DengXian; font-size: 10pt">&ge;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30%
improvement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reimbursement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
technology specific CAT III CPT Code (0720T) was published on December 30, 2021 and effective on July 1, 2022. A CAT III CPT code is
viewed as a temporary CPT code, and we expect to engage with AAP and NASPGHAN to submit for our permanent CAT I CPT code in 2023
and receive approval in early 2024 - 2025. As of the date of this prospectus, there are three (3) commercial written insurance
coverage policies that cover our CPT Code, including BCBS Nebraska, which covers approximately 700,000 lives, BCBS Massachusetts,
which covers approximately 3 million lives, and Quartz Wisconsin, which covers approximately 300,000 lives. </FONT>A total
of approximately 4 million lives are now covered by the three (3) commercial written insurance coverage policies that cover our CPT Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; margin: 0; font: 10pt Times New Roman, Times, Serif">Moreover, we are actively leveraging publications to expand the coverage.
We are expecting position paper from the academic society and guideline changes that support IB-Stim as standard of care.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Marketing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
market our products through search engine optimization, or SEO, internet channels and to physicians via the academic society. We plan
to extensively ramp-up our marketing efforts to patients and physicians as we gain additional indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patients/Customers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current patient base is children, who ages 11-18 and suffering from functional abdominal pain. Our customers are primarily children&rsquo;s
hospitals who serve these children.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="forms-1a_018.jpg" ALT="" STYLE="height: 302px; width: 625px"></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property consists of patents, trademarks, and trade secrets. Our trade secrets consist of product formulas, research,
and development, and unpatentable know-how, all of which we seek to protect, in part, by confidentiality agreements. To protect our
intellectual property, we rely on a combination of laws and regulations, as well as contractual restrictions. Federal trademark law protects
our registered trademarks. We also rely on the protection of laws regarding unregistered copyrights for certain content we create and
trade secret laws to protect our proprietary technology. To further protect our intellectual property, we enter into confidentiality
agreements with our executive officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Trademarks</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has 10 registered trademarks, eight (8) of which are being used in commerce:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 14%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trademark</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Reg. No.</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Reg. Date</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 41%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Class/Goods</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Status</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">NEURO-STIM and Design</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5105257&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">20-Dec-2016&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10 Int. nerve stimulator apparatus</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">NSS THE NEUROSTIM SYSTEM and Design</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4905470</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23-Feb-2016&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10 Int. nerve stimulator apparatus </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">THE NEURO-STIM SYSTEM and Design</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5105258&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">20-Dec-2016&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10 Int. nerve stimulator apparatus </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">NSS</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4852008&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10-Nov-2015&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10 Int. Medical apparatus, namely, electrical nerve stimulators;
    medical device, namely, a non- implantable neurological pain management generator, with percutaneously-implantable needle arrays;
    medical system and apparatus consisting of a non-implantable modulating frequency generator, providing neuromodulation therapy to
    cranial and peripheral nerves; medical system and apparatus consisting of implantable arrays for transmitting current into auricular
    and peri-auricular tissue; medical device for peripheral nerve and nerve field stimulation; medical system and apparatus consisting
    of a non-implantable modulating frequency generator and implantable needle arrays for transmitting current into auricular and peri-auricular
    tissue for use in pain management, namely, patient stimulators for auricular and peri-auricular peripheral nerve field neuromodulation
    therapy; medical apparatus, appliances and instruments for peripheral nerve field stimulation in cranial and peripheral nerves and
    occipital nerve branches, for pain control, headache control, control of phantom limb pain, stump pain, reflex sympathetic dystrophy
    (RSD), peripheral neuropathies and other types of sympathetically mediated pain </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 66; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; width: 8%"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-size: 10pt">IB-STIM</FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 9%"><FONT STYLE="font-size: 10pt">5926831&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%"><FONT STYLE="font-size: 10pt">03-Dec-2019&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 41%"><FONT STYLE="font-size: 10pt">10 Int. medical apparatus, namely, electrical nerve
    stimulators; medical device, namely, a non- implantable modulating frequency generator, providing neuromodulation therapy to cranial
    and peripheral nerves; medical apparatus consisting of percutaneously implantable arrays for transmitting current into auricular
    and peri-auricular tissue; medical device for peripheral nerve and nerve field stimulation; medical device consisting of a non-implantable
    modulating frequency generator and percutaneously implantable needle arrays for transmitting current into auricular and peri-auricular
    tissue for use in pain management and FGID (functional gastrointestinal disorders), namely, patient stimulator for auricular and
    peri-auricular peripheral nerve field neuromodulation therapy; medical apparatus, for peripheral nerve field stimulation in cranial
    and peripheral nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional dyspepsia, functional abdominal
    pain, nausea, functional nausea, abdominal migraine, Crohn&rsquo;s Disease, visceral hypersensitivity, chronic inflammatory bowel
    disease, changes in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and anxiety, satiety and changes
    in autonomic nervous system and other types of sympathetically mediated pain </FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 8%"><FONT STYLE="font-size: 10pt">Registered </FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">IB-STIM and Design</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5926832</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">03-Dec-2019</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10 Int. medical apparatus, namely, electrical nerve stimulators;
    medical device, namely, a non- implantable modulating frequency generator, providing neuromodulation therapy to cranial and peripheral
    nerves; medical apparatus consisting of percutaneously implantable arrays for transmitting current into auricular and peri-auricular
    tissue; medical device for peripheral nerve and nerve field stimulation; medical device consisting of a non-implantable modulating
    frequency generator and percutaneously implantable needle arrays for transmitting current into auricular and peri-auricular tissue
    for use in pain management and FGID (functional gastrointestinal disorders), namely, patient stimulator for auricular and peri-auricular
    peripheral nerve field neuromodulation therapy; Medical apparatus, for peripheral nerve field stimulation in cranial and peripheral
    nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional dyspepsia, functional abdominal pain, nausea,
    functional nausea, abdominal migraine, Crohn&rsquo;s Disease, visceral hypersensitivity, chronic inflammatory bowel disease, changes
    in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and anxiety, satiety and changes in autonomic
    nervous system and other types of sympathetically mediated pain </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">IB-STIM AURICULAR STIMULATOR</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5978411&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">04-Feb-2020&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10 Int. medical apparatus, namely, electrical nerve stimulators;
    Medical device, namely, a non- implantable modulating frequency generator, providing neuromodulation therapy to cranial and peripheral
    nerves; Medical apparatus consisting of percutaneously implantable arrays for transmitting current into auricular and peri-auricular
    tissue; Medical device for peripheral nerve and nerve field stimulation; Medical device consisting of a non-implantable modulating
    frequency generator and percutaneously implantable needle arrays for transmitting current into auricular and peri-auricular tissue
    for use in pain management and FGID (functional gastrointestinal disorders), namely, patient stimulator for auricular and peri-auricular
    peripheral nerve field neuromodulation therapy; Medical apparatus, for peripheral nerve field stimulation in cranial and peripheral
    nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional dyspepsia, functional abdominal pain, nausea,
    functional nausea, abdominal migraine, Crohn&rsquo;s Disease, visceral hypersensitivity, chronic inflammatory bowel disease, changes
    in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and anxiety, satiety and changes in autonomic
    nervous system and other types of sympathetically mediated pain </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">IB-STIM AURICULAR STIMULATOR and Design</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;5978412</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">04-Feb-2020&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10 Int. medical apparatus, namely, electrical nerve stimulators;
    medical device, namely, a non- implantable modulating frequency generator, providing neuromodulation therapy to cranial and peripheral
    nerves; medical apparatus consisting of percutaneously implantable arrays for transmitting current into auricular and peri-auricular
    tissue; medical device for peripheral nerve and nerve field stimulation; medical device consisting of a non-implantable modulating
    frequency generator and percutaneously implantable needle arrays for transmitting current into auricular and peri-auricular tissue
    for use in pain management and FGID (functional gastrointestinal disorders), namely, patient stimulator for auricular and peri-auricular
    peripheral nerve field neuromodulation therapy; medical apparatus, for peripheral nerve field stimulation in cranial and peripheral
    nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional dyspepsia, functional abdominal pain, nausea,
    functional nausea, abdominal migraine, Crohn&rsquo;s Disease, visceral hypersensitivity, chronic inflammatory bowel disease, changes
    in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and anxiety, satiety and changes in autonomic
    nervous system and other types of sympathetically mediated pain </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Registered</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>


<!-- Field: Page; Sequence: 67; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; width: 8%"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 14%"><FONT STYLE="font-size: 10pt">NEURAXIS</FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 9%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 41%"><FONT STYLE="font-size: 10pt">10 Int. Nerve stimulator apparatus; nerve stimulator
    apparatus for FGID, irritable bowel, functional dyspepsia, functional abdominal pain, nausea, functional nausea, abdominal migraine,
    Crohn&rsquo;s Disease, visceral hypersensitivity, chronic inflammatory bowel disease, changes in FGID co- morbidities, sleep disturbances,
    psychological disorders, including mood, anxiety, and satiety, pain control, headache control, control of phantom limb pain, stump
    pain, reflex sympathetic dystrophy (RSD), peripheral neuropathies and other types of sympathetically mediated pain </FONT></TD>
    <TD STYLE="text-align: center; width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 8%"><FONT STYLE="font-size: 10pt">Filed</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">US</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">NEURAXIS (STYLIZED)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">10 Int. Nerve stimulator apparatus; nerve stimulator apparatus for
    FGID, irritable bowel, functional dyspepsia, functional abdominal pain, nausea, functional nausea, abdominal migraine, Crohn&rsquo;s
    Disease, visceral hypersensitivity, chronic inflammatory bowel disease, changes in FGID co- morbidities, sleep disturbances, psychological
    disorders, including mood, anxiety, and satiety, pain control, headache control, control of phantom limb pain, stump pain, reflex
    sympathetic dystrophy (RSD), peripheral neuropathies and other types of sympathetically mediated pain </FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Filed</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no unregistered trademarks.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I></I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Patents</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has eight (8) granted patents and nine (9) applied for patent applications in the United States and nine (9) applied
for foreign patent applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Country</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Owner</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 11%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Serial
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Actual
    Filing Date</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 6%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issue
    Date</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Anticipated
    Expiration Date</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Application
    Status</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licensing
    Status</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3096494</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Apr-2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">201980027574.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Apr-2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19850021.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Apr-2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-509961</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23-Oct-2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2020-7034010</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Apr-2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/040766</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23-Sep-2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11369791</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Jun-2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Jun-2039</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/715121</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07-Apr-2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/314028</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Feb-2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE AND METHODS FOR USING THE SAME &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/315371</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">01-Mar-2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    NERVE FIELD STIMULATION DEVICE AND METHODS FOR USING THE SAME &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/014169</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Jun-2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10322062</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18-Jun-2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    PERIPHERAL NERVE FIELD STIMULATOR AND METHOD OF OPERATING SAME &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/408004</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">09-May-2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11077019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Aug-2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    PERIPHERAL NERVE FIELD STIMULATOR AND METHOD OF OPERATING SAME</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/363620</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Jun-2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR
    PERIPHERAL NERVE FIELD STIMULATOR AND METHOD OF OPERATING SAME </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/830411</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">02-Jun-2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEVICE
    AND METHOD FOR ERADICATING PATHOGENS IN NASAL PASSAGES &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 68; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/589082</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Jan-2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL
    AUDITORY CANAL PHOTOBIOMODULATION AND AUDIO THERAPY DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/861646</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jul-2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL
    AUDITORY CANAL THERAPY DEVICE</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3143304</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Dec-2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL
    AUDITORY CANAL PHOTOBIOMODULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202080060202.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23-Jun-2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL
    AUDITORY CANAL PHOTOBIOMODULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20830917.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Dec-2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL
    AUDITORY CANAL PHOTOBIOMODULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-576915</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Dec-2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL
    AUDITORY CANAL PHOTOBIOMODULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/617364</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">08-Dec-2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL
    AUDITORY CANAL PHOTOBIOMODULATION DEVICE &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/488416</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-Apr-2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10413719</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-Sep-2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-April-2037</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    OF TREATING DISEASE USING AURICULAR PERIPHERAL NERVE FIELD STIMULATION &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/534159</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">07-Aug-2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11331473</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-April-2037</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    OF TREATING DISEASE USING AURICULAR PERIPHERAL NERVE FIELD STIMULATION &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/725761</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Apr-2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS
    OF TREATING DISEASE USING AURICULAR PERIPHERAL NERVE FIELD STIMULATION &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied
    for</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/595185</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15-May-2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9839577</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Dec-2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYSTEM
    AND METHOD FOR AURICULAR PERIPHERAL NERVE FIELD STIMULATION &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/811278</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-Nov-2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10010479</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Jul-2018</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYSTEM
    AND METHOD FOR AURICULAR PERIPHERAL NERVE FIELD STIMULATION &nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
    Inc.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/277158</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2014</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9662269</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-May-2017</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYSTEMS
    AND METHODS FOR AURICULAR PERIPHERAL NERVE FIELD STIMULATION</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>TKBMN
Exclusive License Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 7, 2020, the Company entered into an exclusive license agreement with TKBMN, LLC to obtain an exclusive license under certain patent
rights (the &ldquo;Patent Rights&rdquo;) owned by TKBMN. Dr. Thomas Carrico, our Chief Regulatory Officer, is the manager of TKBMN.
Brian Carrico, our Chief Executive Officer, and Matt Carrico, our National Sales Director, are members of TKBMN. TKBMN owns the rights
to &ldquo;Systems and Methods for Electro-Therapy Treatment,&rdquo; US Patent No. 10,792,500 (the &ldquo;TKBMN Patent&rdquo;). The expiration
date of the TKBMN Patent is Oct 18, 2037, if all maintenance fees remain paid. Thomas Carrico is the author and inventor of the TKBMN
Patent and has assigned the auricular portion of the TKBMN Patent to the Company.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the exclusive license agreement, TKBMN agreed to grant an exclusive, worldwide, non-transferable, royalty-free license under Patent
Rights, which including three patents applications filed by TKBMN in connection with systems and methods for elector-therapy treatment,
to the Company to develop, market, and sell licensed products, in the field of electro-therapy treatment by stimulation of cranial nerves,
cranial nerve branches, auricular nerves, auricular nerve branches, auricular nerve bundles, and/or auricular anatomical structures in
human patients (the &ldquo;Field&rdquo;), in consideration of a one-time license fee of $1.00. The Company has the right to grant sublicenses
to the Patents Rights in the Field. The exclusive license agreement expires upon the expiration of the last to expire valid claim within
the Patent Rights and may be terminated by the Company upon 60 days prior written notice. Upon expiration or termination of the exclusive
license agreement, all rights in the Patent Rights will revert to TKBMN. There are no royalties or any other form of committed revenue
to TKBMN or any of its members, Under the agreement, the Company has agreed to cover fees and expenses associated with maintenance, prosecution,
and additional associated/continuation patent filings for the TKBMN Patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Masimo
License and Collaboration Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, the Company entered into a license and collaboration agreement with Masimo. As consideration, in part, Masimo entered
into a Series A Preferred Stock purchase agreement with the Company. Under the license and collaboration agreement, the Company
grants an exclusive, fully paid-up, royalty-free license to specifically identified patents and trademarks in a limited Field
of use. At all times, the Company remains the owner of all licensed intellectual property rights, and there is a possibility
of joint ownership of collaboratively developed products and methods. The licensed patents are generally directed to a device
and the treatment of opioid withdrawal symptoms. The licensed trademarks are generally directed to the NSS-2 Bridge mark.
The license agreement includes a collaboration component to efficiently develop, obtain regulatory approval, and commercialize
products for the limited field of use. The term of the agreement is in effect until the expiration or lapse of the last intellectual
property rights. Masimo paid a one-time fee of $250,000. The license and collaboration agreement may not be terminated by the Company
for any reason, and the sole remedy for any breach or default by Masimo shall be to seek monetary damages and equitable remedies. The
license and collaboration agreement may be terminated by Masimo if there is material breach by the Company that remain uncured for thirty
(30) days or without cause by providing thirty (30) days prior written notice. See <I>&ldquo;&mdash;Our Corporate History</I>&rdquo;
for more information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being a Smaller Reporting Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &ldquo;smaller reporting company&rdquo; as defined in Rule 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage
of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We
will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our shares held by non-affiliates
equals or exceeds $250 million as of the prior June 30<SUP>th</SUP>, or (2) our annual revenues equaled or exceeded $100 million during
such completed fiscal year and the market value of our shares held by non-affiliates equals or exceeds $700 million as of the prior June
30<SUP>th</SUP>. Such reduced disclosure and corporate governance obligations may make it more challenging for investors to analyze our
results of operations and financial prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information, see &ldquo;<I>Risk Factors &ndash; Because the Company is a &lsquo;smaller reporting company,&rsquo; we may take
advantage of certain scaled disclosures available to us, resulting in holders of our securities receiving less Company information than
they would receive from a public company that is not a smaller reporting company&rdquo; and &ldquo;As a smaller reporting company,&rdquo;
we may at some time in the future choose to exempt our Company from certain corporate governance requirements that could have
an adverse effect on our public stockholders.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company&rdquo; as defined in the JOBS Act. We will remain an emerging growth company until the earlier
of (1) December 31, 2024, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion,
(3) the last day of the fiscal year in which we are deemed to be a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2 under
the Securities Exchange Act of 1934, as amended, or the Exchange Act, which would occur on the date on which we have issued more than
$1.0 billion in non-convertible debt securities during the prior three-year period. An emerging growth company may take advantage of
specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable
to public companies. As an emerging growth company, we may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">present
    only two years of audited financial statements, plus unaudited condensed financial statements for any interim period, and related
    management&rsquo;s discussion and analysis of financial condition and results of operations in this prospectus;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">avail
    ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal
    control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide
    reduced disclosure about our executive compensation arrangements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not
    require stockholder non-binding advisory votes on executive compensation or golden parachute arrangements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the JOBS Act, an emerging growth company can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. We have elected not to take advantage of the extended transition period
for complying with new or revised accounting standards provided to emerging growth companies under the JOBS Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products and our operations are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, and other federal,
state, and local authorities in the United States, as well as comparable authorities in foreign jurisdictions. Our products are subject
to regulation as medical devices in the United States under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>United
States Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA regulates, among other things, the development, design, non-clinical and clinical testing, manufacturing, safety, effectiveness,
labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, adverse event reporting, advertising,
promotion, marketing and distribution, and import and export and post-marketing surveillance of medical devices in the United States
to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements
of the FDCA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>FDA
Premarket Clearance and Approval Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
an exemption applies, each new or significantly modified medical device commercially distributed in the United States requires FDA clearance
of a 510(k) premarket notification. The 510(k) clearance can be resource intensive, expensive, and lengthy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDCA, medical devices are classified into one of three classes&mdash;Class I, Class II or Class III&mdash;depending on the degree
of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness.
Class I devices are those for which safety and effectiveness can be assured by adherence to the FDA&rsquo;s general controls for medical
devices, which include compliance with the applicable portions of FDA&rsquo;s current good manufacturing practices for devices, as reflected
in the Quality System Regulation, or QSR, establishment registration and device listing, reporting of adverse medical events, and truthful
and non-misleading labeling, advertising, and promotional materials. Some Class I devices, also called Class I reserved devices, also
require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I devices are exempt
from the premarket notification requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
II devices are subject to the FDA&rsquo;s general controls, and any other special controls deemed necessary by the FDA to ensure the
safety and effectiveness of the device. These special controls can include performance standards, special labeling requirements, post-market
surveillance, patient registries and FDA guidance documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA requesting permission to
commercially distribute the device. The FDA&rsquo;s permission to commercially distribute a device subject to a 510(k) premarket notification
is generally known as 510(k) clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a new medical device does not qualify for the 510(k) premarket notification process because no predicate device to which it is substantially
equivalent can be identified, the device is automatically classified into Class III. The Food and Drug Administration Modernization Act
of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to
the absence of a predicate device, called the &ldquo;Request for Evaluation of Automatic Class III Designation,&rdquo; or the de novo
classification process. This process allows a manufacturer whose novel device is automatically classified into Class III to request down-classification
of its medical device into Class I or Class II on the basis that the device presents low or moderate risk. If the manufacturer seeks
reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable
assurance of the safety and effectiveness of the medical device. The FDA may reject the reclassification petition if it identifies a
legally marketed predicate device that would be appropriate for a 510(k) or that general controls would be inadequate to control the
risks and special controls cannot be developed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
FDA marketing authorization, de novo down-classification, or approval for medical devices is expensive and uncertain, and may take several
years, and generally requires significant scientific and clinical data.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
pre-amendment devices are unclassified, but are subject to FDA&rsquo;s premarket notification and clearance process in order to be commercially
distributed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 72; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Investigational
Device Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are sometimes required to support a 510(k) submission. In the United States, absent certain limited exceptions, human clinical
trials intended to support medical device clearance or approval or to determine safety and effectiveness of a device for an investigational
use must be conducted in accordance with the FDA&rsquo;s investigational device exemption, or IDE, regulations which govern investigational
device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities
of study sponsors and study investigators. If the device presents a &ldquo;significant risk,&rdquo; to human health, as defined by the
FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human
clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that
it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE application must be approved in
advance by the FDA for a specified number of subjects. Generally, clinical trials for a significant risk device may begin once the IDE
application is approved by the FDA and the study protocol and informed consent are approved by appropriate institutional review boards
at the clinical trial sites. There can be no assurance that submission of an IDE will result in the ability to commence clinical trials,
and although the FDA&rsquo;s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not
bind the FDA to accept the results of the trial as sufficient to prove the product&rsquo;s safety and effectiveness, even if the trial
meets its intended success criteria.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the device under evaluation does not present a significant risk to human health, then the device sponsor is not required to submit an
IDE application to the FDA before initiating human clinical trials, but must still comply with abbreviated IDE requirements when conducting
such trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient
and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating
disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application
must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans
and that the testing protocol is scientifically sound. The IDE will automatically become effective thirty (30) days after receipt by
the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or
other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regardless
of the degree of risk presented by the medical device, clinical studies must be approved by, and conducted under the oversight of, an
Institutional Review Board, or IRB, for each clinical site. The IRB is responsible for the initial and continuing review of the IDE,
and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs,
human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the
FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for
the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring
the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. Acceptance
of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective,
the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant
the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator
may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of
human subjects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting
clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping
and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators
in the clinical study are also subject to FDA&rsquo;s regulations and must obtain patient informed consent, rigorously follow the investigational
plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements.
Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons,
including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    FDA or other regulatory authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
    do not enroll in clinical trials at the rate expected;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
    do not comply with trial protocols;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient
    follow-up is not at the rate expected;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
    experience serious adverse events;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients
    die during a clinical trial, even though their death may not be related to the products that are part of the trial;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Device
    malfunctions occur with unexpected frequency or potential adverse consequences;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Side
    effects or device malfunctions of similar products already in the market that change the FDA&rsquo;s view toward approval of result
    in the imposition of new requirements or testing;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Institutional
    review boards and third-party clinical investigators may delay or reject the trial protocol;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
    clinical investigators decline to participate in a trial or do not perform a trial on the anticipated schedule or consistent with
    the clinical trial protocol, investigator agreement, investigational plan, good clinical practices, the IDE regulations, or other
    FDA or IRB requirements;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
    investigators are disqualified by the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    or third-party organizations do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent
    with the clinical trial protocol or investigational or statistical plans, or otherwise fail to comply with the IDE regulations governing
    responsibilities, records, and reports of sponsors of clinical investigations;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
    clinical investigators have significant financial interests related to us or our study such that the FDA deems the study results
    unreliable, or the company or investigators fail to disclose such interests;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory
    inspections of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective
    action or suspend or terminate our clinical trials;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in government regulations or administrative actions;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    interim or final results of the clinical trial are inconclusive or unfavorable as to safety or effectiveness; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    FDA concludes that our trial design is unreliable or inadequate to demonstrate safety and effectiveness.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>510(k)
Clearance Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 510(k) process, the manufacturer must submit to the FDA a premarket notification submission demonstrating that the proposed device
is &ldquo;substantially equivalent,&rdquo; as defined in the FDCA, to a legally marketed predicate device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior
to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class
II or I, or a device that was found substantially equivalent through the 510(k) process. A device is considered to be substantially equivalent
if, with respect to the predicate device, it has the same intended use and has either (i) the same technological characteristics; or
(ii) different technological characteristics, but the information provided in the 510(k) submission demonstrates that the device does
not raise different questions of safety or effectiveness than the predicate device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
the FDA will accept a 510(k) premarket notification for substantive review, the FDA will first assess whether the submission satisfies
a minimum threshold of acceptability. If the FDA determines that the 510(k) submission lacks necessary information for substantive review,
the FDA will issue a &ldquo;Refuse to Accept&rdquo; letter which generally outlines the information the FDA believes is necessary to
permit a substantive review and to reach a determination regarding substantial equivalence. An applicant must submit the requested information
before the FDA will proceed with additional review of the submission. If a 510(k) submission is accepted for substantive review, the
Medical Device User Fee Amendments sets a performance goal of 90 days for FDA review of a 510(k) submission, but the review time can
be delayed if FDA raises questions or requests additional information during the review process. As a practical matter, clearance often
takes longer, and clearance is never assured. Thus, as a practical matter, clearance often takes longer than 90 days. Although many 510(k)
premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make
a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device
is substantially equivalent, it will grant clearance to commercially market the device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that the device is substantially equivalent to a predicate device, it will grant 510(k) clearance to commercially
market the device. If the FDA determines that the device is &ldquo;not substantially equivalent&rdquo; to a previously cleared device,
the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous requirements of the
PMA approval process, or can request a risk-based classification determination for the device in accordance with the &ldquo;<I>de novo</I>&rdquo;
process, which is a route to market for certain novel medical devices that are low to moderate risk and are not substantially equivalent
to a predicate device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices can only be marketed for the indications for use for which they are cleared or approved. After a device receives 510(k) clearance,
any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification
in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or <I>de novo </I>reclassification.
The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k), <I>de novo </I>request or
a PMA in the first instance, but the FDA may review this determination to evaluate the regulatory status of the modified product at any
time and may require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) marketing clearance
or PMA approval is obtained or a <I>de novo </I>request is granted. Also, in these circumstances, the manufacturer may be subject to
significant regulatory fines or penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements
for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process
for their products. For example, in November 2018, FDA officials announced steps that the FDA intended to take to modernize the premarket
notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to
drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset
certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that
have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. These proposals
have not yet been finalized or adopted, although the FDA may work with Congress to implement such proposals through legislation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 75; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
recently, in September 2019, the FDA issued revised final guidance describing an optional &ldquo;safety and performance based&rdquo;
premarket review pathway for manufacturers of &ldquo;certain, well-understood device types&rdquo; to demonstrate substantial equivalence
under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA,
thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices
in the clearance process. The FDA has developed and maintains a list device types appropriate for the &ldquo;safety and performance based&rdquo;
pathway and continues to develop product-specific guidance documents that identify the performance criteria for each such device type,
as well as recommended testing methods, where feasible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>PMA
Approval Process</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
III devices require PMA approval before they can be marketed, although some pre-amendment Class III devices for which FDA has not yet
required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process.
In a PMA, the manufacturer must demonstrate that the device is safe and effective for its intended use, and the PMA must be supported
by extensive data, including data from preclinical studies and human clinical trials. The PMA must also contain a full description of
the device and its components, a full description of the methods, facilities, and controls used for manufacturing, and proposed labeling.
Following receipt of a PMA, the FDA conducts an administrative review to determine whether the application is sufficiently complete to
permit a substantive review. If it is not, the agency will refuse to file the PMA. If FDA accepts the application for substantive review,
it has 180 days under the FDCA to complete its review of a filed PMA application, although in practice, the FDA&rsquo;s review often
takes significantly longer, and can take up to several years. During this review period, the FDA may request additional information or
clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&rsquo;s
response to deficiencies communicated by the FDA. The FDA considers a PMA or PMA supplement to have been voluntarily withdrawn if an
applicant fails to respond to an FDA request for information (e.g., major deficiency letter) within a total of 360 days. Before approving
or denying a PMA application, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application
and provide recommendations to the FDA as to whether the FDA should approve the submission, approve it with specific conditions, or not
approve it. The FDA may or may not accept the panel&rsquo;s recommendation. Prior to approval of a PMA, the FDA may conduct inspections
of the clinical trial data and clinical trial sites, as well as conduct inspections of the applicant or its third-party manufacturers&rsquo;
or suppliers&rsquo; manufacturing facility or facilities to, among other things, ensure compliance with the QSR. PMA applications are
also subject to the payment of user fees, which for fiscal year 2021 includes a standard application fee of $365,657.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall,
    the FDA review of a PMA application generally takes between one and three years, but may take significantly longer. The FDA can delay,
    limit or deny approval of a PMA application for many reasons, including:</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    device may not be shown safe or effective to the FDA&rsquo;s satisfaction;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    manufacturing process or facilities may not meet applicable requirements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in FDA approval policies or adoption of new regulations may require additional data.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which
usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have
been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device,
subject to the conditions of approval and the limitations established in the approval letter. The FDA may approve a PMA with post-approval
conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion,
sale and distribution, and collection of long-term follow-up data from patients in the clinical study that supported PMA approval or
requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance
when deemed necessary to protect the public health or to provide additional safety and effectiveness data for the device in a larger
population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number
of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval
can result in material adverse enforcement action, including withdrawal of the approval. If the FDA&rsquo;s evaluation of a PMA application
or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may
determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or
years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the
data are available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been
sought by other companies have never been approved by the FDA for marketing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
changes to an approved medical device, such as changes in manufacturing facilities, methods, quality control procedures, sterilization
(if applicable), packaging, expiration date, labeling, device specifications, materials, or design of a device, or other changes which
affect the safety or effectiveness of the device that has been approved through the PMA process require submission of a new PMA or PMA
supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited
to information needed to support any changes from the device covered by the original, approved PMA and may not require as extensive clinical
data or the convening of an advisory panel, depending on the nature of the proposed change. Certain other changes to an approved device
require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical
basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that
were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Ongoing
Regulation by the FDA</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after the FDA permits a device to be marketed, numerous and pervasive regulatory requirements continue to apply. These include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishment
    registration and device listing with the FDA;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">QSR
    requirements, which require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, supplier/contractor
    selection, compliant handling, documentation and other quality assurance procedures during all aspects of the design and manufacturing
    process;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labeling
    regulations, advertising and promotion requirements, restrictions on sale, distribution or sale of a device, each including the FDA
    prohibition against the promotion of products for any uses other than those authorized by the FDA, which are commonly known as &ldquo;off-label&rdquo;
    uses;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Medical Device Reporting, or MDR, regulations, which require that a manufacturer report to the FDA if a device it markets may have
    caused or contributed to a death or serious injury, or has malfunctioned and the device or a similar device that it markets would
    be likely to cause or contribute to a death or serious injury, if the malfunction were to recur;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
    device correction and removal reporting regulations, which require that manufacturers report to the FDA field corrections or removals
    if undertaken to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recall
    requirements, including a mandatory recall if there is a reasonable probability that the device would cause serious adverse health
    consequences or death;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
    order of repair, replacement, or refund;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Device
    tracking requirements; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-market
    study and surveillance requirements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute
a major change in its intended use, will require a new 510(k). The FDA requires each manufacturer to make this determination initially,
but the FDA can review any such decision and can disagree with a manufacturer&rsquo;s determination. If the FDA disagrees with a manufacturer&rsquo;s
determination not to seek a new 510(k) clearance, the FDA may retroactively require it to seek 510(k) clearance. The FDA could also require
the manufacturer to cease marketing and distribution and/or recall the modified device until 510(k) clearance is obtained. Also, in these
circumstances, the manufacturer may be subject to significant regulatory fines and penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
regulations require us to register as a medical device manufacturer with the FDA. Additionally, some states also require medical device
manufacturers and/or distributors doing business within the state to register with the state or apply for a state license, which could
subject our facility to state inspection as well as FDA inspection on a routine basis for compliance with the QSR and any applicable
state requirements. These regulations require that we manufacture our products and maintain related documentation in a prescribed manner
with respect to manufacturing, testing and control activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
processes for medical devices are required to comply with the applicable portions of the QSR, which cover the methods and the facilities
and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution,
installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device
master file, device history file, and complaint files. As a manufacturer, we are subject to periodic scheduled or unscheduled inspections
by the FDA. Failure to maintain compliance with the QSR requirements could result in the shutdown of, or restrictions on, manufacturing
operations and the recall or seizure of marketed products, which would have a material adverse effect on our business. The discovery
of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing severity
or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice
of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory
device recalls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has broad regulatory compliance and enforcement powers. If the FDA determines that a manufacturer has failed to comply with applicable
regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warning
    letters, untitled letters, fines, injunctions, consent decrees and civil penalties;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recalls,
    withdrawals, or administrative detention or seizure of our products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    restrictions or partial suspension or total shutdown of production;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refusing
    or delays in processing, clearing, or approving submissions or applications for new products or modifications to existing products;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suspension
    or withdrawal of 510(k) clearances or PMA approvals that have already been granted;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
    refusal to issue certification to foreign governments needed to export our products for sale in other countries; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Criminal
    prosecution.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
facilities, records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. Failure to comply with the
applicable United States medical device regulatory requirements could result in, among other things, warning letters, untitled letters,
fines, injunctions, consent decrees, civil penalties, unanticipated expenditures, repairs, replacements, refunds, recalls or seizures
of products, operating restrictions, total or partial suspension of production, the FDA&rsquo;s refusal to issue certificates to foreign
governments needed to export products for sale in other countries, the FDA&rsquo;s refusal to grant future premarket clearances or approvals,
withdrawals or suspensions of current product clearances or approvals and criminal prosecution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Regulation
of Medical Devices in the European Union</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Union, or EU, has adopted specific directives regulating the design, manufacture, clinical investigations, conformity assessment,
labeling and adverse event reporting for medical devices. EU directives must be implemented into the national laws of the EU member states
and national laws may vary from one member state to another.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, there is currently no premarket government review of medical devices. However, the EU requires that all medical devices placed
on the market in the EU must meet the relevant essential requirements laid down in the Council Directive 93/42/EEC, or the Medical Devices
Directive, and the Council Directive 90/385/EEC, or the Active Implantable Medical Devices Directive. The most fundamental essential
requirement is that a medical device must be designed and manufactured in such a way that it will not compromise the clinical condition
or safety of patients, or the safety and health of users and others. In addition, the device must achieve the performances intended by
the manufacturer and be designed, manufactured, and packaged in a suitable manner. The European Commission has adopted various standards
applicable to medical devices. These include standards governing common requirements, such as sterilization and safety of medical electrical
equipment and product standards for certain types of medical devices. There are also harmonized standards relating to design and manufacture.
While not mandatory, compliance with these standards is viewed as the easiest way to satisfy the essential requirements as a practical
matter. Compliance with a standard developed to implement an essential requirement also creates a rebuttable presumption that the device
satisfies that essential requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
demonstrate compliance with the essential requirements laid down in Annex I to the Medical Devices Directive, medical device manufacturers
must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. Conformity
assessment procedures require an assessment of available clinical evidence, literature data for the product, and post-market experience
in respect of similar products already marketed. Except for low-risk medical devices (Class I non-sterile, non-measuring devices), where
the manufacturer can self-declare the conformity of its products with the essential requirements (except for any parts which relate to
sterility or metrology), a conformity assessment procedure requires the intervention of a Notified Body. Notified Bodies are independent
organizations designated by EU countries to assess the conformity of devices before being placed on the market. A Notified Body would
typically audit and examine a product&rsquo;s technical dossiers and the manufacturers&rsquo; quality system (which must, in particular,
comply with ISO 13485:2016 related to Medical Devices Quality Management Systems). If satisfied that the relevant product conforms to
the relevant essential requirements, the Notified Body issues a certificate of conformity, which the manufacturer uses as a basis for
its own declaration of conformity. The manufacturer may then apply the CE Mark to the device, which allows the device to be placed on
the market throughout the EU.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notified
Body certificates of conformity are valid for a fixed duration (which shall not exceed five years). Throughout the term of the certificate,
the manufacturer will be subject to periodic surveillance audits to verify continued compliance with the applicable requirements. In
particular, there will be a new audit by the Notified Body before it will renew the relevant certificate(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based,
among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions
of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use,
that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended
performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. All manufacturers
placing medical devices into the market in the EU must comply with the EU medical device vigilance system. Under this system, incidents
must be reported to the relevant authorities of the EU member states, and manufacturers are required to take Field Safety Corrective
Actions, or FSCAs, to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device
that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance
of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might
have led to the death of a patient or user or of other persons or to a serious deterioration in their state of health. An FSCA may include
the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its
legal representative to its customers and/or to the end users of the device through Field Safety Notices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
advertising and promotion of medical devices is subject to some general principles set forth by EU directives. According to the Medical
Devices Directive, only devices that are CE-marked may be marketed and advertised in the EU in accordance with their intended purpose.
Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair commercial practices, while
not specific to the advertising of medical devices, also apply to the advertising thereof and contain general rules, for example requiring
that advertisements are evidenced, balanced and not misleading. Specific requirements are defined at national level. EU member states
laws related to the advertising and promotion of medical devices, which vary between jurisdictions, may limit or restrict the advertising
and promotion of products to the general public and may impose limitations on promotional activities with healthcare professionals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
EU member states have adopted specific anti-gift statutes that further limit commercial practices for medical devices, in particular
vis-&agrave; -vis healthcare professionals and organizations. Additionally, there has been a recent trend of increased regulation of
payments and transfers of value provided to healthcare professionals or entities. In addition, many EU member states have adopted national
&ldquo;Sunshine Acts&rdquo; which impose reporting and transparency requirements (often on an annual basis), similar to the requirements
in the United States, on medical device manufacturers. Certain countries also mandate implementation of commercial compliance programs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 25, 2017, Regulation 2017/745, or the EU Medical Devices Regulation, entered into force, which repeals and replaces the Medical Devices
Directive and the Active Implantable Medical Devices Directive. Unlike directives, which must be implemented into the national laws of
the EU member states, regulations are directly applicable, without the need for adoption of EU member state laws implementing them, in
all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The
Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory
framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medical Devices Regulation was originally intended to become applicable three years after publication, but in April 2020 the transition
period was extended by the European Parliament and the Council of the EU by an additional year &ndash; until May 26, 2021. Devices lawfully
placed on the market pursuant to the Medical Devices Directive and the Active Implantable Medical Devices Directive prior to May 26,
2021 may generally continue to be made available on the market or put into service until May 26, 2025. Once applicable, the new regulations
will among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthen
    the rules on placing devices on the market and reinforce surveillance once they are available;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establish
    explicit provisions on manufacturers&rsquo; responsibilities for the follow-up of the quality, performance and safety of devices
    placed on the market;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improve
    the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set
    up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available
    in the European Union, or EU; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthen
    the rules for the assessment of certain high-risk devices, which may have to undergo an additional check by experts before they are
    placed on the market.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus
Norway, Liechtenstein and Iceland. Other countries, such as Switzerland, have entered into Mutual Recognition Agreements and allow the
marketing of medical devices that meet EU requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU-UK Trade and Cooperation Agreement, or TCA, came into effect on January 1, 2021. The TCA does not specifically refer to medical devices.
However, as a result of Brexit, the Medical Devices Regulation will not be implemented in the UK, and previous legislation that mirrored
the Medical Devices Regulation in the UK law has been revoked. The regulatory regime for medical devices in the UK will continue to be
based on the requirements derived from current EU legislation, and the UK may choose to retain regulatory flexibility or align with the
Medical Devices Regulation going forward. CE markings will continue to be recognized in the UK, and certificates issued by EU recognized
Notified Bodies will be valid in the UK, until June 30, 2023. For medical devices placed on the UK market after this period, the UK Conformity
Assessment, or UKCA, marking will be mandatory. In contrast, UKCA marking and certificates issued by UK Notified Bodies will not be recognized
on the EU market. The TCA does provide for cooperation and exchange of information in the area of product safety and compliance, including
market surveillance, enforcement activities and measures, standardization related activities, exchanges of officials, and coordinated
product recalls (or other similar actions). For medical devices that are locally manufactured but use components from other countries,
the &ldquo;rules of origin&rdquo; criteria will need to be reviewed. Depending on which countries products will ultimately be sold in,
manufacturers may start seeking alternative sources for components if this would allow them to benefit from no tariffs. The rules for
placing medical devices on the Northern Ireland market will differ from those in the UK.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Healthcare
Fraud and Abuse Laws</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, we are subject to a number of federal and state healthcare regulatory laws that restrict business practices in the
healthcare industry. These laws include, but are not limited to, federal and state anti-kickback, false claims, transparency and other
healthcare fraud and abuse laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying,
soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing,
leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service reimbursable,
in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &ldquo;remuneration&rdquo; has been broadly
interpreted to include anything of value, including cash, improper discounts, and free or reduced-price items and services. Among
other things, the Anti-Kickback Statute has been interpreted to apply to arrangements between medical device manufacturers on the one
hand and prescribers and purchasers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting
some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. The government can exercise enforcement
discretion in taking action against unprotected activities. Further, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation. The majority of states also have anti-kickback laws,
which establish similar prohibitions, and in some cases may apply to items or services reimbursed by any third-party payor, including
commercial insurers and self-pay patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal false claims, including the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly
making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government,
or knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A claim
includes &ldquo;any request or demand&rdquo; for money or property presented to the U.S. government. Actions under the civil False Claims
Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Moreover, a
claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the federal civil False Claims Act. In addition, various states have enacted false claim laws analogous to the
federal False Claims Act, although many of these state laws apply where a claim is submitted to any third-party payor and not merely
a federal healthcare program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Health Insurance Portability and Accountability Act of 1996 created additional federal criminal statutes that prohibit, among
other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including
private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a
criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or
making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits,
items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment
is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program, with specific exceptions, to report annually
to CMS, information related to payments or other transfers of value made to physicians
(defined to include doctors, dentists, optometrists, podiatrists and chiropractors), and teaching hospitals, and applicable manufacturers
and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their
immediate family members. Beginning in 2022, such obligations will include payments and other transfers of value provided in the previous
year to additional healthcare professionals, including physician assistants, nurse practitioners, clinical nurse specialists, certified
nurse anesthetists, anesthesiologist assistants and certified nurse midwives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violations
of fraud and abuse laws, including federal and state anti-kickback and false claims laws, may be punishable by criminal and civil sanctions,
including fines and civil monetary penalties, the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid),
disgorgement and corporate integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on
companies. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such
companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Coverage
and Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, our currently cleared products are not separately reimbursed by any third-party payors and if covered, are paid for
as part of the procedure in which the product is used. Outside of the United States, there are many reimbursement programs through private
payors as well as government programs. In some countries, government reimbursement is the predominant program available to patients and
hospitals. Our commercial success depends in part on the extent to which governmental authorities, private health insurers and other
third-party payors provide coverage for and establish adequate reimbursement levels for the procedures in which our products are used.
Failure by physicians, hospitals, ambulatory surgery centers and other users of our products to obtain coverage and adequate reimbursement
from third-party payors for procedures in which our products are used, or adverse changes in government and private third-party payors&rsquo;
coverage and reimbursement policies, may adversely impact demand for our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our experience to date, third-party payors generally reimburse for the procedures in which our products are used if medical necessity
is met and a prior approval is completed with a favorable response. Some payors are moving toward a managed care system and control
their healthcare costs by establishing coverage policies that categorically restrict coverage of certain procedures, or by limiting authorization
for procedures, including elective procedures using our devices. No uniform policy of coverage and reimbursement among payors in the
United States exists and coverage and reimbursement for procedures can differ significantly from payor to payor. Third-party payors are
increasingly auditing and challenging the prices charged for medical products and services with concern for upcoding, miscoding, using
inappropriate modifiers, or billing for inappropriate care settings. Some third-party payors must approve coverage for new or innovative
devices or procedures before they will reimburse healthcare providers who use the products or therapies. Even though a new product may
have been cleared for commercial distribution by the FDA, we may find limited demand for our product unless reimbursement approval can
be obtained and/or maintained from governmental and private third-party payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to uncertainties surrounding coverage policies, there are periodic changes to reimbursement levels. Third-party payors regularly
update reimbursement amounts and also from time to time revise the methodologies used to determine reimbursement amounts. This includes
routine updates to payments to physicians, hospitals and ambulatory surgery centers for procedures during which our products are used.
These updates could directly impact the demand for our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the overall escalating cost of medical products and services being paid for by the government and private health insurance has
led to, and will continue to lead to, increased pressures on the healthcare and medical device industry to reduce the costs of products
and services. Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs through prospective
reimbursement and capitation programs, group purchasing, redesign of benefits, and exploration of more cost-effective methods of delivering
healthcare. In the United States, some insured individuals enroll in managed care programs, which monitor and often require pre-approval
of the services that a member will receive. Some managed care programs pay their providers on a per capita (patient) basis, which puts
the providers at financial risk for the services provided to their patients by paying these providers a predetermined payment per member
per month and, consequently, may limit the willingness of these providers to use our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted
price ceilings on specific product lines and procedures. In the European Union, member states are facing increased pressure to limit
public healthcare spending. There can be no assurance that procedures using our products will be covered for a specific indication, that
our products will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be available or that
the third-party payors&rsquo; reimbursement policies will not adversely affect our ability to sell our products profitably. More and
more, local, product specific reimbursement law is applied as an overlay to medical device regulation, which has provided an additional
layer of clearance requirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Healthcare
Reform</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change
the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United
States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare
costs, improving quality or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare
costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures
that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our
revenue from the sale of our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
implementation of the Affordable Care Act (the &ldquo;ACA&rdquo;) in the United States, for example, has changed healthcare financing
and delivery by both governmental and private insurers substantially, and affected medical device manufacturers significantly. The ACA,
among other things, provided incentives to programs that increase the federal government&rsquo;s comparative effectiveness research,
and implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and
other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Additionally,
the ACA expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee,
identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. Since its enactment,
there have been judicial, executive and political challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court
dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality
of the ACA. It is unclear how healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or
replace the ACA will impact the law or our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of
2011, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due to subsequent
legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020
through March 31, 2021, unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among
other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period
for the government to recover overpayments to providers from three to five years. The Medicare Access and CHIP Reauthorization Act of
2015 repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed
annual updates and a new system of incentive payments that began in 2019 that are based on various performance measures and physicians&rsquo;
participation in alternative payment models, such as accountable care organizations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect additional state and federal healthcare reform measures to be adopted in the future, any of which could limit the amounts that
federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or
additional pricing pressure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Data
Privacy and Security Laws</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access
to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal
and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA,
and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure,
and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition,
certain state and non-U.S. laws, such as the CCPA, the CPRA and the GDPR, govern the privacy and security of personal information, including
health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other
in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where
applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security
laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and
can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data
processing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Europe, the GDPR went into effect on May 25, 2018 and introduces strict requirements for processing the personal data of European Union
data subjects. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory
enforcement of data protection requirements and potential fines for noncompliance of up to &euro;20 million or 4% of the annual global
revenues of the preceding financial year of the noncompliant company, whichever is greater.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to
provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms
between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework
for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020
by the Court of Justice of the European Union.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom General Data Protection Regulation, or the UK
GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines
under the GDPR, i.e., fines up to the greater of &euro;20 million (&pound;17.5 million) or 4% of global turnover. The relationship between
the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is also unclear
how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from
the United Kingdom will be regulated in the long term. Currently there is a four- to six-month grace period agreed in the EU and United
Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, while the parties discuss an adequacy decision. The European
Commission published a draft adequacy decision on February 19, 2021. If adopted, the decision will enable data transfers from EU member
states to the United Kingdom for a four-year period, subject to subsequent extensions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Environmental
Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our current operations, environmental protection requirements do not have a significant financial and operational effect on the capital
expenditures, earnings and competitive position of our Company in the current financial year and are not expected to have a significant
effect in the reasonably foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Manufacturing Services Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 21, 2020, the Company entered into a
Manufacturing Services Agreement with GMI Corporation (&ldquo;GMI&rdquo;), dated as of August 21, 2020 (&ldquo;MSA&rdquo;), for the manufacture
and supply of the Company&rsquo;s IB-STIM device based upon the Company&rsquo;s product specifications as set forth in the MSA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company provides the necessary equipment to
GMI and retains ownership. GMI bears the risk of loss of and damage to the equipment and consigned materials. Performance under the MSA
is initiated by orders issued by the Company and accepted by GMI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The initial term of the MSA was 24 months and
automatically renews for terms of twelve months unless either party provides a written termination notice to the other party within 180
days prior to the end of the then-current term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">GMI was established in
1990 and manufactures our IB-Stim device in its 69,000 square foot facility that including offices, factory, environmentally
controlled room, warehouse, parts processing, assembly, quality control, of which approximately 1,000 square feet is dedicated to
producing our product, located in Indiana.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With controlled, repeatable, monitored production
process, GMI has kit production capacity that is sufficient for all our projected needs. There is a new, dedicated, environmentally controlled
build room built in 2022 for our equipment and production. All of our material are now maintained in this room.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">GMI has a quality management system that is ISO
13485:2016 certified, FDA registered, and ITAR registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In connection with the MSA, the Company entered
into a quality agreement with GMI, dated as of August 24, 2020, for GMI to test product provided by the Company and perform quality assurance
services.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, we had 16 full-time employees and one  part-time employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Facilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">Our
corporate headquarter is located in Carmel, Indiana, where we leased an office space for employees, <FONT STYLE="background-color: white">pursuant
to a lease agreement with SEPRO DEVELOPMENT COMPANY II, LLC. The three-year term of this lease commenced March 1, 2021 and is scheduled
to end on February 28, 2023. Over the term of this lease, base rent is $1,675.88 through March 2023, and $1,716.75 thereafter. The lease
may be extended for one year with an annual base rent of $21.50 per rentable square foot.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><FONT STYLE="background-color: white"></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">We
also lease </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">981 rentable <FONT STYLE="background-color: white">square
feet of space in </FONT>Versailles<FONT STYLE="background-color: white">, Indiana, where we lease </FONT>a total of 3,825 rentable <FONT STYLE="background-color: white">square
feet of office space pursuant to two lease agreements with Hashbo Properties, LLC. The lease term of each lease agreement commenced January
1, 2022 and is scheduled to end December 31, 2023, with an automatic one year renewal. Rents are payable monthly at a rate of $1,664
and $469.85, respectively.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Legal
Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business.
As of September 30, 2022, other than those described below, there were no pending or threatened legal proceedings that could reasonably
be expected to have a material effect on the results of the Company&rsquo;s operations. There are also no proceedings in which any of
the Company&rsquo;s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company&rsquo;s
interest.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2019, plaintiff Ritu Bhambhani, M.D., initiated a lawsuit against Innovative Health Solutions, Inc. and others in the
United States District Court for the District of Maryland. Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with
the Third Amended Complaint (&ldquo;Complaint&rdquo;) containing the most recent set of allegations. The Complaint asserted claims under
the RICO Act, as well as of fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and sought
compensatory damages in excess of $5 million, pre-judgment interest, punitive damages, attorney&rsquo;s fees, court costs and designation
of the case as a class action. The Complaint states that the Company, distributors of the Company&rsquo;s product, and medical billing
and coding consultants allegedly made misrepresentations to the plaintiffs that the Company&rsquo;s NeuroStim device and related procedures
could be billed to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim
to have suffered damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, the Company filed a motion for summary judgment based upon the plaintiffs not being proper parties to assert claims
against the Company. On June 14, 2022, the Court granted the Company&rsquo;s motion for summary judgment and dismissed the
Complaint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, plaintiffs Ritu Bhambhani and Sudhir Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. The Company
filed a motion to dismiss. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">On January 4, 2023, the
Court issued an order that stated it was deferring a ruling on the motion to dismiss the appeal and that </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
would address those arguments at the same time that it addressed the substantive merits of the case. &nbsp;The parties&rsquo; appellate
briefing is scheduled to be concluded in early April 2023.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
While it is too early to predict the ultimate outcome of this matter, we continue to believe we have meritorious defenses, that the dismissal
of the Complaint should be upheld, and intend to continue to defend this matter vigorously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, plaintiffs Ritu Bhambhani, LLC; Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and
SimCare ASC, LLC initiated a lawsuit against the Company and others in the United States District Court for the District of Maryland.
The plaintiffs in this lawsuit are business entities owned or partially owned by the plaintiffs that initiated the litigation described
above. The Complaint asserted claims under the RICO Act, as well as fraudulent misrepresentation, intentional misrepresentation by
concealment, and civil conspiracy and seeks compensatory damages in excess of $75,000, pre-judgment interest, punitive damages, attorney&rsquo;s
fees, and court costs. The Complaint states that the Company, distributors of the Company&rsquo;s product, and medical billing and
coding consultants allegedly made misrepresentations to the plaintiffs that the Company&rsquo;s NeuroStim device and related procedures
could be billed to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim
to have suffered damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The
Company has filed a motion to dismiss all claims, but no ruling has been issued. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
it is too early to predict the ultimate outcome of this matter, we believe we have meritorious defenses and intend to defend this matter
vigorously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_001"></A>MANAGEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors were elected to serve until the next annual meeting of stockholders and until their respective successors will have been elected
and will and will have qualified. The following table sets forth the name, age, and position held with respect to our present executive
officers and directors and our director nominees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Directors
and Executive Officers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information with respect to our directors and executive officers:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Age</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Position</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer, and Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Seale</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    Clarence*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Operating Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adrian
    Miranda*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer, Senior Vice President of Science and Technology</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carrico*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Regulatory Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Robin Brown</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of Innovation and Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Peterson*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director
    of Design and Engineering and Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    Henrichs**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley
    Mitch Watkins**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beth
    Keyser**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Dan
Clarence, Adrian Miranda, Thomas Carrico and Gary Peterson are current members of our board of directors and have effectively
resigned from the board of directors immediately upon the effectiveness of the registration statement of which this prospectus forms
a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**Timothy
Henrichs, Bradley Mitch Watkins, and Beth Keyser have accepted nomination to our board of directors and will become members of our board
of directors immediately upon the effectiveness of the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Brian
Carrico, President, Chief Executive Officer and Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
Carrico joined the Company in 2012. During his tenure, Mr. Carrico has held multiple leadership positions of increasing responsibility,
including Vice President of Sales and President before becoming CEO on January 1, 2018. As an early employee in the Company&rsquo;s life
cycle, Mr. Carrico was instrumental in setting the strategic agenda for the Company, raising start-up capital, championing new product
development, and bringing the Company&rsquo;s technology to market. Prior to joining Neuraxis, Mr. Carrico worked selling in the operating
room at Bard Medical and in the Cath lab at St. Jude Medical. He attended Indiana State University and holds a Bachelor of Science in
Business Marketing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>John
Seale, Chief Financial Officer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: #FEFEFE">John
Seale</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is a certified public accountant and a certified
information technology professional. He has served as our Chief Financial Officer since August 2022 and is also the managing partner
of RBSK Partners PC (&ldquo;RBSK&rdquo;), a CPA firm that offers a blend of accounting, audit, tax and specialized advisory services
to individuals and business clients and has been with RBSK since 1984. Mr. Seale, through RBSK, has prepared the Company&rsquo;s
financial statements since 2017. Mr. <FONT STYLE="background-color: #FEFEFE">Seale</FONT> specializes in delivering services to
clients in a variety of industries, including health care, manufacturing, professional services, agriculture, warehousing, real estate
and not-for-profits. Mr. <FONT STYLE="background-color: #FEFEFE">Seale</FONT> is also a qualified to perform peer reviews of CPA firms
in accordance with standards established by the Peer Review Board of the AICPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
<FONT STYLE="background-color: #FEFEFE">Seale</FONT> is a member of the American Institute of CPAs (AICPA), the Indiana CPA Society,
the Ohio CPA Society and the Association of Certified Fraud Examiners. He formerly served on the Indiana Society&rsquo;s Peer Review
Committee and the Review Acceptance Board, is a former member of the AICPA Information Technology Executive Committee and was the designated
audit committee financial expert on the board of directors of MainSource Financial Group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 86; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dan
Clarence, Chief Operating Officer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
Clarence, a proven senior executive with results oriented general management skills and a consistent track record of successful sales
and marketing initiatives over his career of thirty plus years, has served as our COO since 2018. Mr. Clarence attained a bachelor&rsquo;s
degree from Central Michigan University, followed by Graduate Studies at the University of Chicago MBA program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
his role as VP of Sales and Senior Director of Sales at Euro-Pro/Shark Ninja, a multi-Billion dollar privately held corporation, from
2011 to 2018, Mr. Clarence was responsible for pioneering the Wal-Mart/Sam&rsquo;s Club business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Adrian
Miranda, Chief Medical Officer, Senior Vice President of Science and Technology</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adrian
Miranda has served as our Chief Medical Officer since 2018 and brings a unique background of research and clinical expertise to
his role. Prior to joining Neuraxis, Dr Miranda was an Assistant professor at the Medical College of Wisconsin. He is a board-certified
pediatric gastroenterologist. He obtained his undergraduate degree in Biology from San Diego State University and obtained his medical
degree from the Medical College of Wisconsin. He completed his residency and subspecialty training in pediatric gastroenterology at Children&rsquo;s
Hospital of Wisconsin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a physician scientist, he has spent the past 20 years of his career investigating the pathophysiology of visceral and somatic pain, as
well as exploring new therapeutic options. His focus has been on studying the effects of adverse early life events, neuroplasticity and
the development of chronic pain. He has an extensive publication record and has lectured nationally and internationally.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Thomas
</I></B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Carrico, Chief Regulatory Officer</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carrico has served as our Chief Regulatory Officer
since November 2017. He joined the Company in February 2012 as Director of Regulatory Affairs. Prior to and during his early years with
Neuraxis, he was President &amp; Clinic Director at Spine and Neuromuscular Associates in Lawrenceburg, Indiana from January 2002 to
December 2018. He has over 40 years of experience in the healthcare field and has been involved in the study and application of techniques
and treatments that directly affect the autonomic nervous system, especially regarding homeostasis and balance of the parasympathetic
and the sympathetic nervous system. Dr. Carrico has a history of working with attorneys while serving on state and national boards, which
has positioned him to integrate into regulatory responsibilities at the Company. Dr. Carrico received his undergraduate education from
Indiana University and his Doctorate from Palmer College of Chiropractic.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Christopher
Robin Brown, Director of Innovation, Founder and Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Brown is a co-founder of the Company. He developed clinical protocol, initial practice guidelines, designed and implemented the practitioner
certification program, initiated the company 401K, and personally financed the first two years of the Company. After developing the technique
of transillumination to isolate auricular neurovascular bundles, he authored and designed the initial studies establishing neurovascular
and tissue energy transfer theories upon which the devices&rsquo; use are based. Dr. Brown establish initial communications with Dr.
Thomas Carrico (Chief Regulatory Officer), Dr. Adrian Miranda (Chief Medical Officer), John Seale (Accountant &amp; CFO) and our
IP attorneys at Barnes and Thornburg. Dr. Brown is listed as the sole or principal inventor on all Neuraxis patents and is currently
active in further device development working closely with compliance, product design and engineering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
graduation from the Indiana University School of Dentistry in 1982, while serving as clinic chief in the United States Army Reserve (USAR)
dental corps at Fort Benjamin Harrison in Indianapolis, Indiana, Dr. Brown started a private practice (current) concentrating in head,
neck, and facial pain developing the first hospital based facial pain clinic in Indiana. He received his master&rsquo;s degree in Biomechanical
Trauma in 1996 from Lynn University, one of only 12 dentists in the United States to hold the combination of DDS and MPS degrees. Dr.
Brown has authored several textbook chapters, published peer reviewed articles on the physics of soft tissue trauma, pain, financial
management, was regional editor for a national facial pain management Journal, and has lectured extensively nationally and internationally.
He served on the Board of Directors of the American Academy of Pain Management for 15 years, helping grow the organization from 800 members
to over 5000. Throughout his tenure, he developed educational tracks, served as Industry liaison, one term as treasurer and one term
as President. He served on the national board of The Alliance of TMD practitioners, serving one term as president.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
his career, Dr. Brown has been active in the purchasing and management of several destressed clinics, re-structuring them into profitable
enterprises. He has performed extensive volunteer work overseas providing surgical care in the Dominican Republic, local dental clinics
serving the underprivileged, and recently provided dental screenings for the deployment of soldiers in the USAR and National Guard.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Gary
Peterson, Director of Design and Engineering</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
Peterson is our founder, Director of Design and Engineering, and Director. Mr. Peterson was the Chief Executive Officer of the Company
from the time of founding in 2011 until January 1, 2018. Mr. Peterson then moved to a member of the board of directors and Director of
Design and Engineering of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Timothy
Henrichs, Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
</FONT>Henrichs has been a finance executive for the last 14 years. Mr. Henrichs currently serves as the Chief Financial Officer
of HomeRenew Buyer, Inc. (d/b/a Renovo Home Partners), a privately held short-term home improvement installer of bathrooms, kitchens,
windows, doors, cabinets, roofing and siding across the United States. Prior to joining Renovo Home Partners, Mr. Henrichs served as
the Executive Vice President and Chief Financial Officer from 2008 to 2022 of Follett Corporation, a privately held retailer and distributor
of print and digital course materials, textbooks, trade books, library books and general merchandise and developer of software technology
to the educational market including 80,000 schools. From 2005 to 2008, Mr. Henrichs served as the Global Controller of General Electric
Company&rsquo;s Healthcare Clinical Systems division responsible for the manufacture and distribution of patient monitoring, maternal
and infant care, ultrasound, diagnostic cardiology and anesthesiology equipment. From 2003 to 2005, Mr. Henrichs served as the Financial
Reporting Manager at Federal Signal Corporation. From 1995 to 2003, Mr. Henrichs served in various roles of increasing responsibility
at Ernst &amp; Young LLP in Chicago, Illinois and Frankfurt, Germany including Capital Markets and Mergers and Acquisitions Transaction
Support, ultimately serving as a Senior Manager in the Audit and Assurance practice. Mr. Henrichs holds a B.B.A in Accounting from the
University of Notre Dame and is a Certified Public Accountant with an inactive license in the State of Illinois.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Bradley
Mitch Watkins, Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley
Mitch Watkins has overseen four companies through their early commercialization periods within the medical device sector over the last
12 years. He has reported to the CEO or BOD directly and operated as the lead for all field operations. These duties have groomed Mr.
Watkins with a wide array of responsibilities beyond sales, including marketing, clinical study design, manufacturing, research and development,
FDA submissions as well as fiscal oversight are all areas of experience and competence. Mr. Watkins has been the National Sales Manager
of Terumo Interventional Systems since 2015, where he has led multiple new technology sales teams within the peripheral IV and Electrophysiology
markets. He now manages corporate accounts and GPO contracts for the Cardiovascular line of products. Over his 18 years in a multitude
of medical device markets, Mr. Watkins has overseen $410 million in company acquisitions in an array of leadership roles. He has reported
directly to CEOs and Board of Directors and has thrived in early commercialization, recruitment, and strategic company direction. Mr.
Watkins received his bachelor&rsquo;s degree in Behavioral Science from the University of Maryland. Mr. Watkins agreed to join the Company&rsquo;s
board of directors with proven expertise in commercial operational efficiency and sales effectiveness for startups and large corporations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Beth
Keyser, Director</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
more than 20 years&rsquo; experience in executive roles in population health, Beth Keyser is skilled at understanding the unique, complex
needs of multiple market segments and devises solutions that meet their specific goals. Ms.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Keyser is the President, BCBS of Indiana at Anthem, Inc. since 2020. From 2018 to 2020, Ms. Keyser served as the President, Create at
Brighton Health Plan Solutions. From 2015 to 2020, Ms. Keyser served as the Senior Vice President, International and Hawaii Markets at
Sharecare, Inc. Ms. Keyser received her master&rsquo;s degree in Executive Master of Science, Health Administration, from University
of Alabama at Birmingham.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
Carrico, our Chief Executive Officer and Director, is the son of Thomas Carrico, our Chief Regulatory Officer. There are no other
family relationships between or among any of our executive officers or other directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Role
of the Board</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the paramount duty of the board to oversee our management in the competent and ethical operation of the Company on a day-to-day basis
and to assure that the long-term interests of the stockholders are being served. To satisfy this duty, the directors take a proactive,
focused approach to their positions, and set standards to ensure that we are committed to business success through maintenance of ambitious
standards of responsibility and ethics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Director
Terms; Qualifications</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are elected for a term of one year and until their successors qualified, nominated, and appointed or elected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
considering whether directors and nominees have the experience, qualifications, attributes and skills to enable the board of directors
to satisfy its oversight responsibilities effectively in light of the Company&rsquo;s business and structure, the board of directors
focuses primarily on the industry and transactional experience, and other background, in addition to any unique skills or attributes
associated with a director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Director
or Officer Involvement in Certain Legal Proceedings</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no material proceedings to which any director or officer, or any associate of any such director or officer, is a party that is adverse
to our Company or any of our subsidiaries or has a material interest adverse to our Company or any of our subsidiaries. No director or
executive officer has been a director or executive officer of any business which has filed a bankruptcy petition or had a bankruptcy
petition filed against it during the past ten years. No director or executive officer has been convicted of a criminal offense or is
the subject of a pending criminal proceeding during the past ten years. No director or executive officer has been the subject of any
order, judgment or decree of any court permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement
in any type of business, securities or banking activities during the past ten years. No director or officer has been found by a court
to have violated a federal or state securities or commodities law during the past ten years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Directors
and Officers Liability Insurance</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has and plans on maintaining directors&rsquo; and officers&rsquo; liability insurance insuring its directors and officers against
liability for acts or omissions in their capacities as directors or officers, subject to certain exclusions. Such insurance may also
insure the Company against losses, which it may incur in indemnifying its officers and directors. In addition, officers and directors
also have indemnification rights under applicable laws, and the Company&rsquo;s Articles of Incorporation and Bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Director
Independence</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
listing rules of Nasdaq require that independent directors must comprise a majority of a listed company&rsquo;s board of directors. In
addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&rsquo;s audit, compensation,
and nominating and governance committees be independent. Audit committee members must also satisfy the independence criteria set forth
in Rule 10A-3 under the Exchange Act. Under the rules of Nasdaq, a director will only qualify as an &ldquo;independent director&rdquo;
if, in the opinion of that company&rsquo;s board of directors, that person does not have a relationship that would interfere with the
exercise of independent judgment in carrying out the responsibilities of a director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has undertaken a review of the independence of our directors and considered whether any director has a material relationship
with it that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based
upon information requested from and provided by each director concerning his background, employment and affiliations, including family
relationships, the board of directors has determined that three are &ldquo;independent&rdquo; as that term is defined under the applicable
rules and regulations of the SEC and the listing standards of Nasdaq. In making these determinations, our board of directors considered
the current and prior relationships that each non-employee director has with the Company and all other facts and circumstances our board
of directors deemed relevant in determining their independence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Board
Committees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the effectiveness of the registration statement of which this prospectus forms a part, the following three standing committees will
be established: Audit Committee; Compensation Committee; and Nominating and Corporate Governance Committee. Each
of our independent directors, Timothy Henrichs, Bradley Mitch Watkins, and Beth Keyser, will serve on each committee. Our board has adopted
written charters for each of these committees, and those charters will be effective upon the effectiveness of the registration statement
of which this prospectus forms a part. Upon completion of this offering, copies of the charters will be available on our website. Our
board may establish other committees as it deems necessary or appropriate from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Audit
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee, among other things, will be responsible for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing;
    approving the compensation of; overseeing the work of; and assessing the independence, qualifications, and performance of the independent
    auditor;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the internal audit function, including its independence, plans, and budget;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 89; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving,
    in advance, audit and any permissible non-audit services performed by our independent auditor;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our internal controls with the independent auditor, the internal auditor, and management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the adequacy of our accounting and financial controls as reported by the independent auditor, the internal auditor, and management;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    our financial compliance system; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    our major risk exposures regarding the Company&rsquo;s accounting and financial reporting policies, the activities of our internal
    audit function, and information technology.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors has affirmatively determined that each member of the Audit Committee meets the additional independence criteria applicable
to audit committee members under SEC rules and Nasdaq listing rules. Effective upon the completion of this offering the board of directors
will adopt a written charter setting forth the authority and responsibilities of the Audit Committee. The board of directors has affirmatively
determined that each member of the Audit Committee is financially literate, and that Mr. Henrichs meets the qualifications of an Audit
Committee financial expert.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee will consist of Timothy Henrichs, Bradley Mitch Watkins, and Beth Keyser. Mr. Henrichs will chair the Audit Committee.
We believe that, after consummation of this offering, the functioning of the Audit Committee will comply with the applicable requirements
of the rules and regulations of the Nasdaq listing rules and the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation
Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee will be responsible for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in">&#9679;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and making recommendations to the Board with respect to the compensation of our officers and directors, including the CEO;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    and administering the Company&rsquo;s executive compensation plans, including equity-based awards;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating
    and overseeing employment agreements with officers and directors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    how the Company&rsquo;s compensation policies and practices may affect the Company&rsquo;s risk management practices and/or risk-taking
    incentives.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee will consist of Timothy Henrichs, Bradley Mitch Watkins, and Beth Keyser, and Mr. Watkins will serve as chair
of the Compensation Committee. The board of directors has affirmatively determined that each member of the Compensation Committee meets
the independence criteria applicable to compensation committee members under SEC rules and Nasdaq listing rules. The Company believes
that, after the consummation of the offering, the composition of the Compensation Committee will meet the requirements for independence
under, and the functioning of such Compensation Committee will comply with, any applicable requirements of the rules and regulations
of Nasdaq listing rules and the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Nominating
and Corporate Governance Committee</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee, among other things, will be responsible for:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and assessing the development of the executive officers and considering and making recommendations to the Board regarding promotion
    and succession issues;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    and reporting to the Board on the performance and effectiveness of the directors, committees and the board of directors as a whole;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">working
    with the board to determine the appropriate and desirable mix of characteristics, skills, expertise and experience, including diversity
    considerations, for the full Board and each committee;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">annually
    presenting to the board a list of individuals recommended to be nominated for election to the board;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    evaluating, and recommending changes to the Company&rsquo;s committee charters;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    to the board individuals to be elected to fill vacancies and newly created directorships;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the Company&rsquo;s compliance program, including the Code of Conduct; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    and evaluating how the Company&rsquo;s corporate governance and legal and regulatory compliance policies and practices, including
    leadership, structure, and succession planning, that may affect the Company&rsquo;s major risk exposures.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee will consist of Timothy Henrichs, Bradley Mitch Watkins, and Ms. Keyser will serve as chair.
The Company&rsquo;s board of directors has determined that each member of the Nominating and Corporate Governance Committee is independent
within the meaning of the independent director guidelines of Nasdaq listing rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Compensation
Committee Interlocks and Insider Participation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the Company&rsquo;s executive officers serves, or in the past has served, as a member of the board of directors or compensation committee,
or other committee serving an equivalent function, of any entity that has one or more executive officers who serve as members of the
Company&rsquo;s board of directors or its compensation committee. None of the members of the Company&rsquo;s compensation committee is,
or has ever been, an officer or employee of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Code
of Business Conduct and Ethics</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s board of directors has adopted a code of business conduct and ethics (&ldquo;Code of Conduct&rdquo;) applicable to its
employees, directors and officers, in accordance with applicable U.S. federal securities laws and the corporate governance rules of Nasdaq.
The Code of Conduct will be effective upon the effectiveness of the registration statement of which this prospectus forms a part and
publicly available on the Company&rsquo;s website following completion of this offering. Any substantive amendments or waivers of the
Code of Conduct may be made only by the Company&rsquo;s board of directors and will be promptly disclosed as required by applicable U.S.
federal securities laws and the corporate governance rules of Nasdaq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_002"></A>EXECUTIVE
OFFICER AND DIRECTOR COMPENSATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Executive
Officers Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Summary
Compensation Table</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning all compensation earned by or paid to our Chief Executive Officer and two other persons
who served as executive officers as, at, or during the year ended December 31, 2022, and who earned compensation exceeding $100,000
during 2022 (the &ldquo;Named Executive Officers&rdquo;), for services as executive officers for the last two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Name and Principal Position</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Year</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Salary ($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Bonus($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Total($)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 38%; text-align: left">Brian Carrico</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">2022</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">373,578</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right"><P STYLE="margin: 0">373,578</P></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chief Executive Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">369,231</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">494,732</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">863,963</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Thomas Carrico</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">287,196</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">&mdash;</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">287,196</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chief Regulatory Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">297,347</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">141,243</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">438,590</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adrian Miranda</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2022</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">266,346</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">&mdash;</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">266,346</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chief Medical Officer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">254,231</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">&mdash;</P></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><P STYLE="margin: 0">254,231</P></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
  <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents payments to
  our executive officers pursuant to their respective employment agreements. For more information, see &ldquo; <I>&mdash;Employment Agreements.</I></FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Outstanding
Equity Awards at Fiscal Year-End</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding equity awards held by the Named Executive Officers as of December 31, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Name</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of Securities Underlying Unexercised Options, Exercisable (#)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of Securities Underlying Unexercised Options, Not Exercisable (#)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">Option</P>
                                                                                <P STYLE="margin-top: 0pt; margin-bottom: 0pt">Exercise</P>
                                                                                <P STYLE="margin-top: 0pt; margin-bottom: 0pt">Price</P>
                                                                                <P STYLE="margin-top: 0pt; margin-bottom: 0pt">($)</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><P STYLE="margin-top: 0pt; margin-bottom: 0pt">Option</P>
                                                                                <P STYLE="margin-top: 0pt; margin-bottom: 0pt">Expiration</P>
                                                                                <P STYLE="margin-top: 0pt; margin-bottom: 0pt">Date</P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 32%; text-align: left">Brian Carrico</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">320,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">6.94</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 12%">09/13/29</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Thomas Carrico</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">306,236</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">09/13/29</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adrian Miranda</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.94</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">09/13/29</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    option awards were granted under the Innovative Health Solutions, Inc. 2017 Stock Compensation Plan and vested
    fully upon grant.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Innovative Health Solutions,
Inc. 2017 Stock Compensation Plan, As Amended</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 12, 2017, the Company adopted the
Innovative Health Solutions, Inc. 2017 Stock Compensation Plan, as amended on September 13, 2019, September 9, 2021, and November 1,
2022 (collectively, the &ldquo;2017 Plan&rdquo;). The purpose of the 2017 Plan is to grant incentive stock options, nonqualified
stock options, or restricted stock awards to our officers, employees, directors, advisors, and consultants. The maximum numbers of
shares of common stock that may be issued pursuant to awards granted were 1,319,394. Cancelled and forfeited stock options and stock
awards may again become available for grant under the 2017 Plan. As of the date of September 30, 2022, options to purchase all
1,319,394 shares of common stock have been granted under the 2017 Plan and remain outstanding, and no shares remain available for
issuance under the 2017 Plan. The following summary briefly describes the principal features of the 2017 Plan and is qualified in
its entirety by reference to the full text of the 2017 Plan, which is filed as an exhibit to the registration statement of which
this prospectus forms a part.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Purpose
of the 2017 Plan</I>: The purposes of the 2017 Plan are to encourage ownership of shares by eligible employees and key
non-employees in order to attract and retain such eligible employees in the employ of the Company or an affiliated entity, or to attract
such key non-employees to provide services to the Company or an affiliated entity, and to provide additional incentive for such persons
to promote the long-term success of the Company or an affiliated entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Administration
of the Plan</I>: The 2017 Plan is administered by the board of directors, or the committee to which the board of directors delegates
the power to act. Among other things, the administrator has the authority to select persons who will receive awards, determine the types
of awards and the number of shares to be covered by awards, and to establish the terms, conditions, restrictions and other provisions
of awards. The administrator has authority to establish, amend and rescind rules and regulations relating to the 2017 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Eligible
Recipients</I>: Persons eligible to receive awards under the 2017 Plan are those officers, employees, directors, advisors, and
consultants of the Company or an affiliated entity who are selected by the administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Shares Available under the 2017 Plan</I>:
The maximum number of shares of our common stock that may be delivered to participants under the 2017 Plan is 1,319,394 shares,
subject to adjustment for certain corporate changes affecting the shares, such as stock splits. No new grants will be made under the
2017 Plan, and shares subject to an award under the 2017 Plan for which the award is canceled, forfeited or expires will become available
for grants under the 2022 Plan described below. Shares subject to an award that is settled in cash will not again be made available for
grants under the 2017 Plan.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>General</U><I>.
</I>Subject to the provisions of the 2017 Plan, the administrator has the authority to determine all grants of stock options,
although there are currently no shares of common stock remaining reserved for grants under the 2017 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Option
Price</U>. The exercise price for stock options is determined at the time of grant. The exercise price may not be less
than the fair market value on the date of grant. Additionally, incentive stock option grants to any person owning more than 10%
of our voting stock must have an exercise price of not less than 110% of the fair market value on the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exercise
of Options</U><I>.</I> An option may be exercised only in accordance with the terms and conditions for the option agreement as established
by the administrator at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price.
Payments may be made in cash or, at the option of the administrator, by actual or constructive delivery of shares of common stock to
the holder of the option based upon the fair market value of the shares on the date of exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expiration
or Termination</U><I>.</I> Options, if not previously exercised, will expire on the expiration date established by the administrator
at the time of grant. In the case of incentive stock options, such term cannot exceed ten years provided that in the case of holders
of more than 10% of our voting stock, such term cannot exceed five years. Options will terminate before their expiration date only if
the holder&rsquo;s service with our Company or an affiliate terminates before the expiration date and the holder is terminated
for cause. The option may remain exercisable until the expiration date of the option after terminations of employment for any reason
other than for cause, including terminations as a result of death, disability or retirement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Incentive
and Non-Qualified Options</U><I>.</I> An incentive stock option is an option that is intended to qualify under certain provisions of
the Internal Revenue Code, for more favorable tax treatment than applies to non-qualified stock options. Any option that does not
qualify as an incentive stock option will be a non-qualified stock option. Under the Code, certain restrictions apply to incentive
stock options. For example, the exercise price for incentive stock options may not be less than the fair market value of the shares
on the grant date and the term of the option may not exceed ten years. In addition, an incentive stock option may not be
transferred, other than by will or the laws of descent and distribution and is exercisable during the holder&rsquo;s lifetime only
by the holder. In addition, no incentive stock options may be granted to a holder that is first exercisable in a single year if that
option, together with all incentive stock options previously granted to the holder that also first become exercisable in that year,
relate to shares having an aggregate market value in excess of $100,000, measured at the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Restricted Stock Awards:</I> Restricted stock
awards could have also been granted under the 2017 Plan, although there are currently no shares of common stock
remaining reserved for grants under the 2017 Plan. A restricted stock award is a grant of shares of common stock or of a right
to receive shares in the future.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>


<!-- Field: Page; Sequence: 93; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Material Provisions</I><B>:</B> Awards are evidenced by a written agreement, in such form as may be approved by the administrator. In
the event of various changes to the capitalization of our Company, such as stock splits, stock dividends and similar re-capitalizations,
an appropriate adjustment will be made by the administrator to the number of shares covered by outstanding awards or to the exercise
price of such awards. The administrator is also permitted to include in the written agreement provisions that provide for certain changes
in the award in the event of a change of control of our Company, including acceleration of vesting. Except as otherwise determined
by the administrator at the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution.
Prior to any award distribution, we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements.
Our board of directors also has the authority, at any time, to discontinue the granting of awards. The Plan may be amended by the board
of directors and such amendment shall become effective upon adoption by the board of directors; provided, however, that any amendment
shall be subject to the approval of the stockholders of the Company at or before the next annual meeting of the stockholders of the Company
if such stockholder approval is required by applicable laws. No amendment that would adversely affect any outstanding award made under
the Plan can be made without the consent of the holder of such award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">No new grants can be made under the
2017 Plan. The terms and conditions of awards granted under the 2017 Plan prior to the effective date of the 2022 Plan
will not be affected by the adoption or approval of the 2022 Plan, and the 2017 Plan will remain effective with respect to such
awards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neuraxis,
Inc. 2022 Omnibus Securities and Incentive Plan, As Amended</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 1, 2022, the Company adopted the
Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (as amended January 18, 2023, the &ldquo;2022 Plan&rdquo;). The purpose
of the 2022 Plan is to attract, retain and provide incentives to key management employees and non-employee directors of, and non-employee
consultants to, the Company and its affiliates, and to align the interests of such employees, non-employee directors and non-employee
consultants with those of the Company&rsquo;s stockholders. The maximum numbers of shares of common stock that may be issued pursuant
to awards granted are 300,000. Cancelled and forfeited stock options and stock awards may again become available for grant under
the 2022 Plan. As of the date of this prospectus, no awards have been granted under the 2022 Plan, and 300,000 shares of
common stock remain available for issuance under the 2022 Plan. The following summary briefly describes the principal features of the
2022 Plan and is qualified in its entirety by reference to the full text of the 2022 Plan.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Purpose
of the 2022 Plan</I>: The purposes of the 2022 Plan is to benefit the stockholders of the Company, by assisting the Company to
attract, retain and provide incentives to key management employees and non-employee directors of, and non-employee consultants to,
the Company and its affiliates, and to align the interests of such employees, non-employee directors and non-employee consultants
with those of the Company&rsquo;s stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Administration
of the 2022 Plan</I>: The 2022 Plan shall be administered by the board of directors or the committee designated by the board of directors.
Among other things, the administrator has the authority to select persons who will receive awards, determine the time or times when an
award shall be made, what type of award shall be granted, the term of an award, the date or dates on which an award vests (including
acceleration of vesting), the form of any payment to be made pursuant to an award, the terms and conditions of an award (including the
forfeiture of the award (and/or any financial gain) if the holder of the award violates any applicable restrictive covenant thereof),
the restrictions under a restricted stock award and the number of common stock which may be issued under an award, all as applicable.
In addition, subject to the express provisions of the 2022 Plan, the administrator is authorized to construe the 2022 Plan and the respective
award agreements executed thereunder, to prescribe such rules and regulations relating to the 2022 Plan as it may deem advisable to carry
out the intent of the 2022 Plan, to determine the terms, restrictions and provisions of each award, and to make all other determinations
necessary or advisable for administering the 2022 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Eligible
Recipients</I>: Persons eligible to receive awards under the 2022 Plan will be those officers, employees, directors, advisors, and consultants
of the Company or an affiliated entity who are selected by the administrator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shares
Available under the Plan</I>: The maximum number of shares of our common stock that may be delivered to participants under the 2022 Plan
is 300,000 shares, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject
to an award under the 2022 Plan for which the award is lapses, expires, is canceled, terminated unexercised or ceases to be exercisable
again become available for grants under the 2022 Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
Options</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>General</U><I>.
</I>Subject to the provisions of the 2022 Plan, the administrator has the authority to determine all grants of stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Option
Price</U>. The exercise price for stock options is determined at the time of grant. The exercise price may not be less than
the fair market value on the date of grant. Additionally, incentive stock option grants to any person owning more
than 10% of our voting stock must have an exercise price of not less than 110% of the fair market value on the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Exercise
of Options</U><I>.</I> An option may be exercised only in accordance with the terms and conditions for the option agreement as established
by the administrator at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price.
Payments may be made in cash or, at the option of the administrator, by actual or constructive delivery of shares of common stock to
the holder of the option based upon the fair market value of the shares on the date of exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 94; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Expiration
or Termination</U><I>.</I> Options, if not previously exercised, will expire on the expiration date established by the administrator
at the time of grant. In the case of incentive stock options, such term cannot exceed ten years provided that in the case of holders
of more than 10% of our voting stock, such term cannot exceed five years. Options will terminate before their expiration date if the
holder&rsquo;s service with our Company or a subsidiary terminates before the expiration date. The option may remain exercisable
for specified periods after certain terminations of employment, including terminations as a result of death, disability or retirement,
with the precise period during which the option may be exercised to be established by the administrator and reflected in the grant evidencing
the award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Incentive
and Non-Qualified Options</U><I>.</I> As described elsewhere in this summary, an incentive stock option is an option that is
intended to qualify under certain provisions of the Code, for more favorable tax treatment than applies to non-qualified stock
options. Any option that does not qualify as an incentive stock option will be a non-qualified stock option. Under the Code, certain
restrictions apply to incentive stock options. For example, generally, the exercise price for incentive stock options may not be
less than the fair market value of the shares on the grant date and the term of the option may not exceed ten years. In addition, an
incentive stock option may not be transferred, other than by will or the laws of descent and distribution, and is exercisable during
the holder&rsquo;s lifetime only by the holder. In addition, to the extent that the aggregate fair market value of common stock with
respect to which incentive stock options are exercisable for the first time by an individual during any calendar year under all plans
of the Company and any parent corporation or subsidiary corporation thereof which provide for the grant of incentive stock options
exceeds $100,000, the portion of such incentive stock options that exceeds such threshold shall be treated as non-qualified stock
options. Incentive stock options shall be granted to employees only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restricted
Stock Awards:</I> Restricted stock awards can be granted under the 2022 Plan. A restricted stock award is a grant of shares of common
stock or of a right to receive shares in the future. These awards will be subject to such conditions, restrictions and contingencies
as the administrator shall determine at the date of grant. Those may include requirements for continuous service and/or the achievement
of specified performance goals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Unrestricted
Stock Awards</I>: Unrestricted stock awards can also be granted under the 2022 Plan. An unrestricted stock award is a grant of shares
of common stock which is not subject to restrictions, in consideration for past services rendered thereby to the Company or an affiliate
or for other valid consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Restricted
Stock Unit Awards</I>: Restricted stock unit awards (&ldquo;RSUs&rdquo;) can be granted under the 2022 Plan upon the satisfaction
of predetermined individual service related vesting requirements. The holder of a restricted stock unit shall be entitled to receive
a cash payment equal to the fair market value of shares of common stock, for each unit awarded to the holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Performance
Stock Unit Awards</I>: Performance stock unit awards can be granted under the 2022 Plan. A holder of performance stock units shall be
entitled to receive a cash payment equal to the dollar value or number of shares of common stock assigned to such units if the holder
and/or the Company satisfy the predetermined performance goals and objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Distribution
Equivalent Rights</I>: Distribution equivalent right awards can be granted under the 2022 Plan. A distribution equivalent right award
entitles the holder to receive bookkeeping credits, cash payments and/or common stock distributions equal in amount to the distributions
that would have been made to the holder had the holder held a specified number of common stock during the period the holder held the
distribution equivalent right.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Stock
Appreciation Right</I>s: Stock appreciation rights can also be granted under the 2022 Plan, which is a right, granted alone or in
connection with a related Option, to receive a payment on the date of exercise. The base value of the stock appreciation right shall
be set forth by the administrator and shall not be less than the fair market value of the common stock at the date of grant for the
stock appreciation right which is not a tandem stock appreciation right. No stock appreciation right shall be exercisable after the
expiration of ten (10) years from the date of its grant. Upon the exercise of some or all of the portion of a stock appreciation
right, the holder shall receive a payment from the Company, in cash or in the form of common stock having an equivalent fair market
value or in a combination of both. If the administrator grants a stock appreciation right which is intended to be a tandem stock
appreciation right, the tandem stock appreciation right shall be granted at the same time as the related option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 95; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other
Material Provisions</I>: Awards are evidenced by a written agreement, in such form as may be approved by the administrator. In the event
of various changes to the capitalization of our Company, such as stock splits, stock dividends and similar re-capitalizations,
an appropriate adjustment will be made by the administrator to the number of shares covered by outstanding awards or to the exercise
price of such awards. The administrator is also permitted to include in the written agreement provisions that provide for certain changes
in the award in the event of a change of control of our Company, including acceleration of vesting. Except as otherwise determined
by the administrator at the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution.
Prior to any award distribution, we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements.
Our board of directors also has the authority, at any time, to discontinue the granting of awards. The 2022 Plan may be amended by the
board of directors and such amendment shall become effective upon adoption by the board of directors; provided, however, that any amendment
shall be subject to the approval of the stockholders of the Company at or before the next annual meeting of the stockholders of the Company
if such stockholder approval is required by applicable laws. No amendment that would adversely affect any outstanding award made under
the 2022 Plan can be made without the consent of the holder of such award. The 2022 Plan shall continue in effect, unless sooner terminated,
until the tenth (10th) anniversary of the date on which it is adopted by the board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employment
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Brian
Carrico</I>, our Chief Executive Officer, entered into an employment agreement with the Company, dated August 9, 2022, which has a five-year
initial term and provides for a base salary of $330,000, which shall be increased each year by not less than 3% per annum. Mr. Carrico
also will receive an one-time incentive payment in the amount of $494,732, which amount consists of accrued and unpaid salary and a bonus
to incentivize Mr. Carrico to remain with the Company for future service. Neither the accrued and unpaid salary or bonus were the subject
of any contract or agreement between Mr. Carrico and the Company prior to the execution of the employment agreement. The agreement contemplated
that the incentive payment would be paid by December 15, 2022, but due to administrative impracticability, payment will now be made with
a portion of the proceeds from this offering. See &ldquo;<I>Use of Proceeds</I>.&rdquo; In addition, Mr. Carrico is entitled to payment
of a deferred bonus in an amount equal to (i) the aggregate of the strike price or exercise price of all 320,000 unexercised options
to purchase stock or shares of the Company held by Mr. Carrico (the &ldquo;Aggregate Strike Price&rdquo;) plus (ii) a tax gross-up payment
on the Aggregate Strike Price reasonably calculated by the Company at the highest marginal rates so that after payment of all ordinary
income taxes on such Aggregate Strike Price, there remains an amount sufficient to pay such ordinary income taxes. The special deferred
bonus will be paid in substantially equal 20% installments on January 2 on each of 2024, 2025, 2026, 2027, and 2028, with a condition
that on or before each scheduled payment date, Mr. Carrico shall exercise at least 64,000 of the stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause, Mr. Carrico will receive any accrued compensation (as defined in
the employment agreement) and is entitled to severance payments as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs during the initial term, the severance payment shall be the amount equal
                                            to the greater of (a) three times Mr. Carrico&rsquo;s base salary as of the termination date;
                                            and (b) three times the total amount of Mr. Carrico&rsquo;s bonus payments the Company paid
                                            Mr. Carrico over the one year prior to the termination date, to be paid in substantially
                                            equal monthly installments over the course of the three years.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs after the initial term, the severance payment shall be the amount equal
                                            to the greater of (a) one and one half (1.5) times Mr. Carrico&rsquo;s base salary as of
                                            the termination date; and (b) one and one half (1.5) times the total amount of Mr. Carrico&rsquo;s
                                            bonus payments the Company paid Mr. Carrico over the one (1) year prior to the termination
                                            date, to be paid in substantially equal monthly installments over the course of 18 months
                                            following the termination date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition, as part of the severance payment, we agreed to pay Mr. Carrico monthly COBRA premiums
                                            for continuation of health coverage for 18 months post termination.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Mr. Carrico will receive any unpaid base salary that has been earned
at the time of such termination, reimbursement of any expenses properly incurred prior to the Mr. Carrico&rsquo;s termination date; and
accrued and unused paid time off (&ldquo;PTO&rdquo;), if any, in accordance with the Company&rsquo;s PTO policy in effect on Mr. Carrico&rsquo;s
termination date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Carrico may terminate the employment agreement without good reason upon more than thirty (30) days&rsquo; prior written notice or for
good reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the deferred bonus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Mr. Carrico also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) will not,
directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business
connection or business or employment relationship with any entity or person which competes with the Company during his employment and,
(v) will not, directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership,
management, or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing,
sale or servicing of any service or product with which Mr. Carrico was involved during his last year of employment with the Company;
or which the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service)
and about which Mr. Carrico gained any confidential information in the course of his employment with the Company for a period of 24 months
after his separation from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dan
Clarence</I>, our Chief Operating Officer, entered into an employment agreement with the Company, dated August 9, 2022, which provides
has a two-year initial term and provides for a base salary of $275,000 with annual compensation increase. Mr. Clarence also will receive
a one-time incentive payment in the amount of $116,897.24, which amount includes accrued and unpaid salary and a bonus to incentivize
Mr. Clarence to remain with the Company for future service. Neither the accrued and unpaid salary or bonus were the subject of any contract
or agreement between Mr. Clarence and the Company prior to the execution of the employment agreement. The agreement contemplated that
the incentive payment would be paid by December 15, 2022, but due to administrative impracticability, payment will now be made with a
portion of the proceeds from this offering. See &ldquo;<I>Use of Proceeds</I>.&rdquo; In addition, Mr. Clarence shall be entitled to
payment of a deferred bonus in an amount equal to (i) the aggregate of the strike price or exercise price of all 68,818 unexercised
options to purchase stock or shares of the Company held by Mr. Clarence (the &ldquo;Aggregate Strike Price&rdquo;) plus (ii) a tax gross-up
payment on the Aggregate Strike Price reasonably calculated by the Company at the highest marginal rates so that after payment of all
ordinary income taxes on such Aggregate Strike Price, there remains an amount sufficient to pay such ordinary income taxes. The special
deferred bonus will be paid in substantially equal 20% installments on January 2 on each of 2024, 2025, 2026, 2027, and 2028, with a
condition that on or before each scheduled payment date, Mr. Clarence shall exercise at least 13,764 of the stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause occurs during the term of the agreement, Mr. Clarence will receive
any accrued compensation (as defined in the employment agreement) and is entitled to certain amount of severance payments as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs during the initial term, the Company shall provide Mr. Clarence with severance
                                            compensation in the form of salary continuation at his Base Salary as of the termination
                                            date and ending the later of (i) 6 months or (ii) on the expiration date of the initial term.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs after the initial term, the severance payment shall be the amount equal
                                            to one half (1/2) of Mr. Clarence&rsquo;s Base Salary as of the termination date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition, if termination occurs during the initial term, as part of the severance payment,
                                            we agreed to pay Mr. Clarence reimbursement of his monthly COBRA premiums for continuation
                                            of health coverage for 18 months post termination.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Mr. Clarence will receive any unpaid base salary that has been earned
at the time of such termination, reimbursement of any expenses properly incurred prior to the Mr. Clarence&rsquo;s termination date;
and accrued and unused PTO, if any, in accordance with the Company&rsquo;s PTO policy in effect on Mr. Clarence&rsquo;s termination date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Clarence may terminate the employment agreement without good reason upon more than thirty (30) days&rsquo; prior written notice or for
good reason without prior written consent and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the deferred bonus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Mr. Clarence also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) will not,
directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business
connection or business or employment relationship with any entity or person which competes with the Company during his employment and,
(v) will not, directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership,
management, or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing,
sale or servicing of any service or product with which Mr. Clarence was involved during his last year of employment with the Company;
or which the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service)
and about which Mr. Clarence gained any confidential information in the course of his employment with the Company for a period of 24
months after his separation from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Adrian
Miranda</I>, our Chief Medical Officer and Senior Vice President of Science and Technology, entered into an employment agreement with
the Company, dated August 17, 2022, which has a two-year initial term and provides for a base salary of $300,000 with annual compensation
increase. In addition, Dr. Miranda shall be entitled to payment of a special deferred bonus in an amount equal to (i) the aggregate of
the strike price or exercise price of all 337,204 unexercised options to purchase stock or shares of the Company held by Dr. Miranda
(the &ldquo;Aggregate Strike Price&rdquo;) plus (ii) a tax gross-up payment on the Aggregate Strike Price reasonably calculated by the
Company at the highest marginal rates so that after payment of all ordinary income taxes on such Aggregate Strike Price, there remains
an amount sufficient to pay such ordinary income taxes. The deferred bonus will be paid in substantially equal 20% installments on January
2 on each of 2024, 2025, 2026, 2027, and 2028, with a condition that on or before each scheduled payment date, Dr. Miranda shall exercise
at least 67,441 of the stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause occurs during the term of the agreement, Dr. Miranda will receive
any accrued compensation (as defined in the employment agreement) and is entitled to certain amount of severance payments as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs during the initial term, the Company shall provide Dr. Miranda with severance
                                            compensation in the form of salary continuation at his Base Salary as of the termination
                                            date and ending the later of (i) 6 months or (ii) on the expiration date of the initial term.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs after the initial term, the severance payment shall be the amount equal
                                            to one half (1/2) of Dr. Miranda&rsquo;s Base Salary as of the termination date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition, if termination occurs during the initial term, as part of the severance payment,
                                            we agreed to pay Dr. Miranda reimbursement of his monthly COBRA premiums for continuation
                                            of health coverage for 18 months post termination.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Dr. Miranda will receive any unpaid base salary that has been earned
at the time of such termination, reimbursement of any expenses properly incurred prior to the Dr. Miranda&rsquo;s termination date; and
(iii) accrued and unused PTO, if any, in accordance with the Company&rsquo;s PTO policy in effect on Dr. Miranda&rsquo;s termination
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Miranda may terminate the employment agreement without good reason upon more than thirty (30) days&rsquo; prior written notice or for
good reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the special deferred bonus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Dr. Miranda also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) not, directly
or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business connection
or business or employment relationship with any entity or person which competes with the Company during his employment and (v) will not,
directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership, management,
or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing, sale or
servicing of any service or product with which Dr. Miranda was involved during his last year of employment with the Company; or which
the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service) and about
which Dr. Miranda gained any confidential information in the course of his employment with the Company for a period of 24 months after
his separation from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-indent: 20pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Thomas
Carrico</I>, Chief Regulatory Officer, entered into an employment agreement with the Company, dated August 9, 2022, which has a two-year
initial term and provides for a base salary of $275,000 with annual compensation increase. Mr. Carrico will also receive a one-time incentive
payment in the amount of $141,243.17, which amount includes accrued and unpaid salary and a bonus to incentivize Mr. Carrico to remain
with the Company for future service. Neither the accrued and unpaid salary or bonus were the subject of any contract or agreement between
Mr. Carrico and the Company prior to the execution of the employment agreement. The agreement contemplated that the incentive payment
would be paid by December 15, 2022, but due to administrative impracticability, payment will now be made with a portion of the proceeds
from this offering. See &ldquo;<I>Use of Proceeds</I>.&rdquo; In addition, Mr. Carrico shall be entitled to payment of a deferred bonus
in an amount equal to (i) the aggregate of the strike price or exercise price of all 306,236 unexercised options to purchase stock
or shares of the Company held by Mr. Carrico (the &ldquo;Aggregate Strike Price&rdquo;) plus (ii) a tax gross-up payment on the Aggregate
Strike Price reasonably calculated by the Company at the highest marginal rates so that after payment of all ordinary income taxes on
such Aggregate Strike Price, there remains an amount sufficient to pay such ordinary income taxes. The special deferred bonus will be
paid in substantially equal 20% installments on January 2 on each of 2024, 2025, 2026, 2027, and 2028, with a condition that on or before
each scheduled payment date, Mr. Carrico shall exercise at least 61,247 of the stock options.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause occurs during the term of the agreement, Mr. Carrico will receive
any accrued compensation (as defined in the employment agreement) and is entitled to certain amount of severance payments as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs during the initial term, the Company shall provide Mr. Carrico with severance
                                            compensation in the form of salary continuation at his Base Salary as of the termination
                                            date and ending the later of (i) 6 months or (ii) on the expiration date of the initial term.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs after the initial term, the severance payment shall be the amount equal
                                            to one half (1/2) of Mr. Carrico&rsquo;s Base Salary as of the termination date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition, if termination occurs during the initial term, as part of the severance payment,
                                            we agreed to pay Mr. Carrico reimbursement of his Medicare, Medicare Supplement and prescription
                                            drug coverage insurance premiums for continuation of health coverage for 18 months post termination.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Mr. Carrico will receive any unpaid base salary that has been earned
at the time of such termination, reimbursement of any expenses properly incurred prior to the Mr. Carrico&rsquo;s termination date; and
(iii) accrued and unused PTO, if any, in accordance with the Company&rsquo;s PTO policy in effect on Mr. Carrico&rsquo;s termination
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Carrico may terminate the employment agreement without good reason upon more than thirty (30) days&rsquo; prior written notice or for
good reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the special deferred bonus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Mr. Carrico also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) not, directly
or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business connection
or business or employment relationship with any entity or person which competes with the Company during his employment and (v) will not,
directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership, management,
or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing, sale or
servicing of any service or product with which Mr. Carrico was involved during his last year of employment with the Company; or which
the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service) and about
which Mr. Carrico gained any confidential information in the course of his employment with the Company for a period of 24 months after
his separation from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Christopher
Robin Brown</I>, our Director of Innovation, entered into an employment agreement with the Company, dated August 9, 2022, which has a
two-year initial term and provides for a base salary of $200,000 with annual compensation increase. Mr. Brown also will receive a one-time
incentive payment in the amount of $250,843.88, which amount includes accrued and unpaid salary and a bonus to incentivize Mr.
Brown to remain with the Company for future service. Neither the accrued and unpaid salary or bonus were the subject of any contract
or agreement between Mr. Brown  and the Company prior to the execution of the employment agreement. The agreement contemplated that
the incentive payment would be paid by December 15, 2022, but due to administrative impracticability, payment will now be made with a
portion of the proceeds from this offering. See &ldquo;<I>Use of Proceeds</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause, Mr. Brown will receive any accrued compensation (as defined in the
employment agreement) and is entitled to certain amount of severance payments as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs during the initial term, the Company shall provide Mr. Brown with severance
                                            compensation in the form of salary continuation at his Base Salary as of the termination
                                            date and ending the later of (i) 3 months or (ii) on the expiration date of the initial term.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs after the initial term, the severance payment shall be the amount equal
                                            to one fourth (1/4th) of Mr. Brown&rsquo;s Base Salary as of the termination date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition, if termination occurs during the initial term, as part of the severance payment,
                                            we agreed to pay Mr. Brown reimbursement of his Medicare, Medicare Supplement and prescription
                                            drug coverage insurance premiums for continuation of health coverage for eighteen (18) months
                                            post termination.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Mr. Brown will receive any unpaid base salary that has been earned at
the time of such termination, reimbursement of any expenses properly incurred prior to the Mr. Brown&rsquo;s termination date; and accrued
and unused PTO, if any, in accordance with the Company&rsquo;s PTO policy in effect on Mr. Brown&rsquo;s termination date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Brown may terminate the employment agreement without good reason upon more than thirty (30) days&rsquo; prior written notice or for good
reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid balance
of the special deferred bonus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Mr. Brown also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) not, directly
or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business connection
or business or employment relationship with any entity or person which competes with the Company during his employment and (v) will not,
directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership, management,
or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing, sale or
servicing of any service or product with which Mr. Brown was involved during his last year of employment with the Company; or which the
Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service) and about which
Mr. Brown gained any confidential information in the course of his employment with the Company for a period of 24 months after his separation
from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Gary
Peterson</I>, our Director of Design and Engineering, entered into an employment agreement with the Company, dated August 9, 2022, which
has a two-year initial term and provides for a base salary of $200,000 with annual compensation increase and a one-time incentive payment
in the amount of $53,277.01, which amount includes accrued and unpaid salary and a bonus incentivize Mr. Carrico to remain with
the Company for future service. Neither the accrued and unpaid salary or bonus were the subject of any contract or agreement between
Mr. Peterson and the Company prior to the execution of the employment agreement. The agreement contemplated that the incentive payment
would be paid by December 15, 2022, but due to administrative impracticability, payment will now be made with a portion of the proceeds
from this offering. See &ldquo;<I>Use of Proceeds</I>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause, Mr. Peterson will receive accrued compensation (as defined in the
employment agreement) and certain amount of severance payments as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs during the initial term, the Company shall provide Mr. Peterson with severance
                                            compensation in the form of salary continuation at his Base Salary as of the termination
                                            date and ending the later of (i) 6 months or (ii) on the expiration date of the initial term.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            termination occurs after the initial term, the severance payment shall be the amount equal
                                            to one half (1/2) of Mr. Peterson&rsquo;s Base Salary as of the termination date.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            addition, if termination occurs during the initial term, as part of the severance payment,
                                            we agreed to pay Mr. Peterson reimbursement of his COBRA premiums for continuation of health
                                            coverage for 18 months post termination.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement terminates for any reason except termination by the Company for cause occurs, Mr. Peterson will receive any
unpaid base salary that has been earned at the time of such termination, reimbursement of any expenses properly incurred prior to the
Mr. Peterson&rsquo;s termination date; and accrued and unused PTO, if any, in accordance with the Company&rsquo;s PTO policy in effect
on Mr. Peterson&rsquo;s termination date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Peterson may terminate the employment agreement without good reason upon more than thirty (30) days&rsquo; prior written notice or for
good reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the special deferred bonus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Mr. Peterson also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) not, directly
or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business connection
or business or employment relationship with any entity or person which competes with the Company during his employment and (v) will not,
directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership, management,
or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing, sale or
servicing of any service or product with which Mr. Peterson was involved during his last year of employment with the Company; or which
the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service) and about
which Mr. Peterson gained any confidential information in the course of his employment with the Company for a period of 24 months after
his separation from the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
none of our directors is compensated for their service as directors, and we do not expect to compensate directors who also our employees
in the future. Following completion of this offering, we do expect to compensate our independent directors $100,000 annually, with
an additional $20,000 payable to the chair of our board of directors, apportioned equally between cash and RSUs and payable quarterly
as of March 31, June 30, September 30 and December 31 of each year, beginning with a pro-rated payment on March 31, 2023. The
RSUs will be granted under the 2022 Plan, and the number of RSUs granted will be determined at the discretion of the Compensation Committee
based on one or more accepted valuation methodologies, such as the Black-Scholes model. The RSUs will vest upon the third anniversary
of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_003"></A>PRINCIPAL
STOCKHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information, as of December 31, 2022, with respect to the holdings of: (i) each person who is
the beneficial owner of more than 5% of our common stock, (ii) each of our directors, (iii) each executive officer, and (iv) all of our
executive officers and directors as a group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
ownership of the common stock is determined in accordance with the rules of the SEC and includes any shares of our common stock over
which a person exercises sole or shared voting or investment power, or of which a person has a right to acquire ownership at any time
within 60 days of December 31, 2022. Applicable percentage ownership in the following table is based on (i) 1,963,321 shares of
common stock issued and outstanding on December 31, 2022, plus an aggregate of 1,013,270 shares of common stock issuable upon conversion
of our Series A Preferred Stock and an aggregate of 230,954 shares of common stock issuable upon conversion of our Series Seed Preferred
Stock, as all shares of our preferred stock are expected to convert into shares of common stock in connection with this offering, and
(ii) after the offering, assumes the issuance of 1,875,000 shares of common stock in the offering, which excludes shares of common stock
which may be sold upon exercise of the Underwriter&rsquo;s over-allotment option, (iii) after the offering, assumes the issuance of 88,926
shares of common stock issuable to Exchange Listing, LLC upon the listing of our common stock on Nasdaq, (iv) plus, for each individual,
any securities that person has the right to acquire within 60 days of December 31, 2022 through exercise of warrants, stock options or
otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the best of our knowledge, each of the persons named in the table has sole voting and investment power with respect to the shares of
our common stock beneficially owned by such person, except to the extent such power may be shared with a spouse. To our knowledge, none
of the shares listed below are held under a voting trust or similar agreement. To our knowledge, there is no arrangement, including any
pledge by any person of securities of the Company, the operation of which may at a subsequent date result in a change in control of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Name of Owner</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares of Common Stock</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Owned Beneficially</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent of Class Before the Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percent of Class After the Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">5% Holders</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 55%; text-align: left">Masimo Corporation (1)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">821,327</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">23.5</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 11%; text-align: right">15.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Brian P. Hannasch (2)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,496</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.5</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Executive Officers and Directors (3)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Brian Carrico (4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">347,118</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.3</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">John Seale</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Dan Clarence (5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">275,709</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8.4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.3</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Adrian Miranda (6)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">337,204</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.5</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.1</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Thomas Carrico (7)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">316,236</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.8</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Christopher Robin Brown</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">792,837</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24.7</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.3</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Gary Peterson (8)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">543,120</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.5</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Timothy Henrichs*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Bradley Mitch Watkins*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Beth Keyser*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Officers and directors as a group (10 persons)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,612,224</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61.6</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">42.1</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*Timothy
Henrichs, Bradley Mitch Watkins, Beth Keyser have accepted nomination to our board of directors and will become members of our board
of directors immediately upon the effectiveness of the registration statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            business address for Masimo Corporation is 52 Discovery, Irvine, California 92618. Shares
                                            of common stock beneficially owned includes 531,548 shares of common stock issuable
                                            upon the conversion of Series A Preferred Stock, and 289,779 shares of common stock
                                            issuable upon the exercise of prefunded warrants.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            business address for Mr. Hannasch is 8815 West State Road 46, Columbus, Indiana 47201. Shares
                                            of common stock beneficially owned includes 245,710 shares of common stock issuable
                                            upon the conversion of Series A Preferred Stock, and 52,852 shares of common stock
                                            issuable upon the exercise of warrants.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            business address for each executive officer and director is 11550 N. Meridian Street, Suite
                                            325 Carmel, IN. 46032.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            of common stock beneficially owned includes 320,000 shares of common stock issuable
                                            upon the exercise of stock options.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            of common stock beneficially owned consists of 5,299 shares of common stock issuable
                                            upon the conversion of Series A Preferred Stock, 28,069 shares of common stock issuable
                                            upon conversion of Series Seed Preferred Stock, and 68,818 shares of common stock
                                            issuable upon the exercise of stock options.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            of common stock beneficially owned consists of 337,204 shares of common stock issuable
                                            upon the exercise of stock options.</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares
                                            of common stock beneficially owned includes 306,236 shares of common stock issuable
                                            upon the exercise of stock options.</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
                                                                                                <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">(8)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">In
                                            January 2023, Mr. Peterson sold 25,000 shares of common stock to an existing investor. Giving
                                            effect to this transaction, Mr. Peterson&rsquo;s beneficial ownership before the offering
                                            is 16.2% and after the offering will be 10.1%.</TD></TR>
                                                                                                </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_004"></A>CERTAIN
RELATIONSHIPS AND RELATED PERSONS TRANSACTIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC
rules require us to disclose any transaction since the beginning of our last fiscal year or any currently proposed transaction in which
we are a participant in which the amount involved exceeded or will exceed $120,000 and in which any related person has or will have a
direct or indirect material interest. A related person is any executive officer, director, nominee for director, or holder of 5% or more
of our common stock, or an immediate family member of any of those persons.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two demand notes receivable from its two founding shareholders, Christopher Robin Brown and Gary Peterson, related to the
sale of common stock on January 1, 2016. Both notes initial balances were $506,400, with interest calculated monthly based on applicable
federal rates. No payments have been received on the notes. As of September 30, 2022, the balances of both notes were $506,400.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has loans payable to Christopher Robin Brown, one of our founders and a member of our board of directors, related to funding
needs for operations with original principal amounts of $55,000 and $50,000 each bearing interest at 15%
per annum. As of September 30, 2022, the outstanding balances of the loans were $20,051 and $38,000, respectively.
We will use a portion of the proceeds from this offering to repay these loans payable. See &ldquo;<I>Use of Proceeds</I>.&rdquo;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
Seale, our Chief Financial Officer, is also the managing partner of RBSK. Mr. Seale, through RBSK, has prepared the Company&rsquo;s financial
statements since 2017. For the nine months ended September 30, 2022, and the fiscal years ended December 31, 2021 and 2020, the Company
paid RBSK $78,241, $80,394 and $167,489, respectively, for accounting services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_005"></A>DESCRIPTION
OF OUR SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation authorizes us to issue up to 101,120,000 shares of capital stock, consisting of 100,000,000 shares of common
stock, par value $0.001 per share, and 1,120,000 shares of preferred stock, par value $0.001 per share, 1,000,000 of which are designated
as Series A Preferred Stock and 120,000 of which are designated as Series Seed Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, there were 1,951,547 shares of our common stock, 506,367 shares of our Series A Preferred Stock, and 115,477
shares of our Series Seed Preferred Stock issued outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation authorizes the issuance of 100,000,000 shares of common stock, par value $0.001 per share. The holders of
common stock are entitled to one vote per share on each matter submitted to a vote at any meeting of stockholders. Shares of common stock
do not carry cumulative voting rights and, therefore, a majority of the shares of outstanding common stock will be able to elect the
entire board of directors and, if they do so, minority stockholders would not be able to elect any persons to the board of directors.
Our bylaws provide that a majority of our issued and outstanding shares constitutes a quorum for stockholders&rsquo; meetings, except
respecting certain matters for which a greater percentage quorum is required by statute or the bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stockholders have no pre-emptive rights to acquire additional shares of common stock or other securities. The common stock
is not subject to redemption and carries no subscription or conversion rights. In the event of our liquidation, the shares of common
stock are entitled to share equally in corporate assets after satisfaction of all liabilities and after the payment of liquidation
preferences, if any, on any outstanding shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock are entitled to receive such dividends as the board of directors may, from time to time, declare out of funds legally
available for the payment of dividends. We seek growth and expansion of our business through the reinvestment of profits, if any, and
do not anticipate that we will pay dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividend
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled
to receive dividends out of funds legally available if our Board, in its discretion, determines to declare and pay dividends and then
only at the times and in the amounts that our Board may determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to one vote for each share held on all matters properly submitted to a vote of stockholders on which
holders of common stock are entitled to vote. We have not provided for cumulative voting for the election of directors in our Certificate
of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
Pre-emptive or Similar Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is not entitled to pre-emptive rights, and is not subject to conversion, redemption or sinking fund provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Right
to Receive Liquidation Distributions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we become subject to a liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would
be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the
payment of liquidation preferences, if any, on any outstanding shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Preferred
Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation authorizes the issuance of 1,120,000 shares of preferred stock, par value $0.001 per share, 1,000,000 of
which are designated as Series A Preferred Stock and 120,000 of which are designated as Series Seed Preferred Stock. As of the date of
hereof, there are 506,635 shares of our Series A Preferred Stock, and 115,477 shares of our Series Seed Preferred Stock outstanding.
The requisite holder of our outstanding Series A Preferred Stock and Series Seed Preferred Stock have delivered a consent, dated December
22, 2022, to automatically convert all shares of preferred stock into shares of common stock (on a 2-for-1 basis) upon consummation
of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Series A Preferred Stock and Series Seed Preferred Stock shall vote together with the Common Stock on an as-converted basis,
and not as separate classes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Series A Preferred and Series Seed initially convert 1:1 to Common Stock at any time at option of holder, subject to adjustments for
stock dividends, splits, combinations, and similar events and as described below under </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal">Anti-dilution
Provisions.</FONT>&rdquo; Due to a 4-for-1 stock split that occurred in September of 2021, and a subsequent 1-for-2 reverse stock
split that occurred in January of 2023 each (1) share of Series A Preferred and Series Seed is currently convertible to two (2)
shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Series A Preferred will carry an annual 8% cumulative dividend, payable upon any liquidation, dissolution or winding up of the Company
(the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal">Accruing
Dividend</FONT>&rdquo;<FONT STYLE="font-weight: normal">). For any other dividends or distributions, participation with common stock
on an as-converted basis.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">In
the event of any liquidation, dissolution or winding up of the Company, the proceeds shall be paid in the following priority:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">First,
                                            to the Series A Preferred in proportion to each holder</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&rsquo;<FONT STYLE="font-weight: normal">s
                                            respective pro rata Series A original purchase price, plus any pro rata share of the
                                            Accruing Dividend until the entire Series A original purchase price and Accruing Dividend
                                            are paid; </FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Second,
                                            to the Series Seed Preferred Stock in proportion to each holder</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&rsquo;<FONT STYLE="font-weight: normal">s
                                            respective pro rata Series Seed original purchase price until the entire amount of
                                            the Series Seed original purchase price is paid;</FONT></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#9679;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Thereafter,
                                            the Series A Preferred Stock and Series Seed Preferred Stock participate with the common
                                            stock pro rata on an as-converted basis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">A
merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares
of the surviving or acquiring corporation) and a sale, lease, transfer, exclusive license or other disposition of all or substantially
all of the assets of the Company will be treated as a liquidation event (a </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<FONT STYLE="font-weight: normal">Deemed
Liquidation Event</FONT>&rdquo;<FONT STYLE="font-weight: normal">), thereby triggering payment of the liquidation preferences described.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Anti-dilution
Provisions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">The
Series A Preferred have full-ratchet anti-dilution protection so that the conversion price will be reduced to 80% of the price at which
any future shares are issued, if less than the Series A original purchase price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Stockholders&rsquo; Agreement</B>:</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All stockholders of the Company currently are
subject to the Innovative Health Solutions, Inc. Amended and Restated Shareholders&rsquo; Agreement dated as of October 12, 2017, as
amended on January 30, 2019 (collectively, the &ldquo;Stockholders&rsquo; Agreement&rdquo;). The Stockholders&rsquo; Agreement contains
provisions restricting the transfer of the Company&rsquo;s shares by our current stockholders, provisions related to certain preemptive
rights and rights of first offer, and certain corporate governance requirements and restrictions, among other things. Upon the effectiveness
of the registration statement of which this prospectus forms a part, the Stockholders&rsquo; Agreement will terminate and be of no further
force or effect pursuant to an amendment to the Stockholders&rsquo; Agreement dated January [&#9679;], 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Restrictions on Transfer</I>: As a general
matter, the Stockholders&rsquo; Agreement currently provides that no stockholder may transfer the whole or any part of their shares,
except as otherwise permitted by the Stockholders&rsquo; Agreement. The Company&rsquo;s board of directors may, however, waive in writing
any or all of the restrictions on transfer set forth in the Stockholders&rsquo; Agreement. Furthermore, transfers to any one or more
members of a class consisting of a stockholder&rsquo;s spouse, descendants, guardian or conservator, or to a trust for the benefit of
any one or more members of such class (a &ldquo;Family Transferee&rdquo;) are free of any restrictions on transfer; <I>provided, however</I>,
that such no such transfer shall be permitted unless the transferring stockholder retains the sole legal and equitable rights to vote
the shares being transferred to the Family Transferee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Preemptive Rights and Rights of First Offer</I>:
Except as otherwise permitted in the Stockholders&rsquo; Agreement, a stockholder may not transfer any or all of the shares of the Company
owned by that stockholder to any transferee unless (i) the stockholder desiring to effectuate the transfer shall have first made the
offer to sell to the Company, then to non-transferring stockholders within the circumstances and time periods prescribed in the Stockholders&rsquo;
Agreement and (ii) that offer shall not have been accepted by the Company or the non-transferring stockholders within the prescribed
circumstances and time periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>Governance Provisions</I>: The Stockholders&rsquo;
Agreement currently requires the stockholders to vote in such a manner as to ensure the current directors of the Company are elected,
appointed, and maintained as directors. Furthermore, certain extraordinary business decisions must be approved affirmatively by one of
Gary Peterson or Christopher Robin Brown (&ldquo;Group 1 Stockholders&rdquo;), before the Company may implement them (&ldquo;Extraordinary
Decisions&rdquo;). Such Extraordinary Decisions include (a) amending the Company&rsquo;s certificate of incorporation, (b) amending the
Company&rsquo;s Bylaws, (c) amending the Stockholders&rsquo; Agreement, (d) acquiring substantially all of the assets of the Company
or another business (with certain exceptions), (e) incurring debt or liability in excess of $100,000 in each instance, (f) issuing options
or equity in the Company, (g) undertaking a matter outside the ordinary course of business, (h) substantially changing the scope of an
officer&rsquo;s duties with the Company, (i) terminating a Group 1 Stockholder&rsquo;s employment with the Company, (j) making distributions,
and (k) conducting certain affiliate transactions.</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0">Transfers during Lifetime and upon Death: The
Stockholders&rsquo; Agreement also currently prescribes that, upon the termination of an employment agreement between the Company and
any stockholders except for the Group 1 Stockholders for any reason other than death, the Company may purchase all of the stockholder&rsquo;s
shares of the Company at an agreed value established by the Board each year or the fair market value as of the date of such termination.
Furthermore, upon the death of a stockholder, the Company shall have the right, for the longer of 3 months following receipt of notice
of the death or 6 months from the date of death, to purchase such stockholder&rsquo;s shares at an agreed value established by the Board
or the fair market value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Masimo
Side Letters</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, the Company entered into a side letter with Masimo (the &ldquo;Masimo Side Letter&rdquo;) in connection with Masimo&rsquo;s
purchase of shares of our Series A Preferred Stock under that certain purchase agreement (the &ldquo;Masimo Series A Purchase
Agreement&rdquo;). Pursuant to the Masimo Side Letter, Masimo is entitled to specify one individual to serve as a non-voting observer
at all meetings of the board of directors and certain information and inspection rights. The Company also agreed to not enter into any
agreement or arrangement with any investor providing for rights, benefits, powers, preferences, priorities or privileges more favorable
to such investor than the rights, benefits, powers, preferences, priorities or privileges provided to Masimo under the Masimo
Series A Purchase Agreement, unless Massimo is offered such opportunity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a new letter agreement with Masimo, dated December 22, 2022, pursuant to which Masimo has
agreed to relinquish its rights under the Masimo Side Letter immediately upon the effectiveness of the registration statement of
which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Brian
Hannasch Side Letters</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2019, the Company entered into an investor rights agreement with Brian Hannasch (the &ldquo;Investor Rights Agreement&rdquo;)
in connection with Brian Hannasch&rsquo;s purchase of shares of our Series A Preferred Stock under certain purchase agreements (the &ldquo;Series
A Purchase Agreements&rdquo;). Pursuant to the Investor Rights Agreement, Mr. Hannasch is entitled to certain information and inspection
rights. As long as Mr. Hannasch holds at least 62,500 shares of Series A Preferred Stock, he is considered a major investor and,
as such, is entitled to right of first offer if the Company proposes to sell any new securities, which shall terminate immediately before
the consummation of this offering, or when the Company becomes subject to periodic reporting requirements of Section 12(g) or 15(d) of
the Exchange Act, or upon the closing of a Deemed Liquidation Event, and may appoint one (1) observer to attend and be present at the
meeting of board of directors. The Company also agreed not to, without Mr. Hannasch&rsquo;s approval (so long as Mr. Hannasch holds at
least 62,500 shares of Series A Preferred Stock), (i) make any loan to any person, subsidiarity or other entity except expenditures
in the ordinary course of business or under an employee stock option plan, (ii) own any securities of any subsidiarity or other entity
unless it is wholly owned by the Company, (iii) guarantee any indebtedness except for trade accounts arising in the ordinary course of
business, (iv) make any investment inconsistent with any investment policy approved by the board of directors, (v) enter into any material
transaction with insiders of the Company outside the ordinary and usual course of business, (vi) authorize any plan for the issuance
of any employee incentive equity rights, management incentive plans payable on the basis of equity proceeds or amend the 2017 Stock Compensation
plan, or (vii) allow previous common stockholders who own more than $100,000 of common stock, except for certain common stockholders
as indicated in the Investor Rights Agreement, to participate in the purchase of Series A Preferred Stock, unless such common stockholder
purchases at least $100,000 of Series A Preferred Stock valued at the Series A original issue price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a new letter agreement with Brian Hannasch, dated July 7, 2022, pursuant to which Mr. Hannasch
has agreed to relinquish his rights under the Investor Rights Agreement immediately upon the effectiveness of the registration
statement of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of September 30, 2022, warrants to purchase an aggregate of 288,258 shares of our common stock, and 144,890 shares of preferred
series a stock were outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2019, we issued warrants to purchase 40,000 shares of common stock  to Brian P. Hannasch, in connection with certain
his purchase of our Series A Preferred Stock. Pursuant to the terms of the warrants, the warrant exercise price is equal to $0.01 per
share, subject to certain adjustments. If unexercised, these warrants will expire on the 10<SUP>th </SUP>anniversary of their issuance
dates. The warrants will neither expire nor be automatically exercised upon the closing of this offering. The warrants provide that the
holder thereof may elect to exercise the warrant on a net &ldquo;cashless&rdquo; basis at any time prior to the expiration thereof. Assuming
the closing of this offering occurs, the fair market value of one share of our common stock in connection with any cashless exercise
shall be the based on the average of the daily closing prices per share for the 30 consecutive trading day period ending on the second
trading day prior to such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, we issued pre-funded warrants to purchase 144,890 shares of Series A Preferred Stock (which are convertible into 289,779
shares of common stock) to Masimo, in connection with its purchase of our Series A Preferred Stock. Pursuant to the terms of the
warrants, the warrant exercise price is equal to $0.0001 per share, subject to adjustments, and these warrants will not expire. The aggregate
purchase price of these warrants, in the amount of approximately $2.7 million, equating to $18.87 per warrant share, was pre-funded to
the Company and, consequently, no additional consideration shall be required to be paid by Masimo to effect any exercise of the warrants,
except for the payment of the exercise price. The warrants will neither expire nor be automatically exercised upon the closing of this
offering. The warrants provide that Masimo may elect to exercise the warrant on a net &ldquo;cashless&rdquo; basis at any time prior
to the expiration thereof. Assuming the closing of this offering occurs, the fair market value of one share of our Series A Preferred
Stock in connection with any cashless exercise shall be (i) the closing price or last sale price of a share of common stock reported
for the business day immediately before the date on which Masimo delivers this warrant together with its notice of exercise to the Company,
multiplied by the number of shares of common stock into which a share of Series A Preferred Stock is then convertible, if the common
stock is then traded on a trading market, or (ii) the fair market value of Series A Preferred Stock, as mutually determined in writing
by the Company and Masimo. Masimo may not exercise the warrant in excess of that number of shares which would cause the aggregate number
of shares of common stock beneficially owned by Masimo to exceed 19.99% of the total number of issued and outstanding shares of common
stock following such exercise, or the combined voting power of the securities beneficially owned by Masimo to exceed 19.99% of the combined
voting power of all of the securities of the Company then outstanding following such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into SPAs to provide for advances of up to $3.0 million in proceeds to us, subject to our satisfaction of certain conditions.
Pursuant to the SPAs, from June through November of 2022, we issued Notes with an aggregate principal amount of $3,333,333, which amount
included OID of $333,333, and legal fees of $130,000, resulting in advance proceeds to us of $3.0 million. In connection with the issuance
of the Notes, we also issued five-year warrants exercisable for an aggregate of 353,111 shares of common stock with an exercise
price of the lower of (a) $11.80 and (b) a 12% discount to the price per share in any subsequent offering by the Company. For
more information regarding the SPAs, see &ldquo;<I>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&mdash;Recent
Developments</I>.&rdquo; The warrants provide that the holder may elect to exercise the warrant on a net &ldquo;cashless&rdquo; basis
at any time after the six-month anniversary of the issuance date of the warrants, the market price of one share of common stock is greater
than the exercise price of the warrants and the shares to be issued pursuant to the warrants are not registered under an effective registration
statement. &nbsp;A holder may not exercise the warrant in excess of that number of shares which would cause the aggregate number of shares
of common stock beneficially owned by such holder to exceed 4.99% of the total number of issued and outstanding shares of common stock
following such exercise, or the combined voting power of the securities beneficially owned by such holder to exceed 4.99% of the combined
voting power of all of the securities of the Company then outstanding following such exercise. The warrants will neither expire nor be
automatically exercised upon the closing of this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certain
Anti-Takeover Provisions of Delaware Law, Our Certificate of Incorporation and Our Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
203 of the DGCL provides that if a person acquires 15% or more of the voting stock of a Delaware corporation, such person becomes an
&ldquo;interested stockholder&rdquo; and may not engage in certain &ldquo;Business Combinations&rdquo; with such corporation for a period
of three years from the time such person acquired 15% or more of such corporation&rsquo;s voting stock, unless: (1) the board of directors
of such corporation approves the acquisition of stock or the merger transaction before the time that the person becomes an interested
stockholder, (2) the interested stockholder owns at least 85% of the outstanding voting stock of such corporation at the time the merger
transaction commences (excluding voting stock owned by directors who are also officers and certain employee stock plans), or (3) the
merger transaction is approved by the board of directors and at a meeting of stockholders, not by written consent, by the affirmative
vote of 2/3 of the outstanding voting stock which is not owned by the interested stockholder. A Delaware corporation may elect in its
certificate of incorporation or Bylaws not to be governed by this particular Delaware law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation, our bylaws and the DGCL contain provisions that could have the effect of rendering more difficult, delaying,
or preventing an acquisition deemed undesirable by our board of directors. These provisions could also make it difficult for stockholders
to take certain actions, including electing directors who are not nominated by the members of our board of directors or taking other
corporate actions, including effecting changes in our management. For instance, our certificate of incorporation does not provide for
cumulative voting in the election of directors. Our board of directors are empowered to elect a director to fill a vacancy created by
the expansion of the board of directors or the resignation, death, or removal of a director in certain circumstances; and our advance
notice provisions in our bylaws require that stockholders must comply with certain procedures in order to nominate candidates to our
board of directors or to propose matters to be acted upon at a stockholders&rsquo; meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
authorized but unissued common stock will be available for future issuances without stockholder approval and could be utilized for a
variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence
of authorized but unissued and unreserved common stock could render more difficult or discourage an attempt to obtain control of us by
means of a proxy contest, tender offer, merger or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certificate
of incorporation and Bylaws</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
other things, our certificate of incorporation and our bylaws:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">do
    not provide for cumulative voting in the election of directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provides
    for the exclusive right of the board of directors to elect a director to fill a vacancy created by the expansion of the board of
    directors or the resignation, death, or removal of a director by stockholders;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">requires
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that a special meeting of stockholders may be
    called only by the Board of Directors, or by a committee of the Board of Directors that has been designated by the Board of Directors;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limits
    the liability of, and providing indemnification to, our directors and officers;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">controls
    the procedures for the conduct and scheduling of stockholder meetings;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">grants
    the ability to remove directors only for cause by the affirmative vote of at least two-thirds of the voting power of all of the then
    outstanding shares of voting stock of the Company entitled to vote at an election of directors; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provides
    for advance notice procedures that stockholders must comply with in order to nominate candidates to the board of directors or to
    propose matters to be acted upon at a stockholders&rsquo; meeting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
combination of these provisions will make it more difficult for our existing stockholders to replace our board of directors as well as
for another party to obtain control of us by replacing our board of directors. Since our board of directors has the power to retain and
discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change
in management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and its policies
and to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to reduce our vulnerability
to hostile takeovers and to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect
of discouraging others from making tender offers for our shares of common stock and may have the effect of delaying changes in our control
or management. As a consequence, these provisions may also inhibit fluctuations in the market price of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><B>Forum for Litigation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Article VIII of our Certificate of Incorporation
identifies the Court of Chancery of the State of Delaware (referring to Delaware State Courts) as the exclusive forum for certain litigation,
including any derivative action. To the extent that the applicability such provision may be sought in connection with actions arising
under the Securities Act or Exchange Act, pursuant to Section 27 of the Exchange Act, exclusive federal jurisdiction is
created over all suits brought to enforce any duty or liability created by the&nbsp;Exchange Act&nbsp;or the rules and regulations thereunder,
which would result in federal courts instead having jurisdiction over such claims. Pursuant to Section 22 of the Securities Act, concurrent
jurisdiction is created for federal and state courts over all suits brought to enforce any duty or liability created by the&nbsp;Securities
Act or the rules and regulations thereunder. Accordingly, there is uncertainty as to whether a court would enforce such provision
in an action arising under the&nbsp;Securities Act or Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company does not intend for such exclusive
forum provision to apply to claims arising under the Securities Act or the Exchange Act. With respect to claims arising
under the Securities Act, note that investors cannot waive compliance with the federal securities laws and rules and regulations
thereunder.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Limitation
of Liability and Indemnification</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
bylaws provide that we will indemnify our directors to the fullest extent authorized or permitted by applicable law. Under our Bylaws,
we are required to indemnify each of our directors and officers if the basis of the indemnitee&rsquo;s involvement was by reason of the
fact that the indemnitee is or was our director or officer or was serving at our request as a director, officer, employee or agent for
another entity. We must indemnify our officers and directors against all expenses (including attorneys&rsquo; fees), judgments, fines
and amounts paid in settlement actually and reasonably incurred by the indemnitee in connection with such action, suit or proceeding
if the indemnitee acted in good faith and in a manner the indemnitee reasonably believed to be in or not opposed to the best interests
of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe the indemnitee&rsquo;s conduct
was unlawful. Our bylaws also require us to advance expenses (including attorneys&rsquo; fees) incurred by a director or officer in defending
any civil, criminal, administrative or investigative action, suit or proceeding, provided that such person will repay any such advance
if it is ultimately determined that such person is not entitled to indemnification by us. Any claims for indemnification by our directors
and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available
to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vstock
Transfer LLC is the Company&rsquo;s transfer agent with respect of our common stock. The principal business address of 18 Lafayette Place,
Woodmere, NY 11598. Phone: 212-828-8436.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 107; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_006"></A>SHARES
ELIGIBLE FOR FUTURE SALE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
to this offering, there has no public market for the Company&rsquo;s common stock, and a liquid trading market for its common stock may
not develop or be sustained after this offering. Future sales of substantial amounts of the Company&rsquo;s common stock in the public
market, or the anticipation of these sales, could materially and adversely affect market prices prevailing from time to time, and could
impair the Company&rsquo;s ability to raise capital through sales of equity or equity-related securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Only
a limited number of shares of the Company&rsquo;s common stock will be available for sale in the public market for a period of several
months after completion of this offering due to contractual and legal restrictions on resale described below. Nevertheless, sales of
a substantial number of shares of the Company&rsquo;s common stock in the public market after such restrictions lapse, or the perception
that those sales may occur, could materially and adversely affect the prevailing market price of its common stock. Although the Company
intends to list its common stock on the Nasdaq, the Company cannot assure you that there will be an active market for its common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of
the shares to be outstanding immediately after the completion of this offering, we expect that the shares to be sold in this offering
will be freely tradable without restriction under the Securities Act unless purchased by our &ldquo;affiliates,&rdquo; as that term is
defined in Rule 144 under the Securities Act; these restricted securities may be sold in the public market only if registered or pursuant
to an exemption from registration, such as Rule 144 or Rule 701 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
144</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144 as currently in effect, once the Company has been subject to the public company reporting requirements of Section
13 or Section 15(d) of the Exchange Act for at least 90 days, a person who is not deemed to have been one of the Company&rsquo;s affiliates
for purposes of the Securities Act at any time during the 90 days preceding a sale and who has beneficially owned the shares of its common
stock proposed to be sold for at least six months is entitled to sell those shares without complying with the manner of sale, volume
limitation or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. If such a person
has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than
Company affiliates, then that person would be entitled to sell those shares without complying with any of the requirements of Rule 144.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
general, under Rule 144, as currently in effect, the Company&rsquo;s affiliates or persons selling shares of its common stock on behalf
of its affiliates are entitled to sell upon expiration of the market standoff agreements and lock-up agreements described above, within
any three-month period, a number of shares that does not exceed the greater of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1%
    of the number of shares of the Company&rsquo;s capital stock then outstanding; or </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    average weekly trading volume of the Company&rsquo;s common stock during the four calendar weeks preceding the filing of a notice
    on Form 144 with respect to that sale.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
under Rule 144 by the Company&rsquo;s affiliates or persons selling shares of its common stock on behalf of its affiliates are also subject
to certain manner of sale provisions and notice requirements and to the availability of current public information about the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Rule
701</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rule
701 generally allows a stockholder who purchased shares of the Company&rsquo;s common stock pursuant to a written compensatory plan or
contract, such as stock options granted under the 2017 Plan, and who is not deemed to have been an affiliate of the Company during
the immediately preceding 90 days to sell these shares in reliance upon Rule 144, but without being required to comply with the public
information, holding period, volume limitation, or notice provisions of Rule 144. Rule 701 also permits affiliates of the Company to
sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701
shares, however, are required to wait until 90 days after the date of this prospectus before selling such shares pursuant to Rule 701
and until expiration of the lock-up period described below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the Company, and its officers, directors and 5% stockholders have agreed to a &ldquo;lock-up&rdquo; period,
in the case of the Company, a period of 180 days after the date the registration statement, of which this prospectus forms a part is
declared effective, and in the case of our directors and executive officers and our 5% and greater stockholders, a period of 180 days
after the date the registration statement, of which this prospectus forms a part, is declared effective, with respect to the shares that
they beneficially own, including shares issuable upon the exercise of convertible securities and options that are currently outstanding
or which may be issued. This means that, for a period of 180 days following the closing of this offering, such persons may not offer,
sell, pledge or otherwise dispose of these securities without the prior written consent of the Underwriter. Officers&rsquo; and directors&rsquo;
180-day restricted period is subject to extension upon certain events and the terms of the lock-up agreements may be waived at the Underwriter&rsquo;s
discretion. The lock-up restrictions, specified exceptions and the circumstances under which the 180-day lock-up period may be extended
are described in more detail under &ldquo;Underwriting.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_007"></A>MATERIAL
UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of some of the possible U.S. tax consequences that should be anticipated in connection with an investment in our
common stock. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;), the U.S. Treasury
regulations promulgated thereunder and administrative and judicial interpretations thereof, all as in effect on the date hereof and all
of which are subject to change, possibly with retroactive effect. There can be no assurance that their Internal Revenue Service (the
&ldquo;IRS&rdquo;) will not challenge one or more of the tax consequences described herein, and we have not obtained, and do not intend
to obtain, an opinion of counsel or ruling from the IRS with respect to the U.S. federal income tax considerations relating to the purchase,
ownership, or disposition of our common stock. <B>Each prospective investor is urged to consult their own tax advisor about the tax consequences
of an investment in our common stock in light of the investor&rsquo;s own circumstances</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consequences
For U.S. Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following discussion describes the material U.S. federal income tax consequences relating to the ownership and disposition of our common
stock by U.S. Holders. As used in this discussion, the term &ldquo;U.S. Holder&rdquo; means a beneficial owner of our common stock that
is, for U.S. federal income tax purposes, (1) an individual who is a citizen or resident of the United States, (2) a corporation (or
entity treated as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of the United States,
any state thereof, or the District of Columbia, (3) an estate the income of which is subject to U.S. federal income tax regardless of
its source, or (4) a trust (i) with respect to which a court within the United States is able to exercise primary supervision over its
administration and one or more United States persons have the authority to control all of its substantial decisions, or (ii) that has
elected to be treated as a domestic trust for U.S. federal income tax purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
discussion applies to U.S. Holders that purchase our common stock pursuant to this offering and hold such common stock as capital assets.
This discussion does not address all of the U.S. federal income tax consequences that may be relevant to specific U.S. Holders in light
of their particular circumstances, or to U.S. Holders subject to special treatment under U.S. federal income tax law (such as certain
financial institutions, insurance companies, broker-dealers and traders in securities or other persons that generally mark their securities
to market for U.S. federal income tax purposes, tax-exempt entities, retirement plans, regulated investment companies, real estate investment
trusts, certain former citizens or residents of the United States, persons who hold our common stock as part of a &ldquo;straddle&rdquo;,
&ldquo;hedge&rdquo;, &ldquo;conversion transaction&rdquo;, &ldquo;synthetic security&rdquo; or integrated investment, persons that have
a &ldquo;functional currency&rdquo; other than the U.S. dollar, persons that own directly, indirectly or through attribution 10% or more
of the voting power of our common stock, corporations that accumulate earnings to avoid U.S. federal income tax, persons subject to special
tax accounting rules under Section 451(b) of the Code, partnerships and other pass-through entities, and investors in such pass-through
entities). This discussion does not address any U.S. state or local or non-U.S. tax consequences or any U.S. federal estate, gift or
alternative minimum tax consequences. If an entity treated as a partnership for U.S. federal income tax purposes holds our common stock,
the U.S. federal income tax consequences relating to an investment in our common stock will depend in part upon the status and activities
of such entity and the particular partner. Any such entity should consult its own tax advisor regarding the U.S. federal income tax consequences
applicable to it and its partners of the purchase, ownership and disposition of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Distributions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder that receives a distribution with respect to our common stock generally will be required to include the gross amount of such
distribution in income as a dividend when actually or constructively received, to the extent of the U.S. Holder&rsquo;s pro rata share
of our current and/or accumulated earnings and profits (as determined under U.S. federal income tax principles). To the extent a distribution
received by a U.S. Holder is not a dividend because it exceeds the U.S. Holder&rsquo;s pro rata share of our current and accumulated
earnings and profits, it will be treated first as a tax-free return of capital and reduce (but not below zero) the adjusted tax basis
of the U.S. Holder&rsquo;s common stock. To the extent the distribution exceeds the adjusted tax basis of the U.S. Holder&rsquo;s common
stock, the remainder will be taxed as capital gain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sale,
Exchange or Other Disposition of our Common Stock</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
U.S. Holder generally will recognize capital gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition
of our common stock in an amount equal to the difference, if any, between the amount realized (i.e., the amount of cash plus the fair
market value of any property received) on the sale, exchange or other disposition, and such U.S. Holder&rsquo;s adjusted tax basis in
the shares that were transferred. Such capital gain or loss generally will be long-term capital gain or long-term capital loss if, on
the date of sale, exchange or other disposition, the transferred shares were held by the U.S. Holder for more than one year. Long-term
capital gains of individual investors are generally subject to lower tax rates than those imposed on ordinary income. Any capital gain
of a non-corporate U.S. Holder that is not long-term capital gain is taxed at ordinary income rates. Capital losses might not be permitted
to offset the full amount of an individual&rsquo;s ordinary income.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Medicare
Tax on Net Investment Income</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
U.S. Holders who are individuals, estates or trusts are subject to an additional 3.8% U.S. federal income tax on all or a portion of
their &ldquo;net investment income,&rdquo; which generally includes dividends on the shares, and net gains from the disposition of common
stock. U.S. Holders that are individuals, estates or trusts should consult their tax advisors regarding the applicability of the Medicare
tax.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Information
Reporting and Backup Withholding</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
we must report annually to the IRS (with a copy of such report provided to you) the amount of dividends paid to you, your name and address,
and the amount of tax withheld, if any. Backup withholding may apply to amounts subject to reporting if the U.S. Holder (1) fails to
provide an accurate United States taxpayer identification number or otherwise establish a basis for exemption, or (2) is described in
certain other categories of persons. However, U.S. Holders that are corporations generally are excluded from these information reporting
and backup withholding tax rules. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules
generally will be allowed as a refund or a credit against a U.S. Holder&rsquo;s U.S. federal income tax liability if the required information
is furnished by the U.S. Holder on a timely basis to the IRS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Foreign
Account Tax Compliance Act</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Foreign Account Tax Compliance Act (&ldquo;FATCA&rdquo;) generally imposes withholding tax at a rate of 30% on dividends on and gross
proceeds from the sale or other disposition of securities that are beneficially owned by certain U.S. persons where held in a &ldquo;foreign
financial institution&rdquo; (as specially defined under those rules), unless such institution enters into an agreement with the U.S.
government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information
regarding the U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as
certain account holders that are foreign entities with U.S. owners), or otherwise establishes an exemption. If a U.S. Holder owns our
common stock in a foreign financial institution, they should obtain specific advice from an expert on the implications of FATCA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consequences
to Non-U.S. Holders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of the material U.S. federal income tax considerations for Non-U.S. Holders relating to the purchase, ownership
and disposition of the common stock purchased in this offering. A &ldquo;Non-U.S. Holder&rdquo; is a beneficial owner of our securities
(other than a partnership or an entity or arrangement treated as a partnership for U.S. federal income tax purposes) that, for U.S. federal
income tax purposes, is not a U.S. holder. This summary is for general information purposes only and does not purport to be a complete
analysis of all the potential tax considerations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Distributions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below regarding effectively connected income, any dividend (including any taxable constructive stock dividend) paid
to a Non-U.S. Holder generally will be subject to U.S. withholding tax either at a rate of 30% of the gross amount of the dividend, or
such lower rate as may be specified by an applicable income tax treaty. In order to receive a reduced treaty rate, a Non-U.S. Holder
must provide us with an IRS Form W-8BEN, IRS Form W-8BEN-E or other applicable IRS Form W-8 properly certifying qualification for the
reduced rate. These forms must be updated periodically. A Non-U.S. Holder eligible for a reduced rate of U.S. withholding tax pursuant
to an income tax treaty may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the
IRS. If a Non-U.S. Holder holds our common stock through a financial institution or other agent acting on the Non-U.S. Holder&rsquo;s
behalf, the Non-U.S. Holder will be required to provide appropriate documentation to the agent, which then may be required to provide
certification to us or our paying agent, either directly or through other intermediaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividends
received by a Non-U.S. Holder that are effectively connected with its conduct of a U.S. trade or business (and, if required by an applicable
income tax treaty, attributable to a permanent establishment or fixed base maintained by the Non-U.S. Holder in the United States) are
generally exempt from such withholding tax if the Non-U.S. Holder satisfies certain certification and disclosure requirements. In order
to obtain this exemption, the Non-U.S. Holder must provide us with an IRS Form W-8ECI or other applicable IRS Form W-8 properly certifying
such exemption. Such effectively connected dividends, although not subject to withholding tax, are taxed at the same graduated U.S. federal
income tax rates applicable to U.S. holders, net of certain deductions and credits. In addition, dividends received by a corporate Non-U.S.
Holder that are effectively connected with its conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate
of 30% or such lower rate as may be specified by an applicable income tax treaty. Non-U.S. Holders should consult their own tax advisors
regarding any applicable tax treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Gain
on Sale, Exchange or Other Taxable Disposition of Common Stock</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the discussion below regarding backup withholding and foreign accounts, a Non-U.S. Holder generally will not be required to pay U.S.
federal income tax on any gain realized upon the sale, exchange or other taxable disposition of our common stock unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    gain is effectively connected with the Non-U.S. Holder&rsquo;s conduct of a U.S. trade or business (and, if required by an applicable
    income tax treaty, the gain is attributable to a permanent establishment or fixed base maintained by the Non-U.S. Holder in the United
    States);</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    Non-U.S. Holder is a non-resident alien individual who is present in the United States for a period or periods aggregating 183 days
    or more during the calendar year in which the sale or disposition occurs, and certain other conditions are met; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
    of our common stock constitute U.S. real property interests by reason of our status as a &ldquo;United States real property holding
    corporation&rdquo; (a USRPHC) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding
    the Non-U.S. Holder&rsquo;s disposition of, or the non- U.S. holder&rsquo;s holding period for, our common stock. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that we are not currently and will not become a USRPHC for U.S. federal income tax purposes, and the remainder of this discussion
so assumes. However, because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property
relative to the fair market value of our other business assets, there can be no assurance that we will not become a USRPHC in the future.
Even if we become a USRPHC, however, as long as our common stock is regularly traded on an established securities market, such common
stock will be treated as U.S. real property interests only if the Non-U.S. Holder actually or constructively holds more than five percent
of such regularly traded common stock at any time during the shorter of the five-year period preceding the Non-U.S. Holder&rsquo;s disposition
of, or the Non-U.S. Holder&rsquo;s holding period for, our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the Non-U.S. Holder is described in the first bullet above, they will be required to pay tax on the net gain derived from the sale, exchange
or other taxable disposition under regular graduated U.S. federal income tax rates, and a corporate Non-U.S. Holder described in the
first bullet above also may be subject to the branch profits tax at a rate of 30%, or such lower rate as may be specified by an applicable
income tax treaty. An individual Non-U.S. Holder described in the second bullet above will be required to pay a flat 30% tax (or such
lower rate specified by an applicable income tax treaty) on the gain derived from the sale, exchange or other taxable disposition, which
gain may be offset by U.S. source capital losses for the year (provided the Non-U.S. Holder has timely filed U.S. federal income tax
returns with respect to such losses). Non-U.S. Holders should consult their own tax advisors regarding any applicable income tax or other
treaties that may provide for different rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Information
Reporting and Backup Withholding</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Generally,
we must report annually to the IRS (with a copy of such report provided to you) the amount of dividends paid to you, your name and address,
and the amount of tax withheld, if any. Pursuant to applicable income tax treaties or other agreements, the IRS may make these reports
available to tax authorities in your country of residence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments
of dividends on or of proceeds from the disposition of our common stock made to you may be subject to backup withholding unless you establish
an exemption, for example, by properly certifying your non-U.S. status on an IRS Form W-8BEN or IRS Form W-8BEN-E or other applicable
IRS Form W-8. Notwithstanding the foregoing, backup withholding may apply if either we or our paying agent has actual knowledge, or reason
to know, that you are a U.S. person. Backup withholding is not an additional tax; rather, the U.S. federal income tax liability of persons
subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund
or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 111; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_008"></A>UNDERWRITING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, we will enter into an underwriting agreement with Alexander Capital L.P. as the Underwriter of this offering.
The Underwriter, and each other underwriter named in the underwriting agreement, if any, has severally agreed to purchase from us, on
a firm commitment basis, the number of shares, set forth opposite its name below, at the public offering price, less the underwriting
discount set forth on the cover page of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 80%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number
    of <BR>
    Shares</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alexander
    Capital L.P.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">WallachBeth Capital LLC</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">[&#9679;]</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriter is committed to purchase all of the shares offered by us other than those covered by the option to purchase additional securities
described below, if they purchase any such securities. The obligations of the Underwriter may be terminated upon the occurrence of certain
events specified in the underwriting agreement. Furthermore, pursuant to the underwriting agreement, the Underwriter&rsquo;s obligations
are subject to customary conditions, representations and warranties contained in the underwriting agreement, such as receipt by the Underwriter
of the officers&rsquo; certificates and legal opinions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed to indemnify the Underwriter against specified liabilities, including liabilities under the Securities Act of and to contribute to payments the Underwriter may be required to make in respect thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriter is offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal
matters by their counsel and other conditions specified in the underwriting agreement. The Underwriter reserves the right to withdraw,
cancel or modify offers to the public and to reject orders in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Over-allotment
Option</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the Underwriter an over-allotment option. This option, which is exercisable for up to 45 days after the date of this prospectus,
permits the Underwriter to purchase up to a total of 281,250 shares of common stock (equal to fifteen percent (15%) of the aggregate
number of shares of common stock sold in this offering) and exercisable at a price per share equal to the public offering price less
the underwriting discounts and commissions set forth on the cover of this prospectus in any combination thereof. We will be obligated,
pursuant to the option, to sell these additional shares of common stock to the Underwriter to the extent the option is exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discount</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. The information assumes
either no exercise or full exercise by the Underwriter of its over-allotment option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Per
    Share</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    Without Over-Allotment Option</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Total
    With Over Allotment Option</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public
    offering price</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting
    discount (7.0%)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds,
    before expenses, to us</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[&#9679;]</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriter proposes to offer the shares offered by us to the public at the public offering price per share set forth on the cover of
this prospectus. In addition, the Underwriter may offer some of the shares to other securities dealers at such price less a concession
of $[&#9679;] per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will pay the out-of-pocket accountable expenses of the Underwriter in connection with this offering. The underwriting agreement,
however, provides that in the event the offering is terminated, any advance expense deposits paid to the Underwriter will be returned
to the extent that offering expenses are not actually incurred in accordance with FINRA Rule 5110(g)(4)(A). The Company will receive
a $25,000 advance expense deposit towards accountable expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has agreed to pay the Underwriter an Underwriter&rsquo;s fee of seven percent (7%) of the amount raised in this offering.
If any capital is raised in a pre-offering bridge round, the placement fee will be equal to a nine percent (9%) cash fee, plus
the Underwriter&rsquo;s Warrants. The Company has agreed to pay for a certain amount of the Underwriter&rsquo;s accountable expenses,
including actual accountable road show expenses for the offering; prospectus tracking and compliance software for the offering; the
reasonable and documented fees and disbursements of the Underwriter&rsquo;s counsel up to an amount of $[&#9679;]; background checks
of the Company&rsquo;s officers and directors; preparation of bound volumes and cube mementos in such quantities as the Underwriter may
reasonably request. The total amount of accountable expenses to be paid, reimbursed, or paid on behalf of the Underwriter will not
exceed $175,000. In addition, we have also agreed to pay to the underwriters a non-accountable expense allowance in the amount of
1% of the gross offering amount (including shares purchased upon exercise of the over-allotment option).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates that the total expenses of the offering payable by us, excluding underwriting discounts and commissions, will be approximately
$[&#9679;].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been advised by the Underwriter that it proposes to offer the shares offered by us to the public at the public offering price per
share set forth on the cover of this prospectus. In addition, the Underwriter may offer some of the shares to other securities
dealers at such price less a concession of $[&#9679;] per Share. After the initial offering, the public offering price and concession
to dealers may be changed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter
Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the closing of this offering, we have agreed to issue to the Underwriter a five-year warrant to purchase up to six percent (6%) of the
common stock sold by us in this offering. The Underwriter&rsquo;s Warrants will be exercisable at a per share exercise price equal to
one hundred twenty percent (120%) of the public offering price per share). The Underwriter&rsquo;s Warrants will be exercisable at any
time, and from time to time, in whole or in part, during the period from the effective date of the offering, which period shall not extend
further than five years from the date of commencement of sales in this offering in compliance with FINRA Rule 5110. The Underwriter&rsquo;s
Warrants are also exercisable on a cashless basis. The Underwriter&rsquo;s Warrants have been deemed compensation by FINRA and are therefore
subject to a 180-day lock-up pursuant to FINRA Rule 5110. Except as permitted by Rule 5110, the Underwriter (or permitted assignees under
the Rule) will not sell, transfer, assign, pledge, or hypothecate the Underwriter&rsquo;s Warrants or the securities underlying the Underwriter&rsquo;s
Warrants, nor will any of them engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective
economic disposition of the option or the underlying securities for a period of 180 days from the commencement of sales under this prospectus.
The exercise price and number of securities upon exercise of the Underwriter&rsquo;s Warrants may be adjusted in certain circumstances
including in the event of a share dividend, extraordinary cash dividend or our recapitalization, reorganization, merger or consolidation.
However, the Underwriter&rsquo;s Warrant exercise price or underlying shares will not be adjusted for issuances of shares of common stock
at a price below the Underwriter&rsquo;s Warrant exercise price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Underwriter&rsquo;s
Warrants include piggy-back registration and mandatory registration rights in favor of the Underwriter. The piggy-back registration rights
provide that the Company will, subject to certain limitations, include common stock underlying the Underwriter&rsquo;s Warrants in any
registration statement filed by the Company while the Underwriter&rsquo;s Warrants are exercisable. The mandatory registration rights
require the Company to prepare and file at the written request of the warrant holder, on a one-time basis, a registration statement on
Form F-3 covering any remaining unregistered common stock underlying the Underwriter&rsquo;s Warrants so long as such warrants are exercisable.
The underwriting agreement and the accompanying exhibits, including the form of the Underwriter&rsquo;s Warrant agreement, have been
filed with this offering&rsquo;s registration statement of which this prospectus forms a part as Exhibit No. 1.1.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Discretionary
Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriter does not intend to confirm sales of the securities offered hereby to any accounts over which they have discretionary authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lock-Up
Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the underwriting agreement and certain &ldquo;lock-up&rdquo; agreements, the Company, its executive officers, directors and certain
holders of the Company&rsquo;s common stock and securities exercisable for or convertible into its common stock outstanding immediately
upon the closing of this offering, have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge, contract
to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement
or arrangement that transfers, in whole or in part, the economic risk of ownership of, directly or indirectly, engage in any short selling
of any common stock or securities convertible into or exchangeable or exercisable for any common stock, whether currently owned or subsequently
acquired, without the prior written consent of the Underwriter, for a period of 180 days from the date of effectiveness of the registration
statement, of which this prospectus forms a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 113; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Right
of First Refusal</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have granted the Underwriter a right of first refusal, for a period of 12 months from the closing of this offering, to act as sole investment
banker, sole book runner and/or sole Underwriter at the Underwriter&rsquo;s discretion, for each and every future public or private equity
financing for the Company, or any successor to or subsidiary of the Company. The right of first refusal may be terminated by the Company
for cause, which including a material breach by the Underwriter or a material failure by the Underwriter to provide services as contemplated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Electronic
Offer, Sale and Distribution of Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
prospectus in electronic format may be made available on the websites maintained by the Underwriter, if any, participating in this offering
and the Underwriter participating in this offering may distribute prospectuses electronically. The Underwriter may agree to allocate
a number of shares for sale to its online brokerage account holders. Internet distributions will be allocated by the Underwriter that
will make internet distributions on the same basis as other allocations. Other than the prospectus in electronic format, the information
on these websites is not part of, nor incorporated by reference into, this prospectus or the registration statement of which this prospectus
forms a part, has not been approved or endorsed by us or the Underwriter in its capacity as the Underwriter, and should not be relied
upon by investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stabilization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the Underwriter may engage in stabilizing transactions, over-allotment transactions, covered transactions,
penalty bids and purchases to cover positions created by short sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stabilizing
    transactions permit bids to purchase shares of common stock so long as the stabilizing bids do not exceed a specified maximum and
    are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is
    in progress.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over-allotment
    transactions involve sales by the Underwriter of shares of common stock in excess of the number of shares of common stock the Underwriter
    is obligated to purchase. This creates a covered short position which may be either a covered short position or a naked short position.
    In a covered short position, the number of shares of common stock over-allotted by the Underwriter is not greater than the number
    of shares of common stock that they may purchase in the over-allotment option. In a naked short position, the number of shares of
    common stock involved is greater than the number of shares of common stock in the over-allotment option. The Underwriter may close
    out any short position by exercising its over-allotment option and/or purchasing shares of common stock in the open market.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Covered
    transactions involve purchases of shares of common stock in the open market after the distribution has been completed in order to
    cover syndicate short positions. In determining the source of shares of common stock to close out the short position, the Underwriter
    will consider, among other things, the price of shares of common stock available for purchase in the open market as compared with
    the price at which it may purchase shares of common stock through exercise of the over- allotment option. If the Underwriter sells
    more shares of common stock than could be covered by exercise of the over-allotment option and, therefore, have a naked short position,
    the position can be closed out only by buying shares of common stock in the open market. A naked short position is more likely to
    be created if the Underwriter is concerned that after pricing there could be downward pressure on the price of the shares of common
    stock in the open market that could adversely affect investors who purchase in the offering.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Penalty
    bids permits the Underwriter to reclaim a selling concession from a syndicate member when the shares of common stock originally sold
    by the Underwriter are purchased in stabilizing or covered transactions to cover short positions.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 114; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
stabilizing transactions, covered transactions and penalty bids may have the effect of raising or maintaining the market price of the
shares of common stock or preventing or retarding a decline in the market price of its shares of common stock. As a result, the price
of the common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither the Company
nor the Underwriter make any representation or prediction as to the effect that the transactions described above may have on the price
of the Company&rsquo;s common stock. These transactions may be effected on the Nasdaq Capital Market, in the over-the-counter market
or otherwise and, if commenced, may be discontinued at any time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Passive
Market Making</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with this offering, the Underwriter may engage in passive market making transactions in the Company&rsquo;s common stock on
The Nasdaq Capital Market in accordance with Rule 103 of Regulation M under the Exchange Act, during a period before the commencement
of offers or sales of the shares and extending through the completion of the distribution. A passive market maker must display its bid
at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive
market maker&rsquo;s bid, then that bid must then be lowered when specified purchase limits are exceeded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Relationships</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Underwriter and their respective affiliates may, in the future provide various investment banking, commercial banking and other financial
services for the Company and its affiliates for which they have received, and may in the future receive, customary fees. However, except
as disclosed in this prospectus, the Company has no present arrangements with the Underwriter for any further services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Offer
Restrictions Outside the United States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than in the United States, no action has been taken by us or the Underwriter that would permit a public offering of the securities offered
by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be
offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with
the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result
in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are
advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in
any jurisdiction in which such an offer or a solicitation is unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 115; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_009"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
validity of the common stock offered by us in this offering will be passed upon for us by Lucosky Brookman LLP, Woodbridge, New Jersey.
Certain legal matters will be passed upon for the Underwriter by Carmel, Milazzo &amp; Feil LLP, New York, New York.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_010"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements as of December 31, 2021 and 2020, included in this registration statement have been so included in reliance upon
the report of Rosenberg Rich Baker Berman, P.A., an independent registered public accounting firm, given on the authority of said firm
as an expert in auditing and accounting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ka_011"></A>WHERE
YOU CAN FIND MORE INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered
by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information
set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules
and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement,
including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents
of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration
statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract
or document filed as an exhibit is qualified in all respects by the filed exhibit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information
with the SEC. These reports, proxy statements and other information will be available on the website of the SEC referred to above. The
information contained in, or that can be accessed through, our website is not part of this prospectus, and you should not consider the
contents of our website in making an investment decision with respect to our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 116; Value: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="eds_001"></A>INDEX
TO  FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unaudited
Interim Financial Statements</B></FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Nine Months Ended September 30, 2022 and 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page(s)</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ds_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
    Balance Sheets as of September 30, 2022 (unaudited) and December 31, 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ds_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
    Statements of Operations (unaudited) for the Nine Months Ended September 30, 2022 and 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ds_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements
    of Stockholders&rsquo; Equity (Deficit) (unaudited) for the Nine Months Ended September 30, 2022 and 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ds_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
    Statements of Cash Flows (unaudited) for the Nine Months Ended September 30, 2022 and 2021</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#ds_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statements (Unaudited)</FONT></A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Statements</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Years Ended December 31, 2021 and 2020</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page(s)</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#eds_002">Report of Independent Registered Public Accounting Firm</A> (PCAOB Firm ID 0089)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-31</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#eds_003">Balance Sheets as of December 31, 2021 and 2020</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-32</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#eds_004">Statements of Operations for the Years Ended December 31, 2021 and 2020</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-34</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#eds_005">Statements
    of Stockholders&rsquo; Equity (Deficit) for the Years Ended December 31, 2021 and 2020</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-35</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#eds_006">Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-36</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#eds_007">Notes to Financial Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-37</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 117; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ds_001"></A>Condensed
Balance Sheet</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Assets:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,820</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">320,858</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    receivable, net</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">320,244</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,301</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">57,321</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">39,180</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaids
    and other current assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16,151</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15,670</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">401,536</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">491,009</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and Equipment, at cost:</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">405,845</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">404,455</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    - accumulated depreciation</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(310,506</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(286,913</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, net</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">95,339</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">117,542</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Other Assets:</P>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><P STYLE="margin: 0pt 0pt 0pt 10pt">Deferred offering costs</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0"><B>694,524</B></P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">&mdash;</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right of use asset</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108,030</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">127,975</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
    assets, net</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,501</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,956</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,331,930</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">760,482</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to financial statements are an integral part of these statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Condensed
Balance Sheet</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Unaudited)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    Liabilities:</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,450,272</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">483,790</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">817,821</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">561,638</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of long-term notes payable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">192,091</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">192,356</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of operating lease payable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,942</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,582</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    payable - related party</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,051</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    payable - convertible notes</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,973</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    deposits</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">77,099</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69,337</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,586,124</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,514,726</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,757,099</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,424,856</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-current
    Liabilities:</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease payable, net of current portion</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84,548</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109,594</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    payable, net of current portion</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,692</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,692</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    non-current liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">136,240</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">161,286</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,893,339</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,586,142</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and contingencies (see note 14)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders&rsquo;
    Equity (Deficit)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    Series A Preferred stock, $0.001 par value; 1,000,000 shares authorized; 506,637 issued and outstanding as of September 30, 2022
    and December 31, 2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">507</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">507</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    Series Seed Preferred Stock, $0.001 par value; 120,000 shares authorized; 115,477 issued and outstanding as of September 30, 2022
    and December 31, 2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock, $0.001 par value; 100,000,000 shares authorized; 1,951,547 and 1,928,004 issued and outstanding as of September
    30, 2022 and December 31, 2021, respectively.</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,952</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,928</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid in capital</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,353,818</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,323,157</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33,917,800</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29,151,367</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders&rsquo; equity (deficit)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,561,408</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(825,660</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Liabilities and Stockholders&rsquo; Equity (Deficit)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,331,930</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">760,482</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to financial statements are an integral part of these statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ds_002"></A>Condensed
Statements of Operations (Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Nine Months Ended September 30,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Sales</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,071,653</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,254,520</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cost
    of Goods Sold</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">221,846</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">398,318</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    Profit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,849,807</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,856,202</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
    Expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">344,892</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">380,743</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
    and Development</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">144,239</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">157,120</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and Administrative</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,746,688</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,447,069</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    Loss</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,386,012</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,128,730</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Income (Expense):</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financing
    charges</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,473,892</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(161,291</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(24,776</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of warrant liability</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(660,189</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22,007</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of derivative liability</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(68,032</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accretion
    of debt discount and issuance cost</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28,973</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    income</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,956</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    other income (expense), net</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,380,421</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(46,783</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Loss</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,766,433</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,175,513</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per-share
    Data</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted loss per share</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2.69</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Average Shares Outstanding</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,984,399</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,968,004</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to financial statements are an integral part of these statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ds_003"></A>Condensed
Statements of Stockholders&rsquo; Equity (Deficit) (Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Nine Months Ended September 30, 2022, and 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    Series A Preferred Stock</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    Series Seed Preferred Stock</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    Paid</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholder&rsquo;<B>s Equity</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amount</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    Capital</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deficit</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">(Deficit)</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 28%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    January 1, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">479,612</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">480</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,477</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,928,004</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,928</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,764,539</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(26,123,335</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,643,727</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    based compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,381</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,381</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sale
    of Convertible Series A Preferred Stock</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">509,977</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">510,004</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss for the nine months ended September 30, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,175,513</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,175,513</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">506,637</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">507</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,477</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,928,004</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,928</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,310,897</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(28,298,848</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,599</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    January 1, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">506,637</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">507</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,477</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,928,004</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,928</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,323,157</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29,151,367</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(825,660</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    based compensation</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,319</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,319</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    stock commitment shares from convertible notes</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23,543</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,342</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,366</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss for the nine months ended September 30, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,766,433</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,766,433</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance,
    September 30, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">506,637</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">507</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,477</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,951,547</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,952</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,353,818</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(33,917,800</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,561,408</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to financial statements are an integral part of these statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ds_004"></A>Condensed
Statements of Cash Flows (Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
    the Nine Months Ended September 30,</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    Flows from Operating Activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Loss</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,766,433</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,175,513</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjustments
    to reconcile net loss to net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash
    used by operating activities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accretion
    of debt discount and issuance cost</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">28,973</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
    and amortization</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,047</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,925</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provisions
    for losses on accounts receivable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,795</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,691</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-cash
    lease expense</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19,945</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,108</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    based compensation</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,319</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36,381</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Finance
    Charges</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,473,892</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of derivative liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,032</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change
    in fair value of warrant liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">660,189</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,007</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in operating assets and liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    receivable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(247,738</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventory</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(18,141</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,500</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaids
    and other current assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(481</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">134,377</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">359,652</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">91,706</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">256,184</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(239,906</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
    deposits</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,762</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 30pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liability</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(20,686</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,483</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used by operating activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,083,689</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,038,707</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    Flows from Investing Activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additions
    to property and equipment</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,390</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash used by investing activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(11,390</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    Flows from Financing Activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from sale of convertible Series A Preferred Stock, net of fees of $0 and $1,446,040, respectively</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">510,004</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal
    payments on notes payable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(122,265</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(92,954</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from notes payable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">122,000</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
    from convertible notes</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,870,000</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Offering costs paid</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">(87,694</P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 20pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    cash provided by financing activities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,782,041</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">417,050</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Decrease in Cash and Cash Equivalents</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(313,038</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,621,657</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and Cash Equivalents at Beginning of Period</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">320,858</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,895,475</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and Cash Equivalents at End of Period</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,820</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">273,818</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
    Disclosure of Non-cash Cash Activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for interest</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">118,391</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,226</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    paid for income taxes</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental
    Schedule of Non-cash Investing and Financing Activities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value of warrant liabilities of warrants from convertible notes</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,822,435</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    value of derivative liabilities of conversion feature from convertible notes</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,518,092</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Relative
    fair value of shares issued with convertible notes</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,365</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left">Deferred offering costs in accounts
    payable</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0">606,830</P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">&mdash;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to financial statements are an integral part of these statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neuraxis,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="ds_005"></A>Notes
to Condensed Unaudited Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Basis of Presentation, Organization and Other Matters </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo; the &ldquo;Company,&rdquo; or &ldquo;Neuraxis&rdquo;) was established in 2011 and incorporated
in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions, Inc. The name was changed to Neuraxis, Inc.
in March of 2022. Additionally, the Company filed a Certificate of Conversion to become a Delaware corporation on June 23, 2022. The
authorized shares were increased, and a par value established. See Subsequent Events footnote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 7, 2021, the Company&rsquo;s board of directors authorized a 4-for-1 stock split. They also increased the number of authorized
common stock shares from 2,700,000 to 10,800,000. Furthermore, on September 9, 2021, the board authorized and increase of authorized
shares of common stock from 10,800,000 to 13,400,000 in anticipation of a capital offering. All share and per share amounts for the common
stock have been retroactively restated to give effect to the split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Furthermore, on January 10, 2023, the Company&rsquo;s
board of directors authorized a 1-for-2 reverse stock split. All per share information has been adjusted for this reverse stock split.
The reverse split became effective on January 12, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the conversion to a Delaware corporation, the total number of shares of all classes of stock which the Corporation shall have
authority to issue is (1) 100,000,000 shares of Common Stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;) and (ii) 1,120,000
shares of Preferred Stock, par value $0.001 per share (&ldquo;Preferred Stock&rdquo;), 1,000,000 of which is hereby designated as &ldquo;Series
A Preferred Stock&rdquo; and 120,000 of which is hereby designated as &ldquo;Series Seed Preferred Stock&rdquo; with the rights, preferences,
powers, privileges and restrictions, qualifications and limitations set forth in this Article IV of the Delaware Certificate of Incorporation.
All share amounts have been retroactively restated to give effect to these changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is headquartered in Versailles, Indiana. The Company specializes in the development, production, and sale of medical neuromodulation
devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has developed three FDA cleared products, the IB-STIM (DEN180057, 2019), the NSS-2 Bridge (DEN170018, 2017), and the original
510(K) clearance (K140530, 2014).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            IB-STIM is a percutaneous electrical nerve field stimulator (PENFS) device that is indicated
                                            in patients 11-18 years of age with functional abdominal pain associated with irritable bowel
                                            syndrome. The IB-STIM currently is the only product marketed and sold by the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            NSS-2 Bridge is a percutaneous nerve field stimulator (PNFS) device indicated for use in
                                            the reduction of the symptoms of opioid withdrawal. The NSS-2 Bridge device was licensed
                                            to Masimo Corporation in April 2020, and the Company received a one-time licensing fee of
                                            $250,000 from Masimo. Masimo markets and sells this product as its Masimo Bridge, and the
                                            Company will not receive any further licensing payments or other revenue from this product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 22.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            original 510(K) device was the EAD, an electroacupuncture device, now called NeuroStim. The
                                            EAD is no longer being manufactured, sold or distributed but reserved only for research purposes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of significant accounting policies of <FONT STYLE="font-weight: normal; text-transform: none">Neuraxis, Inc.</FONT> is presented
to assist in understanding the Company&rsquo;s financial statements. The financial statements and notes are representations of the Company&rsquo;s
management, who is responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting
principles and have been consistently applied in the preparation of the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing
the Company&rsquo;s financial statements in conformity with accounting principles generally accepted in the United States of America
(&ldquo;GAAP&rdquo;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
of Presentation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s condensed financial statements have been prepared in accordance with accounting principles generally accepted in the
United States of America (&ldquo;U.S. GAAP&rdquo;) and following the requirements of the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;)
for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by
U.S. GAAP can be condensed or omitted. These interim financial statements have been prepared on the same basis as the Company&rsquo;s
annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments,
which are necessary for a fair statement of the Company&rsquo;s financial information. These interim results are not necessarily indicative
of the results to be expected for the year ending December 31, 2022, or any other interim period or for any other future year.
These unaudited condensed financial statements should be read in conjunction with the Company&rsquo;s audited financial statements and
the notes thereto for the year ended December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates and Critical Accounting Estimates and Assumptions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance for doubtful
accounts, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of intellectual property.
Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
and Cash Equivalents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">December
31, 2021</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trade
Accounts Receivable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable are stated at the amount management expects to collect from balances outstanding at year-end. Management considers
the following factors when determining the collectability of specific customer accounts: customer creditworthiness, past transaction
history with the customer, current economic industry trends, and changes in customer payment terms. Based on management&rsquo;s assessment
of the credit history with customers having outstanding balances and current relationships with them, it has concluded that realization
losses on balances outstanding at year-end will be immaterial. Interest is not charged on past due customer accounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Allowance
for Doubtful Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable are stated net of an allowance for doubtful accounts. We estimate allowance for doubtful accounts by evaluating specific
accounts where information indicates our customers may have an inability to meet financial obligations, such as customer payment history,
credit worthiness and receivable amounts outstanding for an extended period beyond contractual terms. We use assumptions and judgment,
based on the best available facts and circumstances, to record an allowance to reduce the receivable to the amount expected to be collected.
The allowance for doubtful accounts was <FONT STYLE="font-weight: normal; text-transform: none">$34,867 and $11,770 at September 30,
2022 and December 31, 2021, respectively. During the nine months ended September 30, 2022 and 2021, the Company recorded $42,795 and
$5,691, respectively as a bad debt expense.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Customer
Deposits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
deposits consists of billings and payments from clients in advance of revenue recognition. The Company will recognize the customer deposits
over the next year. As of <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT>, and <FONT STYLE="font-weight: normal; text-transform: none">December
31, 2021</FONT>, the Company had customer deposits of <FONT STYLE="font-weight: normal; text-transform: none">$77,099</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">$69,337</FONT>,
respectively</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inventories</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost or net realizable value. The inventory is comprised of finished medical devices on hand. Certain components
within the devices have an expiration date that are removed from current inventory and expensed at the date of expiration. For the nine
months ended <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">2021</FONT>,
<FONT STYLE="font-weight: normal; text-transform: none">$0</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">$48,488
</FONT>were expensed as expired inventory, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Deferred
Offering Costs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs consist of costs incurred in connection with the preparation of an initial public offering. These costs, together with
the underwriting discounts and commissions, will be charged to additional paid in capital upon completion of the proposed public offering
or charged to operations if the proposed public offering is not completed. As of <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022 and December 31, 2021</FONT>, the Company had deferred offering costs of <FONT STYLE="font-weight: normal; text-transform: none">$694,524
</FONT><FONT STYLE="font-weight: normal; text-transform: none">and $0, respectively</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property
and Equipment </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated using the following estimated useful lives:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 78%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Classification</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold Improvements</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and Equipment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7-10</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and Fixtures</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-10</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was <FONT STYLE="font-weight: normal; text-transform: none">$23,592 </FONT>and <FONT STYLE="font-weight: normal; text-transform: none">$26,470
</FONT>during the nine months ended <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">2021</FONT>,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for research and development are expensed as incurred. Research and development expense consists primarily of clinical research studies,
new product development, and manufacturing improvements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intangible
Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of patents and are stated at their historical cost and amortized on a straight-line basis over their expected useful lives.
Capitalized patent costs, net of accumulated amortization, includes legal costs incurred for patent applications. In accordance with
ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line
method. If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment
annually or when events or circumstances indicate that their carrying amount may not be recoverable. During the nine months ended <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">2021</FONT>, the Company recorded no impairment charges for
intangible assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was <FONT STYLE="font-weight: normal; text-transform: none">$1,455 </FONT>and <FONT STYLE="font-weight: normal; text-transform: none">$1,455
</FONT>during the nine months ended <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">2021</FONT>,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted accounting rules that prescribe when to recognize and how to measure the financial statements effect, if any, of
income tax positions taken or expected to be taken on its income tax returns. These rules require management to evaluate the likelihood
that, upon examination by relevant taxing jurisdictions, those income tax positions would be sustained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on that evaluation, if it were more than 50% probable that a material amount of income tax would be imposed at the entity level upon
examination by the relevant taxing authorities, a liability would be recognized in the accompanying balance sheet along with any interest
and penalties that would result from that assessment. Should any such penalties and interest be incurred, the Company&rsquo;s policy
would be to recognize them as operating expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the results of management&rsquo;s evaluation, adoption of the rules did not have a material effect on the Company&rsquo;s financial
statements. Further, no interest or penalties have been accrued or charged to expense as of <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">2021 </FONT>and for the periods then ended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s income tax returns are subject to examination by the taxing authorities until the expiration of the related statutes
of limitations on those tax returns. In general, the federal and state income tax returns have a three-year statute of limitations. As
of <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT>, the following tax years are subject to examination:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 49%; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Jurisdiction</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 49%; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Open
    Years for Filed Returns</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019
    &ndash; 2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indiana</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019
    &ndash; 2021</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advertising
Cost</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
costs are expensed as incurred and amounted to <FONT STYLE="font-weight: normal; text-transform: none">$14,900</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">$28,828
for the nine months ended September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">2021, </FONT>respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Derivative
Financial Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as
derivatives to be separately accounted for in accordance with paragraph 815-10-05-4 and Section 815-40-25 of the FASB Accounting Standards
Codification. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market on each balance
sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in
fair value is recorded in the condensed statement of operations as other income or expense. Upon conversion, exercise, or
cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise, or cancellation,
and then the related fair value is reclassified to equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed
at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification
are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will
be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument
is expected within 12 months of the balance sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 815-40-15 of the FASB Accounting Standards Codification (&ldquo;Section 815-40-15&rdquo;) to determine whether
an instrument (or an embedded feature) is indexed to the Company&rsquo;s own stock. Section 815-40-15 provides that an entity should
use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock,
including evaluating the instrument&rsquo;s contingent exercise and settlement provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price, an expected remaining term of each warrant as of the valuation
date, estimated volatility, drift, and a risk-free rate. The Company records the change in the fair value of the derivative as other
income or expense in the condensed statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&ldquo;ASC 820&rdquo;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 24.3pt 0pt 4.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &ndash; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 24.3pt 0pt 4.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &ndash; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 24.3pt 0pt 4.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &ndash; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&rsquo;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets. Management
believes the estimated fair value of these accounts on <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT>
approximate their carrying value as reflected in the balance sheets due to the short-term nature of these instruments or the use of market
interest rates for debt instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Level 2 assets/liabilities include certain of the Company&rsquo;s notes payable and capital lease obligations. Their
carrying value approximates their fair values based upon a comparison of the interest rate and terms of such debt given the level of
risk to the rates and terms of similar debt currently available to the Company in the marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Level 3 assets/liabilities include derivative liabilities. Inputs to determine fair value are generally unobservable
and typically reflect management&rsquo;s estimates of assumptions that market participants would use in pricing the asset or liability.
The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models.
Unobservable inputs used in the models are significant to the fair values of the assets and liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables provides a summary of the relevant assets and liabilities that are measured at fair value on recurring basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Fair
Value Measurements as of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>September
30, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level
    1)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level
    2)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level
    3)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,514,726</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,514,726</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,586,124</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,586,124</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,100,850</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,100,850</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>Fair
Value Measurements as of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>December
31, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level
    1)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level
    2)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Level
    3)</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities:</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the valuation methodology and unobservable inputs for Level 3 assets and liabilities measured at fair value on
recurring basis as of <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">December
31, 2021</FONT>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    Value<BR> As of<BR> September 30,<BR> 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    Value<BR> As of<BR> December 31,<BR> 2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation<BR>
    Methodology</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unobservable<BR>
    Inputs</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,514,726</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monte
    Carlo model</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Project
    simulated cash flows</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,586,124</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Monte
    Carlo model</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Project
    simulated cash flows</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between any of the levels during the nine months ended <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022</FONT> and year ended <FONT STYLE="font-weight: normal; text-transform: none">December 31, 2021</FONT>. In addition to assets
and liabilities that are recorded at fair value on a recurring basis, the Company&rsquo;s assets and liabilities are also subject to
nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment
charges.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basic
and Diluted Net Income (Loss) per Share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">Earnings
or loss per share (&ldquo;EPS&rdquo;) is computed by dividing net income (loss), net of preferred stock dividends, by the weighted average
number of shares of common stock outstanding during the period. Basic weighted average shares for the year ended September 30, 2022 include
40,000 vested warrants to purchase common shares. As the shares underlying these warrants can be purchased for little to no consideration
($0.01 per share exercise price), they are included in the computation of basic earnings per share. Diluted EPS is computed by dividing
net income (loss) by the weighted average of all potentially dilutive shares of common stock that were outstanding during the periods
presented. Preferred stock dividends (not declared or paid) were $1,997,307 and $1,425,209 as of September 30, 2022</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
<FONT STYLE="font-weight: normal; text-transform: none">December 31, 2021, respectively.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common
shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares
outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, which
is the case for <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">2021
</FONT>presented in these financial statements, the weighted-average number of common shares outstanding excludes common stock equivalents
because their inclusion would be anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">The
Company had the following potentially dilutive common stock equivalents at September 30, 2022</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">and
<FONT STYLE="font-weight: normal; text-transform: none">2021:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Convertible Series A Preferred Stock</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,013,270</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">1,013,270</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible Series Seed Preferred Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,954</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">230,954</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,319,394</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,319,394</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Pre-Funded Warrants for Convertible Series A</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Preferred Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">289,779</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">289,779</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible Bridge Debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">235,406</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">248,258</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">12,852</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt">Totals</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,337,061</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,866,249</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the Nine Months Ended</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September 30,</FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerator</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 60%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    loss</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,766,433</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,175,516</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    stock dividends</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(572,098</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(556,037</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5,338,531</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,731,553</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Denominator</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average
    shares of common stock outstanding - basic and diluted</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,984,399</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,968,004</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
    and diluted net loss per share</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2.69</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1.39</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">The
Company accounts for all stock-based payments and awards under the fair value-based method. The Company recognizes its stock-based compensation
expense using the straight-line method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an
actual forfeiture of a stock option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">The
Company accounts for the granting of stock options to employees and non-employees using the fair value method whereby all awards are
measured at fair value on the date of the grant. The fair value of all employee stock options is expensed over the requisite service
period with a corresponding increase to additional paid-in capital. Upon exercise of stock options, the consideration paid by the option
holder is recorded in additional paid-in capital, while the par value of the shares received is reclassified from additional paid in
capital to common stock. Stock options granted to employees are accounted for as liabilities when they contain conditions or other features
that are indexed to other than a market, performance, or service condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">Stock-based
payments to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee
stock awards is recognized over the requisite service period following the measurement of the fair value on the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue
Recognition </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">Neuraxis,
Inc.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">specializes in the development, production, and
sale of medical neuromodulation devices to healthcare providers primarily located in the United States. Patented and trademarked neuromodulation
devices is the Company&rsquo;s major product line. Products are generally transferred at a point in time (rather than over time). Essentially
all the Company&rsquo;s revenue is generated from purchase order contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">In
accordance with FASB&rsquo;s ASC 606, Revenue from Contracts with Customers, (&ldquo;ASC 606&rdquo;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">be entitled in exchange for those goods or services,
in an amount that reflects the consideration which the Company expects to be entitled in exchange for those goods or services. To determine
revenue recognition for arrangements that the Company determines are within the scope of ASC 606, it performs the following five steps:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the contract(s) with a customer&#894;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract&#894;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the transaction price&#894;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
    the transaction price to the performance obligations in the contract&#894; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.35in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    revenue when (or as) the entity satisfies a performance obligation.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all of the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 130; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates credit losses on accounts receivable by estimating expected credit losses over the contractual term of the receivable
using a discounted cash flow method. When developing this estimate of expected credit losses, the Company considers all available information
(past, current, and future) relevant to assessing the collectability of cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program extends potential self-pay
discounts for IB-Stim devices, based upon household income and size.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebates or invoice credit where the insurance payment and patient responsibility (i.e., deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table disaggregates the Company&rsquo;s revenue based on the customer&rsquo;s location by state for the periods ended <FONT STYLE="font-weight: normal; text-transform: none">September
30</FONT>:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wisconsin</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">560,345</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">513,795</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ohio</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">374,670</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">454,565</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">California</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">269,805</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">463,782</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Florida</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">179,075</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">78,830</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Oregon</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,825</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">212,710</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    other states</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">645,933</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">530,838</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,071,653</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,254,520</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 1.8pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following economic factors affect the nature, amount, timing, and uncertainty of the Company&rsquo;s revenue and cash flows as indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type
of customer:</B> Based on dollar amounts of revenue, essentially all of the goods sold by the Company are sold to healthcare customers
including hospitals and clinics. Sales to healthcare customers lack seasonality and have a mild correlation with economic cycles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Geographical
location of customers: </B>Sales to customers located within the United States represent essentially all of the Company&rsquo;s sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type
of contract:</B> Sales contracts consist of purchase order contracts that tend to be short-term (i.e., less than or equal to one year
in duration).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opening and closing balances of trade receivables, contract assets, and contract liabilities from contracts with customers are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
    Receivables</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
    Assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract
    Liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    1/1/2021</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 2%; text-transform: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-transform: none; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 16%; text-transform: none; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">311,329</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-transform: none; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    12/31/21 and 1/1/2022</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">115,301</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance
    9/30/2022</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">320,244</FONT></TD><TD STYLE="font: normal 10pt Times New Roman, Times, Serif; text-transform: none; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Company&rsquo;s
Performance Obligations with Customers:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Timing
of Satisfaction</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations as goods are delivered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goods
that are shipped to customers are typically shipped FOB shipping point with freight prepaid by the Company. As such, ownership of goods
in transit transfer to the customer when shipped and the customer bears the associated risks (e.g., loss, damage, delay). In some cases,
a customer will take delivery directly from the Company&rsquo;s inventory (i.e., consigned inventory), at which point ownership and the
associated risks pass to the customer at that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
and handling costs are recorded as general and administrative expenses in the Statement of Operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Significant
Payment Terms</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for goods sold by the Company is typically due, after an invoice is sent to the customer, within 30 days. However, other payment terms
are frequently negotiated with customers ranging from due upon receipt to due within 90 days. Some payment terms may call for payment
only after the healthcare provider receives their insurance reimbursement. Invoices for goods are typically sent to customers within
three calendar days of shipment. The Company does not offer discounts if the customer pays some or all of an invoiced amount prior to
the due date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the Company&rsquo;s contracts have a significant financing component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Nature</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer. The manufacture
is located within the state of Indiana and maintains compliance with FDA manufacturing guidelines. In no case does the Company act as
an agent (i.e., the Company does not provide a service of arranging for another party to transfer goods to the customer).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Returns,
Refunds, etc. </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund
    the price paid for any defective or nonconforming products</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply
    and deliver to the customer replacement conforming products</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimburse
    the customer for the cost of repairing any defective or nonconforming products</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also maintains
appropriate accounts to reflect the effects of expected returns on the Company&rsquo;s financial position and periodically adjusts those
accounts to reflect its actual return experience. Historically, returns have been immaterial, and the Company currently does not provide
a provision for this liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warranties</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
most cases, goods that customers purchase from the Company are covered by manufacturers&rsquo; warranties. The Company does not sell
warranties separately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturer guarantees the product for the period up to the expiration date printed on the device&rsquo;s label or twelve months from
the date of purchase, whichever comes first. The guarantee applies to flaws of material and workmanship. The Company&rsquo;s warranties
provide customers with assurance that purchased devices comply with published specifications, inspection standards, and workmanship.
At the time revenue is recognized, the Company estimates the cost of expected future warranty claims but does not exclude any amounts
from revenue. The Company maintains appropriate accounts to reflect the effects of expected future warranty claims on the Company&rsquo;s
financial position and periodically adjusts those accounts to reflect its actual warranty claim experience. Historically, warranty claims
have been immaterial, and the Company currently does not provide a provision for this liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations for goods at a point in time. In most cases, goods are shipped by common carrier
to customers under &ldquo;FOB Shipping Point&rdquo; terms. As such, customers typically obtain control of the goods upon shipment. The
Company&rsquo;s management exercises judgment in determining when performance obligations for goods have been satisfied. In making such
judgments, management typically relies on shipping information obtained from common carriers to evaluate when the customer has obtained
control of the goods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&rsquo;s management uses in establishing the prices
of goods to be sold.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company adopted Accounting Standards Updated (&ldquo;ASU&rdquo;) No. 2016-02, <I>Leases (Topic 842)</I> (&ldquo;ASU
2016-02&rdquo; or &ldquo;ASC 842&rdquo;), using the full retrospective method, the cumulative effect of the accounting change is recognized
as an adjustment to the opening balance of retained earnings in the first comparative period presented. At the inception of an arrangement,
the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement.
Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease
liabilities, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&rsquo;s assessment
unless there is reasonable certainty that the Company will renew.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected the following practical expedients, which must be elected as a package and applied consistently to all of its leases
at the transition date (including those for which the entity is a lessee or a lessor): i) the Company did not reassess whether any expired
or existing contracts are or contain leases; ii) the Company did not reassess the lease classification for any expired or existing leases
(that is, all existing leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases,
and all existing leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases); and iii)
the Company did not reassess initial direct costs for any existing leases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
leases that existed prior to the date of initial application of ASC 842 (which were previously classified as operating leases), a lessee
may elect to use either the total lease term measured at lease inception under ASC 840 or the remaining lease term as of the date of
initial application of ASC 842 in determining the period for which to measure its incremental borrowing rate. In transition to ASC 842,
the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components.
The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based
on the respective relative fair values to the lease components and non-lease components.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impairment
of Long-Lived Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
and Uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2021, the World Health Organization declared Coronavirus (COVID-19) a pandemic. The continued spread of COVID-19, or any similar outbreaks
in the future, may adversely impact the local, regional, national, and global economies. The extent to which COVID-19 impacts the Company&rsquo;s
results is dependent on the breadth and duration of the pandemic and could be affected by other factors the Company is not currently
able to predict. These impacts may include, but are not limited to, additional costs for responding to COVID-19, potential shortages
of labor, potential shortages of material and supplies, and loss of, or reduction to, revenue. Management believes the Company is taking
appropriate actions to respond to the pandemic, however, the full impact is unknown and cannot be reasonably estimated at this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Concentrations
of Credit Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across the
country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables
consist of unsecured amounts due from customers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.15pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the Company&rsquo;s customers that accounted for greater than 10% of its revenues in one of the periods ended
<FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and 2021, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of Sales</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Percentage
    of Sales</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital
    A</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">444,425</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">444,565</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital
    B</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">362,500</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">426,285</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital
    C</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">248,725</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">259,860</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospital
    D</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">215,920</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,055,650</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,346,630</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 1.25in; text-align: justify; text-indent: -67.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company&rsquo;s bank balances may exceed the FDIC limit of $250,000; however, management does not feel that this has
a material impact on the financial condition. At <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and
<FONT STYLE="font-weight: normal; text-transform: none">December 31, 2021</FONT>, the Company&rsquo;s uninsured cash balances totaled
$0 and $20,850, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT>, we had an stockholders&rsquo; deficit
of approximately $5.7 million. At <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT>, we had short-term
and long-term borrowings outstanding of approximately $279 thousand and $52 thousand, respectively. As of <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022</FONT>, we had cash of approximately $8 thousand and a working capital deficit of approximately $5.8 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our technologies,
the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other proprietary rights,
our ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including
regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue and achieve profitability requires
us to successfully market and secure purchase orders for our products from customers currently identified in our sales pipeline and to
new customers as well. The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial
insurance carriers nationally, so this is a top priority of the Company. These activities, including our planned research and development
efforts, will require significant uses of working capital through the end of first quarter 2023 and beyond. Based on our current operating
plans, we believe that our existing cash at the time of this filing will only be sufficient to meet our anticipated operating needs through
March 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern Evaluation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&rsquo;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers, will allow the Company to achieve profitability in the near term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no assurance
that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is dependent
upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise additional funds by
way of a public or private offering. Because, under current accounting standards, neither future cash generated from operating activities,
nor management&rsquo;s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered
probable, substantial doubt is deemed to exist about the Company&rsquo;s ability to continue as a going concern. As we continue to incur
losses, our transition to profitability is dependent upon achieving a level of revenues adequate to support its cost structure. We may
never achieve profitability, and unless and until doing so, we intend to fund future operations through additional dilutive or nondilutive
financings. There can be no assurances, however, that additional funding will be available on terms acceptable to us, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Adopted Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &ndash; Contracts
in Entity&rsquo;s Own Equity (Subtopic 815-40), which simplifies accounting for convertible instruments by removing major separation
models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for
the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. The guidance is effective
for interim and annual periods beginning after December 15, 2021. Early adoption is permitted, but no earlier than fiscal years beginning
after December 15, 2020, including interim periods within those fiscal years. FASB has specified that an entity should adopt the guidance
as of the beginning of its annual fiscal year. The guidance is to be applied using either a full retrospective or modified retrospective
method. In applying the full retrospective method, the cumulative effect of the accounting change should be recognized as an adjustment
to the opening balance of retained earnings in the first comparative period presented. In applying the modified retrospective method,
the cumulative effect of the accounting change should be recognized as an adjustment to the opening balance of retained earnings at the
date of adoption<B>. </B>The Company early adopted ASU 2020-06 effective January 1, 2021, under the modified retrospective approach.
The adoption of this guidance did not have a material impact on the Company&rsquo;s financial statements</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Issued Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments &ndash; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which requires measurement and recognition of expected credit losses for financial assets held and requires enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &ndash; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amends
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&ldquo;SRC&rdquo;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard will not be effective until the beginning of 2023. The Company is evaluating the effect that ASU
2016-13 will have on its financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two demand notes receivable from shareholders related to the sale of common stock on January 1, 2016. Both notes initial
balances were $506,400, with interest calculated monthly based on applicable federal rates. No payments have been received on the notes.
Since repayment is not assured, the Company provided an allowance for the entire balance of principal and interest as of December 31,
2019. The current allowance is <FONT STYLE="font-weight: normal; text-transform: none">$1,096,775</FONT> as of <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022</FONT>. The current loan balances are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 4.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">506,400</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,054</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,506</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">506,400</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">41,920</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,506</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,012,800</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">83,974</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13,012</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowance
    for Collection Risk</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,012,800</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(83,974</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(13,012</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Balance</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivable</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">506,400</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,548</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">827</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">506,400</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">35,414</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">827</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,012,800</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">70,962</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,654</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allowance
    for Collection Risk</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,012,800</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(70,962</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,654</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
    Balance</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has loans payable to shareholders related to funding needs for operations. The current loan details for all related party loans
are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    &amp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service
    Fee</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    Date</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June,
    2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,409</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June,
    2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,056</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Convertibles</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,648</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">96,113</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    &amp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Service
    Fee</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Due
    Date</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rate</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paid</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Demand</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.15</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June,
    2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,153</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June,
    2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17,781</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholder
    3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June,
    2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,582</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    Convertibles</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66,648</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">58,051</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89,582</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,592</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Chief Financial Officer, John Seale, CPA.CITP, is contracted for services through RBSK Partners PC (RBSK). Mr. Seale
is RBSK&rsquo;s managing partner and majority shareholder. RBSK is engaged by the Company to provide accounting and tax services on a
continuous basis. Fees paid to RBSK for services were $78,241 and $65,833 for the periods ended <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">2021</FONT>, respectively. The Company owed RBSK for open
invoices of $64,013 and $4,978 as of <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">2021</FONT>,
respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Accrued Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wages</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">480,779</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">451,974</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee
    benefits</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,792</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,734</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commissions</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">181,062</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,785</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    taxes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">882</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">563</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interest
    expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">130,306</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">89,582</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    accrued expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">817,821</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">561,638</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Notes Payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company borrowed $250,000 on December 16, 2021, from Channel Partners Capital. The note calls for 65 weekly payments of $4,923.08
with the final payment scheduled for March 16, 2023. The note&rsquo;s interest rate computes to a nominal rate of 40.856%. The
principal outstanding at <FONT STYLE="font-weight: normal; text-transform: none">December 31, 2021 was</FONT> $244,048. The Company
borrowed $122,000 on September 16, 2022 to bring the principal balance back to $250,000. The terms of the note are the same as the
previous note with the final payment scheduled for December 16, 2023. The principal outstanding at <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022 was</FONT> $243,783. The Company believes that the advancement of additional funds is a minor modification to the terms
of the existing loan since the difference in present value of the cash flows under the terms of the new loan is less than 10% of the
present value of the remaining cash flows under the terms of the original loan. As a result, the modification was accounted for as a
modification of debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lender was granted and assigned a continuing security interest in all the Company&rsquo;s personal property assets including, but not
limited to, business equipment, inventory, accounts, accounts receivable, intellectual property, chattel paper, instruments, deposit
accounts, commercial tort claims, contract rights, licenses, claims, and general intangibles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum principal payments are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 68%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 28%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,949</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">202,834</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">243,783</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Convertible
Notes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September 30, 2022,
the Company conducted multiple closings of a private placement offering to accredited investors for aggregate gross proceeds of $2,222,223
or net proceeds of $1,870,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2022 Convertible Note Offering consisted of (a) a Convertible Promissory Note that accrues interest at the greater of Prime rate plus
8.5% or 12%. The notes convert into common shares at the lower of $9.44 or 30% discount to the price per share of any subsequent
offering. The notes mature on the one-year anniversary date from issuance. (b) a five-year warrant to purchase common stock equal to
one hundred percent (100%) of the shares into which the 2022 Convertible Notes can be converted into at issuance. The warrants have an
exercise price at the lower of $11.80 per share or a 12.5% discount to the price per share of any subsequent offering. (c) shares
of the Company&rsquo;s common stock equal to 10% of the principal amount of these notes, at a value per share equal to the conversion
price. The 23,543 shares of common stock issued to investors had a relative fair value of $3,365</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an additional incentive for entering into the Convertible note offering, the Company offered an original issue discount equal to 10%
of the principal amount of the notes. The Company also paid $130,000 to law firms related to this offering. The fees were recorded as
a debt discount and amortized over the life of the note at the effective interest rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has applied ASC 815, due to the potential for settlement in a variable quantity of shares. Since these convertible notes and
warrants have the option to convert or be exercised at a variable amount, they are subject to derivative liability treatment. The conversion
feature has been measured at fair value using a Monte Carlo model at the date of issuance and is adjusted to fair value at each reporting
period. The fair value of the embedded derivative and the warrant liability at date of issuance was $1,518,092 and $1,822,435,
respectively. See note 11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
value of the incentives given to investors totaled $3,696,115. Since the value of the incentives given to investors was in excess
of the principal value of the notes, the Company recognized $2,222,223 as debt discount and expensed the reaming $1,473,892 as
financing fees. The debt discount is being accreted over the life of these notes to accretion of debt discount and issuance cost,
based on the effective interest rate method.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the nine months ended September 30, 2022, the Company accrued interest of $80,668 relating to these notes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s leases are comprised of operating leases for office space. At the inception of the lease, the Company determines whether
the lease contract conveys the right to control the use of identified property for a period of time in exchange for consideration. Leases
are classified as operating or finance leases at the commencement date of the lease. Operating leases are recorded as operating lease
right-of-use assets, other current liabilities, and operating lease liabilities in the Balance Sheets. The Company did not have any finance
leases at <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022 and December 31, 2021. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">The
Company had three leases primarily consisting of office space in Versailles and Carmel Indiana. Two of the leases in Versailles started
January 1, 2017. Both have an initial term of five years with an option for an additional five-year term. The monthly lease payments
for these leases are $550 and $1,600 with a 3% per annum increase starting with the optional five-year term. The lease in Carmel started
March 1, 2016. The initial term is five years and three months with an option for an additional three-year term. The monthly lease payment
started at $1,472 with an annual increase of approximately 2.7%. On December 16, 2020, the Company entered into an amendment of the Carmel
lease that extended the initial term by two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">Operating
lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the
lease term. As the implicit interest rate is generally not readily determinable, the Company uses an incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate
reflects the estimated rate of interest that the Company would pay to borrow on a collateralized basis over a similar economic environment.
Lease expense for the operating lease is recognized on a straight-line basis over the lease term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">Leases
may include renewal options, and the renewal option is included in the lease term if the Company concludes that it is reasonably certain
that the option will be exercised. Certain leases may contain rent escalation clauses, either fixed or adjusted periodically for inflation
of market rates, that are factored into the calculation of lease payments to the extent they are fixed and determinable at lease inception.
The Company also has variable lease payments that do not depend on a rate or index, primarily for items such as common area maintenance
and real estate taxes, which are recorded as expenses when incurred. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">For
the periods ended September 30, 2022 and 2021, the Company recognized $36,266 and $4,725 of operating lease expense, including short-term
lease expense and variable lease costs, which are immaterial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">The
following table presents information related to the Company&rsquo;s operating leases:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">As
of September 30, 2022, the maturities of the Company&rsquo;s operating lease liabilities were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    30, 2022</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2021</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 56%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right-of-use assets</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">108,030</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">127,975</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    current liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31,942</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">27,582</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liabilities</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">84,548</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">109,594</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,490</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">137,176</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average
    remaining lease term (in years)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.25</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average
    discount rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 78%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">46,832</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34,731</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2025</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,800</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2026</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,800</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2027</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,800</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    lease payments</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">158,963</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    imputed interest</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">42,473</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    present value of lease payments</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">116,490</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Common Stock and Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 7, 2021, the Company&rsquo;s board of directors authorized a 4-for-1 stock split. They also increased the number of authorized
common stock shares from 2,700,000 to 10,800,000. Furthermore, on September 9, 2021, the board authorized and increase of authorized
shares of common stock from 10,800,000 to 13,400,000 in anticipation of a capital offering. As part of the conversion to a Delaware Corporation
in June of 2022, the total number of common stock shares authorized was increased to 100,000,000. All share and per share amounts for
the common stock have been retroactively restated to give effect to the split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in">Furthermore, on January
10, 2023, the Company&rsquo;s board of directors authorized a 1-for-2 reverse stock split. All per share information has been adjusted for this reverse
stock split. The reverse split became effective on January 12, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with a bridge loan, the Company issued a warrant to a shareholder, Brian Hannasch, on September 18, 2018. The warrant allows
the holder to purchase common stock from the Company at a share price of $8.76 per share. The number of shares was based on a
formula tied to the amount of loans made by the holder. The number of shares based on this formula is 12,852. The warrant contains
certain rights in the event of liquidation, merger, or consolidation of the Company. If the fair market value of one share is greater
than the warrant price, the holder may elect to receive a number of shares equal to the value of the warrant. If the exercise in in connection
with the sale of the Company, the holder may, at its option, condition its exercise of the warrant upon the consummation of such transaction.
The warrant expires on September 18, 2028, and can be exercisable either in whole or from time to time in part prior to the expiration
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued a second warrant to Brian Hannasch on September 6, 2019, under similar terms. This is a penny warrant that allows the
holder to purchase 40,000 shares of common stock and is subject to adjustment for certain equity events. The warrant contains
certain rights in the event of liquidation, merger, or consolidation of the Company. The warrant expires on September 6, 2029.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued a third warrant to Masimo Corporation on April 9, 2020. This warrant was pre-funded in the amount of $2,734,340. The warrant
allows the holder to purchase 289,780 shares of Series A Preferred Stock at $9.44 per share and is subject to adjustment
for certain equity events. The warrant contains certain rights in the event of liquidation, merger, or consolidation of the Company.
There will be no additional purchase price for the Warrants. In the event that all outstanding shares of Series A Preferred Stock are
converted, automatically or by action of the holders thereof, into Common Stock, including, without limitation, in connection with the
Company&rsquo;s initial, underwritten public offering and sale of its Common Stock pursuant to an effective registration statement under
the Act (the &ldquo;IPO&rdquo;), then from and after the date on which all outstanding shares of Series A Preferred Stock have been so
converted, this Warrant shall be exercisable for such number of shares of Common Stock into which the Warrant Shares would have been
converted had the Warrant Shares been outstanding on the date of such conversion, and the Exercise Price shall equal the Exercise Price
in effect as of immediately prior to such conversion divided by the number of shares of Common Stock into which one share of Series A
Preferred Stock would have been converted, all subject to further adjustment thereafter from time to time in accordance with the provisions
of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in">The Company issued 235,406
warrants in connection with convertible debt. See note 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for common stock during the periods ended <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022 </FONT>and <FONT STYLE="font-weight: normal; text-transform: none">December 31, 2021:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-Avg.</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    for</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,852</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled/Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">52,852</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.14</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">235,406</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.80</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled/Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of September 30, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">288,258</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.03</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Weighted average remaining contractual life</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">5.10</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for preferred stock during the periods ended <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">December 31, 2021:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-Avg.</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants
    for</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Stock</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">144,890</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled/Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">144,890</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled/Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of September 30, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">144,890</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif">Weighted average remaining contractual life</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">No
                                            Expiration</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&rsquo;s warrants outstanding and exercisable as of <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrants</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expiration</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Hannasch W-01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,852</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">35.0200</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    18, 2028</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Hannasch W-02</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">40,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0200</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September
    6, 2029</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Masimo
    Corporation PSA-01</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">144,890</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0001</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible
    Notes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">235,406</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4400</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Various</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">433,148</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is a party to two investment banking and advisory agreements with a consulting firm engaged in connection with listing our common
stock for trading on Nasdaq. Pursuant to the first advisory agreement, dated March 3, 2022, the Company agreed to pay the consulting
firm a monthly consulting fee of $5,000 and a final payment of $50,000 upon a successful Nasdaq listing, and, also upon such listing,
to issue the consulting firm shares of our common stock representing 1.5% of our outstanding shares after giving effect to the offering
and to issue the consulting firm  five-year warrants to purchase shares of our common stock representing 2.0% of our outstanding shares
after giving effect to this offering on a fully-diluted basis with an exercise price per share representing the public offering price
per share. Pursuant to the second advisory agreement with consulting firm, dated June 20, 2022, and amended December 20, 2022, the Company
agreed to pay fees in the aggregate of up to $136,166 for advice in connection with communication and other related matters leading up
to, and in connection with, this offering and to issue the consulting firm 12,500 shares of common stock upon a successful Nasdaq
listing. The Company agreed to piggyback registration rights with respect to all shares issued to the consulting firm under both advisory
agreements, including shares issuable upon exercise of the warrants. The Company evaluated the agreements and determined that the shares
will not be recorded and valued until the performance condition is satisfied.</FONT></P>

<P STYLE="margin: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has authorized 1,120,000 shares of preferred stock of which 1,000,000 has been designated Series A Preferred and 120,000 has
been designated Series Seed Preferred, of which 506,637 shares of Series A Preferred and 115,477 shares of Series Seed Preferred are
issued and outstanding as of <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">December
31, 2021</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate purchase price of the Series A Preferred Stock was $9,321,165, of which $7,692,664 was comprised of cash and the remaining
$1,628,501 was comprised of converted debt and common stock. The aggregate purchase price of the Series Seed Preferred shares was $0,
as all the Series Seed shares were converted from common stock as an incentive to reinvest in Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of Preferred Stock terms<FONT STYLE="font-weight: normal; text-transform: none">:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal; text-transform: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Voting
Rights</U> - The Series A Preferred and Series Seed Preferred shall vote together with the Common Stock on an as-converted basis, and
not as separate classes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conversion
</U>- The Series A Preferred and Series Seed initially convert 1:1 to Common Stock at any time at option of holder, subject to adjustments
for stock dividends, splits, combinations, and similar events and as described below under &ldquo;Anti-dilution Provisions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Dividends
</U>- The Series A Preferred will carry an annual 8% cumulative dividend, payable upon any liquidation, dissolution or winding up of
the Company (the &ldquo;Accruing Dividend&rdquo;). For any other dividends or distributions, participation with Common Stock on an as-converted
basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Liquidation
</U>- In the event of any liquidation, dissolution or winding up of the Company, the proceeds shall be paid in the following priority:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
to the Series A Preferred in proportion to each holder&rsquo;s respective pro rata Series A Original Purchase Price, plus any pro rata
share of the Accruing Dividend until the entire Series A Original Purchase Price and Accruing Dividend are paid;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
to the Series Seed Preferred in proportion to each holder&rsquo;s respective pro rata Series Seed Original Purchase Price until the entire
amount of the Series Seed Original Purchase Price is paid;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter,
the Series A Preferred and Series Seed Preferred participate with the Common Stock pro rata on an as-converted basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares
of the surviving or acquiring corporation) and a sale, lease, transfer, exclusive license or other disposition of all or substantially
all of the assets of the Company will be treated as a liquidation event (a &ldquo;Deemed Liquidation Event&rdquo;), thereby triggering
payment of the liquidation preferences described.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Anti-dilution
Provisions</U> - The Series A Preferred have full-ratchet anti-dilution protection so that the conversion price will be reduced to 80%
of the price at which any future shares are issued, if less than the Series A Original Purchase Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for shareholders to make an additional investment in the Company, upon the purchase of the Series A Preferred stock by
the shareholder, the Company converted the existing common shares held by shareholders to Series Seed Preferred Stock at a $100 million
valuation and at a 120% share premium. As of <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022 and December
31, 2021</FONT>, there were 195,404 common shares converted into 115,477 shares of Series Seed Preferred shares that have no par
value and are outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Stock Options and Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of stock option activity for the periods ended <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022 and December 31, 2021:</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
                                            of</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options</FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
                                            Avg. Remaining Contractual Life</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
                                            years)</FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted
    Avg. Exercise Price</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin: 0">Aggregate</P><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intrinsic
    Value</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2020</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,319,394</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.78</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.94</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled/Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of December 31, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,319,394</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.78</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.94</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forfeited</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled/Expired</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding
    as of September 30, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,319,394</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.94</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vested
    and Exercisable as of September 30, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,309,704</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.05</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.94</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense is classified in the Company&rsquo;s statements of operations as general and administrative expense. The amounts
were <FONT STYLE="font-weight: normal; text-transform: none">$27,319 </FONT>and <FONT STYLE="font-weight: normal; text-transform: none">$36,381
</FONT>for periods ended <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">2021</FONT>,
respectively. As of <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT>, there was $0 of total unrecognized
compensation expense related to unvested options granted under the Company&rsquo;s share-based compensation plans.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Warrant Liabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified derivative instruments arising from an adjustable exercise price for warrants that are issued and outstanding
as of <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">December
31, 2021</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price, an expected remaining term of each warrant as of the valuation
date, estimated volatility, drift, and a risk-free rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note adjusted to be on a continuous return basis to align
with the Black-Scholes option-pricing model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring
dividends in the near future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility:
The Company calculates the expected volatility based on comparable company&rsquo;s historical stock prices with a look back period commensurate
with the period to maturity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
term: The Company&rsquo;s remaining term is based on the remaining contractual maturity of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the warrant liabilities during the year ended <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">December 31, 2021</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liabilities as of January 1, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,760</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addition</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in fair value of warrant liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,342</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liabilities as of January 1, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32,102</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addition</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,822,435</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in fair value of warrant liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">660,189</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liabilities as of September 30, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,514,726</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Derivative Liabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified derivative instruments arising from the conversion shares discussed in the Convertible Notes section of note 6
as of <FONT STYLE="font-weight: normal; text-transform: none">September 30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">December
31, 2021</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for commitment shares that have an option to convert at a variable number of shares to
compute the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs
utilized in the application of the Monte Carlo model included a starting stock price, an expected remaining term of each warrant as of
the valuation date, estimated volatility, drift, and a risk-free rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note adjusted to be on a continuous return basis to align
with the Black-Scholes option-pricing model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring
dividends in the near future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility:
The Company calculates the expected volatility based on comparable company&rsquo;s historical stock prices with a look back period commensurate
with the period to maturity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
term: The Company&rsquo;s remaining term is based on the remaining contractual maturity of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the warrant liabilities during the year ended <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">December 31, 2021</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    1</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    2</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
    3</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    liabilities as of January 1, 2021</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addition</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in fair value of Derivative liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    liabilities as of January 1, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addition</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,518,092</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes
    in fair value of Derivative liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">68,032</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Derivative
    liabilities as of September 30, 2022</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&mdash;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,586,124</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.
Retirement Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sponsors a 401(k)-retirement plan for its employees. Employees are eligible to participate in the elective deferral portion of
the plan after twelve months and 1,000 hours of service. The Company matches the employee&rsquo;s contribution up to 3%. The Company
can also make an optional profit-sharing contribution to the employee accounts on an annual basis. There was an expense of <FONT STYLE="font-weight: normal; text-transform: none">$13,058
</FONT>and <FONT STYLE="font-weight: normal; text-transform: none">$19,348</FONT> for periods ended <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022</FONT> and <FONT STYLE="font-weight: normal; text-transform: none">2021</FONT>, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14</B>.
<B>Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, the Company entered into a license agreement with Masimo Corporation (Masimo) granting certain exclusive rights and licenses,
access to Company&rsquo;s research and development capabilities, and to enable the development, manufacture, and commercialization of
products in a specific &ldquo;field&rdquo;, primarily related to pain associated with substance abuse withdrawal symptoms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&ldquo;field&rdquo; excludes the following pediatric and adult conditions (including the associated symptoms and any pain caused thereby):
chronic nausea, gastroparesis, functional gastrointestinal disorders, chemotherapy induced nausea/vomiting, concussions and post-concussion
syndrome, headaches (migraine or benign, non-specified), symptoms resulting from traumatic brain injury, post-traumatic stress disorder,
fatty liver disease, cyclic vomiting syndrome, movement disorder including Parkinson&rsquo;s disease, chronic sleep disorders, inflammatory
bowel disease, pancreatitis, pulmonary inflammatory disorders, dysautonomia and postural orthostatic tachycardia syndrome, tic disorders,
tinnitus, TMJ disorders, autoimmune disorders, seizure disorders, diabetes, and modulation of exercise physiology and recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
also entered into a collaboration agreement with Masimo to induce Masimo to enter into the purchase of Series A Preferred Stock and Pre-funded
Warrants for Series A Preferred Stock and as part of that agreement received a one-time, upfront and non-refundable fee of $250,000 for
the license agreement. More information is contained in footnote 8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing
Services Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, the Company entered into a Manufacturing Services Agreement (MSA) for the manufacture and supply of the Company&rsquo;s
IB-STIM device based upon the Company&rsquo;s product specifications as set forth in the MSA. This agreement terminated any prior manufacturing
agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides the necessary equipment to the manufacturer and retains ownership. The manufacturer bears the risk of loss of and damage
to the equipment and consigned materials. Performance under the MSA is initiated by orders issued by the Company and accepted by the
manufacturer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the MSA is 24 months and shall automatically renew for renewal terms of twelve months unless either party provides a written
termination notice to the other party within 180 days prior to the end of the then-current term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Litigation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time in the normal course of our business operations, we may become subject to litigation that may result in liability material
to our financial condition as a whole or may negatively affect our operating results if changes to our business operations are required.
The cost to defend such litigation may be significant and may require a significant diversion of our resources, and there is no guarantee
that we will be able to successfully defend against any such litigation regardless of particular merits. There also may be adverse publicity
associated with litigation that could negatively affect customer perception of our business, regardless of whether the allegations are
valid or whether we are ultimately found liable. Insurance may not be available on favorable terms, at all, or in sufficient amounts
to cover any liabilities with respect to these or other matters. A judgment or other liability in excess of our insurance coverage for
any claims could adversely affect our business, financial condition and the results of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2019, Plaintiff Ritu Bhambhani, M.D., initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United
States District Court for the District of Maryland. Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the
Third Amended Complaint (&ldquo;Complaint&rdquo;) containing the most recent set of allegations. The Complaint asserted claims under
the RICO Act, as well as of fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and sought
compensatory damages in excess of $5 million, pre-judgment interest, punitive damages, attorney&rsquo;s fees, court costs and designation
of the case as a class action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 11, 2022, the Company filed a motion for summary judgment. On June 14, 2022, the Court granted
the Company&rsquo; motion for summary judgment and dismissed the Complaint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, Plaintiffs Ritu Bhambhani and Sudhir Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. On January
4, 2023, the Court issued an order that stated it was deferring a ruling on the motion to dismiss the appeal and that it would address
those arguments at the same time that it addressed the substantive merits of the case. &nbsp;The parties&rsquo; appellate briefing is
scheduled to be concluded in early April 2023. While it is too early to predict the ultimate outcome of this matter on appeal, we
believe we have meritorious defenses and intend to defend this matter vigorously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, Plaintiffs Ritu Bhambhani, LLC; Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare
ASC, LLC initiated a lawsuit against NeurAxis, Inc. and others in the United States District Court for the District of Maryland. The
Complaint asserted claims under the RICO Act, as well as fraudulent misrepresentation, intentional misrepresentation by concealment,
and civil conspiracy and seeks compensatory damages in excess of $75,000, pre-judgment interest, punitive damages, attorney&rsquo;s fees,
and court costs. While it is too early to predict the ultimate outcome of this matter, we believe we have meritorious defenses and intend
to defend this matter vigorously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated subsequent events through the date of issuance. The following changes occurred subsequent to September 30, 2022:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Addition
Borrowing</U> &ndash; The Company borrowed additional funds subsequent to <FONT STYLE="font-weight: normal; text-transform: none">September
30, 2022</FONT>, and up through the date of this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
October 3, 2022 to November 30, 2022, we issued additional Senior Secured Convertible Promissory Notes (&ldquo;Notes&rdquo;) with an
aggregate principal amount of $1,111,111, which amount included original issue discount (&ldquo;OID&rdquo;) of $111,111, resulting in
advance proceeds to us of $1 million. The notes have the same terms as the &ldquo;Convertible Notes&rdquo; detailed previously. The notes
also included a five-year warrant to purchase common stock equal to one hundred percent (100%) of the shares into which the 2022 Convertible
Notes can be converted into at issuance. The warrants have an exercise price at the lower of $11.80 per share or a 12.5% discount
to the price per share of any subsequent offering. The notes also included shares of the Company&rsquo;s common stock equal to 10% of
the principal amount of these notes, at a value per share equal to the conversion price. The notes resulted in the issuance of 11,770
shares of common stock. The total balance of the notes now has an aggregate
principal amount of $3,333,333, which amount included original issue discount (&ldquo;OID&rdquo;) of $333,333, resulting in advance proceeds
to us of $2.87 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
December 2022 through January 2023, the Company issued unsecured convertible promissory notes to three existing investors with an aggregate
principal amount of $222,222, which amount included an OID of $22,222, resulting in advance proceeds to us of $200,000. The notes carry
an OID of 10% of the principal amount and have an interest rate of 12% per annum. The notes will mature at the earlier of (i) twelve
(12) months from the issue date or (ii) the date upon which the Company completes a registered public offering of shares of the Company,
which encompasses the closing of this offering. The notes are convertible into shares of common stock at the higher of (i) $9.44
per share, or (ii) the price per share of common stock issued pursuant to the next registered public offering of shares of the Company
made prior to the conversion of any portion of the note. Interest accrues on the aggregate principal amount (which includes OID) and
is payable on the maturity date, at the Company&rsquo;s election, in cash or in-kind. The holders of the notes are entitled to piggyback
registration rights on any registration statement filed by the Company, other than the registration statement of which this prospectus
forms a part and any registration filed on Form S-4 or Form S-8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment
Agreements &ndash; The Company, as authorized by the board of directors, entered into employment agreements with nine key employees to
provide incentives to improve shareholder value and to contribute to the growth and financial success of the Company. The agreements
have an employment start date of October 1, 2022, with initial terms from 2 to 5 years and optional one-year renewals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total base salaries for the nine key employees in the agreements is $1.92 million per year with various provisions for annual increases.
In addition to base salaries, eight of the employees have a provision for a special one-time incentive payment to be paid in a lump sum
after the start date. The total amount of these special incentive payments is $1.19 million. The special incentive payment amount includes
any accrued back pay wages for the employee. That accrued amount was $431,098 that is reflected in the financial statements at September
30, 2022. The payments are being delayed until after the public offering. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are seven key employees that have stock options of the Company totaling 1,238,712 shares. These key employees have a provision
in their agreements whereas the Company will pay a special bonus equal to the aggregate of the strike price or exercise price of all
their stock options plus a tax gross-up payment. The special bonus shall be paid in twenty percent (20%) installments starting January
2, 2024, and the same date each of the next four years. As a condition of the payment, the key employee must exercise at least 20% of
their stated number of stock options. There are additional provisions to cover termination and change of control events.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>2022
Stock Compensation Plan</U> &ndash; The Company adopted a new compensation plan effective November 1, 2022. The 2022 Plan will be applicable
only to awards granted on or after the date the 2022 Plan becomes effective according to its terms and will replace the 2017 Plan for
awards granted on or after the effective date. No new grants will be made under the 2017 Plan after the effective date. The terms and
conditions of awards granted under the 2017 Plan prior to the effective date was not be affected by the adoption of the 2022 Plan, and
the 2017 Plan will remain effective with respect to such awards.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">300,000
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock, par value $0.001 per share,
of common stock will be set aside and reserved for issuance pursuant to the 2022 Plan, subject to adjustments as may be required in accordance
with the terms of the Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Furthermore, on January 10, 2023, the Company&rsquo;s board of directors authorized a 1-for-2 reverse stock split. All per share information
has been adjusted for this reverse stock split. The reverse split became effective on January 12, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="eds_002"></A>AUDITOR&rsquo;S
REPORT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders
of Neuraxis, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Neuraxis, Inc. (the Company) as of December 31, 2021 and 2020, and the related statements
of operations, stockholders&rsquo; equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred
to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position
of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity
with accounting principles generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Restatement
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 17 to the financial statements, certain disclosures in the accompanying financial statements have been restated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Substantial
Doubt about the Company&rsquo;s Ability to Continue as a Going Concern</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to
the financial statements, the Company has experienced operating losses and negative cash flows from operations since inception that raise
substantial doubt about its ability to continue as a going concern. Management&rsquo;s plans in regard to these matters are also described
in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Rosenberg Rich Baker Berman, P.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Somerset,
New Jersey</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">September 27, 2022, except
for the effects of the restatement discussed in Note 17 to the financial statements, as to which the date is November 9, 2022, and
the effects of the reverse stock split discussed in Note 1, 8, and 16, as to which the date is January 25, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&rsquo;s auditor since 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>


<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="eds_003"></A>Neuraxis,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance
Sheet</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">320,858</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">1,895,475</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Accounts receivable, net</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">115,301</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">311,329</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Inventories</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">39,180</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">106,846</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaids and other current assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">15,670</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">148,289</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total current assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">491,009</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,461,939</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property and Equipment, at cost:</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">404,455</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">403,065</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less - accumulated depreciation</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(286,913</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(252,146</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Property and equipment, net</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">117,542</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">150,919</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other Assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Operating lease right of use asset, net</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">127,975</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">150,786</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Intangible assets, net</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">23,956</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25,897</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">760,482</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,789,541</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to financial statements are an integral part of these statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neuraxis,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Balance
Sheet</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left">Accounts payable</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">483,790</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">164,558</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Accrued expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">561,638</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">667,004</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Current portion of long-term notes payable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">192,356</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Notes payable - related party</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">58,051</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">151,005</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Customer deposits</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">69,337</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Warrant liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">32,102</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,760</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Current portion of operating lease payable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">27,582</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,311</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; padding-bottom: 1.5pt; text-align: left">Total current liabilities</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,424,856</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,008,638</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Non-current Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Operating lease payable, net of current portion</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">109,594</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">137,176</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Note payable, net of current portion</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">51,692</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; padding-bottom: 1.5pt; text-align: left">Total non-current liabilities</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">161,286</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">137,176</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; padding-bottom: 1.5pt; text-align: left">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,586,142</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,145,814</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Commitments and contingencies (see note 14)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Stockholders&rsquo; Equity (Deficit)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Convertible Series A Preferred stock, $0.001 par value; 1,000,000 shares authorized; 506,637 and 479,612 issued and outstanding
    as of December 31, 2021 and 2020, respectively</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">507</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">480</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Convertible Series Seed Preferred Stock, $0.001 par value; 120,000 shares authorized; 115,477 issued and outstanding as of
    December 31, 2021 and 2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">115</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Common stock, $0.001 par value; 100,000,000 shares authorized; 1,928,004 issued and outstanding as of December 31, 2021
    and 2020</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,928</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,928</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Additional paid in capital</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">28,323,157</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,764,539</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(29,151,367</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(26,123,335</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; padding-bottom: 1.5pt; text-align: left">Total stockholders&rsquo; equity (deficit)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(825,660</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,643,727</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total Liabilities and Stockholders&rsquo; Equity (Deficit)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">760,482</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,789,541</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to financial statements are an integral part of these statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="eds_004"></A>Neuraxis,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements
of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; font-weight: bold; text-align: left">Net Sales</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">2,721,286</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">1,930,228</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cost of Goods Sold</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">467,656</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">481,089</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Gross Profit</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,253,630</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,449,139</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Selling Expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">455,879</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">521,034</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Research and Development</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">203,414</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">166,798</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">General and Administrative</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">4,564,371</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,882,045</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Operating Loss</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(2,970,034</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,120,738</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Other Income (Expense):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest expense</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(36,928</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(75,711</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Interest income</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">License revenue</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Gain on loan forgiveness</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">220,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Change in fair value of derivative financial instruments</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(29,342</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,911</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Other expense</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,923</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other income</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">8,272</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">275</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other income (expense), net</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(57,998</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">394,589</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net Loss</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(3,028,032</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,726,149</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Per-share Data</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Basic and diluted loss per share</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1.92</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2.19</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Weighted Average Shares Outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Basic and diluted</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,968,004</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,968,004</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to financial statements are an integral part of these statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 150; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="eds_005"></A>Neuraxis,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements
of Stockholders&rsquo; Equity (Deficit)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
the Years Ended December 31, 2021 and 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Convertible
    Series A Preferred Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Convertible
    Series Seed Preferred Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Common
    Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Additional Paid
    In</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Accumulated</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Stockholder&rsquo;s</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Capital</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Deficit</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 8pt"><B>Equity</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; font-weight: bold"><FONT STYLE="font-size: 8pt">Balance, January 1, 2020</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">189,092</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">189</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">115,477</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">115</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">1,928,004</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">1,928</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">20,945,095</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">(22,397,186</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="width: 4%; text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;&nbsp;&nbsp;(1,449,859</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left"><FONT STYLE="font-size: 8pt">Stock based compensation</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">48,774</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">48,774</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-size: 8pt">Sale of Convertible Series A Preferred Stock, net
    of fees</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">290,520</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">291</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,036,330</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">4,036,621</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-size: 8pt">Issuance of Pre-Funded Warrants for Preferred Stock</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,734,340</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">2,734,340</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-size: 8pt">Net loss for the year ended
    December 31, 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(3,726,149</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 8pt">(3,726,149</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">Balance, December 31, 2020</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">479,612</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">480</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">115,477</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">115</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">1,928,004</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">1,928</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">27,764,539</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(26,123,335</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">1,643,727</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-size: 8pt">Stock based compensation</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">48,641</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">48,641</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt"><FONT STYLE="font-size: 8pt">Sale of Convertible Series A Preferred Stock</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">27,025</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">27</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">509,977</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">510,004</FONT></TD><TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-size: 8pt">Net loss for the year ended
    December 31, 2021</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(3,028,032</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(3,028,032</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">Balance, December 31, 2021</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">506,637</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">507</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">115,477</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">115</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">1,928,004</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">1,928</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">28,323,157</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(29,151,367</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><FONT STYLE="font-size: 8pt">(825,660</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><FONT STYLE="font-size: 8pt">)</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to financial statements are an integral part of these statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 151; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="eds_006"></A>Neuraxis,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statement
of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Years Ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows from Operating Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 60%; text-align: left">Net Loss</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">(3,028,032</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">(3,726,149</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Adjustments to reconcile net income to net cash provided by operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Depreciation and amortization</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">36,708</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">35,787</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Provisions for losses on accounts receivable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">11,770</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Non-cash lease expense</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">22,811</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,620</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Stock based compensation</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">48,641</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48,774</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Gain on loan forgiveness</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(220,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left">Change in fair value of derivative liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">29,342</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,911</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt; text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; text-align: left">Accounts receivable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">184,258</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(223,008</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt">Inventory</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">67,666</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">323,764</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; text-align: left">Prepaids and other current assets</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">132,619</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,286</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-align: left">Accounts payable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">319,232</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(664,247</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; text-align: left">Accrued expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(105,367</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">286,851</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-align: left">Customer deposits</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">69,337</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 30pt; text-align: left">Payroll withholding</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(467</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(23,311</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(19,629</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash used by operating activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(2,234,326</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(4,139,329</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows from Investing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Additions to property and equipment</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,390</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(27,719</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash used by investing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,390</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(27,719</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Cash Flows from Financing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from sale of convertible Series A Preferred Stock, net of fees of $0
    and $1,446,040, respectively</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">510,004</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,036,621</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Proceeds from pre-funded warrants for Series A Preferred Stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,734,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Principal payments on line of credit</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(150,000</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Principal payments on notes payable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(98,905</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,036,938</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from notes payable</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">250,000</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">470,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">661,099</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6,054,023</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Net Increase (Decrease) in Cash and Cash Equivalents</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,574,617</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,886,975</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at Beginning of Period</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,895,475</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at End of Period</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">320,858</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,895,475</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental Disclosure of Non-cash Cash Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left">Cash paid for interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">31,631</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">74,490</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Cash paid for income taxes</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left">Supplemental Schedule of Non-cash Investing and Financing Activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left">Non-cash share issuance costs</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">350,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notes
to financial statements are an integral part of these statements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 152; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="eds_007"></A>Neuraxis,
Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2021 and 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Basis of Presentation, Organization and Other Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo; the &ldquo;Company,&rdquo; or &ldquo;NeurAxis&rdquo;) was established in 2011 and incorporated
in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions, Inc. The name was changed to Neuraxis, Inc.
in March of 2022. Additionally, the Company filed a Certificate of Conversion to become a Delaware corporation on June 23, 2022. The
authorized shares were increased, and a par value established. See Subsequent Events footnote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 7, 2021, the Company&rsquo;s board of directors authorized a 4-for-1 stock split. They also increased the number of authorized
common stock shares from 2,700,000 to 10,800,000. Furthermore, on September 9, 2021, the board authorized and increase of authorized
shares of common stock from 10,800,000 to 13,400,000 in anticipation of a capital offering. All share and per share amounts for the common
stock have been retroactively restated to give effect to the split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the conversion to a Delaware corporation, the total number of shares of all classes of stock which the Corporation shall have
authority to issue is (1) 100,000,000 shares of Common Stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;) and (ii) 1,120,000
shares of Preferred Stock, par value $0.001 per share (&ldquo;Preferred Stock&rdquo;), 1,000,000 of which is hereby designated as &ldquo;Series
A Preferred Stock&rdquo; and 120,000 of which is hereby designated as &ldquo;Series Seed Preferred Stock&rdquo; with the rights, preferences,
powers, privileges and restrictions, qualifications and limitations set forth in this Article IV of the Delaware Certificate of Incorporation.
All share amounts have been retroactively restated to give effect to these changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
on January 10, 2023, the Company&rsquo;s board of directors authorized a 1-for-2 reverse stock split. All per share information has been
adjusted for this reverse stock split. The reverse split became effective on January 12, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is headquartered in Versailles, Indiana. The Company specializes in the development, production, and sale of medical neuromodulation
devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has developed three FDA cleared products, the IB-STIM (DEN180057, 2019), the NSS-2 Bridge (DEN170018, 2017), and the original
510(K) clearance (K140530, 2014).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    IB-STIM is a percutaneous electrical nerve field stimulator (PENFS) device that is indicated in patients 11-18 years of age with
    functional abdominal pain associated with irritable bowel syndrome. The IB-STIM currently is the only product marketed and sold by
    the Company.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    NSS-2 Bridge is a percutaneous nerve field stimulator (PNFS) device indicated for use in the reduction of the symptoms of opioid
    withdrawal. The NSS-2 Bridge device was licensed to Masimo Corporation in April 2020, and the Company received a one-time licensing
    fee of $250,000 from Masimo. Masimo markets and sells this product as its Masimo Bridge, and the Company will not receive any further
    licensing payments or other revenue from this product.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    original 510(K) device was the EAD, an electroacupuncture device, now called NeuroStim. The EAD is no longer being manufactured,
    sold or distributed but reserved only for research purposes.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Summary of Significant Accounting Policies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of significant accounting policies of Neuraxis, Inc. is presented to assist in understanding the Company&rsquo;s financial
statements. The financial statements and notes are representations of the Company&rsquo;s management, who is responsible for their integrity
and objectivity. These accounting policies conform to U.S. generally accepted accounting principles and have been consistently applied
in the preparation of the financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing
the Company&rsquo;s financial statements in conformity with accounting principles generally accepted in the United States of America
(&ldquo;GAAP&rdquo;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 153; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use
of Estimates and Critical Accounting Estimates and Assumptions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates
are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance for doubtful
accounts, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of intellectual property.
Actual results could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cash
and Cash Equivalents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of December 31, 2021 and 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trade
Accounts Receivable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable are stated at the amount management expects to collect from balances outstanding at year-end. Management considers
the following factors when determining the collectability of specific customer accounts: customer creditworthiness, past transaction
history with the customer, current economic industry trends, and changes in customer payment terms. Based on management&rsquo;s assessment
of the credit history with customers having outstanding balances and current relationships with them, it has concluded that realization
losses on balances outstanding at year-end will be immaterial. Interest is not charged on past due customer accounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Allowance
for Doubtful Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable are stated net of an allowance for doubtful accounts. We estimate allowance for doubtful accounts by evaluating
specific accounts where information indicates our customers may have an inability to meet financial obligations, such as customer payment
history, credit worthiness and receivable amounts outstanding for an extended period beyond contractual terms. We use assumptions and
judgment, based on the best available facts and circumstances, to record an allowance to reduce the receivable to the amount expected
to be collected. The allowance for doubtful accounts was $11,770 and $0 at December 31, 2021 and 2020, respectively.
During the years ended December 31, 2021 and 2020, the Company recorded $11,770 and $4,027, respectively as a bad debt
expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Customer
deposits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
deposits consists of billings and payments from clients in advance of revenue recognition. The Company will recognize the customer deposits
over the next year. As of December 31, 2021, and 2020, the Company had customer deposits of $69,337 and $0, respectively</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inventories</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost or net realizable value. The inventory is comprised of finished medical devices on hand. Certain
components within the devices have an expiration date that are removed from current inventory and expensed at the date of expiration.
For the years 2021 and 2020, $48,488 and $14,072 were expensed as expired inventory, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 154; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
inventories of $96,587 held on December 31, 2020, are comprised of device components that were acquired from the previous contract
manufacturer during the switch to a new contract manufacturer. The components were utilized by the new contract manufacturer in 2021.
The balance is reported on the prepaids and other current assets line of the balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property
and Equipment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over
the estimated useful lives of the assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated using the following estimated useful lives:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Classification</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left">Leasehold Improvements</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 24%; text-align: right">10-20</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Machinery and Equipment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7-10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Furniture and Fixtures</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5-10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $34,767 and $33,846 during the years ended December 31, 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for research and development are expensed as incurred. Research and development expense consists primarily of clinical research studies,
new product development, and manufacturing improvements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intangible
Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of patents and are stated at their historical cost and amortized on a straight-line basis over their expected useful
lives. Capitalized patent costs, net of accumulated amortization, includes legal costs incurred for patent applications. In accordance
with ASC 350, once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line
method. If the patent is not granted, we write-off any capitalized patent costs at that time. We review intangible assets for impairment
annually or when events or circumstances indicate that their carrying amount may not be recoverable. During the years ended December
31, 2021 and 2020, the Company recorded an impairment charge of $0 for intangible assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $1,941 and $1,941 during the years ended December 31, 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Income
Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has adopted accounting rules that prescribe when to recognize and how to measure the financial statements effect, if any, of
income tax positions taken or expected to be taken on its income tax returns. These rules require management to evaluate the likelihood
that, upon examination by relevant taxing jurisdictions, those income tax positions would be sustained.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on that evaluation, if it were more than 50% probable that a material amount of income tax would be imposed at the entity level upon
examination by the relevant taxing authorities, a liability would be recognized in the accompanying balance sheet along with any interest
and penalties that would result from that assessment. Should any such penalties and interest be incurred, the Company&rsquo;s policy
would be to recognize them as operating expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the results of management&rsquo;s evaluation, adoption of the rules did not have a material effect on the Company&rsquo;s financial
statements. Further, no interest or penalties have been accrued or charged to expense as of December 31, 2021 and 2020 and for the years
then ended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s income tax returns are subject to examination by the taxing authorities until the expiration of the related statutes
of limitations on those tax returns. In general, the federal and state income tax returns have a three-year statute of limitations. As
of December 31, 2021, the following tax years are subject to examination:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jurisdiction</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Open
    Years for Filed Returns</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 30%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return
    to File in 2022</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018
    &ndash; 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indiana</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2018
    &ndash; 2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 155; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Advertising
Cost</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
costs are expensed as incurred and amounted to $34,316 and $89,709 for the years ended December 31, 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Derivative
Financial Instruments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluates its debt and equity issuances to determine if those contracts or embedded components of those contracts qualify as
derivatives to be separately accounted for in accordance with paragraph 815-10-05-4 and Section 815-40-25 of the FASB Accounting Standards
Codification. The result of this accounting treatment is that the fair value of the embedded derivative is marked-to-market on each balance
sheet date and recorded as either an asset or a liability. In the event that the fair value is recorded as a liability, the change in
fair value is recorded in the statement of operations as other income or expense. Upon conversion, exercise, or
cancellation of a derivative instrument, the instrument is marked to fair value at the date of conversion, exercise, or cancellation,
and then the related fair value is reclassified to equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed
at the end of each reporting period. Equity instruments that are initially classified as equity that become subject to reclassification
are reclassified to liability at the fair value of the instrument on the reclassification date. Derivative instrument liabilities will
be classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument
is expected within 12 months of the balance sheet date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Section 815-40-15 of the FASB Accounting Standards Codification (&ldquo;Section 815-40-15&rdquo;) to determine whether
an instrument (or an embedded feature) is indexed to the Company&rsquo;s own stock. Section 815-40-15 provides that an entity should
use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock,
including evaluating the instrument&rsquo;s contingent exercise and settlement provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price, an expected remaining term of each warrant as of the valuation
date, estimated volatility, drift, and a risk-free rate. The Company records the change in the fair value of the derivative as other
income or expense in the statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measurements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&ldquo;ASC 820&rdquo;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &ndash; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &ndash; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &ndash; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&rsquo;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 156; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets.
Management believes the estimated fair value of these accounts at December 31, 2021 approximate their carrying value as reflected
in the balance sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Level 2 assets/liabilities include certain of the Company&rsquo;s notes payable and capital lease obligations. Their
carrying value approximates their fair values based upon a comparison of the interest rate and terms of such debt given the level of
risk to the rates and terms of similar debt currently available to the Company in the marketplace.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Level 3 assets/liabilities include derivative liabilities. Inputs to determine fair value are generally unobservable
and typically reflect management&rsquo;s estimates of assumptions that market participants would use in pricing the asset or liability.
The fair values are therefore determined using model-based techniques, including option pricing models and discounted cash flow models.
Unobservable inputs used in the models are significant to the fair values of the assets and liabilities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables provides a summary of the relevant assets and liabilities that are measured at fair value on recurring basis:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measurements as of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2021</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 44%; text-align: left; padding-bottom: 1.5pt">Derivative liabilities</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">32,102</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">32,102</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total Liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,102</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">32,102</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fair
Value Measurements as of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 1)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 2)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(Level 3)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 44%; text-align: left; padding-bottom: 1.5pt">Derivative liabilities</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">2,760</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1.5pt solid; text-align: right">2,760</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Total Liabilities</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,760</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,760</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the valuation methodology and unobservable inputs for Level 3 assets and liabilities measured at fair value on
recurring basis as of December 31, 2021 and 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value<BR> As of<BR> December 31,<BR> 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair Value<BR> As of<BR> December 31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Valuation<BR> Methodology</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Unobservable<BR> Inputs</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; text-align: justify">Derivative liabilities</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">32,102</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">2,760</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 18%; text-align: justify">Monte Carlo model</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 26%; text-align: justify">Project simulated cash flows</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between any of the levels during the years ended December 31, 2021 and 2020. In addition to assets and liabilities
that are recorded at fair value on a recurring basis, the Company&rsquo;s assets and liabilities are also subject to nonrecurring fair
value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 157; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basic
and Diluted Net Income (Loss) per Share</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
or loss per share (&ldquo;EPS&rdquo;) is computed by dividing net income (loss), net of preferred stock dividends, by the weighted average
number of shares of common stock outstanding during the period. Diluted EPS is computed by dividing net income (loss) by the weighted
average of all potentially dilutive shares of common stock that were outstanding during the periods presented. Preferred stock dividends
(not declared or paid) were $748,832 and $589,156 for the years ended December 31, 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common
shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares
outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, which
is the case for December 31, 2021 and 2020 presented in these financial statements, the weighted-average number of common shares outstanding
excludes common stock equivalents because their inclusion would be anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially dilutive common stock equivalents at December 31, 2021 and 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31,</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left">Convertible Series A Preferred Stock</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">506,637</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 18%; text-align: right">479,612</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Convertible Series Seed Preferred Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,477</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">115,477</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,638,788</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,638,788</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Pre-Funded Warrants for Convertible Series A Preferred Stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,890</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">144,890</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25,704</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25,704</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt; font-weight: bold">Totals</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,431,496</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,404,471</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table shows the calculation
of the basic and diluted net loss per share and the effect of preferred stock dividends.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Numerator</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; width: 56%; text-align: left">Net loss</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 18%; font-weight: bold; text-align: right">(3,028,032</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 18%; text-align: right">(3,726,149</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Preferred stock dividends</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(748,832</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(589,156</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(3,776,864</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(4,315,305</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Denominator</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Weighted-average shares of common stock outstanding - basic and diluted</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,968,004</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,968,004</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Basic and diluted net loss per share</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1.92</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2.19</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for all stock-based payments and awards under the fair value-based method. The Company recognizes its stock-based compensation
expense using the straight-line method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an
actual forfeiture of a stock option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the granting of stock options to employees and non-employees using the fair value method whereby all awards are
measured at fair value on the date of the grant. The fair value of all employee stock options is expensed over the requisite service
period with a corresponding increase to additional paid-in capital. Upon exercise of stock options, the consideration paid by the option
holder is recorded in additional paid-in capital, while the par value of the shares received is reclassified from additional paid in
capital to common stock. Stock options granted to employees are accounted for as liabilities when they contain conditions or other features
that are indexed to other than a market, performance, or service condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">payments to non-employees are measured based on
the fair value of the equity instrument issued. Compensation expense for non-employee stock awards is recognized over the requisite service
period following the measurement of the fair value on the grant date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 158; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue
Recognition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. specializes in the development, production, and sale of medical neuromodulation devices to healthcare providers primarily located
in the United States. Patented and trademarked neuromodulation devices is the Company&rsquo;s major product line. Products are generally
transferred at a point in time (rather than over time). Essentially all the Company&rsquo;s revenue is generated from purchase order
contracts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB&rsquo;s ASC 606, Revenue from Contracts with Customers, (&ldquo;ASC 606&rdquo;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to be entitled in exchange for those goods or services, in an amount that reflects the consideration which the Company expects to be
entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within
the scope of ASC 606, it performs the following five steps:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; white-space: nowrap">(i)</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">identify
    the contract(s) with a customer&#894;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract&#894;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">determine the transaction price&#894;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">allocate the transaction price to the performance obligations in the contract&#894; and</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">recognize revenue when (or as) the entity satisfies a performance obligation.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all of the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates credit losses on accounts receivable by estimating expected credit losses over the contractual term of the receivable
using a discounted cash flow method. When developing this estimate of expected credit losses, the Company considers all available information
(past, current, and future) relevant to assessing the collectability of cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program extends potential self-pay
discounts for IB-Stim devices, based upon household income and size.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebates or invoice credit where the insurance payment and patient responsibility (i.e. deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table disaggregates the Company&rsquo;s revenue based on the customer&rsquo;s location by state for the years ended December
31:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%">Wisconsin</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 24%; font-weight: bold; text-align: right">665,157</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 24%; text-align: right">450,568</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>California</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">549,466</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">353,810</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Ohio</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">462,350</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">348,666</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">North Carolina</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">260,753</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">325,155</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">All other states</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">783,560</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">452,029</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2,721,286</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,930,228</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 159; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following economic factors affect the nature, amount, timing, and uncertainty of the Company&rsquo;s revenue and cash flows as indicated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type
of customer:</B> Based on dollar amounts of revenue, essentially all of the goods sold by the Company are sold to healthcare customers
including hospitals and clinics. Sales to healthcare customers lack seasonality and have a mild correlation with economic cycles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Geographical
location of customers:</B> Sales to customers located within the United States represent essentially all of the Company&rsquo;s sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Type
of contract:</B> Sales contracts consist of purchase order contracts that tend to be short-term (i.e., less than or equal to one year
in duration).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
opening and closing balances of trade receivables, contract assets, and contract liabilities from contracts with customers are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Trade Receivables</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contract Assets</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Contract Liabilities</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%">Balance 1/1/2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">88,321</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">0</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Balance 12/31/20 and 1/1/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">311,329</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Balance 12/31/2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">115,301</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Company&rsquo;s
Performance Obligations with Customers:</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Timing
of Satisfaction</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations as goods are delivered.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goods
that are shipped to customers are typically shipped FOB shipping point with freight prepaid by the Company. As such, ownership of goods
in transit transfer to the customer when shipped and the customer bears the associated risks (e.g., loss, damage, delay). In some cases,
a customer will take delivery directly from the Company&rsquo;s inventory (i.e., consigned inventory), at which point ownership and the
associated risks pass to the customer at that time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
and handling costs are recorded as general and administrative expenses in the Statement of Operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Significant
Payment Terms</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for goods sold by the Company is typically due, after an invoice is sent to the customer, within 30 days. However, other payment terms
are frequently negotiated with customers ranging from due upon receipt to due within 90 days. Some payment terms may call for payment
only after the healthcare provider receives their insurance reimbursement. Invoices for goods are typically sent to customers within
three calendar days of shipment. The Company does not offer discounts if the customer pays some or all of an invoiced amount prior to
the due date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the Company&rsquo;s contracts have a significant financing component.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Nature</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer. The manufacture
is located within the state of Indiana and maintains compliance with FDA manufacturing guidelines. In no case does the Company act as
an agent (i.e., the Company does not provide a service of arranging for another party to transfer goods to the customer).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Returns,
Refunds, etc.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund
    the price paid for any defective or nonconforming products</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply
    and deliver to the customer replacement conforming products</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimburse
    the customer for the cost of repairing any defective or nonconforming products</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 160; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also maintains
appropriate accounts to reflect the effects of expected returns on the Company&rsquo;s financial position and periodically adjusts those
accounts to reflect its actual return experience. Historically, returns have been immaterial, and the Company currently does not provide
a provision for this liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Warranties</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
most cases, goods that customers purchase from the Company are covered by manufacturers&rsquo; warranties. The Company does not sell
warranties separately.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturer guarantees the product for the period up to the expiration date printed on the device&rsquo;s label or twelve months from
the date of purchase, whichever comes first. The guarantee applies to flaws of material and workmanship. The Company&rsquo;s warranties
provide customers with assurance that purchased devices comply with published specifications, inspection standards, and workmanship.
At the time revenue is recognized, the Company estimates the cost of expected future warranty claims but does not exclude any amounts
from revenue. The Company maintains appropriate accounts to reflect the effects of expected future warranty claims on the Company&rsquo;s
financial position and periodically adjusts those accounts to reflect its actual warranty claim experience. Historically, warranty claims
have been immaterial, and the Company currently does not provide a provision for this liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations for goods at a point in time. In most cases, goods are shipped by common carrier
to customers under &ldquo;FOB Shipping Point&rdquo; terms. As such, customers typically obtain control of the goods upon shipment. The
Company&rsquo;s management exercises judgment in determining when performance obligations for goods have been satisfied. In making such
judgments, management typically relies on shipping information obtained from common carriers to evaluate when the customer has obtained
control of the goods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&rsquo;s management uses in establishing the prices
of goods to be sold.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective
January 1, 2021, the Company adopted Accounting Standards Updated (&ldquo;ASU&rdquo;) No. 2016-02, <I>Leases (Topic 842)</I> (&ldquo;ASU
2016-02&rdquo; or &ldquo;ASC 842&rdquo;), using the full retrospective method, the cumulative effect of the accounting change is recognized
as an adjustment to the opening balance of retained earnings in the first comparative period presented. At the inception of an arrangement,
the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement.
Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets and current and non-current lease
liabilities, as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&rsquo;s assessment
unless there is reasonable certainty that the Company will renew.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 161; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company elected the following practical expedients, which must be elected as a package and applied consistently to all of its leases
at the transition date (including those for which the entity is a lessee or a lessor): i) the Company did not reassess whether any expired
or existing contracts are or contain leases; ii) the Company did not reassess the lease classification for any expired or existing leases
(that is, all existing leases that were classified as operating leases in accordance with ASC 840 are classified as operating leases,
and all existing leases that were classified as capital leases in accordance with ASC 840 are classified as finance leases); and iii)
the Company did not reassess initial direct costs for any existing leases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
leases that existed prior to the date of initial application of ASC 842 (which were previously classified as operating leases), a lessee
may elect to use either the total lease term measured at lease inception under ASC 840 or the remaining lease term as of the date of
initial application of ASC 842 in determining the period for which to measure its incremental borrowing rate. In transition to ASC 842,
the Company utilized the remaining lease term of its leases in determining the appropriate incremental borrowing rates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 842, components of a lease should be split into three categories: lease components, non-lease components, and non-components.
The fixed and in-substance fixed contract consideration (including any consideration related to non-components) must be allocated based
on the respective relative fair values to the lease components and non-lease components.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all of the contract consideration to the lease component only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Impairment
of Long-Lived Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
and Uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2021, the World Health Organization declared Coronavirus (COVID-19) a pandemic. The continued spread of COVID-19, or any similar outbreaks
in the future, may adversely impact the local, regional, national, and global economies. The extent to which COVID-19 impacts the Company&rsquo;s
results is dependent on the breadth and duration of the pandemic and could be affected by other factors the Company is not currently
able to predict. These impacts may include, but are not limited to, additional costs for responding to COVID-19, potential shortages
of labor, potential shortages of material and supplies, and loss of, or reduction to, revenue. Management believes the Company is taking
appropriate actions to respond to the pandemic, however, the full impact is unknown and cannot be reasonably estimated at this time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Concentrations
of Credit Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across the
country.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables
consist of unsecured amounts due from customers. The balance at December 31, 2021 and 2020 of accounts receivable was $115,301
and $311,329, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 162; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the Company&rsquo;s customers that accounted for greater than 10% of its revenues in one of the years ended December
31, 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.5in">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Percentage of Sales</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Percentage of Sales</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-align: left">Hospital A</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 14%; font-weight: bold; text-align: right">574,185</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">21</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">430,211</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">22</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Hospital B</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">444,965</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">336,627</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Hospital C</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">321,964</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">231,568</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12</TD><TD STYLE="text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Hospital D</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">226,293</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">285,717</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">15</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,567,407</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">58</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,284,123</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">67</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company&rsquo;s bank balances may exceed the FDIC limit of $250,000; however, management does not feel that this has
a material impact on the financial condition. At December 31, 2021 and 2020, the Company&rsquo;s uninsured cash balances totaled $20,850
and $1,450,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2021, we had an stockholders&rsquo; deficit of approximately $826 thousand. At December 31, 2021, we had short-term
and long-term borrowings outstanding of approximately $250 thousand and $52 thousand, respectively. As of December 31, 2021, we had cash
of approximately $321 thousand and a working capital deficit of approximately $934 thousand.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our technologies,
the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other proprietary rights,
our ability to establish collaborative arrangements, marketing activities and competing technological and market developments, including
regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue and achieve profitability requires
us to successfully market and secure purchase orders for our products from customers currently identified in our sales pipeline and to
new customers as well. The primary activity that will drive all customers and revenues is the adoption of insurance coverage by commercial
insurance carriers nationally, so this is a top priority of the Company. These activities, including our planned research and development
efforts, will require significant uses of working capital through the end of 2022 and beyond. Based on our current operating plans, we
believe that our existing cash at the time of this filing will only be sufficient to meet our anticipated operating needs through November
2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Going
Concern Evaluation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&rsquo;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers, will allow the Company to achieve profitability in the near term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no assurance
that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is dependent
upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise additional funds by
way of a public or private offering. Because, under current accounting standards, neither future cash generated from operating activities,
nor management&rsquo;s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered
probable, substantial doubt is deemed to exist about the Company&rsquo;s ability to continue as a going concern. As we continue to incur
losses, our transition to profitability is dependent upon achieving a level of revenues adequate to support its cost structure. We may
never achieve profitability, and unless and until doing so, we intend to fund future operations through additional dilutive or nondilutive
financings. There can be no assurances, however, that additional funding will be available on terms acceptable to us, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 163; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Adopted</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B> Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued an update (ASU 2016-02, Leases) which requires lessees to record most leases on their balance sheet and
recognize leasing expenses in the income statement. The guidance modifies the recognition and accounting for lessees and lessors and
requires expanded disclosures regarding assumptions used to recognize revenue and expenses related to leases. The guidance is effective
for annual and interim reporting periods beginning after December 15, 2019 for SEC filers, December 15, 2020 for public business
entities that are not SEC filers, and December 15, 2021 for all other entities, including EGCs that have elected to defer adoption until
the guidance becomes effective for non-public entities, with early adoption permitted. The Company elected to adopt early. Early
adoption is permitted and modified retrospective adoption is required. The guidance is to be applied using either a full retrospective
or modified retrospective method. In applying the full retrospective method, the cumulative effect of the accounting change should be
recognized as an adjustment to the opening balance of retained earnings in the first comparative period presented. In applying the modified
retrospective method, the cumulative effect of the accounting change should be recognized as an adjustment to the opening balance of
retained earnings at the date of adoption. The Company early adopted ASU 2016-02 effective January 1, 2020, under the full retrospective
approach.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements
for Fair Value Measurement, which adds disclosure requirements to Topic 820 for the range and weighted average of significant unobservable
inputs used to develop Level 3 fair value measurements. This ASU is effective for interim and annual reporting periods beginning after
December 15, 2019. The Company adopted this standard as of January 1, 2020, and the adoption did not have a material impact on the Company&rsquo;s
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic
606, which, among other things, provides guidance on how to assess whether certain collaborative arrangement transactions should be accounted
for under Topic 606. The amendments in this ASU are effective for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2019, with early adoption permitted. The Company adopted this standard on January 1, 2020, and the adoption did not
have a material impact on the Company&rsquo;s financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
August 2020, FASB issued ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &ndash; Contracts
in Entity&rsquo;s Own Equity (Subtopic 815-40), which simplifies accounting for convertible instruments by removing major separation
models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for
the derivative scope exception, and it also simplifies the diluted earnings per share calculation in certain areas. The guidance is effective
for interim and annual periods beginning after December 15, 2021. Early adoption is permitted, but no earlier than fiscal years beginning
after December 15, 2020, including interim periods within those fiscal years. FASB has specified that an entity should adopt the guidance
as of the beginning of its annual fiscal year. The guidance is to be applied using either a full retrospective or modified retrospective
method. In applying the full retrospective method, the cumulative effect of the accounting change should be recognized as an adjustment
to the opening balance of retained earnings in the first comparative period presented. In applying the modified retrospective method,
the cumulative effect of the accounting change should be recognized as an adjustment to the opening balance of retained earnings at the
date of adoption<B>. </B>The Company early adopted ASU 2020-06 effective January 1, 2021, under the modified retrospective approach.
The adoption of this guidance did not have a material impact on the Company&rsquo;s financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2014, the FASB issued an update (ASU 2014-09, Revenue from Contracts with Customers) that supersedes most current revenue recognition
and industry-specific guidance. These standards update clarifies the principles for recognizing revenue and develops a common revenue
standard for U.S. GAAP and International Financial Reporting Standards. The standards update intends to provide a more robust framework
for addressing revenue issues; improve comparability of revenue recognition practices across entities, industries, jurisdictions, and
capital markets; and provide more useful information to users of financial statements through improved disclosure requirements. The guidance
is effective for nonpublic entities for annual reporting periods beginning after December 15, 2019. The Company adopted ASU 2014-09 effective
January 1, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 164; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recently
Issued Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments &ndash; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which requires measurement and recognition of expected credit losses for financial assets held and requires enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &ndash; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amends
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&ldquo;SRC&rdquo;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard will not be effective until the beginning of 2023. The Company is evaluating the effect that ASU
2016-13 will have on its financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two demand notes receivable from shareholders related to the sale of common stock on January 1, 2016. Both notes initial
balances were $506,400, with interest calculated monthly based on applicable federal rates. No payments have been received on the notes.
Since repayment is not assured, the Company provided an allowance for the entire balance of principal and interest as of December 31,
2019. The current allowance is $1,083,762 as of December 31, 2021. The current loan balances are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Loan</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">December 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%">Shareholder 1</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">506,400</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">35,548</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">827</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Shareholder 2</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">506,400</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">35,414</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">827</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,012,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70,962</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,654</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Allowance for Collection Risk</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,012,800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(70,962</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Balance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Loan</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%">Shareholder 1</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">506,400</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">34,721</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">2,921</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Shareholder 2</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">506,400</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">34,587</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,921</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,012,800</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69,308</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,842</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Allowance for Collection Risk</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,012,800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(69,308</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,842</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Balance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has loans payable to shareholders related to funding needs for operations. The current loan details for all related party loans
are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Interest &amp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Loan</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Service Fee</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Interest</B></FONT></TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">December 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Due Date</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Paid</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%">Shareholder 2</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 12%">Demand</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">0.12</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">10</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Shareholder 1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">June, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,153</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Shareholder 1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">June, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,781</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Shareholder 3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">June, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,582</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">Other Convertibles Various</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">5.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">66,648</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 10pt"><B>Total</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">58,051</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">89,582</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,592</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 165; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Interest &amp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Loan</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Service Fee</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Interest</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Due Date</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Paid</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%">Shareholder 2</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right">Demand</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">0.15</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">61,861</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">8</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">36,403</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Shareholder 1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">June, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">20,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,145</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,051</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Shareholder 1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">June, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">38,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,081</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Shareholder 3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: right">June, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,093</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,403</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,619</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other Convertibles</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-bottom: 1.5pt">Various</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">5.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">66,648</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-weight: bold; padding-bottom: 1.5pt">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">151,005</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">84,285</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">55,073</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s Chief Financial Officer, John Seale, CPA.CITP, is contracted for services through RBSK Partners PC (RBSK). Mr. Seale
is RBSK&rsquo;s managing partner and majority shareholder. RBSK is engaged by the Company to provide accounting and tax services on a
continuous basis. Fees paid to RBSK for services were $80,394 and $167,489 for the years ended December 31, 2021 and 2020,
respectively. The Company owed RBSK for open invoices of $3,386 and $6,270 as of December 31, 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.
Prepaids and Other Current Assets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company made cash advances to its manufacturer in the amount of $1,123,000. Production invoices from the manufacturer for the years 2017-2020
in the amount of $1,123,000 have been applied to the advance balance leaving a net balance of $0 and $38,240 as of December 31, 2021
and 2020, respectively. The vendor deposit balance is reported within prepaids and other current assets on the balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
Accrued Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%">Wages</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">451,970</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">525,791</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Employee benefits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,735</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,736</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Commissions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,786</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">50,639</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Property taxes</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">563</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">554</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Interest expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">89,582</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">84,285</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total accrued expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">561,636</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">667,005</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Long-term Notes Payable</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company borrowed $250,000 on December 16, 2021, from Channel Partners Capital. The note calls for 65 weekly payments of $4,923.08 with
the final payment scheduled for March 16, 2023. The note&rsquo;s interest rate computes to a nominal rate of 40.856%. The principal outstanding
at December 31, 2021 was $244,048.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lender was granted and assigned a continuing security interest in all the Company&rsquo;s personal property assets including, but not limited
to, business equipment, inventory, accounts, accounts receivable, intellectual property, chattel paper, instruments, deposit accounts,
commercial tort claims, contract rights, licenses, claims, and general intangibles.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
minimum principal payments are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-weight: bold; text-align: justify">2022</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 26%; text-align: right">192,356</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: justify">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">51,692</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Leases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&rsquo;s leases are comprised of operating leases for office space. At the inception of the lease, the Company determines whether
the lease contract conveys the right to control the use of identified property for a period of time in exchange for consideration. Leases
are classified as operating or finance leases at the commencement date of the lease. Operating leases are recorded as operating lease
right-of-use assets, other current liabilities, and operating lease liabilities in the Balance Sheets. The Company did not have any finance
leases at December 31, 2021 and 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 166; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had three leases primarily consisting of office space in Versailles and Carmel Indiana. Two of the leases in Versailles started
January 1, 2017. Both have an initial term of five years with an option for an additional five-year term. The monthly lease payments
for these leases are $550 and $1,600 with a 3% per annum increase starting with the optional five-year term. The lease in Carmel started
March 1, 2016. The initial term is five years and three months with an option for an additional three-year term. The monthly lease payment
started at $1,472 with an annual increase of approximately 2.7%. On December 16, 2020, the Company entered into an amendment of the Carmel
lease that extended the initial term by two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the
lease term. As the implicit interest rate is generally not readily determinable, the Company uses an incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate
reflects the estimated rate of interest that the Company would pay to borrow on a collateralized basis over a similar economic environment.
Lease expense for the operating lease is recognized on a straight-line basis over the lease term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
may include renewal options, and the renewal option is included in the lease term if the Company concludes that it is reasonably certain
that the option will be exercised. Certain leases may contain rent escalation clauses, either fixed or adjusted periodically for inflation
of market rates, that are factored into the calculation of lease payments to the extent they are fixed and determinable at lease inception.
The Company also has variable lease payments that do not depend on a rate or index, primarily for items such as common area maintenance
and real estate taxes, which are recorded as expenses when incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2021 and 2020, the Company recognized $4,725 and $2,268 of operating lease expense, including
short-term lease expense and variable lease costs, which are immaterial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to the Company&rsquo;s operating leases:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use assets</TD><TD STYLE="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 16%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">127,975</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 16%; border-bottom: Black 1.5pt solid; text-align: right">150,786</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Other current liabilities</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">27,582</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">23,311</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">109,594</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">137,176</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">137,176</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">160,487</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Weighted-average remaining lease term (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Weighted-average discount rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">15.0</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the maturities of the Company&rsquo;s operating lease liabilities were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 72%; text-align: left">2022</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 24%; text-align: right">46,319</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2023</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">46,832</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,731</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25,800</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">2026</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25,800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Total lease payments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">179,482</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">42,306</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Total present value of lease payments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">137,176</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Common Stock and Warrants</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 7, 2021, the Company&rsquo;s board of directors authorized a 4-for-1 stock split. They also increased the number of authorized
common stock shares from 2,700,000 to 10,800,000.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Furthermore, on September 9, 2021, the board authorized and increase of authorized shares of common stock from 10,800,000 to 13,400,000
in anticipation of a capital offering. As part of the conversion to a Delaware Corporation in June of 2022, the total number of common
stock shares authorized was increased to 100,000,000. All share and per share amounts for the common stock have been retroactively
restated to give effect to the split.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 167; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Furthermore, on January
10, 2023, the Company&rsquo;s board of directors authorized a 1-for-2 reverse stock split. All per share information has been adjusted
for this reverse stock split. The reverse split became effective on January 12, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with a bridge loan, the Company issued a warrant to a shareholder, Brian Hannasch, on September 18, 2018. The warrant allows
the holder to purchase common stock from the Company at a share price of $8.76 per share. The number of shares was based on a
formula tied to the amount of loans made by the holder. The number of shares based on this formula is 12,852. The warrant contains
certain rights in the event of liquidation, merger, or consolidation of the Company. If the fair market value of one share is greater
than the warrant price, the holder may elect to receive a number of shares equal to the value of the warrant. If the exercise in in connection
with the sale of the Company, the holder may, at its option, condition its exercise of the warrant upon the consummation of such transaction.
The warrant expires on September 18, 2028, and can be exercisable either in whole or from time to time in part prior to the expiration
date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued a second warrant to Brian Hannasch on September 6, 2019, under similar terms. This is a penny warrant that allows the
holder to purchase 40,000 shares of common stock and is subject to adjustment for certain equity events. The warrant contains
certain rights in the event of liquidation, merger, or consolidation of the Company. The warrant expires on September 6, 2029.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued a third warrant to Masimo Corporation on April 9, 2020. This warrant was pre-funded in the amount of $2,734,340. The warrant
allows the holder to purchase 144,890 shares of Series A Preferred Stock at $4.72 per share and is subject to adjustment
for certain equity events. The warrant contains certain rights in the event of liquidation, merger, or consolidation of the Company.
There will be no additional purchase price for the Warrants. In the event that all outstanding shares of Series A Preferred Stock are
converted, automatically or by action of the holders thereof, into Common Stock, including, without limitation, in connection with the
Company&rsquo;s initial, underwritten public offering and sale of its Common Stock pursuant to an effective registration statement under
the Act (the &ldquo;IPO&rdquo;), then from and after the date on which all outstanding shares of Series A Preferred Stock have been so
converted, this Warrant shall be exercisable for such number of shares of Common Stock into which the Warrant Shares would have been
converted had the Warrant Shares been outstanding on the date of such conversion, and the Exercise Price shall equal the Exercise Price
in effect as of immediately prior to such conversion divided by the number of shares of Common Stock into which one share of Series A
Preferred Stock would have been converted, all subject to further adjustment thereafter from time to time in accordance with the provisions
of this Warrant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for common stock during the years ended December 31, 2021 and 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted-Avg.</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Warrants for</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; font-weight: bold">Outstanding as of December 31, 2019</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">52,852</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">2.14</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cancelled/Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">52,852</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.14</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cancelled/Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of December 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">52,852</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.14</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following is a summary of warrant
activity for preferred stock during the years ended December 31, 2021 and 2020:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted-Avg.</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Warrants for</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold">Outstanding as of December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cancelled/Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%">Granted</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">144,890</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">0.0001</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Cancelled/Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of December 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">144,890</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0.0001</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 168; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&rsquo;s warrants outstanding and exercisable as of December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Number of</B></TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center"><B>Warrants</B></TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Exercise</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">Expiration</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: center"><B>Outstanding</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 24%">Common Stock</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 22%; text-align: right">12,852</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 22%; text-align: right">35.0200</TD><TD STYLE="width: 2%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 23%; text-align: center">September 18, 2028</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Common Stock</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">40,000</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.0200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">September 6, 2029</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Preferred Stock</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">144,890</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">0.0001</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">None</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">197,742</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Preferred Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has authorized 1,120,000 shares of preferred stock of which 1,000,000 has been designated Series A Preferred Stock and 120,000
has been designated Series Seed Preferred Stock, of which 506,637 and 479,612 shares of Series A Preferred Stock and 115,477
shares of Series Seed Preferred Stock are issued and outstanding as of December 31, 2021 and 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate purchase price of the Series A Preferred Stock was $9,321,165, of which $7,692,664 was comprised of cash and the remaining
$1,628,501 was comprised of converted debt and common stock. The aggregate purchase price of the shares of Series Seed Preferred Stock
was $0, as all the shares of Series Seed Stock were converted from common stock as an incentive to reinvest in Series A Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of Preferred Stock terms:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Voting
Rights</U> - The Series A Preferred Stock and Series Seed Preferred Stock shall vote together with the Common Stock on
an as-converted basis, and not as separate classes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Conversion
</U>- The Series A Preferred Stock and Series Seed Stock initially convert 1:1 to Common Stock at any time at option of
holder, subject to adjustments for stock dividends, splits, combinations, and similar events and as described below under &ldquo;Anti-dilution
Provisions.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Dividends
</U>- The Series A Preferred Stock will carry an annual 8% cumulative dividend, payable upon any liquidation, dissolution or winding
up of the Company (the &ldquo;Accruing Dividend&rdquo;). For any other dividends or distributions, participation with Common Stock on
an as-converted basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Liquidation
</U>- In the event of any liquidation, dissolution or winding up of the Company, the proceeds shall be paid in the following priority:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
to the Series A Preferred in proportion to each holder&rsquo;s respective pro rata Series A Original Purchase Price, plus any pro rata
share of the Accruing Dividend until the entire Series A Original Purchase Price and Accruing Dividend are paid;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
to the Series Seed Preferred Stock in proportion to each holder&rsquo;s respective pro rata Series Seed Original Purchase Price
until the entire amount of the Series Seed Original Purchase Price is paid;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter,
the Series A Preferred Stock and Series Seed Preferred Stock participate with the Common Stock pro rata on an as-converted
basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares
of the surviving or acquiring corporation) and a sale, lease, transfer, exclusive license or other disposition of all or substantially
all of the assets of the Company will be treated as a liquidation event, thereby triggering
payment of the liquidation preferences described.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Anti-dilution
Provisions</U> - The Series A Preferred have full-ratchet anti-dilution protection so that the conversion price will be reduced to 80%
of the price at which any future shares are issued, if less than the Series A Original Purchase Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for shareholders to make an additional investment in the Company, upon the purchase of the Series A Preferred stock by
the shareholder, the Company converted the existing common shares held by shareholders to Series Seed Preferred Stock at a $100 million
valuation and at a 120% share premium. As of December 31, 2021, and 2020, there were 195,404 common shares converted into 115,477
shares of Series Seed Preferred Stock that have no par value and are outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 169; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.
Stock Options and Awards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 12, 2017, the Company adopted the 2017
Stock Compensation Plan authorizing the issuance of 1,435,652 shares of common stock. On September 13, 2019 the Company entered into
a Stock Option Cancellation agreement with all holders of these stock options effective on that date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This plan was then amended on September 13, 2019,
to increase the share amount to 2,638,788. This plan was enacted to enable the Company to retain the services of certain key employees,
officers, and directors of the Company. The Plan provides for the grant of stock options, including incentive stock options, or ISOs,
and nonqualified stock options, or NSOs and restricted stock, and they were estimated using the Black-Scholes option-pricing model with
the following weighted-average assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
                                            as of</FONT></P>
                                                                                <P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
                                            31, 2019</FONT></P></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fully&nbsp;</B></FONT>Vested</P>

</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Partially&nbsp;Vested</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 56%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
    of Shares</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,319,394</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,070</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
    price</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.74</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.74</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise
    price</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.94</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.94</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    term</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5&nbsp;years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9&nbsp;years</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
    volatility</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">63.69</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">69.4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
    interest rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.17</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
    rate</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of stock option activity for the years ended December 31, 2021 and 2020:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted Avg.</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Remaining</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Number of</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Contractual Life</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Weighted Avg.</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Aggregate</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(in years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Exercise Price</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Intrinsic Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; font-weight: bold">Outstanding as of December 31, 2019</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">1,319,394</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">7.78</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">6.94</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Cancelled/Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of December 31, 2020</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,319,394</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.78</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.94</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Forfeited</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Cancelled/Expired</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; padding-bottom: 1.5pt">Exercised</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Outstanding as of December 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,319,394</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.78</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">6.94</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Vested and Exercisable as of December 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,309,704</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">5.78</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">6.94</P></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense is classified in the Company&rsquo;s statements of operations as general and administrative expense. The amounts
were $48,641 and $48,774 for years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, there was
$27,319 of total unrecognized compensation expense related to unvested options granted under the Company&rsquo;s share-based compensation
plans that is expected to be recognized over a period of approximately 0.56 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.
Derivative Liabilities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified derivative instruments arising from an adjustable exercise price for warrants that are issued and outstanding
as of December 31, 2021 and 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price, an expected remaining term of each warrant as of the valuation
date, estimated volatility, drift, and a risk-free rate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note adjusted to be on a continuous return basis to align
with the Black-Scholes option-pricing model.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 170; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
yield: The Company uses a 0% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring
dividends in the near future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility:
The Company calculates the expected volatility based on comparable company&rsquo;s historical stock prices with a look back period commensurate
with the period to maturity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
term: The Company&rsquo;s remaining term is based on the remaining contractual maturity of the warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the derivative liabilities during the year ended December 31, 2021 and 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 46%; font-weight: bold">Derivative liabilities as of January 1, 2020</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">4,745</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Addition</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Changes in fair value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,247</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold">Derivative liabilities as of January 1, 2021</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,498</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Addition</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Changes in fair value</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">28,816</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Derivative liabilities as of December 31, 2021</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">32,314</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.
Retirement Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sponsors a 401(k)-retirement plan for its employees. Employees are eligible to participate in the elective deferral portion of
the plan after twelve months and 1,000 hours of service. The Company matches the employee&rsquo;s contribution up to 3%. The Company
can also make an optional profit-sharing contribution to the employee accounts on an annual basis. There was an expense of $22,501
and an over accrual of $7,048 for years ended December 31, 2021 and 2020, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13</B>.
<B>Payroll Protection Program Loan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company received a loan in the amount of $220,000 under the Paycheck Protection Program (&ldquo;PPP&rdquo;). The PPP, established as
part of the Coronavirus Aid, Relief and Economic Security Act (&ldquo;CARES Act&rdquo;), provides for loans to qualifying businesses
for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable
after eight or twenty-four weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent
and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees
or reduces salaries during the eight-week period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six
months. The Company has used the proceeds for purposes consistent with the PPP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2020, the Company was notified by their bank that the SBA had paid off their PPP loan which was approved for total forgiveness.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14</B>.
<B>Commitments and Contingencies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License
Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, the Company entered into a license agreement with Masimo Corporation (Masimo) granting certain exclusive rights and licenses,
access to Company&rsquo;s research and development capabilities, and to enable the development, manufacture, and commercialization of
products in a specific &ldquo;field&rdquo;, primarily related to pain associated with substance abuse withdrawal symptoms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
&ldquo;field&rdquo; excludes the following pediatric and adult conditions (including the associated symptoms and any pain caused thereby):
chronic nausea, gastroparesis, functional gastrointestinal disorders, chemotherapy induced nausea/vomiting, concussions and post-concussion
syndrome, headaches (migraine or benign, non-specified), symptoms resulting from traumatic brain injury, post-traumatic stress disorder,
fatty liver disease, cyclic vomiting syndrome, movement disorder including Parkinson&rsquo;s disease, chronic sleep disorders, inflammatory
bowel disease, pancreatitis, pulmonary inflammatory disorders, dysautonomia and postural orthostatic tachycardia syndrome, tic disorders,
tinnitus, TMJ disorders, autoimmune disorders, seizure disorders, diabetes, and modulation of exercise physiology and recovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 171; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company
also entered into a collaboration agreement with Masimo to induce Masimo to enter into the purchase of Series A Preferred Stock and
Pre-funded Warrants for Series A Preferred Stock and as part of that agreement received a one-time, upfront and non-refundable fee
of $250,000 for the license agreement. More information is contained in footnote 8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing
Services Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, the Company entered into a Manufacturing Services Agreement (MSA) for the manufacture and supply of the Company&rsquo;s
IB-STIM device based upon the Company&rsquo;s product specifications as set forth in the MSA. This agreement terminated any prior
manufacturing agreements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides the necessary equipment to the manufacturer and retains ownership. The manufacturer bears the risk of loss of and damage
to the equipment and consigned materials. Performance under the MSA is initiated by orders issued by the Company and accepted by the
manufacturer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the MSA is 24 months and shall automatically renew for renewal terms of twelve months unless either party provides a written
termination notice to the other party within 180 days prior to the end of the then-current term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Litigation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time in the normal course of our business operations, we may become subject to litigation that may result in liability material
to our financial condition as a whole or may negatively affect our operating results if changes to our business operations are required.
The cost to defend such litigation may be significant and may require a significant diversion of our resources, and there is no guarantee
that we will be able to successfully defend against any such litigation regardless of particular merits. There also may be adverse publicity
associated with litigation that could negatively affect customer perception of our business, regardless of whether the allegations are
valid or whether we are ultimately found liable. Insurance may not be available on favorable terms, at all, or in sufficient amounts
to cover any liabilities with respect to these or other matters. A judgment or other liability in excess of our insurance coverage for
any claims could adversely affect our business, financial condition and the results of our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On February 6, 2019, plaintiff Ritu Bhambhani,
M.D., initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United States District Court for the District of
Maryland. Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the Third Amended Complaint (&ldquo;Complaint&rdquo;)
containing the most recent set of allegations. The Complaint asserted claims under the RICO Act, as well as of fraudulent misrepresentation,
intentional misrepresentation by concealment, and civil conspiracy and sought compensatory damages in excess of $5 million, pre-judgment
interest, punitive damages, attorney&rsquo;s fees, court costs and designation of the case as a class action. The Complaint states that
the Company, distributors of the Company&rsquo;s product, and medical billing and coding consultants allegedly made misrepresentations
to the plaintiffs that the Company&rsquo;s NeuroStim device and related procedures could be billed to, and reimbursed by, Medicare and
other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim to have suffered damages when Medicare administrative
contractors declined to pay plaintiffs for their use of the device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On February 11, 2022, the Company filed a motion
for summary judgment based upon the plaintiffs not being proper parties to assert claims against the Company. On June 14, 2022,
the Court granted the Company&rsquo;s motion for summary judgment and dismissed the Complaint.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On July 14, 2022, plaintiffs Ritu Bhambhani
and Sudhir Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. The Company filed a motion to dismiss. The Court
suspended briefing on the merits while it considers the Company&rsquo;s motion to dismiss the appeal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On July 14, 2022, plaintiffs Ritu Bhambhani,
LLC; Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare ASC, LLC initiated a lawsuit against Neuraxis,
Inc. and others in the United States District Court for the District of Maryland. Those plaintiffs are business entities owned
or partially owned by the plaintiffs that initiated the litigation described above. The Complaint asserted claims under the RICO
Act, as well as fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and seeks compensatory
damages in excess of $75,000, pre-judgment interest, punitive damages, attorney&rsquo;s fees, and court costs. While it is too early
to predict the ultimate outcome of this matter, we believe we have meritorious defenses and intend to defend this matter vigorously.
The Complaint states that the Company, distributors of the Company&rsquo;s product, and medical billing and coding consultants allegedly
made misrepresentations to the plaintiffs that the Company&rsquo;s NeuroStim device and related procedures could be billed to, and reimbursed
by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim to have suffered damages when Medicare
administrative contractors declined to pay plaintiffs for their use of the device.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company has filed a motion to dismiss
all claims, but no ruling has been issued yet. While it is too early to predict the ultimate outcome of this matter, we believe we
have meritorious defenses and intend to defend this matter vigorously.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.
Income Taxes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company did not recognize a current provision for income taxes for 2021 and 2020 since there were net operating losses reported
in both years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 172; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
income taxes are provided for the temporary differences between the financial reporting basis and the tax basis of the Company&rsquo;s
assets and liabilities. Differences are primarily attributable to net operating loss carryforwards and depreciation on assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not reflect a deferred tax asset in its financial statements but includes that calculation and valuation in its footnotes.
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net deferred tax amounts include the following
components:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><B>2021</B></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Net deferred tax assets - Non-current</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 60%">Depreciation</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left"><B>$</B></TD><TD STYLE="width: 16%; text-align: right"><B>(22,010</B></TD><TD STYLE="width: 1%; text-align: left"><B>)</B></TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 16%; text-align: right">(27,955</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Amortization</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>(5,992</B></TD><TD STYLE="text-align: left"><B>)</B></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(6,539</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Accrual to cash</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>509,743</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">377,185</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>3,667,546</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,690,014</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Expected income tax benefit from NOL carry-forwards</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><B>2,409,546</B></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,817,929</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><B>(6,558,833</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><B>)</B></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(5,850,634</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Deferred tax assets, net of valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><B>$</B></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><B>&mdash;</B></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income taxes
is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 60%; text-align: left">Federal statutory income tax rate</TD><TD STYLE="width: 2%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; font-weight: bold; text-align: right">21.0</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">%</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 16%; text-align: right">21.0</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">State tax rate, net of federal benefit</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">4.0</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Nondeductible expenses</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.5</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Nontaxable income</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(5.9</TD><TD STYLE="text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance on net deferred tax assets</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(25.0</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(20.9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Effective income tax rate</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">&mdash;</TD><TD STYLE="text-align: left">%</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2021, the Company has Federal and state net operating loss (NOL) carryforwards totaling $9,629,835 and $9,650,176,
respectively. These loss carryforwards may be offset against future taxable income. There is no limitation on the number of years
to utilize the Federal NOL. The Federal deduction will be limited to 80% of modified taxable income. The state deduction for NOL allows
up to 100% of taxable income to be offset and can be carried forward no longer than twenty years after the year of the taxable loss.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state tax laws impose limitations on the utilization of net operating losses and credit carryforwards in the event of an ownership
change for tax purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&rsquo;s ability to utilize
these carryforwards may be limited as a result of an ownership change which may have already happened or may happen in the future. Such
an ownership change could result in a limitation in the use of the net operating losses in future years and possibly a reduction of the
net operating losses available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
not used, the state carryforwards will expire as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 40%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: justify">2038</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 26%; text-align: right">888,389</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">2039</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,898,067</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">2040</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,457,495</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">2041</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,406,225</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>16.
Subsequent Events</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated subsequent events through the date of issuance. The following changes occurred subsequent to the Company&rsquo;s year end:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Name
and Entity Change</U> - The Company changed its name from Innovative Health Solutions, Inc. to Neuraxis, Inc. by filing amended and restated
articles of incorporation with the State of Indiana on March 11, 2022. Additionally, the Company filed a Certificate of Conversion to
become a Delaware corporation on June 23, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 173; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Delaware
Shares -</U> The total number of shares of all classes of stock which the Corporation shall have authority to issue is (1)
100,000,000 shares of Common Stock, par value $0.001 per share (&ldquo;Common Stock&rdquo;) and (ii) 1,120,000 shares of Preferred
Stock, par value $0.001 per share (&ldquo;Preferred Stock&rdquo;), 1,000,000 of which is hereby designated as &ldquo;Series A
Preferred Stock&rdquo; and 120,000 of which is hereby designated as &ldquo;Series Seed Preferred Stock&rdquo; with the rights,
preferences, powers, privileges and restrictions, qualifications and limitations set forth in this Article IV of the Delaware
Certificate of Incorporation. All share amounts have been retroactively restated to give effect to these
changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Addition
Borrowing &ndash; The Company borrowed additional funds subsequent to December 31, 2021, and up through the date of this report. From
June 3, 2022 to August 15, 2022, we entered into Securities Purchase Agreements (the &ldquo;SPAs&rdquo;) which provide for advances of
up to $2.4 million in proceeds to us, subject to our satisfaction of certain conditions. Pursuant to the SPAs, from June 3, 2022 to August
15, 2022, we issued the Senior Secured Convertible Promissory Notes (&ldquo;Notes&rdquo;) with an aggregate principal amount of $2,222,223,
which amount included original issue discount (&ldquo;OID&rdquo;) of $222,223, and legal fees for $130,000,&nbsp;resulting in advance
proceeds to us of $1.870 million. In connection with the issuance of the Notes, we also issued five-year warrants exercisable for an
aggregate of 235,406 shares of common stock with an exercise price of the lower of (a) $11.80 and (b) a 12% discount to
the price per share in any subsequent offering by the Company, and we entered into a Pledge and Security Agreement dated June 3, 2022.
Pursuant to a Pledge and Security Agreement, dated as of June 3, 2022, the Company granted a security interest in all of its assets in
favor of the lender, in its capacity as collateral agent for the purchaser&rsquo;s parties under the SPAs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes carry an OID of 10% of the principal amount and have an interest rate of the greater of (a) the prime rate of interest, as published
by the Wall Street Journal, plus 8.5% per annum, or (b) 12%. The Notes will mature in twelve (12) months from the issue dates. Any amount
of principal, interest, other amounts due hereunder or penalties on this Note, which is not paid by maturity date, shall bear interest
at the lesser of the rate of twenty four percent (24%) per annum or the maximum legal amount permitted by law, from the due date thereof
until the same is paid in full, including following the entry of a judgment in favor of Holder. The Notes are convertible into shares
of common stock at the lower of (a) $9.44 per share, or (b) a discount of 30% to the price per share in any subsequent offering,
subject to adjustment in the event of common stock distribution, stock splits, fundamental transactions, dilutive issuances or similar
events affecting our common stock and the conversion price. Interest accrues on the aggregate principal amount (which includes OID) and
is payable monthly, at the Company&rsquo;s election, in cash or in-kind.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the advance of the consideration under the SPAs, the Company is required to issue to the noteholders a number of shares of common stock,
calculated based on the value of 10% of the principal amount of the Notes issued in such advance, at a value per share equal to the conversion
price of the Notes. Accordingly, from June 3, 2022 to August 15, 2022, in connection with the initial advance and issuance of Notes,
we will be issuing 23,543 shares of common stock to the noteholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Notes have certain restrictions on the Company&rsquo;s issuance of securities, including (i) the Company shall not without the noteholder&rsquo;s
written consent (a) pay, declare or set apart for such payment, any dividend or other distribution (whether in cash, property or other
securities) on the common stock of the Company other than dividends on common stock solely in the form of additional common stock, or
(b) directly or indirectly or through any subsidiary make any other payment or distribution in respect of common stock or equivalents,
(ii) unless approved by the noteholders in writing, the Company shall not enter into an agreement or amend an existing agreement to effect
any sale of securities involving, or convert any securities previously issued under, a variable rate transaction, which means a transaction
in which the Company (A) issues or sells any convertible securities either (a) at a conversion, exercise or exchange rate or other price
that is based upon and/or varies with the trading prices of, or quotations for, the common stock, or (b) with a conversion, exercise
or exchange price that is subject to being reset at some future date after the initial issuance of such convertible securities or upon
the occurrence of specified or contingent events directly or indirectly related to the business of the Company, or the market for the
common stock, or (B) enters into any agreement whereby the Company may sell securities at a future determined price (other than standard
and customary &ldquo;preemptive&rdquo; or &ldquo;participation&rdquo; rights), (iii) the noteholders have the right, but not the obligation,
to participate in the purchase of the securities being offered up to an amount equal to thirty percent (30%) of the principal amount
of the Notes (the &ldquo; Participation Right&rdquo;) when the Company or its subsidiary proposes to offer and sell its securities, whether
in the form of debt, equity financing, or any other financing transaction (each a &ldquo;Future Offering&rdquo;); provided that, the
Participation Right shall not exceed the lesser of (i) one-third of the aggregate amount of the Future Offering, and (ii) an amount equal
to the principal amount (allocated to the noteholder&rsquo;s pro-rata to their portion of the principal amount).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to pay to the noteholders any outstanding principal amount of the Notes, all accrued and unpaid interest, and fees and penalties,
if any, from any future financing proceeds (which includes proceeds to us from this offering) and other future receipts, at the noteholder&rsquo;s
discretion, except for the right of the Company to make bona fide payments to vendors with common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the SPAs, so long as no event of default has occurred under the Notes, the closing of additional tranches, in each
case consisting of Notes in the aggregate advance amount of up to $400,000 and an aggregate principal amount (including the ) of up to
$444,444, shall occur (i) upon the Company filing a registration statement with the SEC on Form S-1 and (ii) upon the effectiveness of
the CPT codes issued the Company, but in any event not later than December 3, 2022.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt">Furthermore, on January
10, 2023, the Company&rsquo;s board of directors authorized a 1-for-2 reverse stock split. All per share information has been adjusted
for this reverse stock split. The reverse split became effective on January 12, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>17.
Restatement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements have been restated for certain disclosures that have been expanded or have added clarifications. The restatements
did not impact the balance sheet, statement of operations, equity or statement of cash flows. The following disclosures were restated:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    2 &ndash; a table showing the calculation of basic and diluted net loss per share and the effect of preferred stock dividends has
    been included.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    8 - The table has been corrected to reflect the actual weighted average exercise price and distinguish between warrants for the purchase
    of common stock and preferred stock.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    9 - The aggregate purchase price of the Series A Preferred Stock and Series Seed Preferred Stock from cash and converted debt and
    common stock has been disclosed.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note
    14 &ndash; Additional disclosure and clarification of the status of litigation was updated.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: justify; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 174; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1,875,000
</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="forms-1a_001.jpg" ALT="" STYLE="height: 120px; width: 320px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>NEURAXIS,
INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Sole
Book Running Manager</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ALEXANDER
CAPITAL L.P.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[&#9679;]<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">,
2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Through
and including [&#9679;], 2023 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities,
whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&rsquo;s obligation
to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 175 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
13. Other Expenses of Issuance and Distribution.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is an estimate of the expenses (all of which are to be paid by the Company) that we may incur in connection with the securities
being registered hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Offering
    Expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 82%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC registration
    fee</FONT></TD><TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="width: 14%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,273</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><P STYLE="margin: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nasdaq
                                 listing fee</FONT></P>


</TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">50,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FINRA filing fee</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,274</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees and expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">400,000</FONT></P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting fees and expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">250,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miscellaneous</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0">93,453</P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD><TD STYLE="text-align: right"><P STYLE="margin: 0">800,000</P></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
14. Indemnification of Directors and Officers.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(a) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party to or is threatened to be
made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative
(other than an action by or in the right of the corporation), because he or she is or was a director, officer, employee or agent of the
corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against expenses (including attorneys&rsquo; fees), judgments, fines and amounts
paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding, if he or she acted
in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, with
respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(b) of the DGCL provides, in general, that a corporation may indemnify any person who was or is a party or is threatened to be made
a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor
because the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses
(including attorneys&rsquo; fees) actually and reasonably incurred by the person in connection with the defense or settlement of such
action or suit if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests
of the corporation, except that no indemnification shall be made with respect to any claim, issue or matter as to which he or she shall
have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court
determines that, despite the adjudication of liability but in view of all of the circumstances of the case, he or she is fairly and reasonably
entitled to indemnity for such expenses that the Court of Chancery or other adjudicating court shall deem proper.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
145(g) of the DGCL provides, in general, that a corporation may purchase and maintain insurance on behalf of any person who is or was
a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer,
employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against
such person and incurred by such person in any such capacity, or arising out of his or her status as such, whether or not the corporation
would have the power to indemnify the person against such liability under Section 145 of the DGCL.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 176; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
our bylaws eliminates our directors&rsquo; liability to the fullest extent permitted under the DGCL. The DGCL provides that directors
of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors, except for liability:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    any transaction from which the director derives an improper personal benefit;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    any unlawful payment of dividends or redemption of shares; or</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for
    any breach of a director&rsquo;s duty of loyalty to the corporation or its stockholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability
of the Company&rsquo;s directors will be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are also expressly authorized to carry directors&rsquo; and officers&rsquo; insurance to protect our directors, officers, employees and
agents against liabilities for actions taken in their capacities as directors and officers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
15. Recent Sales of Unregistered Securities.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following information relates to all securities issued or sold by us within the past three years and not registered under the Securities
Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
2019, the Company granted stock options to purchase 1,319,394 shares of common stock in the aggregate under the Innovative Health
Solutions, Inc. 2017 Stock Compensation Plan adopted October 12, 2017 (the &ldquo;Plan&rdquo;) with exercise prices of $6.94
per share and a term of ten years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
September 2019 to November 2019, we entered into Series A Preferred Stock Purchase Agreements with 16 investors. Pursuant to the Series
A Preferred Stock Purchase Agreements, we issued a total of 189,092 shares of Series A Preferred Stock, at a price of $18.87
per share, all of which will be converted into shares of common stock upon the closing of this offering. Pursuant to the Series A
Preferred Stock Purchase Agreements, we issued a total of 115,477 shares of Series Seed Preferred Stock in exchange of the share
of common stock held by the investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2019, in connection with the conversion of certain secured convertible promissory note, in the amount of $347,379.45, that
the Company issued to Brian Hannasch on January 31, 2019, we issued 20,056 shares of Series A Preferred Stock to Brian Hannasch,
at a conversion price of $17.32 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 6, 2019, we issued warrants to purchase 40,000 shares of common stock to Brian P. Hannasch, in connection with certain
Series A Preferred Stock Purchase Agreement. Pursuant to the terms of the warrants, the warrant exercise price is equal to $0.02
per share. If unexercised, these warrants will expire on the 10<SUP>th</SUP> anniversary of their issuance dates. The warrants will neither
expire nor be automatically exercised upon the closing of this offering. The warrants provide that the holder thereof may elect to exercise
the warrant on a net &ldquo;cashless&rdquo; basis at any time prior to the expiration thereof. Assuming the closing of this offering
occurs, the fair market value of one share of our common stock in connection with any cashless exercise shall be the based on the average
of the daily closing prices per share for the 30 consecutive trading day period ending on the second trading day prior to such date.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 177; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">From April 2020 to June
2021, we entered into five Series A Preferred Stock Purchase Agreements with investors. Pursuant to the Series A Preferred Stock Purchase
Agreements, we issued a total of 315,545 shares of Series A Preferred Stock, at a price of $18.87 per share, all of which
will be converted into shares of common stock upon the closing of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On April 9, 2020, we entered
into a Series A Preferred Stock Purchase Agreements with Masimo. Pursuant to the Series A Preferred Stock Purchase Agreement, we issued
a total of 265,774 shares of Series A Preferred Stock, at a price of $18.87 per share, all of which will be converted into
shares of common stock upon the closing of this offering.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
the same day, we issued pre-funded warrants to purchase 144,890 shares of Series A Preferred Stock to Masimo, in connection with
its Series A Preferred Stock Purchase Agreement. Pursuant to the terms of the warrants, the warrant exercise price is equal to $0.0001
per share, subject to adjustments, and these warrants will not expire. The aggregate purchase price of this Warrant, in the amount of
$2,734,340.40, equating to $18.87 per warrant share, was pre-funded to the Company and, consequently, no additional consideration
shall be required to be paid by Masimo to any Person to effect any exercise of this Warrant, except for the payment of the exercise price.
The warrants will neither expire nor be automatically exercised upon the closing of this offering. The warrants provide that Masimo thereof
may elect to exercise the warrant on a net &ldquo;cashless&rdquo; basis at any time prior to the expiration thereof. Assuming the closing
of this offering occurs, the fair market value of one share of our Series A Preferred Stock in connection with any cashless exercise
shall be the closing price or last sale price of a share of common stock reported for the business day immediately before the date on
which Masimo delivers this warrant together with its notice of exercise to the Company, multiplied by the number of shares of common
stock into which a share of Series A Preferred Stock is then convertible, if the common stock is then traded on a trading market, or
the fair market value of Series A Preferred Stock, as mutually determined in writing by the Company and Masimo. Masimo may not exercise
the warrant in excess of that number of shares which would cause the aggregate number of shares of common stock beneficially owned by
Masimo to exceed 19.99% of the total number of issued and outstanding shares of common stock following such exercise, or the combined
voting power of the securities beneficially owned by Masimo to exceed 19.99% of the combined voting power of all of the securities of
the Company then outstanding following such exercise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">On
October 19, 2020, the Company entered into a Series A Preferred Stock Purchase Agreement with Dresner Investment Services, Inc. d/b/a
Dresner Partners (&ldquo;Dresner&rdquo;). Pursuant to the Series A Preferred Stock Purchase Agreement, the Company issued 18,546
shares of Series A Preferred Stock to Dresner and six (6) of its designees in consideration of the fee owed to Dresner in connection
with an engagement letter, dated April 16, 2020, at a price of $18.87 per share. We plan to convert all of the Series A Preferred
Stock into shares of common stock upon the closing of this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On September 9, 2021,
the Company cancelled and reissued all previously issued stock options in connection with a 4-to-1 stock split that occurred on the same
date. No new optionees were awarded options on this date, but all prior stock option holders received four times the number of options
they had before the split, and the exercise price was divided by four due to the split.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
June 3, 2022 to November 30, 2022, the Company entered into Securities Purchase Agreements (the &ldquo;SPAs&rdquo;) with Leonite Fund
I, LP, Emmis Capital II, LLC, District 2 Capital Fund, LP, and Exchange Listing, LLC, which provide for advances of up to $2.4 million
in proceeds to us, subject to our satisfaction of certain conditions. Pursuant to the SPAs, from June 3, 2022 to November 30, 2022, we
(i) issued the Senior Secured Convertible Promissory Notes (&ldquo;Notes&rdquo;) with an aggregate principal amount of $2,777,777, which
amount included an OID of $222,223, resulting in advance proceeds to us of $2.370 million. In connection with the issuance of the Notes,
we also issued five-year warrants exercisable for 353,111 shares of common stock with an exercise price of the lower of (a) $11.80 and
(b) a 12.5% discount to the price per share in any subsequent offering by the Company, and we entered into a Pledge and Security Agreement
with Leonite Fund I, LP, dated June 3, 2022. The Notes carry an OID of 10% of the principal amount and have an interest rate of the greater
of (a) the prime rate of interest, as published by the Wall Street Journal, plus 8.5% per annum, or (b) 12%. The Notes will mature in
twelve (12) months from the issue dates. The Notes are convertible into shares of common stock at the lower of (a) $9.44 per share, or
(b) a discount of 30% to the price per share in any subsequent offering, subject to adjustment in the event of common stock distribution,
stock splits, fundamental transactions, dilutive issuances or similar events affecting our common stock and the conversion price. Interest
accrues on the aggregate principal amount (which includes OID) and is payable monthly, at the Company&rsquo;s election, in cash or in-kind.
Upon the advance of consideration under the SPAs, the Company is required to issue to the noteholders a number of shares of common stock,
calculated based on the value of 10% of the principal amount of the Notes issued in such advance, at a value per share equal to the conversion
price of the Notes. Accordingly, from June 3, 2022 to November 30, 2022, in connection with the initial advance and issuance of Notes,
we also issued 35,317 shares of common stock to the noteholders. We plan to use a portion of the proceeds of this offering to repay
the entire amount owed pursuant to these Notes. See &ldquo;<I>Use of Proceeds</I>&rdquo; for additional information. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
December 2022 through January 2023, the Company issued unsecured convertible promissory notes to three existing investors, Todd Maxwell,
Rogan O&rsquo;Donnell and Michael &amp; Michele Robuck, with an aggregate principal amount of $222,222, which amount included an OID
of $22,222, resulting in advance proceeds of $200,000. The notes carry an OID of 10% of the principal amount and have an interest
rate of 12% per annum. The notes will mature at the earlier of (i) twelve (12) months from the issue date or (ii) the date upon which
the Company completes a registered public offering of shares of the Company, which encompasses this offering. The note is convertible
into shares of common stock at the higher of (i) $9.44 per share, or (ii) the price per share of common stock issued pursuant
to the next registered public offering of shares of the Company made prior to the conversion of any portion of the note. Interest accrues
on the aggregate principal amount (which includes OID) and is payable on the maturity date, at the Company&rsquo;s election, in cash
or in-kind.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2023, we filed a certificate of amendment to our certificate of incorporation with the Secretary of State of the State of
Delaware and effectuated a reverse stock split of our common stock at a ratio of 1-for-2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 178; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise stated above, the issuances of these securities were made in reliance upon exemptions provided by Section 4(a)(2) of the Securities
Act, Regulation D promulgated thereunder, or Securities Act Rule 701 for the offer and sale of securities not involving a public offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
underwriter was engaged in connection with the foregoing sales of securities. The Company has reason to believe that all of the foregoing
purchasers were familiar with or had access to information concerning the operations and financial conditions of the Company, and all
of those individuals purchasing securities represented that they were accredited investors, acquiring the shares for investment and without
a view to the distribution thereof. At the time of issuance, all of the foregoing securities were deemed to be restricted securities
for purposes of the Securities Act and the certificates representing such securities bore legends to that effect<B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
16. Exhibits and Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex1-1.htm" STYLE="-sec-extract: exhibit">Form
    of Underwriting Agreement (incorporated by reference to exhibit 1.1 to Registration Statement on Form S-1, filed on January 26,2023) </A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation (incorporated by reference to exhibit 3.1 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex3-2.htm" STYLE="-sec-extract: exhibit">Certificate
    of Amendment to Certificate of Incorporation (incorporated by reference to exhibit 3.2 to Registration Statement on Form S-1,filed
    on January 26, 2023) </A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex3-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws (incorporated by reference to exhibit 3.3 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of warrant issued to Brian P. Hannasch (incorporated by reference to exhibit 4.1 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-Funded Warrant to Purchase Series A Preferred Stock issued to Masimo Corporation, dated April 9, 2020 (incorporated by reference to exhibit 4.2 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to Leonite Fund I, LP, dated June 3, 2022 (incorporated by reference to exhibit 4.3 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to Leonite Fund I, LP, dated July 8, 2022 (incorporated by reference to exhibit 4.4 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to Leonite Fund I, LP, dated October 3, 2022 (incorporated by reference to exhibit 4.5 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to Leonite Fund I, LP, dated November 30, 2022 (incorporated by reference to exhibit 4.6 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to Emmis Capital II, LLC, dated June 10, 2022 (incorporated by reference to exhibit 4.7 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex4-8.htm" STYLE="-sec-extract: exhibit">Common
    Share Purchase Warrant issued to Emmis Capital II, LLC, dated November 30, 2022 (incorporated by reference to exhibit 4.8 to Registration
    Statement on Form S-1, filed on January 26, 2023) </A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.9**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to Exchange Listing, LLC, dated July 12, 2022 (incorporated by reference to exhibit 4.9 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.10**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to Exchange Listing, LLC, dated October 4, 2022 (incorporated by reference to exhibit 4.10 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.11**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to District 2 Capital Fund LP, dated August 15, 2022 (incorporated by reference to exhibit 4.11 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.12**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to District 2 Capital Fund LP, dated October 4, 2022 (incorporated by reference to exhibit 4.12 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.13**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to District 2 Capital Fund LP, dated November 30, 2022 (incorporated by reference to exhibit 4.13 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.14**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to Bigger Capital Fund, LP, dated August 15, 2022 (incorporated by reference to exhibit 4.14 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.15**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Share Purchase Warrant issued to Bigger Capital Fund, LP, dated October 4, 2022 (incorporated by reference to exhibit 4.15 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.16**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement between Innovative Health Solutions, Inc. and Masimo Corporation, dated April 9, 2020 (incorporated by reference to exhibit 4.16 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.17**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Side Letter between NeurAxis, Inc. and Masimo Corporation, dated December 22, 2022 (incorporated by reference to exhibit 4.17 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.18**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Side Letter between NeurAxis, Inc. and Brian P. Hannasch, dated July 7, 2022 (incorporated by reference to exhibit 4.18 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.19**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investor Rights Agreement between Innovative Health Solutions, Inc. and Brian Hannasch, dated September 6, 2019 (incorporated by reference to exhibit 4.19 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.20**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amended and Restated Shareholders&rsquo; Agreement, dated June 13, 2016, and First Amendment to Shareholders&rsquo; Agreement, dated January 30, 2019 (incorporated by reference to exhibit 4.20 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.21**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to Shareholders&rsquo; Agreement, dated January 8, 2023 (incorporated by reference to exhibit 4.21 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.22**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex1-1.htm" STYLE="-sec-extract: exhibit">Form of Underwriter Warrant (included as Exhibit A to Exhibit 1.1)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex5-1.htm" STYLE="-sec-extract: exhibit">Legal
    opinion of Lucosky Brookman LLP (incorporated by reference to exhibit 5.1 to Registration Statement on Form S-1, filed on January
    26, 2023) </A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">License and Collaboration Agreement, dated April 9, 2020, by and between Innovative Health Solutions, Inc. and Masimo Corporation (incorporated by reference to exhibit 10.1 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exclusive License Agreement, by and between Innovative Health Solutions, Inc. and TKBMN, LLC (incorporated by reference to exhibit 10.2 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex10-3.htm" STYLE="-sec-extract: exhibit">Securities
    Purchase Agreement, dated June 3, 2022, by and between the Neuraxis, Inc. and Leonite Fund I, L.P., Emmis Capital II, LLC, Exchange
    Listing, LLC, District 2 Capital Fund LP, and Bigger Capital Fund, LP (incorporated by reference to exhibit 10.3 to Registration
    Statement on Form S-1, filed on January 26, 2023) </A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Convertible Note related to Exhibits 10.3 (incorporated by reference to exhibit 10.4 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated December 19, 2022, between the Neuraxis, Inc. and Michele and Michael Robuck (incorporated by reference to exhibit 10.5 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsecured Convertible Promissory Note issued to Michele and Michael Robuck, dated December 19, 2022 (incorporated by reference to exhibit 10.6 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated December 19, 2022, between the Neuraxis, Inc. and Rogan O&rsquo;Donnell (incorporated by reference to exhibit 10.7 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsecured Convertible Promissory Note issued to Rogan O&rsquo;Donnell, dated December 19, 2022 (incorporated by reference to exhibit 10.8 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated December 19, 2022, between the Neuraxis, Inc. and Todd Maxwell (incorporated by reference to exhibit 10.9 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unsecured Convertible Promissory Note issued to Todd Maxwell, dated December 19, 2022 (incorporated by reference to exhibit 10.10 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 179; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 88%; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pledge and Security Agreement, dated June 3, 2022, between Neuraxis, Inc. and Leonite Fund I, LP (incorporated by reference to exhibit 10.11 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12&dagger;**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Brian Carrico, dated as of August 9, 2022 (incorporated by reference to exhibit 10.12 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13&dagger;**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Adrian Miranda, dated as of August 17, 2022 (incorporated by reference to exhibit 10.13 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14&dagger;**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Thomas Carrico, dated as of August 9, 2022 (incorporated by reference to exhibit 10.14 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15&dagger;**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Dan Clarence, dated as of August 9, 2022 (incorporated by reference to exhibit 10.15 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16&dagger;**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Christopher Robin Brown, dated as of August 9, 2022 (incorporated by reference to exhibit 10.16 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17&dagger;**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Gary Peterson, dated as of August 9, 2022 (incorporated by reference to exhibit 10.17 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-18.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory note of Gary Peterson, dated as of January 1, 2016 (incorporated by reference to exhibit 10.18 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-19.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory note of Christopher Robin Brown, dated as of January 1, 2016 (incorporated by reference to exhibit 10.19 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20&dagger;**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-20.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovative Health Solutions, Inc. 2017 Stock Compensation Plan, as amended (incorporated by reference to exhibit 10.20 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21&dagger;**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-21.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (incorporated by reference to exhibit 10.21 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-22.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing Services Agreement between Neuraxis, Inc. and GMI Corporation, dated as of August 21, 2020 (incorporated by reference to exhibit 10.22 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-23.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quality Agreement between Neuraxis, Inc. and GMI Corporation, dated as of August 24, 2020 (incorporated by reference to exhibit 10.23 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-24.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisory Agreement, date March 3, 2022, between Exchange Listing, LLC and Neuraxis, Inc. (incorporated by reference to exhibit 10.24 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-25.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advisory Agreement, date March 3, 2022, between Exchange Listing, LLC and Neuraxis, Inc., as amended December 22, 2022 (incorporated by reference to exhibit 10.25 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"> 10.26&dagger;** </P>
</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex10-26.htm" STYLE="-sec-extract: exhibit">First
                                            Amendment to Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (incorporated by
                                            reference to exhibit 10.26 to Registration Statement on Form S-1, filed on January 26, 2023) </A></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex14-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Code of Ethics and Business Conduct (incorporated by reference to exhibit 14.1 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex21-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries of Neuraxis, Inc. (incorporated by reference to exhibit 21.1 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex23-1.htm">Consent of Rosenberg Rich Baker Berman, P.A.</A> </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2**</FONT> </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex5-1.htm" STYLE="-sec-extract: exhibit">Consent of Lucosky Brookman LLP (included in Exhibit 5.1)</A> </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.2**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#vj_001">Power of Attorney (included on the signature page hereto)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Timothy Henrichs (incorporated by reference to exhibit 99.1 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Bradley Mitch Watkins (incorporated by reference to exhibit 99.2 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.3**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex99-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Beth Keyser (incorporated by reference to exhibit 99.3 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Instance Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Schema Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Calculation Linkbase Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Definition Linkbase Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Label Linkbase Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Presentation Linkbase Document</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107**</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex107.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table (incorporated by reference to exhibit 107 to Registration Statement on Form S-1, filed on January 10, 2023)</FONT></A></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**
Previously filed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger; Executive compensation plan or arrangement.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 180; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
17. Undertakings.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
    post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
    forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
    the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
    of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b)
    if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price
    set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement; and</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to
    include any material information with respect to the plan of distribution not previously disclosed in the registration statement
    or any material change to such information in the registration statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment will be deemed
    to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time will
    be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
    remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
    termination of the offering.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser, each prospectus filed
    pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on
    Rule 430B or other than prospectuses filed in reliance on Rule 430A, will be deemed to be part of and included in the registration
    statement as of the date it is first used after effectiveness. <U>Provided</U>, <U>however</U>, that no statement made in a registration
    statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
    into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract
    of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that
    was part of the registration statement or made in any such document immediately prior to such date of first use.</FONT></TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">That,
    for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution
    of the securities:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will
be considered to offer or sell such securities to such purchaser:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
    424;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
    the undersigned registrant;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
    or its securities provided by or on behalf of the undersigned registrant; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    other communication that is an offer in the offering made by the undersigned registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.
In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred
or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is
asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part
of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule
424(b) (1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was
declared effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at
that time shall be deemed to be the initial bona fide offering thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 181; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-1 and has duly caused this registration statement or amendment thereto to be signed on its behalf
by the undersigned, thereunto duly authorized on February 6, 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neuraxis,
    Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian Carrico</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="poa_001"></A>POWER
OF ATTORNEY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities
held on the dates indicated.</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 28%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian Carrico</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    6,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal
    executive officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    John Seale</I></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I> </I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financing Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    6,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Seale</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(principal
    financial officer and principal accounting officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    6,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
    Clarence</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    6,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adrian
    Miranda</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    6,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carrico</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    6,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Robin Brown</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    6,</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> 2023</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gary
    Peterson</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A NAME="vj_001"></A>*
POWER OF ATTORNEY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
Carrico, by signing his name hereto, does sign this document on behalf of each of the persons indicated above for whom he is attorney-in-fact
pursuant to a power of attorney duly executed by such person and filed with the Securities and Exchange Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian Carrico</I> </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico<BR>
    Chief Executive Officer and Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 182; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the inclusion in this Registration Statement of Neuraxis, Inc. on Form S-1/A of our report dated September, 27, 2022, except
for the effects of the restatement discussed in note 17 to the financial statements, as to which the date is November 9, 2022 and the
effects of the reverse stock split discussed in Note 1, 8, and 16, as to which the date is January 25, 2023, with respect to our audits
of the financial statements of Neuraxis, Inc as of December 31, 2021 and 2020 and for each of the two years in the period ended December
31, 2021, which report appears in the Prospectus, which is part of this Registration Statement. Our report includes an explanatory paragraph
as to Neuraxis, Inc.&rsquo;s ability to continue as a going concern.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also consent to the reference to our Firm under the heading &ldquo;Experts&rdquo; in such Prospectus.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Rosenberg Rich Baker Berman, P.A.</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Somerset,
New Jersey</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
6, 2023</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"> &nbsp; </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>forms-1a_001.jpg
<TEXT>
begin 644 forms-1a_001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #@ E8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BC-% !1110 4449H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML=OI=W_-H@OZUR6M?\%Q_P!@G2"P@\8:M?8_Y\K&'GG_ &YEK\M#_P $<_\
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M:PG=G='X=MR3[?-(17Y\;E]:-R^M;?ZG9'_*_P#P)F/_ !$'B3^:/_@*/O\
M/_!?G]IS'&LI_P"$W9__ !5.7_@OQ^TP5RVMKGT'AFS_ /BJ_/[<OK2@YZ4?
MZFY'_*__  )C_P"(A<2?S1_\!1^@B_\ !?+]I)N&\2QK]?"]K_\ %5I6/_!?
MSX_1F,W.IZ3(% W"?PR/GX[[)!^F*_.FBLWP7DK_ )E\_P#@&D?$7B*._(_^
MW?\ )GZ6VG_!P-\9ACSG\(_]MO#=W_[+-6OIW_!P)\5BZBXL/A_*O\6[2+^-
MC^)N,#\J_+NCK6,N!\I>TYKYK_Y$Z(>)6>1^*G3?RDO_ &X_770O^"_-]*N=
M4^'GA&X/_3OXA>W)Z]G#GT_R>.Q\-_\ !=?P]JCJFH? 6-U_BDTWQ<DQQW^4
MVX_G7XL;1UQ0% Z5RU. \,_@K->JO^J.ZEXGXN/\3#1?I)K\TS]W]#_X+3_L
M\W95/$'PW\86.[^*""UG5?K^^4_D#]*[GPU_P57_ &+M?*K>_$*^TEFZ)J6@
MW/\ .))%'XG%?SYV&OZ]I3;M+UN\MS_TPNG3^1K8L/BY\1],C,=OXKN''_3P
MJS'\W!->?6X#Q4?X5:+]4U^7,>IA_$[+Y?QJ$H^C4OSY3^COPG^U[^R[XVC6
M3P]\?O"<C/\ =AN-:B@E/_;.5E;]*]"M;RTOK=;RRN8YH9%W1RQ.&5AZ@CJ*
M_F?TW]H[QK:^6FHZ;872+_K&\MDD?\0VT?\ ?-=W\//VU=:\$WXU/P_J?B+P
MW=AL)<Z#JK(P![ED:-OP ->/B.$<ZH:JGS+R:?X:/\#WL+QUPWBM'5Y'_>37
MXJZ_$_HIR**_&?X.?\%A?VB?#,MK:Z=\=K77K>WD_P"0;XKLTE:X)'W6E<)<
M,/\ =DKZD^$__!;+2YHX;+XW?!R:%O))FU3PK="19'SP!;3E2BXZGSF.1TYX
M\&MA<3AI<M6#B^S33_$^GP^,PN,AST*D9KO%IK\+GWI17F_P7_:Z_9U^/X6#
MX8_%'3[R];/_ !*;AC;W@P!G$,H5V R/F4%?>O2,USG2%%%% !1110 4444
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M'6F^-OB^/@#HK0W7]GZ6FJ^-FY86MK(S):6C888>Y=)6((93#;2JRCSHVKT
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M^)?B1I/[/6BW?^B^&X5U#6D&?FOIH_W2$$?P0,&!4D'[20>5K[]^+GQ,\/\
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MHP]05)!HE)I@D?B;\6OV<_CI\"947XL_"_5=%CDD"1WD\.^V=R"0BSH6C9L
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M51J1E:3V:?3R/H/#G 8[!XZNZ]*4$XJW-%J^OFD?F1_P<G_\EF^&7_8L7O\
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MU;XW_&+X?:5KD6L7?V/P[:ZUIL=S$D$+$2SJK[ER\N8\E0R^0V#AS7@FC?\
M!+O]M?4=8M=/U'X1"PM[BYCCGOIM=L'2V1F :1E2<L0H^8A020. 3Q7ZL?#K
MP)H'PO\  >C_  Z\+6YCT[1--ALK-6QN*1H%#,0!ECC)/<DGO52EV%$Y?_AD
MG]EC_HV[P)_X2=G_ /&Z/^&2?V6/^C;O G_A)V?_ ,;KT*BHYI%'GO\ PR3^
MRQ_T;=X$_P#"3L__ (W1_P ,D_LL?]&W>!/_  D[/_XW7H5%'-(#\G?^"G_[
M->E_ #X_+K7@S0H=/\->*K3[7IMK9PB.&UG3"7$"*#P =DF  H$P4#"U\Y6%
M_?:5?0:KIEU)!<6TRRV\T3;6C=3E6![$$9!K]??^"@W[-%_^TW^SY=^'/"NF
MI<>)-)NDO_#Z-(L?FRK\KP[F( #QLP&2!N"$D 5^>X_X)C_MQ_\ 1#)/_"@T
M[_Y(K6,M-26C]-OV5/CA9_M$_ 7P[\5(6C%U>V8CU6&,8$5Y'\DRX[#>"RY_
MA93WK:^-7QA\&_ ?X9ZK\4_'=[Y6GZ7;ES&N/,N)#PD,8/5W;"CMDY) !(^9
M?^"7GP6_:K_9SO?$7P_^,GPTDTSPWJD:W]C>-J]G,L%ZNV-DV0RLW[R/;\V,
M#R /XJ^9?^"E'[8Q_:1^)O\ P@O@G4"W@WPO=/'8O%,&34KH95[OY>"F,K'U
M^3+9'F%1GRWD.^AXQ\=_C7XS_:$^*>J_%;QS<;KS4ILQ6\9_=VD"\1P1CLJ+
M@>I.6.68D]%^R'^S)XC_ &J?C%9?#_31-;Z7#BY\1:I&!_H=H#\Q!((\QON(
M,'+')&U6(\ZT#0=9\5:[9^&/#FFS7FH:C=1VUC9VZ[GFF=@J(H[DD@5^Q'[%
M7[*NA_LH_!VW\)*(;C7M0*W7B34HU_U]QC_5J3SY<8.U>F?F; +D5I)\J)6I
MQO[>'[)VJ?$3]DFW^&/P.22Q3P>8KK3?#MJ28]0A@B9?(/5FD"G<I).YQ@Y+
M!E_)TJRDJZX8'!'I7[Z'I7Y^?M]_\$T/B/XJ^+7_  L[]F?P6NI6_B!I)M=T
MJ.^M[<6=WD;I4\Z1 4ER6*C)5PYX#*!,9=&.2,C_ ()/?MDGP;K\?[,GQ(U?
M&DZI<%O"=U<2<6EV[9:UR>B2DY4<8DR,$R<?HU7Y#P_\$ROVZ[>9;BW^"4D<
MD;!D=/$FFAE8="#]IX-?I=^RCJ_Q_P!2^#MA8_M*^"6T?Q3IO^B74WVZWG&H
MQJHV77[B1PK,.'4D9=68 *P 4K;H$?EO_P % ?\ D\KX@?\ 8;_]I)71_P#!
M++_D][PE_P!>^I?^D$]=_P#MA?L"?M;_ !0_:9\8>/\ P+\(WOM(U35/.L;P
M:U8Q^:GEH,[9)U8<@]0#6U^P'^PU^U/\%_VJ/#OQ%^)GPK;3-&L8;Y;J\.L6
M4VPR6DT:?+%,S'+,HX!QGGBKNN4.I]Y?%_XH^&_@K\,M:^*GBXR?V?HEBUQ,
MD*[GD/18U']YF*J,X&6Y(&37XT_%;]HCXF_%?XV7WQYOO$=WI^N7%YYUA-I]
MT\;:=&O$44+*0RA%PH(P3R3DDD_MI?V%CJMC-IFJ645Q;7$;1W%O/&'25&&"
MK*>""."#P17PC^U?_P $@FU._NO'/[+6H6]N9"TLWA'4IMB;L$XMICD+DX C
MDPHR3Y@ "B(N/4;.(^"7_!93XP^$+6/1OC3X)L?%L*87^U+.06-Y@N26<*IA
MDPI"@*D?W>6))->XVO\ P6>_9?EMWEN?!'CB&15RL?\ 9MHV_P!@1=?SQ7Y_
M_$3]F/\ :&^$[W7_  L'X,>(M-@LY-EQJ#Z7)): XSQ<(&B8>ZL17"[6Z;:O
MEBQ79]-_MU?\%%]8_:LTJ'X;^"_"\VA^$[>\6XE6\F5KK4)%!V&3;\L:+DGR
MP6R<,6. !\S1QR32+%#&S,S855&23Z"NU^&_[-?[0'Q>>V_X5O\ ![Q!JD%W
M-Y<.H0Z:ZV@;&?FN' B3ZLX'YU]V?L/?\$M5^$?B"R^+W[0-U9ZAKEFR3Z3H
M%HWF6]A+U$LKXQ+*IZ!?D4C<&<[2I>,4+<^AOV._A7??!3]F7P;\-M6@:&^L
M=)$NH0.<F*YG=IYD_P" R2LOX5Z71THK$L*",C%%%  !@8%%%% !1110 444
M4 %%%% !1110 5^??_!P5\:M2\+?LYZ9\'=!U'RWUZX:\U98Y2&-M$\<21L.
MA1WE9N<_- #VK]!*_*+_ (."XK_4/B=9V%NC,L?P_M)@OIMU&Z9S_P!\IG\*
M]#*>7^U*'-MSQO\ ^!(\O//:?V+B>3?V<[6WORNQ^7 &.@HH!STHK]Z/Y?/1
M?V4OVF/'W[(?QVT/X[_#J9FNM)N,7NGM,4BU*T?B:UDP#\KKT)!VL%<#<BD?
MT0_LS?M*?"G]K'X/:7\:?@_KGVO2]2CQ-;RX6XL+@ >9:SH"=DJ$X(R000RE
MD96/\S)&>#7L'[&7[<'QS_8;^(__  G?P?UE7L[S8FO>'+YF:RU6%2<+(H/R
MNN3LE7#IDC)5G5OE^).'HYQ352E958K3LUV?Z/\ ST^TX1XKED-9T:UW1D];
M;Q?\R_5>C6UG_2)17SC^Q!_P4^_9I_;?T>#3_"?B!=!\8+;J^H>"M8F5;I&P
M=QMVX6[C&"=T?S!=I=(RP6OH[(/2OR3$87$8.LZ5:+C)='_7XG[M@\9A<?AU
M6P\U*+V:_K1]T]4!&>M%%%8'4  '2BBB@ HHHH ,#KBBBB@ P,YQ1110 4$9
MZBBB@!-B^E&Q?2EHH **** "BBB@ HP,8Q110   =!1110 8[8HZ<"BB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKC/C_P#$KQ)\*/A7JGB_P9X!U7Q-
MK4<7E:1HNDZ?+<O/<-PA<1@E8E/S.QQ\JD#+%00#YB_X*N?ME#X>^%9?V;/A
M[J0_MS7;3_BH[F%_FL;%Q_J>.DDPZYZ1D\?O%(_-OC->K>-?V=_VS?'WBO4/
M&WC+X#>/K_5-5NGN;Z\D\*W1:21CDGB/ '8*,      "O2/V+/\ @GE\4OBM
M\8[=OC=\,M>\/^%=%*W>J+KFES6;:CAODM8O,52P8CYV7[J!N0S)G96BB=SW
M+_@DQ^QL?#>E1_M3?$33674-0A9/"-G-'CR+9QM>\YYW2*2J=/W98_,)%V_<
ME1VMK;6-M'9V5ND,,,:I%%&H544# 4 <  =JDK)NY04444@"BBB@ HHHH **
M** # ]*,#THHH ,#THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MO@G_ (+9_!6XU?2?"_QMM---Q:P1RZ)KFX;E6-R9("1_=),ZDGC+(.IY^]JP
MOB9\.?"?Q<\!:K\-_'6EK>:3K%FUO>0L!G!Y#J2#M=6"NK=595(Y JHR<970
MI14HV9_,G\0/!-[X$\12Z3.K-;LQ>SG;_EI'V_$=#[^Q%8E?=_[<G["OBSX#
M^)I? _C^PDO-%NI6?P[XFMX=J7"]N>=DH'#QGZC<I5C\8^.?AEXE\!W#&^@-
MQ9EOW=]"IV'T#?W#['\":_8.'^(J.948TJSM57_DWFO/NONT/P/BKA'%9/7E
M7P\7*@];K['D_+L]K;Z[\]10#D45]2?$$MA?7NE7\.J:7>36UU;S++;W%O(4
MDBD4Y5E8<J0>01R#7V_^R9_P7B_:L^ \%MX5^,EM#\2M A4(KZM<F#5(E P
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWY-_S^0JW;?\&Y_P0213>?&6ZD7/S"/0Y%)'L3=MC\C7Z-T5/]L9M_T$3_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>forms-1a_002.jpg
<TEXT>
begin 644 forms-1a_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,J!: # 2(  A$! Q$!_\0
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M9I/-7^X1^%1B:7/*G]3_ %IPN"/O9_%0*+H.1]AX=<<EC_GZTGF+G ./JO\
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MXX_6HFD=3RQ'U7%1!G4X(_\ 'L_UJ0H_!"_B5_\ K4N9LKE2'+-*?XL_1O\
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M>^ZIC)M'?\\5$L1QE6S]!4;^83A@WX\4[R0639-Q)R8@?^V@IAV'A4(/U_\
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MX T!P/NM^:B@%6Z.X^O-!1O[_P"8J2[(-Q/5%-*-AZQ$?1JC "G(=L_[(_\
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M<C_EG^6?Z4U78$\1G_@-/06J(O+7NC TH![%L>ZU. #T4(?;%#*4ZO\ I_\
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MP;;P#GZ9_I2/&,<G/XTSGLZGVVDT;"W'ED'WY1] 33?,B4\*I]R#_A33&V>
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M1TP?H<TY8AV!/T.*]V_X4KX;_P"?S5/^_L?_ ,11_P *6\.G_E_U7_OY%_\
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MLR/S_P :58Q_>3_OLU[N/@IX<'_+]JW_ ']C'_M.G?\ "EO#G>]U4_66,_\
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ML?\ \;I_6:8O83N> B0#G@?0C^M2QSY!QO\ Q/\ ]:O=S\$/#/:]U8?2:/\
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MZU3[L7U>?9'@PE(/* _5J<9CV4+_ +H/]:]X_P"%*>&N]YJC?66/_P"(I?\
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M6VNY#J12O<[ZBBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKRK'*AB5'BW$88%>"!G/?([U7^!2*?$.J.1\PM  ?8N/\!5?XK@#XH69'>*
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MZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYE1&6VCCC(2)CT;!8Y'L,?6NM\%>"#X1TF^TV;41?VUT^_;Y'E[<KM;^(YR
M/3I77443Q%2:M)Z!&E"+ND>01? XV^K)<6^OE;=) Z!K?+C!R 3N /3K^E=#
MK'PT_M;QY%XG_M?RO+FAE^S?9MV?+V\;MPZ[?3C-=]13>)JMW;\@5&"TL<SX
MP\#Z9XRM(TNR\-S#GR;F/&Y<]01W'M_*N @^!+^>HN?$&ZW4_=CML,1WZM@?
MK7LM%*&(J07+%Z!*E"3NT96F>'['1M!_L?3H_)MPC*"?F)+=6)[FN:\"?#G_
M (0J_N[K^U?MGVB(1[?L_E[<'.<[CFNZHJ%4G9J^^Y7)&Z?8X'Q9\-/^$H\4
M0:U_:_V;RDC7R?LV_.TD_>W#KGTJYXV^'6G>,FCN6G>SOXUV+.B[@R]@R\9Q
MSW'6NRHJE6J*UGL)TXN^FYX_%\$[N=HHM1\3RRVD1^6-(B3CVW,0OY&O4](T
MJTT/2K?3;&/R[:!=J G)]23[DDD_6KM%*I6G4TDPA3C#9!11161H%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 8O\ :=SZK^5']IW/JOY53HH N?VG<^J_E1_:=SZK^54Z* +G
M]IW/JOY4?VG<^J_E5.B@"Y_:=SZK^5']IW/JOY53HH N?VG<^J_E1_:=SZK^
M54Z* +G]IW/JOY4?VG<^J_E5.B@"Y_:=SZK^5']IW/JOY53HH N?VG<^J_E1
M_:=SZK^54Z* +G]IW/JOY4?VG<^J_E5.B@"Y_:=SZK^5']IW/JOY53HH N?V
MG<^J_E1_:=SZK^54Z* +G]IW/JOY4?VG<^J_E5.B@"Y_:=SZK^5']IW/JOY5
M3HH N?VG<^J_E1_:=SZK^54Z* +G]IW/JOY4?VG<^J_E5.B@"Y_:=SZK^5']
MIW/JOY53HH N?VG<^J_E1_:=SZK^54Z* +G]IW/JOY4?VG<^J_E5.B@"Y_:=
MSZK^5']IW/JOY53HH N?VG<^J_E1_:=SZK^54Z* +G]IW/JOY4?VG<^J_E5.
MB@"Y_:=SZK^5']IW/JOY53HH N?VG<^J_E1_:=SZK^54Z* +G]IW/JOY4?VG
M<^J_E5.B@"Y_:=SZK^5']IW/JOY53HH N?VG<^J_E1_:=SZK^54Z* +G]IW/
MJOY4?VG<^J_E5.B@"Y_:=SZK^5']IW/JOY53HH N?VG<^J_E1_:=SZK^54Z*
M +G]IW/JOY4?VG<^J_E5.B@"Y_:=SZK^5']IW/JOY53HH N?VG<^J_E1_:=S
MZK^54Z* +G]IW/JOY4?VG<^J_E6)J6M:;HXC.H7D5L)<[/,.-V,9_F*J0>+O
M#US*L46L6A=CA09 ,G\:I0DU=(ER2=KG3?VG<^J_E1_:=SZK^54Z*DHN?VG<
M^J_E1_:=SZK^54Z* +G]IW/JOY4?VG<^J_E69=WEM86[7%W/'!"OWGD8*!^)
MK.L?%>@ZC<BVM-4MY)B<*F[!8^V>OX52C)JZ0G))V;.D_M.Y]5_*C^T[GU7\
MJQM0UC3]*:%;Z[CMS,2(PYQN(QG'YBA]8T^/5$TQ[N-;UQE82?F(P3_(&CE?
M8+HV?[3N?5?RH_M.Y]5_*J=%2,N?VG<^J_E1_:=SZK^58VG:QI^KK(VGW<=P
M(R Y0YVDU=IM-.S$G?8N?VG<^J_E1_:=SZK^54Z*0RY_:=SZK^5']IW/JOY5
MC0ZQI]QJ4NG17<;WD0)>$'YE''7\Q0NK6+ZL^EK<*;U(_,:$ Y"\<YZ=Q^=5
MROL*Z-G^T[GU7\J/[3N?5?RJG14C+G]IW/JOY4?VG<^J_E5.B@"Y_:=SZK^5
M']IW/JOY53HH N?VG<^J_E1_:=SZK^54Z* +G]IW/JOY4?VG<^J_E65?:A::
M9:FYO9T@@4@%W/ )Z4^WNH+NUCN;>59()%W(Z]"/6G9VN*ZV-+^T[GU7\J/[
M3N?5?RK%TW6-.U=)'T^[BN%C(#F,YP35ZAIIV8)I[%S^T[GU7\J/[3N?5?RJ
MG12&7/[3N?5?RH_M.Y]5_*J=% %S^T[GU7\J/[3N?5?RJG10!<_M.Y]5_*C^
MT[GU7\JIT4 7/[3N?5?RH_M.Y]5_*J=% %S^T[GU7\J/[3N?5?RJG10!<_M.
MY]5_*C^T[GU7\JIT4 7/[3N?5?RH_M.Y]5_*J=% %S^T[GU7\J/[3N?5?RJG
M5:^U"TTRU-S>SI! I +N> 3TII7T0;&K_:=SZK^5']IW/JOY5FV]U!=VL=S;
MRK)!(NY'7H1ZU7TW6-.U=)'T^[BN%C(#F,YP319BNC:_M.Y]5_*C^T[GU7\J
MIT4AES^T[GU7\J/[3N?5?RJG10!<_M.Y]5_*C^T[GU7\JIT4 7/[3N?5?RH_
MM.Y]5_*J=% %S^T[GU7\J/[3N?5?RJG10!<_M.Y]5_*C^T[GU7\JIT4 7/[3
MN?5?RH_M.Y]5_*J=% %S^T[GU7\J/[3N?5?RJG10!<_M.Y]5_*C^T[GU7\JI
MT4 7/[3N?5?RH_M.Y]5_*J=% %S^T[GU7\J/[3N?5?RJG10!<_M.Y]5_*C^T
M[GU7\JIT4 7/[3N?5?RH_M.Y]5_*J=% %S^T[GU7\J/[3N?5?RJG10!<_M.Y
M]5_*C^T[GU7\JIT4 7/[3N?5?RH_M.Y]5_*J=% %S^T[GU7\J/[3N?5?RJG1
M0!<_M.Y]5_*C^T[GU7\JIT4 7/[3N?5?RH_M.Y]5_*J=% %S^T[GU7\J/[3N
M?5?RJG10!<_M.Y]5_*C^T[GU7\JIT4 7/[3N?5?RH_M.Y]5_*J=% %S^T[GU
M7\J/[3N?5?RJG10!<_M.Y]5_*C^T[GU7\JIT4 7/[3N?5?RH_M.Y]5_*J=%
M%S^T[GU7\J/[3N?5?RJG10!<_M.Y]5_*C^T[GU7\JIT4 7/[3N?5?RH_M.Y]
M5_*J=% %S^T[GU7\J/[3N?5?RJG10!<_M.Y]5_*C^T[GU7\JIT4 7/[3N?5?
MRH_M.Y]5_*J=% %S^T[GU7\J/[3N?5?RJG10!<_M.Y]5_*C^T[GU7_OFJ=%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%!32BE@Q4%AT..13J* $95=2K ,#U!&:4# P*** $95=2K*&4]01D4!0JA5
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MT)#2Q3,ZJ1R<D1^]:QIUDK1?X_\ !,W.F]7^1W=[I=CJ-@;&[M8Y;4@#RR,
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MB?#&E'3?L_V3SV\O[/MV?=/3'%/N/!?C35H8].U77;=K!",D$LQ Z?P@L?\
M>-:OB?P-+J'AS3=(TB2")+-B<W#$;A@Y/ /))S6]+DISBW*^OR,Y\TXOW3-\
M<2R)XN\*JCLJF1,@'&?WBU1U2RN-7^+EWIJWUQ;0RQJ)6A?!V")20/3.*ZCQ
M+X4OM8U[1+ZWEMEBL&4RB1F#'# _+@'T[XIT?A:^3XD3>(C+;_8WCVA-S>9G
MRPO3&.H]:J%6,8K76S^^XI0DY/3JOR.;\,6\OASXH7.A6]U-)9-&3MD;.<H'
M!/;(SC-)H.HRV/B[QG=[F?[+'<2JC$D95R0/TKI4\+7R_$>3Q$9;?[&T>T)N
M;S,^6%Z8QU'K46C>#KFS\2:]>WKV\EGJ8D41QLV[:[9P<@8X/8T.K!W;>Z7W
MWU$H25DN[.4\/^$Y_&>BW6M7FK7/]HM*RP$O\BD ?>XSCGMC KH]>L[S3_ D
M5EJ_B46TB/M>Y6-F:9><)P<GW/MSWK,7P+XKTRVN]*TG5[;^R[HG<),AL$8.
M?E.,CC@\U=U7X<S3^$K'3+2]#75K(TA>;(20L.1WQC Q]/>JE.+FFYJU]--A
M*+47[NMCB(Y[32?$&DW'A^75$C>55DENE"K-\PSMQU&#R#ZBNNA_Y+E<?]<1
M_P"B5I-1\%^+=9FL;R_U'3GGM&'EPC<J*!@YR%ZD@=JW8_"U\OQ'E\1&6W^R
M/'M"!F\S/EA>F,=1ZTYU8-;ZV:_K048273JCKJ***\P[0HHHH **** "BBB@
M KEOB/\ \B%J?_;+_P!&I74UE>(]&_X2#0;G2_/\CS]O[S9NV[6#=,CT]:TI
M-1FF^Y$TW%I'E%D;CP7]AOQO?2]8L0)1_=<KS^()R/8D5+I^LW>C?"AWLG:.
M6XU!H?,7J@* G!['C%>CW7A2WO?!\7A^XEW>3"J)/LP5=1@,!G],]"15&P\!
M6D'A*;0+RZ:Y228S+,J>64;  (&3TQ^M=WUBG)7EO?[TKG-[*:>G8Y+7_#\_
M@[2++7M/U>[:],B";S'RLA()X'<<=#GBM"_O9-#\=:1KCNT=AJ\"B968[48@
M _3'R'\ZNQ?#>::2VBU77[F^T^U(,5L4VC'H3N/T^GI70^*?#,'B;1EL&E%N
MT;J\4@3=LQQC&1Q@D=:EUH72D[[W=NC_ ,AJG*S:5MK'#Z1J=Y<?\)1XS!=E
MC5HK-&R5!XP<>PV_F:K0^&IKSP3)XJEUF]_M0(]PK>;\H"L?E]<\>O7M7HND
M^'+33/#*Z&^)X#&R2L1M\S=G<>O'7UXKES\-+A86T^+Q'=)I+ON:UV9[YQG.
M/TZ]J(UX7=G;5=.BZ Z<K*ZO_F='X,U6XUGPG8WMT<SLK([8QN*L5S^./SKA
MO$:ZFWQ:A&CO$E_Y \LR_=_U;9S^&:]-T[3[?2M/@L;1-D$*[4']3[GK6-+X
M4\SQQ#XD^VX\N/9]G\KK\A7.[/OGI6-.I&,Y2Z-.QI.$G%+T*MA'XI2PU3_A
M()K1XOLK^4(!R&P<YX':J'PE_P"12G_Z_'_] 2NVNH/M-G/;[MOFQLF[&<9&
M,UP%I\,]1L8&M[;Q==P6[$LT<,3("3P>!)[4XSC.$HR=KVZ XRC)-*^Y!X*>
M./XA>)FA*K9KYA8C[H(D_E]ZN3EUG2-8UCQ!?ZN\@:YB,=D!'NVG/RGVP%7\
MS7IUGX(M],\,7NDZ?=O%/>KB:[=-S'L1@$<8R!SQFKOA[PO9:%HT5@4BN70E
MGF>( N2<].<=AU[5K[>FFY+?1?=U,_93:2]687PLUG[?X<:PD;,UB^T9[QMR
MOZY'X"NZKE]-\'#2?%MUK5I>A(+D$/9B'CG!X;=_>&>G?%=17+7<93<H]3>F
MI*-I= HHHK$T"BBB@"K<Z;8W;^9<V5O,X& TD2L<>F2*\T^$UA9WEIJANK2"
M<J\>TRQAL<-TS7JIZ&O._A9INH:?9:HMY9W%J[NFSSXF3/#=,@9KJIR_<S5^
MQA-?O(Z=RMJNJ^,K9[R4W>FZ):VX/D6LK1%I%&<!>&R< >E68?&FIW?PSO-:
M4QQW]M,L)<("&^9.<'CHU<M8:5J,%SJ5OJ7A>[U+5IR1%<RY,:$Y!8D_*1GG
M.?RK0TW2M37X4ZSISZ9>K=M=HZ0M;N&=<Q\@8R?NGI77*$+*]MUV_P _S,%*
M5WOLS9\.:WXLO($UW4I8%T1()))$1%#.$4\CN,D>N/:JNE^(/&VMVMUKEDUD
MMA S8M'7F0 9(4XSG'?(YKI]#TQY?AW#IEVCVSR6;Q2"12ICW C)!Z8SFN+T
M2?Q5X?TB\T*'1#.KES'>!OW48(P3NQ@CC(Y!_E6:Y9<UDKI_@6[JUV_^":.C
M>/;]/!.H:OJ!2XN8K@0P+L"@DJ",X[=3^%9__"9>*M,L[36;V\T^ZL[AAFT3
M;O0$9&<#(X]S[U2\-Z%<>(/AQJ=M:@&XCOA+&I.-Q"#(S]":BM]/GDMK/3X/
M S'45(6>>Z641N.F>H SUSG%;<E)2DK+?RVL9\T[+7H6?%LFJW?CW2;BVGAS
M<"*33F(X52<C=Q_>R>]>MV"W2Z?;+>LCW8B43,GW2^/F(]LYKSGQEINH:=KW
MAW4;/3)+J"QBC0QVRLP!1L[>Y QT)KT73[F2\TZWN9K=[:66,.\+_>C)'*G@
M=/I7)7=Z<+;&])6G*YYV_P#R7:/_ '/_ &W->FUY5KZ:QIGQ/?6K/1+R^BC1
M0OEPN5;,6T_, >F?TK>TSQCK]_J4%K-X3O+2.5MK3R+)MC]SE!_.G5IN<8R7
M1+JA4YJ+:?<R]8UCQI%-?7$E[I^C6\.6AMYWB+RCG 7ALG\N35F#QGJ5W\,K
MW6E,<>H6LJP[P@(;YDYP>.CUREAI6HP7.I6^I>%[O4M6G)$5S+DQH3D%B3\I
M&><Y_*MGP_H6I7'PQUK2'L;F"\>?S8XYHC&7 V$8W 9^X16\H4TE>VC7;;[[
M_>91E-MVOLSH+GQ%J4?PN77%E47YB1M^P8R9 IXZ=#63K7C'6;+P1H>J0SH+
MJZ8B9C&I#8SVQQTK'>Z\0WG@(^'(_#=ZI@ $LS1L,J'# *N,DYQTSP/RG\0Z
M/JDWP[\/6L6FWDEQ$S>9$D#%TZ]1C(I1IP37-;XGVVL-SDT[7V_$LZSXF\9^
M'GLM3U!K,V=TV?LD:@[!UVDXSG!Z@GI6UXJ\4ZI'KUEX?T!8A>W"AVFD&0H.
M2.OL"3P:K_$_3KV_T/3H[*SN+ETFRRPQ,Y4;>X JOXITK5M,\5:=XGTVQDO5
MCC59H8P2P(!4\#G!4]<<8J8>SDHMI7U_X!4N:-TF[:?\$U?#UYXPM]>?3==M
MUNK4KD7L2!54XR.0!D=NF<UQGA7_ (2&77M>M] DMH)'E+2SSC(4!FP!P>3D
M]NU==X?UCQ5KOB0W$UE)IVBHO,,\8RQQQAB 22>?0 56^'FG7UEK?B&2[LKB
MW2653&TL3('&Y^A(YZBB_(IW2O9:?,+<SC:^[+O@#Q-J.N+J%GJNQKJR=09%
M4#=G((('&05[>M=I7G_P]TZ^LM>\0R75G<01RR@QM+$RAQN?H2.>H_.O0*Y<
M0HJH^78VI-N&H4445@:A1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >8?&+_ (]](_WY?Y+4'Q%O[VQ3
MP\;.ZFA8P$XC<@,1LQD=ZT?BMIM_J,&EBQLKFZ*-+O$$3/MR%QG XJI\0-*U
M&];P]]EL+J?RHB)/*A9MA^3K@<=#7IT7'EIW\SBJ)WG;R,SQ;I&N>%H;+6&\
M074]U+)MD(8@*^-V!SRO!&,?AVK8\=^*-031=&MK&5H)M1A665XSM;! PH/8
M$D_E6C\4K"\U#0+2.RM)[F1;H,5AC+D#:W. *S?%WA?4=0\+Z%>6,$C7EC;(
MDD 7Y\;5Z#KD$=.O-$)QDH2G;=_\ )1<>91\C%\7^%-3\.^'(Y7UF:\@ED5;
MB%\[5?!(89)]QV-7/$-W<VGPM\.O;7$L+%E!:-RI(VMZ5%XBU/Q5XMT%+<^'
M;F".!E>9EC<M*_0;5(SCDDCGZU;\2:3J4_PUT"UAT^[DN8G7S(4A8NGRMU &
M16B;]Q5&KW\NQ+2][EO:Q-XP\2:A8>&=!L+&=X[F^MD:28-\^-JC /49)Z]>
M*1_ _BG2)[2[TC6Y+FX)S.LCE5!]\D[AVZ?_ %I?%WA74=3\,:'=V,+M>6-L
MBR08P^-J] >X(Z>]5;CQ%XW\0/:65CI5SILR,/.GV,JDXQR6& .^.:SC\"Y+
M=;WL5+XGS7Z6-CQS;ZI<FQ\[7;32=/*CSU\]E=G_ (L #YP!C S7':-JATCQ
MS86ND:Y<7]A/+'%(9 RJVYL$;6].H-:GC;1]5A\4:?J,]A-K%E%%&K*J$ABO
MW@P4<9//3'-4KBUU>\\7:/JX\+W%A8Q2Q;(8+<G:B/DE@H&#R>H%722]G9M6
M:?;_ (>Y,V^>_GY_\,5];T*X/Q,73O[3E$MS*'6XP=T0;) 'S=NG45M>+I+W
M2O$WABP34+AA'#!'(P=E\TA\%B,]\>]+XSM-5T[X@VFN6FF3WD*JC*(D+ D9
M!4D X-+XIM-5U?Q'X:U!=)NQ^ZA:=5A9A"V_)#''&/>A2YN1MJUGVWL#5N9+
M>Y+XRU?5=7\8P>%=+NGM4^42NC%2Q*[B21S@+V[\UFZM;ZW\.+^RNX=7EOK.
M9B'CDR 2,$J5)/4=".?ZZOC+0M8T_P 6P^*=&MFNB-IDC1=S @;>@Y(*\<>]
M9NI)XC^(>H65O+I$NFV,!)=Y%8 9QDY8#)P. *5-KEC:W+;7;?\ ,<[W>_-?
M0F^(&J:@/$NB-I=W+$9X(WC"N0I8N<$CH>W6L_Q5I^M>"[NPU&/7KJZFG+;V
M<D?,N#@@DY4YZ5M>--'O9/&/A]K*PN9K:W6)&DCB9E0"3N0,#BK/Q5TV^U&S
MTQ;&RN+HI)(6$$3/MX'7 XI4YI>SCI9IWV'.+?,^IZ!#)YL$<F,;U#?F*?4-
MHI6R@5@01&H(/;BIJ\Q[G:%%%%( HHHH **** "BBB@ HHHH **** "BBB@
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MHHH JZAJ5GI5FUW?W"00+P7<]_0#N?85C6'COPYJ5XMI;ZBOG.VU!)&R!CZ
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M>I/Y ?A6K1142DY.[*225D%%%%(84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'F7Q"_Y'CPU_UT3_T:*C^+JR^?HSG MP9 2PRH
M;*]?P_K7?:AX>TO5;ZVO;VU\VXMB#"_F,NW!R. 0#SZU8U'3;+5K-K2_MTG@
M;DJWKZ@]0?<5UPKQBX.VUSGE2;4O,\KO[>XN_%&CO>^(=(>[1XS +2-SN&X8
M&44CZ9J;5[16\;WUQX<\116FI'/GPW :(9!&X!B,-R <?C7=Z5X,T#1;O[79
M6"K./NN[LY7Z9)Q2ZOX/T+7+C[1?6*O/C!D1V1C]<'G\:T^L1YO*UME^1/L9
M6\_G^9Q'A?69K[3_ !)IMW967GPVDKM<VT2+YA (.XKPW)R"/>K7PVN+7_A"
M]0M_.A^U;YG\O<-^W8O..N,]Z[C2] TK1;62VT^SCABD_P!9U8O]2<D]ZIZ;
MX-T+2;J6XLK+RY)4:-CYKD;3U !-1*M"2DDK7M^!4:<DT_4\TT;_ )(_K_\
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MS[K_ )Y?^/#_ !KPJBC^R_[WX?\ !#ZY_=/=?[/NO^>7_CP_QH_L^Z_YY?\
MCP_QKPJBC^R_[WX?\$/KG]T]U_L^Z_YY?^/#_&C^S[K_ )Y?^/#_ !KPJBC^
MR_[WX?\ !#ZY_=/=?[/NO^>7_CP_QH_L^Z_YY?\ CP_QKPJBC^R_[WX?\$/K
MG]T]U_L^Z_YY?^/#_&C^S[K_ )Y?^/#_ !KPJBC^R_[WX?\ !#ZY_=/=?[/N
MO^>7_CP_QH_L^Z_YY?\ CP_QKPJBC^R_[WX?\$/KG]T]U_L^Z_YY?^/#_&C^
MS[K_ )Y?^/#_ !KPJBC^R_[WX?\ !#ZY_=/=?[/NO^>7_CP_QH_L^Z_YY?\
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M^->%44?V7_>_#_@A]<_NGNO]GW7_ #R_\>'^-']GW7_/+_QX?XUX511_9?\
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MNES<*L?EHS@#Y-BCC(!/)X_&H]#TO2O#T^J7;^(-.F2>UDBMD2<;F4\_-[\
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MH ?FC-,S1F@!^:,TS-&: 'YHS3,T9H ?FC-,S1F@!^:,TS-&: 'YHS3,T9H
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MJ?W?Q_X ?4_[QX517OM[>3PW3(DF% '&!5?^T+K_ )Z_^.C_  H_M3^[^/\
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MM3^[^/\ P ^I_P!X\*HKW7^T+K_GK_XZ/\*/[0NO^>O_ (Z/\*/[4_N_C_P
M^I_WCPJBO=?[0NO^>O\ XZ/\*/[0NO\ GK_XZ/\ "C^U/[OX_P# #ZG_ 'CP
MJBO=?[0NO^>O_CH_PH_M"Z_YZ_\ CH_PH_M3^[^/_ #ZG_>/"J*]U_M"Z_YZ
M_P#CH_PJQ%>3M9SR&3YE*X.!QS1_:G]W\?\ @!]3_O'@5%>Z_P!H77_/7_QT
M?X4?VA=?\]?_ !T?X4?VI_=_'_@!]3_O'A5%>Z_VA=?\]?\ QT?X4?VA=?\
M/7_QT?X4?VI_=_'_ ( ?4_[QX517NO\ :%U_SU_\='^%']H77_/7_P ='^%'
M]J?W?Q_X ?4_[QX517NO]H77_/7_ ,='^%']H77_ #U_\='^%']J?W?Q_P"
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MC^U/[OX_\ /J?]X\*HKW7^T+K_GK_P".C_"C^T+K_GK_ ..C_"C^U/[OX_\
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M9C3L[HMWM[-J%[-=W+[YIG+N?<U7S3,T9H225D%[C\T9IF:,TQ#\T9IF:,T
M/S1FF9HS0 _-&:9FC- #\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T /S
M5W3M/EU"<(@.W/)INFZ=-J,X1 =N>37I^B:)%80+\HW8KR\;C?9_NZ>_Y?\
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M]XTRW_X^8O\ ?'\Z?>?\?<O^\: (**** "BBB@ HHHH **** "BBB@ HHHH
M:[;5)KD=0\1ZC9731;;<KGY6VGD?G77D9&*YW7=%%U&9(^''(K6E.,9>^KHB
M<6UH[,Q_^$NU#^Y;_P#?)_QH_P"$NU#^Y;_]\G_&L"6-X)#'(N&%,W5[D,/0
MFN:,58\]U:D79LZ+_A+M0_N6_P#WR?\ &C_A+M0_N6__ 'R?\:YW=1NJ_JE'
M^5"]M/N=%_PEVH?W+?\ [Y/^-'_"7:A_<M_^^3_C6%;V]Q=.4MX)9F'41H6/
MZ4DL,T$OE30R1R?W'4@_D:7U:A>W*OZ^8>UJ=S>_X2[4/[EO_P!\G_&C_A+M
M0_N6_P#WR?\ &N?D22&0QRHR..JL""/PINZCZK1_E0>VGW.B_P"$NU#^Y;_]
M\G_&C_A+M0_N6_\ WR?\:YW=1NI_5*/\J#VT^YT7_"7:A_<M_P#OD_XT?\)=
MJ']RW_[Y/^-<[NIYCE6)96C<1L<*Y4X/T-+ZK1_E0>VGW-__ (2[4/[EO_WR
M?\:/^$NU#^Y;_P#?)_QKG=U*N68*H)). !WI_5:/\J#VT^YT/_"7:A_<M_\
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M)KFZ*/J]+^5?<'M9]V=)_P )]XF_Z"?_ ) C_P#B:/\ A/O$W_03_P#($?\
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M/#/_ $!?_)J3_&C_ (1CPS_T!?\ R:D_QK1HH^L5?YG]X>RAV1G?\(QX9_Z
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M4G^-;>HC%ZV/0?RJK1]8J_S/[P]E#LC._P"$8\,_] 7_ ,FI/\:/^$8\,_\
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M#EEV'[VV[=QV]<9XK=_MZWMO!XT>Q25;BYE,E[*P # ?=5<'ITST_6N?V/\
MW&_*C8_]QORJ).G*UVM-=U_F4E-;(7-&:38_]QORHV/_ '&_*K]I#NOO7^9/
M++L+FC-)L?\ N-^5&Q_[C?E1[2'=?>O\PY9=A<T9I-C_ -QORHV/_<;\J/:0
M[K[U_F'++L+FC-)L?^XWY4;'_N-^5'M(=U]Z_P PY9=A<T9I-C_W&_*C8_\
M<;\J/:0[K[U_F'++L+FC-)L?^XWY4;'_ +C?E1[2'=?>O\PY9=A<T9I-C_W&
M_*C8_P#<;\J/:0[K[U_F'++L+FC-)L?^XWY4;'_N-^5'M(=U]Z_S#EEV%S1F
MDV/_ '&_*C8_]QORH]I#NOO7^8<LNPN:,TFQ_P"XWY4;'_N-^5'M(=U]Z_S#
MEEV%S1FDV/\ W&_*C8_]QORH]I#NOO7^8<LNPN:,TFQ_[C?E1L?^XWY4>TAW
M7WK_ ##EEV%S1FDV/_<;\J-C_P!QORH]I#NOO7^8<LNPN:,TFQ_[C?E1L?\
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MQZ77^ZO\ZJ5;MO\ CTNO]U?YU4H **** "BBB@ HHHH **** "BBB@ HHHH
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M[Y7_ !H^K5OY6'M8=RQ_PC5G_<'Y4?\ "-6?]P?E5?\ X3&S_P">-Q_WRO\
MC1_PF-G_ ,\;C_OE?\:/JU;^5A[6'<L?\(U9_P!P?E1_PC5G_<'Y57_X3&S_
M .>-Q_WRO^-'_"8V?_/&X_[Y7_&CZM6_E8>UAW+'_"-6?]P?E1_PC5G_ '!^
M55_^$QL_^>-Q_P!\K_C1_P )C9_\\;C_ +Y7_&CZM6_E8>UAW+'_  C5G_<'
MY4?\(U9_W!^55_\ A,;/_GC<?]\K_C1_PF-G_P \;C_OE?\ &CZM6_E8>UAW
M+'_"-6?]P?E1_P (U9_W!^55_P#A,;/_ )XW'_?*_P"-'_"8V?\ SQN/^^5_
MQH^K5OY6'M8=RQ_PC5G_ '!^5'_"-6?]P?E5?_A,;/\ YXW'_?*_XT?\)C9_
M\\;C_OE?\:/JU;^5A[6'<L?\(U9_W!^5'_"-6?\ <'Y57_X3&S_YXW'_ 'RO
M^-'_  F-G_SQN/\ OE?\:/JU;^5A[6'<L?\ "-6?]P?E1_PC5G_<'Y57_P"$
MQL_^>-Q_WRO^-'_"8V?_ #QN/^^5_P :/JU;^5A[6'<L?\(U9_W!^5'_  C5
MG_<'Y57_ .$QL_\ GC<?]\K_ (T?\)C9_P#/&X_[Y7_&CZM6_E8>UAW+'_"-
M6?\ <'Y4?\(U9_W!^55_^$QL_P#GC<?]\K_C1_PF-G_SQN/^^5_QH^K5OY6'
MM8=RQ_PC5G_<'Y4?\(U9_P!P?E5?_A,;/_GC<?\ ?*_XT?\ "8V?_/&X_P"^
M5_QH^K5OY6'M8=RQ_P (U9_W!^5'_"-6?]P?E5?_ (3&S_YXW'_?*_XT?\)C
M9_\ /&X_[Y7_ !H^K5OY6'M8=RQ_PC5G_<'Y4?\ "-6?]P?E5?\ X3&S_P">
M-Q_WRO\ C1_PF-G_ ,\;C_OE?\:/JU;^5A[6'<L?\(U9_P!P?E5^TTV"T'R(
M!61_PF-G_P \;C_OE?\ &KVG>(+349#''O1Q_#( "?IS4RH58J[CH-5(-V3-
M;I10#FBL2PHHHH *MZA_Q\+_ +@JI5O4/^/A?]P4 5**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** +=M_QZ77^ZO\ .JE6[;_CTNO]
MU?YU4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP;I^_#;\CT*-?F]V6YT5% .:*\TZ@JWJ'_'PO^X*J5;U#_CX7_<% %2BBB@
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M_P"%D)_T XO_  (/^%'_  LA/^@'%_X$'_"CZC7[?B@^LT^YU]%<A_PLA/\
MH!Q?^!!_PH_X60G_ $ XO_ @_P"%'U&OV_%!]9I]SKZ*Y#_A9"?] .+_ ,"#
M_A1_PLA/^@'%_P"!!_PH^HU^WXH/K-/N=?17(?\ "R$_Z <7_@0?\*/^%D)_
MT XO_ @_X4?4:_;\4'UFGW.OHKD/^%D)_P! .+_P(/\ A1_PLA/^@'%_X$'_
M  H^HU^WXH/K-/N=?17(?\+(3_H!Q?\ @0?\*/\ A9"?] .+_P "#_A1]1K]
MOQ0?6:?<[JV_X]+K_=7^=5*Y)?B9L5E718@&ZCSSS^E-_P"%D)_T XO_  (/
M^%'U&OV_%!]9I]SKZ*Y#_A9"?] .+_P(/^%'_"R$_P"@'%_X$'_"CZC7[?B@
M^LT^YU]%<A_PLA/^@'%_X$'_  H_X60G_0#B_P# @_X4?4:_;\4'UFGW.OHK
MD/\ A9"?] .+_P "#_A1_P +(3_H!Q?^!!_PH^HU^WXH/K-/N=?17(?\+(3_
M * <7_@0?\*/^%D)_P! .+_P(/\ A1]1K]OQ0?6:?<Z^BN0_X60G_0#B_P#
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M_"R$_P"@'%_X$'_"C_A9"?\ 0#B_\"#_ (4?4:_;\4'UFGW.OHKD/^%D)_T
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M110 4444 %%%% $EO_Q\Q?[X_G3[S_C[E_WC3+?_ (^8O]\?SI]Y_P ?<O\
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M\_M_^2?X4?\ " :'_P _M_\ DG^%']H4._X!]5J'FU%>D_\ " :'_P _M_\
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M_A -#_Y_;_\ )/\ "C_A -#_ .?V_P#R3_"C^T*'?\ ^JU#S:BO2?^$ T/\
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M6[;_ (]+K_=7^=5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"WJ7_'Z_T'\JJ5;U+_ (_7^@_E52@ HHHH **** "BBB@"4QVD
M]D8[N)9@LJR+&W0L.F?:F22-*Y=SEC3:*=W:P6"BBBD 4444 %%%% !1110
M4444 %6X?^0=<_5?YU4JW#_R#KGZK_.@"I1110 4444 %%%% !1110 4444
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M>@_\(/%Z4?\ "#Q>E']JP_E?X!]2EW//LT9KT'_A!XO2C_A!XO2C^U8?RO\
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M^X*J5;U#_CX7_<% %2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8F=O_P )C9?\\;C_ +Y7_&C_ (3&R_YXW'_?*_XUQ&ZC=1]0H^?WA]8F=O\
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M=W<QM)!:S2HGWFCC+ ?4BH,UZQX<@N4\+:5<!YK**U#R3PB+)N%Y.<=>>O\
MD5YAJ\WVC5+F[6W>"&XD:6)67'RDY%94:WM)RC;;^O\ @ESARQ3[E7-&:CW4
M;JZK&-R3-&:CW4;J+!<DS1FH]U&ZBP7),T9J/=1NHL%R3-&:CW4;J+!<DS3X
MY7BD62-BKJ<@CM4&ZC=2M<=ST/P_XA2_003D+<*.G][W%=$#FO'(YGBD62-B
MKJ<@CJ*[_P .^(DU&,03D+<J.1V;W%>'C,&Z?OPV_+_@'H4*_-[LMSI*MZA_
MQ\+_ +@JH#FK>H?\?"_[@KS#K*E%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% %NV_X]+K_ '5_G52K=M_QZ77^ZO\ .JE !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!;U+_C]?Z#^55*M
MZE_Q^O\ 0?RJI0 4444 %%%% !1110 458GN+.YU)[")]E]'$LAC/'F*1U7U
MQ5<C!P>M-IK<2:>P4444AA1110 4444 %%%% !1110 5;A_Y!US]5_G52K</
M_(.N?JO\Z *E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% #H_]:G^\*FOO^/V7ZC^50Q_ZU/\ >%37W_'[+]1_*@"O1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% $EO\ \?,7^^/YT^\_X^Y?]XTR
MW_X^8O\ ?'\Z?>?\?<O^\: (**** "BBB@ HHHH **** "BBB@ HHHH ****
M "HY8EE0JPR#4E% '#>(?#Q!:>!>?2N08%&*L,$=17LDT:.A# 8KS3Q'':_V
MJMO;NOF%@K'.%7/J:]7+Z\U+V=KK\CBQ5.-N?9_F=!.-,\8Z/8,=3M[+5+2(
M0R)<MM60#N#^O'J:KW<6A:%I4%C'<6U_J<MPCR7,?*PJ",@-^'ZGIQ7,:QI%
MWH=^;.]51*%# J<@@]P:4Z->+H(UE@BVC2^4N6^9F]A^!_(UZ2I125I^ZWHO
M^#^AR.;U]W4ZG4-0M'^*B7:W<#6HFB/G"0%,!%!^;IUK3TK7X?-\0:?;:K!8
MW,U])<6MU)M,;@GIDY'0#\^*\RS1FJEA(RBDWLDON=P5=IW/3-0U=H!I5MJ'
MB&*^NFOHI)A!Y7DQ(K@Y+!0<_B.]5M-U*R3XH7EW)>6ZVS;]LS2@(?E&,-TK
MSS-7VTFZ71$U8[/LKS^0/F^;=@GIZ<5/U6$59O>ZZ==?T'[:3=TMM3<\/7EO
M!X8\212W$4<LL<0B1G 9R"V<#OU%;&L6FF>++RVU>/6K*UC:)5N8IY-LD9'7
M [^E<K%X8U6349K!H5BN8;?[0Z2..$X]._(XK&S5>QC*;G"6ORZJWZ"]HU'E
MDM#TNWU_3=3\:ZDPNHX+:;3VM(9ICM5CD<\_C^58VO/;V_@W2]-2^M;B>WN9
M@X@E#<;FP?H<UQN:,TXX6,9)IZ*WX)K]1.LVFFCTB'Q#8:?J'A>=[B-XH[#R
M9S&P8Q$J!R!TP>U:+ZO=67VN[O/%]M-9JI-O%:"$RN>P(*''Z_A7DV:VHO#.
MH2_V8 85DU'<8(V8AMH_B/' /:L9X6FK.3_!>;^1<:TWLOZV-'Q#>V\_A?PY
M#%<122Q1R^:B."4)*XR!T[UV1U&WM_L4FD:WI5AHZ(IE3"F=L=1M(.21^/7K
M7'GX=Z[DJILW<?P+.,US-W:W%C=R6MU$T4\3;71NH-'LJ55*,9WM?\?ZT8<\
MX.[C_2/5 MGJFI>+MM_;BUN(+<"X60,B_(1DD<=17-7IL_#W@^ZTH:A;7E[?
M3*S"V?>D:J0>3Z\?K[5S>GZU/IVG:A911QM'?(J2%@<J!GIS[U7TZSFU+4(+
M.WVF:9MJ[C@9]ZJ&&<&^:7NJWX(4JW-LM=?Q9Z-8ZU"G@-=:<'^T+2%["-SW
M)*X/O@8/YURNF^-M8TK3XK*V>$0Q9V[H@3R2>OXU:UZ?5M6TN[4VME9V&D3[
M)8+;Y1YA;;D#OSG\S7'YHH4(2C+F5[O;>W;\_P 0J5))JSZ'>6NHV8\->&HW
MNX!+%J8DE0R %%WL=Q'8>]-MM0LU^*K7C7< M?.<^>9!LQY9 ^;IUKD+;3[N
M[M+JZ@B+06JAIGR %!.!53-6L-%\UGO=??J3[5Z:=OP.\MY['7=!O=%?4+>T
MN8[]KBW>=ML<@.1C=^)_2KDUWIFB6GAFW74[:Z%G=,T[PN&VY.2<#G S^.*X
M;5-)NM'E@CNMFZ>%9TV-GY6SC/OQ5%?F8#<%R<9/04OJT9:J7N[_ (6'[5K1
MK7^F>J:7::5IGBZ[UF77].:*Y:1H4689RYR=W88Y'O6'$EEXF\*:;9#4[6RO
M;!G5DN7V*ZL>H/?H/UKE=7TJZT6^-I=;"VT.KH<JZGH0>XJAFE##7M-3N]+/
M3IH.56WNN)Z9H^HZ%H6HW6EZ?J0B:>V53?L0T8G7/3/&.<^G:H];U6ZMO#EU
M%J7B2"^NISLC@LA$5V]RQV9_E7F^:,T_J<>;F;OMT73SZ"]N[6L>C7\.F>)M
M3L=<&LV=K&J)]JAFD"R*5/\ ".^>G^-<YXUNH+KQ=?36TT<T3;-LD;!E.$4<
M$>]<YFC-73P_)).]TE9$SJ\RM8ZR\O;<_#S3;9+B,W,=X[M$'&]1\W)'4=17
M16_B>QU7P5J!O)H8]56U,#;W"M, #M(]>I_'/K7F.:,TI86,EJ^M_P#@#59I
M_*QZM#>PQ:5IW]B:UI6FV:Q+]J+[?/W=^"#DTEUJFE7/BK4H3J5LL&HZ9Y*3
MB0%%8Y&">Q[X->59HS6?U&-V^;\O7YE?6'V._FMK#1? NJZ?_:]E=7LTD;E(
M)0> Z\#U. 2?2MS3=0BA%L;?Q)93Z*(P)8-0=3,G'0<#/X_K7DF:,TY8/F33
MEN[[(%7L]$>GZ7K]I+8ZCI^CZG;Z7,MV\MJ\ZJ(WC)Z?,./IC/3WI+S5;/[9
MH]EK>MQZGB<RW/EK&8$(5@OW5!ZD=3C&<BO,<T9H^I1O>_Y7VMON'UAVM;^O
M0]GLM7^RZQ(;[Q%I"Z>VX6UO;LHXZ@L>W ]<$UY""(;D;MKA'YP<AL&JV:,U
MI1PRI-N^_E8BI6<['K3WMK>>(;3Q#:>([2"R6()+;S28<#NNWW_F,\US_CZ\
ML-473[_3]0BE@V&);=1ADP>3CMV'..@Q7"YHS44\&H34K[:=-OZZE2KN46K;
MDF:,U'FC-=EC"Y)FC-1YHS18+DF:,U'FC-%@N29HS4>:,T6"Y)FC-1YHS18+
MDF:,U'FC-%@N29I\<SPR+)&Q5U.0PZ@U!FC-%DPN>D^'/$B:C&()R%N5'([,
M/45L>*/%5IH6HPVTVGO<,\"R;UEVX!)&,8]J\FLA,]W&+=BL@8$,.WO77?$K
M/]O663D_8(\_]]/7BRPE)8E1Z--V['>J\W2YNJZE_P#X6+I__0&E_P# C_ZU
M'_"Q=/\ ^@-+_P"!'_UJ\]HKJ^HT.WXLQ^LU.YZ%_P +%T__ * TO_@1_P#6
MH_X6+I__ $!I?_ C_P"M7GM%'U&AV_%A]9J=ST+_ (6+I_\ T!I?_ C_ .M1
M_P +%T__ * TO_@1_P#6KSVBCZC0[?BP^LU.YZ%_PL73_P#H#2_^!'_UJ/\
MA8NG_P#0&E_\"/\ ZU>>T4?4:';\6'UFIW/0O^%BZ?\ ] :7_P "/_K4?\+%
MT_\ Z TO_@1_]:O/:*/J-#M^+#ZS4[GH7_"Q=/\ ^@-+_P"!'_UJ/^%BZ?\
M] :7_P "/_K5Y[11]1H=OQ8?6:G<]"_X6+I__0&E_P# C_ZU'_"Q=/\ ^@-+
M_P"!'_UJ\]HH^HT.WXL/K-3N>A?\+%T__H#2_P#@1_\ 6H_X6+I__0&E_P#
MC_ZU>>T4?4:';\6'UFIW/0O^%BZ?_P! :7_P(_\ K4?\+%T__H#2_P#@1_\
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M_A8NG_\ 0&E_\"/_ *U'_"Q=/_Z TO\ X$?_ %J\]HH^HT.WXL/K-3N>A?\
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M%KAI"65BF\!?0 <=:Y_['8Z=X0MM0>SCN)H]6,3%R1YB -\I]N!47_"66/\
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MNWI<QJ_%\D/S1FF9HS709#\T9IF:,T /S1FF9HS0 _-&:9FC- #\T9IF:,T
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MI]CB?^%;WO\ T%+#_OIO\*/^%;WO_04L/^^F_P *[:BC^T*_?\ ^JT^QQ/\
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M_:%?O^ ?5:?8XG_A6][_ -!2P_[Z;_"C_A6][_T%+#_OIO\ "NVHH_M"OW_
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M/4FDHHKS3K"BBB@ HHHH **** "BBB@ JW#_ ,@ZY^J_SJI5N'_D'7/U7^=
M%2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!T?^M3
M_>%37W_'[+]1_*H8_P#6I_O"IK[_ (_9?J/Y4 5Z*** "BBB@ HHHH ****
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M[?@._P"$'A]!1_P@\/H*;_PEVH?W+?\ [Y/^-'_"7:A_<M_^^3_C1]5Q/?\
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M\)L]A;75_J=K8"ZY@28_,X]?8<C\Z/;4[7N')*]K'/[J-U6=6TRYT;49+*[
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M);_\?,7^^/YT^\_X^Y?]XTRW_P"/F+_?'\Z?>?\ 'W+_ +QH @HHHH ****
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M ._S?_$T?\*WU3_H(:7_ -_F_P#B:/K=#^9!["IV.-HKLO\ A6^J?]!#2_\
MO\W_ ,31_P *WU3_ *"&E_\ ?YO_ (FCZW0_F0>PJ=CC:*[+_A6^J?\ 00TO
M_O\ -_\ $T?\*WU3_H(:7_W^;_XFCZW0_F0>PJ=CC:*[+_A6^J?]!#2_^_S?
M_$T?\*WU3_H(:7_W^;_XFCZW0_F0>PJ=CC:*[+_A6^J?]!#2_P#O\W_Q-'_"
MM]4_Z"&E_P#?YO\ XFCZW0_F0>PJ=CC:*[+_ (5OJG_00TO_ +_-_P#$T?\
M"M]4_P"@AI?_ '^;_P")H^MT/YD'L*G8XVBNR_X5OJG_ $$-+_[_ #?_ !-'
M_"M]4_Z"&E_]_F_^)H^MT/YD'L*G8XVBNR_X5OJG_00TO_O\W_Q-'_"M]4_Z
M"&E_]_F_^)H^MT/YD'L*G8XVBNR_X5OJG_00TO\ [_-_\31_PK?5/^@AI?\
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M44 %%%,EE2&-G=@J@9))Z4 $LJ0QEW8*H&23VKS3Q/XH;4I&M+1B+4'#,/\
MEI_]:F^*/%+:G(UI:,1:@X9A_P M/_K5R^:][!8+EM4J+7HCS<1B+^Y#8?FC
M-,S1FO7. [CQ:ZZAI'AW7(_FB, MIF'\+IS@_P#CWY5F>.-5L]8\32W=A-YT
M#1HH?:5Y YX(!K'BU>[ATB?2U=3:3NLC(R@X8=P>U4LUS4J/(U?I>WH]3:=3
MF^=CHO!VOQ>']>%S<*YMY8VAE*?>53@Y'X@5T=QK6D:?I]](GB?5-7FF0K;6
M[2S1B//=CD9Q^'TKSK-&:=3#QG+F?]6^7Y"C5<58[@7_ (?\1Z'ID&K:E+IU
MWIR>22(3()8QC&,=#@#]>#6K-XJT'_A*&NH+LBS&C&T0F)\A]V0N,9Z=^GO7
MF6:,U#PL7U=M=/7<I5VNG](]*@\0:3<^&M+M4\17&C&UB"7,$$+%I3QDAEZ9
M.3WZ\TEYXKT63Q[HVL174C6D5J89BT;;HR0_7(Y^^,XST->;9HS2^IPNW=]>
MW7?H/V\K?=^!V^J:CHMOX5U+2[#4OM4DU^+B/]RRY4JN>HQP0144/B6TLO#G
MAU(9/,O+"[>:6':1\I8GKC'(/:N-S1FK6'C:S=];_A8GVKO='H4TW@F35[G7
MIKZ2Y$VZ3^SF@8'S".<MTZGZ>YJKH$BZ?X,\1ZK*BQK> 6ENH[DYW >P#?H:
MX?-7;G5[N[TZTL)7'V:TW>4BJ ,DY)/J:EX=V4;MK3?LAJKK>W?\2KFC-,S1
MFNLP'YHS3,T9H ?FC-,S1F@!^:,TS-&: 'YHS3,T9H ?FC-,S1F@!^:,TS-&
M: 'YHS3,T9H ?FC-,S1F@!^:,TS-&: 'YHS3,T9H ?FC-,S1F@!^:,TS-&:
M'YHS3,T9H ?FC-,S1F@!^:,TS-&: 'YHS3,T9H ?FC-,S1F@!^:,TS-.C5Y7
M"(,L>@%)M)78TKZ(>BM(X1!ECT KN/#?AO;MGG7+'UI/#7AK8%GG7+'UKN(H
MEB0*HP!7SN,QCK/DA\/YGJX?#\GO2W"*)8D"J, 5)117FG6%6]0_X^%_W!52
MK>H?\?"_[@H J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 6[;_CTNO\ =7^=5*MVW_'I=?[J_P ZJ4 %%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH **** +>I?\?K_0?RJI5O4O^/U_H/Y54H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *MP_\@ZY^J_SJI5N'
M_D'7/U7^= %2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!T?^M3_>%37W_'[+]1_*H8_]:G^\*FOO^/V7ZC^5 %>BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** )+?_CYB_WQ_.GWG_'W+_O&F6__
M !\Q?[X_G3[S_C[E_P!XT 04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4K,S'+$D^YI** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!0S $!B >H!ZTE%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 K,SG+,6
M/J3FDHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *4,
MP4J&(4]1GK244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !TI68L26))/<TE% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%%  "000<$=Z4DL2222>YI** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,
MMO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+
M;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z
M,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^
MS+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_L
MRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.
M@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH
M_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO
M[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1O
MSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\
MZ/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BM
MK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T
M;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&
M_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%H
MK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV
M]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO
M1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q
M:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,
MMO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+
M;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z
M,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^
MS+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_L
MRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.
M@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH
M_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO
M[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1O
MSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\
MZ/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BM
MK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T
M;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%HK:_LRV]&
M_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV]&_.@#%H
MK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO1OSH_LRV
M]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH Q:*VO[,MO
M1OSH_LRV]&_.@#%HK:_LRV]&_.C^S+;T;\Z ,6BMK^S+;T;\Z/[,MO1OSH N
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVK_]_H__ (W1R4?YG]W_  0YJG\OXGIE%>9_\*.\,_\ /]J__?Z/_P"-T?\
M"CO#/_/]J_\ W^C_ /C=')1_F?W?\$.:I_+^)Z917F?_  H[PS_S_:O_ -_H
M_P#XW1_PH[PS_P _VK_]_H__ (W1R4?YG]W_  0YJG\OXGIE%>9_\*.\,_\
M/]J__?Z/_P"-T?\ "CO#/_/]J_\ W^C_ /C=')1_F?W?\$.:I_+^)Z917F?_
M  H[PS_S_:O_ -_H_P#XW1_PH[PS_P _VK_]_H__ (W1R4?YG]W_  0YJG\O
MXGIE%>9_\*.\,_\ /]J__?Z/_P"-T?\ "CO#/_/]J_\ W^C_ /C=')1_F?W?
M\$.:I_+^)Z917F?_  H[PS_S_:O_ -_H_P#XW1_PH[PS_P _VK_]_H__ (W1
MR4?YG]W_  0YJG\OXGIE%>9_\*.\,_\ /]J__?Z/_P"-T?\ "CO#/_/]J_\
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MVK_]_H__ (W1R4?YG]W_  0YJG\OXGIE%>9_\*.\,_\ /]J__?Z/_P"-T?\
M"CO#/_/]J_\ W^C_ /C=')1_F?W?\$.:I_+^)Z917F?_  H[PS_S_:O_ -_H
M_P#XW1_PH[PS_P _VK_]_H__ (W1R4?YG]W_  0YJG\OXGIE%>9_\*.\,_\
M/]J__?Z/_P"-T?\ "CO#/_/]J_\ W^C_ /C=')1_F?W?\$.:I_+^)Z917F?_
M  H[PS_S_:O_ -_H_P#XW1_PH[PS_P _VK_]_H__ (W1R4?YG]W_  0YJG\O
MXGIE%>9_\*.\,_\ /]J__?Z/_P"-T?\ "CO#/_/]J_\ W^C_ /C=')1_F?W?
M\$.:I_+^)Z917F?_  H[PS_S_:O_ -_H_P#XW1_PH[PS_P _VK_]_H__ (W1
MR4?YG]W_  0YJG\OXGIE%>9_\*.\,_\ /]J__?Z/_P"-T?\ "CO#/_/]J_\
MW^C_ /C=')1_F?W?\$.:I_+^)Z917F?_  H[PS_S_:O_ -_H_P#XW1_PH[PS
M_P _VK_]_H__ (W1R4?YG]W_  0YJG\OXGIE%>9_\*.\,_\ /]J__?Z/_P"-
MT?\ "CO#/_/]J_\ W^C_ /C=')1_F?W?\$.:I_+^)Z917F?_  H[PS_S_:O_
M -_H_P#XW1_PH[PS_P _VK_]_H__ (W1R4?YG]W_  0YJG\OXGIE%>9_\*.\
M,_\ /]J__?Z/_P"-T?\ "CO#/_/]J_\ W^C_ /C=')1_F?W?\$.:I_+^)Z91
M7F?_  H[PS_S_:O_ -_H_P#XW1_PH[PS_P _VK_]_H__ (W1R4?YG]W_  0Y
MJG\OXGIE%>9_\*.\,_\ /]J__?Z/_P"-T?\ "CO#/_/]J_\ W^C_ /C=')1_
MF?W?\$.:I_+^)Z917F?_  H[PS_S_:O_ -_H_P#XW1_PH[PS_P _VK_]_H__
M (W1R4?YG]W_  0YJG\OXGIE%>9_\*.\,_\ /]J__?Z/_P"-T?\ "CO#/_/]
MJ_\ W^C_ /C=')1_F?W?\$.:I_+^)Z917F?_  H[PS_S_:O_ -_H_P#XW1_P
MH[PS_P _VK_]_H__ (W1R4?YG]W_  0YJG\OXGIE%>9_\*.\,_\ /]J__?Z/
M_P"-T?\ "CO#/_/]J_\ W^C_ /C=')1_F?W?\$.:I_+^)Z917F?_  H[PS_S
M_:O_ -_H_P#XW1_PH[PS_P _VK_]_H__ (W1R4?YG]W_  0YJG\OXGIE%>9_
M\*.\,_\ /]J__?Z/_P"-T?\ "CO#/_/]J_\ W^C_ /C=')1_F?W?\$.:I_+^
M)Z917F?_  H[PS_S_:O_ -_H_P#XW1_PH[PS_P _VK_]_H__ (W1R4?YG]W_
M  0YJG\OXGIE%>9_\*.\,_\ /]J__?Z/_P"-T?\ "CO#/_/]J_\ W^C_ /C=
M')1_F?W?\$.:I_+^)Z917F?_  H[PS_S_:O_ -_H_P#XW1_PH[PS_P _VK_]
M_H__ (W1R4?YG]W_  0YJG\OXGIE%>9_\*.\,_\ /]J__?Z/_P"-T?\ "CO#
M/_/]J_\ W^C_ /C=')1_F?W?\$.:I_+^)Z917F?_  H[PS_S_:O_ -_H_P#X
MW1_PH[PS_P _VK_]_H__ (W1R4?YG]W_  0YJG\OXGIE%<CX4^'6D>#]1FOM
M/N;Z666$PL+AT9<$@\84<_**ZZL9**?NNZ+BVUJ@HHHJ2@HHJKJ6H6^E:=/?
M7;[(($W,>Y] /<G@>YII7T0FTE=EJO(_B9JFKVOBNWMM.O[V$/:J?*@F906W
M-V!Z\5ZQ;F1K>-I@%D9064= 3V_"O,?%W_)7= ^D'_HQJZ,-I-W[,Y,9=TTE
MI=HZ[P3XE7Q+H*32,/ML&([E1_>[-CT(Y^N1VKF_!FI7]U\1?$%M<7MS+;Q&
M;RXI)694Q* , G XXK.U&-_AUX[CU"!&&C7Y(D1>B@GYACU4_,/;CUJIX=OV
MMO%?C/4+1U=H[:ZFB<<@XDR#[CO6ZIJTG'9K3[SG=9\T(SWBW?[MSTS4_%>A
M://Y%]J<$4PX,8)9E^H7)'XU?L=1L]3MA<6-U%<0YQOB8, ?0^AY'%>'^&9-
MMM-=3>#KO7999#FY)=E]QPA&<\DYSS71^ X-3L_&MP\>A7VF:9=1G,4R.40@
M9'S$#OG'UQ43P\8IZZKT_P"'-*>+E*2NM'ZZ?A8]+L=5T_4_,^PWL%SY1 ?R
MG#;<],X^AI9=3L8;^.QENX4NY1NCA9P'8<\@=>Q_*O//A%Q)KP/42Q9'_?=3
M:ZZM\9]#"L"5M@& /0_O#_(BLW12J.%]E?\  U6(;I1G;=V_&QVD_B+1K62>
M.?5+2.2W&94:4;DZ#D=>X_.G:7KVE:TK'3KZ&X*_>53AA[E3R!7F5IH-EX@^
M+.L6VH(SP1;YC&&*[R"HP2.<?-GCTKT*ST;1?"5K?7EE;BWC90\OSDYV@X R
M?<\>II5(0@K7=]!TJE2H[V5KM>>AB>+]3OKC5[31=)FD2X/S2>4Y4Y(X!(Z8
M'/X^U7_!&L2:EI<EO<R,]U;-AF<Y+*>A)/?J/P%<IX?\065MKEYJVJ>:T\N?
M+"+NVYZ]3Q@8 ]J6UUVRL_&QU"S9UL[DXE#K@KNZ_AGFL#I/2KJ_M+';]JN8
MH=^=OF,%S],T7-]:6<*S7-S%%$QPKNX /T-5M<T^VU+29X;I@B*I<2G_ )9D
M#[W^>V:X/2K=/$.K6D$\S?V79_NH5D;F8CD@?7J<=!@>E &_XDM[F_U;1;FR
M\1+8V^X,8A(1YPR#D <-GI@\<^]=%?:K8:8@:]NHH<] QY/T'4URWC$ >(-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8^H>%
M=#U3)NM.A9C_ !*-ISZ\=?QKG;CX4>'Y03$]U$QZ8<$#\,5W5%7&<H[,B5.$
MOB5SS-O@Y9DG;J\P'IY(/]:C/P;@_AUN0?6W'_Q5>H45I]8J_P QB\+1?V4>
M8)\'D0Y77I5^D&/_ &:K,7PLEBQM\37JC_93'_LU>C44/$57U!86BMH_U]YQ
M,'P\,?\ K/$NLM_N3[?\:N)X$M5QNUG7)/\ >O3_ $ KJJ*GVL^_]?<6J%-=
M/Z^\P$\':0H D%Y,?62]E/\ [-5F/PQHD?\ S#+=_P#KJOF?^A9K6HJ>>7<M
M4X+H5X;&TMAB"U@B'HD87^56***@NU@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>forms-1a_004.jpg
<TEXT>
begin 644 forms-1a_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ('!2D# 2(  A$! Q$!_\0
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MS.QP /4T[.]@'XI<57LK^TU*W%Q97$=Q"20'C8,,CKS5BDU8!1UIS4T=:<U
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MNK2'PW\7;*ZC.V#58PDRCH6Z9_E3K:67QAXYMK^&"2.RM2K;F'93D?F:B^(
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M/&":LQ"*",1PQ+&@Z*HP!245E=ED.HVL.IZ;<6,ZYBGC*-[9[USG@G2;[2]
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M[T!Q],U,*,TG)MW&DEH5[O3[*_55N[6&<+]T2(&Q3I+&TEM5MI+:)X%&!&R
MJ!]*FI:5V%BM::?9V"E;.UA@!Z^6@7/Y4Z^B>>PN84QODB95R>Y!%3YI*+ZW
M"QP7P_\ !<^C:-=VFO6=K(\EQYD8R) !@#\*[N*..&-8XD5$7@*HP!2BEJIS
M<W=BC%15D4Y='TV>X\^6PMGF_OM&":N84+MP-N,8[445-V.Q331],CN?M":?
M;+-G.\1#-6+BUM[M ES!',H.0)%##]:DS11=A80 ( J@!0, #M2L%=2K %2,
M$$=:3O2TAE*#1],M9_/@L+:.7^^D8!JW+%'/$T4L:R1MP589!IU%-ML5AD,,
M-M$(H(DBC'147 %,AL[6V=W@MXHF?EBB %OK4U%*[ HW.EV$MR+F2RMWG'21
MHP6_.EM[2WMM_D01Q;SEMB@;OK5J2HQ3NPL4/[&TQ;G[0+"V$V<[_*&:GGM+
M>Z4+<01RJIR Z@X/XU+(&(^6G ?+SUIW86*]Q:6US$L<\$<J+T5U! IDD4,L
M'D2P1R18QL901^566Z5"1S1=@0VEI:6((M+2& 'KY: 9IMU86%ZX>ZLK>9QT
M9XP35C%&*+N]Q60L92&-8XHU1%X"J, 4XRY&"!BF8HQ2&54TW3H[C[0EA;+-
MG.\1C-69TANH_+N(4E3.=KJ"*7%&*=V*PJ,L:*D:*J*,!0, "F7$4%W'Y=S;
MQS)_=D4$4[%&*0R&TM+.Q!%I:0P9Z^6@&:;/8V-U.L]Q96\LJ]'>,$U8Q1BG
M=[BL1I;6L<KRI:PK(XPS*@!8>].MX(+562W@CA5CDB-0,G\*?B@#FB[ K-H^
MFR7'VA["V:;.=YC&<U9EACFB,4L:O&PP589!'TJ04=Z+L+',Z_9:O8:8L?A&
MRM(Y9'(F4JJ_+CJ/>JOP^\(7'AFTN;C461K^[;+[#D*/3/?DDUV*]:&J_:RY
M.42@N:X_-4KG3+&\N%EN;."61>C.@)%6E/K1_%6:;130L=C9QR&5+6%9&7:S
MA "1Z9IT%I:VL;1V]O%$C?>5$ !J8=**5V%B*WM;:T5EMH(X58Y(C4*"?PJ$
M:5IPN&N!8V_G-P7\L9/XU;Q2XIW86(8+:WM(C';PQPH3G;&H49_"G2Q17$1B
MFC62-NJL,@T\CB@#BE<"K::986#%K2R@@8]3&@!-2/:6LEPMP]O$TR_=D* L
M/QJ?%&*=V! ]I:O<K<O;Q-.OW9"@W#\:#:6IN?M)MXO/''F[!N_.I\48HNP*
MMWIUC?X^UVD,Y'0R(&Q4L,,,$7DQ1(D0& BJ /RJ7%(HR:+O8"B-'TR+S&CT
M^V4R<.1$/F^M/CM+:*W,$<$2PGK&J@+^56Y!B,U!VIW86*<&E:?9RF2VLH(I
M#U9(P#7%>-M$\9>([EM+M%M5T9F5O,9P#[Y[\?2N^'WJM@<"JA4<)<V[)<4U
M8H:'I<.A:)9Z9 <I;QA-V/O'N?Q.35UU256CD4,C##*PR"*=BDQ\U0VV[LJU
ME8C6PLTMFMEM81 W6,(-I_"E%I;+:_9A;Q"WQCR@HVX^E3T4[L1#!##;1"*"
M)(HQT5%P!^%+-%#<1&*:-)(SU5QD&GXI,5(RM::;86!)M+." MU,:!<TX6EJ
MMT;E;>(3G@R!!N/XU/BD-.["Q5-G;?:C<BWB\\\>;M&[\Z@2QM(6E\JVA3S/
MO[4 W?7UJZ>IJ,]31=@5H;6"U0I;PQQ(3G:B@"JXTK3UF>865N)'&&;RQDUH
M8IA%.[%8J_V?9&W%O]DA\D'<(]@VY]<581%C0(BA5 P !P*=12N,J#1]->Z^
MT/86S3==YC&<U;NK2VND5;B".55.5#J"!3T^]3WZ4[L5BI<6=M<QK'/!'*B]
M%=00*D"A0    , 5)2$4AC,48I:* #%%!'%,5B&PU #QUJ:JVXJ_/2K&Y?6@
M!**** "G4VG4 %%%% !2-TI:1NE $=%+24 +C(I5&*0''6HGO[.$XENH(S_M
MR ?SHM<+EQ>E1R]JJKK.EC_F)V?_ ($)_C3)=9TLX_XF=G_X$)_C5<LNPKKN
M6**I_P!L:7_T$K/_ +_K_C2?VQI?_02L_P#O^O\ C1RR[!S+N7<4E5/[8TO_
M *"5G_W_ %_QI/[8TO\ Z"5G_P!_U_QHY9=@YEW+E%4_[8TO_H)6?_?]?\:3
M^V-+_P"@E9_]_P!?\:.678.9=R[2U2_MC2_^@E9_]_U_QH_MC2_^@E9_]_U_
MQHY9=@YEW+M%4O[8TO\ Z"5G_P!_U_QH_MC2_P#H)6?_ '_7_&CEEV"Z[EVB
MJ7]L:7_T$K/_ +_K_C1_;&E_]!*S_P"_Z_XT<LNP77<NT52_MC2_^@E9_P#?
M]?\ &C^V-+_Z"5G_ -_U_P :.678+KN7:*I?VQI?_02L_P#O^O\ C1_;&E_]
M!*S_ ._Z_P"-'++L%UW+M*!5$:QI?_02L_\ O^O^-._MC2_^@E9_]_T_QHY9
M=@NB[3TZ&J']LZ7_ -!*S_[_ *?XTY-9TK!_XF=E_P"!"?XT<LNP77<O4M4/
M[9TO_H)V7_@0G^-*-9TO_H)V7_@0G^-'++L%UW+PI:H_VSI7_03LO_ A/\:/
M[:TK_H)V7_@0G^-'++L%UW+](>E4O[:TK_H)V7_@0G^-!UG2L?\ (3LO_ A/
M\:7++L%UW))&VMBD1SO%5)-6TMC_ ,A*S_\  A/\:1-6TL'/]I6?_?\ 3_&G
MRR[!==S4F^X*AJ"36=*,?_(3LO\ P(3_ !J'^V-+_P"@E9_]_P!?\:7++L%T
M7:*I?VQI?_02L_\ O^O^-']L:7_T$K/_ +_K_C3Y9=@NNY=HJE_;&E_]!*S_
M ._Z?XTHUC2_^@E9_P#@0G^-'++L%UW+P%.JD-9TO_H)V7_@0G^-']LZ7_T$
M[+_P(3_&CEEV"Z[FBO2D?[IJDNLZ5C_D)V7_ ($)_C0^LZ5M/_$SLO\ P(3_
M !HY9=@NNY+15/\ MC2_^@E9_P#?]?\ &GQ:G83R+%#?6LDC=$2923^ -+E?
M8+KN6:B?[U35"_WJ0Q%H)Q0M.P* &XQ1CC-/HH 8!D9HQ@<T\D"F>YH /<TX
M'&&;GT%-]S3AQ\QY/84 /;@;GZGH*CYS[T2RI&-TKJI/]XXQ5&36M+A)5]1M
M0W?,HIJ+>R$VEN7NG Y-2(F.3UK*7Q'H:]=6L\_]=14@\3:%_P!!:S_[^BJ]
MG/L_N%S1[FL!2]ZR?^$GT+_H+V?_ ']%+_PD^A?]!>S_ ._HH]G/L_N#FCW-
M@?=J$CFL\>*-!V_\A>S_ ._HJ/\ X2;0L_\ (6L_^_HH]G/L_N#FCW-0"G"L
MH>)M"_Z"]G_W]%+_ ,)/H7_07L_^_HH]G/L_N#FCW-7O4G/:L7_A)]"_Z"]G
M_P!_14H\4:#_ -!BS_[^BE[.?9_<'-'N:N6]:,MZUE_\)1H'_08L_P#OZ*3_
M (2C0/\ H,6?_?T4>SGV?W#YH]S5RWK29;UK,_X2C0/^@Q9?]_11_P )1H'_
M $&++_OZ*/9S[/[@YH]S3RWK1EO6LS_A*- _Z#%G_P!_11_PE&@?]!BS_P"_
MHI>SGV?W!S1[FGEO6CYO6LS_ (2C0/\ H,6?_?T4A\4:!_T&+/\ [^BG[.?9
M_<'-'N:GS>M'S>M9?_"4:!_T&+/_ +^BE_X2C0/^@Q9_]_11[.?9_<'-'N:?
MS>M)\WK6;_PE&@?]!BS_ ._HH_X2C0/^@Q9_]_11[.?9_<'-'N:?S>M'S>M9
MG_"4:!_T&+/_ +^BC_A*- _Z#%G_ -_11[.?9_<'-'N:?S>M)\WK68/%&@?]
M!BS_ ._HI?\ A*- _P"@Q9_]_11[.?9_<'-'N:?S>M'S>M9G_"4:!_T&+/\
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M_P"_PIH\8^'0>-;L?^_PH]G/L_N#GCW-V3[N*A*BL@^,?#Q/_(;L?^_PI/\
MA+O#G_0<L/\ O\*?LY]G]P<\>YK;<'-3J<K6"?%WAW_H-V'_ '^%*OC#P\O_
M #&['_O\*7LY]G]P<\>YOT@^]6(/&/AP]=;L1_VV%'_"8>&]W_(<L?\ O\*/
M9S[/[@YX]S=)I*Q/^$Q\-_\ 0<L?^_PH_P"$Q\-_]!RQ_P"_PH]G/L_N#FCW
M-NBL3_A,?#?_ $'+'_O\*/\ A,?#?_0<L?\ O\*/9S[/[@YX]S;IIZUC?\)C
MX;_Z#EC_ -_A33XP\-_]!RQ_[_"CV<^S^X.>/<USU-1GK62?%_AS)_XG=C_W
M^%1GQ=X=S_R&K'_O\*?LY]G]P<\>YLT5C?\ "6^'?^@U8_\ ?X4?\);X=_Z#
M5C_W^%'LY]G]P<\>YKD48K(_X2WP[_T&K'_O\*/^$M\._P#0:L?^_P */9S[
M/[@YX]S:0<TY^E8B^+O#H/\ R&['_O\ "E;Q=X=/_,;L?^_PH]G/L_N#GCW-
M>BL;_A+?#O\ T&K'_O\ "C_A+?#O_0:L?^_PH]G/L_N#GCW-@BDK(_X2WP[_
M -!JQ_[_  J2W\2:)>7"6]MJMI+-(<(B2@EC[4>SGV8<T>YITC)N%.Q2U!1"
MIYV/3_LX_O4KIN'O3?+E_O4 2T444 %.IM.H **** "@C(IDTT=O"\LSJD:#
M+,QP *\I\6?$R:=I++0F,471KK'S-_N^@]^M;4:$ZKM$SJ58TU=G=:YXKTCP
M^I%W<AI\<0Q_,W_UJ\[U;XJ:C<,R:;;QVT?9G^9O\*X)W>5V>1V=V.2S')--
MKUJ6!IP^+5G!/$SEMH:5YXAUC4&)N=2N7!_A$A _(5FL2QRQ)/N:2BNM12V1
M@VWN)@>@HP/04M%,0F!Z"C ]!2T4@$P/048'H*6DH 3 ]!1@>@I:* $P/048
M'H*6B@!,#T%&!Z"EI,T## ]!1@>@HHI )@>@HP/04M% "8'H*,#T%+10 F!Z
M"C ]!2T9H 3 ]!1@>@HHH ,#T%)@>@I:* $P/048'H*6B@!,#T%&!Z"EHI )
M@>@HP/04M% ";1Z"C ]!2T9H 3 ]!1@>@HS1F@ P/048'H*** # ]!1@>@HH
MH ,#T%&!Z"BB@ P/05TG@$#_ (3C3./XV_\ 037-UTG@'_D>-+_WV_\ 036=
M;^'+T9=/XT>^U"_WJFJ%_O5\\>N"TM-6EH 6@G%(3BFT +[FDS@9-5KZ_MM-
MM'NKN41Q(.2?Z5Y-XG\>W>K.UO8EK>SZ<'YG^I_I6]##SK/3;N95*L::U.]U
MKQSI.C[D$GVFX'_+.,\ ^YK@=4^(^L7K$6Q6U3ML'/YUQY)8DDDD]S25ZU+!
MTH;J[.&>(G+R+5SJ=]>.7N+N:1CW9R:JEB>Y_.DHKJ22V,&V]PS1113$%%%%
M( HS244 &:*** "BBB@ HHI*!BYI,FBBD 4444 %%%% !1129H 7-&:2B@ R
M:,T44 %%%% !1112 **** "BBC- !129HH 6BDHH 6C/O244 +GWHS[TE% "
MY]ZW_!/_ "-^G?\ 72N?KH/!'_(X:=_UTJ*OP2]"Z?Q(^@J***^=/7$-%+28
MH *6D%+0 4$@#). *IZGJ=II%C)>7LPCB0=3U)] .YKQWQ3X]O\ 77>WM6>U
ML.FQ3AG_ -X_TKHH8>=9Z;=S*K6C36IZ!KOQ"TC2"\4#_;+E>-L1^4'W:O/M
M5^(VNZ@2L$JV<1[1#G\S7(T5ZU+!TH=+OS.">(G+R)[F]NKQR]S<RS,>[N35
M>BBNE)+8QN%%%%,04444@"BDHH **** "BBB@ HHI*!BTE%%( HHHH ****
M"BBDS0 M&:2B@ HHHH **** "BBBD 4444 %%%&: "BDS10 M%)10 M%)10
MM%)10 M=!X'_ .1UTK_KM_0USU=#X&_Y';2O^NW]#45?X<O1ET_C1]"XI*=3
M';9CCBOG3UQ1UI]1E@%W=J3[0E #J***8@IU-IU(84V66.&)Y975(T!9F8X
M [TZO*OB;XJ+R'0K.3"#FY93U/9:UHT75GRHSJ5%3CS,Q/&_C:7Q!<M:63M'
MIL9P.QE/J?;T%<;117T%.G&G'EB>5*3F[L*2BBK)"BBB@ HHHI %)110 444
M4 %%%% !1244AA1110 4444 %%%)F@!:3-%% !1110 4444@"BBB@ HHS24
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M@ HHI* %I*** "BBB@ HHHI %%%% !129HH 6C-)10 9HHHH **** "BBB@
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M\1]4-]XC:V4_N[5=G_ N_P#GVKCJ]W!TN2DGU>IYF(GS3MV"DHHKK.<****
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M3F.V'E+]>]<K7O8.E[.DN[U/,Q$^:?H%)11748!1110 444E( HHHH ****
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MC'!SQP:HZ)K%UH&KV^IV0C-Q <IYBY7\1D5I[*5IKOM]UB.=>[Y?YFS\2/\
MDH6M?]?!_D*Z[XJ_\B=X1_Z]A_Z M>;:QJMSKFK7.IW8C%Q</O?RUPN?85?U
MWQ;J?B'3M/L;X6XAL4V0^6A4XP!SR<]*?LY>YY?Y!SKWO/\ S.]^(O\ R3'P
M9_USC_\ 1=,^,_\ QZ^%O^O1_P#V2N&U?Q?J>MZ+INDW8MQ;:> (3&A#<# R
M<\\4GB/Q;J?BA+%-0%N!91F.+RD*\''7).>@K.%&47%OHW^)4JD6GYV.[^%7
M_(F^+_\ KW;_ - -,^%NAZ8/#FK^)KRP74+FR)6&W9=P&%!SCU.?TKB-"\7:
MGX>T[4+&Q%N8;]"DWFH6.,8XY&.M+X7\9:OX1N))-,E39* )895W(_U'K1.E
M-\]NM@C4BN6_0] T/XD>*_$FOVNF:5I]K:0/,OF^5"3L3/.3T'&>U3^/01\:
MM /JT/\ Z%7*ZC\7/$=Y;M#:I9:<'^^]I%AV_P"!$G'X5DZMX[U?6=:T_5[I
M+07=@08F2(@-@Y&[GFIC0DI<RBDK-%.JN6S=]36^,?\ R4B]_P"N,/\ Z *X
M+-:OB+Q!>^)]9DU34!$+B154B)2JX48'!)K*KII1<8*+Z&,VI2;1[/XTU"\T
M_P"$GA:2RNY[9V1 6AD*$C9[5Y3-K^LW$9CFU:^D0]5:X8@_K5_5O&.J:SX?
ML-$NA;BTL0!$40AN!CDYY_*N?J*-+EC:2UNRJD^9Z%O2K1=0UBRLY'V)<7$<
M3/Z!F )_6O9_&'B*'X9S6ND:!H%J T0;[3-'G<>G7J3^->'*Q1@RDA@<@CL:
M]!M?C%XBALH[>YM]/OFC&$EN(27_ !P>:FM3E)II77;8=.:BFMGW/0=.U/Q#
MKGPMU_4=>0(TT3_9HQ'LP@7KCKR<]:Y3PO\ \D&\2_[Y_FM<Z?BKXHD-Z)YK
M:XBNX_+:&6+Y$7GA ",=?>L>R\7:G8>%KWP["MO]AO"3(60EQTZ'/'3TK*-"
M:35ENF6ZL;KT:.Z\+?\ )#/$G_70_P#LM<?\.?\ DH6B?]?(JK8^+M3T_P ,
M7GA^ 6_V*[;=(60E^W0Y]O2L[1]5N=$U:VU*TV&XMWWIY@RN?<5LJ<K3\_\
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M$>E2:#XPU3PYJMUJ-B+<SW082>:A9>3DX&115HRDYVZI"A4BE&_1L[OX-_\
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M<YZY_I5NE+D@NUB>=<TGWN8-%%%=!B%%%% !1110 4444 %;_@K_ )&[3_\
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M ./B7_?/\Z97TRV/&8444E @HHHH **** "BDHH&%%%%( HHHH *3.>E=?\
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M6M0I#(>C,J_>/T_QJI)Z<GVE;^OQ%&VO-TU/)-5UN;5O%MQK+,1)-=>:O^R
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M^'+T9=/XT>_5'+VJPX 4D#FHE42C)XKP#U2$5D^*#_Q2^H_]<36[Y ]:PO%
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M7B#Q)::9-*\4<Q(+H 2, GO]*&[*X)7=C&HKM/'O@:/PB+26VN)9X)\JS2
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M4E !1110,**** "BBB@ HI** %S2444@"BBB@ HHHH **** "BBB@ HHHS0
M44F:,T +71>!O^1RT[_KI7.9KHO O_(Y:=_UTJ*GP/T*A\2/HFBBBOGSU@K"
M\9_\B9J__7LU;M87C/\ Y$S5_P#KV:KI?''U1,_A9\\4445](>,%'4X%%/@<
M).C-T!YJ*DG&#E%7:6QM0IQJ58PF^5-I-]DWO\@>"6-=S(0/6HZU+FXB,# ,
M&+#@"LNN++L55Q%-RJPY6GY_J>QGV6X7 5XT\+5YTU=[.WW::[A1117>>$3V
M?_'VGX_RIMW_ ,?4GUI;+_C[3\?Y4EW_ ,?4GUKSO^9B_P#!^I] _P#D0K_K
MZ_\ T@AJQ*DHMHV9\H>@]*KU=N/^0?#6F*FXU*2767Z,Y\LHQJ8?%2;?NPOH
MVOM+?NO)C!8R$*VY0I&<GM2263)&71U<#KBI;QB+:%0>"*;8$[)AVQ7G+$XK
MV'UES5D[6MNN:V_<]YY?ECQJRY4G>4;\W,]'R<VBVMZ]RK%$\S[4&35D6.3M
M$R;O2F6@F+,L) !ZD]JD6VBC<%[@9!Z"M\5B9QJRBJG+9:)+F?S[''EF749X
M:%25!SNW>4I\D4K_ &==7W\]"K+$T,A1QR*FCLG9 [NJ*>F:EO5#7D0/0@?S
MIFH,?/"_P@<"E#%UJ\:4(/E<DVW:^VFB\QULKPF"GBJM6+G&G)1C&]KN6NK6
MMDNVY'-:O"H?(9#W%37G_'G!]/Z56$\@A,0^X?:K5W_QZ6]*HJT:U%5FFU)Z
MKJN5[KHQX=X6>%Q<L*G%.G&Z>MGSJ]GU1!#9O*F\D(GJ:=)9.J%T974=<5)?
MDJD48X7%-TYB)RG\)'(J?K&)E0>+4E9:\MNB=M][FOU#+H8V.5RIMR=DY\SO
MS-7TCM;IW)-.CX9]PY&,=Q4*P.ET$CE7<><CM4UD +B<#H!4%E_Q^#\:S<IJ
MKB*B>G*G:R[:?=^)O&%&6'P.'<+/VDE=2=]))-KU_#H1M%(]RT?WGW<FIS8,
M./-3?_=J:W&+RY;N,XK.+MYA?)W9SFMZ=6O7ER4Y**C&/2]VU?Y+T.&OAL%@
MJ?ML13=1U)S2]YJT8R:OYR?F7=0!"0@]0M0PV;RIO)")ZFIK\[T@)ZD<U/=Q
M1LD:-,(U X&.M<E+%3I8>E33LY.5W:]K-[(]7%9;2Q6/Q->:YHP4+1<E&[<5
M:\GLDOOV*4MDZ1^8C!U'4BJU:=L(;?=_I 96'2LUL!VQTSQ7H8'$5*DI0GJE
M:SLU?Y>1X&<X"AAX4JU)*+E=.*DIV:ZIIO1KN)1117HG@A1244 +FDHHI %%
M%% !1110 4444 %%%% !111F@ HHS29H 6NA\"_\CMI7_7;^AKG<UT/@;_D=
M=+_Z[?T-9U/@?HRH?$CZ(W#UI"1CK4=!Z5X!ZP0CYS5FJ\!RQJ>@".BBB@!:
M9+_J)?\ </\ *G4V7_42_P"X?Y4(1\QS_P#'Q+_OG^=,I\__ !\2_P"^?YU'
M7TW0\9[A4EO!)=7,5O"NZ65PB#U).!4=2VUQ):74-S$<21.'4^X.10!Z5>_!
MVYMM&>XBU,2WL<9=H?+PK8&2 <UYA7J5[\8I+C1G@AT[R[V1"AD+Y521@D"O
M+:RI>TUYS2IR:<H4E%%:F9J^&?\ D:-+_P"OE/YUT_Q=_P"1W;_KW2N8\,_\
MC1I?_7RG\ZZ?XNG_ (K=O^O=*Q?\5>AJOX;]3EO#VJ3Z/KMG>6[E2DJA@#PR
MD\@UW/Q9T^$>*=+NU4#[9$%DQ_$0V,_D17$^&M(GUO7[2SMXV?,BF0@<*H.2
M37:_%34(I_&&EV$3!OL:*'QV9F!Q^0%*7\16[,(_ [F;XY\*VMAXETO3-%MR
MC7D*84L3ERQ'>M?4=,\$>"%AL=4M9]5U%D#2[#@+^H ]JV=?>./XM^%FE("^
M0 ,^IW ?KBJOC3Q%H>E^)IX-2\+1W<Q56%P[8\P8_P BLE*3Y5Y&CBE=F!XC
M\*Z+?>%_^$G\+-(MNAQ<6S]4]?H1G\JZ;P?=Z!_PK;5'%A<?9HHR+Y-W,IV\
ME>?\*SAXF%SX*U0:1X3:VTV57666.0;5; !..^.*J^#O^24>*?\ =?\ ] %$
MKN-GW!64KKL<!JTMA-JD\FF02063']U'(<LHQW_&M[X:_P#(_P"F?5O_ $$U
MR==9\-/^1_TSZM_Z":WGI!^AE#XD>B>)_P#BI_#/B.P^]=:5<&6,=]H&?Y;A
M7G'P\TD:MXPM XS!;_OY">F%Z?K79Z/JJV/QDU2RE(\B_8PD'H6QD?U'XTR/
M2O\ A!/#WB>]8;99IC:VA/4H>A'X']*P3Y4XKK:WS-6N9\W8T_%6K?VW\+=3
MO@?D:[98_P#=67 _05R?A/PCI(\/2^)O$LCK8(<1PKD%^W;DY/ %:,7/P"DS
MU\]O_1M&O*]Q\%=(DMP3'#(OF[>W4<_B?UHCHN5=P>KN^PNEVO@'QC,^F6=A
M<Z9>LI\EV/WOU(_ UR%KX/O9_&O_  C3L%E60J\@' 0<EORJ/P1#-<>,]+6
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M/*X.3CI5_37^&M[J<>B1:=<L9&\M+QR0';\\C/TJUX)D5]$\<21'"D3%2/\
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M^(M'TBQ2S> V"%2[."'R ./3I7+4N*%3BMAN;9WVC_$2W_L./1O$FE+J=K$
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M0 M%-S10(=FDS244 +FC-)10 N:Z#P.?^*TTO_KM_0USU=!X'_Y'32_^NO\
M0U%3X'Z,J'Q(^@Z*,BC->">J*O!J3)]:C%.I#'T444 %-E_U$G^X?Y4ZF2_Z
MB3_</\J$!\QS_P#'Q+_OG^=,I\__ !\2_P"^?YTROID>,PH-%"JSL%4$LQP
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MOK]QQ9DYPRR<*M*4;R5O:3N[ZWY5:]K;N]MB"BC-)FO:/C1:3-)10(,T444
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M7+D\[LYS7J_Q#_?6'@ZYF'^DNP#$]<80G]:SQ:_#J[U#^V7U*:)&;S7L2O\
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M/).:M64T<4DA<X!'%5!U!KKHP:Q-636ZC^3/*Q=:$LOPU.,M5*;:OM>2M?\
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M4J*NV&D:CJAE%A9S7!A7=)Y:YVCU-4J+A8**** "BC-)0,6BDHH 7-)FBBD
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MT$TE(04444 %%%)0,6DHHH ****0!1110,**,TE "T4E% "YI,T44@#-%%%
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M'AG8VH6X\ESA9HSN0GTSVHT?P?K&NZ=)>Z? LL:2"(C=ALG';\:]4MM'DM/
M.J:-K6LV5^-C-;,DF2F!G'/N.*Q/ >HS:3\+M>OX#B:%F9#Z-@ ']:7M7RZ;
MA[-7.6U3X<Z[I,EFDXMV-U*(H]LG\1[5-;?"WQ+<7$T;0PPK$VWS)),*Q]O6
MJ/AC5+^_\7:0EW>3SJ+H,!(Y8 GOS6W\5]9OG\8262W,B6]K&FQ$8@;B,D_7
MG]*J\[\MQ6C:YDR?#CQ)'K"Z;]B#.R[A*&_=X]=U+KGP[U[0=/:^N(XI;=?O
MM"^[;]:[3Q;KM_%\*M&=+AUFO J2R X8J!TS[\52^'5W<7G@_P 36MS,\L,<
M.Y%<YP2ISC\JGGG;F'R1O8Y[PJ?$8\+:[_9(MS8;#]K\S[V-A^[^&:R=*\'Z
MSK>E-J%A;B:%9!%M#?,3]*[/X=_\D^\6_P#7-O\ T6:L>#=0GTKX1:U>VS;)
MXW;8P_A)P,_K0YM-V[H%%.U^Q@2_";Q+':F4);.ZC)B67+5D^#_#UWJWBJ&U
M6%,VLBR7$<I ^56 (P>OTJ_\/-7OQXZL0UW,XN'*RAG)W CO5G6A]G^,3+"2
M@:_BR%.,Y*DT[RNXOL*T=&C1^+/AV]35I-;58A8[(X@ P!!Y[>E>8YKO/BW+
M)_PFTL>]MGDH=N>/RK@ZJE?D5Q5/B9ZUX5MK'P1X%;Q9=VZS:A<_+;*W;/0#
MTSU)]*Y*X^)GBR>[,ZZHT0SD11HNP>V"*ZKQUF;X4>')81F%7CW8Z#Y"!_6O
M**B$5*\F5-M62/9-.OK?XI>%;NTU""--9LDW1S(,9]"/KC!%<?X"7Q)#?ZG'
MH"V_G+%MN!/V )Z?C6K\&$D_X26^E&?*2U(<]N6&/Y&M/X8,C^*_$[1_<*DC
M_OLU+]WF2V*7O6;*/PASYFO9Z_93_6O,F^^WUKTWX1?Z[7_^O8_UKS%OOM]3
M6D?C?R(E\*$S1115D!1110 4444 %%&:3- "T4F:* %KI?A__P CSI?^^W_H
M)KF:Z7X?_P#(\Z7_ +[?^@FHJ_ _0N'Q(^@****\0](*R/%'_(K:E_UP-:]9
M'BC_ )%;4O\ K@:NG\:]29?"SYZHHHKZ$\@***5"!(I;[H/-3)V39<(\TE%N
MUV!1PNXJ0/7%-K:EDB\AB2I4BL6O/R['2Q<9.4.6S/<S[)J65SIQIU>?F5^F
MGW-Z/H%%%%>B>"26ZA[E%;H35J\N)XYBB_(@Z8'6J*!BPV Y]JN)J!QMFC#X
MXSWKRL91G*O&JH*:2MRM_BKZ'TV4XRE#!SPTZKHRE)-32=G9?"VM5WT%ANQ)
M&\=R001P<5#9HKW2AN0.1[U9$=K=@B,;),9JBJR)*0H.]3VK*@J4XUH4[TY-
M:IZ6Z77J=&-GB*53"UL0XUX1>DHZN233<7?6ZZ)HLW5U<),R@E%!XXI5NDFM
MG2X(W?PG%"ZB&&)H@WN*?Y%M=HQ@^5QVKGE"%*$8UZ7):WO1L_G??7K<]"%6
MMB:U2I@L4JO.I?NYW3::>B3T;72UMB/3/]>WTJ-[RX#L!(<9]*DTWBX8>U/,
M]GYA#0D<\G%:U7'ZY4;I<^D>B=M^YS8:-1Y104,0J+YY[N2OMV[>8ZRN'N&:
M.7#+CKBJL"A;]5'0/BKEPYMH-UO&H1OXAVJA:<W<?UJ<-%2IUJT%RQ:LEYI.
M[:Z%9E.5*O@\'6FZE6$DW*SVDXV2;UDNMQ]_S>O^'\J5;"9E!.U<]B:==,$U
M+<1D @FK$UN+MO,BG&<=#5?6IT:-&*?+%QW:;U[$?V;1Q>+Q<W%U)QF[04E%
MVN[O7?M9&?+#)"VUQBHZM7?V@*B3 8'1AWJK7IX:I*I24I--^6Q\UF6'IX?$
MRITU))6TDK-:;/\ SZ[ENQC +SO]V,9'UJLS/-*3R68U<7Y=)8C^(TW35!G9
MC_"N:X57Y/;XEZ\KY5\O\VSW)8+VOU/+HNRFN>3\Y7U^48V0T:?.1GY0?0FH
M=DD4ZJ1AP1C-$DTCS%RQSGCGI4IN&N+B$LH!! R.];)XJ*O4LTT[]+:?BCCE
M'+)RY</S0FI12N[\RNDWLN5K=;DABFEO@)0NX $_2C4H&$AEXV<"G71QJ:?A
M46HD_:R.V!Q7%AW4G7HR327)M;SUZGL9A&A2P>+A)2DU52NWJW9V;TZ:W77R
M(XK*:5=P "^IXHFLIH4WL 5]0:LM%=74:$A8T X&<5+'$8K.9&E$G'0=J)YA
M4@TW.+=[<JUTO;?:XJ.0X:K%QC2FERMJ<FE=I7^!ZV>W?J06'_'M<_[O]#5.
M*&29]L:Y-7+#_CVN?]W^AIT+&#2VD3AF.,U4J\J-6MR+WG**7S1G#!4\5A<)
M[9M0A3J2=M[*>R]2!M.G521M..P-5E1FD" ?,3C!J2WG>.=6#'D\^]6[I0NI
MQ$?Q$$UO[>O2FZ=5IWBVFE;;HT<*P."Q=!8C#*4;3C&2;OI)Z-.R^:(1ITY)
M! &.Y-0SV\EN0'7@]".E6-2E9KDIDA5'2I(V,^E2!^2AX)K.&)Q,:=.M4MRR
M:5DMK[.YTULMRZI7KX/#J2G34FI-II\NK5K::;._0K1V4TJ*RJ,-TYILMK+#
M(J$ LW3%73*T6D(4."3C-5+::87"E!YCXP :JE7Q,^>IIRQ<E;:]O/H9XG Y
M=1=&A:?/-0DVM;<VZ4;7;?0D&FSD<[0?3-5IH9('VR#!JXUE</(9)9D0DY^]
MTIVJ#]U!SN./O>M9T<;-UH0<U)2OLGII??J;XS):,<'5KQI3IN%K<TD^9-VU
M6Z[_ (%9;&=PA51AAD'-++83Q*#M##_9JS=2LFG0*I(W 9Q1I\K"TG.2=O(S
M]*AXO%>R=96LI6M;?6VYK'*<L>)6"?/S."ES75E[JE:UM>O4@_LVXVYPN?3/
M-506CD!'#*:LV,LAODRY.[.:CO<"\E'O771J5?;NA6L]+Z*W6UCRL7A\)]3A
MC<&I1:GRM-WV5TTTE8FOXPZQW*=''S?6J5:"_/HIS_"W'YUG9IX"3Y)4W]AM
M?+I^#)SVG%UZ>(BK>UA&;]7H_O:O\Q:*3-%=QX@M=!X(_P"1OT__ *Z5SU=%
MX&Y\8Z?_ -=*BI\#]"H?$CW_  :,&IME&P5X1ZA#BL7Q>/\ BD-5_P"O=JZ#
M96'XQ4#P=JQ_Z=VJZ?QQ]43/X6?/M%%%?1GCA1124@"BBB@ HHHH&)1110 4
M444@"DHHH&%%%% !1124 %%%%( HHHH *2BEH ***"<4#"FT44A!1110 4E%
M% PHHHI %%%% PHI** "BBBD 4444 %%%% !11FDS0 M%)FB@!:Z'P+_ ,CK
MI?\ UU_H:YVNB\"?\CMI?_77^AJ*GP/T94/B1]"T445X9Z84M%% $E%%%(84
MR;_42?[A_E3Z9-_J)/\ </\ *A ?,<__ !\2_P"^?YU'4D__ !\2_P"^?YU'
M7TJ/&>X4E%% @R<8R<>E%%% PI*4TE &KX:8+XGTQF( %RF23@#FNE^+4D<O
MC5FCD1U^SIRK C]*X6C&.E0X^]S%<WN\H5UWPZ\26_AWQ$S7IVVEU'Y,K?W>
M<@_2N1I*<DI*S"+L[H]/U'X6/?ZF]WI.K63:=.^\.TG* \]NM8OCN#PUID%I
MI>BK'-=PC_2;I&SN..GIG-<6&8*5#$ ]0#Q33TJ%"5]64Y+HCW/6?#]MXD\!
MZ!9/>16MZ($:U,IP'.P97\JS-$TRR^&-C>ZKJM];SZE+&8X+>%LD]\?B<9-8
M/C?6].U'P9X;M+.[CEN+90)44\I\@'/XUY\Q+')))]364*;<;-Z%RFD[I:GK
M'PHDCN[;Q'+?,!',NZ=CZ')8_J:J6OPMCBU-;Z?6;(Z*C>:)0_++UQZ5G_#_
M %G3M+T3Q!#>W4<,EQ 5B5OXSM/ K@MQV[<G;Z9XJN67-*SL+F7*KH[KQAXS
MBO/&]CJ&F_/;:8RB$]GVG)_ ]*Z7Q)X;LOB&\.N:!J5LL[1A9H96P1CU[@BO
M'Z4,5.5)!]CBG[.UN5["Y[WOU/2=4\/^'?!_A*>'4I;>_P!=G_U2QOGR_3IT
M Z\]:;X9FB7X0>(XVE0.6.%+ $_=[5YMU.>]&!UQ3]GIJPY]=$;?A!E3Q?I3
M,P51<+DDX K5^)\B2>/;]HW5U*QX*G(^X*Y"DZ#BGR^]S$W]VQZ5XPFB;X6>
M&D65&=3RH8$CCTH^&<T4?AOQ0))40M ,!F S\K=*\TP*,#TJ?9^[RE<_O7/3
M?A[-%'X!\6*\J*S1MM#, 3^[/2FZ!-$OP7UR,RH)#)PA89/S+VKS3 ]*0X]*
M'3NWZ@IG2^ '6/QSI3.RJHEY+' '%:/BB[A@^+$EVTBF&.\C=G!R,#&:XFBF
MX^]<7-I8]5^*GAX7<C^)[74+:6W*(GEJP+'W'M7E5%%$(N*L$G=W/2/!7BG2
MKGP_-X3\2,$LY,^1.W1.^">V#R#4DGP@GEFWV6N64EFW*R,>0/P.*\SH#,%*
MAB >H!J7!IWB[%<RM9H]9O=6T/X>^&KG2-&NTOM7N1B:9""%/3DCICL*I?!V
M>.+4=9,TJ)NMEY=@,G)]:\RHP#U%+V?NM=PY]4STSX2S112Z]YDJ)FV.-S 9
MZUYHWWV^M)@'M15*-FV2W=)!11FDJA"TF:** "BBB@84449H **3-&:0"UTO
MP_\ ^1YTO_?;_P!!-<S73?#[_D>M+_WV_P#0345?@?H5#XD?0%%+BC%>*>D)
M61XH_P"16U+_ *X&MBLCQ3_R*VI?]<#5T_C7J3+X6?/-%%%?0'D!2444 %%%
M% PI*#10!+;3>3,KGIT-6Y+2.X8R0RK\W)%9]%<5?"2G4]M2GRRM;:Z:\T>O
M@\SA2P[PN)I*I3O=:M-/:Z:[]4:,4,=D3+)("V. *KV]SLNFD;[K=?:JU)41
MP*:G[:7,Y*S>VGD;5,[E&5)82"IQIOF2NW=O=MO?33T-![%)6WPRKM/.*=&D
M=@K.SAI", "LVBLW@:LX^SJ56X=K*[\FS>.=86E4>(P^&4:NMGS-I-]5'YZ:
MV+NG-_I#$D#(JI)_K&^M-I*ZH8=0K2JWW25O0\NMCG5P=/"M? Y._?FM_D7[
M&=64V\OW2.,U$D?D7Z*2"-W!]JJT5E]32G.4964UJO/N=7]KN5&C"I"\J334
MKZ\MT^5^6FCZ%N[9/[0);YDXS4KV6]_,MI%"GWZ5GT=*GZI.,8*G.W*K;73^
M12S6C4J598BCS*<N;1VE%]E*VWE\R_>R*MLD)??(.IK/HI:VPN'6'I\B=]6_
MFSDS+'RQ]?VLE:R22WT2LM7JWW9>A_>Z;*@ZKS4-E.()\M]UA@TEI/Y$V3]Q
MN&J.=5CE948,O8BN54$YU:$U[L]5^3^:=F>G+'25'#8VDUSTO<:]+N+MV:;3
M+;Z?ND+)(GEDYSGI39GA^TPI$!A2,L.]4:*N.$J73J5+V32TMNK7?<PJ9M04
M6L/04')IR=V]G>T;KW5?YE^\=1J"-D8&.:??1 R"Y#J5XXK-I*4<"X.FXR^%
M6VW7Z%U,[C55=5*5_:2YUJ_=DMNFJ\C6NHFNPCPRKLQTS1!''#;RPB16D(R<
M&LFBL?[-G[)4?:>ZMM%WOJ^IU?ZQ4OK+Q?L/WDDTVY.VJL^56T_$T+$@6]R"
M0#M_H:2TDCEMVMI&VD\J35"BMJF!4W-N6LFFO)I''0SN=&-&*@FH1E%IOXE)
MW:\OZ9H1V'E2"2:5-BG/7K3'G%QJ4;+]T, *I$T^!@EQ&S' ##)J7A9KFJU)
M<TN5I:6Z=N[-(YG2?L\-AZ?LX<\9.[NVTU:[=K)&E>68N)BT<BAA]X$U%.T=
MK9_9D<-(Q^;%5[Z19+IF1LC Y%5JQPN#J2I4_:S]U6=K=?-^1UYGFU"GB<1]
M6I)3E>+GS-JSW:6R;6[N_(ORD'28AD9W=/SINFRI'<$.0-PP":I45T_4DZ,Z
M+?Q-O[]3SO[9FL91Q<8*]-15N_*K?C?Y&A)82&0O+,NS.=Q-+J)1K:$QL"HX
MK.S25$<'4YX3G._+LK)+:QK4S>A[&M1HT;>TW;DY.][]5MY?B:%XP-C; $$X
M_I18L!9W.2!Q_2L^BJ^I+V'L>;K?\;D+.7]=6+Y-H<MK_P!SDO>WS+%@0+V(
MDX&3_*DO2#>2D'C-04^%!)*JLP52>2:UE34:KQ#?V;6^=SEIXF53"QP$8[SY
MKW[KEM^M[EZ0^3HZ*>LAS6=5F]N!-, O^K086JV:C!4Y0IN4]Y-M_/\ X%C;
M.L1"KB%3I.\:<5!/ORK5_-W"BDS1FNL\D6NB\"_\CEIW_72N<KH_ G_(YZ=_
MUTJ:GPOT*A\2/HBC%.Q1BO"/3&UA^,O^1-U;_KW:M[%87C,?\49J_P#U[-5T
M_CCZHF?PL^>:***^B/'"DHHH ****!A2444 %%%%( I*6DH&%%%% !1124 %
M%%%( HHHH *2BEH ***":0P)IM%% @HHHH&%)110 4444@"BBDH&%%%%( HH
MHH **3-% "TF:** "BBB@84449H **3-&:0"UT7@3_D=M+_ZZ_T-<Y71>!/^
M1VTO_KK_ $-34^!^@X_$CZ&HHHKQ#TQ:2BBD!+1112&%,F_X]Y?]P_RI],F_
MX]Y?]P_RH0'S'/\ \?$O^^?YU'4D_P#Q\2_[Y_G45?2H\9A1110(**,TAH&%
M%%% !0>.HJSIX#:E:@C(,R9!^HKO_BQ;P0>*-+6&&.-6@7(10 ?G/I4.5I*)
M2C=-GFY!'48I*].^*&C3W?B#3X-+TYY&^RY9+>+WZG%>=WVFWVF2B.^LY[9S
MR!*A7/TS2A-25QRBXNQ5HIT<;RR+'$C.['"JHR2?85I7'AK7+6W-Q/I-['"!
MDNT)P![U5TB;,RZ2GPPRW,RPP1O+*YPJ(,DGV%7X?#VM7"2M%I5XZQ'$A6%O
ME/H:&T@2,VBI[:RNKRX^SVMM---_SSC0LWY5:OM!U?3(O-O=-NK>/^_)$0/S
MI70[,SJ2BM1/#>N26OVI-(O6@QG>(6QCUH;2W%:YETM6);&[M[>.XFM9HX9.
M$D="%;Z'O4ECI6HZFQ%A8W%R5Z^5&6Q]:+H=BG3:OW^BZII8#7^GW-NIX#21
MD#\ZJ0037,RPP1/+*W"HBEB?P%%T#N1T5J7/AO7+.W,]SI-[%$!DNT)P/K6G
MX#T%->\3VT-S:R360.9BH.T<< GM4N22N-1=[',4E=%XUTB32_$U^%LI+>S,
M[+ 2A5"!_=/>N=IIW5P:L["@$G !)/84A!!P001V-=_X#TZ#3M(U'Q??1AX[
M)2EJC#AI/7\,BF_#O0[?Q9XGOK[5AYL5NOGR1]G9CP#[=:AS2OY%*&WF<((W
M89",1Z@4TUZA=?%I;2Z>WT[0+);.-BJAUP2!]*?XDMM"\6^!W\2Z?;0V-_ V
M)HE(&XCJ,=^N0:GG?5#Y%T9Y9@GH#^5&UO[I_*NXT#XB)HFBV^GG0K.Y,0(\
MV0#<V3GGBO0)O%-M%\/8O$PT2R,CR!/)V# Y(ZX]J)3DN@U!/J>#X/H?RI#Q
MUXKO=5^)":I;1VXT.SML3)(9$49PK XZ5;^+EA MUI.JVD21P7=OCY% &1SV
M]C34W=)H7*K73/-^3T&:2O5/A3965GI6I:[J44;0!T@0R*"!DCU]R*YSXG:0
MND^-KGRHPD%TBW$848 R,''X@T*=Y<H.%HW..P2,X-%>H000:%\$YKJ2"(W>
MHR;(V9 6 8XX/^Z#7EU.,KW$U86BO1/A1I]I-<ZQJ-_;13V]G:YVRJ&&2<]_
M934Y^)VBY./!]@1]%_PJ7-WLD-15KMGF@#,<*"3Z 4AZ\UO2>)-GB_\ MZRM
M([51*'6W4#:!@ C\:W/B/H5O;W-GX@TY,6&K1B7 '"28R1^/7\Z?-JDQ<NET
M<+12T9JA"48HS1F@ Q73?#[_ )'K2_\ ?;_T$US.:Z;X?'_BNM+_ -]O_036
M=7X'Z%0^)'T#1117C'I!61XI_P"16U+_ *X&M>LCQ3_R*VI?]<#5T_C7J3+X
M6?/-%%)7T!Y 4444 %%%)0,****0!13D0NX5>I.*O2-#8@($#R$9)-<N(Q7L
MI*G&/-)[+]7V1ZF RUXFG.O4FH4XVO)ZZO9)+5LSSGTI*O+?ACB6)2I]*BO(
M%A<,GW&&144\5/VBI5H<K>VMTS7$9926'EB<)5]I&+2DK.+5]G9[HK44Y8W<
M_(I;Z"AXI(Q\Z,OU%=7M(<W+=7]3S%0JN'M%%\O>SM]]K?B-I*NZ<H+2Y /R
M]ZK>3*06$;%?7%8+%1]K.G+3EMUWN=D\MJ+#4L1"\N?FT2;MRNW2Y'113TBD
M<91&8>H%;RE&*O)V.&%.=27+"+;\DW^0RDISHZ'#J5^HH",5W!21ZXHYXM7O
MH-TJBDXN+NNEG?[K#:6GF&55W&-@/7%,HC.,OA=PJ4JE-VG%KU37YI!3:D6&
M6096-B/4"F,I4X8$'T-)3BWRIZCE1J1BIRBTGUL[??82BG;'P#L;!Z<=:5X9
M47+1L!ZD4O:0O:Z^\:P]5IR4'9>3_P B.BK%E")KA0RDIWISJ8+[/E$J&X7'
M6L98J*J.DMTK]/N.RGEM26'AB9:0E+EV;MMKMMK\WH5:*EG8RW#$1E2?X<4U
M896)"QL2.O'2KC57*I2TT[HYYX:?M90I)R2;2:3UMY6^=MQE)3G5D;#*5/H1
M3:T335T82BXOEDK,****!!1124 +FDHHH&%%%)FD M&:2B@ S112XH 2BEHS
M0 E&*,T9H ,5TG@/_D<]._ZZ5S>:Z/P&?^*TT[_KI43^%E0^)'T91117AGIA
M6%XS_P"1,U?_ *]FK=K"\9_\B9J__7LU73^./JB9_"SYWHHI*^B/'"BBB@ H
MHI*!A1110 8STH[X[UUWPOBCG^(VD1RQK(A:3*N,@_NV[5H>*((4^-!A2)%B
M^W0#8% 7'R]JR=6T^2W2Y:A>/-YV.!VM_=/Y4A!'48KW[Q[XYM?!NOQZ;%X>
ML+A7MUFWL@!R21CI[53\-Z[X=^)LMSHNH>'K>TN?),D<L( (QQD$#@C(K!8B
M7+SN.GJ:NBK\JEJ>&TY4=_NHS?09KI] \*KJ'Q#3P[<2$Q1W+QR,.K*A/\\5
MZ!XC^(ECX*U>;0-"\/68CM"$D>5<;FQ^9^IK2=5IJ,%=[D1IZ7D['BS J<$$
M'WI*]OLKOP_\5= U"*ZT^UTW6+9-T<R$*,]CGN,C!%>(D$$@]0<&JIU.>Z:L
MT*<.6S3NF)2[6_NG\J0]*]_U?Q%:^#? 7AV\31;.[>YB5&\Q ,84'.<4JM1P
M:25VQP@I7;=K'@)!'4$?A3:]=M/BSH6H7"V^L^%+);5SM=XT!*CUQBL;XG^"
M;/0'M-8T8YTF_P#N@'(C;&0 ?0CI]*F-9\RC-6N-TU:\7<\\P<9QQ179:IK+
M7'PZTW3#H4D"Q2AAJ!CPLO7@''/7U[5R]CIM]J<QAL+.>ZD')6&,L1^5:1E=
M7>A#C;1%6FUJW_AK7-,A\^^TF\MXAUDDA(4?4U2M+"\ORXM+6:X,:[G\I"VT
M>IQ3YDU=,33V*]%:4GA_68M.74)-+O%LV&1,83M(]<^E+#X;URXN5MXM(O6F
M9/,""%LE?7Z4N:/<?*^QF<GH#25ZY\,]*,'AWQ?%J-CLN(;5OEGBPR'8WJ.*
M\ZB\*^()K,7<6BW[VY&X2"!L$>O2H55.378ITVDGW,BBE(*L58$$'!!'(K0T
M[0-7U=2^G:9=W2#@M%$6 _&K;2U9*5S.I*LWVG7NF7'D7]I/;2]=DR%3^M-M
M+*ZO[@6]G;2W$QZ1Q(6;\A1=6N%NA!16Q=^%/$-C;F>ZT6^BA R7:%L#Z^E8
M])-/8&FMPHHI*8"YI***!A1129I +1FDHH ,T44N* $HI:,T )1BC-&: #%=
M%X$_Y';2_P#KK_0USN:Z+P(?^*VTO_KK_0U$_@?H5'XD?0U%%%>(>D%%%% $
MM%%%(84R;_CWE_W#_*GTR;_CWE_W#_*A ?,4_P#Q\2_[Y_G4=23_ /'Q+_OG
M^=1U]*CQF%6=.@BN=3M()WV0R3(CMZ*2 :K44,$?1VJ>#O#9\.SVITZUAACA
M)694 =,#AMW6OG"M6?Q+K5QIPT^;4[E[4#'EESC'I6565*#@G=W-*DU+9!11
M16AF6=._Y"EI_P!=D_F*]#^+O_(UZ3_U[K_Z&:\\T[_D*6G_ %V3^8KT/XN_
M\C7I/_7NO_H9K*7\1?,TC\#.@^)7C.^\/?9+'2V6&YFCWR3[06"]@,U1T35)
M/B%X(U:QUA4EOK)?,BG"@$\$@\=#P0<5)\4O"FI:M)9:EIML]R8XO+ECC&6'
M<''>H/#.FS>!O ^L:IK"_9[F\39# Q^;H0 ?<D]/:L%R^S5MS9\W.[[#?AGI
M)L?"^H>(K>R^V:G\T=M'CD8XP/3)Z^PJQH^I_$F/6XWU*PEGLI7"RQ&)0JJ3
MU&.>*A^'5X^K>!M3T&SO/LNJ(6>%PV#SR"/;(P?K67IFE_$:\UE+*YN-3MH0
M^)9W?Y57N0>A_"FU>4KV^8ELK%W4M#M]$^,VE?9(Q'!=LMP(P,!2200/;(S^
M-3^-_B-JFA^)9M-TI+>.&$8D+QY+N1R?:LYD6W^+VE6:ZM<:F;=U1I9R"5;D
ME01Z9_.N<^(W_(^:I_OC^0JHQ4I+FUT$VTG;N=HE]_P@?PVM-0LXT;5M4(=I
MW7)!;G]!53P/X]U/6-;71=>D2^M+T%!OC4%3CIP.0:M36+^.?A;IT>F%9+_3
M<*\&0"<#&/Q&"*R_A]X)U:W\21:KJMI)8V=EF0M.-I9L< #T[YJ?=Y9<VX_>
MYE;8L^&?!MFGQ4O[26,26>GYFCC89!)^Z#ZXS^E9VJ_%77_^$@FELITCL8I2
ML=N8P0R@X^8]<FM?PYXNLF^+&HSO*JVE_F".0G R/N_G@_G6)JWPO\1+X@FA
MLK036<LI:.XW@*JDY^;G(Q35N;W^PG>WN=SH?BC>Q:EX(T"]B01QSRB0*!C&
M4)-4E\5:K-X?L=,\$:9=P+$N)YA "6;V/3UYJ_\ $O3XM,\'>'-/+AHH)UC9
MAW 3DUH>,IO$6E:7ID'A"VD&GF(;GM(][9[=.<8[U,;<J7J4[W;)](C\2:EX
M.UBV\76X8>2QA:15#'@GG'IQS7,_"!+<KK7D-"NL>6!;-*,X7!Z?CC/X5TOA
M#3/$$/AS5[GQ!/,UW=0MY<$SY=5"GDCMG->?>"/"L?B&UU*6UU*:VUBTY@B1
M@N[C@D]<9X_*A6M)7!WO%G50:UX_\-ZD\VO6DVI:>01(L2*P]BI X^E8O@'7
MI&^(DL.G*;/3K^9G>U(!QP2!G'&#GI6[X,N_B%'KL%EJ=M</8 XG>Z3A5]F[
M_K6? ]@GQV/V(QB'S-IV?=\S9\V/QS1IJK=.@=GYG.?$77M2U'Q)>:==7)DM
M+.X;R(]H&SMU R?QKCJ[#XBZ%J6G^)[[4+JT>.SNKAO)FR"K]ZX\]*VA;E5C
M*=^9W/4/%J_V5\(_#MA%E1<[99/<D%S^IKC_  ?XKN/"6L_;(XQ+#*OESPDX
MWKG/'N*[#QBPU/X2^&[Z([E@"QOCL0I4C\Q5/X8+HNI1ZGH>I10BYNDS;RR*
M-W0@A3ZC@UFFN1W+?Q*QKRS?#+Q7(9I@^F7<ARQ!,>3[]5-8?BCX:MI6E-JV
MC:@-0T]1N;IN4>O'!K/U'X8>*;&[:&+3FNXL_)-"RD,/H3D5VFE:=<^!?AQJ
M_P#;TR))=@B&UWAMI(QCZGV]*5^6W*[CM?XD>-UZI=_\D%MO^NX_]"->55ZK
M=_\ )!+;_KN/_0C5U.GJ1#J>55ZAJS?V_P#!.QNQ\TVF3*CGN!G;_5:\OKU#
MX4F+6-)UWPU<-B.XC$J^W8X_\=HJ:*_8<-[=QGB4GP_\*-%TI3LGO6^T28Z^
MO^%3^/8CXC\%>&=>B&Z5@+>0CU;C_P!"4_G6/\6M16Y\6+8Q']S8PK$ .@/4
M_P!*Z?X5F'7O"ESHMT<BRO$G0?[).[^8/YUGM%3+WDXF1\5)UL--T#P]&<+;
M6XD<>^,#^OYUYE73_$#4_P"UO&NH3!LQQOY2?1>*YFM(*T49S=Y'I'@#Q+X>
MT#PIJL.J,9)[F3)M@I_>(%P!GWR:TM#\6^$O$E]'HE]X6L[.*X/EPR(J\,>@
M) !!]\UB^$_"6E>*O!M_]ES_ ,)!;L=JM)@$=5..G/(_"H_!WP^UZ7Q1:37]
MA-9VMI,LLLDPVYVG("^N2.U9M1U=]2US:&%XT\.CPOXEGT]'9X,"2%FZ[#Z_
M3I79P_\ $W^ TOF\OI\YV$]@K _R8BN;^)FLP:UXSN)+5P\-NH@#@\,1G)'X
MFNCM3_97P%N&E.UK^X;RQZY8#^2DTW?EC?<$E=V/+****U,PHHHH *Z;X??\
MCWI?_71O_037,UTWP^_Y'O2_^NC?^@FHJ? _0J'Q(^@Z2EHKQCT1*R/%/_(K
M:E_UP-:]9/BG_D5M2_ZX&KI_&O4F7PL^>*2BBOH#R IR -(H/0GFFT4I*Z:1
M=.2C)2:NET-B2VA\@C8H '7'2L:I&FD9-A=BOIFHZ\_+\)5PT9*I/FN_/]3W
M<^S7#9C.G+#TN3E5GMK]UM%T"BBBO0/ +-@ ;M<^AJ.[)-W)G^]38I#%*KCL
M:NW-M]I_?P$-GJ*\NM.-#&JI4TC*-K]$T[_B?386C/&Y.\/A]9PGS./5Q:M=
M+K9D$5D98P_FH,]C3;BU:!58N&!XXI4LKACC9M'J34U]M2&*+<"R]<5F\3/Z
MS"$*BDFW=)+16[HW67T7EU6K5P[IRBE:3DUS2NE\+MYOJ(+A_(2.UC88^\<5
M8A$\D$BW*Y&.":;<F:.*,6RG9CDJ*=:),$=IB=S#@$UY=:4'0=2*BM>]YWO^
M'^1]+A*=6&.6'J2G*T+.R4:5N3HM;_FV5],X>0GLM,.H3>=D$! ?NX[4_31E
MY0>ZU";*?SMFPXS][M7HRCAGC*OM[;+?M;4^?A/,893A5@N;XI7Y;[W5KVZ;
M[Z=R6^1!)'+CY7Y(%.DN)Y-HMD94 ["EN6C-Q;PD@JN U.NVNA*%A5@F.-HK
MEIRYH4H22;LVN9Z6OIIU=OP/2KP<*N*K4Y24>:"DJ:3DY<J;UZ1O>_=BS"1]
M.8SK\Z\BF63B*QD<C.TYQ3V21--D$A)<\GG.*99Q^;82H#@D\5DG!X::DUR^
MT6VUM+V\CI<:JS*C*"?M'0E\5G*Z3MS=&]B*"^F,X#MN5C@C'2EDM5_M(1@?
M(WS8IL%G,9UWH553DDT][E?[45\_(ORYKLGRQK2^J6^!WMM?IMU/(HNK/"4_
M[4O_ !HVY][?;WUY=K]":X:[$FV!"L:],#K3;E'FL?,E3;*GZTV[2[$Q:)G9
M&Z;>U,GCDCM-TTS;V_@S7-1C&U)QE%.ZVOS/NG^MSTL94FY8J%2%1QY97YG%
M07\KCITTY;:LE\XP:9&Z@%N@SVI+&YDN'>*8A@1Z5'/_ ,@F'_>']:;I?_'T
M?]VK="F\)6JM>]S2UZZ,QCCL1'-<'AHS:@X4[KH[Q=[KK\PL'9+PQ _*2<BG
M>=))J:HS957X'I4=F<:C_P "-2>3)'JBLRX5GX/K6U94_;S<K7=/\=?QL<F#
MG7>!I1@WRJO9[V2NK)^5_E<'_P"0P/K_ $I;V]EBN&CB(4#KQU-(_P#R&1_O
M?TJO?_\ ']+]1_*E1I0JUJ2FKI4U^88S%UL-@\3*A)Q;KM76CM9O<LWC>?I\
M4S ;\XR*S:T)?^0/'_O5GUV9<E&G**V4I)?>>3Q#)SQ%.I+>5.#;[NVX4E%%
M=YX(4444#"DS112 **,4M !BBDS24@%S1FDHH ****!A1110 5TG@/\ Y'33
MO^NE<W72> _^1TT[_KI4S^%CC\2/HRBBBO#/3"L+QG_R)FK_ /7LU;M87C/_
M )$S5_\ KV:KI_''U1,_A9\[TE!HKZ(\<****!A2444 %%%%(#L?A5_R4O1_
M]Z3_ -%M6CXJ_P"2WG_K_@_]EK.^%7_)2]'_ -Z3_P!%M6CXJ_Y+>?\ K_@_
M]EKEG_&?^$WC_#7J>@?$/3_ =UXABD\2ZC=6]]]F4*D38&S)P?NGOFG>#;+P
M=:1WP\$WD4VM20D1M>.6('TP./H*Q?BOX)\1>(O%<-YI6G-<6ZVB1EQ(J_,&
M8XY(]157X<_#7Q!I'BJVUG5XDL;:T#-@RJ6<E2,<'@<YY]*Y4H^QUGTV_2QO
M[WM/A^9YV+[5_"GC-[R?Y=4M;@M*'Z.Q/.?8YKTN;Q5\./'&V7Q!8O8:B5 :
M894Y_P!]>H^M9\/B+P_??&J[N+V.WGTZ?_1TED *;P  WTR,9JCXN^$FO6NL
M3W&BV@OM/F<O%Y+*&0'G:02.GJ*WDX2:Y_==M]OD9)22?+JKFAJ?PDL+_39=
M0\':T+X("3;NP)/L&'?ZBO.=+\-ZSK1F&G:?/<&$[9-B_=/H:]9^&'A/5_!T
M]]KWB%QIMBMN0T4D@RW(.X@' QCZ\UYQ:^.-8T?5-3N=$N?LD5[<-*4V \$D
MCK]:=.<VY1B^:W44XQT;5KE'5/">O:-9FZU'3)[>#<%WNN!D]!7HWQ-_Y)EX
M1_W1_P"@"N"UOQWXB\0Z<;'5+\SV^X/L\M1R.G05ZEXQ\-:OXE^'/A>'2+,W
M,D4:LX#JN 4'J114;4H.I9:_H."34E'L>%5[-KI,_P"SOI;SY+H\6PGKPQ _
M2N8TSX.^+;V[2.[M([*W)^>6693M'L 22:VOBSK>GV>D:9X,TJ59([$*UPRG
M(!485?KR2?PHJ3C4G&,'>SN$(N$9.0>)/^2#:!_U\+_)JAT#Q?>6?@>WT?P;
MI-U_:V[-W=" ."3U(/Y 9[5+XE_Y(+H/_7PO\GKI;Y]8TCX7:&W@6V,@EB1K
MF2WC#R9*Y8X]=V<^E9-KELUO)^GS+L[W\D7_  "_C>^2^M/&%L9-/D@.QYT4
M-NZ;<#J"">OI7*?!BWBA\8>(+<*#$D93:>?E#D8_*NC^&6G>+7O[O5O%%S=*
M)(##;V]R^&8D@EMO;&,?C6#\)4:/QSXH1@0RAP0?]\UF]JB5MEML6MX/UW.9
M\2_%76]<-[ID8MX=+FDV1QK'AE0-QS[@<UZ'\1?'-[X.TG1H]*CA%[=P@O-(
MF["*!QCZM_.OGX?\?(_W_P"M>J?&[[_AK_KR;_V6MYTH*<(VTU_(RC4DXR=S
M>^%OB*XU8^*]<U0)(YC$DB*/E*JIX /; KF-'^+WB>Z\6VIFGB^PSSK&;18E
M"JI..#C.1ZYJY\)/^13\8?\ 7HW_ *+:O-- _P"1ATW_ *^8_P#T(4E3@YSN
MOZL-SDHQU_JYZ%\0_#EO=_&*TTZ!!$FHM"9-HQRQPQ_3-=IXR;QGI3VVC>"=
M*>WTVWB7]]#&I+'TY_7UKF/B3J::-\9=(U*7_5VRP2/C^[N.?TK9^(UIXSFU
M"'6/"M]>W6F7,2GR[-\[#ZX'4&LM7R7M:W78O1<UN_0GO=,UKQ;\--13Q;IG
MV?5K &2WN"@4N ,YXZ=P>U<9X*\7'1O!]SIWAO2+B?Q'.V6N1"'4#/\ 0= >
M,UJS:1XDL/ %[K'BKQ)J5E.P*PV1E!+@C ##U/IV%:V@C4-,^"]O=^#;59M4
MD8&X:-0T@Y.X@=R..*-%%K=7^7_#!JW?R^9<^']W\19]8V>(X))-+D0[VN(T
M4J>V,?RKQ7QC9PZ?XSUFTMUV0Q7<BHH[#/2O7?AU9>.-0\2)JOB6XOH;.%6"
M171*>8Y[!#7EGQ"C:+XA:ZK @_:V//H<$5I1TJM:;="*GP+]3FJ***[# *3-
M%%( HHQ2]* #%%)FDI +FC-)10 4444#"BBB@ KHO G_ ".NE_\ 77^AKG:Z
M/P'SXVTO_KK_ $-1/X'Z,<?B1]" TX'-(5(IM>(>F/HI :,BF(FHHHI#"F3?
M\>\O^X?Y4^F3?\>\O^X?Y4(#YBG_ ./B7_?/\ZCJ2?\ X^)?]\_SJ.OI4>,]
MPHHH- "4444 %%%%(!4=HY%="0RG(([&K>H:OJ&JSQSW]W+<2QC:CN>0.M4J
M*5AF[%XR\1PW7VE=7N?-VA22V01Z8Z52U77-4UN59-2O9;@K]T.>%^@Z5GT4
MN5+6PVV2VUW<65REQ:SR0S(<J\;8(K;G\=>)[BW,$FL7&PC!VD D?45SU%#2
M>Z!-K8GMKRYL[M+NWF>.X1MRR \@^M%Y>7.H7<EU=S--/(<O(_4U!1185RYI
MVK:AI%QY^GW<MO(>"8VQGZCO5[4?%^OZO;FWO=4GDA/5 =H/UQUK$I:.57N-
M-[&]X.LM'U'Q!'9ZW,T-M*A59%?;M?MDUWD_@SQTEP]E9:X[:43B.4W'2/MG
MOT]Z\EJ87]XL7E+=SB/^X)#C\LU$HMNZ9<9)+4] ^)^J62V6C^';*X%P=/3]
M](IR-V H&?7K^=<GIWC'Q#I5L+:SU2>.%>%0D$+],]*PZ*(P25F)R;=S77Q3
MKJ7TEZNJW/VF1=C2;\DKZ?2J%KJ%Y8W@O+6YDAN 2?,1L'FJU%59"NSHKCQW
MXGNK<P2ZQ<;",':0I(^HK!BGE@G6>*1TE1MRNIP0?7-1T4DDM@NWN:FJ>)-9
MUFWC@U+4);F*-MRJ^.#C&:RJ**$DM@;N>B^!+R+6_#NI^#KIU#SJ9;,M_?ZX
M_3/YUP$T4]C=O$X:*>%RIQP58&HXY'AD62)V1U.0RG!'XT22/+(TDCL[L<EF
M.23]:E1LVQMW2.AM_'OBBUB$4>LW!4# WX8_F:R-2UC4=8G$VHWDURXZ&1LX
M^@[52HIJ*6M@NPJ\VM:D^E+I;7LIL%.X09^4&J-)0]0"K>G:I?:1=?:=/NI+
M:8J5WQG!P>U5*7%# ENKJ>]NI+FYE:6>0[G=CRQJSINLZCHTDDFG7DMJTB[7
M,9QN%4":2E8!TDC2.SNQ9F)+$]2:;110!9L;^[TVZ6YLKF2WF7H\;8-:][XW
M\2ZA:FVN=7N&B88900NX>Y%<_12LF--EO2]-GU?5+;3[92TL[A!CM[UVOQ+U
MBW4V'A?3W!L]*C"R%>C2XQ^G\R:X*&:6WE$D,KQ2#HR,5(_$4UF+,68EF)R2
M3DDTG&[N4G96$HI,T51(M%)10 M=-\/O^1[TO_KHW_H)KF*Z;X>_\CWI?_71
MO_0345/@?H7#XD?0E%%%>,>@%9'BG_D5M2_ZX&M>LCQ3_P BMJ7_ %P-73^-
M>I,OA9\[T445] >0%%%!H&)1110 444&D E.21XSE&*_2FT5,HJ2M)71<*DZ
M<E*#::ZK0F-W.PP9#4).3DT45,*5.G\$4O1&E;$UZ]O:S<O5M_FR1+F:-=JR
M$#TI/M$N\OYC;NF:CHJ?84KM\JN_)%_7<3RJ/M)66VKT]-1ZRNA)5B">M/%U
M.%VB1L5#11*C3E\44_D@IXS$4E:G4DO1M;[]0)).2>:E6ZG"[1*V*AI:<Z4)
MJTXI_(FCB:U%MTIN+>]FU^3'B:0!AO;YNOO5RW.--F(.#FJ%)G\JPKX6-6*B
MM-4]NQV8+,ZF&J.<[R]V45J].9;]>NI*UU.R[3(V*AHHK>%.$-()+T.*KB*U
M=IU9.37=M_F2I=31KM60@5&\CRMEV+'WIM%)4J<9<RBD_0J>*KS@J<YMQ71M
MV^ZX\RNT8C+$H.@I(Y'B;<C%3[4VBGR1LXVT9/MJO,I\SNMG=W5MK,7<0VX$
M@YSFGM<S,5+2$E3D>U145,J<).[2'#$5H)QA-I/>S?\ F/,KF3S-QW^M([L[
M%F.6/4FFT4U"*=TA2JU))J4FTW??KW]?,>97,8C+'8.@J.BBFHJ.R%*<IV<G
M>VFO;L%%%)02%%%+0 E+2$TE(!2:2BB@ HHHH&%%%% !129HH 6BDHH 6NC\
M!?\ (Z:=_P!=*YNND\!?\CIIW_72IG\+*C\2/HVBBBO#/2"L+QG_ ,B9J_\
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M1II#=Z\0](2C%*124 .HHHH *9-_Q[R_[A_E3Z9-_P >\O\ N'^5" ^8I_\
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MI5 );KFG4P^(K>UE))<T4DK]GU(P^89?A/JU.G-R5.;E)\MMU;17+FG?\?\
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M&*Y%.2:7O7BUJW?6]]MA)O\ D$1?[U-@M(EM_M%RQ"GHH[TZ;_D$1?[U.O\
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M*6DH-,D0T444@"BBDH&%%%% !2444 %%%)2 ****0!1110 44E% Q<TF:**
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MQPLJ$8'U]ZS:*YGEU!OK:][7=K^AZ4.(,=&-DXWM;FY5S-6M9O=EBTNVM7)
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M%)FD,6C-)10 9KIO '_(ZZ=_UTKF:Z7P!_R.NG?]=*F7PLJ.Z/I"DHHKQCT
MK#\9_P#(F:O_ ->S5N5A^,_^1,U?_KV:KI?&O5$S^%GSM24M)7T1Y 4444@
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M!V.*VC6A.;@MTD_OV.*K@ZM*C&O->[)M+O>.^@E%6KNU2 Q;23O'.:L26-M
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M?Q3+<[<K! >?0GC_ !J*CM!OR*@KR1[I2$?G2T5Y!WB _G2TA&:.: &T444
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MMP!S7=.$GBHSMIRO\T>)2K4UE56DY>\YQ:76R3NRK11176>2%)112 *,TE%
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M?_7 ULUC>*_^14U/_K@:NG\:]43/X6?.-%%%?1'D!110:0"4444#"D-+2&@
MHHHI %)2TE "BBBBD,;1110(*2EI*!A1112&)1112 *2EI* "DI:2D,44AZT
MM-[T@"BBB@8&DH-%  :2@T4 %)2TE( HHHI )1110,*2BBD,*2EI*0PI***
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M_P!_/_K4?\*Q\-_\\9_^_G_UJ[*BCZQ5_F8>RAV.-_X5AX;_ .>,_P#W\_\
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M +^?_6KM!2T>WJ?S![.'8XK_ (57X8_YX3?]_/\ ZU'_  JOPQ_SPF_[^?\
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ME#L<1_PJGPU_<N?^_O\ ]:D_X53X:_YYW/\ W]_^M7<4E/V]7^8/90['#_\
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M00#_ &$ /YU<HJ95)2W8U&*V044E+4%!1110 O6DHI>OUH **3-+0 E%+24
M5Z***H04444 %****0!1110 4444 )2444P"BBB@ HHHH **** "BBB@ I:*
M* "BBB@ HHHH **** "BBB@!:*** "BBB@ HHHH 6BBB@ HHHH *0T44 -)S
M2445(Q0,G%2J !110 M%%%  10!110 H%+110 M%%% !WHHHH 0<\TM%% !1
M110 4444 %%%% "=Z,T44 )N/H*49P2:** "BBB@ HHHH 44444 %%%% !11
M10 V1MJ5 @R:** )@.*<*** %HHHH 6@T44 %%%% !1110 "G"BB@!:*** "
MBBB@ H-%% "4444 %%%% !33110 4E%% !1110 E%%% !1110 4444 %%%%
M!1110 4444 +1110 4444 %**** %I:** "D-%% #:*** "BBB@ HHHH ***
M* "BBB@ HHHH 2DHHH 2F,,T44 1=#5F-MZT44 .HHHH **** "BBB@ HHHH
9 *!110 4444 %+110 'UHHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>forms-1a_005.jpg
<TEXT>
begin 644 forms-1a_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #B D # 2(  A$! Q$!_\0
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MQ&_Y$74/K'_Z&*RH?Q8^J+J? _0\'K9T?PKJ>NZ;?W]DL1AL5W2[WP3P3Q^
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MUUOIKMUZ>FENMST%4PT^3GG'V?NMQY?>NM9:V5KOK=IW2LK:+-&K.C1KM5^
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MZ9R ,8 .S)_ 5E]<Y7RI*R\_3;[SJ>4^UCSN3<F]6T]O>;;N[IZ=64%1G5F
MX49-(&*L".HK0=%#2C&T%%)XQWJ.0$^>KQA8T'RG&,>G-*..4]UH[?<[+YZO
M[@JY*Z5K3U5^CW5W?^ZK+=]2D22<GJ:2M"127=&C B$><[>^.N:0_-<+&J(%
M5 W*^WZTUCDU\/2^ZV_S\B9Y*U*SGUM\+NW>W?;=WZE"DS6EM5GMV*[LE@25
MQG\*C67,43[$W&3:3M'3CBA8UO:/X^O^0/)E%OGJ6Z_"WI:+[_WU^)3V-Y>_
M^'.*;5O 'VQ,?*.@_'BJ>:Z*57VE_E^*3/.Q>&5#EMUO?UC)Q?R=KHE@_P"/
MB+_?7^=?4$-Q^XB^7^!?Y5\O0?\ 'Q%_OK_.OJ"&,>1%_N+_ "KEQWV0PO4Y
MSXA3;O ^H#'9?_0A7@]>[_$% /!&H'V7_P!"%>$5OE_\-^IEB_C04E%%=QRA
M2444#"DHHI#"DHHI %)12]* #I2$TF:*0PI,T44@"BDS10,7-)FBC-( HI,T
M9H ],^#O_(2U7_KBG_H5>MUY)\'/^0EJO_7%/_0J];KR<7_%9WT/@1+7*_$;
M_D1;_P"L?_H8KJJY7XC?\B+?_6/_ -#%94/XL?5&E3X'Z'@U)170Z!X=LM7T
M?5;VYU>&SELX]T<+XS+P3Z^V./6O?DTE=GDI7>ASQIT<DJ!Q$\BAEPX0D97T
M..U,'(KHO"0!77<@'&DS8R/I2D[*XTKLYWYD8=5(Y'8UH0:U>IJ-G>7-Q-=&
MUE61$FE+#@YQSTKLM6TW1M7UBWT[;=1ZF^E12),&'E!EAW!2N,X('7-1VO@>
MP^QV45U)(L]U;"=KK[3&B0EAE5V'EATR?>LW4C;4OD?0Y.YUV\N]52]GFED2
M.X\]('D+*GS;L#/3TIFKZU>:S>3S3SRF*25I%@:0LD>3G !KI+?PQH\ZZ+8%
M[L:CJ,7G/,&4QQ*"V[ QDDA3BHK7P[I/B&$-HQNK9H[V*VD6Y</N1R0'& ,'
M@\4<T0Y9'+R:A>S6JVLEY</;K]V)I"5'X=*8;JX\PR&>7S&786WG)7&,9],<
M5U4FC>'[S3=3ETX:A'-8W$4/[Q@_F*S[2V ,YX^[5G5O"-A;Z+?W4<-W:26;
M1X:XG1S*C-M)9%Y0]\4<\0Y6<4MS.GE;9Y%\HYCPY&P^WI1]KN0NT7$VW##&
M\XP>H_'OZUW&I>%](T^.*[MH+NYM([B$"ZBG22.="1G< ,QGT!S6#XT2W'C3
M4HK.$PH)RFTD$;NG& ,#VH4DV#BT8R7%U'Y!CEG7RR3#M8C:>^WT/TIDWGO<
M,9A*T[G<V\'<Q]>>37?F]M=$\77-H\<T=II]B+6*ZBB\PVKD F7'?+$\^]5-
M=O-431K34H-8MM5CMKK$>HQJ5N(69>$<'L>HZU//J5RZ'*37FJSVPMY[B^D@
M7I&[.5'X'BJXN+H 1K+/\J% @8\*>HQZ>HKM/$/B;68_#?AYUU"7==6LK3GC
M]X1(1SQZ<5LQ3VVDZW=^*I(D:VOX[58P5&W,V/-Q] K?G2YK+8?+KN>68)!(
M!P.IQ0%9NBD_09KL/$E@/#GAU]*P/,NM2EESW\J/Y4_ Y)J3PUJ^GZ;X;6V?
M5+JPO+B]+-+!:B3Y H R6XQDDX'-/GTNA<NMCBRK 9*D#.,D=Z;FNU>PGSXK
MT;495N)[9/MT<X&,NI&6'IN5NE<5FFI7$U8*]>^#O_()U3_KX7_T&O(,UZ_\
M'/\ D$:I_P!?"_\ H-<^*_A,UH?&>DUX)X\_Y';4_P#KH/Y"O>Z\$\>?\CMJ
M?_70?R%8X#^(_0TQ7P(YRBCO4MQ$L+*%D#Y&>*]*52,9J#W?Z'/##U)TI5E\
M,;7U77;3=_(AIP>0+A6;'H#3:MNS1ND4;A%V@Y]:RKU.6T;)WOOMI\F=&#H<
MZE4<G%*RTW;D[);I6T=[LJ*[*<JQ'T-!9B2<G)ZU::+?,Q=<G:#A.A_&G")(
MG<'.TQ;L9R17.\936MKNW^74[HY3B'HY6@FUK=6WUMLKVULV]>V]($C."1GK
M2AW!R&(/KFIQ!&Y1E#E6!^7OD>].-M'YD>=P5E)(R#C%5+%T;VDOP[=/P,Z>
M58QKF@U:ZMJ^MK->6OKOIN5,DG).33WF+%2,AE&,@]:F2!)MAC+*"VT@\]LT
MOV6-F3&5R^TC<"<>M3/%4$[26JOTV_JQ=++,:X-TVK2MK??9II^5_)[[ZE0N
MQ))8G/7GK2^9(#D.WIG-6!%"<.H;"R!2">M/>)9)"H+!3-M(_"E+%4T[..GH
M.GEF(:YE4UOI9O6_6^G6Z?7J4B['JQ_.@R.0%+,0.Q-321Q&%GCW#:VTY/6J
M];TY0J*Z6WD<&(IU:$N64KW5]&VFM?U3)99WE8DD@<?+GBH][!MP8Y]<TVBJ
MC",8\J6AG4KU:DW4G)ML<9')R7;/UI-QQC)P.:;13LELB'.;U;?WO_,D\T^4
M4QRQRQ]:CHS1FDHJ-[#G4E.W,]E;^OO)(/\ CYB_WU_G7U/"H^SQ?[B_RKY7
M@/\ I,7^^O\ .OJF'_CWB_W%_E7%COLG1ANIS/Q$&/ VH_1?_0A7@=>^_$3_
M )$74?HO_H0KP&M\O_AOU,<7\:"BBDKN.84*6S@$XY.!TI3%+LW^5)MZ[MIQ
M^==1X) (\19 .-'G(R/I7<P7ZVK^$X9/%$6G6[Z?;F2Q>W+B;).<G&/FZ<UA
M.JXNR7]6N:PIW5SQU(WE;;&CNW7"J2?TII!!((((Z@UZ7;7D6C?VUILEQ-X9
MNY-2=HKR.#S(RH_Y8[AR ,@\5E^(_#^NZ[KD#HFGW4DEFDBW=K(J)=("1YAW
M8^;/!^E"JZZZ('3TT.*6*5UW+%(R^H4D4P MG )QUP.E=[=ZQJ_AKP)H4-C=
MO:2FYNEF\O:=Q5@.3WJ_J-JNH6O]KY^R7=[X;DNKI(%"K*ZOMR1C@, "<4O:
M]UH/V9YGTIM>C1>!M.GTB<_9[^"9-/-VEU/,B^8X7<5\G[VWW_&FP>%?"\FK
MZ9I$C:E]HGLA>W$P==JKY1<JHQR>*/;Q#V4CSL@[=V#CIG'%)7HV_P +-X%@
MDDLM2-BVKLD,0F029\L;BS8Z=P*(?A_96\^M2S>=>065XMK!"MPD#/E=VYF;
MC@$<#J:7MEU#V3Z'G-)7H(\$Z;!J^I1(EWJ<$"1/"L,\<:*'&2))3E05Z8'6
MN=\9Z';^'?$3V-J[O T,<R;V#%0Z@XR.#CU%.-6,G9 X-*Y@4F:*2K(%HS24
M9%*XPS11FDS1<#TWX.?\A+5?^N*?^A5ZY7D7P</_ !,M5_ZXI_Z%7KN<UY.*
M_BL[Z'P(EKE?B/\ \B+?_6/_ -#%=57*_$?_ )$6_P#K'_Z&*SH?Q8^J+J?
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M\>\7^XO\J^5(#_I,7^^O\Z^JX?\ CWB_W%_E7!C?LG5ANIS7Q$_Y$74?HO\
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MTF1ZU]-CPQH/_0&L?^_(H_X1C0/^@-8_]^11]=CV#ZL^Y\QDCUI"1ZU]._\
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M - 6Q_[\BE]>CV8?59=SYHR/6D)'K7TQ_P (KX?_ .@+8_\ ?D4?\(KX?_Z
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<3I110!)%_JA3J** "BBB@ [T444 +0*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>forms-1a_021.jpg
<TEXT>
begin 644 forms-1a_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %. J<# 2(  A$! Q$!_\0
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MBH$PLFT$!MPS^/-55\):0J;#',ZY8L'E)W%AM.>YXKT;R8O^>2?]\BCR8O\
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M4TAB,Q3;?XE\T[6^H[UZ+Y,7_/)/^^11Y,7_ #R3_OD4@.,L+&#3;06UMO\
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M!<, .GS$4ZXT6Z?7!J$?V<X=)0SDAQM0KY8P#\I)S^?% &T;F ;\SQC8</\
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M3B) Q&<$@;L?4C([5TE,$,0;<(DSG.=HZ^M/H **** "BBB@ HHHH ****
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MOI@Y_2IZ** "BBB@ HHHH **** "H9KAHI(U6WFE#G!9,87ZY(J:B@ HHHH
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MQ,YA<G/&.0,#O52VM-2@UJ>=XIVC9I [B8$2*Q'E[5)^7:,YX'XUT)=0P4L
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M5:/RRXPJ,264<9P2<^O YIG_  CVGL_F/=W#R.?WSLZYF ((#8'0;1TQ4]%
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MGEHC1LK;L;N01QQSD^M:%94>B!#$WVV=I$G6=G95RY5=H!XX 'I6K0 4444
M%%%% #9)$AB>61MJ("S'T JE%K%G,]JL9E(NEW0OY3!6&">N..!5Y@61@&VD
MC 8#.*SK;1UM8X5%U,[P0^3&[!<J"<DX QD\#/I0!8LM1M=01VMI"X0@-E2O
M7H>>WO3[N\M[&S>[N90D"#)?K^6.M9]OH$5G875K;RG]_C)=< 8&/X2"3ZG.
M3WI3H%O-H\6GW3,ZQ A'C9E*G&,\L><'Z4#+4^J6=O<)!+*5=E#?=) !SC)Q
M@9P<9ZU)97D-_:K<VY8Q/]TLI&?>J<FAQR7 E:ZFQ\FY,+AMF=F>,\9_'O5G
M3[!-/ADC1RYDD,C,5"C)P. H  X[4"+=%%% !111T- %)=7L6DG03X,"LSEE
M(7"\,0<8.#P<5$->TX[,S.I8X(:)@4Y RPQ\HR1R?6HV\/P,TP-Q-Y<BN@C^
M7"*YRX!QGD]^U,/AR%G:1[NX>27B=B%'G*"I (QQC:.E S0M+^WOO,\AF)C(
M#!D*D9Z'!'0^M6:IZ?8M8K-ONI+EYI#(TDBJ&)_ #/\ 2KE C5A_U*?0440_
MZE/H**0Q]4+W_7#_ ':OU6N+9II P8#C'- &;+((H9)""0BEB!U.!FL236KV
M+38+YX;0Q3;7)1V?R8R,Y8 9/IQTKJ/L+_WUJK_PCUER/L=I@MO/[D?>]>G6
MF!B0:Y+)J26DL$:,]QY:KDY\LAB'ST.=O:HXO$$LLK$I!%#&R[VD+;B'8JN
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M .=?7'AO=,LIX46YN=OGX)VQ$@D '')R.G:M"+4;:>^ELXW8S1 %AM('/O\
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M:2_?M7<44 <;H/B+6+SQ,=+U&.*'RX-S((&!9L#G.2!USS[8[UV5&!G..:*
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MJ2:M8/<S6ZW*>; "T@.0 !UYZ'&1G'2@"[168OB'2F2-A>+B1MHRK YXZC'
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MZ,!V]*=_94W]JO?B^;>4\M%,:_*N02#Z]./3/>M"">*YB$L$BR1GHRG(-24
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M;&_=\\'!.$8<_P!ZJMOX5O8;I)SJ'_+16D1&<;R !N)R3DX/'3DT =3Y4?\
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MH!'1(()-VP1MM.UL <'TH=8(HVD=8U102S$   =ZY\^';\SLZZCM5F)4 O\
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M5<HH JSZ;97)8SVL4A9@S%E') P#^7%.-C:&(1&VB,8<N%VC&XYR<?B:L44
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H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>forms-1a_014.jpg
<TEXT>
begin 644 forms-1a_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $% G # 2(  A$! Q$!_\0
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M7J$EH<I=V%_<6LM_?R'*CY4]/\*W?#__ "!H?J?YT_7/^0-<_P"Z/YTSP_\
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MLRU1114%!1110 4444 =3X=_Y L?^^_\ZU:RO#O_ "!8_P#??^=:M0,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I1UI*4
M=: //8O]6/J?YT^F1?ZL?4_SI]6)A1110 4444 %%%% !1110 4444 %%%%
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M^^34U% 7(<7/]^+_ +Y-&+G^_%_WR:FHH"Y#BY_OQ?\ ?)HQ<_WXO^^34U%
M7(<7/]^+_ODT8N?[\7_?)J:B@+D.+G^_%_WR:,7/]^+_ +Y-344!<AQ<_P!^
M+_ODT8N?[\7_ 'R:FHH"Y#BY_OQ?]\FC%S_?B_[Y-344!<AQ<_WXO^^32,+G
M:?GBZ?W34](WW3]* N=O8_\ (/M_^N:_RJQ5>Q_Y!]O_ -<U_E5BH&]S \6^
M*;;PII0NI4\ZXE.R"$'&]O?V%<:-=^),]I_:<5G:I;XWB#RN=OTSFH/&]U:W
M'Q.TRWU&54L+*)9)-W3NQ_/@5HR_%VQ20F'1;V2S!QYQ(7(^F/ZUTQ@U%<L;
MW,VU?5G0^"_%T?BO3I&>(07MN0L\0/'/0CVK9U/2X-7M1;7#SH@<-F&4QMD>
MXK&\(1>'+F&?5]!C"FY.)^S*V<X8=JZ8<&L)Z2TT*6VIYOHUN-+T2^\0!KV[
MGT^^F3RY+IROE*VT\9P2%)/X5T&K^+S8O>?8[1;J*UM([AWWXRTC (H^H.:L
MVUA!X<\/ZBMXSW-O)/-.ZQQECMD/W=HZ]:Y>#0;FS^&%^/+G-Y>,L@5AF14#
M@("/4*!6EXR=WW%JMC=D\6W6E-,->TZ.V_T5KJ'R)=^\+C*'/1N1[57TSQRU
MS>QV]W;V9,\+RPBRN?.8%5W;''8D=/>K#^$[G56F?7M06Z)M6M81#%Y>Q6QE
MCZMP*-/\+7\-U')>:E 4@A:*+[+;+$S$C&]SW(I>Y8-1/#7BVZUZ[C1[6S6&
M2,OF"XW20D?PR(<$'Z5?U;6KV#5H-)TJRBNKV2(SN9I"D<: XY(YR36?I?A*
M[MM:M-1OKVWF>T1E1H;<1R2Y&,R,/O5HZKHUY/JL&JZ7>QVM['$8&\V/>DB$
MYP1Z@]*3Y>;0>MCE];U?4/$$&DVL=J(-U^UM>0?:&0^8@)V[E_AQSFNB\66^
MH-X?2'3!.VR2/SHX)-LKPC[RJWKTJ*T\)M;K8.]Z9;B&^>]N)"F/-=@00!V'
M-:6NZ0^KVL(@NWM+JWE$T$R#.UAZCN/:FY*ZL%F<CH]U;07EXNC7-_;SBSD8
MZ9J>\%G R'4G/3OBM3PKKU_/;:%8WT2/)>63S^?YA9F"XP3[G-6;;P]J5SJ:
M7^MZE%<RPPR0P);P>6J[QAF/J<54MO"FK6,&F-:ZM;B[TY'MXG>WRC0MC@C/
MWACK3;BQ69-_PEMU.L5O9:?'+?SWDUO%&\A5 L?5V/7\!6-::G=F]N6U&*2.
M8ZY%%Y27!VQ_N^Q[KWQ[UJP>#[NSM+9[;5%_M.VN9;A+AXLJXD^\K+Z4ZW\(
MW>XRWFHI/.^HI?2,(MH.U<;0.U%X+8+,HI\14>X6?R;,:<UQY(_TH?:<;MN_
MR_3/;KBK:^,KF77Y;"&RM3'%<_9VC>XV7!']\(>"O]*;!X*N;:1;6&_@73%G
M\Y1]F7SP,[MF_P!,_C2ZAX-N]1OF\_4(7LS<B=6>W!N(\'.Q9.PX_*C]W</>
M.PHH)R<T5B6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 #K7G\?
MW/Q/\S7H ZUY_']S\3_,TX@.K/U35(M.@/(:<CY$_J?:K[9*,%ZXXKF9M",%
MC<W5U*9)@I(YKHHQ@Y>_]W<YZ\JBC[B^?8U]%NY;W3EFF(+[B,@8HU;5%TR
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MY;R2N5(*A>A'M6H;NW#P)YHW7 S$!_$,9K$B\S4=9LW;39H(8[>2*1I% &2
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M2BEFQP *K1W#NPC* GVXKBQ6+=&481C=O^OO%=7L6Z*;@YY/Y5)*;=-BK/\
M.W16&,UU0FY2<>5Z?UH*4XPUD[#:*@FN1$Z1K&\DC D(OH._--^WP+GS6,1'
M4/UZ9J[HJQ9HJN][;H2/,5F&.![_ /ZZ/MUKS^_3CK1=!9EBBJYOK4!29T^8
M9'-+;7D-U_JB2,9SC'?']*+H+,GHHHH *1ONGZ4M(WW3]* .WL?^0?;_ /7-
M?Y58JO8_\@^W_P"N:_RJQ4#>X4F!G.!GZ4M% !1110 4444 %%%% !11BB@
MHHHH **** "BBB@!DT2SP20O]V12I^A&*YE;2V329=,06VGZND81)7&T.RD%
M9%/\0X!P.AKJ:CE@BN$V31)(OHZ@TF@3.3U*UT*RMI8U9+B:1%A=B=\=N,!6
MD8#A<]3W)Q7464MM+9Q?9)!)"BB-3W^48P>X--FT^VFL9+01B*)Q_P L@%(/
M8CZ5FPI?Q:M&3;N)F;;<S( (9X\</UX<=,?TI;#W-RBBBJ$%%%% !11@T4 %
M%%% !116%K5[]GU;3X)-1N+*"2.5V,"@EF4I@<JWJ:3!&[17(V/V2SLU@/B;
M4R5+'*Q#'))[Q>]%Y]DNA !XFU,>5.DOS1#^$]L1=:5QV.NHK&T&[-S)?HM]
M->112JJ23* PRH)'"KW]JV:8@HHHI@ ZUY_']S\3_,UZ .M>?Q_<_$_S-.(#
MJ***H04444 )@9S@4M%% !1110 4444 -D198VC<95@01[5':6D%C;K;VT8C
MC7H!4U%, HHHI %%%% !1110 4444 %%%'?% !1110!5O]7&C0?:/),KM\J#
M. #[UAV?BBXN[F?SU1W4#:JC:%'\S6UJEE_:&GR0#A_O(?<5YXT=S97YE1<.
M#AT;C\*SEI+4]3 4</47[Q7?7T/1+*^2\5L+M=>JU//-;1*C7CA85?=[Y]JY
MW1]4L8E:2>;RI&&-A!X_&K\]UI^J316Q9CSE6Q@'V_&JY[+W7J9XC 4IUW'E
M;IK5Z7L6;Z>V*+J'GO;KSL;;R0>V#UJE%<63SL7:Z64QL?WT>TN-N"1[XJ;5
MHF1K*X2(R16TF7C49.,=0/:EDU2WO(Y8K=))28FRVP@)QWS2ZG%ITV'6]G#-
M9J8II/L\H$@0@9SQSZ]JC@^R27%HBF8/L)0.F,A6YS^-4K>T6WCT::-'65R!
M(<GD;3P:BM7DA-A(VY6,4R*S _?+<"E<=C4N;6WLU#/-*J2R*K!0#N;=D?2K
M=M9K;.2'9LC:,]ADG^M<X%MC:V@59C?"=//W!LYSSGM4YMIO[-O;B%9#<>>Z
MYR<A-W.!0I>0->9TM,FE6"%Y6!*HNXA1DXKF2F;6[:UE39]G(>.)7Y/8\]ZN
MK9QP:CIQC1L2Q,)LDD-P.N:?,3RFU'(LL22+]UU##/I06#1DJ01CJ#7-G9#J
MF5 N6:?&TAUD0?R*BNAC@CMX#'$H5!G %-.XFK'=V/\ R#[?_KFO\JL57L?^
M0?;_ /7-?Y58I ]PHHK/NM>TBRE>*ZU*VADC^^KO@K]:0&A17-#Q:?,P; !1
M"+DKY_[P0DXW;=OXXS6K::[I-_*D5IJ-M.[C**CY+#VHN@LS0HHHI@%%9E_K
M]AIUT;>X:?S%C$K>7 [A4)(R2H.!P:LVVI6=XLCP7",D;!6;.!D@,,$]>"*=
MGN*YR-W<S0QZOJ2:K<)=VVH&*"W\T%'&5 39[Y-3S>+[V"#[4]O:&&83>3$K
MGS(S&<'S/8\_2ND_LO3!?_:OL5I]L)W^9L7>3Z^OXU#+#HMM<^8\%HLM\QA:
M0(#YAQDAC]/6KYD^@K,PM0UZ_D\0QVUA-:(L+RH?.<[' B5^<=QVJF/&%\)7
M>WM][W;(Z))EEA A#$ 9'4G^M=4=#T7R4MSIUEY>=R1F->3Z@5!JSZ';!(+Z
MTCE:;YUA2W,K-M&-VU03@#C-"E':P6?<S-:U*YO-!T2Y@$L+WEP@>**X$9(*
MME=_0#(K'BUN_CB6.6YF+0O/&R&8,1B2/:"X^]@-U]\5VHCTK5].MP8[:XLW
M :%'4;3CCA3Z4V:#1K"S+20V<5O .0%7" D=AZG%"DEI8+'/MXMU&&'[1/:V
MACF60VX1F&TI($RY].<\=*UO#MS>7$NK+>S12R17>P&$DH!L4X7/UK1:UT\Q
M[6BMMBJRX(7 #=1^-5K6?2-.N_[+M$BMY6<#RHH\ L5)'3CH*3::T0&G13?,
MCV%_,38.K;AC\ZCM;J&]M4N;=]\4F2K8QG!Q_2H&34444#&N<1L1UP:YJUUR
M:'P?IERLD4]Y<>5%NE?@,QQN?'.*Z>L]-"TB)95CTRT42KMD"Q ;AUP:::ZB
M9SLGBO50URD=O8,UE%))</N;;)L;'R?4'OT(JPGBF[:_B)@@-G)/+"(H\M<#
M8I;.WH<^E:]XNDZ/IYDFM8H[8*(=L<.[(8\*% R<D]*R]+L-'N]:FUB"YE,T
M#DM%-&(FB9ACG(#8QTSQ5WBU>PM2#6CYMWI]ZESJD$5PLK26XD,9PD98#;V.
M15>R\7:M=0PQ)9VRW$[0"%I"0H$A(^;DDXQU[UUK364MZL+O"US%'YH!P2JG
M(W9]#R*9;:9IL W6MG;(&<29C0<L.AX[TN96LT%CF'\3:X S+;Z=L\NXD&2^
M<0G#?GV]*Z^"7S[>*8#'F(&QZ9&:9]BM,8^S18PR_<'1OO#\>]3*H50J@!0,
M #L*4FGLAI"US/BJ:6WD\Z!V25-/NBC*<$',?0]JZ:N:\40&XFBB9)?+FL[B
M R);O,JLQ3&X*,X.#4/8I;E&Y2[CU.RA6"\5)#)N7^U0=V%R.<<574WI36"8
MKS-NS"/_ (F@^3]V#Z<\G-)+;1RW<$_]GZ:OD[OD&B7&&R,<\=JC%A&%OA]A
MTX_:B3SHEQ^[RH7CCVS4%'3:"[227CN2780%B>Y\I:VJQ?#XYO"J3",&)%:6
M%H]VV, D!@#C-;56B'N%%%%, '6O/X_N?B?YFO0!UKS^/[GXG^9IQ =115>]
MNTL;1YW&<<*HZL3T%6E<DL$@#)( ]335='^XRM]#FO.;_6KG4;P1^8I+-M!8
M_(OT'3'N:L)#<VB"6*?=,@+.%79T_NL, _0BMW0LM69^TOLCT"C%9&A:P-3@
MVR$&91G<!C>OKCL>QK.UN6Z_M2Z$,DP$5J)%V3A AR>2#][Z5FJ;YN5EN2M<
MZBBN?_MVX:"::!(&AMHT:0RL5>3(SP.U)+K=VSW$82* &)G@WYW-A<Y!'&?:
MCV<@YD=#16!;:M?RQVL"BU:=K?SWDD<A2/0>_KZ5&/$%Y<1N]K;0!8[;SW\Q
MCZG(&.O3BCV<@YT='145M-]HM8IL8\Q V/3(J6LR@HHHH **** "BBB@"&Z6
M=H&%M(J2]BPS^%9>KZFZZ0LMNS0EY5BFD(Y@'\1/I]?>MJN3\2R21:M!"D68
M;D*)B >><<XK.J[09UX'#/$UE37KKY:DVDW^_5)XM.EFO+1;<N1(Y/[S/ !;
MIGFB?[ _AB[U#5-3N8]=1"\5LK;1$W.$51][. #58)!9WC?9TBBB<!8I%)W-
M\A9B!_=X'6JWV1+93<VEQ'*EN$DEE$C(B,1D8_O<\?6N2&E-0<F[=>Y[,LHJ
M^T<X-:^J.RM)/-LH)-I7=&IP>W%35D>';^?4M/:YF8D%RJ@@9&/I6O7=%W5S
MP*]&5&K*G+=,*S]1T>UU'YG!27M(O7\?6M"BFTGN1"<H/FB[,Y4^%;A9,K/&
MZ#U!!JY!X><.&FG  .<)U_.MZBL_91N=L<SQ,8N,7:_DK@!@ 9)QW-%%%:'
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M>&C^A/(_48_&MJ5N=7,Y_"S'TJQ23P^\AL\NQ.V9H\_-T&#G@#UK5U&U?4;
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MV\MQ*ZX3[3;$H#[A5&0>E,2Z@GETFWBO7O;A;P2RMY;  ;&S@8PJC( %=+^
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M%7!;P@8$2@>F*<J*@PJ@#VHL%RK_ &59[<>4<85?OGHIROY&KE%%,5PHHHH
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MTV>2VB,KI+<!-JM&P 9AD*3C ..U:U<NGA"3[=;74VIM*T#Q2#,0SE%VX'/
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M2/<U:*R+?5KV2>)9M(GCBE.%?<#CZCM6O42BX[E1DI;!1114E!1110 4444
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M3_Z8_P#CW_UJ/[3_ .F/_CW_ -:BB@.5!_:?_3'_ ,>_^M1_:?\ TQ_\>_\
MK444!RH/[3_Z8_\ CW_UJ/[3_P"F/_CW_P!:BB@.5!_:?_3'_P >_P#K4?VG
M_P!,?_'O_K444!RH/[3_ .F/_CW_ -:C^T_^F/\ X]_]:BB@.5!_:?\ TQ_\
M>_\ K4?VG_TQ_P#'O_K444!RH/[3_P"F/_CW_P!:C^T_^F/_ (]_]:BB@.5!
M_:?_ $Q_\>_^M1_:?_3'_P >_P#K444!RH/[3_Z8_P#CW_UJ/[3_ .F/_CW_
M -:BB@.5!_:?_3'_ ,>_^M1_:?\ TQ_\>_\ K444!RH/[3_Z8_\ CW_UJ/[3
M_P"F/_CW_P!:BB@.5!_:?_3'_P >_P#K4?VG_P!,?_'O_K444!RH/[3_ .F/
M_CW_ -:C^T_^F/\ X]_]:BB@.5!_:?\ TQ_\>_\ K4?VG_TQ_P#'O_K444!R
MH/[3_P"F/_CW_P!:C^T_^F/_ (]_]:BB@.5!_:?_ $Q_\>_^M1_:?_3'_P >
D_P#K444!RH/[3_Z8_P#CW_UJ0ZEE2/)[?WO_ *U%% <J/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>forms-1a_025.jpg
<TEXT>
begin 644 forms-1a_025.jpg
M_]C_X  02D9)1@ ! 0$ 9 !D  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (T!$P# 2(  A$! Q$!_\0
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MFJ"]N])BDMH!<7S 3O \-I9RA-5U'Q2?7;:)6@EFU2[G@>W6WAU'P]97;O\
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MGU&\9(=,MKNX:ZM%U&_BBDN-2DY@M-(G6\M;;4YXD5I(W%]?L/,1"TTA>:3
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M$#:-#:7.FWD<B312"5_$RS:C$VV*(V\%REV)OL\DMG&PAC;H[71&+V4DIO\
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M*7[1-]I?AO4%<M#J$>I:A\-_^)KJ303R+]AMTG\.V.9"@N+QF*<S_P ,!?\
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M "WDZ:A;2MK+:M):I)(]A;PQO%'$'GU:"-DN$]_L_P#@FO\ M_-<V[O^Q/\
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M'J,G'6GT5_ RA"*M&$(I;*,8Q2]%&,4ODD?Z W>]W?O=W^^]_P 1NQ./E'
M''( )('T&3@4AC0G)12?< T^BJVVT"[[R_\  I?_ "0PQH0044@C!&U<$'J.
MG0]Q[4&-"""H(8%6!&0RG.00<Y!R<CW/J:?14>S@G=0@GO=0A>[=V[\M[MZM
MWU>KN]17?=_>]?777YW&&-&^\H;G/(!YZYSC.<DGKWH$: $!% /4!0,_7 ]>
M?K3Z*JR[+[E_D.[VN[=KNWW7M^ W:./;@=#@>@R#_C^'%&Q?[H]>1G^?2E+
M'!/Z&EZT679?^ JWR]VWW"U\U]ZO]UK_ (C-B9)VC) !X'(!)&3C)P22 20#
MR!FCRT^7Y%^7E?E&5.",J<?*<$C(QP:?11RQ_ECIJO=CH_N"[6S:]')?DUZ>
MFFPPQH?X1_WRIZ<#J#TH$:C. !DY. .2 %R1C&< #(QQ3Z*?W_>_\]?F*RO>
MROWLK_?O^(P1H.0H!XP0.1@DC\B2<=,DF@Q1DDE%)(*G*J=P)R020203R03C
MVI]%3R0NGR0NM4^6-T][I\MT[ZZ-:Z[E7?=O2VK;5NUFVK>5K>0TJ#UY^O/\
M^G4],=:-B]A_D?YZ'CVIU%#A!N[A!ONXQ;^]Q;_$6O=_>_\ ,C$40&!&F/3:
M .N<X P#GG( YYZT[8F,;5 SD@# )/<XQDTZBCEC_+'9+X8[+9?#LNBV71(+
MON__  *7_P D,\J,KM**5]"H(Z8X!Z<<<4NQ>  !C.. <9))QD'&2<G'4\TZ
MBGRQ_ECIJO=6FJ>FFFJ3TMJD]TFB[[O[W_G_ %T&[%Y&!R<G@<].N ,]!UI/
M+3CY5XSC  QGKT]:?12<8O1QBUV<4U]S37X!=K9M>C:7W)I?@,,:$8**1QP5
M!'&<=N""<@C!SWI=B\<#C..!D9X.#U&1P<'D<4ZBGRQ_EC_X"O\ (/F_O?\
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M,7O&+]8Q?YIA=]W][_S&>6F0=J\-N'RCAL8W XSN(X)SD@D'@T>6F -BX&
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M.K[?#/#KA^LH.EF4<3[;V$Z4Y5(4HTHU)8AUY?5_8^V3@O9_M[*>6$OKM/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&>I:'!KMEIDGB"'QQ->1KX/7Q+IF@VCZKJJZ;?\ KW_!,?X*_P#!0O\ ;?\
M^")]Q\.?A;^T[XT^ 'B'2/VLM0E_9W^-EU\2OB_X5U^X^!'@;1M/TOQAX$TC
MQ=\.[JS\:W7P^TWXJW/C30/#-E_PD.HV%O>>'M9\.W5K8:1X8T72$_=6Q_X(
MG?\ !*O3+^TU*T_8?^"LUU97,5U%%J]CXB\1:5,\3[_*U'0==\3WVBZQ9RD!
M;G3]6L+[3KR(O!>6EQ"[(?TX\+^%O#7@SP[H?A3PCX>T/PMX8\-:38:%X?\
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M8ZCX@N= \2>&DTSPOI6L^*?$.IG1/"UQ;77R5\-_VBO^#>O]L_\ 9\M/BO\
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M5_GY?&[X[^(?VGO^"87B;]H']K3_ (*\^._B)^T/XJ\56?@_X=?\$_O#NO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 & >HS00#U /UHHH **** "DP.N!GUQ2T4 %%%%
M6# YX'/7W^M& .@ HHH 3 ]!^5+110 4444 %%%% !1110 F >H!_"EP/044
M4 %)@#H /PI:* # ]!1110 48'H*** $P.F!CTQ1@>@_(4M% !@>E&!Z444
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M\5;GX6V?C35]*\10:AK7A;XL?$E?$6D06^D>,F33^([67B/X+?\ !S!\1O\
M@FQJG[5_B;X-:K\#_P#@DUKWP$^)>L7?[5UQ\3K_ .$_@3Q#IES\9I=$\;?M
M "#X]ZC\.O!/@SPQ\4=,FD\0ZC<Z=9?"+PQJ=GIDUQ\-],MW'^C"MO&H 7S
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M:QTQ;>QL]*<'5G&G"SE)V775^EW^'X7,ZL_9TYU+7Y(\S7DK7^=MN[/XXO\
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MSZ=K_A3P3X?TMM!FT#PSZ=\/_AK\4?C%X8_;E\6>/OCC^U-H=G^RE_P;C_\
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MW%PQ4MOR4+2GR\AV&$VC;M4 *B!7>4FTK\^"P<GS9 Y8,&!,F_S#@@  M@(
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M?B=^W#^RM\)8-)\2_%N"[\7^/O'W@;X=_$6]TZ'5+A=4@\-:[H.FV6J^"_\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:Q
M&3G&0..I+?*H]LL5&> !U.* '45XQJ?QE\-Z??W=E*FLB2TN;BUD\JPMI8S)
M;RO&^QVOXG*;D.TM&A88)53D"C_PO#PS_=UW_P %EI_\LZ]>GP]GU6$*E/*L
M5.G4A&I3G&%U.$TI0FGS:J46FGYGDSSW**<YTZF84(3ISE3G%\]XS@VI1>FZ
M::?W[-'NM%>%?\+P\,_W==_\%EI_\LZ/^%X>&?[NN_\ @LM/_EG5_P"K7$/_
M $*,7_X+_P#MB/\ 6#)?^AEA_P#R?_(]UHKPK_A>'AG^[KO_ (++3_Y9T?\
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M_P"':\>__+BNB_X3O3?^?;4/RA_^*H_X3O3?^?;4/RA_^*HY*W\K_P# %_\
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MXKHO^$[TW_GVU#\H?_BJ/^$[TW_GVU#\H?\ XJCDK?RO_P  7_R(>TH=I_\
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M&W_YYM_WV:.9^7W+_(-/Y8_?/_,X+_A3>C_]#M\9?_#N>.__ )<T?\*;T?\
MZ';XR_\ AW/'?_RYKO?^$AM_^>;?]]F@^(K8<F-^HZ.<\G'I1S/R^Y?Y!I_+
M'[Y_YG!?\*;T?_H=OC+_ .'<\=__ "YH_P"%-Z/_ -#M\9?_  [GCO\ ^7->
MB7&N6D!6/YFE(5BGSJ A7.=V ,@E1M^\<DGH:@_X2&W_ .>;?]]FCF?E]R_R
M#3^6/WS_ ,S@O^%-Z/\ ]#M\9?\ P[GCO_Y<T?\ "F]'_P"AV^,O_AW/'?\
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M16__ #S/_?7_ -:ES8OO3^[_ .U#7LOO?^1P_P#PJ6'_ **'\5__  X5]_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *AE;E4QU>,Y^DB-T^E356E_UB?[Z?\ H25,VTKK
M^:"^3G%/\&QQ5Y)/:TOPA)K\4C\_/$TK#Q7KZ80@:WJPY4<C[?<#G@_Y)/7K
ME<^@_,_X5H^)_P#D;O$/_8<U;_TX7%9]?TIEL8QR[+^56_X3\(MV]J,$MS\
MS*M4^O8MW5Y8FO-Z+63K5DWY:16FWWB<^@_,_P"%'/H/S/\ A2TQB,\MM&..
M0,]<]>N./I^-=LI**<G>RMMJ]78XE5G_ #)?]NH=SZ#\S_A1SZ#\S_A3,I_S
MT_\ 'Q2G &=YY&1EA@XY[]16?MH?WO\ P'Y=_,?M9_S+_P !'<^@_,_X4<^@
M_,_X4F]/[R_]]#_&E!R,CD9P""""<9QP<]/:M2?;5.Z^Y!SZ#\S_ (4<^@_,
M_P"%+10'MJG=?<AC9VMP/NMT)]#["O:?!/\ R+%IV_XG&K'CU-CIYSSQ^'05
MXN_W&_W6_D:]H\%?\BQ:?]AC5?\ T@T_\Z^2XU?+DOM$KRABZ3CM>[IU%IS)
MQ5]%=IVWZ'UO!=JV=*%5.<'AZEXI\O,KZKMLNNFEGHSI-P54W':"OREF" [5
M4L,\<@,A(R2 RDX#<RXZ9# E589+#*NH9&'/W74AE(R&5E8$@BOYDO\ @IG^
MV1\4?A1_P4MT/X$ZQ_P46\?_ + O[.5S^QSX5^)=QXJ\(_!G2/C7'>?%"7QY
M\3K1=+/AM?#.K>)8[GQ/H&CR)%?)J4>C6-QX=LK9;)+[6))KG4^$O_!8GXW?
ML_?LC?LKW_[5?PTN_C#^T+^TWXX_:(C^#GB?XB^*OA/^PWX*\=? [X-7>AW.
MD_$_XF>.?B1INC^ /AWK_C&/Q-::/\/M'O?#6E#QII4/AW7]:U&SG\5>'=<\
M;^ N#LXGEV48[#O"XRKG&&PV*HX"A1Q<,3&AB<+F&+]K"KB:4,%B(X:GE>+E
MF"H8FM4P5%4*]:A"GB(SA]1+B3+:.-S#!5%4P\,LJXBA7Q%L/4HQEAZF!IRE
M7C0JU,5A_;5,QP\</*KA:5#$35:%*M*5&5.7]+.![_F?\:" /7M_$?SZ]NM?
MEEI'_!4KP;;>./A]HWQ2^"GCSX-^ ?B?^PE\2OVW_!?COQ5XC\/ZOK>MCX+3
MZKJ7Q:^!NG>"?#MK>Z/JGCGPS\.=(N?BSHVN:1\2-2T?Q+X&N]#NY['PW<ZS
M'#9^&>$O^"R7BKXG6'@72O@S^P)\<_C%\5-1_9D\._M@_%?X8^#?B+X$MKSX
M6? OQ?XAN(/!TOA_5?$&E:;??&KXI^-O ESX.^(?@OX5>!_#%I?^)8/'FC^&
M-)UR[U/2M>N[#ACPYGLDY1RY*G%)RKU*^6TL+&[KI>TQ5;'T<-"TL-5A+GKQ
MY9J%.4HSJTE+N_MC+.526-IR4FXQ5*%>M.33@GRQHX:LT[34H\RBI1C*4>=4
MYI?M\""2/0[3\Y.#P<8SG[I#<@<<].:=@>_YG_&OY]?'O_!2G]I7X>_MK_$M
M_#_[/?QY^)_PGL_^"7_PP_:TU/\ 99UZX^&?P>\1? #5['Q!-XE^*'BGXH^(
MO'L::QX?\3^&/"%[K'@W5O ?A^Y\8WGB/QQI-G9Z)X4DL)IO&NF?26M_\%8$
M\::C\'?!7['?[*GQ&_:Q^,'Q3_9*TK]MS6?A:/B?\-?@I??#+X"ZW<:=I.EI
MXB\0>)G\6Z=KOQ4N_$FM:%I-M\-?"MMJ5U?:?K>C>)K?63I>L:2E_57AO.*5
M/#UOJ]&K1Q.&IXM8BG6P,<-0I5:-7$+ZU6GBO982,:=&5JN)JTZ-6<J=.A6K
MSJ4E4R6=X!5*]&I5J4JV'K3H^QGA\3*O7<:E*DI8:G#"\V*3G5C=8:-:4(*=
M2I&G3IU)4_UVW+N*Y.0,D;CD#.W.,Y"YR-QP,@@9-*,'/7@XZM_C7X+67_!4
M?PY\7?VC?^">/QI^''Q6\2>"?V,_BY^R5^W'\;OCKX*\3:5X9631M2_9Z\)W
MNHZXWCNWM4US4--UOX83^'M5O8AX<\36]GK>G16&JQRZCHNLVGG^O? __@KI
M9_$;XA?LS:9\7_V6_'G[,OP/_;93Q>/V2_VB?'?Q=^$_BOP[X[OO"MK+J$&E
M?%#P=X;N[;4?@KJ7B:Q&GP^'+74?$'B^;4]?UG1]%LTN[2?4M<TFJO#.=TJ;
MJO!<ZAA:N*K0BJ%*IAUAYYG'$8:="O6IXC$8_#TLFS'%U<-@J6)G]0P\L53I
M3IQE9PSK+Y5)0>(WJPA2G"-2M0J4JBP/L\2ZM'#RA0H5*F8X:BJV)JT:?MI2
MHNU2&O[%GCU/K\QX !)/7H ,GH .2:0X!QSG=M(W,"#QU!P0>0<8Z$<\BOQH
M^$'_  61T+XMZU^RSK>C_LD?&+2O@;^V/^TO+^SW^SW\<M?^(?PGAT;Q5)H7
MB#QCX;\4^*_$/@/1=>U/XD>"[G3-<\*Q6^C^&-0T9X/$&GR>)=1_X331;OPQ
MIFE>+?F']DG_ (*S:_9? SP;I>I>#?C_ /M9_M,_M!_MJ_M'? 7]G[X;^)?'
M?P>T74=4@^$O@_X9^)=1DUOXCZ3\.OA?X%\ _"SP?#XZ\,VMW?7O@[Q/XJM#
MKGB3Q=.FL:?9#1M*T7"N?>RK3GETHSHU(4Y0<L%I)U<=1KNK7^O+#82&!J9=
MB_K\L75@J4:?+[LDYRA<097.5!4\2IQK1JS4N3$0G:%/"U**I4*F$C6KRQ7U
MVA["-*+=6,TX6E[LOZ-\#W_,_P"- 4G.%<X!9B-Q"HH8ER1T4!')/0!'R?D;
M'Y%?$#_@I_\ %#P#\!O!WQ;UO_@GY\;_ (?^*M=^)WQ*^&/C#PG^TG\6?@_^
MRU\,?AA=?"^QLM1O?%?BO]HWXJ7L7@*;P9\0H;F]M?@MXBTW1YM$^*%YX=\3
M+I&JVGV31%\1>-V?_!1/Q7^TG\2O^"*7Q+^">J^+/A?\(?VQ/B+^VGHOQ@^%
M>LVFA:C=:S+\$O!2:7IN@Z]J&HZ%)=@>%_'7A[5-5TK4O#KZ!)J4$]L^K6Y9
M$TZPPH\.YM6BZCH4:=!5<=0>)C6P&*HPKY?@<?F%6E.6"Q>+4'5H9;BEAY3<
M5B)0_=)1:JO6>;X*\Z5.K.IB(QP<E1]EB*+DL;C,'@:?OXC"TZ:=.MCJ+K1O
MS4X^]>HE**_>K2P/[1TW(Y$U_C(^93_9=_ZC(./H:S0,E\\G=U/)Y5<\]>YK
M1TH 7^FJ  %FOE '0 :5?XK.7J_^\/\ T!:^?BW=MJ-VHMJRDD[-M1O?1.Z7
MDE<]B?/"U-MVC=K5:J5FN;ELFVK75K)W2T%P/?\ ,_XT8'O^9_QI:*OF?:/_
M (!'_(RN^XF![_F?\:,#W_,_XTM%',^T?_ (_P"07?<3 ]_S/^-&![_F?\:6
MBCF?:/\ X!'_ ""[[B8'O^9_QHP/?\S_ (TM%',^T?\ P"/^07?<3 ]_S/\
MC1@>_P"9_P :6BCF?:/_ (!'_(+ON)@>F?KS_//K6EJ8S9:.3R?)4#/.!YDA
M(Y]R3U[GI6=6EJ?_ !XZ-_UQ'_HQZ5]5I'_P"/;T*4Y1O9O5--;JSWT>GX&9
MM'O^9_QHP/?\S_C2T4^9]H_^ 1_R)NQ,#W_,_P"-&![_ )G_ !I:*.9]H_\
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M\B_+_P#L PG_ *9IG\]YE_OV)_Z_UO\ T_7/SE_X*P?'CXL_LV?L*_%SXO?
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MJJ$?:N[;FT]+V:I.TG%)-IMI-I:*5E\0/]QO]UOY&O:/!7_(L6O_ &%]5_\
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M;_2K?QWI$&H:EX=&IZP]OX<U5[RS_L[O?A%_P3*T'X2W/_!+":S^,VOZX?\
M@E_X<_: \.:*MWX(TBP/QJ7]H#P%:>#=2N=5>W\5WJ>!8_#$]FNHZ9:V;^)4
MU*WDDTO4KK2@D6L3_;YACN!\17K8_#X"O&G6PU5T\NCA\QROZCB,)@<W]DW1
MR_$8^C6CF6)P_#=.3>+JN,:V:8GV>'K8KV6&^3PF'XHH4:.#JXF%2=&?M*^.
MYZ6+CC:>(KY?)TX3K4<,HO!*6=?N_8491C'"TU5Q,:5.I/Y;\7?\%1]1^*#_
M /!-'Q;\,;CXQ_!63X[?MK_$+]F_XZ? :S\-_ ?QOK=]XG^&?B_P9X1U_P"$
M7CGQ9X]M+Z;PM97=QK-G?:9XS^&>N^$-;?1/%$LFH/HVI2:=?^%O)/A__P %
MM/C!X,^#W[1WQC_:&_95\=:S<:'_ ,%-;O\ 8J^$GP[\%ZGX'\(7OAMM6^&/
MB?5].^$.KZK<7_C6R\1?$_X9ZU\*+VY^*?B ZSK&DZQXH^-^D#P5JUMX*\/Z
M3H&D_5NB_P#!'?PKH7B']E[7=/\ CYXE:/\ 9U_;X^,/[>.H65_\/?#\LOCC
M7?BCXQ\,>+-,^&5E>6_BFQ7P5HGA:Q\"Z)HFH>)C%XXOO%=]<:IJJ:9X3M=6
MTK1?#_ >-O\ @B[J_C32_BCX0D_;!NK'X>^/_P#@II8_\%.-"\(_\,X:9=W?
M@WX@7-C\3=)\;^!G\7_\+CT2Y\4V/BS1O%W@72[+7=1TW1E\-M\.)+ZS\*S2
M>,=2BTWLHXCP_;6'K0;PJQ,%5JSP^:QQ=+"K/LTJUZ.%Q6&IRKMK+7A:<:V(
MIUZTL/"E05554ZDHJTN*5*=:E6E&M&E4A3I4G@X4:E7^S,+2IXB=/$RG3IN>
M*IU:CI4N>,9U6U%)2;YOXB_\%0_B9\(_VG-?U+XN> /CI\+O"_@+_@FIX_\
MVJ_'7[%6OV7[/-X=.\9>&_C;XF^'FAZCJ/QFT:#5/&FF^(M<TS1]/U&/2-/\
M2S^ K#PAK>CZS=:(?$]CK.CZQO?&'_@M#JOACX7?$?4/"O[&G[07@7XH:I^R
M3??M:?LQ1?&>R^%O_"(?%3X56VEK)K/Q/\0V/A#XWS:IH6B?#>&]M_'GC3X7
M2ZO:_%R\^'FFSW8T+1]5O(;>MS_@J-_P3Y\6?&#4/VN?VQ?AYKOB3QW\1/$7
M_!.GQ?\ LH^$?V:?#7P[EUO5/%%[/\1%^(<OB+2/%%CXCNM8UK6I["6\T?2_
M .G> 1=ZE>0PR6&N7=Y+%HTV!\/_ /@DA\3OB+X(M=>_:G_; \=?$?QQ>?L
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MXQ>,YM4^%_PO^'7PXMVTFU@\0>&;SXC>.-9\*^!?%?Q[U>]CNO$7AW]G_P
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MZY_8U-X;&8I9USTZ]"K0G3S)9;1C6PM/,L4\+1Q>'JX%T,6ITOF<[I9]5Q6
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MVC@U\:6W_!3_ .)?P@^/?CW]AC6O@%\7_P!L'XG_ +(_PI^%/B#]IO\ :O\
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M90\.J3I3]_#<N)I5)8[12S2%2,</"%_J?-74:;_:[X0_%/P9\<?A7\-OC/\
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M)\$_!/Q%OOAO_P %%_CM^VWJ'[%O[27B>#P!\*_$NM?#1OV:=5;4OVJ?':>
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M\4_LJWOB&7P%XJ^#P\+W^IA_"?BCQO=I)XIU*^N9;T^$-0\5_#_Q)[?\+_\
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M7R^K/VKQ&+A4Q,J5:%*>%]K!.%XSDOO"BBBOA3ZD**** .BT'_4ZA_UTL?\
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MD@ =:B:DTDHR;<H='TG%N^FBLGJ]/O1491O?FC91FWJNL)+OW:7S/SX\3_\
M(W>(?^PYJW_IPN*SZW/%-M*/$_B!ELKV0MK>K?-';3NC 7\X)61(V7.XX(7H
M>"<X%8?E7O\ SXWQ]_L-US[_ .KK^D,OQ%%9?E]ZM-?[!A5_$I=*5.^CK)JV
MVJ3[I.Z7X!F5&M]>Q5J%=VQ%>+:HU6KJM6>C4&FK2BTUHTTTV%%'E7O_ #X7
MW_@#=?\ QNCRKW_GPOO_  !NO_C==GUFA_S]I_\ @RE_\N.+V-;_ )\5_P#P
M16_^5A11Y5[_ ,^%]_X W7_QNCRKW_GPOO\ P!NO_C='UFA_S]I_^#*7_P N
M#V-;_GQ7_P#!%;_Y6%%'E7O_ #X7W_@#=?\ QNCRKW_GPOO_  !NO_C='UFA
M_P _:?\ X,I?_+@]C6_Y\5__  16_P#E844>5>_\^%]_X W7_P ;H\J]_P"?
M"^_\ ;K_ .-T?6:'_/VG_P"#*7_RX/8UO^?%?_P16_\ E8U_N-_NM_(U[/X*
M_P"17M?^POJO_I!I]>-&&]8%?L%_R".+&Z)Y&/\ GG7M?@JWG_X1FU4P7(/]
ML:L"#;3;\BQL!C9MW=0,$CD9XXS7R?&=>C+)7&-6FY?6J+454IMM*,T[)5)7
MU:5M&VTDF?7<%0J0SI.=.I!?5YKWZ<X?:6RE%-KNUHNK.A3^'_KFO]*DIHBN
M5('V.\.%V\VLXSM.,_ZOZ<4[9<_\^5Y_X#3_ /QNOSB+O"'^"/Y,_1Y?%+_$
M_P Q\;^7(DF,['5\=,[6#8SVSC%?CEX5_P""5.K>&OV3/^"CG[,3?'G3;ZY_
M;Y^-WQ@^,-CXWC^%]W;6WPGA^*TGAYD\.7GAR7X@S3>.KC0!HC^9K$&M^$8-
M7^U*L>E:28F:3]BMES_SY7G_ (#3_P#QNC9<_P#/E>?^ T__ ,;KT<%FF.RZ
M-2.#KNBJN(R[$U$H4YJ=;*L;',,#)J<)75'%PC4</@J).G5C.G*47R8C!X;%
M2A+$4E4E3I8NC!MM<L,;A_JV(MRM.\J6B=]&KV>Q^1GQ9_X)3:-\;OB';>(?
M'GQBOU\%W?\ P2XT?_@F[X@T'P]X4N=.\4RW^@?$W3_B?H_QST?Q3-XMN+"W
M_LW6]&TR2+X::GX9U&SO'B:VU;Q5JFF23V<WSE\'O^").O\ PW^%'Q\^'.K?
M'']G5K[XN_LAZY^RSX?\3?"G]@CX8?"+Q-I%_P"(KKP;-K/Q;^(_Q!L/'FN_
M%WXG>)M2M?"$-EJOAYOB5H/A/Q-=7USXE\1:=+XB2WO$_H V7/\ SY7G_@-/
M_P#&Z-ES_P ^5Y_X#3__ !NO2H<6<08:C3P]','&A1J82M2I_5L):E4P5>6(
MHU*+5*FZ4W5E^_FE5=>E&-"I'V*43A_L#*/:*M]2I^UY:D)5.:?-.G4H+#NG
M4_G@H*\8N5E-N33LHGXW?'W_ ()5^*_C'^RY^P7^SMI'[1'A?2D_8G\,>%O#
M^LZ-\4/@#9?&;]GW]HJ]\+?#;P[X TG6_BI\!]1^(OAFWNY/#=SH=WK_ ('L
MM0\5^)(/"TOB?Q!A=2U8:5JUE^?US_P3&_:C_9J_:-_X)G?#[]G7XOWMSK/A
M7XS?\%-?C-KO[5VF?LGV&I_"+X&1_%KX-_!\:%X'^(_PJT?Q>_P_T+2OBC;^
M%?%7PA\/V5GXJ\'0JOBB^'PWL-+U3PIIL-A_4ELN?^?*\_\  :?_ .-TWRKK
M&#9WF.>/LL_<H3C,9QS'&>F?W<><E%(TPO%N=X>C+#/$8>O@YO,YU,)B,%@Z
ME"OB<W_M)XG&8R,J$EF%2CB,WQ^-I4<;3JPJ5:WU>=582%/#4C%9#EV*JPKJ
MG4P]>"P4(UJ%?$QG&C@ZF G&G3MB4J<I++L.E*"24N=V7/[O\V7[8'[&?C7]
MFO\ X)]>+O@#X*TC]IG]K_\ ;'_:*_;+UC]M?PA\9OV>/@_JG@_2_ '[8]_X
MU^'>IR?$K7#X-\3WVC_L^> [+2([NU\-ZMK6M7EA_:Y\07^D7VB7D-G_ &)^
MTW[$O[-FG?L@_LG_  '_ &<[)M,NM0^&O@2PM/&>L:3+>W=AXB^)OB&\OO&'
MQ3\26&H:I#!JM[I>O_$?Q'XKU?1I;Z"V=-)OK6.&RT^ )90?4YBN2,&SO2/F
M !M9L .%#\>7_$$0-@C<$0-D**417(_Y<KSJ3Q:SCEN6_P"6?.3D\]S7)C,_
MS#'Y;3RW$34J:S3&9QBJLIN,L5B\3AZ.%H*%"E2AA\'A\%0H15+!8?\ V;VL
MJF)NZL]-L+E.#P>,>,H1C3<<MI991HP4TJ-&%>6)JR52=6HZ\\17G4E4KU8Q
MKNE.5#2-I"T4;+G_ )\KS_P&G_\ C=&RY_Y\KS_P&G_^-UXAZ1H:7_R$--_Z
M[7__ *:]0K-7J_\ O#_T!:U=*CF-_IVZWN8L37_^L@E3(_LO4.1N5<Y/;]36
M:8;E68"TO&!.0?LLX[ ?W#GIG(-+J_1?J-II*_6_Z"44;+G_ )\KS_P&G_\
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M_"7#?_* ^NXS_G]^-7_,V/\ A)_%W_0QZO\ ^!]Q_P#'*/\ A)_%W_0QZO\
M^!]Q_P#'*Q]H[Y&>F5 S],KS_P#7'J*7:/\ (7_XFC^S\!_T X+_ ,)<-_\
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M]),]U<71(73+\@+]I>8)@C.4"L>A)&,9IU'4W9R=4U0?-T74]1  VJ< ?:N
M,^IJ;2_^0AIO_7:__P#37J%9J]7_ -X?^@+248W?NQV7V8^;_E[C;=EJ^O7T
M+?V_4_\ H*ZK_P"#34?_ )+H^WZG_P!!75?_  ::C_\ )=5J*=H_RQ_\!C_\
MB*[[O[W_ )EG[?J?_05U7_P::C_\ET?;]3_Z"NJ_^#34?_DNJU%%H_RQ_P#
M8_\ R(7?=_>_\RS]OU/_ *"NJ_\ @TU'_P"2Z/M^I_\ 05U7_P &FH__ "75
M:BBT?Y8_^ Q_^1"[[O[W_F6?M^I_]!75?_!IJ/\ \ET?;]3_ .@KJO\ X--1
M_P#DNJU%%H_RQ_\  8__ "(7?=_>_P#,L_;]3_Z"NJ_^#34?_DNC[?J?_05U
M7_P::C_\EU6HHM'^6/\ X#'_ .1"[[O[W_F6?M^I_P#05U7_ ,&>H'^=T1^8
M(]16GJ6IZL+32L:C>8EA3>ZRK%(?GD#$20K'*A&% *,IQD<@FL.M+4_^/'1O
M^N(_]&/1RQNO=CU^S'M_A"[[O[W_ )E;[?J?_05U7_P::C_\ET?;]3_Z"NJ_
M^#34?_DNJU%%H_RQ_P# 8_\ R(7?=_>_\RS]OU/_ *"NJ_\ @TU'_P"2Z/M^
MI_\ 05U7_P &FH__ "75:BBT?Y8_^ Q_^1"[[O[W_F6?M^I_]!75?_!IJ/\
M\ET?;]3_ .@KJO\ X--1_P#DNJU%%H_RQ_\  8__ "(7?=_>_P#,L_;]3_Z"
MNJ_^#34?_DNC[?J?_05U7_P::C_\EU6HHM'^6/\ X#'_ .1"[[O[W_F6?M^I
M_P#05U7_ ,&FH_\ R71]OU/_ *"NJ_\ @TU'_P"2ZK446C_+'_P&/_R(7?=_
M>_\ ,L_;]3_Z"NJ_^#34?_DNNBT'4=1>2]":G>'9I@N?WL\MPXE-Y;0$A[KS
MG$?EROB-7";_ )P 22W)GI^(_4@5O^&?]?J/_8#_ /<C9UCC*$7A74=DU>RB
MDNJ34K)7Z-?/N73^.%_YUW[HWQ=:N1EM0N 23P#$ .>WR'C\3_0+]IU;_H(W
M'YQ?_&Z2,DH"3D\\_B:?7SQZHW[3JW_01N/SB_\ C='VG5O^@C<?G%_\;IU%
M #?M.K?]!&X_.+_XW1]IU;_H(W'YQ?\ QNG44 -^TZM_T$;C\XO_ (W1]IU;
M_H(W'YQ?_&Z=10 W[3JW_01N/SB_^-T?:=6_Z"-Q^<7_ ,;IU% #?M.K?]!&
MX_.+_P"-TAN]77##4[E2"N&!BR,D \&(CD''(/7C!P0^F2?</U7_ -"% %B]
MFO8[I4ANI8W,(=W4KELE=V=RD ,=K' '(&,#(,'VG5O^@C<?G%_\;J>^_P"/
M\?\ 7L/_ $)*BH ;]IU;_H(W'YQ?_&Z/M.K?]!&X_.+_ .-TZB@!OVG5O^@C
M<?G%_P#&Z/M.K?\ 01N/SB_^-TZB@!OVG5O^@C<?G%_\;H^TZM_T$;C\XO\
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M3+*[:Z='M+749[3Z'A;$8S#9U0G@,+]=Q-3"YGA8T+T$G3QV5XW!5ZLGBO\
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M $$TY?\ 6P?]=D_K36_X^KK_ 'H__030 ZBBB@ HHHH **** "BBB@ HHHH
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M_B_5M4A\2Z;+^T''\%C\,+F+1=2M]8CU+1X?!GB?ZG_80_X)U?%O]G/XY?\
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M"*U]4U2C?IYV]4S\DS"E4^NXSW):XS$/ILY76[7<6BDY]!^9_P *.?0?F?\
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M!C'3UYSS3_,3^\*_-4K1BNJBD_57/TB7Q2_Q,?13/,3^\*/,3^\*!#Z3&?\
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M9=T[VZ2ZVMTZW5GMJM47O[1F_P"@;X=_\$%I_P#':/[1F_Z!OAW_ ,$%I_\
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M^#)__)A?R7]?,N?VC-_T#?#O_@@M/_CM']HS?] WP[_X(+3_ ..U3HHY:?\
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MCCI0<@'ID UR6@_ZG4/^NEC_ .A2UUJ]!]!_*@!:*** "BBB@ HHHH ****
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M=>%=4BM[YM,MD\6Z/?#7+OQKJ-UK;W<S0W'@O2? /].MC\,?AMIJ01:=\.O
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M>WOXO%E[:6UA?>*+>[MM'@N+;Q%J-E:06>J:Y!(FKZC;1Q0W%^4MK06_8@$
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MF)3*5M(IS&K)YWE>9'N=7YE_\%$?V<_C]\0KS]G_ /:._9-UB>3]H/\ 9?\
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MM?AU8?#C0[#3]!M+'PW9FUMO[+]\_ W3X7) )E(!)0D@'@9,49..IC0G)12
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M4NUO[C_]\-_A1M;^X_\ WPW^% "44NUO[C_]\-_A1M;^X_\ WPW^% %_2_\
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MT>9'_P ]$_[Z7_&@!]%,\R/_ )Z)_P!]+_C1YD?_ #T3_OI?\: 'T4SS(_\
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MS^%"C?K+YR:']WW%_P S2_\ GTU'_P &Q_\ E71YFE_\^FH_^#8__*NJ(SW
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M^/'1O^N(_P#1CUE*A&4E)S=KKW4WS72W;::M^(?UL1>9I?\ SZ:C_P"#8_\
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MG_SXM_W]7_&C?9_\^+?]_5_QJ&B@";?9_P#/BW_?U?\ &C?9_P#/BW_?U?\
M&H:* )M]G_SXM_W]7_&C?9_\^+?]_5_QJ&B@";?9_P#/BW_?U?\ &C?9_P#/
MBW_?U?\ &H:* )M]G_SXM_W]7_&C?9_\^+?]_5_QJ&B@";?9_P#/BW_?U?\
M&C?9_P#/BW_?U?\ &H:* .MT&XB\BYCCA,$<3Q,1N#DM*553P2<L(R",<8'0
M$9Z,'(!]1FN1T'_4ZA_UTL?_ $*6NM7H/H/Y4 +1110 4444 %%%% !1110
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M\5_L6GWLB?R,_LV>#[;]KFV_8E_95^">@_L?_";XDZ!^P/\ \%%?V=+3XR?
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M-?[C?[K?R->S^"O^17M?^POJO_I!I]>,/]QO]UOY&O9_!7_(KVO_ &%]5_\
M2#3Z^2XU_P"1(_\ L+H_^D3/K^"/^1VO^P>I_P"E(Z=/X?\ KFO]*DJ-/X?^
MN:_TJ2OS./PP_P $?U/TJ7Q2_P 3"BBBF(#P#7@_Q"_:7^"?PJ^*_P '/@IX
M]\9C0?B1\>=2U31OACH=QI&L/::_J6D6L5W?:;/X@@L9M T*^N8KBR72XO$.
MI:6-0EN[6&P-_<7/D0>\5\A?MF_L=>!OVTOACHG@7Q9XE\0>!/$O@?QAH/Q
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M=/JVJM>W]LL[LUG8W-K9*Q2!0/1:0 *JJ. D<42CKMCAC6*)<]3LC15#,2Q
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M:??'N/ECRX$:1OFRI5 9&SM4%BM=6"FH8FG*5[+FO97W6]O+<PQ+_=+SF_\
MVT\\ #*,@'@+R,_*"<+_ +HR<#H,GCFGJ2KB525D4[ED4D2*VX/N#@A@V]5;
M<#G<JMG*@BR8]+R=NL\#I_Q)-='8$Y_T<]R>M)Y>F_\ 09_\HFN__(U>_.<9
MR<E=Q;;C=/9ZJRY;+331+R.!MW;N]?/_ ()SNF^&O#6BW%S>:+X;\.Z->7L!
MM;V\T?0M*TN[O;4S1W#6MW=6%I;SW5LUQ##.UO/))"9X8I2ADC1EV-B@Y"@'
M(.<#.0P8'/7(8!@<Y# '.1FK7EZ;_P!!G_RB:[_\C4>7IO\ T&?_ "B:[_\
M(U$JDI.\ISD[)7DZDG9))*\G)V2225[))))))*4N56BE%7O:-HJ_>T>57\[7
M\RKL3IM4#&, 8&/3 XQ0%4 *  H& !P ,DX &  "S$#L6)'))-KR]-_Z#/\
MY1-=_P#D:CR]-_Z#/_E$UW_Y&I<VSN[K;26GIII\K#U[O3;7;TUT^5BKL7&W
M:-O.%Q\HW?> '0!OX@!\W?-&Q2<E03SR1D\XSD]2#M7(/!P,]!5KR]-_Z#/_
M )1-=_\ D:CR]-_Z#/\ Y1-=_P#D:ES+3?3;26GIII\K!KW?W_\ !*VU?0#&
M<8&,9ZD>A/<CD\9Z"D"J     "H Z!3M)4#H%)1#M'&44X^5<6O+TW_H,_\
ME$UW_P"1J/+TW_H,_P#E$UW_ .1J+J]];][._P!]K_B&O?RWZ=MRKL49(4 G
MDLHPQ. ,DCDG  YSD#%,_=@%=ORD %<#:0,8! .T@8&!C  &.@J[Y>F_]!G_
M ,HFN_\ R-1Y>F_]!G_RB:[_ /(U6ZKDDI.325DO>2M:STY==%;8N$YT[N#Y
M6]&U;5:Z=^KZVU>FKO379]T+@$DE< *25522O0G:J+G&=J*/NJ,.VJ<Y&<@
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MC^&"03XNO3M(8?\ %%:KP1T/_(6^H_&GR:5X7DV_\57?+MP?^1,U4Y(((/\
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M[/\ Y^G_ ._5!:S;"_:7Y*_\LO<4 27W_'^/^O8?^A)456[Q;83+*]RV3&J
MB,="%;&/PSG]:J[[/_GZ?_OU0 E%+OL_^?I_^_5&^S_Y^G_[]4 )12[[/_GZ
M?_OU1OL_^?I_^_5 "44N^S_Y^G_[]4;[/_GZ?_OU0 E%+OL_^?I_^_5&^S_Y
M^G_[]4 )4<O^K;\/_0A4N^S_ .?I_P#OU2%K)@0;ER#_ -,OQ[4 +%_Q[:O_
M -?NF?\ ILN*8GW%_P!U?Y"K,2VPMKT_:2ZW$\$[/Y>"A@MWMTCP.,[78Y/7
M(/H1 'L@ !<O@  ?NNW:@ HI=]G_ ,_3_P#?JC?9_P#/T_\ WZH 2BEWV?\
MS]/_ -^J-]G_ ,_3_P#?J@!**7?9_P#/T_\ WZHWV?\ S]/_ -^J $HI=]G_
M ,_3_P#?JC?9_P#/T_\ WZH 2BEWV?\ S]/_ -^J-]G_ ,_3_P#?J@!%_P!;
M!_UV3^M-;_CZNO\ >C_]!-3PFS>>%?M+DF5<9CP,@''2F2?9DNKD/<MDLN,1
MYZ @_3]?PZ4 -HI=]G_S]/\ ]^J-]G_S]/\ ]^J $HI=]G_S]/\ ]^J-]G_S
M]/\ ]^J $HI=]G_S]/\ ]^J-]G_S]/\ ]^J $HI=]G_S]/\ ]^J-]G_S]/\
M]^J $HI=]G_S]/\ ]^J-]G_S]/\ ]^J $HI=]G_S]/\ ]^J-]G_S]/\ ]^J
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M*E5PV'RJ..J>UHS4H5:N&Q]2-+ZQ&O3]I5CB<+AJ%.C#"/VE/%3<ZBG"#?\
M01I.H1:[HNE^(]'EEU#0=:TS3]9TG5(H;Z&VOM,U6RAU+3KE$O8+6Y@-U87$
M%RL-W;V\\2R;)8E9& O,MPL:S%9EB9O+61O-$;2;5?8KY",VQT?:I+%71MN&
M!/\ &UXJG^-]E^WU\#?B-HOPX_:H^'&N_#?]N7]BKX9^-?$=U9?MD>,]0\1?
MLDR>&/A]X6^(-W;7FAZ1X:_9 ^&?[(.K:%%*[_#:XT#Q_P#'/6O$GB#6-6UO
MQ1;^&9/$\=S]"_LX6GQJT#]HBZA\?Z3_ ,%*[G_@IG>?'W]KG_A,+_0M4^+E
MS^PE:>#)M+\?WW[-^D_%^X\>F3X)7_[(FCWFM:%XF\$P?#N]D\0:;<^,;A+N
M>2*70M#LGB.#*E"C&M_:F'?-ERS#V+ITY5J456Q%*<L0_P"U*=*&"I4X4:V)
MQ=)UJM+VM)1P,_:*G&:7$U&K",%@*_,L0L.\4JLH4:J^KPK?N(U,'*7UJK/V
MU*A0J0A2E.FH3Q-.5YG]-7Q,^(GA'X-?#GQG\7/BAKO_  A_PW^'GA76_''C
M/Q9>V6L7UCH7A/PU93:EKVMRVFC6>I:O?V^F6%O/<2V^D:=J-_,T:P6UI--(
MJCI]-U*VUC2=(UW3+K[;H^O:5I^MZ/J,7VE+;4=)U2VCO-/O[8W"03?9[NUE
MCFA,T$,H#!98HY5DC3^'[X(^%_V[O&'PI_:YL/%_A/\ :5M_%NN?L#?MP:5^
MVK:?$30_VL/&ES\;?C#J=OXQT?X/V?B"S^+.C:7\&?"/QC\-:G_9.F^ -/\
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M#X%W<6G1?#NTUFZ2*&35-5\06]K+XN.IRK<R3:?J]M;I<R6WV:5OLM1@8/\
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M5->GPWX:U#5+.TUS7X-+A^T:M<:/IMQ-'=W]MIL3Q/?7-G%<"V616V.@F:$
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M;OAOF?46/+#1003R<_VC:+G)R<[7=<YSM9AT)%8)Z?BO\Q6_X9_U^H_]@/\
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MOAL/1K4U.G*5)24:U:C5]E6<764X0DU*H?M.G_!7#]FG3OA5^T'\3?&7A?\
M:/\ A9XE_9F^(_@/X4?$[]G_ .(GPLM-'_:/;Q[\4TAD^$FC^'? >A^-?$.@
MZS#\3@VKCP3J]]XVTO1KJR\/ZYJNH7VD>'5L-5U'Z _9J_;*\-_M+^+/BUX$
MMO@Y^T_\ OB%\%9/!H\8>"_VF/A5%\+=>O-*\?V>NW'AKQ!X3O=%\6^,O#_B
MC0[X>'-<MKF2SUT7EO/:>=<V)M+NUNY_PL^"/[$?[6G@']G3_@H9X?F_85L?
MB+\#OC=\5OV>/&?PE_8:_:U_:#\/>,OC9XXTGX=1:7HWQ@\0:I^T/\-?&A30
M?&]]%X;\(:W\*HO%_BZZM-!/A^6#19(8(I+#XF_:W_!*_P#9[_:!^!7QB_:5
MCN/@[\??V:/V*M3\'?"W2O@1^SU^TA^T?X>_:#\3>%?B1H]WKH\7:Y\,8O"G
MB3QK8?#OX;-X9?3M"U#1M6\8:[J^M7MMX4OFU?5TT\Z3X#O'Y)PW3PF=/"XF
MC6Q6"JX>6"Q53,\-.G65:GD53$8:A@J4ZU1XWZSB<QKS5:.-P[A0JJAG>&J8
M)4,5IE^-S6MBLKABJ,Z-'%4\32Q5.E@$FG[;,J5*O*M7I>S^I/#X7!QG.G6P
ME;D=G@FZT.;]MU9U;>DLB.>?,CD='W9!W!T(97!4%74AT(RA4YR(6C8/&[HP
MS@HY0@'(*Y4@[6!*NN=KHS(X9&92U>Q'3YOU/%.KXAQ49.UF]%S)*[22BM5V
MBDEKHDDM$CZ23;=FW+E=HMZV47>-KWM9ZJSLGJM=1ZRSJ<K<W8QN(Q=W& 9"
MQE;'FXW3%F\]C\TX8B4N#BF#(1(]S>7&_F1QDYCCDV[!(B'*I(%"A74!E"1!
M2/*BV%%3RQ::<8V:::Y8VDGJU+W?>3;;:ES)O5IO45W=RN[N/*WU<=?=;W<?
M>EI>VKTU=U+.QC9I)':)62)Y':5XT9E=HU>0NXC:11*4#;#.7GQYTLCN.SR,
M'EEFG8;P#<S2W.!(%$@ N'D 63;F10,2,\K.&,TQ=**?1KHTTUHTU)WDFFGI
M)ZON]7<%*2O:35W&3L[7E%6C)V^U%:1>Z6B:6@/ND*F2265E "O+(\K]78DO
M(6=B\DDDLK,6:6=WGE+S,9*"7(13+*4C(*(97\M2)%EXCW;,>:JR%=NTR*'8
M%P#112Y8I6LK:Z65O>WTM;7KWZB_5.+VUBTXN+T^%IM-;--IIIM.0RS&0R^=
M+YK9S+YC&4@L[$>827QNED.,X&]P,!B#"J*H 48 & ./J2>Y9CEF9B6=RSL2
MS,2ZBBR[+[E_=\O[D?\ P&/\JL/5\SUEHN9ZNRYK*]KV7/.VNG/*UN:7,G<?
M0_S6GV_WX_\ MI_Z+DIG<?0_T_PI]O\ ZR,=_P!YQ_VS?_$?G5=O0U37U:NK
MJ[E&ROJ_=ELMW\D>%^+/^1M\4?\ 8Q:Y_P"G.>L&MSQ8RCQ;XG&1D^(]= 'J
M?[3N/\_K6%D^A_3_ !K]ERMI9?E]VE_PGX/=V_Y=1[GX?F"_V[&_]AF(_P#2
MWW%HI,GT/Z?XT9/H?T_QKT>:/\T?O7^9Q6_JZ_S(G'(92%E1E:*0]8I5<2PN
MI&<+YJ(9<@YC,@"DG!_&+Q9_P3#^)LOQ.^,W@/X:_%;PWX,_8E_:9\7>#/B+
M\:/AM'%J;^/])\5Z)K\^N^,M#^'MO%I!T>TT?XC7(@;6[ZZU%KYM'U*YL/M)
MBT/3K8_M%G_9/Z?XTG_ 3S].YSUSFO.QV78/,'"5?>"<;QG;FBTERR2:NE:^
MM[OH=V$Q^)P<,12IR4Z.(<).G5C3FJ<H+>G)QYHMRUO>ZVNWJ4-/T[3=+M+.
MPTC3DTG2M.MK?3]*TF.020Z1IEA$FGZ?I5JR101BQL+2VAM]/BBMK6.WL8[>
MW\G?&TLFC_G\3R:8 !SM/YC_ .*IV3Z']/\ &NVC"E1I4Z,&E"E!0BN97Y5M
M?7?5G')RE*4I2YG)WV2LM-/B=[:ZZ;["T4F3Z']/\:,GT/Z?XUIS1_FC]Z_S
M)M_5U_F(_P!QO]UOY&O9_!7_ "*]K_V%]5_](-/KQ=S\K<'[K>GH?>O:/!8/
M_"+VO'75]6_](-/_ #_"ODN-6GDCLT_]KH[-/[$_,^PX(TSI?]@\_P#TI'3I
M_#_US7^E25&G\/\ US _ET]?PJ2OS1)J,4]&HQ33T:>NZ>J/TF7Q2_Q,****
M8@K\[?\ @H#^QAXG_:BT7X3?$'X->*M'^'O[4'[.'CW3?B!\#?'&OO>Q:%ON
M]2T@>*O!_BJZTZQU&6#PQK^GZ=;W-R1H]_<>;ILNF7-U-HNMZEI[_HE28'H.
M,_K0!\7_ +&'[,WBKX!^'_BGXW^+?B71?'7[1O[2/Q%U7XK?'GQMX>L;W3]!
MN-3F9-'\&>!/"ZWLHNCX.^'?@ZQTO0=$BDL]/BDDDU*]>T::XB^S_:/3_/H
M!^0 '\^:3:,YQS2T %%%% !1110!H:7_ ,A#3?\ KM?_ /IKU"LU>K_[P_\
M0%K2TOG4-- Y/GWXQWS_ &7J!_'BLQ3RW^]C\D7_ #_/FINN9JZO9.UU?KTO
M?\!]/O\ T'T4450@HHHH **** "BBB@ HHHH *TM3_X\=&_ZXC_T8]9F?8G\
MOZD5IZE_QXZ-_P!<1_Z,?_#]12;2:O**?9RBGJM-&T]>FFH&;11UHI@%%%%
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M?$-[# NVQFGT]M0O+.VTZ*V_6%551M554#HJJJJ._"J HR>3@#)R3R2:7%%
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M110 +_K8/^NR?UIK?\?5U_O1_P#H)IR_ZV#_ *[)_6FM_P ?5U_O1_\ H)H
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M[.3_ *"?AW_P>04?V<G_ $$_#O\ X/(*H8'O^9_QHP/?\S_C71RR_P"?L?\
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MS_C1@>_YG_&@!VU_[H_[Z_\ K4;7_NC_ +Z_^M3<#W_,_P"-&![_ )G_ !H
M=M?^Z/\ OK_ZU->-V4C !)&#G(SN'7C_ !HP/?\ ,_XTU^%)!/5>Y_O#WH M
MW<$@N!(SJS&-4V C*C"G/"CCCJ3W^E0;7_NC_OK_ .M4E]DWP&3C[,#C)ZYC
M&?KCCZ<=*AP/?\S_ (T .VO_ '1_WU_]:C:_]T?]]?\ UJ;@>_YG_&C ]_S/
M^- #MK_W1_WU_P#6HVO_ '1_WU_]:FX'O^9_QHP/?\S_ (T .VO_ '1_WU_]
M:C:_]T?]]?\ UJ;@>_YG_&C ]_S/^- #MK_W1_WU_P#6HVO_ '1_WU_]:FX'
MO^9_QHP/?\S_ (T .VO_ '1_WU_]:D,;,""H(/\ M?CV%)@>_P"9_P :9)PC
M$$@\<Y/J/>@"W';R?9;O#(%N+B&61R>4:&!X(XL;=N"C,V[&3@9)ZU $< #:
M. !UQT]L''TR:=$3]EU89;"WNF[1N.!G39R<#/&3R?4@$Y(J-1E5))R5'<^@
M]Z '[7_NC_OK_P"M1M?^Z/\ OK_ZU-P/?\S_ (T8'O\ F?\ &@!VU_[H_P"^
MO_K4;7_NC_OK_P"M3<#W_,_XT8'O^9_QH =M?^Z/^^O_ *U&U_[H_P"^O_K4
MW ]_S/\ C1@>_P"9_P : ';7_NC_ +Z_^M1M?^Z/^^O_ *U-P/?\S_C1@>_Y
MG_&@!VU_[H_[Z_\ K4;7_NC_ +Z_^M3<#W_,_P"-&![_ )G_ !H GMXB]Q K
M[0/-7JQP>&QR!G(.#[X-,FA=+JYY1LNOW6)P #U) Z]J8O$L."?]<G<^_O37
MYNKK))^9.Y_NGWH ?M?^Z/\ OK_ZU&U_[H_[Z_\ K4W ]_S/^-&![_F?\: '
M;7_NC_OK_P"M1M?^Z/\ OK_ZU-P/?\S_ (T8'O\ F?\ &@!VU_[H_P"^O_K4
M;7_NC_OK_P"M3<#W_,_XT8'O^9_QH =M?^Z/^^O_ *U&U_[H_P"^O_K4W ]_
MS/\ C1@>_P"9_P : ';7_NC_ +Z_^M1M?^Z/^^O_ *U-P/?\S_C1@>_YG_&@
M!VU_[H_[Z_\ K4;7_NC_ +Z_^M3<#W_,_P"-&![_ )G_ !H =M?^Z/\ OK_Z
MU&U_0#WW=/?IVIN![_F?\:,#W_,_XT =9H%J$@N2TBRF61%=0>0L6QHV^4+T
M,CC P#G+9P!72@   = ,#Z"N1T'(AU#!/$ED!R>,M+G'/&>^.O'H*ZU>@^@_
ME0 M%%% !1110 4444 %%%% !1110 4444 (>0?H:_F\_P""SOB35O!?_!0+
M_@E%XZ\-WZ:1XJ\%_ W_ (+0^,_"6M"VL+NYT;Q!X7_85T;Q!HVK6]MJ-K>V
M<YL-2TRTNS;7UG=Z?<20PPWUI<QNL,G](A. 3Z#-?"7[97Q@_9.^ DGP^^)_
M[4WBWX*^ TL+W6O!/PR\5_%2P\/WOB2'7?&NEKI/BC0?AFMUI>K^+C=^*O#I
M&F>+K#P?;'^U- 1+7Q"L^E91/>X:Q<\%F]*I3P5;,9XC"9GE\<'AZ<JM6M+,
M\LQ>7JU..'Q3E&G]8=2I%T)1E3C.+E33]I'R<[HPKY;7IU*\,-34\-5G5G45
M)1A0Q-.O**G*I2BIS5/EA>:3E9-2^$_F5\/_ +27_!2%SX9T6]_X* >*TU/Q
M?_P0JTC_ (*U7&MI\!OV<+V;0O'OABYUV[T'X7>&;.?X=0:9:^%/$5K>^&YO
MBWXCUJV\4>(_&&HV&N+8WGAG2=:TRVT$^-W_  4@_:<N=9\;ZG<?M^?#O]EI
M/ W_  2[_99_;=^&?@'6_ ?[.BV/[0/[0OBSX,P?$'Q9\(]$N?B1HEYXZ\1:
M1\1[^^N;5/ WA;5?$%Y837>@#1DTC3+*_M]9_I ^!WQ*_9A_:6\ Z;X__9]U
M_P"#OQ?^'-EI^N?!_3M<\"Z=H&L:7H.CK::%+KOPDFL4TF*X\+Z9)H]GX0O=
M6^'5[:Z9IMYHP\)WT>E:CHXTF[7RC4OV9?V3_"G[2/B?XG_$?_A6&K^/?VEM
M$^#?PV^'_P (?B[IWPKU#PU'J'[+GA_QU/H0^ G@;Q'X=EU\^,-,\)^/M:O_
M !0="FU./2=&T[2_L-OX9L'*7WZ7'B;*GC*OUWAK#T,12E-QH8?+LKA7J8F&
M+<L50K8>KEE*E0B\)4FL1*K2<,#3P-25&%.KBE*/RN(RG&U*,)X/.:E2E7G2
ME.K5Q>*A2G1JQC"C5C6I8FJZD?K4Z$8JDKU*E2ES.<)5(K\C]0_;$_;N^('Q
MQ_:A\>^#/BY=_#/PS^RG_P $X/@=^W':_LG0? WX>^,=#^(?Q,^(7[+.J>.M
M6^%'B/Q&(YOC%H/AN#QR([B33O#WQ)\23Q16EG!9WD%U86UU#Y#\+/VN/VXO
MBSX5\.> _P!FO_@H#IW[5?QG_:;_ ."?WCK]J?Q)8_##X;_L]:WXI_8;_:<\
M#:5\-/B3X:^$LP\(>$/$FAZ#X$^*^H:WK'[,]K\._B;H5YXSL_&UQ_PD^D0^
M&M:\007>I?U&6?@[PKI7B34_'5CX1\-:7XT\26.EZ7KGC6R\-Z1I_BSQ'IFB
M8_L72]9\3V]C#K6N:;HW TG3]0O[NSTT8%E!!GGAH_#GP)_9VT/QKX\M?#?P
M6^ /AF2&'Q%\2/&UIH'P_P#A!H$T-K/=-;ZYX^\56]EX;TUX;>YUR^:#5_$^
MH&&"YUF[V727.K2"Z\]<39=[!T:'#^ <XT<'1PM-T<+7I3Q-'"?5)K$S=">.
MK1ACY/,*+H5UBZU=O!X]O"<],Z%DV,A5A5J9IB$I5,1/%595,6I*,ZR=*KAJ
M;JPPBJ_5W/#SIXB$L+2DUB,/>K?D_E_U3_@K]^W%\3/V5?VJOV]_@VUGH/PA
M^&7@S]EC]F_X=://\+/#$WAGPM^T?\6?#_PR\2_M1_'O6KC6M+\1:QK4?PA\
M631?#7X4>'=<\8CX7K8_%KPGXE\:^&]<U'3&TG5>-U[_ (*4?MV:S\(M9\*_
M"G]HK1?$7AN']L"R^$7P\^*/BCXN_P#!/?P=^U3\9_ 6N_".;Q;JWPHT[XA_
M#?5OCE^QGI/C?P#XWU3PKJ<GCK0[A_$7C7PWXA\+V'A&RU'4=-\9:!H']:>A
M^#?AO-X'D\+^'O!GP_/PR\5:7J]S+X7T'PSX7;X=^*-#\>&?7==N9-"TNQ/A
M77M)\:'Q#>:MKTCVEW9>(KC6;Z]OWU%;\W=WF3_!+X+S>!;;X7W7P7^$DWPO
M2\;5;/X:7'PN\#R_#J/49+FYO6U2T\#2>'V\*QW[WEU>7C7\&DK<M=7-S<F8
MS3RR/V?ZTY!3KUIPX0P-+_A2A5H0G["M4IY=0I2HT\'7JUZ<*M;$T*OMU]:5
MUB8U95,12=>C1E#GGD>:U*<$L_Q$I2PDH5Y*-2,9XQU*\O:TU!_[NX3H*5&H
MG.$L.G3:A4DCX._89_:!\1?M0_\ !,FP^,_C/QUJ7Q&\6:_\-?VA=!\4>,]?
M^'/@3X1:GJVK^!=4^(O@N]EO_"/PU\4>*/AXOV,Z$+&'Q-X4U;3M'\5VMG#K
MZ>'_  HUS)HME^-?_!)C_@GEXT^)7@?_ ()4_M?:=X"_90^!7@'X":1\0?%^
ML_%SX5Z]\19OVMOVAM!U/5OB?H,G@OXMZ#:?"KPE\,(]!U#5=1NO#>KRZEXY
M\?>)XO!$6I:?8ZIM\6W_ (5TK^I;4U^'7PE^&FLW%YIWA3X?_"3X=^#?$FKZ
MM8V.A:=H?@?PIX&\,Z3J>N>*&3P_I%A#I5GH>F:/::O?:CI]EIIB-O'>9M)6
M9T;@M/\ B[^SQ\/OV<--^/.A>+/AUX,_97\/_#*Q^(NA>._#%C!HOPMT7X4)
MI=OK5GKFB6'A_2+>STW0K?39XYXK#3M)A%E(WV>XM[&XBNH[;RUQ!7P^'SNG
ME& >&IYUFU66%J2A&I2P='$9;FV#>6+D<,)/$SPF92=&V$E%0I7I8>594ZT?
M3ADM+$ULOJ9CBE5_LW+Z4,32C*<:V*JTL;@:T,;.+2KRPT<1AIPJKVE+WJZC
M5DX.:/Y.=%_X*4_M&?$RR^,>G_\ #1VJ?M ? W]HK_@GO_P4B^)4.F?'GX9?
MLCZ7I,^K? WX6?%V^\)>(/!?[,'@F_\ B1XL^$'PN?4/"NH^!D\%_M-^)?B)
M9_'GPAI_B75]>\*-;3Q2:)[MK/[77[9-[\,M5\,_"7]H^#]G;PC^S]_P0D_8
M]_;W\/\ A3X5? 3]G5-%NOB7I/P^\)W]_P"#=*L]<^'6I:9X3^$'B2,Q:7<^
M#/#NFIX;\.:7HFB:%X.@T+PU'XD\,>)_Z5=$^!/[-'B'3K3QEX=^!7[/^L:9
MXJL-;\3V?B?3/@[\-KF#Q!I_Q;\,1:1XIUY=4A\+/+J$/Q0\&7<.C>*[YY)9
M/&OANY31]>;5--D%K6/\,Y/V5?B[9_%"T^%>A_!#QM8>!M;UO]D7XO6/ASP+
MX2FMM"U'X.)%HFK_ +.OC*R?P]!%<:'\/+;68=-M/ %Q'?>$-(T_5$AT:T%G
M=D-[$^*<F]JJF'X4C3^IQI7=:EEM2%!N>$PU*IB*5/!0P:JSHX;%86DJF&BJ
MSK<^DXR;\BCDF8PYJ<\Z;E43E35*KB8IP@JTK47*=2K.E&=6%2I::E2Y4I7B
MHQ.A_9K\?:U\5_V;_P!G7XK>)4TJ/Q+\5/@#\%?B=XDCT*TGL-#C\1?$/X8^
M%O&.O)HMC=W>H7=EI"ZMK5X--M;K4+^ZM[(0Q7%]=S*]Q)[35/3-*T_1=.T[
M0]%TNRT?2-%T^RTG2-%TC3K?3-*T?2-*M(K+3=*TK2[""WLM,TO3-/MX+/3]
M/LK>"SL;*"&VM88H(D1;A..N1]01W([CID$9Z9!'45\%6E"=:M.G#V5.I6K3
MITKI^RISK5JE.DFE%/V5.I3I748I^RNHQ327U-*$H4J4)2<Y0I4H2GK[\X4J
M4)SUU]^<)U-=?WFNMPHHHK,L**** "BBB@!.X^A_FM/M_OQ_]M/_ $7)3.X^
MA_FM/M_OQ_\ ;3_T7)3[>C-5_NN(_P 4?_29'A?BS_D;?%'_ &,6N?\ ISGK
M!K>\6?\ (V^*/^QBUS_TYSU@U^S95_R+\O\ ^Q?@_P#TU$_#LP_WW&_]AF(_
M]+84445Z)QC#N+(@(S(ZQJ"0"TDC%(D3)&YG8QJJ+EG9L*"<BJ5_=V]EI]_J
M=SJ-CI^F:7;7]WJNK7MS;Q6.B6FF1O-J%_J)=]_V>RBAF69(E>=)@FZ+:&QH
MPR>7<POM4^4QE1F5743H-T*88CRV+899URT+ ,JYP1^%/B3]B_\ ;%\->)_V
M@/V7/A/JNGW/[(/[4OCO3?&&I?%GQ=\0M/N_''P>\)>(]9U#5/C%X*TGPQ<Z
MA-XDU.[\8Z;);Z%HVL6UE)8Z'8_V?<0/!J(U;3[3QLRQ>)PW/]7I5J]25-PI
M4Z:YHJ<K>_-;)17;6]['H9;A:6,Q$:5;$4L/34H3E*I)Q<XQ<N:%-_S-6O=V
MM;N?HY^Q_P#M!>+OVF_AOJOQFU;PMI/@GX?^*O&_B.U^"MLMOJW_  E'C3X6
M:3>75AI'C;Q.]SJMWI.G?VY<VIU'2K+2K9F73+S3EN[NYGD>5OK@'(!'0@'\
MZYWPIX3\,^!O#6B>"_"&F+I/A/PQHFD^&?#NCAEFCTOP_H4$5KH^GI((81(+
M6"WC+RB&/S+AI9BOF2,QZ.NS 4Z]+#1CB9*==^_5:YK1=1*:@N9M^Y%J.[5T
M[:6.?%QIK$570?\ L\IOV"ZJ$+4FW;3WIPE/3I)7UN%%%%=ISC7^XW^ZW\C7
ML_@K_D5[7_L+ZK_Z0:?7C#_<;_=;^1KV?P5_R*]K_P!A?5?_ $@T^ODN-?\
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M+V5L]OX9U'3[/2H9[>[\4>,/$T-QX9L+769(K-5:"[<1EP]?:*X&0JA5W/L
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M'I^*_P Q6_X9_P!?J/\ V __ '(V=8!Z?BO\Q6_X9_U^H_\ 8#_]R-G1C/\
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M#VO2Z1XS^&VG:?K,&L^)+B37YM;R=(TK]H#]FGX+?#^P^$_C3]J[03\8O^"
M?B'XB>,M#U#XE_'?5++P1\>_">H:!/X#OOAMHESK0M_@WXM\*>&+&V\->#M)
M\'6N@7.E>#-6U*+2;%;OQ'JNKZA_8M\.OAII'PI^'7PZ^$_P]\-SZ5\/?A/X
M%\&_#;P!H*:WJVH+X:\&> O#6G>$_"NAC6O$VIZQX@U^72M#TJSLVU[7-2O=
M=U-H%OM9O;S47:Y;MA!X@7?ML-24/(TK!=<4 RNH1I-OF;0SJ '( WY;=G))
M[*_',7B<0J.18-X&MBGB98>M6<Y57&%6&'594\IIT[81_5HX5452]GAZ$*<I
MUG3]M5P_U9O3HREF<UB:>'IT7.E1Q/)3;]DL2J,<1F$W-8F"K5*JJUYQ>+K3
M<94Z35-?QH>/_C3HOQ._;Z_9$'Q%_:3_ ."AWP/\#?"KX)?L_>*OVB?B'!XB
M_;%U+1/'WQSOO@U\*=&U?X+? 'P3\)/"NLZ9\+-)\;W*?;_VC/BUXKMM)MO'
M.M:M\3)AJ-D^FZ'J?B[W+PMJO[47Q>_:T\-?![Q=\6_VP]/^%/B[_@N=_P %
M6/A+XMM/!WQA^.W@,C]ES0OAC\*];\!>"(O$GA77]+U#PY\(-%>X\1S?#S^Q
M]0TS1O!D&H:[?_#:_P##>K;=2M?ZP-GB3&!::MC+DXU[:6,C%G+LLH9RS$G+
MEBN<+@<4QH->92C:;?NA2*,A]9C;<D*E85;<S%Q&&8H6)*NS2 [V9CR3XMI<
MD:='),,X4LH_LO#+$8C#S^KUG7S?$3QL+Y%0E*JZ^;)QEB)UW1HX/#T*$_8T
M>5]=/((IMULSK.=3'+&5ZE.C6BJM#V67T7A94X9M62:HX*K!<D8\TZ[]K*49
M:?QX?"+QI\8)/AC^P7X3_:X^(?\ P4#@_8]\+_M ?M]?#'QQX[^#VI_M'WWQ
M33QIX%UOPJ?V-O#?C[Q3\%K6^^->OZ7H,]MKFK?".VM=.UBUF\26%F$8^$?#
M=YI&A?NC_P $?_'_ ,0_BG_P3C_9U\>?%?QCX^\?_$+6K_\ :%M?$/BSXIZO
M+KWQ$U'_ (1W]JKXZ^&='M?%VJ322M-JNB:!HVE: UM"_P!@TN+2X=(TN*WT
MW3[2T@^G/VA/V*_@C^U)XE^%_C;XS_#CQ=JWCKX)R>)7^$GC[P/\:_BE\%?B
M!X 'C&UTJU\40^'_ !]\$?&_P[\:PVFN1Z)I7VVQNO$-Y9(]A%<6=M9SS7;3
M^D?!+X!> OV<OA7X,^"7P5^&Z>!/A=\/M/N]-\)>%++Q!>ZI%IL6I:KJ/B#6
M+F?5O$.H:OXAU;5-<\1:QK&OZWJVMZQJ>I:MK6J:AJ=Y=/=7D[OGG?$&7YOE
MD*,,N^I9C4S.IC:WL:-&."I4FLQJ.-"K",*D:V*6*H4L8Z<*5.K/"X=.G%)N
M2RS)JV7XZ=5XQ8C"PP,,-3;GB*>(G6C]3C2;@ZDHJCAJ="I""Y>:TY*=2LFF
MO2:*M?V;JG_0%N/_  9V_P#C1_9NJ?\ 0%N/_!G;_P"-?(GN%6BK7]FZI_T!
M;C_P9V_^-']FZI_T!;C_ ,&=O_C0!5HJU_9NJ?\ 0%N/_!G;_P"-']FZI_T!
M;C_P9V_^- %3N/H?YK3[?[\?_;3_ -%R58_LW5/^@+<?^#.W_P :FMM-U%IX
MEDTZ6UW301B22^AG3%Q*D+GRT!<L$9L$ !3\QXS0_P D:IKV%:"UE)IJ/5VB
MUI]_='S[XL_Y&WQ1_P!C%KG_ *<YZP:[7Q/X8\47/B7Q!=VVB:S<6]QK>JS1
MS6VE1S6[B2^G=C#,U[$TBJ3M9RD9)R0N#QA?\(EXM_Z%[7/_  30_P#R=7ZY
MEN/P4,#@HRQ>&4H8+"PDG7I)J4:<>9-.HFFKZIK\4TOQ?'X/%2QN-Y</5E_M
MF(V@^LKHQZ*V/^$2\6_]"]KG_@FA_P#DZC_A$O%O_0O:Y_X)H?\ Y.KO_M+
M?]!F&_\ !]+_ .6')]1QG_0-6_\  '_F8^ >HI,>R]<Y.<KZ[<$#YN V0> *
MV?\ A$O%O_0O:Y_X)H?_ ).H_P"$2\6_]"]KG_@FA_\ DZC^TL!_T&8;_P '
MTO\ Y8'U+&?] U;_ , ?^9CT5L?\(EXM_P"A>US_ ,$T/_R=1_PB7BW_ *%[
M7/\ P30__)U']I9?_P!!F&_\'TO_ )8'U'&?] U;_P  ?^9CT5L?\(EXM_Z%
M[7/_  30_P#R=1_PB7BW_H7M<_\ !-#_ /)U']I8#_H,PW_@^E_\L#ZCC/\
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MC_P9V_\ C1_9NJ?] 6X_\&=O_C0!5HJU_9NJ?] 6X_\ !G;_ .-']FZI_P!
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MY$_]U?UH\B?^ZOZT 1T5)Y$_]U?UH\B?^ZOZT 1T5)Y$_P#=7]:/(G_NK^M
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MIM-T:=K+5_8WMT28/%8I)OV^(=K:1E5D]6HKX;VU:5Y-+ST=K?VN]/26]/\
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MBES>W^L 1I T FFM_I?D%@=N0SCY"2G#$?(6RQ08^0L68K@EF)+$ F^UWO\
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M !H^UWO_ #\M_P!\C_&H:* )OM=[_P _+?\ ?(_QH^UWO_/RW_?(_P :AHH
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M9]*K^9+_ '_T_P#KT^^_X_Q_U[#_ -"2HJ '>9+_ '_T_P#KT>9+_?\ T_\
MKTVB@!WF2_W_ -/_ *]'F2_W_P!/_KTVB@!WF2_W_P!/_KT>9+_?_3_Z]-HH
M =YDO]_]/_KT>9+_ '_T_P#KTVB@!WF2_P!_]/\ Z](99 ,E\ =\?_7I*CE_
MU;?A_P"A"@"U%<S?9[YMV/L\]M#@YRQN+62X)]@GEX&.#DD\"HA+(0#OQD X
MQGJ/J*(O^/;5_P#K]TS_ --EQ3$^XO\ NK_(4 2>9+_?_3_Z]'F2_P!_]/\
MZ]-HH =YDO\ ?_3_ .O1YDO]_P#3_P"O3:* '>9+_?\ T_\ KT>9+_?_ $_^
MO3:* '>9+_?_ $_^O1YDO]_]/_KTVB@!WF2_W_T_^O1YDO\ ?_3_ .O3:* )
MH9Y8YX&W9(F08Z=<CU-1R32M=767/WT[>H)]?_K>U-7_ %L'_79/ZTUO^/JZ
M_P!Z/_T$T 2>9+_?_3_Z]'F2_P!_]/\ Z]-HH =YDO\ ?_3_ .O1YDO]_P#3
M_P"O3:* '>9+_?\ T_\ KT>9+_?_ $_^O3:* '>9+_?_ $_^O1YDO]_]/_KT
MVB@!WF2_W_T_^O1YDO\ ?_3_ .O3:* '>9+_ '_T_P#KT>9+_?\ T_\ KTVB
M@!WF2_W_ -/_ *]'F2_W_P!/_KTVB@#I_#SG%X[L/W;6ZY/'$I;.?3;LX]2Q
MST%=3W.#N'&#QR" <\<=\<5R.@_ZG4/^NEC_ .A2UUJ]!]!_*@!:*** "BBB
M@ HHHH **** "BBB@ HHHH *^+/VD_V4?@3^T)\2OA%\0_BM\-6\=^,O@MX/
M^-7ASX;ZF/%'Q T6+P]X=_:,\#0?"_XUZ=>:'X2\4:+X>\36GC7P%;PZ [^+
M=(UR;P[SJGA6YT+6':_/VD3@9_+ZU_/A_P %P?A)>?&OXA?L(^"=$^+'P%D\
M16OBSX[>(='_ &,?VDOBG\4?@]\,OVQ!H?@_P/!</'XR^%^HZ->P^/?@A#JT
MFJ>"+76M9T?2IKSXAWJW5SJ>DR:UX5\2>]PS0EB<[P="&82ROVBQ2ECH1Q,O
M8TXX/$U*L9_5+58TJ].E*A5J3E##4Z=253&5*>%C5J0\S.*D:678BI+#1QG)
M[)QPTJGLHU9^WHQ@G/EFTH2FJC4*=2;Y$H4YS<8O[<C_ &(_V7].FT1?^%.:
M9:W'AC]D*[_8*TJ1M<\<Q:A;?LBW<6F12?!2[G/B=)=0T2"VTNSBL/$>IBZ\
M>Z8UQJ]SI?BZRN]>UB>]^*?$7_!';]F/XH?'OXD^-OC+X&TWQK\%;OX&?LN_
M!'X(_"S1O'?QQ\"ZM\/- _9_\+^-O"&N:1XCU[P+\0/"UUXZ\(>*M'U7P-!;
MZ)XEU7Q%#<2>#[>^UV":_P#)N)?S._9M_;/\:?#CX%?LY_LE?LNVGAK]F#QA
M\4O^"@'[3?[*'Q(^('QO^*MS^VC\.?V6/%_PS\(>$/BYXETGX$:G<ZIX'\/^
M/?"FO/\ $*S3X7:5XP\=Z_9Z%JLFN0ZIK'Q/\3^)K_QK;>\^ _V^OV[OCA\0
M_P!GO]FGP9X__9I\%_$K4/VG/^"A_P"RI\9/CWIGP>U+XG_"OQQ9_L=_"KX2
M_$30OC-\,_A[=?%#P]>Z9JNHV'C?5;&Z\-WOC9/";>,H?MK0WGA6PAT.;]+6
M2\5976Q=2AF;PU.5'&4O;U\?BL-B(X#"3Q%=XOV,7F4<'>O@L2J4<)FN)QE6
M,L/)KZABX8@^.EF60XOD]M@8U*L9T9QHT**Q5.KB<1&%&G2YISP-9JC4QV'J
M3]M1HT:DN:DYUIPE2C^TNC_LC_LXZ)XZ^*WQ(TKX3:''XH^-'PH\)? ?XI)+
MJ7BJ]\*^)?A%X&\/OX1\,_#M_A_>>(+GP%H.@:9X>DDT*2/POX:T#4-3TY_L
M6LWFHQJD4?GO[-?_  3W_8W_ &0O%>K^-OV>O@E9>"?%^K:!%X-?6];\=_%+
MXH7VA^%(M2N-7N?"'@O_ (6[XZ\=Q_#WPUJ&MW%S?:[X?\#1^'M.UZ=+"'6[
M:_@T32H;/\:_V7_^"GG[:_BCX8_LA_M _'7QU^S$?AG^U1^R9_P4)^)D^F3?
M!SX@Z';_  3U_P#X)[Z1>.?B=XT\8^#O&_C?Q+XOL_BKJ2R:]\1_"W@?X;VM
MAX=\.Z*ND_#3PE;^(=:,Z?*GCK_@H=^W]\3/V7/V]OAWJ_Q8U.?5O#?[%?P?
M_; ^%?QW\$_ U_V9/B?8_#_Q9\8?AGI/BFQ^&.F_#KXI>(O%.F?"OQO\/-6\
M0ZU\/OB7\0[#P9\7+OP3=7FM^*/!OAG2-8LX+(APIQ54Q>(RUYG0A3E5PF7X
MN=3-<QKX:5&EF-3(%%0IX>%"M'+ZBFZ^&<E4KY?.E4H4JE*,J+<\]R6E0HUZ
M>63=3V=:KAH?4,'&I&=3#QQD9>UGC)SA#$Q@JE.:E'V>)E"%*]2491_I!\+_
M /!.S]C3P7^S3X\_9'\+?L]>&-+_ &</B5KFN:_XV^'8OO%]U;:WXIUBZT>_
M;77\7W?B&?QYI/B+16\.^%T\(:GH'BO2;[X?VOA7PA;^ W\,V7AK2+6W\\M_
M^"4G_!/ZS\->'?#.G?L^+I<GA'XF-\9?#?Q TOXM_'O2OCQHOQ4:.SME\;V?
M[2.E_%6T_: 358(=-TFUMK:3XE2Z7:P:3IEO;V,+:?826_XX?M*?MP?%W]C+
MXMZI\0[3PO\ !WXN?&OPW_P0O_9J\<I\89='^*EAIVL>*?''[;W@?X16!U'P
M5%\9M;\"-\.="@^)FH^-]1O)-$7Q[JGB714^T>/[7PAK$?A&R_;7]C#XA?'G
M6O'_ .T3\'_V@OV@/V0_VD?$_P %_$/PC@TRZ_9JL=7\*?$3P]#\2O"E_P"*
M-7T?X\?#&[UWQ5H/A&RNI52P^">NZ)XAGG\?>'=)\0:QXHAT;7K6XT?3/*QN
M$XCRS 3S'^UL34PN)='&U+YMFD,5BZN(<</5QJH+#8BC)T*;PD*M7,,5@JM6
MG45"&%Q-3#R</1RW'Y+C<1#"_P!G49UZ:E1C.>&P52.%P[OB\-36*G54**KJ
M=7$)8?"8KZNXU.>O"56-.?TM\#OV??AM^S/\+= ^$GP5\#S>!OAEX7EUV_TC
M1I-2\5^*)/M_BKQ)J_BKQ'J^K>*/'&L^)/%'B;5M>\1ZYJ>HZIK7B77=5U34
M+BX*WEW.5!KX<T[_ ((W?\$RM+\3CQ5I_P"RCH2SIXUOOB';>$+GXG?'#4O@
M_;>+;_5)M8EOK?X!ZC\2[OX'1:<FHSL]OX6B^'4?@ZRMO+TO3/#UCI,5K8V_
MX"_ CPQX6_9_^/G[*7[0OC7Q1\+OVN/!/Q2_;\3PUX&_X*"?L[?MG_$WPS^T
M1XI\>_%3Q[XF\.V7AC]IO]GSXD76OZ#XQT'4-+OKCPW\3_!_PU\%>$!_PB<,
M\2?$.?1[S6'^(OZV>$?V_/VF]5_:]MOV M;A^%<?[0_A7]MGX@OX_P!>C^&N
MO7GA2Z_X)M^"O@YH7QP\)?$.VTN'XA16FA_$OXK1^*?#/PUTOQ-=:]J6AZ'X
MDNKZ['A2\U*UCTR/T<7D.=8*IB7E6>8K%T\7@,3F>9X]XK&Y74Q$*%3$T<?7
ME)8OZU4HX22E#%O'X#"9EAOKM"E*A;'TI8GBCFF4XBE1CC\OI4H4\5'#T:*5
M',VO;TH5J4)3G0I0I\]/GJ4*>%K5\-B/JM>5&K#ZK7C1^WOB1_P35_8@^,#_
M !3NOB-\"8?$NI?&;XQ>&?CS\1->/Q*^,^D^(KSXP^"]!N/#_A_QOX5\0>'_
M (CZ3JWPOUFPT.[N;&]M?AA>>#M%U6TN[G^U=%N@8O*S?$/_  3 _8.\5?!/
MP)^SWKW[/VG7/PD^&OC_ %[XL^%/#]K\0?B[I&J1?%7Q1I^LZ;KOQ*\0^/M,
M^(-I\2O''CF]@UV\DA\2^//&7B?4=.N+70;O3I+:^\,>&[G2?QI^ G[<W_!4
MSXT/^P]H%]\=OV8_#FM?MS?L@_'/XR:?J$W[+.H>(E^"=Q\"(_$=[IOB&WAC
M^,F@VWC[X@_%.'0]/BU:WU#3/"_PU^',FMO%X>\"^*+_ ,.QW7B+M;;_ (*3
M_MT?'?4?@%X;^%WQ)_95_9YU+Q__ ,$D--_X*.>,_$'C_P"%6N^)=(O_ (@^
M&/BKXZ\,:I\,/#5QK?Q:TVT\*^#?B NB^$],U74-4D\2Z_X/T.+Q;XG\-W%]
MKMMHG]F3+A_BS!5(T_[;7)@I5<399[F]6EA'@XU,MEBZ5&.$=5UHK!XG+:,:
M*G5DZ$H_5%0E5J#HYKD%2-2K5ROEJSA'#6GE67.5;GA'%3I2KXG&1C&-Z].M
M[:M64/9N;?[WV2J?J^G_  2Z_8/MO /PX^'.D_ -O#GA_P"$?COQQ\3/ 6K^
M$OBY\=O!_P 1M+\>_%'2TT3XE^(=7^,OA;XGZ1\7_&EU\0= M-.\/>+K/QWX
MZ\3:=KGAS1?#_A[4+2YT'POX8TW1NO\ A%_P3Z_8_P#@-K/P/U_X3?!Z?PCJ
MO[-OA[XM>%?@C(_Q1^,_B*T\ >'?CKK^I^(_BAI-CI'BOXBZUI&JV'B'5]7U
M2^M+?Q'8:S%X:N+VZ'A=-&MG2"/\4/ O[=7[3OB_]K[1?VMKG5I=.^$\_P#P
M0(^('[=%C^RIJ5QXZ/PZU?7/">O-<^(O ?@RX/B(:38?$O7_ (G^$-'\4P?&
ME/!'BKQ!9? 2?3?AL_@R\,]OXIT[:TG_ (*5?MJ^"?A;X6\>^._BI^S-\7G_
M &L?^";G[7/[:_PMT?X1?#!?"FO_ +&OQ"^ ?P!B^,'AWP'XUTO4OB=XPM_B
M-\/;B;5K#PU<7?B^V3QO??$K3/$^DW3_ /".^'=3FNW+A[BRM&GAUG?M_KE*
MA.IA_P"U\U:AC,QHY@\?A<1.I1G"K6H8+#8NOF&)>)I4,33K.&#ABL94G@F0
MS7)(^\L#*G&G5G2A.C@\&E[##5,/2P]>E3PU:C-*I6JX>%*$HUJU!TG6K0I4
MJ=.I4_73X^_\$T?V)?VG?&OCCQ]\<?@OJ'BSQ3\4_"GA7P;\1I-,^,/QZ^'>
MC?$/0OA^7/@7_A,O!_PR^*'@WPEXHUCP29C%X<\4ZKH5UXIT:S^S6-EK5O;6
M&FK:[^K?\$^/V0-<T'QWX7U?X07.I:1\2OVBM#_:P\=K>?%+XUOJOB3]H;PT
MEC'HWQ!U'7$^(T.M1M:G3XY9?"EE?6G@N^O)[V]OO#EQ?7UY<W'XG^+/V\/^
M"H'A"\_: TF]^,7[*<^J_"+_ ()N?"W_ (*8:M96W[,/B,Z;;+?66D7.L_LN
M>&;<?'3S;W0?$L,]U'XE^-?B^34_$YDM(Y?!O@;P7!K%G)X5VOVO/^"I7[9'
MP9_:-LY-/NOAUX)_9@\!^#_V5O%WC?Q3X<^ ,_[1_@73+#XX>%/#NH_$6Z_:
ML\1^"OCA9?&+]EY= \3ZGJ>C?!;PQIO@>;Q#\0;2STW49X=>LKBU;Q&8?(>*
M:L\+A,+FRJ*-&>,PD:6<8R@J$*.&AB:,:5'ZK@4ZU6@W'"X>BY57.G).;A2I
MP6-3->'Z<*U;%Y?[&2J?5\2JF6T.9U9XF>$G.KB'BJU9052/[VO[)+EG9Q2J
MU6_U7\1?\$I?^"?/BCXRZW^T!K/[.EC/\5/$'Q8TSXZZIK5K\3_C=I'AVX^,
M&E>(K#Q9!\08?AMHGQ-T[X9V7B&]\0:9;7OB.XT_PA:Q^+(KWQ#9^)8=3MO%
M/B!=1_0P,SEG<[G=W=CZEV+=0 #UY8 ;CEB,DU+/$8;BXA*E##<7$1C:02O&
M8IY8PK2+'$K[D5)(V5!NA>-CEF8F.OC*^.QF,AAXXK&8K&0PU"G0POUK%XO%
M/#T8PIQ=&D\35FXT_P!S22]U3_<PO*2Y8P^GI4,-14I4,-A\/*M+VM7ZOAZ-
M!59SO4<ZGLX*<Y\U633E)J,9<L8QM>11117,:B=Q]#_-:?;_ 'X_^VG_ *+D
MIG<?0_S6GV_WX_\ MI_Z+DI]O1FJ_P!UQ'^*/_I,CPOQ9_R-OBC_ +&+7/\
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M?YF-]J@_YZ+^8_QH^U0?\]%_,?XUL_VWKW_08G_\!-+_ /D"C^V]>_Z#$_\
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MG=_<O\S&^U0?\]%_,?XT?:H/^>B_F/\ &MG^V]>_Z#$__@)I?_R!1_;>O?\
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MSNI*VMG&2=I1E&*=\>Q_I_C3[?\ UD9[YD.??RV_^)'Y4SN/H?YK3[?[\?\
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M]D_\%#/%7BWP#XI_8Q\=?#S08O%'Q+\%?$;]K_Q5\//"<VFWVL-XF\=>'O\
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M !2\8_#[X>Z)9:/8:[X<@@L=4\66^L>(+S58;?1M-O$L+^:V^CX3Q>:8'/\
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M$/X0V'AGQ+H-OK?COX;GQ%!X<U+X91^+'\+20WDKZ[)/X:T*]\5^'?O?X?\
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M'(5UC61V1B'18+EF4+;RE/YS+_X0?M0:I\&_VC_C%\6M0_:J3]K7X._LN?\
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MBS@UV>T&I0V12XGAN=/2]6T03F*XM5,ZHWXA>.(/B@GQOUC6+!?VNT_;/?\
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M'[45O\(+W]D'X0^*]3\-_M(G]JS1Y7^)!^-GQ2\-W7BG2/"_[6]CI?Q#AO\
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MZ4:;JU(8B%&"4H87#I1@HQ53NK[_ (_Q_P!>P_\ 0DJ*I;[_ (_A_P!>P_\
M0D_STS[5\ZQ?M0_!Z7]I2+]DA=?O!\<)?ABWQ;&A_P!C:HWAX>%1J8TZ/3_^
M$SCMG\-GQK/;[O$<?@L7W]M+X.C/BFXC@TJ6UEN/(HX?$8CVOU>A6K^PP]7%
M5_8TY5?8X:@HNM7J<E^2E34X\TY:7=E=II>E5K4:+IJM5ITG6K4L/2YY*/M:
M]9S5*C3NGSU)N$^6$;NT6VE'4^A#U'US^&"/YD5^'.C_ +2'[-?P _X*'?\
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MN[6:-9(;JRNX9)8+B">,QRQW%O*\4D;HRL5<9LM_Q]77^]'_ .@FOF,TQ_\
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M%%%%<IN%%%% !1110 4444 )W'T/\UI]O]^/_MI_Z+DIG<?0_P UI]O]^/\
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M<_A30_"VJ^((M4U;QUHOB&<>#?$OA70H]6U/1O&MO=^%IUDU2$1/V>N_M$?
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MF\.K16(@XZ4ZSC^GUS\6?A=IGQ'T[X1W_P 5?AMI_P 8=3TJ+7M)^%&H>/\
MPE9_%#4]#EEOK>+6=-^'UUK,/B_4-%EETW485U.UT>;3Y#97J^>1!.%\&T+X
ML_L[?!_X%_$VU_9I;P7\4_"W[*OAWQ)J?B7X'_LW^.O OCCQ?X+2PE\1>+=:
M\&P>&K?Q7<-X>\8S_8O%U[X=\!Z[>:)J6J7VDWWAO0;..6UBLK3XH^(/[('Q
MA\0?M3_$?Q5X+\ Z9X7\*>/OC[H/Q,G^(%WK?P3^(OPE-I#\%_#?P^NOCR/"
M/C#3Q^U'\*/VN_ %SHTGA+X:WOP$\3:1\,KHP:)J=[=>'+#4_&=MJ6'^RO\
M"[Q]^QGIGA_XY?M0Z5JOPX^''['W[$7B3X4>(/$NN?$G]F'4_ M[%I?C#X=>
M(;K1?A7X1_9Y^!/PZ\4ZS\,[O3/A3!K&AZS^T+J%S\4[?Q)XM\/^$/"W@35-
M;U'QUXHU7:.5Y7'"T9X7,WC*OL<#B%E*AAHNOC*JP\OJ7)AYU$ZE6>(JX+#5
MZ=3%5Z6(G2Q.(BJ:E2J<?]J9I/$U(XO+'A:4)8N,\QE"52.'PL.>M7Q$?;T8
MRFL+"GA:U>C5C3C4IPK4(5:G/4G1_87PCXQ\/?$#PEX6\>^#];MO$?@_QUX7
M\.^,O"OB"PD:;3O$'A?Q3H]CX@\.:U83.B&:RU31M0L]1LI"JB2VNH9 N& K
MQ;XR?LD_L]?M!:[9>)/C#\/1XRU:T\,2^!KECXM\>>'=-\2^ I]<M?$UQ\/O
MB!X?\)>*=!\/?$[X>W/B.QLM=NO 7Q&TKQ5X0NM3M8KBXT67,BR<W^PIX!\1
M_"W]BW]E?X?^,;*\TGQ;X;^!/PZC\4Z!?+-%<^&/$6IZ%!KFM>$I()Y&9)/"
M%[J4OA22>-+6"\;1#<I86$DLMI#]8UY-?_8<?C'@JM2DJ6-Q^'H8FE-4ZM6A
M0QF(HQJ2JT8TG*=1PG[2HE!U91YG9.G&E[=.7U_!8.IC*4*DZN%PM:M2J1YZ
M4*]2C0Q,XPI5)580A"52G*$$FH*;@KPNJD4,$-M%#;VT,-K;6\4<%O:VT206
MUO;PHL<%O;P1A8X8((D2*&)%"QQHJ#@5KZG_ ,>.C?\ 7$?^C'K-K2U/_CQT
M;_KB/_1CUPMMN[=V]V]V[;M[MNVK=VWJVVVWU2E*3O)MO:^FRV22222V2244
MK*,8I)+.#R)_JY'C]=C,H/3LK '@8Y!XP.U-!9,E79<]=IP?O;LY')YY.<\\
M]:6D/3\1_,5,E&TW)N/-&2G./\11<7S.,K2E%QBFXJ*5FK*+4ZD*M*K5C#DA
M)M)\\:3:]G*HHN,7*+M"\K1BYR5TG?GBXJ</!IOVFO@A:?&SQK^SSJ7Q(\,:
M3\3OAW\&K#X]^,M+U7Q!H>F67AWX<W^K:EI5SJNL7M[J<7]DW&B066G^(_$$
M&J0V:Z3X3\3>$O$5S<#3M?T^:2>7]J']FBS\$:/\3[O]I;]GRP^&GB#4-:TC
MP_\ $F[^.'PPL_A]KFL^'([F;Q'H^A>-[KQ5%X8U;5= BM+R76],T[5;F^TN
M.QOGOX($LKIH?@']N?\ 92^-_P :?B9\4_$'PL\)Z'?V7Q#_ &6/@)X$TWQO
M=>(?AUHNK>'/&7[-/[8Z?M.WWPV>Q\?:3K\=_H'[1?A:XB^'3:[?>&_%_P /
M-!\0:-X?;XH^!O$_@N/55T_S+PU^Q?\ &OQ/\?/@[\9/&_PZU232;']LU/C!
M\5+;XP?$;]E_Q;XCG\$^'/V1==^%>A>.M7\*?L__  X^&_P:M?$.I^/-1T72
MET?PE;>,?$5_HWA#PWXR\5:AI\^DP16?U5+)>'JF&HXFMFT,&W@O;8W"QGEE
M>M2QZP>.Q%7".G4]BI_6L1A\/@J+JTYT\/[-0QSJU,5AJD?!Q&9YK]>KX;#Y
M>ZE*EC)X?"XN5+,*5.M@WCJ6'I5I2I1J^U4<$JN+K5(5&ZEFJ,O8QQ5*M^I,
M/[4W[,%V-<-O^T[^SI=CPUX;U'QQXF,'QV^%<_\ PC?@[2-;?PQJ_C/Q'Y?B
MYSH7A31_$J/X<U;Q/J@L]%TS7U.BWU_;ZGBU/I=GX\\%:AX.L/B)IOCGPAJ/
MPZU?2K#Q#I?C_3O%>A7_ (#U70M8$!TO7].\86FHS>'-1T75([VU-AK%GJ<V
MG7RWEK]GN94NH#)^7OP"_80O?">I?"#4_BG\(OAIJ>M> O\ @H[^V3^TCJ>K
M21^$]9NHOAK\7O"'[1FB_"_7[BZ"F^UVYN]2\6?"R(>$-4CN9_#K:%I5_-H\
M+>#M.NM*3Q=^Q=\4]?\ ^"6OBG]D/3=/\+Z/\38O'.N^._!_AM];TYO"[V'A
M/]O#5/VI?ASX)M-0CD;2M'D\0^"-!\.^$-+/E+I'A/4;Q+:>2'2/#&HRV..*
MRWAZ.(IT,/G56I%X_!8.OBJU'+G06"Q-:IA:V*H+"RE4M0IJE6BITX15*JH*
M]2=UG0QV<JA7K8G*J+J?4\36HPI/,%6^MX>C2Q6'H5Y8^$J;=2<XX>7)*4O;
MT*JO]7C31^F'C;XK?#+X:Z'KOB3XD_$_X>_#GPSX5O-.TOQ1XA^(7CKPQX)\
M/^&-1UF&VN=(TWQ+J_BC5M*TW0K_ %B"[M)M)LM5NK2XU..>![&*X#J3Y[XA
M\9?LQ>&?B'\-OBGXK^(OP0\+_$GXD^$_^%4_"/Q?X@^)7@KPYK7Q3\'^+/$W
MASQ+9>"O $U]XBL(_B?::AXIBT/5/"MEH\7B2YL-0U^[/A.2R3QSK::]^</Q
M4^!G[4_QR\>:S\;?%O[/&J?#3Q#:_'_PGXI\ P?"WX_? ?5/CU\-O!MA^S'K
M'PUU?Q]X:U+XCP:M^S/XTUZZ\4>)-<\-^)O GQ-L+?2+WP'JD]QX-U*77+._
M\0WGCWC7]AC]J)O"UQIMG\.M&U"V^*_[">B?LN>,/AI\#M;_ &1O@YX#\%Z[
MHWQ#^-6NS^&O'=K\3O@?X_\ ^$:\"^-_#GQP@OO&>L_L:VGAW5K?XA^#_%TV
M@^"=8L+CX0:EX=UPN2Y/#ZJL1GV&P]=JI2Q='"XK+JD*<:T,%>E2JT*\Z=6-
MJTYU_:5XTHRP3H8:3QV(P\W%7.<XE5K2P^35*T*<H2P3Q%+%QJ.?M,1"G&=/
M%4*=6BZU>C"DE*S2K0FTK.,OV9\&_&S0_%WQ=^,WP.DTKQ!X;\;_  :A^'FN
MW%MK8L19^./ ?Q1T2_O_  I\0?!$EC>73W^@)XE\.^.?A_K,5W!9:MI'B_P1
MJD5]I\%CJ&B7%_Z'XN\*^'?'_A/Q9X$\::39>)/!WCKPSX@\&^,/#FIH\NG>
M(?"OBK2+W0?$.B:BL4D,LEEJVCZC?6%T(Y8I3!<R&.2*0JZ_%'P]DL?%/[?W
MCYO#VJ7.M6?[,?[&?PN^ OQ"UMKR;4+B]^*/Q>^(9^*<'A;5]9-MIHU+Q%X3
M^&W@'0O&FM-<QW]P+3XWZ!=7EGX:DN8+?7?O=><D]>/RP#_4UXV,PT,)6HRI
M0E3J3P.68JK-SE*<,5B:->HU3E.,*U&A.E0HXS"8>3E+"TL7"E&K4Y56G[6#
MQE;%X7$4ZM3VM*&,Q^&C%14:<L-1G&A:=--PG6A6Q.,P5>O&,)8AX:527(Y*
M,/#O@Q^S;\%?V>E\52?"3P6?#NH^.9?#Q\8>(]7\3>,O'OC+Q)9>#[&ZT?P-
MH6K>-_B+XB\6^+[KPK\/M!OKGP[\/?"3:X/#7@?P](=%\,:5IE@3"?HOP\\B
MSZGL4%O[!W*"I8%_[2LPJGD8#' )S\N=W.*QCT_$?S%;_AG_ %^H^G]B _B-
M1L_\.?IS7)F-2=?"5*M>I4JU:B]^K.;J59*/)&/OU7)/D48J$6O9P48I04;Q
M?1AZ5.C[.G1A"E!33C"$5&"=U=\JTO+5R>LI-WE*3]X_'7]H_P#8L_:H_:Y^
M*_[67CS2OBK'^SOIL&C> /@+^SSHGB?X9:)XZU+7=%^!]WX*_:.\*_'/PCXP
MT?XLZ _PYFUK]JW49I-(U75/#^I^*+:Q^$7AC4[C1[6Q-KIS^K_#3P)^TE\0
M/%7PU^+'Q7^$-[\)_'7B7]H'X,?%#XCZ!'KGA;5++P)J6G_\$\_B'\'_ !]J
M&G7FCZ[J<&H^'_#_ ,:M8MO#>E36,EU>:A;7FG:I;63:7YU]'^J*?.@)[Y_]
M"//KGCUIQ13U&?\ /MQUP>,<@5S5>)<75H4,-+"X!4L+0AAL+*EAXT:V'H1R
M^67RI1Q%.V(Q/UA6QF(J8V=6<L;4KU8**DN?)</X:-6I76)QKJUZ\L5BFZ\I
M4<5B5C8XFC5>&J.=+"*E1B\/&.$<6H2G&I4J0DE3_F0^%'[ WQTM_@UXR^&.
MN? /XD>$?&T/_!.7]I/]F_XJ>(=)\-?LF_##PA^T!\4_'\'@CPW865QXD^'?
MBGQI\3?VA-4\6:YX>\:?&#PO\7OBC>?#O4O"MSXAN=5UXCQ-\6_B!X+L///^
M"D7P)_9[^$.@_P#!1_X>Z'^QS\-?&Z>+/!?[/$/[._BWX>0_L\:3I/[)D_B?
M1+/PMX;\%0>%=>^(/A#XM?"[Q1\2_CCIOC7XI>$=%^"/PW\5:3\=O$GQ O8/
M$=Q=:Q<^._[*_JRV+DG')[UY9K?P2^#OB;XA^'/BUXD^$WPM\0_%+PA&(_"?
MQ+U[X?\ A'5?B)X6C6*\A2#P[XVO]&N/$VC6\<>HZ@D=O8:K;PQ&]NWC17N)
MB_TF6^(N88?-8YCCJ>(E2A6>->#RS,,;@85,;#%X7&T.><,9AO9X2G4P\\,J
M-%5%# 598*G2EA7+#3\;'\(T)9:L'@IPCB)4YX7ZYB</2KU(X6I@<3@*LN6=
M.I&6(J4\2Z[DE2@\7!5I2YE&2_'/QA^RUXXL/VG_ (W?&#XM?L:ZC^UG\%?$
M?Q3_ &UKCPE\)[(? OQ///K7QA^%7[&?ACP5\4F\,?%?XB>%='MM(\<^&OA'
M\:_@E<^(?M:^+?",&OP3W?A]/A_XNNO$5K]8?'_X"^._B7^R'^R1\'O#7@'Q
M/\-=7\(_%O\ 85OO%WA'P1\5CXF\6_ KP?\ #CQ3X-D\?OH7QJUN]BU'QAJW
MP?T6QOHK3XCPO>^(_$]SHR>)K"SOM2O5B/Z6B-.NQ026=L*JY>1VDD9L ;G>
M1V=W;+LS$LQ-'E)Z?Y_SZY]Z^=Q'%.9UZ^68MPPOUG*O9O#IRQ[PKEALNQ.
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M7@'4?!,'CCX/Z!\/_P!GWQ_X>\6>(M.E\7Z;XJ\'ZC>:9XINM)\)W%K)X?\
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MG4?'?B*TO]1U;3]8-O+XEU2Z?48$_1\11CHH XX' & !^6!C'3T[4V1%5&(
M!X_F*US'C#-LTH8K#8BGAH4,:L3]8I4)XQ4Y3Q-*A3=:<*M>I3K5Z,Z+J4*L
MX.=.=;$3A.$ZLIRC!\-9=@YX:M%UIXC!SH3H5:BP\IQ6&YN2E"I"E"K2HU5/
MEQ%*$U&I"G14HSY+$\(!AU-20%;4M(5BQ8 (=.G#MN57*[%R^=CD[=BHS,HK
M^?R^_94_;O>SO_VW_#VN0/\ 'N+]KC5/VR=*_8]UOP!X.TGQ[?>'[.PF_9QL
M_@#>_M!6_P 6KKPS:QZU^Q3I>E^&+O1V\+ZKHMQXZBTN[;4K_7M'\.>)+/\
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M'A+XT/\ %FY\&1ZYX@\/_$;XAW%C^Y1B0C&T8]..<X')ZGIUSGWZ4"*,'(4
M^HX_3I^G6O0QG'&9X["_5*^$P4*,GBZE14*^;4:LZ^+Q%7$3JO$4\P4HISQ$
MWB84H488Z.'P\,32A[2M)9QX;PL*].M'$8EJC'#0IQJT\!6A"E2C#GHTX5,+
M+V4>:FHX>M&JZV&IU*D:;;5/E_FJ\*_L(?M&Z5\+O#?PT\'?L_WWPX'P[_9P
M_:\^#OC.#1?%O@_X:Z#\9%\1?\% /V2OC3J7A_P!K?@G5[V^M-+_ &HOV;O
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MBISY'&FX.,:5/'5I05*/-&&'BH13A3B_7M0_:J_9ITO4_&FA/^T9\!+GQ/\
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M_B#\4M=^$>E_&OX?:5XOAC^%-SX&M/$?CSP%X;E^-VC_ !H^%WA3XN> -?\
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MO"I,I_SQ'Y__ &5&4_YXC\__ +*@"/S$_O"CS$_O"I,I_P \1^?_ -E1E/\
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M\!Z!KULZ?#;X7Z/;WKM9Z-I7@SPA>K;W.C6-A#"NL7^J75V9=1=[H@'Z0 Y
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M O@MI?[0?PV\>0^--4^($'C'PUX T_1= ^(/@S6+.SOOB#87JRZ?H_Y_R_\
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M>I.I*I.C3E&G3C.4_<I3J2C4Q4'&?UE4:$'R*#<ORV_:]_80^)G[9?[4_P
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M(GU$D8']AXSQC/\ :-GQP?\ .:G&_P"XR76STZ[HNG\=/_&OS1NQ?ZM?Q_\
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MYR1^7OZ@^M'-.-I4VE----MI>=^6[V[":35FDUV:NCS8_#JU8DF^GSWQP.
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M_K4?\*XM/^?ZX_/_ .M7I5%'US$_\_7]R_S#V=/_ )]P_P# 3S7_ (5Q:?\
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M_ #_ .V5]*44?ZU\0?\ 0RK?=#_Y$/\ 5+(/^@"'_@<SYK_X9_\ ^IFD_P#
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MH^N8G_GZ_N7^8>SI_P#/N'_@)YK_ ,*XM/\ G^N/S_\ K4?\*XM/^?ZX_/\
M^M7I5%'US$_\_7]R_P P]G3_ .?</_ 3S7_A7%I_S_7'Y_\ UJ/^%<6G_/\
M7'Y__6KTJBCZYB?^?K^Y?YA[.G_S[A_X">:_\*XM/^?ZX_/_ .M1_P *XM/^
M?ZX_/_ZU>E44?7,3_P _7]R_S#V=/_GW#_P$\[M_ <=I,DL-W-(T9=E!'W2\
M<D+$D G+Q2R(2>@)*X8 B'_A75JQ9C?S@L2=JG"J,# '&2.IR>>>IKTG&?\
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M)ZD]3V_D*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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DWFD9S>8XJGS2]G&E1<87]V+:U:71OKW)****T.P**** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>forms-1a_008.jpg
<TEXT>
begin 644 forms-1a_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '4 AT# 2(  A$! Q$!_\0
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M)&* ,-M9<]O2I)7BZ2(0IZ-BE*[$#+AU;H0>E, VQY\L @>H/4U*EK*?N/\
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M<TJ31E,5G&R(;,=O6GP/(I,<H^1>23VJ=[-SAB K+_'V/UJ-R9_DP05_A/\
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MU8O%=R$"31*X'0CBH;W4S>K9PQQ_,P=\$^O_ .JLD1;@-CJV1FG3(BW$ E)
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ME5N!)W7\?0U[#:W45W )8CQG!!X*GN".QJL/). L9%JJV^I/1116YRA1110
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MVUU%#-YLDZ@#;T4?6N$D2.]ODF4+N1-NX=^<T)2WL9SM>R-&:-3I%L(R"-S
MX]=IKM?@<FWQ)JN1R+6,?2N+@MVAT;SY&PF^24 CHH&/YUVWP,62;7M7N0#Y
M2P1H6[;L]*N>E%^J'#X_D>W/;PR1-$\2-&W52H(/X50M[[1KNV+Q36AAWF,@
ME0 PX((/TK3KD;7P);VT\DIO97)=WC'EJ-F[/MR03U-<IL;PDTB5(H0]BZ.?
MW: H0Q'H.^*CCO\ 1FOEM(IK0W#J7"J5^;!P?J?:L"P^'EK9P[);Z:=\Y$C(
MH9><G&.E20> K=,&:]>5U3RT9840JN<\8'7WH V+*TT2RU&>[M6MENKQMKN)
M 6<CL.>WH*UZXNP^'=KI]S9SPWLBO;S&0LL:AI!V4GT]?6NTH *S/$%J+O1;
MB/&<+NQ]*TZ:ZAT96Z,,&A@<'H+7 B%NTWEQ*.L9^9OQ[4FMQR?89X6D+@C<
MA/4XJ []/OKF \%'('TSQ6KJ$(N;:->@;@D5A:QO>[.&M J%6W-@'(!/ K?@
MU"*")G:;:RJ6 8XS]*YHR?9KN6!U;>C$?=-;=BTMU;E2L2 \9;E@.^*GT*MW
M+C6,-G GG1"2&Z(9V;G9*>O_  %OYU/9B/3Y"T:!8G^\%[&KTYC;2;@.H,20
MG()QT'%9&F>?)I\;2745U)Y8,FS&/_UTQ)LO:FJWAMK,K&(Y-S;RN67 'W?0
MG/6J-W:P@D>1NQW=BQ_6K*)]J2*'+*8FW[UZKQ@42?:F5E,*,5)&X-C/N12W
M&<^^]5"NDCD< EL@U5E#,/F)4>@K5N0\3CS"I4]2HQ@UF3DL3MX4>W6D@9SF
MMJ?L@5!C<V*P8;=@W.01T-=1JT8:&/ Z,:RU4$$8YK5/0S:U.NT!?,>VD ',
M8R<=ZZ;7 (FLX[222/4+QQ&#&^,J.[#O5#PSIK0V<)D7# #.>QK0:!)+2ZO4
MQ_:-O<$JTG\.WHGL"#^M9M:6-HO6[,W4]/N-&0ZK8WEQ//"09XY3N$J=^.U7
M;[7/#_B#0+FUM]5MC=QJ)HHRV&5UYQC]*GBU%)KDP3J(+I&"O"6SR>>#W%0^
M);6TTZTTW5X((X9;>[&YHXP"RD<@^M%DD[;#3<I)/?H<5J=_93Q131740=E6
M1>>58<_S%>F6>OV$]C::I:WT"W<L2F:$M@2\<_0^AKSV01L<;5V_,X^4<#DU
MWOASS)O"^EZ=:H%F>'=-,5'[I"3_ ./'M^=1A7JTC?'+W(M[FW;>*M%NHD>/
M4(?G.-I/(/3%,\0^)[7PZUB+@;C=S",?-C:.[?AD5J6]C;6T"0Q0HJ(,#Y13
M+G2[*\E,MS;)*YB,67&?E/45V'F&._C72EG\M?/*!W624QD*@4'+9[CC%1CQ
M[HDD2RPSLR8#.S(0$4DC)/X5H'PYHL<*(UG$L:9 #'CGM^.::GA71(X/)^P1
MF/ !#9.0"2/YF@!^G^(K#4[UK.W\[SU3>ZO$5V#/&<^M:U9VEZ/INF@R:? B
M>8N"ZL6+#.>O?K6C0 4444 %<]KW_(4LO]UOZ5T-<]KW_(3LO]UOZ4 ,-&:6
MFT +3;([-=A/]Y2M.J%3LU:T;_:Q^E %+XHV_G>&87! ,5RK9/T(_K7DLMR8
M8/+B!9W.W('Z"O:/B'"9O!=Z!U4HWT^85X?<MY:1%>BMP>^0*PFO?1O!^XS7
M^QSV<:F<,LI&=B\L/KZ53GU>WL7$;9DN#_RRB&YOQ/:J]YX@N_)AM(81+<.F
M%9SA4'K[GW-8>F,=)\1"&[D ,^ TPYP.XK:---79S2J-.R+<GC34);C9;P00
M'=M_>C>WZUTWA#5[V;7HH[NZ:1)$8;=H !QQT%<7J<-LWBI@WF-;D?)*HVEC
MV)IFFZK<V'B6P,KXCAN%!8# (S15A*2M#16'0J1C*\M7<]NN5PQ/:L+6FQ8L
MJ_QL%_,UT-T 5+#I6)J<6Z&$]A*N:\:2/HJ4M5<O62>7:IGTK@OB3.PA@@7I
M(W/X5WZ',8QZ5Y_X_1I)[7/0$UM'=&5KR..L-/\ ,(9OPKJ;)8K:+D#BLNT
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MPP#<@UJQ.DC@<$>]>E.H^;4\ZG%*.AY7'X7UF*!IKBYMI-Q&"P/W:DATX1N
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MGZ/!::G.MQ-&N#,&)+<^_M6O110 5SVO?\A.R_W6_I70USVO?\A.R_W6_I0
MVD-+10 E5K@[;BV?TE7^=6:JWW$2O_=8']: -+Q?%Y_@_5%STMV;\AG^E?/M
MTI%JC@$C.,_A7TAJ,7VG0[J+ /F6[#!]UKYXN8V?2Y-O0$'/TK&>DDS:G\+1
MS]Y&9;ZRPP5'7!W58UNR6]LA-;PI&JG"L&R7;OQ45Q +O3 !D2IG8P/0C_\
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MY6RM9^=^J\?PK6_0P>Z+V.,4I%+M[TGTI%HY[QW"6LM&F Z"6//X$_UK-TZ
M3V,L#<O;3.!]",_XUO>+5#^';4G[R7#X'L5'^%9VG1>5KFI0=FV/^8(_K7?!
M^[%G!47O21TGA"0-HXC'\!Q705R_@\[5N8O0Y%=1BA[@MB&Y_P"/:3_=-=)H
MW_((MO\ <%<Y<_\ 'M)_NFNCT;_D$6W^X*:%(O4444R0HHHH **** "BBB@
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MVUQ'*T3;9 C9*GT- %BN>U[_ )"EE_NM_2NAKGM>_P"0I9?[K?TH ;2&EH-
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M)TS4[Y=8N+$7#F!4W_-R0<]C5O\ X2*YL=2BBD)N(96V!3]X'US0!U?DQ?\
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M>HHK%U"_>=7BM9< ':74]^],1=O=3ALT?(:1U&=J#-84VHBYB\R64N2.(QP
M?3%$)CYBW$..NX\_6L[5(#:/'J$*[VA.65?XAWH MZ?;QVT98+B68[F)Z_2I
M9DFDA:)0/F[FLFYUN"[C2*P#RW#\A5&"OU]*= FO;,27-L9.NTJ<C\: 'G2=
M54 +J0..S)6AMFCMMLX5]HY*],5E/J.LPW,=L]G&\DGW65^*?=0ZX]NV^6UB
M&.=N2: *&FZO!IT]U8,LC(&\R,HI; /8U<G\0:7=6<D$LI3((PRD&K^FV<6E
MVH0G?*_S2.PY8U7U1([B!EAA0N_&XKTH Q=%UZ.347^U2$K GEQR;3@\]<_2
MN@N;NVN(24E!X]:FM;""TL8[=(D*A><CJ:S+K1-/FEW*TMN2>1$W!_"@ \-W
M4;6US:EAYL<K''J#WK0:Y$*2.RL0!QQUK*;P]!I+B_LI)S<+U+OD,/0BME9H
M[VQ68<#'3TH R/#[&=KW464CS6V(#UPO_P!>BP3[;K$ERW,5ID#W<_X"K6A
M"*]3'R"<D?B*9:,EIKLMHBA8KI3)M'9QU_,4 30NUQ<2RL/W4+=_XFI\US-;
MVL=]9D>:!G'9AW!JM?2_V??Q^0=ZSN%:$=2?45+= V]K':Q.BS74ZQ(3RJ%S
MU]\4 ;\.O >2;J$QI( =Z\@$^M;(((R#D5YYJ4'A[3KR6PU&WO+R>&%)#-+,
M<L&8*2O(&!GGTK4FN;OPU?0:?%=F>SDB9X5G^9TVD94MU(YX/:@#KZ*HZ7J<
M&J6OFQ$!E.UTSRIJ]0 4444 %%%% !1110 4444 %%%% !1110 5SOB#_D)V
M7^ZW]*Z*N=U__D)V7^ZW]* $HHHH H$8-%2,F>AIA4CK5B(YN87'M72:$^_1
M[<YSA<?E7../D/TK<\,ONTA1_=9A^M*0(Y'48O+U:[4+_P M6/YG-1 C\:Z/
M4?#UW=ZG//&T:QN01D\]!38_"DW5[E!]%-<#I2N[([%4C9:F".G45( 2*Z-/
M"R#[]RQ^BU.OAJT'WI)6_'%-49B]K$Y7D=J>,8Z5UR:#8+_RS8_5C4PTS3XO
M^7>(?6J5"0G6B<2P&.M*J-CA6/T&:[;&GP_\^Z?E4;ZOI4'WKNW7_@0JE0\Q
M>W\CD!9W+GY;>5O^ FIET>_?I:N/3/%=!)XKT6+K>HW^[S523QOHZ_=>5S_L
MH::H+N3[=]C.3P[J#]8E7ZM4T?A:\)^>2)?Q)I[^.[7_ )965R_X8JNWCBX;
MB+2W_P"!-BG["(O;2+R>%7_CNE_!:F7PK"/OW,A^@ K&;Q;K4G^KL(D^IS4;
M:YXDEZ>2GT6J]G#L'M)G2)X:L5^\96_X%BI1X=TP,&-N&([L2:Y(W'B*;[U^
M5_W5%1M9ZM+_ *W4IS]&Q3Y(=A<\^YVXT_38O^6$"_7%*9M.@'+VZ8^E<(=$
ME?\ UMW,_P!7-*/#UOGYBS?4T]$3J^IK>--<LU\-W%O:7$3S3D1@(>F37#B6
MVA\'1VP<">[O4=UQTB'RK^E)XGM8[6ZM[6W WE=WXD[1^I%:.M:=%:6NEQ(H
MSY\2'/?!%4WH$5J;%MXDL8?%%]J 622'R(X(@J\C')K/TSQ*L/BO6K]+.1Q<
M*BJ!_#C/6K.F6T+:IJ?R JLJJ/\ OD55\/Q1M>:XVWD3X'MP:38)&KI^?[!T
MNX(P6NW)_$TN@C;8-&?^6<TB?DQJ*TD== L8RWR1R!@/3FK&F+Y=SJ47]VZ8
MX^O/]:&!:O6VV4I_V370:-_R![7_ *YBN8U-_P#1G0>E=/HO_('M?^N8_E30
MF)JMV+=(HMVUIFV]:Y61;JSUB*&PA^TFZ!8P;MH3'5R>PK7U)$U":5&;#QMA
M2.JD5C3-JVE:A%J=M ETZ1F&6+./,CSG@]F!H$5)KV&[9E;7-+BGCW9\N*4E
M,=<G/3^=6-/DN+:6(:M)$89US;7*96*3V(;!5O8UE_;?!R07!ET+58I$BD,V
M(LLH9MS-D-UST-2ZBDOC6PL+*2-XM&&V96N)-\T^/NLQ'0<]* +QU;P_9ZDT
M@U/3DD=-I(G3/\ZL_;XKBZ@>SE2:-FPS1L&&/J*R3X;\,:: LEA;SN!@*T0/
MZ"LN;PLG]HV,^DQR:$9[E8C-"VW<#DD%.ASC'- '93-']LCF+#;'DYS5&]UZ
MSC5E:=.G3-9U\^CV.L7&F/H37;(8T6^O&=D9C][<<<!>.GK3X+'3_P"R+O6+
M.QMK(V\F&M"Q9'&<$,"/E8]L>U %^+7+&2,2/+'G'3=4,WB330=OG)QV%2S6
MNGO(J?8K=689&5 JU%8V$:X-O;8]HQ0!5?Q%9>7N6=/SJC9:W;76HMOE"(@X
M#<;C6K/IVFL-ZVT(8=PM$ME8SQ*KVJ.6'I0 DU]#<_NT<'/4YZ"F2S6\-MY<
M!VC'K4 \+6>"4DGA![*]+;^'+#)\UYY2IZ-(<4 )!J]A8VQ3STW$[F^M9EGK
M5I=:W)<F8*$3RTSW)ZFKVKZKH_AM$CN0A,G$-O%&'ED/H%_KTK'.F:AXD&[5
M0FDZ:>196V/.D'_31QT^@H OWOB'1;*Y,=J)-0U1ONQ6J^8_XMT45GRVVN:[
M<10ZW/'HUH2'2*T^:5R#D;I#T/TJ2"/3O#-S'%ID<<-M*VR2,=<]CFNE\BRO
M(5%T!*#R QX% &1J-SJ<$P@8Z;J3S 1H]S;9F('(!VG!Q5R&.6TBDU#6)3/?
MNF&=@ J+V50. *LQVFF6$Z3VT2B1>-V<D UGZS=_VDW]FVYW2R\<?PCU- %F
MTM[X3+=Q72V[G#>6BC&/0^M=38ZY'<3+;SKY4S<*?X7/M7.V4$K6CVUQ(&:,
M!0Z\%AV-9#:G%%;R6TDW^D6\WR$=>.: /3Z*@L[A;JTBF5@VY03CL<5/0 44
M44 %%%% !1110 4444 %%%% !7.Z_P#\A*R_W6_I715SNO\ _(2LO]UOZ4 )
M1110!6S2]>HI*.:L0UXL@[:KV7B&'0X)()H)I'+DC8. *MU&T,4ARR _6D Q
M_';'_4Z9*?\ >.*B/C'5)/\ 5::B_5JF-K&/NJ*;Y83^'%%D%RLWB'Q%)]V.
M!!_NYJ%]0\22];L)_NK6FA!%.QD4[(+F*R:W-_K-2EY]#BFC2;J7_6WT[?5S
M6NPQ0IP:+(#'/A^,G+R.WU8U(F@VB]5S6N>13:!%"/2;1#_JQ^53?8+=#Q&/
MRJP:7.5QWH 8MM".D8_*G&)!T44]>E+0 Q0!V%/%-Q^5*/0UG)6-$[CJ***D
M84E*:CGD\FWDE_N*6_(4P.*_Y"?C?&,HDHS]$'^)%;7B3YKC2HP,EKI3CZ$5
ME>#(S<W]Y?MV&T'W8Y/Z;:U=8?S/$.D0#^%VD/T /^%.3U81Z%C1#ON-3DR#
MFZ8?D *J^'QLU;7(N<^<&_,&K/AO#:;)-C_6W$C_ /CQJOI0V^+M84="D9_G
M0^H(MH,:%Z%3_6K<3"/7+X9XD2.7'_ <?TJM"%?2+@$])&_G3[@E=:5NTEFA
M_(F@07K;HI#[&NNT7_D#VO\ US'\JX^Y_P"/=_I78:+_ ,@>U_ZYBF2<Y>62
MMJ$UQ#>20S.QW#J#^%1/<:C:D-+''<6X^\\9PRCUQ5J32K43RR,K.SNQ+%CG
MK5< VDGE/(SP2_*I;^$^E %?5XWAFCO+95<D;75ONR(>H-<EI>HOHT]YX?G5
MX6BS-I^XYW1,>4![[3^E=W<6VRW"@DJ!P#7->*[&2[^P:I81!K[32;A%Q_K%
M ^9/Q&: .KM+>**WC( +[1N8CDFJ&MB%K)X[E@T38X)P0>Q![&K-G?6M]I,&
MHVC9MYXQ(A] >WU'2J=E:IJ,YO;C+HK$1(W3([T 5;2Y\3!1%9WOG6^,*U["
M#@?7J?QJ+5/"^I>((0FL:_,=K!T2T01*C#H>/O'ZUU&>,53N=3M[9BGS22=U
M09Q]: .,C@GTS54T_P 2WDSQS,!9:G'\JNW]R3^ZWH>AKJO[&V<+=S C^]@U
MFZQ.^O6,FB)IYEDO5*1@OC81SO)QQM.#6Y8Z5KBZ; #J.G7,D<81F$38=AP>
M0W7\* *,NDW; A+U<?[2572WU>S;(C2=1W1N?R-65UF2*>:WO+&6&>!MLBJP
M8<C((/&014Z:S9.<;G0_[49_I0!E2Z_=I*86LYA)_M+M'YUDZAK.I1W,>G:?
MY<NKW/S!,Y2W3^^_MZ#O6_K^O06&E[H%CN[R=Q!:6Y_Y:2-TR/0=3]*K:/X1
MCTNV,ANY#J4_SW5QC(D?Z'HHZ 4 4M,\$K')+=76HR75[+_K;EA\Y/H/0>PK
M0MM'M%)BN)ITD'K(<,/45<%OJ%L^]=LP]4."?P-4]6O(9;-UF5HKA!N0D8(-
M $[>'=+G0M]G\S'\3$DU /#L:Q%K>[N$4?PALXK8MI(TL(-K J8PV?7(J'3'
M=[6XD;B,RML]Q_\ KH SU\.PRV^XW=RQ(ZA\8J/18(=-^T6N"USNR9&^\ZGI
M2_V_#9375O(<$,&4>OTJAC5-3U2.^M+?RHT4J9)OE!S[=Z .D%O(JMLF"E_O
M$CI4 2TLB(XEC>X<Y+,!D^YK->QU\=+N CNVTU/%X<A/^DW=U+-.PY<-M 'H
M!0!;2_?3;I;A9%V _O%7@,*[:.1)HUDC8,C#((/!%<1#:V:0X*%SG')S26.K
MRZ+JB1/DV$QP5/\ RS/J/:@#NJ*0$,H(.0>0:6@ HHHH **** "BBB@ HHHH
M *YW7_\ D)67^ZW]*Z*N=U__ )"5E_NM_2@!***2@"ODT8/K11VJR1,4H&#2
MT"@!:0C(HI30,B,9'*_E2HQ P:?1C/6@0$!AS4+QD<CFI,$=.: ] $:-GBG$
M=Z&4'YEZ^E"MFF PTE/9<?2F4 .4T\U$*<#0 \4$?_6IH-.!S2L  ^M+2''?
MI1TK-QL:)W%K$\5W7V3P[<L&PS#:*VZXSQ[*TZV.FI]Z>4#\SBB.]P>UC4\'
M6GV7P[ Q&'GS*?QZ?IBJ=[<H?$-]<G[ME9, ?]H_Y-=-#$MO;QQ*,+&H4#Z"
MN*QY]CJ4H)W7M^L"_P"Z",_UHCYC?D=7HD'V;1;.(]1$"?J>36?II'_"8ZL,
M<^4G.:W$ 1%4= ,5S^GDCQ?JQ_Z9)26P=2]9<Z9<KZR/_.I;G_6Z7-_?@9/R
MQ4.EG_0Y/^NK_P ZEG^;2M/E[QW!0_0@_P"%,07',#_2NOT;_D#VO_7,5R%Q
M_J'^E=?HW_('M?\ KF*9)S$]_):ZC<1N-UN92%/=,^M6+RU\ZP=&.&/(8=CV
MINI6):\OXW!PV&0^QJ'2;J>YM'AG&YHF*;O4=J *^DWEY?VC1RB/?$Y1CGT[
MU/>/]B>U9"-WFA>>^:S]%2>'6-0B;"@N&VGKCU%:FH:=]NB +[60[E([$=*
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M"\9X_6K:WVIJ/GT^0?1@:W'\-O%\MC>>2G9&3./QJ!M!U;!(U&$^WEG_ !H
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M! \8Q>IM&KI&'[LCTKF;[">++5CCYK:0#\C4M%)ES0.=&A/KN/ZFM*LW0/\
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M>K>N 3BMN]U/3].,:WU_;6IE.V/SI53>?09/)KE&UW5$TQM-,P;6!?M;>8%
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M45L9"]J;WHHH&+0:**!"BCO110 4HHHH !2T44 +VIPHHH&+1FBBD  TM%%
M"T444 !&>#4!ZT44T =Z<***!#A3J**0PI!110!6N5!C<'H:YF>$^8<3SCV$
MAHHI@1^2W_/Q<?\ ?PTHA;/_ !\7'_?PT44@%$!_Y^+C_OX:1X6"$BXN/^_A
MHHH A"/_ ,_-Q_W\-.,3[3_I-Q_W\-%% ""-_P#GYN/^_AI?+?\ Y^;C_OZ:
M** %\I_^?FX_[^FD\I_^?FX_[^FBB@!WDMC_ (^;C_OZ:!"W_/Q<?]_#113L
M OE-_P _%Q_W\- B;_GXN/\ OX:**0!Y3_\ /S<?]_#2^4W_ #\7'_?PT44
M.$)/_+Q<?]_#3OLY_P">\_\ W\-%%( ^SG_GO/\ ]_#1]G_Z;S_]_#110 [[
M-_TWG_[^&D:VPIQ/<?\ ?PT44 0^2W_/Q<?]_#2^2W_/Q<?]_#114%AY+?\
M/Q<?]_#1Y+?\_%Q_W\-%% "^0?\ GXN/^_AH\@_\_%Q_W\-%% "_9S_SWN/^
M_AH^SG_GO<?]_#110 ?9S_SWN/\ OX:/LY_Y[W'_ '\-%% !]G/_ #WN/^_A
JH\@_\]Y_^_AHHH 46Y_Y[S_]_#6CIENJS!B\CD=-[DT44 ;M%%%(9__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>forms-1a_015.jpg
<TEXT>
begin 644 forms-1a_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+ )L# 2(  A$! Q$!_\0
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M=I; QGC&/:@#0HKD?!T'V#6/$VFQ37,EK:WD0A6XN'F*!H(V(#.2>I)ZUUU
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M,[5;:)%^^,,.3SS@\BNBH **** "BBB@ HHHH **** .7\-_\C;XP_Z_8/\
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M22*10R.ARK \@@]Q0!S7AO\ Y&WQA_U^P?\ I-%745R_AO\ Y&WQA_U^P?\
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M/1110!R_AO\ Y&WQA_U^P?\ I-%745R_AO\ Y&WQA_U^P?\ I-%744 %%%%
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M)+ W-O'*NS:KEHV"%BH)",0 X!.,CCBMFL?P]X<L_#=DUO9[OWFUI?F.TN%
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M<W\MM'+HLOV=1N*F??\ *0 #\WO1X5\2P:_XETY;2_DN1%HI^U## ";?'UR
M"WWOUH [ZBBB@#E_#?\ R-OC#_K]@_\ 2:*NHKE_#?\ R-OC#_K]@_\ 2:*N
MHH AO/\ CRN/^N;?RKX&/4U]\WG_ !Y7'_7-OY5\#'J: "BBB@#W[]F;[_B7
MZ6W_ +5KZ!KYI^ 7B&R\/KX@>\$I\W[.$$:Y/'F9[^]>S?\ "R="X.V[P>_E
M#C]: -'PW_Q_>(O^PH?_ $3#6_7F^A>/M'M[O7&D2Z_?:@9$ C&2OE1CU]C6
MQ_PLG0L [;O'<^4./KS0!V%%,AE$T$<J@@.H8 ]>13Z "BBB@ HHHH ****
M"BBB@#E_#?\ R-OC#_K]@_\ 2:*NHKE_#?\ R-OC#_K]@_\ 2:*NHH AO/\
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L% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>forms-1a_010.jpg
<TEXT>
begin 644 forms-1a_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #* >X# 2(  A$! Q$!_\0
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M_GXB_P"_7_UZ** #[3J'_/Q%_P!^O_KT?:=0_P"?B+_OU_\ 7HHH /M.H?\
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MM_S\0_\ ?8H^UVW_ #\0_P#?8H FHJ'[7;?\_$/_ 'V*/M=M_P _$/\ WV*
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M*8B:BH?M=M_S\0_]]BC[7;?\_$/_ 'V* )J*A^UVW_/Q#_WV*/M=M_S\0_\
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MU3Y=A4\8QTI<H[G-:!<V;:CJMWHT2O;92/[.DA!;!.^7!Z>@]<5D)?#4+KQ
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M1>)+B;4_)2R3[,]P]I&YDPXF5=WS+CA3R*75O#_G:7_9NGV=BL3CF6;.Z)L
M!UP.6P/44R3PY+<:Y#>D6UO]G!*W$8)FE?9M#-GCCD]\\4:AH/\ ^$CFM;'5
M)+^UC%Q8N(PENY=9G9<JJD\Y[&K6FZM-=WD,4\2(MQ9I=1;3TZ!U/T)'YU03
MP@G]F"UGU"XFDC9Y(I5_=-O92"S8^\3GJ:L:/H]Q87=L)G+Q6=DMM&[-N,C$
M@L?8#  H5PT-ZBBBJ)"L;6=9N=/G$-I:)<.EN]U-O?;MC7KCU8]JV:R=6T3^
MTY5E2[EMG,+6\A10=\3=5YZ'CK2?D-#-8\0PZ;HJ7\4?VB24#R80>6R,G/H
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M=;^&\N)Y;F5"$>-E(3+]\DKP.FVDV.QV(NK=KEK<3Q&=5W-$'&X#U(ZXJ/\
MM"R^S-<_;+?R%.UI?,&T'T)Z5Q%[IU]<27%K!9RKJ8GN9I+D(0KQNA"@/WSD
M #MBGI"AO8M072[A=)CEA$MN;<Y++$REMF,D D#I2YF.QW(GA+H@EC+.NY5#
M#+#U'M4E<-H]LMAK&B&2PN$N3!,LLGDL0BL08U9N@P.W:NYIIW$T,D_UMO\
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M<'!PHI?[-L?^?2'_ +X% %CS$_OK^='F)_?7\ZK_ -FV/_/I#_WP*/[-L?\
MGTA_[X% %CS$_OK^='F)_?7\ZK_V;8_\^D/_ 'P*/[-L?^?2'_O@4 6/,3^^
MOYT>8G]]?SJO_9MC_P ^D/\ WP*/[-L?^?2'_O@4 6/,3^^OYT>8G]]?SJO_
M &;8_P#/I#_WP*/[-L?^?2'_ +X% %CS$_OK^='F)_?7\ZK_ -FV/_/I#_WP
M*/[-L?\ GTA_[X% %CS$_OK^='F)_?7\ZK_V;8_\^D/_ 'P*;]BTWS?*^SVW
MF[=VS:,X]<>E %KS$_OK^='F)_?7\ZK_ -FV/_/I#_WP*/[-L?\ GTA_[X%
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MUH44<J#F9G_V'I__ #R?_OZW^-']AZ?_ ,\G_P"_K?XUH44<J#F9G_V'I_\
MSR?_ +^M_C1_8>G_ //)_P#OZW^-:%%'*@YF9_\ 8>G_ //)_P#OZW^-']AZ
M?_SR?_OZW^-:%%'*@YF9_P#8>G_\\G_[^M_C1_8>G_\ /)_^_K?XUH44<J#F
M9G_V'I__ #R?_OZW^-']AZ?_ ,\G_P"_K?XUH44<J#F9G_V'I_\ SR?_ +^M
M_C1_8>G_ //)_P#OZW^-:%%'*@YF9_\ 8>G_ //)_P#OZW^-']AZ?_SR?_OZ
MW^-:%%'*@YF9_P#8>G_\\G_[^M_C1_8>G_\ /)_^_K?XUH44<J#F9G_V'I__
M #R?_OZW^-']AZ?_ ,\G_P"_K?XUH44<J#F9G_V'I_\ SR?_ +^M_C1_8>G_
M //)_P#OZW^-:%%'*@YF9_\ 8>G_ //)_P#OZW^-']AZ?_SR?_OZW^-:%%'*
M@YF9_P#8>G_\\G_[^M_C1_8>G_\ /)_^_K?XUH44<J#F9G_V'I__ #R?_OZW
M^-']AZ?_ ,\G_P"_K?XUH44<J#F9G_V'I_\ SR?_ +^M_C1_8>G_ //)_P#O
MZW^-:%%'*@YF9_\ 8>G_ //)_P#OZW^-']AZ?_SR?_OZW^-:%%'*@YF9_P#8
M>G_\\G_[^M_C1_8>G_\ /)_^_K?XUH44<J#F9G_V'I__ #R?_OZW^-']AZ?_
M ,\G_P"_K?XUH44<J#F9G_V'I_\ SR?_ +^M_C1_8>G_ //)_P#OZW^-:%%'
M*@YF9_\ 8>G_ //)_P#OZW^-']AZ?_SR?_OZW^-:%%'*@YF9_P#8>G_\\G_[
M^M_C1_8>G_\ /)_^_K?XUH44<J#F9G_V'I__ #R?_OZW^-']AZ?_ ,\G_P"_
MK?XUH44<J#F9G_V'I_\ SR?_ +^M_C1_8>G_ //)_P#OZW^-:%%'*@YF9_\
M8>G_ //)_P#OZW^-']AZ?_SR?_OZW^-:%%'*@YF9_P#8>G_\\G_[^M_C1_8>
MG_\ /)_^_K?XUH44<J#F9G_V'I__ #R?_OZW^-']AZ?_ ,\G_P"_K?XUH44<
MJ#F9G_V'I_\ SR?_ +^M_C1_8>G_ //)_P#OZW^-:%%'*@YF48]'L8I4E6)M
..Z'<I,C'!_.KU%% S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>forms-1a_016.jpg
<TEXT>
begin 644 forms-1a_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Q 7 # 2(  A$! Q$!_\0
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M8L?+] V<$4 =G1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 R1BL;$8R!GDXKD[?Q=))?:;!Y$.+HD2,LF0IW$<'\*ZQPI0A@"
MN.<UGPII"-;>0MHK-GR-@7GUVT :=%%% !1110 445GZQ?\ ]E:+?:AY?F&V
M@>;9G&[:,XS0!H45X#_PTJG_ $+3?^!7_P!C1_PTJG_0M-_X%?\ V- 'OU%>
M _\ #2J?]"TW_@5_]C1_PTJG_0M-_P"!7_V- 'OV:2O-/AS\5AX_U6ZL5THV
M?D1"7>9=^[G&.@KT&_NOL=C-<[=WEJ6V],XH2N[(3=E<M45Q/_"P!_SX_P#D
M3_ZU'_"P!_SX?^1/_K5O]6J]C+ZQ3[G;45Q/_"P!_P ^'_D3_P"M1_PL ?\
M/A_Y$_\ K4?5JW8/K%/N=M16#H'B+^VWF46_E>6 ?O9SFMZL90E!\LMS2,E)
M70M%%%(H**** "BBB@ HHHH **S=<U+^QM O]3\OS?LD#S>7G&[:,XS7B?\
MPTJG_0M-_P"!7_V- 'OU%> _\-*I_P!"TW_@5_\ 8T?\-*I_T+3?^!7_ -C0
M![]17@/_  TJG_0M-_X%?_8UVWPX^*8^(%_>6JZ4;/[-&'W>;OW9.,=!0!Z1
M1110 4444 %%%% !1110 4444 %%%% $<B[XV48R1CGI7*V?A2ZM[VRN6O45
MK?*D1(0-NXG &<<YYKJI#LC=L@$ G)Z"N3M?$U]<S:5&MN9([B1EN)HXCLXS
M@#TZ=Z .PHHHH **** "L3QA_P B9K?_ %XR_P#H!K;K$\8?\B9K?_7C+_Z
M: /ANBBB@ HHHH ]J_9P_P"1JU7_ *]!_P"A5]!ZY_R [S_KDW\J^?/V</\
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M110([/X??Z^\^@KNJX7X??Z^\^@KNJ\;%_QF>IA_X:%HHHKG-PHHHH ****
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MH$=G\/O]?>?05W5<+\/O]?>?05W5>-B_XS/4P_\ #0M%%%<YN%%%% !1110
M4444 <]XZ_Y$+7O^O&7_ -!-?$-?;WCK_D0M>_Z\9?\ T$U\0T %%%% !7N'
M[-O_ "'=9_Z]T_\ 0J\/KW#]FW_D.ZS_ ->Z?^A4 >^:]_R [O\ ZYFO(_QK
MUS7O^0'=_P#7,UY&.E>G@?@?J<&,^)"\^M'/K117=8Y KM/A^<RWWT7^M<77
M9_#[_6WWT3^M<V+_ (+-L/\ Q$=W1117CGJ!1110 4444 %8UYH,%]K%OJ<D
MLJS6^ JC&*V:YO49M63Q/9+!$[V)4;@O3=GDD]L"@#I**** "BBB@ K$\8?\
MB9K?_7C+_P"@&MNL3QA_R)FM_P#7C+_Z : /ANBBB@ HHHH ]J_9P_Y&K5?^
MO0?^A5]!ZY_R [S_ *Y&OGS]G#_D:M5_Z]!_Z%7T'KG_ " [S_KD:J'QKU)E
M\+/(QVHH'045[YXX4444".S^'W^OO/H*[JN%^'W^OO/H*[JO&Q?\9GJ8?^&A
M:***YS<**** "BBB@ HHHH Y[QU_R(6O?]>,O_H)KXAK[>\=?\B%KW_7C+_Z
M":^(: "BBB@ KW#]FW_D.ZS_ ->Z?^A5X?7N'[-O_(=UG_KW3_T*@#WS7O\
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M'_?=>YSQ[GD\K[%NBJG]JV'_ #^P?]]TG]JV'_/[!_WW3YX]Q<K['?\ P_\
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M5/\ M6P_Y_8/^^Z/[5L/^?V#_ONNWGCW.7E?8MUVGP^_UM]]$_K7 _VKI_\
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M]^Q1]AM/^?2#_OV*L447 K&QM#UM(#_VS%)_9]E_SYV__?H5:HH J_V?9?\
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FHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>forms-1a_017.jpg
<TEXT>
begin 644 forms-1a_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #G -<# 2(  A$! Q$!_\0
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M*T %>P_LY?\ (^7W_8/;_P!#2O'J]A_9R_Y'R^_[![?^AI0!]/4444 %%%%
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MO%: "O8?V<O^1\OO^P>W_H:5X]7J_P"S_>BS\=7>+>>X=[!PJ0@$_?0YY(H
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M?\E*D_[!\O\ Z$E>45ZO^SU_R4J3_L'R_P#H24 ?5%%%% &5K?W]+_Z_D_\
M06K5K*UO[^E_]?R?^@M6K0 4444 %?-_[2G_ ",>B?\ 7H__ *'7TA7S?^TI
M_P C'HG_ %Z/_P"AT >(4444 >K? "\:T\>W(CMI;AY+!U"1E0?OH<_,0.U?
M2IU.\(P=#O#_ ,#B_P#BZ^:?V>_^2EG_ *\)?YK7U50!EC4KL=-#O!_P.+_X
MNFG6I(Y[>.YTN[@6>41+(S1D!B"1G#$]JUJR=<^]I?\ U_Q_R:@#6HHHH **
M** "BBB@ HJAK5Q=VFCW5Q9!&N(TW*'4L#CKP.<XK/M-8OY+^]B-HUPL1($<
M2A&3#LH!+$ Y4!OQH M>&_\ D7K/_</\S6K63X8);PW8DJ5)CR5/4<GBM:@#
MYJ_:2_Y&W2/^O _^C&KQ6O:OVDO^1MTC_KP/_HQJ\5H *]7_ &>O^2E2?]@^
M7_T)*\HKU?\ 9Z_Y*5)_V#Y?_0DH ^J**** ,K6_OZ7_ -?R?^@M6K65K?W]
M+_Z_D_\ 06K5H **** "OF_]I3_D8]$_Z]'_ /0Z^D*^;_VE/^1CT3_KT?\
M]#H \0HHHH ]5_9[_P"2EG_KPE_FM?55?*O[/?\ R4L_]>$O\UKZJH *R=<^
M]I?_ %_Q_P FK6K)US[VE_\ 7_'_ ":@#6HHHH **** "BBB@ HHJ-)X99)(
MXY4=XSAU5@2I]QVH SO#?_(O6?\ N'^9K5K*\-_\B]9_[A_F:U: /FK]I+_D
M;=(_Z\#_ .C&KQ6O:OVDO^1MTC_KP/\ Z,:O%: "O5_V>O\ DI4G_8/E_P#0
MDKRBO5_V>O\ DI4G_8/E_P#0DH ^J**** ,K6_OZ7_U_)_Z"U:M96M_?TO\
MZ_D_]!:M6@ HHHH *^;_ -I3_D8]$_Z]'_\ 0Z^D*^;_ -I3_D8]$_Z]'_\
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:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>forms-1a_012.jpg
<TEXT>
begin 644 forms-1a_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $G G # 2(  A$! Q$!_\0
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M [S9/^>C_P#?1H\V3_GH_P#WT:;10 [S9/\ GH__ 'T:/-D_YZ/_ -]&FT4
M.\V3_GH__?1H\V3_ )Z/_P!]&FT4 .\V3_GH_P#WT:/-D_YZ/_WT:;10 [S9
M/^>C_P#?1JQ8R.;Z$%V(W=R:JU8L/^/Z'_>H Z6N:UN>*VN+B>9PD4:AG8]
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MBH #< C&!P<<9Q0!T((89!!'J#2U1TG3(M'T]+.%RR*2=Q &<^PJ]0(****
M"J]]]D^RE;W9Y#,JG>2 22 !^>*L56U"RCU'3[BRE9E29"I9>J^A'N#S0!GP
M6GAZY?9!';2-ACA7/9MI[_WN*D?3-$CECB>V@5Y"0H+'D@9/?TJ@W@K3BK!9
M9AEXVP<$#:I!&/<DL?<YI1X-LA*)%N9PPG,X/!^;T;^\/K0!=CT[0Y;J6UC@
M@:>$ R1AFR@/3//?%3?V'I?_ #XQ_FW^-2QV/EZM/?\ GD^=&L9BV  ;22#G
MJ3R:MT 9_P#8>E_\^,?YM_C1_8>E_P#/C'^;?XUH44 9_P#8>E_\^,?YM_C3
M)M(T>W@DFEM(DCC4L[$M@ =3UK3IKHLD;1N R,"K ]P:!F.EMX<DF\I$M6DW
M;-H<_>V[L=?[I!J:72]$@"^;;0KO947+'DMT'7O68O@?3EA\L7%R3Y/E%F(.
M3NW;CZG@+]!3G\%6$GF W$X$@0';@$;<=#V' XH NM8Z EY':-# +B0;DCW-
MEA^>.Q_*K']AZ7_SXQ_FW^-)_9;?VA:737CLEM'L2 QKMSC!;V.*T:!&?_8>
ME_\ /C'^;?XT?V'I?_/C'^;?XUH44 9_]AZ7_P ^,?YM_C1_8>E_\^,?YM_C
M6A10!D7-AH-GC[3!!$"K,"[,.%&6/7L.:6#3]"N=WD06\FT@':Q[@,._H0?Q
MJ?5=)M]8AABN"P6*991M_BQU4^Q!P:R/^$)T_8B_:+C"B1<DC/S$G@]B.GT
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M2W_YXQ_]\BIJ* (?LEO_ ,\8_P#OD4?9+?\ YXQ_]\BIJ* (?LEO_P \8_\
MOD4?9+?_ )XQ_P#?(J:B@"'[);_\\8_^^11]DM_^>,?_ 'R*FHH A^R6_P#S
MQC_[Y%'V2W_YXQ_]\BIJ* (?LEO_ ,\8_P#OD4?9+?\ YXQ_]\BIJ* (?LEO
M_P \8_\ OD4?9+?_ )XQ_P#?(J:B@"'[);_\\8_^^11]DM_^>,?_ 'R*FHH
MA^R6_P#SQC_[Y%'V2W_YXQ_]\BIJ* (?LEO_ ,\8_P#OD4?9+?\ YXQ_]\BI
MJ* (?LEO_P \8_\ OD4?9+?_ )XQ_P#?(J:B@"'[);_\\8_^^11]DM_^>,?_
M 'R*FHH A^R6_P#SQC_[Y%'V2W_YXQ_]\BIJ* (?LEO_ ,\8_P#OD4?9+?\
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M]Q].1S4:>)=2AMG\_2Y7DCC!SM(+L?8#@=OJ* ->ST*VLK]+J-G9HX! @;G
MR3GW.,#Z"M2N<'B6Z+HO]ES;FFV;0K8"X'.<8[\BF+KVKM<1J=,1=R@;27QN
M)3G.WH YS]#0'F=-17-)XEOF21VT>2,(4X8G<<XR0-O/7CZ5KZ5?2ZA:O+-
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M&J3Q_P!KK/.RF"0^2Z6K'"[ >!_&0<_4T 74T>VCNX;A&D'D1^7%'N^1!C'
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MY1/Y8">6X*;LKN5N#G@Y4<\U2G\,23F]<WJE[K#-NB+ ,"I!P6[;<#&, ]Z
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MMH6FGE2*->KNP4#\34E4]2L6OH(U241R12K*C,FY<CU&1D<^M %@W$*B,F5
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M)P&8'<,<'Y<CV^E='+;6LDJRS0PM(/E5W0$_0$TUK6RQ(K06^#AI 4'..A-
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M-!).EG%LV[U5YMK( RJV\8X^]D>N*ZKK4#VEK+O+V\+^9C?E =V.F?6IP
M!@"@ HHHH *H76H-;:K96A2/RKA9"9&DP5*C. ._?FK]0S0VTDL?G1PM)R$W
MJ"??&: .?OO$UU:7-Q%':0SK&5VM'(6R"2 " /O$@#C@$\UMG48%U!+%O,$[
MH7 \LE<#'?&.].$=E&SLJ6ZMO&X@*#O[9]Z5K&V:[%TT*F<# D[B@#(M?$37
M*W9:.WB\N,R1EYL  ,RX<X^4_+GOQ4FGZO>WMY:QF" 1RPF63:Y+(,X4].C=
MAUQGTK2-M8R"8-#;L"29<JIR<<[OP]:6 V<;"*W,"$J,)'@9';@=J +%%%%
M!56\OX;$Q"7<7E;8BJ.I^IX'XFK5-=%D0HZAE/4,,@T <\/$[@79:WB'EJ3$
M/-YXD*?/Q\O//?C-5W\7RQ"0M:1,(B8W"2G+-\WS+QRGR=??VKH_)LRTK>5
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MBX4LKX;E23P#\OICTXS4UA!JJZHD]TX^S&U$8C#Y*,-O4="Q.[G- &Q1110
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M6C\M@04=@> !C.>F /RH&.BUW392<72C#E,L" <8YSZ<CFA==TN0?N[R-F)
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M;%NC.V+EO*:5 N4P,8QVZUT/V6'^Y^M'V6'^Y^M,#-HK2^RP_P!S]:/LL/\
M<_6@1FT5I?98?[GZT?98?[GZT <[?)<&_M'A:Y$4>7E$9^5@.BX[DD_D#64D
MFNNL331SK(MSN9$4A74X^4G^%5]>=U=O]EA_N?K1]EA_N?K0,YY+^5]:DL_)
M A5,K+\V2><CICT[UGO+J8T6Y1?MYNUG<QOY(W.@DX&.F"OZ"NQ^RPXQM_6C
M[+#_ '/UI 9N0>0" ?6BM+[+#_<_6C[+#_<_6F(S:*TOLL/]S]:/LL/]S]:
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M0D\,3,KJFH*H;*<V^?W;,693\PZDXSZ<=\T =&#D9'2BD10B*HP !C@8%+0
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M\\J[.01M(P0%Y['K]*ETC3[FPN[^:ZO$N/M+JX8 @C P>,D = ,>E:?D0_\
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MN-1N[F+4%V30&%4!*,B[E.%/(!(#?-C/-=!Y$/\ SR3_ +Y%'D0_\\D_[Y%
M&#/I%Q>V=G#<_9?,MP3YH)R2%^4# &!G&?\ =]ZCMK'5=,\/O;6TJFZ,NY2"
MKX7C/4J.QZ>OXUN1R6,T\L$9@>6+[Z+@E?K4WD0_\\D_[Y% &/=VES<ZGI]U
MY,)$*[GD,VQ]V#A<#(V\\\\\>E9UYH6H3374CRV]U]J="=TC1F$#=]WJ,@$
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M /W?EQE>.<D=J (CX1'F)(;]F,:@ R1YR/E^4\\I\OW??K3O^$10_,-0F,F
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MT7 ]\4YO"4?F2/%=;0_&TQY &6(7KT&_@>H!JN/#^LI%:QK?1,+?:4:0EBI
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MX+-@ !%')N (7!;)7@D]< <#UJVVG>())R3J2QIDL=C9R<';@%> #MR,\XH
M;_PB,1E9FO9G5MN5?)Z+C'7&,\].M-_X1 !65;]UW$L6"8;)QD@YZG'7T./>
MHH]'\0Q!_*U 1>878CS-YWD  DE>>GH,5J6EIJ,%^ZSS//:-@(7D&Y1MP<C
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M^X%7=3O;[3+H7D)%Q'=A8XX,LP#!6;Y=H/7 'XYKH2 001D'J*3 XX''3VH
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ML2"99 T*J2=@!"EN,CD9X_"N@HH Y>;Q'J5O;RW$NEA8D!"L=PW'C#<C@'/
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>forms-1a_018.jpg
<TEXT>
begin 644 forms-1a_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $N G # 2(  A$! Q$!_\0
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MM[CGK[4+#S;LP=:-KGL%)N&[;D9],U3@N)+/2HIM7GMHY50>=(IVQAO;/:N
MU#6ET3XD^(M48-+%:Z$LPC5N&^9<5G"FY-I%2GRV/3**\^T[Q;XCMM4T:/7+
M?3S;:W&S6YM2VZ%@NX!L]1CO3+/QWJ=QX:\.ZB\-L)M2U,6DR@' 0N5R.>N!
M5>PG_7S_ ,A>UB>B45YHWC/Q/)#XEU"&+35T_19)XL,',DA4?+WQZ9J:Q\:Z
M];:K8+K-O8FTO].DO8UMMV^/8F[!)ZY'\Z/83_K[P]K$]%HKRWP_\0]<UB^L
MXS;6KQZBDGE+%!*/LK@$IO8C# XYQ5_1O'NH:U<>'["&"!;^X>;^TD(.(%B.
M#CG@DXZ^M-X>:W!58L]#HHHK T"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#*TKP_9Z1J&IWML93+J4PFFWMD!@"./3K5'6?!>G:UJQU*2XO
M;>=X/LTWV:;8)HO[K>W/;%='15*<D[WU)Y5:QRD?@#2H'T=X+B^BDTE#' Z3
M8+(3DJW'(I#\/='&F6UG%+>0/:W$ES;W,4VV6)W.6P<=#Z8KK**KVL^X<D>Q
MS<7@G2XH=,C\V[D.GW1NTDEF+L\A&"6)Z]>@Q3;SP+I%];ZS#,;C;JTJ33E9
M,%67H5XX_6NFHI>TGO<.2/8R;CP[97OAIM"OFFN[5HQ&[S/F1L'();US@YK-
MTCP%HVDQ7JM]HO6O81!-)>2[V,8Z(.F!7444*I)*R8<L;WL<KH_@#2-&U&&]
M26]NGMD,=JMU.9%MU/4(.WXU6MOAGHMK<6\D=QJ!CM;H7=O UQF.)\Y.%QT-
M=G13]K/N+V<>QSR^#M,73-9L T_DZO(\MQ\_(+]=O'%2'PGIK7NFW3B5VT^U
M:UB5F^5HV7:=PQSQ6[12]I+N/ECV.5TSP/8:'<I=6=QJ$_V57^R6DUT3#$6[
M*/\ '.*S_!7A:\LO$.M>(M4L8;*YOY,16T<@D\M>K'<.Y/-=U13]K*S3ZBY(
MW7D%%%%9EA1110 4444 %%%% !1110 4444 %%%% !1110 45G)$]P]\6N9U
MW'RU"-C8 .J^AYZU!IVN6TTL%A),6O#&&;Y>,XSC/KCF@#8HKF]5\<:/HVMQ
MZ5=_:O-9HU>9(&:*$R'"!WZ DUMZCJ%KI.G7&H7TRPVMO&9)9&Z*HH LT5S>
M@>-],\074MM#!?VDT<(N M];&'?$>-ZD\$5L+JVFM;"Y74+0VY8J)1,NTD=1
MG.,T 7**J'5=.40$W]J!<?ZDF9?WG^[SS^%.DU"TB1V:YB^1BA <9W 9*_7'
M:@"S17.:/XYT#6S MK>JLDUG]M$<V$98LXR<].A_#FK<WBG1(+JPMCJ-N\E^
M76V$<@82%1DX(XH V**S++7].O+"SNS.MNMWGR8[EA&['., $\GZ5:74;)KK
M[*MY;FX.?W0E7?QUXSGB@"S1110 4444 %%%% !1110 4444 %%%% !1110
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MY4;CK@X([<X_&EROL%T5M!^(4&OZE96\6ES107?RK.TBG#^5YFTJ.>F>:[3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]@-JBN<D\:Z4S;+$7.H2?W;6%F_,]!4?]J>)[_\ X\M%BLT/22]ER1_P%?\
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M_OH4>=%_ST3_ +Z% !Y2>A]>II/)3&,'ICJ:7SHO^>B?]]"CSHO^>B?]]"@
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M.JA]/;2VN(K<#9' HDQD\\MC.6KNZK2Z?9SS/--:PR2O$87=D!+1GJI/I[4
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M!F_NLVUA^!K5ZUFWV@:3J/\ Q]Z?;R-_>V ,/Q'-&@:EZ2>&$*998T#'"EF
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MA0.4&3NZ,.V*EB\)^%;%([R.VCME*!4D,S)\NT@#D_W68?0FFPZ#X2TZ8:C
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M\MMD3:9I4!MHA!JC"%T5'6/ $P484\\CY2,XZXIMEX6M;!$FM-0,,WW%EC5
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M!C &.3CN:B@\*:9YQNA?O+'LPH9P0 W3_P"M5BY\)0W-KI\!N2HLT9 PB7+
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M0Y5@&!]0:336X73%B_X_D_W&_F*O51B_X_H_]QOZ5>I#*FJ?\@B\_P"N#_\
MH)JAX0_Y%'2_^N J_JG_ ""+S_K@_P#Z":H>$/\ D4=+_P"N JOLBZFU1114
MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J"X_UMO\ ]=/Z&IZ@N/\ 6V__ %T_H: )Z*** ,MM1NH[BY!M
M6>.)'8*B-N..G/0[O05AV]_XH@@^SSVNZ=-TC2%=X=3M(4$8&02P_ 5O-K$<
M<TZR1E8X5=BP.3A>N1V]O6L*V\6WPM]ESIK&Z7<\BG,>U."I (.3\V/^ FMH
MIVV,VUW)(+OQ#-IT:B)Q,9X@UPZ8P-R[ODQTZ]ZKOK/B1MR"QDC,B-AA"S%&
MV\$<8QGL?7O5F/Q9,FCR7DUDTDJE?E0XC&<9&['OTQFHI/'*I#+(MB&"DA0)
M3DD$ AOE^7.>,^G:J2E_**Z[C(]<\1R^<L>GD;%+*\D#C=@'Y<>I('YU/_:7
MB)99 +3=L5F),38?;T"^F<^]-_X35W,HBTPNR*7P9L94+DG.TC/;'\J?)XQ:
M%F6332'3*LHER<X8Y'R\K\O+=L]*.5_RH+KN/@U;5YM/NGO+;[(5N$0. 050
MMACR.<#N/6JRZKJ5A:M<R"\FN00L\$T>V,,6V@1G SU'3(Q2V_BV9ED%Q;0M
MRW/FXCVCL&Q\Q.>.G0U8/B*2\T9;J*V2*7SF3:_SA2JEN#@9)QQBCE:Z!==R
MO%K?B"X\P06D<I1I Q\E@H*%AL!/7.!R*!JOB+S)+B*T,T2)M2)H63SCSAAG
ME?3!]*DC\475O*5N=,=4=81&JD9,C@GMG@D?A@TW_A-\&+=IS8<C)27=C(!
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M0 4444 %07?_ ![_ / E_F*GJ"[_ ./?_@2_S% $]5K_ /X\I/P_F*LU6O\
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M'YASS77_ +[_ )]W_P"^A1^^_P"?=_\ OH4>VEY?</V:.&'@S6#=?:7U0-<
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M6D]M +>6:2X?:!'CY0.K')' _.@"W151;\'4WLGMY8R$WQRMC9(.^,'/&1U
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MQOO7;A$*EOF)RW/)YP/8"MNH:2>A2OU"BBBD,**** "BBB@"KJ/V/^SYA?\
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
